<SEC-DOCUMENT>0001636422-21-000046.txt : 20210507
<SEC-HEADER>0001636422-21-000046.hdr.sgml : 20210507
<ACCEPTANCE-DATETIME>20210506183237
ACCESSION NUMBER:		0001636422-21-000046
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210507
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Health Catalyst, Inc.
		CENTRAL INDEX KEY:			0001636422
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370]
		IRS NUMBER:				453337483
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38993
		FILM NUMBER:		21899561

	BUSINESS ADDRESS:	
		STREET 1:		10897 SOUTH RIVER FRONT PARKWAY, #300
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		801-708-6800

	MAIL ADDRESS:	
		STREET 1:		10897 SOUTH RIVER FRONT PARKWAY, #300
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HQC Holdings, Inc.
		DATE OF NAME CHANGE:	20150312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>hcat-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:ac4f3b8b-712a-43a6-9f81-b9cf5889a679,g:b64543c5-cb81-4282-9510-d3dfb10c5ee8,d:697ec2deca434bfbba4eea21a51f5e11--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:hcat="http://www.healthcatalyst.com/20210331" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>hcat-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF8yLTEtMS0xLTA_540d52e3-21e4-4e70-84d1-36aec1c27ba6">0001636422</ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF8zLTEtMS0xLTA_91c7747f-f944-4371-b509-038bbb33a498">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF80LTEtMS0xLTA_70c7273e-baec-48f5-955a-dfd550ed7159">2021</ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF81LTEtMS0xLTA_ae78f65c-c4fe-45de-bb30-02e493b49239">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF82LTEtMS0xLTA_f930a23a-ec45-4fa3-8bfd-196ce846311e">false</ix:nonNumeric><ix:nonNumeric contextRef="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNC0wLTEtMS0w_514a1d19-4d44-47e5-a039-9bdfa2a97ce4">us-gaap:AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i98f9fd2755be4ddca2dadbcf036fe11c_D20190710-20190710" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80MC9mcmFnOjg3OTBhYTgyM2U4MzQ4ZmQ4YjYyNjU2NDY0ZDhiZTZlL3RleHRyZWdpb246ODc5MGFhODIzZTgzNDhmZDhiNjI2NTY0NjRkOGJlNmVfMjYx_a464ec8d-3abf-479e-9bfe-bae5aa44af13">0.5</ix:nonFraction><ix:nonNumeric contextRef="ifb69fcbcfa3c445cae93cdcd8e8f89e1_D20200901-20200901" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcyOQ_4220c2f0-de6b-4637-b12c-d886b4eb2b01">P2Y</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331" decimals="8" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xNTkyL2ZyYWc6NzU1MWNkYjA2NTNmNGY5ZWE2N2JiNmFjMGUyZjkzNTgvdGV4dHJlZ2lvbjo3NTUxY2RiMDY1M2Y0ZjllYTY3YmI2YWMwZTJmOTM1OF8yNzQ4Nzc5MDY5NDg1_9bc5e7a4-3fbe-4526-ac30-7f540d9587ba">0.00326797</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="hcat-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie345a5d82c04411d88183387ca0f2e03_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4dfda2f92ed340caa2877a927d22e736_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6bb236a6d7f468880b49898be6fc30a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ece495212884ea7a688a503a845633c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4ed21d069e44040883da517205949ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13411e0950346e18adca59be7a3a6e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id239684cf62a40bd84edbe1e1929f0b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5246542574fd40a6acee46eddd59f600_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i067e0e6900304a738394616a183db02f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0e3333f61a401497d1869d991e2376_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b73d6b0c08b416fa95d0ffafd4a69be_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice27b80f156b4c7c97e4c9714bf0a308_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e366123354486cababd5831e94051e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i183085abd0424ba1b6749e0788cec760_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd2d729e83a74d25a64ee4134008cfca_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i384152dcce9849d1bba93e9d52950c6b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ffb26487eb34a6cad9855d641b8a555_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f406e1ada1b4b7fa1d2e0eb11b7bd16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32bab634e2c04ca8a0b8272bce5cc112_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1c0fd3c5bb4f7490e1619c30315164_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63dae0960a21470cadf5c35381490d80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73bfc66cbfc34ae8a0fa31cc621730d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e743d83b6e43f6a07eaae2dd2b103a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ee6ea456694392b6844031fc89de02_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0efcef22664d14815854888bb21e26_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386ccc1569bb40d885c8301f5452d4c9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c0cec055bcd4b89865d64d93fd1adbc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963ff9fa8e4f417285df70d02db0ce49_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a78b3ee92264aa6b424fb238b67d7f4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>hcat:segment</xbrli:measure></xbrli:unit><xbrli:context id="i0b1145c0be2f4abd984b071985b91ff7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i570b1a58613c45b78737719cc3a0796e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8806568ffc14910a88f456175540071_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98e1d9087f64f35abf0c9c0b35b25ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2eb546857cc494fa9f8c061084c10cc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7625b67853714c90870b7c5404d9bcbb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1895ebcf2194a20ae75e64ba8b210ad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6b011b06cd4b56805334a4b840ea06_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11cd2ccbecf4ec4889f63e8c0bdbfe6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23793db4aa3a4118a87890e37cc5f76a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eec362ff8b44eebbb405af5d1e31e89_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2ec48709a149158db346873042cfa2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d455966ff3546f28112a01f67004be8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19090821c190424ca2b60933a320196d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752e657a7ed54158a466343124496aef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i98f9fd2755be4ddca2dadbcf036fe11c_D20190710-20190710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-10</xbrli:startDate><xbrli:endDate>2019-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a602fe1da24b898d87f5aa96f55e7e_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hcat:RestrictedSharesPursuantToAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a6f3c1d5434096a8602552e27ccd8b_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hcat:RestrictedSharesPursuantToAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d21b8b985b74d238f472e4e71050a30_I20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7ca50433dfa41afaba5f4dbfd9c4080_I20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice7f7a67b58b4ab7b21087c875b742aa_I20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0acf0e57514eba9c3147edf4b9b2f3_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9289e7751f54283a46cb7fb7436a914_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6bea69d2c8a4cbdb35a5f22ae1b2948_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2cff5f451304355a1795c9ec977b1b3_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdbb8be29c94abbbe84a2dad772a00d_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i498f4874d4104d52939aa8749d65159d_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a417b5d4b4461bb7ff7bef53ae612f_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34094f2ce17c4b68b9c7f3e2545dfc9d_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1734d7abc4744d5683af026b80bc322e_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica753ecaab5f4745ad630406fcb5ecf9_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd704a45bb3466b99382868818856b6_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0271ede7abee462eba0b2b698342faae_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10adc4ae8854029957496d9f5339693_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c0e7f496834c03a071df11af262227_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae6e93b2b18426481d9a6a8da986dc3_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d756d95f7c48f0b87b33dc8c7a743e_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0aa3a878073450c89d3c4a52f80971f_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3be332fe9194ef58f9aceef7fcef46e_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:ContractBacklogsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if53b8b11a34f4165a0b32d5030e61aaf_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb69fcbcfa3c445cae93cdcd8e8f89e1_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52203ce0773e4de29d77d41ca3e6ed52_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i563042bec9ce44faad7f33151e649064_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345542d87cc5467f82f4b9ffbcd77517_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">hcat:AcquisitionRelatedFairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9284427b4344e99bd6a68791952947_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">hcat:AcquisitionRelatedFairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a82e47b69b4d3eb01ecc169fcbbdff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:RecurringTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5b2b2f3eb34e66b9f15ef94b7f93d3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:RecurringTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i072686e691b043fc99a5001437848336_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:OneTimeTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica63ebc6345a4c4e9bf1f23e7fa538d2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:OneTimeTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5ac1f2270243679239715132a65f39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dba3e825a6d4aa18b1576f50bc30986_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c750b2d03c4e43bd847dd5399458fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ffad74837e64a998ce0d0e6a9d0363c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc1260ae65e4a948c0c470387cf66e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcd127174c94e03ada02115a901ebb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db85473fe074ce1a8b9d070f8da1259_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17f9ad5e961945caa4d034f51243794e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260812b8834d48928c9d06e77dee395b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d7975897fb4234a03bea31f1b463be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb53d4219524c099358c824a99b0cab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9514dc5706d84f94969cf5c1179a4865_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fa77551a95d4af6815afe266a065d63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983abe9c75604218bf9215278d6c8786_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie10e2819b49b48ebaeb218115ba93d2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83e5abba43a418b8748534d60c48c2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb60e336f0d243aeb3c25066686e0e13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib630a4b7ddb6454bb0fd041f7d7959a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1f14648338143b69e420b0bcff04694_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7a206018584742a08cdb6786414f22_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib50a93f231d04a3c92f044e1aead7038_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9f4a66d37c421d9e84a17684b6e893_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0db9e7d9d0645fe9a0dd92a5549d8ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i977516e22f8e4f18a06347de98aabdba_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hcat:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88139ab53d0d484f97717e145bade887_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hcat:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb8030fbd94c4883ab8884ca9b7948c1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541592340c83428bbdf196bbddcb23a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i426a8994b6c940268705dd62cb41316b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c3e9e5c69d458f81c897663c923806_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if016bb5751394439b838dd7a5e32d9e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3505f155dd9c49eeaf5dce4bd2bad37d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifddc111015e24dd5a3690fdb5f45cc03_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12990573c5334556ae9ffecfcdd78f8b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87ff6778e0941aea98e91250fcb83cc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1af733c21c145808c8ce5cf39e9aa92_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9cf71f707df4212a1eab4e8b98af652_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d92a783fa4d4b9e8f5c6ddb9773b7ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf00f0e3ce94b20aa839b353e220099_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f8b60d964c412f8bf1c17763bd40bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i935fba8f21d64ab0a83a3fc3303e30db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaaece3cffb845d288b5e4226bc51516_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c52c70966543f9b9649f46f30a1296_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5d15f13d5b4999b2da4743f59a762c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6d29b54640446d8d61a7b0cbdb303b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26f143d773b74a2c97d01a880e1b5979_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9a993228ca419ab4f241d7af9bb937_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ca7f15ccff44c6bb539eb829a8c5a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0ae121e125f4a669af32cafe299e72b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54312b9eac0b49b2837ad56f42f14a85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8206db89dd9e4111863cf8b116f25dc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95cb4a7b357a4575b5c1f13edf15b3a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if66d1b79d4394e83b7b2d962f19c40a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i978e872b2ba845f49001cc6325ebd9fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78fe06353da4595b8d88460f552d5b0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91927ae09dc04b33b971594d8bc54b89_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a4b7862118b4131ac5f06f5aa47e163_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibed91e357c7f439bad5f2441be2f3393_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibebd1cdc445047d992d3cf7740678f7e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide03cc507eb84e43996d3b6131c163af_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56d22cf25cf4054b9132b3db37d4f5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab672b01fe5742f2aa363490a53f34e5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4186455850234995a3fefd4e16a396f4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1976d6b0d3d4e46ad2266bf99b8e8e7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i660b0d75067a411f95ef76e0a4f14bcf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5d27da05ef4dd6820a8bd484966fad_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66dbc4d8aea34408bcdeadf087d32dfe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfcdb2b7b1549cab39eebc5d9febb7e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3baad2ca5dec4ecb9082b1a396901a60_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8799ab7618024c44bc02cda2b7c017c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1265ad6d0a51472194b6f09102f17989_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3257c2bc0d064887835ed5bd428b3341_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2569064bb5554bff8a5d048551e515ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161a412a8549477d870aa84d7450f380_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i527bc64f624c453d86a9fc398fa02162_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c8d4d672174b0eaf8590b94b667b03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78034192027744038e8701e5a608c7d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id682c7555ec54d519592bb14ada245af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f4f44ee228e4ea0ba64867556b0a8ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c3845f6f18439d8fb05984c62fff97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26633d8bfcfd430fb29e89e97d45eb1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5961bc6e1d4847d1aa04aa5a147ce0a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd7c0f92f7040fa9ad243c1f7fbaa69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49bbfddff2d48ce808eae7321a3d727_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80924d762aae4accb35feb372dd0973d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd307786e34047c1a07fb54bd6b2b8d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i969f245e87394c10994db7d2a6a77fb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed4a348fb3e4251a45ae70c403a2faf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59fcfef1efb441dea240055b2986ee9d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if709f4c82b2c40929782386201a2329e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf8b76871176404b8081eb0c5b32f0ba_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed47da29f5f4158b9f99d94735bcba3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86af83c7eb5046eda62a9143eb75002f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hcat:MeasurementInputMarketPriceOfRevenueRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc9d82578fd4a2b800c586e00deda04_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hcat:MeasurementInputRevenueVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c816c8bd444ca6b6af6a54d8586515_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530512a1ce4642378115de9c7b137ee4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddeb3efca1a047968b5e37ad4c74a3e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636c7efe46af4879a27c31281770fbe6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23059744db234f77ac69c30533821763_D20200414-20200414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-14</xbrli:startDate><xbrli:endDate>2020-04-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>hcat:day</xbrli:measure></xbrli:unit><xbrli:context id="i0e584e43e4fa4dfe91200285e31ccff9_I20200414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e636533f649460881507b118b35238e_D20200414-20200414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hcat:DebtInstrumentConvertibleThresholdTypeAxis">hcat:DebtInstrumentConvertibleSalePriceOfStockThresholdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-14</xbrli:startDate><xbrli:endDate>2020-04-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8bc9199ddd4da18bed3e8e6956e62f_I20200414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22bcfd28d2944d7a26478fbca019240_I20200414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4882e61e1b5b46ba931866b40710101e_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id441c0a6737547208b92c291c8d51e05_D20200409-20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hcat:CappedCallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-09</xbrli:startDate><xbrli:endDate>2020-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerInstrument"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>hcat:instrument</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6e1056545f074e48880fc579da87512f_I20200408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hcat:CappedCallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c6064e783e4b6499fe9fac50aae475_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4af7b7557540d99e4a0928fd4dcef7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>hcat:vote</xbrli:measure></xbrli:unit><xbrli:context id="ibf3d7414d599440ab6623f14616c362b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb8e3c8002b8497680d01206475b3c70_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i889328385548411faaca4f9d1d75a560_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cbf6d87e70d4690bbb117a5330e5f92_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c57c1ec8b584886bb5787b258ab2310_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a09a657dd645c4af6df61e20653b67_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a14d8fc64c4c19a75623ef092ff461_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793d72c883b8430fa8d9b3446ef17c9f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5b95cb131b4027a016c3b12f265779_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5291fdd2f49c42f288d38b74d791754d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c02d79a3e94b378178e4a644ab9142_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174b5dc836864ffb956e769476edb3fc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a1ea5338944dbc8ab0f9476e6f521e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c17e8c4ebc4427892a4e5cc329075de_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77eedb5e34f4c26abf4a65346e4650a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9191a8e792e492088d4538b45dbd969_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i783ec453ce724eff8223cbd8f18bb73c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb8e56635cb40dd9af2d7d512c81522_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0228f5aacd43abb6861e9102c54c52_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168ea8840cfb452e9329f1c8021d7a0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84298c0178544899bc7be2bae525267e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639974b37d9546128e75e5929286a25e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b2602642784525904168a8fa8633ce_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2299b3cd854c339e305d26f3393657_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a1e6a0de294ea8abee4a1b9871700e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53167a60f2a467d9c28ab7387d78e93_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83724b12cbb24c4a98f79788141daf04_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd9a3def7806461eb26ce54d85a9d12d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29571c06d3a343e6ad4d8056a8d1af33_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13592f0c308d4c3ca5b28589349e0918_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b84aed76ed431793822e4580b8f1d3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b3f6fdec2a4b278368ed19a4a95efa_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28f76181b1848d096ea303063c91539_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6253c82367944772a2bf9c34f8b31715_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba12a4c71464ef789bdd7bf566ab6c4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c65b644a90a47f8b4b906e0790b6239_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic980a4f37e8843bda75a71bcff67a580_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631a418618034b708e3ac39665cd5ccc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie966431602dc412e8b09acdcfbeffb3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dfe9f7c1913433fbc1d1265932b61f7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0de8ec0b76746a1957ad2b58eb7edac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ad286f2178249fba783e6f88e35ca81_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b97cd002a914ee3aa2c282be09d867b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedce8ff10cd94af1a1617e8a8e551070_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f5fbd68ddc4421b8d0bc58f849fac7_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c99dfaa5084f8b99fb2b86c782d222_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13867759ede9429292155333cf98aa5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63d5a2a619c74cd49c4313f5d1b1c0f3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fbb179f359b4f038e44fe90cd706e8a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:TechnologyAndProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0653e44dccde41d79e0c4dcca4805fd7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3448fe61af4c4aacaf336c73188b521b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b094898f5e4db7b34432cbd11ef1b0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2374c5eff6d04980b4a36a67bb87de2d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ad4008f49a049feb88a7b75269882ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib54854387397459a8c725ddfa3ed8859_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c95150cded4d7da0ed5115a50de8ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375d7f606b334e22897257297115deeb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f46ff336b1840e7b034030cf5eae332_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4830aba629412daaa0cc0a46d3c18e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285babe5ab964ef29cef5180c50abd82_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c07cafe2db4a11803bb4bf98296039_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if49eeee1198d4d19aadbc2d7fd7450bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4814ebae7b6547faaa86c64eccc633f1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35f3002cf13457c85971a5a2c22d04e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib160b8d6aaec4f898595c6488b4def77_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636422</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0xLTEtMS0w_7250e1a3-5ba0-475a-9ed5-653c3392b0eb id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0zLTEtMS0w_09b64410-8c75-432e-ae83-490ea8a3e660 id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0zLTEtMS0w_00c50cdd-e9cd-4b76-8678-954a4470c020 id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0zLTEtMS0w_4b09ec26-7fc3-4a32-b1cf-74667c274ce0 id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0xLTEtMS0w_955fb2f4-dfae-45bb-a8cd-b520deef26f2 id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0xLTEtMS0w_6112616b-0505-4343-83e3-ce6afd1552ae" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMzc3Ng_eda0e928-76c1-4314-a439-b53de6ab4a91 id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtMA_faba9f23-af9a-40a1-8681-f0f00c33ad42 id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMA_93c76e98-5e07-47cd-8681-684959c98a3f id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0xLTEtMS0w_192c6583-7c7a-4592-b6e3-8000c933980e id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMzc3Ng_183754e7-e126-4bbc-8a62-dd5bcff30a7e id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0zLTEtMS0w_1ca04824-0b8b-4f86-8c91-006a1433b454" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i697ec2deca434bfbba4eea21a51f5e11_1"></div><div style="min-height:18pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:right"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk2_abdc4ca5-634a-49bb-8bd8-13bdbf3ab284">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk3_7503474c-0155-4c9f-add8-e258314fa710">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended&#160;<ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yNjg_7c0b6106-f292-4413-aaf0-b608a10576fe">March&#160;31, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Or</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjg5_6936cc8b-e76e-4506-9dcc-c7df6b6944b4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk4_b4ea1693-6ba6-4dc8-aa7a-abd5e99bcb8b">001-38993</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjkx_ad615cee-90b7-490d-af9c-5a2dde48f44e">HEALTH CATALYST, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ODM2M2VjYjExZDM4NDFiNGJlZDE1YjQ2NzgyOThmMDQvdGFibGVyYW5nZTo4MzYzZWNiMTFkMzg0MWI0YmVkMTViNDY3ODI5OGYwNF8wLTAtMS0xLTA_650db3de-90c1-4f03-aa0e-1b8337367cbc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ODM2M2VjYjExZDM4NDFiNGJlZDE1YjQ2NzgyOThmMDQvdGFibGVyYW5nZTo4MzYzZWNiMTFkMzg0MWI0YmVkMTViNDY3ODI5OGYwNF8wLTItMS0xLTA_21ea549d-6c05-4c8f-bb8b-9961cecd8537">45-3337483</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk5_1fa336b6-f5a6-4e6f-ae55-88bbad2c1ebd">10897 South River Front Parkway #300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjg4_05e0308c-74d5-45c6-950b-31fad458962d">South Jordan</ix:nonNumeric> <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjky_5e1093d6-a9bb-49ac-bfdd-c72e5d17c0b4">UT</ix:nonNumeric> <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjkw_e68d4e52-9769-43fc-89b3-8ba003a63825">84095</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMzAw_b86d4232-860a-4fb1-9eeb-c45dcccf9cdd">801</ix:nonNumeric>) <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMzAx_63ddea76-5e67-47bd-8dc1-d6fd0b247ecd">708-6800</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.583%"><tr><td style="width:1.0%"></td><td style="width:35.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ZmFmNjEyYjZhZGIzNDM0NWFhZGQzNDIzZTA0NWM0YTUvdGFibGVyYW5nZTpmYWY2MTJiNmFkYjM0MzQ1YWFkZDM0MjNlMDQ1YzRhNV8xLTAtMS0xLTA_7a47a76a-9242-4591-bcb7-e6dfd9c51e28">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ZmFmNjEyYjZhZGIzNDM0NWFhZGQzNDIzZTA0NWM0YTUvdGFibGVyYW5nZTpmYWY2MTJiNmFkYjM0MzQ1YWFkZDM0MjNlMDQ1YzRhNV8xLTItMS0xLTA_b319bcfc-2f91-491e-930b-e443531c308f">HCAT</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ZmFmNjEyYjZhZGIzNDM0NWFhZGQzNDIzZTA0NWM0YTUvdGFibGVyYW5nZTpmYWY2MTJiNmFkYjM0MzQ1YWFkZDM0MjNlMDQ1YzRhNV8xLTQtMS0xLTA_006a09fa-187d-4704-86cb-bd5f5afd9be8">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjkz_ae209c52-39bb-4cfe-b3f5-95bc05f72f86">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk0_c4b2421d-f906-4829-b654-449b4f3e5140">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.111%"><tr><td style="width:1.0%"></td><td style="width:24.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6NTM5ZDdjZWIxNWUzNDU1Mzk1NTU5ZmQxMjM2Njg0MTMvdGFibGVyYW5nZTo1MzlkN2NlYjE1ZTM0NTUzOTU1NTlmZDEyMzY2ODQxM18wLTAtMS0xLTUyOTk_978c1b57-e267-4039-b4e5-84b736a701f9">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6NTM5ZDdjZWIxNWUzNDU1Mzk1NTU5ZmQxMjM2Njg0MTMvdGFibGVyYW5nZTo1MzlkN2NlYjE1ZTM0NTUzOTU1NTlmZDEyMzY2ODQxM18wLTUtMS0xLTA_970dec15-5599-4c84-b3fe-b0cc49395285">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6NTM5ZDdjZWIxNWUzNDU1Mzk1NTU5ZmQxMjM2Njg0MTMvdGFibGVyYW5nZTo1MzlkN2NlYjE1ZTM0NTUzOTU1NTlmZDEyMzY2ODQxM18xLTMtMS0xLTA_0c373aab-dd78-4ebc-81c7-e19eb1acdb29">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMzAy_d66240c1-a9f0-4d46-a262-26b3e05cbfb9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of April&#160;30, 2021, the Registrant had <ix:nonFraction unitRef="shares" contextRef="ie345a5d82c04411d88183387ca0f2e03_I20210430" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjQ4_6d85b448-19b5-447e-9c25-54f106fac2f1">44,520,749</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_13">Part I. Financial Information</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_16">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_16">Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_19">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_19">March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_19"> (unaudited)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_19"> and December 31, 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_19">20</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_22">Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_22"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_22">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_22"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_25">Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_25"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_25">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_25"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_28">Condensed Consolidated Statements of  Stockholders&#8217; Equity for the Three Months Ended March 31, 2021 and 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_28"> (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_28">unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_28">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_31">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_31">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_31"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_31">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_31"> (una</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_31">udited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_31">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_34">Notes to the Condensed Consolidated Financial Statements</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_34"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_34">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_106">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_106">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_106">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_148">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_148">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_148">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_151">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_151">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_151">57</a></span></div></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_154">Part II. Other Information</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_157">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_157">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_157">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_160">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_160">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i697ec2deca434bfbba4eea21a51f5e11_160">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_163">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_163">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_163">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_166">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_166">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_166">94</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i697ec2deca434bfbba4eea21a51f5e11_169">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_10"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-looking Statements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to &#8220;Health Catalyst,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and similar references refer to Health Catalyst, Inc. and its consolidated subsidiaries. This Quarterly Report on Form 10-Q, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the &#8220;Securities Act&#8221;, and the Securities Exchange Act of 1934, as amended, or the &#8220;Exchange Act&#8221;. These forward-looking statements, which are subject to a number of risks, uncertainties, and assumptions, generally relate to future events or our future financial or operating performance. In some cases, you can identify these statements by forward-looking words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; or the negative version of these words and other comparable terminology that concern our expectations, strategy, plans, intentions, or projections. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about our:&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to attract new customers and retain and expand our relationships with existing customers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to expand our service offerings and develop new platform features;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future financial performance, including trends in revenue, costs of revenue, gross margin, and operating expenses;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to compete successfully in competitive markets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to respond to rapid technological changes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expectations and management of future growth;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to enter new markets and manage our expansion efforts, particularly internationally;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to attract and retain key employees, whom we refer to as team members;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to effectively and efficiently protect our brand;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to timely scale and adapt our infrastructure;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to maintain, protect, and enhance our intellectual property and not infringe upon others&#8217; intellectual property; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to successfully identify, acquire, and integrate companies and assets; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expectations regarding the impact of any natural disasters or public health emergencies, such as the COVID-19 outbreak on our business and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q and as well as other documents that may be filed by us from time to time with the Securities and Exchange Commission (the SEC). Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements and you should not place undue reliance on our forward-looking statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2020, included in our Annual Report on Form 10-K.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_16"></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;Financial Statements</span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_19"></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNS0xLTEtMS0w_b50635e9-78b7-43bb-9f54-566012e99ce1">132,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNS0zLTEtMS0w_bb3b36b2-e062-4dd6-94f0-ba40e1799379">91,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNi0xLTEtMS0w_f88e6615-8212-425b-a657-224cacfca293">133,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNi0zLTEtMS0w_90de1d55-0d15-4f8e-97b9-da5f54eead96">178,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0xLTEtMS0w_192c6583-7c7a-4592-b6e3-8000c933980e">45,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0zLTEtMS0w_1ca04824-0b8b-4f86-8c91-006a1433b454">48,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfOS0xLTEtMS0w_ccbecfec-b3c5-49b3-9f62-eb7c2e37a915">12,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfOS0zLTEtMS0w_ffc38493-6d99-496d-96a8-47d7edc56bfc">10,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTAtMS0xLTEtMA_de6ec829-4034-42dc-9471-76417562aabc">324,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTAtMy0xLTEtMA_9b57883d-56e7-4a45-9593-6f4f0888e5ba">329,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTEtMS0xLTEtMA_0f60ce02-b999-4e13-a4fa-e23c3452075c">18,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTEtMy0xLTEtMA_2d82f770-b494-44ff-a19e-d687585572cf">12,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTItMS0xLTEtMA_58efa802-7b35-488e-8313-fe0db2ea1ae2">91,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTItMy0xLTEtMA_7ab2c670-180b-4586-9c26-84bb27fc88f9">98,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTMtMS0xLTEtMA_9d25535e-2dfd-4ef2-8981-3d721c6dc6e1">24,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTMtMy0xLTEtMA_988cb6c7-04b1-424a-97f2-7d1b07a88c15">24,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTQtMS0xLTEtMA_b577d6cf-45ef-476b-a41d-5e24149b6cc4">107,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTQtMy0xLTEtMA_56a3bcaf-3a1c-4cc8-8c60-1f6f102abf44">107,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTUtMS0xLTEtMA_870efd2f-59e9-4c1f-b458-8084371d70e5">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTUtMy0xLTEtMA_61b6e812-b560-4888-94df-3b0affeb4951">3,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTYtMS0xLTEtMA_e71ac941-0cfd-4de9-aff2-f1dc71b5721b">571,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTYtMy0xLTEtMA_3ad8eb9b-e634-44cb-ae35-ccb020f4cfc0">577,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTktMS0xLTEtMA_e4a87a38-a763-493c-87da-0e3e3ea1ef6d">4,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTktMy0xLTEtMA_2b1a310c-ef7b-4a07-8f51-16b6de8e537a">5,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjAtMS0xLTEtMA_56504df1-dd77-4399-9e9d-ad2d203abc37">12,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjAtMy0xLTEtMA_3179af3c-7d71-4d06-abab-4354d57feb06">16,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMA_93c76e98-5e07-47cd-8681-684959c98a3f">51,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtMA_faba9f23-af9a-40a1-8681-f0f00c33ad42">47,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMA_c2a4f2ab-e07d-4cc8-8874-a228dc62e4ec">2,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMA_9ac31a09-0310-4b18-8d46-ffa3279d6ffb">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMTc1Mg_64b96fdc-a4dc-4a11-af33-af22bf4934f1">15,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtODY_447ee5d4-d113-499e-9d74-4e83ac4bebda">14,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related consideration payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:zerodash" name="hcat:BusinessCombinationConsiderationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMzc3Ng_183754e7-e126-4bbc-8a62-dd5bcff30a7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="hcat:BusinessCombinationConsiderationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMzc3Ng_eda0e928-76c1-4314-a439-b53de6ab4a91">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeniorNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMjE2OA_aac87365-2731-4f35-8754-ee32d919c3dc">171,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SeniorNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMjE2OA_a78ac591-5ec8-4a6d-8b19-214f0383dea8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjQtMS0xLTEtMA_ddbdfff4-1b65-4043-b7d2-bc5056e1edd5">259,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjQtMy0xLTEtMA_649ca2a4-1d6c-4c3e-8e1a-10c1a9f9e518">88,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjUtMS0xLTEtMA_e674c900-f1e1-483e-ac47-3233ba6ccc2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjUtMy0xLTEtMA_3396274d-9131-493f-8a58-b2eb5307f53c">168,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjctMS0xLTEtMA_0d9d5b57-2485-4917-ba90-d7c2b3bc10a4">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjctMy0xLTEtMA_7118b3eb-21b8-4fc3-a50f-0f2aef5dee64">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjgtMS0xLTEtMA_9926cd7a-fede-4900-b76b-08c005fe5dcf">23,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjgtMy0xLTEtMA_3f9c757f-9267-4945-8dce-73c1565045b6">23,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjktMS0xLTEtMA_a7602ec0-df4b-4eb6-83ae-8a32bc2d14d6">16,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjktMy0xLTEtMA_99ee6dba-754e-491e-a2c1-bb38cf60b344">16,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzAtMS0xLTEtMA_59d2a691-8f5f-4a26-880c-a51ecea4464e">2,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzAtMy0xLTEtMA_422b939f-439b-44a9-beea-08f75c48d7ae">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzEtMS0xLTEtMA_216c28a0-3b63-40ea-a74b-e9a4a0fbd866">302,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzEtMy0xLTEtMA_9d241295-87eb-46fe-a84d-ffbe4772097c">301,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzMtMS0xLTEtMA_1c4db66f-b2a0-4e25-b21f-94e844138f2f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzMtMy0xLTEtMA_8baa4806-f138-4c64-982c-50fc8b9e6a25"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzIy_e62c20e4-4e1f-479e-b946-7e4a45530765"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzIy_eb83875b-e9c6-4510-895f-5b0701a626ef">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzQ2_28d15594-c717-4e35-bb8a-13c94101b638"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzQ2_6663a610-5c8f-4a30-a0f1-d72adb476b9b">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2021 and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_0c53de0b-4410-4ce2-a71d-8e8dbced1ac3"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_703b8d6f-fe13-4af5-b70a-cf50df56d7ff"><ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_b3c9123c-73b4-4403-a25c-b11ed3d5000f"><ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_fd76fd1e-0587-4e69-8c6f-6c9cedba5961">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMS0xLTEtMA_1fcdca86-f84e-47c6-88df-265f339b81d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMy0xLTEtMA_151fbde0-1dcf-4c81-81e1-700357eef71f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzE5_527f6a7d-9fc4-46a5-92ae-e811ebd5c2ce"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzE5_ae0e041f-9c4a-4e52-a5a7-53366cdb0332">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzQz_0f82f015-13f8-468b-bf4c-81b4aea9df1f"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzQz_40e2c7a0-0210-49d4-8555-38b8ceeef210">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2021 and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzgx_2c16805d-4c13-4af5-bc00-3031390cc85d"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzgx_683b5fcc-3b73-4eed-ad48-e8df788f0f55">44,340,036</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzg4_93723e6e-dd64-4bd6-ad40-ddb8f24a95b4"><ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzg4_b1829130-589b-4fb9-b5af-fc89a650bd35">43,376,848</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMS0xLTEtMA_ed1ed45f-893e-427e-abe7-be7076d6ae64">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMy0xLTEtMA_e1090f6e-46a7-4f92-9162-c0af37a532c7">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzgtMS0xLTEtMA_bb40f879-c333-4f6c-ac17-c556dd4563db">1,022,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzgtMy0xLTEtMA_9c70937a-4875-4bf2-88a0-8a502087b306">1,001,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzktMS0xLTEtMA_38d08591-f99d-434c-bfdb-62c497a994ce">754,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzktMy0xLTEtMA_67b08a80-f18a-4ce6-b87f-f13ba7c1e909">725,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDAtMS0xLTEtMA_51d88a08-7316-426d-b7f0-2133582439f8">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDAtMy0xLTEtMA_4bfbd9f1-7b71-4625-adbd-f6c6c893ddd6">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDEtMS0xLTEtMA_3adb8458-0f06-49d9-81b3-a9fb906a885e">268,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDEtMy0xLTEtMA_b5654968-774e-4a17-a72d-ac14170446ee">276,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDItMS0xLTEtMA_7241fb35-805f-4db0-8b73-e6077517bf4b">571,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDItMy0xLTEtMA_e292e75a-bf88-446d-920f-7a867951d9b2">577,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes amounts attributable to related party transactions. See Note 16 for further details.</ix:footnote></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dfda2f92ed340caa2877a927d22e736_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0xLTEtMS0w_6112616b-0505-4343-83e3-ce6afd1552ae">33,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6bb236a6d7f468880b49898be6fc30a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0zLTEtMS0w_00c50cdd-e9cd-4b76-8678-954a4470c020">24,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0xLTEtMS0w_7250e1a3-5ba0-475a-9ed5-653c3392b0eb">22,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0zLTEtMS0w_09b64410-8c75-432e-ae83-490ea8a3e660">20,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0xLTEtMS0w_955fb2f4-dfae-45bb-a8cd-b520deef26f2">55,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0zLTEtMS0w_4b09ec26-7fc3-4a32-b1cf-74667c274ce0">45,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue, excluding depreciation and amortization:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dfda2f92ed340caa2877a927d22e736_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNy0xLTEtMS0w_19bb15d4-5894-4fbf-9ed2-1cccaf101408">10,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6bb236a6d7f468880b49898be6fc30a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNy0zLTEtMS0w_6acb084a-b960-4f0f-986d-857c858993be">7,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOC0xLTEtMS0w_2dbe6c04-2ed6-4bf0-b455-80e94dc42fd2">16,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOC0zLTEtMS0w_bb4044d1-7018-48d5-bfcc-ab23ca467e01">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue, excluding depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOS0xLTEtMS0w_e547c30c-6b26-4cfa-9601-91b8d6125728">27,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOS0zLTEtMS0w_f96c8382-ef3e-450e-9df1-96f6375980e4">24,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTEtMS0xLTEtMA_aba4019e-9b31-4ae5-8438-a6ffcf827d00">15,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTEtMy0xLTEtMA_56ee9b16-dd2f-47a1-9bd7-64b0a200321e">13,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTItMS0xLTEtMA_ec42e67e-c96b-4379-9e5a-073ce3d1a40b">14,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTItMy0xLTEtMA_48e3f0e5-946a-4c71-a466-8e5c3d3f6efd">13,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTMtMS0xLTEtMA_c428c74a-2406-45e7-bcdb-4b5becd31bc0">15,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTMtMy0xLTEtMA_385f856e-0614-4c5e-9578-ab650ba3248a">9,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTQtMS0xLTEtMA_ecd43f4d-c3ba-4f33-ab1d-8bbf8db77ced">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTQtMy0xLTEtMA_b4126e4f-91b0-4654-bd13-a25fcd1f8273">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTUtMS0xLTEtMA_908af329-850b-4af5-af70-b00039ead566">52,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTUtMy0xLTEtMA_31ba5b2c-4a1a-41d3-a9f8-cd0487b4b4c8">39,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTYtMS0xLTEtMA_a5e93077-61dd-4c3b-8ae6-4e15542cfc2e">24,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTYtMy0xLTEtMA_6e0fa8fb-f312-45e4-afd6-671d18899b9c">18,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:InterestAndOtherExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTgtMS0xLTEtMA_5ec5ac4f-cb09-4697-b897-f59b7f0baa29">3,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="hcat:InterestAndOtherExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTgtMy0xLTEtMA_f3ad7781-ab05-4b71-8d27-8429ffdd16a0">621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTktMS0xLTEtMA_e221707e-22f7-4812-8e2e-396a216a2565">28,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTktMy0xLTEtMA_7e6e5e4b-7099-4e2b-a580-4fca5cb9f1d1">18,726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjAtMS0xLTEtMA_ab9a519a-c3ad-467e-a62c-60a4267d29ec">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjAtMy0xLTEtMA_35493b04-c1e1-4d9f-b879-a143d97e137f">1,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjEtMS0xLTEtMA_75463e45-424b-4c88-a4ae-4de8b9aab4cb">28,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjEtMy0xLTEtMA_160bdefa-e4bf-4788-81b9-b01d1a62084a">17,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMS0xLTEtMA_a870d792-9456-428e-9c57-2ef5e315f1e4"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMS0xLTEtMA_f5a84a91-9521-42a0-af51-ea6ddf0c00e0">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMy0xLTEtMA_9137fca9-972f-45c4-90d9-676a3d5732e0"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMy0xLTEtMA_b09071f6-7392-40e3-a2be-64d34594d665">0.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used in calculating net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMS0xLTEtMA_a61385a8-884f-43cb-bf7b-6bea063929c0"><ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMS0xLTEtMA_fa25db98-d07b-44ec-be63-7f5e4b97fddd">43,870</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMy0xLTEtMA_874147d6-d8d1-4c96-98a1-bd7b3b511e89"><ix:nonFraction unitRef="shares" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMy0xLTEtMA_d038a766-e57e-4517-a882-f5a7bcad54c0">37,109</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes amounts attributable to related party transactions. See Note 16 for further details.</ix:footnote></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfMi0xLTEtMS0w_2db7b7ad-5727-4070-b0a5-2aeb2b8bf90e">28,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfMi0zLTEtMS0w_6cf4cd8a-22ca-4937-8ae7-95c597c67b4d">17,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains (losses) on available for sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNS0xLTEtMS0w_502adfcc-47d7-4397-84a0-317431d770e9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNS0zLTEtMS0w_19654083-ffd6-4658-8f5c-cf89007b7568">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNi0xLTEtMS0w_23280af4-622e-4c02-bf26-a98a96c47b9b">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNi0zLTEtMS0w_7a24df67-fead-4916-a6f5-9ed9a0ef06f6">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNy0xLTEtMS0w_e7159caa-9389-460d-8ede-c6d1370087fc">28,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNy0zLTEtMS0w_91bc5417-461c-412a-a3b5-1d2ec56a6535">17,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xLTEtMS0w_82053c54-afb7-4630-aa07-7bbc8c6bff74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0zLTEtMS0w_498c9211-4974-4a0f-ab0d-0ec5195aa5c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4ed21d069e44040883da517205949ae_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy02LTEtMS0w_0b890daa-1415-45e4-87b9-73487061b39a">43,376,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ed21d069e44040883da517205949ae_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy04LTEtMS0w_28c3afa6-8e3c-4b6f-9145-0651b2d10420">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13411e0950346e18adca59be7a3a6e5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xMC0xLTEtMA_7a2e5eff-e28e-4ad0-bf6b-097ec3ce9f52">1,001,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id239684cf62a40bd84edbe1e1929f0b3_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xMi0xLTEtMA_203e0283-97c6-4cca-bd72-3601ef26f68a">725,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5246542574fd40a6acee46eddd59f600_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xNC0xLTEtMA_f2076191-ae54-4499-8acc-f2ab8a09ef8b">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xNi0xLTEtMA_66956c7e-ad77-4749-b893-4a0b38a2341a">276,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNC02LTEtMS0w_c96428f0-6818-46ce-8f32-2b8cfdc1ed42">403,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS02LTEtMS0w_92ecb139-2f9a-4331-bfda-d8437669c7db">537,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS04LTEtMS0w_0de71b03-028d-4da4-a38c-23ab07e63be0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067e0e6900304a738394616a183db02f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS0xMC0xLTEtMA_281d8fa0-0453-4500-9b29-740957081e8f">6,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS0xNi0xLTEtMA_de3bb6d2-aabb-4ba4-9a22-49981cf88741">6,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067e0e6900304a738394616a183db02f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNi0xMC0xLTEtMA_116bea7a-b466-4963-9694-16a2b9a1b40c">13,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNi0xNi0xLTEtMA_56bd9edb-bc42-4ba9-ba91-9f13e83172b1">13,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNy02LTEtMS0w_555eacea-ea51-4fa5-8176-de6860fcb9d0">21,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067e0e6900304a738394616a183db02f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNy0xMC0xLTEtMA_a491be19-90fe-4b34-a238-375fa82f34a3">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNy0xNi0xLTEtMA_882cd35b-b142-4366-bca2-27bf378f2c85">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0e3333f61a401497d1869d991e2376_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOC0xMi0xLTEtMA_857798b0-1379-4695-89cc-3833311436e8">28,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOC0xNi0xLTEtMA_846b70ed-396b-491d-a61f-35bada95b3bb">28,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b73d6b0c08b416fa95d0ffafd4a69be_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOS0xNC0xLTEtMA_87fb7dde-1474-4807-8413-7fda3599dac0">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOS0xNi0xLTEtMA_d7bb1b8a-12fa-45e9-8d5b-f4b4eb5e0d11">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMS0xLTEtMA_c7736913-7cb6-4259-93e6-44da89d44f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMy0xLTEtMA_6cfa2e0f-61a3-429e-80f6-6ef56b8540b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice27b80f156b4c7c97e4c9714bf0a308_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtNi0xLTEtMA_525b4a74-160d-4c23-98c2-330c6084cf09">44,340,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice27b80f156b4c7c97e4c9714bf0a308_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtOC0xLTEtMA_8a3ad012-37bf-46b9-87c9-9644c2431800">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e366123354486cababd5831e94051e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTAtMS0xLTA_07f77da1-4aba-4296-b1cd-915546d77554">1,022,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i183085abd0424ba1b6749e0788cec760_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTItMS0xLTA_3a8d21ee-e4c4-49dc-88ea-c5ad02009492">754,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2d729e83a74d25a64ee4134008cfca_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTQtMS0xLTA_b92993e6-d417-4673-b26e-b3bbb2342074">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTYtMS0xLTA_d016d4b7-e5cc-4ff0-9ea7-5d8f11fc6715">268,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xLTEtMS0w_ed535a6c-7555-487b-a198-6cea286c7715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0zLTEtMS0w_4a653f5a-c5dd-4c16-a52f-7f43d3d9f5d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ffb26487eb34a6cad9855d641b8a555_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy02LTEtMS0w_5d4d7d5a-1a9d-4ee1-90e2-086059600acf">36,678,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffb26487eb34a6cad9855d641b8a555_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy04LTEtMS0w_044c8944-9b38-4e4b-807f-97c227c824e5">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f406e1ada1b4b7fa1d2e0eb11b7bd16_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xMC0xLTEtMA_971d0af0-6d64-4a90-ae5d-5add89aef96a">811,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32bab634e2c04ca8a0b8272bce5cc112_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xMi0xLTEtMA_1a922072-fd7a-4a8e-96c9-31a75c082a66">610,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1c0fd3c5bb4f7490e1619c30315164_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xNC0xLTEtMA_3cc18227-1f93-4264-8286-04074f2fcaaa">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xNi0xLTEtMA_5b70fb74-d609-4bca-bb73-66b3b314d742">200,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNC0wLTEtMS0w_514a1d19-4d44-47e5-a039-9bdfa2a97ce4">Impact of adopting the current expected credit loss standard</span></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63dae0960a21470cadf5c35381490d80_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNC0xMi0xLTEtMA_d31f9f64-85a0-4f02-aec1-00d7b551278c">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73bfc66cbfc34ae8a0fa31cc621730d7_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNC0xNi0xLTEtMA_e97fc4f3-e9ce-42b2-bd39-29d2a0c49004">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS02LTEtMS0w_e02d2d3f-c7af-4525-9173-e0af0b04a13e">1,048,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS04LTEtMS0w_ceb166cb-59a0-463f-a867-e00335b3f0c1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS0xMC0xLTEtMA_25e9954e-2246-4401-8e56-f1bb9e5eb9ff">9,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS0xNi0xLTEtMA_b5b1b3bd-4658-4f99-8862-24ef5ecbd15d">9,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNi0xMC0xLTEtMA_ed7ec787-6b19-460a-824c-12173b31f089">8,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNi0xNi0xLTEtMA_5eae75ed-a13a-408e-93f1-ce7e4c05e7e9">8,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for acquisition consideration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNy02LTEtMS0w_939e954b-f953-4727-accf-048ab589a251">110,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNy0xMC0xLTEtMA_4b92961f-71ac-4452-bc58-d5ee2909e313">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNy0xNi0xLTEtMA_f92e97ab-31be-4844-bec9-401fda4a54ef">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67e743d83b6e43f6a07eaae2dd2b103a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOC0xMi0xLTEtMA_b1a742c8-998f-4122-a00c-85b705404189">17,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOC0xNi0xLTEtMA_b06f10eb-347b-40ca-b16f-539910f944dc">17,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2ee6ea456694392b6844031fc89de02_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOS0xNC0xLTEtMA_c65a2936-32a3-4684-b633-73f221bfcd59">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOS0xNi0xLTEtMA_00fc5fb8-6ae3-4f4a-acc0-f0423ba92a5f">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c0efcef22664d14815854888bb21e26_I20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMS0xLTEtMA_cf4de4fe-abe7-4720-8595-ef3a935924ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0efcef22664d14815854888bb21e26_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMy0xLTEtMA_d4ea54f9-50f5-4eea-8ba7-d0251af81afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i386ccc1569bb40d885c8301f5452d4c9_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtNi0xLTEtMA_9968e8ea-3b20-40de-9c00-123514a0c814">37,838,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386ccc1569bb40d885c8301f5452d4c9_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtOC0xLTEtMA_bb90fd41-7a0a-4af9-bc1a-6e1c949d4805">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c0cec055bcd4b89865d64d93fd1adbc_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTAtMS0xLTA_464f1d6b-583d-4796-bf96-b08f52cb494a">832,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i963ff9fa8e4f417285df70d02db0ce49_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTItMS0xLTA_d4d2c02e-84d7-46f1-a672-cb7c134ab475">628,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a78b3ee92264aa6b424fb238b67d7f4_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTQtMS0xLTA_9e56a297-9165-4062-90df-fcb58e7bc485">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0efcef22664d14815854888bb21e26_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTYtMS0xLTA_226c2363-4c25-4f8d-a74c-70e32efd85dd">204,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMy0xLTEtMS0w_6452b4a2-2f3f-43f5-9885-d5def4dd7f09">28,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMy0zLTEtMS0w_fce9cdde-c55f-49c8-9590-4ec4dc9315e1">17,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNS0xLTEtMS0w_c6fd2ce8-8a9e-482d-8770-c99de24b397c">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNS0zLTEtMS0w_23fb42cd-68a3-4d10-84db-5543ca40c8ca">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNy0xLTEtMS0w_99b9eee7-9332-44e1-9025-d182d92ba53e">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNy0zLTEtMS0w_79668bec-a03c-4504-9ac6-a09650c33b23">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" name="hcat:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0xLTEtMS0xNTg4_78e68d3c-d3ff-446a-b6ec-39a81c45c9ee">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="hcat:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0zLTEtMS0xNTg4_7fdfdb9e-57fe-4a79-bebf-82ec91980fdb">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment discount and premium amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0xLTEtMS0w_6cee2d9a-9704-47c1-a015-0242b737fbb8">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0zLTEtMS0w_1c85160f-97f7-45fc-8014-649093d1f18d">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForLoanLossesExpensed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMS0xLTEtMjI1OA_8f60c815-2313-4a50-88ea-16fbb42b30a7">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:ProvisionForLoanLossesExpensed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMy0xLTEtMjI1OA_0f447f07-fd20-4e53-84bb-266db1759239">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMS0xLTEtMA_798ed17e-1f44-4ca4-ad63-a72e7663eeb8">13,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMy0xLTEtMA_79c70004-add4-43d3-a0e1-016a4c71affe">8,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTEtMS0xLTEtMA_873e6f57-564a-4156-9f34-12d0cc7b4e58">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTEtMy0xLTEtMA_52ceb64f-a484-4811-9a90-ab87aa3266a9">1,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTItMS0xLTEtMA_2f293806-f534-4666-b7c3-46219c31591c">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTItMy0xLTEtMA_fc0f54c9-9f42-4c66-88d4-5173c0d8c48b">359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTMtMS0xLTEtMA_db47c74d-df3d-4325-a2a4-3da9375142f1">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTMtMy0xLTEtMA_20b43872-e35c-4995-b5a2-e6b2dd7d8750">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTUtMS0xLTEtMA_94d24fc9-36bf-415b-84c4-5f65cd2b4810">2,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTUtMy0xLTEtMA_26176dba-0767-40f6-b4cc-e75f52bdda7c">7,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTYtMS0xLTEtMA_1d537614-44fb-46ee-b029-cce1f9e9f50b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTYtMy0xLTEtMA_f0abb830-6da6-46d4-bac2-aa4cba78cc3a">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTctMS0xLTEtMA_b89fd568-2d0d-4c39-8882-d7e36e90f183">2,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTctMy0xLTEtMA_c0e842e4-fff6-4c04-b2e6-f29aed79302e">2,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities, and other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="hcat:IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTktMS0xLTEtMA_3194299c-3bac-4c2d-a38d-18f18cd73a6a">5,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="hcat:IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTktMy0xLTEtMA_a52ba284-b2c0-4cbe-891f-8948879333c0">4,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjAtMS0xLTEtMA_71994f0e-7887-4166-94eb-e2132903408e">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjAtMy0xLTEtMA_8c96700b-5067-4db6-8284-52a85660399d">3,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="hcat:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjEtMS0xLTEtMA_4a310056-b48d-40d8-aaa4-a72c689f2919">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="hcat:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjEtMy0xLTEtMA_91bf07cd-b956-49d7-8795-d0b7b91ea6c7">843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjItMS0xLTEtMA_223f45d6-3dce-441b-b1a1-020021f3acd5">3,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjItMy0xLTEtMA_d42b3ae0-8049-453f-b2d5-422aba72c9f8">16,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjUtMS0xLTEtMA_0350d5a5-7ca9-48af-843f-d2311534db0f">5,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjUtMy0xLTEtMA_abb208d0-5358-4afd-97a1-937ee06d3107">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of internal-use software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="hcat:CapitalizedOfInternalUseSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMS0xLTEtMjI0MQ_97fc9370-93a2-4aa5-8533-39243275b017">887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="hcat:CapitalizedOfInternalUseSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMy0xLTEtMjI0MQ_036f2a87-fbed-4aad-8d14-3e262032039c">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMS0xLTEtMA_b5c3aacd-2ac8-47ce-98cf-289f2efd0f03">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMy0xLTEtMA_3c1d2deb-106b-41af-9c4a-bbb7a1380cd0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjctMS0xLTEtMA_9e1e7abd-3276-4b71-a151-dd87a59d4e4d">8,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjctMy0xLTEtMA_6bc1a163-d4de-4929-8eb4-bb30964b5976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale and maturity of short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjgtMS0xLTEtMA_100376dc-09b4-4cd0-aacf-a5f03e329448">53,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjgtMy0xLTEtMA_ffecd9e6-6d21-4807-8d7a-053a118055b4">66,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjktMS0xLTEtMA_29ecb259-1cc0-4ad7-a786-066e81d54373">480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjktMy0xLTEtMA_52b6b083-e71a-4059-a1d3-9d2f2a59f480">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzAtMS0xLTEtMA_d98e0a25-6c7e-4320-826c-9d8ef5b38a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzAtMy0xLTEtMA_f3c422d8-68af-4ca2-b048-963a3db72bc5">15,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzEtMS0xLTEtMA_91b84633-6cc7-4b0e-a0e0-9894eb7d7c52">37,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzEtMy0xLTEtMA_768ca4e6-983e-499b-810a-bad3651b27be">50,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzUtMS0xLTEtMA_9eda1283-ee75-4894-82fd-8f51e0572ff3">6,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzUtMy0xLTEtMA_6ba2449f-3d61-4c8e-8489-10eb8164ecbb">9,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzYtMS0xLTEtMA_4a41894c-68d6-44ce-8841-d36ff00f49ef">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzYtMy0xLTEtMA_86b88d78-4435-4b7f-90b3-d30e393c9084">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of acquisition-related consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzktMS0xLTEtMA_6a877569-265f-4f49-ae4e-eb6419b592bd">1,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzktMy0xLTEtMA_8fa7bde7-6f65-4a3c-baa8-2d5cfbade2db">748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDEtMS0xLTEtMA_7f07f1be-e93b-45ff-9b2f-9fd49bbeaa79">6,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDEtMy0xLTEtMA_d853c1bf-3e7b-401a-9131-b54fdf144fe1">9,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDItMS0xLTEtMA_1ff92bbd-cabf-4064-939a-e5a5a4d09e49">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDItMy0xLTEtMA_a0c9c990-49de-4fa8-8190-55183017c63b">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDMtMS0xLTEtMA_38e77bcb-0eb7-4ce6-b18c-086561776937">40,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDMtMy0xLTEtMA_c18220c8-2666-4311-b82f-86921b00895e">42,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDUtMS0xLTEtMA_26718ec6-c744-4f31-8b6f-2e97a72824d2">91,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDUtMy0xLTEtMA_58fa4b92-25f8-4582-af8a-ce5a56c2d97a">18,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDYtMS0xLTEtMA_66076a58-83df-4280-9ed6-492224842794">132,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0efcef22664d14815854888bb21e26_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDYtMy0xLTEtMA_a2730c16-51c7-4176-b543-b965c8030d3b">60,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMS0xLTEtMjI3Mw_5bfd2e9e-c780-4ba1-9a1f-f722bec2b3c5">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMy0xLTEtMjI3Mw_6d320f64-dc12-4319-84fd-ed4c9758a1a1">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued for settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMS0xLTEtMA_524bf377-83e2-416d-af35-3fd234dd1d53">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMy0xLTEtMA_48829510-5893-4205-8461-a7b0719b9e17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in connection with acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMS0xLTEtMjI4OA_6c78ed95-3194-40fd-b321-5802aba58b80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMy0xLTEtMjI4OA_ffbabae2-f633-43a3-b2bd-f66a2630cfe9">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized as internal-use software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTItMS0xLTEtMjI5NQ_710c5532-1d36-4903-ac06-2628cfcdfa6b">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTItMy0xLTEtMjI5NQ_e083eec2-f6d0-4b00-b518-9f14d13d5807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs included in accounts payable and accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="hcat:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTAtMS0xLTEtMA_8cd94bad-3cf4-4b3c-8ae3-b56ce0768f84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="hcat:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTAtMy0xLTEtMA_15878176-9b61-4935-9590-82a1b2264fcc">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of intangible assets included in accounts payable and accrued liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMS0xLTEtMA_fdfad0e9-2618-4796-b448-22c7d66f8ca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMy0xLTEtMA_80d70535-4e8e-4ae6-ad66-a8f92b50fe67">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_37"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODY_a5574a09-cf4f-4e09-8185-2946201013ab" continuedAt="i793b56d6c2b14fd0a22099aac929186b" escape="true">Description of Business and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i793b56d6c2b14fd0a22099aac929186b" continuedAt="i6c8edd57f2964be5bd0ae848be0c39ff"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of operations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Catalyst, Inc. (Health Catalyst) was incorporated under the laws of Delaware in September 2011. We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Our customers, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDI_c0886998-c48a-451b-85d6-2e20d529c089" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDM5ODA0NjU2ODM1Nw_20a2a629-f35e-4094-99d5-cf45bc5f3d27" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts on the condensed consolidated statements of cash flows have been reclassified to conform to the current year presentation. A reclassification was made to separately present the non-cash operating lease expense as a non-cash reconciling adjustment from net loss and the change in the operating lease liabilities due to cash payments as a change in operating assets and liabilities. This net change is not material and does not affect previously reported net cash used in operating activities in the condensed consolidated statements of cash flows. This reclassification had no effect on our other condensed consolidated financial statements for the three months ended March&#160;31, 2021 and 2020.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim Unaudited Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accompanying interim condensed consolidated balance sheet as of&#160;March&#160;31, 2021, the interim condensed consolidated statements of operations for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020, our interim condensed consolidated statements of stockholders' equity for the&#160;three months ended March&#160;31, 2021 and 2020, and our interim condensed consolidated statements of cash flows for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020&#160;are unaudited. Our condensed consolidated balance sheet as of&#160;December&#160;31, 2020&#160;was derived from audited financial statements, but does not include all disclosures required by GAAP. Our interim unaudited condensed consolidated financial statements have been prepared on a basis consistent with our annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company's financial position, its operations and cash flows for the periods presented. The historical results are not necessarily indicative of future results, and the results of operations for the&#160;three months ended March&#160;31, 2021&#160;are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTM_e72efbc0-05fb-47fa-b2b9-10acde7223ba" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i6c8edd57f2964be5bd0ae848be0c39ff" continuedAt="i0fb34af08bc04c56a06d3b385f8bcdcd"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTA_25b78627-8157-4fd7-b8be-22caa0430bb1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODc_b4cfbde9-39d3-420d-bfe2-eb4da28a5103" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (the CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in <ix:nonFraction unitRef="segment" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDg3MQ_ad21cd3d-26ce-4d4e-86b1-1555162000da"><ix:nonFraction unitRef="segment" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDg3MQ_fdb6f94d-5bdc-4501-ab80-92dcf0755994">two</ix:nonFraction></ix:nonFraction> operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODI_06660096-5dab-43f1-b9dc-67f510525e73" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as the effect is antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTc_965cbeeb-acd5-484a-b598-531b175bf7ea" continuedAt="id41459606ca84d53bf2738c26df708bd" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We derive our revenues primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, we satisfy the performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue net of any taxes collected from customers and subsequently remitted to governmental authorities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology revenue primarily consists of subscription fees charged to customers for access to use our technology. We provide customers access to our technology through either an all-access or limited-access, modular subscription. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i0fb34af08bc04c56a06d3b385f8bcdcd" continuedAt="i06ac8f6b3203409bb155b4e9d5713171"><ix:continuation id="id41459606ca84d53bf2738c26df708bd" continuedAt="i90f0c2bb35cc446dbf03b81d99344933"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our subscription arrangements are cloud-based and do not provide customers the right to take possession of the technology or contain a significant penalty if the customer were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the customer. Most of our subscription contracts have up to a <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:durwordsen" name="hcat:RevenueFromSubscriptionContractTermofContract" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEyNw_2c4f1630-afec-48d2-a6e7-17a06a0ada91">three-year</ix:nonNumeric> term, of which the vast majority are terminable after <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:durwordsen" name="hcat:RevenueFromSubscriptionsContractAllowedTerminationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEwNQ_7ec520c6-13a5-47b8-a131-f15590743bc5">one year</ix:nonNumeric> upon <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:durday" name="hcat:RevenueFromSubscriptionsContractNoticeRequiredForTermination" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEyMA_318d5004-cf0d-4808-8548-a16ff98b66ae">90</ix:nonNumeric> days&#8217; notice.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriptions that allow the customer to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the customer. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have certain perpetual license arrangements. Revenue from these arrangements is recognized at a point in time upon delivery of the software. Technology revenue also includes maintenance and support revenue which generally includes bug fixes, updates, and support services. Revenue related to maintenance and support is recognized over the contract term beginning on the date that the service is made available to the customer.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services revenue primarily includes data and analytics services, domain expertise services, outsourcing services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our customers on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our customer. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the &#8220;right to invoice&#8221; practical expedient. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include customer demographics and the types of users. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we use the residual estimation method due to a limited number of standalone transactions and/or prices that are highly variable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable consideration</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into at-risk and shared savings arrangements with certain customers whereby we receive variable consideration based on the achievement of measurable improvements which may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i06ac8f6b3203409bb155b4e9d5713171" continuedAt="i92eec774d92f4433a1f4e21ce374965f"><ix:continuation id="i90f0c2bb35cc446dbf03b81d99344933"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets resulting from services performed prior to invoicing customers are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of March&#160;31, 2021 and December&#160;31, 2020, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI1NDA_a5d956e1-635a-4288-8cb2-92025e30c49c">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI1NDc_331938cc-8004-4e5c-a7ab-11da2836aab3">1.6</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the customer. As of March&#160;31, 2021 and December&#160;31, 2020, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI4OTU_7b67c3d4-60b1-41aa-8b70-725f3abb07fe">52.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI5MDI_dde3fd94-81da-4ef9-a05d-9c8ae6399665">49.0</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize sales commissions and associated fringe costs, such as payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with customers, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the customer contract. As of March&#160;31, 2021 and December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTc2NA_431bbfef-d4bb-476b-8e36-d8e062d48ab0">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNjA0NzMxNDAxMjIyNw_43d56344-46ae-429e-b04f-8010c24ce5b9">0.5</ix:nonFraction> million, respectively, of deferred contract acquisition costs are expected to be amortized within the next <ix:nonNumeric contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" format="ixt-sec:durmonth" name="us-gaap:CapitalizedContractCostAmortizationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDM5ODA0NjU2ODM2OA_61ec3e26-d15b-45c8-80af-630fbaa1587e">12</ix:nonNumeric> months and were included in prepaid expenses and other assets on the consolidated balance sheets. As of March&#160;31, 2021 and December&#160;31, 2020, the remaining $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTgwNQ_de35a621-f6a5-4722-ad01-500c92ee0bfd">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNjA0NzMxNDAxMjMzMA_ba6fb3c5-d773-4a48-b1ed-b753c55028f3">1.4</ix:nonFraction> million, respectively, of deferred contract acquisition costs were included in non-current other assets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:durwordsen" name="hcat:CommissionPaymentEstimatedBenefitPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEyOA_dcd18ec0-a491-4594-ad01-5589fb15d378">four years</ix:nonNumeric>. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average customer life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average customer life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs is included within sales and marketing expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. As of March&#160;31, 2021 and December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTg0MQ_0046d832-d251-4272-9309-06f464fdc7e7">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTgzMw_d5ef1842-4f96-4dba-9eba-58e99f03545a">0.5</ix:nonFraction>&#160;million, respectively, of deferred fulfillment costs were included in prepaid expenses and other assets on the condensed consolidated balance sheets. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of revenue, excluding depreciation and amortization</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue excludes costs related to depreciation and amortization.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i92eec774d92f4433a1f4e21ce374965f" continuedAt="i2cb68948432c40cd98747b06d53b271a"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTQ_f7f5c4f2-a67c-4a41-b2e3-b914ddd56ee1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">cash equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDY_d9d0bd3e-01b4-4f1f-9c1c-e105d07b65ba" continuedAt="i75a3547d6a344784b9aca86c601000d7" escape="true">Short-term investments</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75a3547d6a344784b9aca86c601000d7">Our investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTg_a0c205ba-0fb1-4abc-a684-3ea7ce6756f4" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, the establishment of specific reserves for customers in an adverse financial condition, and our expectations of changes in macro-economic conditions, including the current COVID-19 pandemic, that may impact the collectability of outstanding receivables. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDM5ODA0NjU2ODM2MA_f466b63b-4b74-417a-9c5a-6bf12f2eb82e" continuedAt="i64437b822175459db0270a828372a909" escape="true">We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="i64437b822175459db0270a828372a909"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses on Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfMS0xLTEtMS0yMTY_bbf09629-b407-4ad4-a49e-f2ba1899538d">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfMi0xLTEtMS0yMjA_615f39a8-f268-461f-9709-183017f238f2">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Write-offs, net of recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfMy0xLTEtMS0yMjA_8865d27c-bb3d-4e3a-a943-0339c868b8a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfNC0xLTEtMS0yMTY_9f8e9629-50ef-4a6e-9fa3-c80de458a225">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDc_dbe202fd-1a41-4745-a03c-c1476681650b" continuedAt="i020092a4097146ed9059817dbbfa5d2e" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTU_4242d26d-a57c-476e-bd8f-87aa8e7ea69f" continuedAt="ieed4cc6f0b9546d49a6285c1ea493479" escape="true">The estimated useful life of each asset category is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="ieed4cc6f0b9546d49a6285c1ea493479" continuedAt="iaac51503c4a042578773ad335d549736"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0b1145c0be2f4abd984b071985b91ff7_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMC0xLTEtMS0wL3RleHRyZWdpb246ZTY5OTc2NzBhMjRmNDQxZWE2ODJhNGE5ODkxODA2NzNfNA_68500de2-682b-4a41-b3d2-efb7ef05835c">2</ix:nonNumeric>-<ix:nonNumeric contextRef="i570b1a58613c45b78737719cc3a0796e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMC0xLTEtMS0wL3RleHRyZWdpb246ZTY5OTc2NzBhMjRmNDQxZWE2ODJhNGE5ODkxODA2NzNfNw_a26e9e95-583d-4580-9888-14f93cde0093">3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8806568ffc14910a88f456175540071_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMS0xLTEtMS0w_11c46ca4-db9f-4d07-bc8b-5e66f28dcbde">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib98e1d9087f64f35abf0c9c0b35b25ed_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMy0xLTEtMS0wL3RleHRyZWdpb246MmQyZDEwNjk5ZWM3NDNmYWJmNzVjMTA5YTA4ZjNkNmZfNA_1b4d62a6-0f2c-4100-a530-7f52b2bbc3fb">2</ix:nonNumeric>-<ix:nonNumeric contextRef="ia2eb546857cc494fa9f8c061084c10cc_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMy0xLTEtMS0wL3RleHRyZWdpb246MmQyZDEwNjk5ZWM3NDNmYWJmNzVjMTA5YTA4ZjNkNmZfNw_5ac198dc-e934-4233-a1cf-0197ab3fbaa6">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7625b67853714c90870b7c5404d9bcbb_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfNC0xLTEtMS0wL3RleHRyZWdpb246ZjZjNjM5NjRlYTUwNDkzYjg1ZTI5ODkwOTM2OThlMDdfNjA0NzMxMzk1Mjc4Mg_fba784c7-f5ce-45c5-acfe-c398c88fba5d">2</ix:nonNumeric>-<ix:nonNumeric contextRef="ic1895ebcf2194a20ae75e64ba8b210ad_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfNC0xLTEtMS0wL3RleHRyZWdpb246ZjZjNjM5NjRlYTUwNDkzYjg1ZTI5ODkwOTM2OThlMDdfNjA0NzMxMzk1Mjc4Ng_c63db072-4a70-4ae3-93f8-fbecd4931b37">3</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i020092a4097146ed9059817dbbfa5d2e">When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset in the asset group. If the carrying amount of the asset group exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets.</ix:continuation> We did <ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTY1MDI_12f38767-6abe-4169-b700-ac037765a5b1"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTY1MDI_4b566f9c-c5d9-406c-8876-3545cb2d3c9f">no</ix:nonFraction></ix:nonFraction>t incur any long-lived impairment charges for the three months ended March&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i2cb68948432c40cd98747b06d53b271a" continuedAt="i3c6559f042254e12a7d504618d839b7a"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDQ_1d98623a-f937-4e2b-9215-5f7967dd86ca" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technologies, customer relationships, customer contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets&#8217; estimated useful lives. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTk_e8700d29-0230-49bd-912b-1a007a1574ea" continuedAt="i26fbfc4b79c54c01b4de52b51b112548" escape="true">The estimated useful life of each asset category is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify"><ix:continuation id="i26fbfc4b79c54c01b4de52b51b112548" continuedAt="i2ccafaa1a0774d209106f34ceff38387"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c6b011b06cd4b56805334a4b840ea06_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMC0xLTEtMS0wL3RleHRyZWdpb246ZDM3OTQyNzFjOTEzNGY0NzlhYjRmZjNmNDlkNTcyMWVfNA_901d1d76-4b6d-4066-9f67-183307c88c76">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ib11cd2ccbecf4ec4889f63e8c0bdbfe6_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMC0xLTEtMS0wL3RleHRyZWdpb246ZDM3OTQyNzFjOTEzNGY0NzlhYjRmZjNmNDlkNTcyMWVfNw_0639091f-a7c4-4076-80e7-559cda70d819">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23793db4aa3a4118a87890e37cc5f76a_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMS0xLTEtMS0wL3RleHRyZWdpb246MmU1OGMyYmFjZmFhNDc5ZjljZjQ2NzkwZjhlMDBiYzVfMTA5OTUxMTYyNzc4Mw_88dd8f42-02ac-42dd-9755-082682f8f10e">2</ix:nonNumeric>-<ix:nonNumeric contextRef="i5eec362ff8b44eebbb405af5d1e31e89_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMS0xLTEtMS0wL3RleHRyZWdpb246MmU1OGMyYmFjZmFhNDc5ZjljZjQ2NzkwZjhlMDBiYzVfMTA5OTUxMTYyNzc5Mg_b3f85cbd-56f5-4a98-b546-c983cab3889c">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa2ec48709a149158db346873042cfa2_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMi0xLTEtMS0wL3RleHRyZWdpb246ZGEwZTM3NjVmZGMwNDI2OTg0Yjk2NDZlNTY2ZmExZGJfNA_06f7fa71-9729-4f98-a2bf-f973de512fa4">2</ix:nonNumeric>-<ix:nonNumeric contextRef="i3d455966ff3546f28112a01f67004be8_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMi0xLTEtMS0wL3RleHRyZWdpb246ZGEwZTM3NjVmZGMwNDI2OTg0Yjk2NDZlNTY2ZmExZGJfNw_3d812076-3a9e-456b-a5a9-a0d6e207d92c">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19090821c190424ca2b60933a320196d_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMy0xLTEtMS0wL3RleHRyZWdpb246ZjM5OGNmZWEwMGRmNGQwZTgwZjk4MmE1YzgyNTU3NTJfMTA5OTUxMTYyNzc4Ng_99d3372a-572f-4353-92bf-d594585be4a4">2</ix:nonNumeric>-<ix:nonNumeric contextRef="i752e657a7ed54158a466343124496aef_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMy0xLTEtMS0wL3RleHRyZWdpb246ZjM5OGNmZWEwMGRmNGQwZTgwZjk4MmE1YzgyNTU3NTJfMTA5OTUxMTYyNzc5MA_fb7f700d-aa98-4b79-87b3-5d2903fcf857">5</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODE_3127c281-5a73-4bbb-9e6e-2fee698c4e21" continuedAt="icb0ca9af904a452ebf914d329cf6af16" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, customer relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually or more frequently if indicators of impairment are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present or circumstances suggest that impairment may exist. </span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb0ca9af904a452ebf914d329cf6af16">Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTgwMTc_1ee0afa8-4bca-419f-9e34-0b148e2fcdac"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTgwMTc_fe0f71a9-4f7a-458f-8970-a183c84db58c">no</ix:nonFraction></ix:nonFraction> impairment of goodwill for the three months ended March&#160;31, 2021 and 2020.&#160;</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDU_591c56f5-6e22-4654-b33c-4b17b8bb5333" continuedAt="i9d6cd1a1f37d41b39a4f7905e6465d37" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the customer-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for customer relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of assets acquired and liabilities assumed in a business combination.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i3c6559f042254e12a7d504618d839b7a" continuedAt="ia781c9bede7846fb8ab0b2495d6e9b64"><ix:continuation id="i9d6cd1a1f37d41b39a4f7905e6465d37" continuedAt="ide46cbdb8ab94769bc69dc6803f75173"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2020, we expensed $<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNjA0NzMxNDAxODE2Ng_2a44a045-377f-40b4-aa82-9c797ea5aae9">0.9</ix:nonFraction> million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our consolidated statements of operations. No such costs were incurred or recorded for the three months ended March&#160;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent consideration liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements. We value the expected contingent consideration and the corresponding liabilities using a probability model such as the Monte Carlo method based on estimates of potential pay-out scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ide46cbdb8ab94769bc69dc6803f75173">The portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes to the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations.</ix:continuation> </span></div><div style="margin-bottom:12pt"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTI_94b243d4-0e24-4143-816f-75e883bfafb3" continuedAt="ic1bd50f3872e48a98b5ef3812bb8f638" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">costs</span></ix:nonNumeric></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1bd50f3872e48a98b5ef3812bb8f638">All advertising costs are expensed as incurred.</ix:continuation> We recorded advertising costs of&#160;$<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTg0OTA_05728347-b8ba-423d-8ae5-94340ff4b412">0.4</ix:nonFraction> million&#160;and&#160;$<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTg0OTc_fab4fb24-0c2b-4fea-802a-37801927f5e7">0.6</ix:nonFraction> million&#160;for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020, respectively.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDA_637e1a8c-6572-420e-a8a5-2dd7201d2166" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development costs and internal-use software</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our customers on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTY_6b7760f2-8bce-4ceb-8773-b79c5d9856f7" continuedAt="i957ccf6f97554cabadb278ce642530db" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="ia781c9bede7846fb8ab0b2495d6e9b64" continuedAt="ib40c7b71e7524d90ad22489fe9a2617c"><ix:continuation id="i957ccf6f97554cabadb278ce642530db"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. Our standard stock-based awards vest solely on a service-based condition. &#160;For these awards, we recognize stock-based compensation expense on a straight-line basis over the vesting period. Awards that contain both service-based and performance conditions are recognized using the accelerated attribution method once the performance condition is probable of occurring. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.</span></div></ix:continuation><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDE_a1ee936b-5037-4959-b9d0-55d9d6895531" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because we have NOLs. Significant judgment is required to evaluate uncertain tax positions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODg_060ae7d8-d6e1-46e1-9fec-f901b75baa45" continuedAt="ia64008539d864fd4861e3a94fba9669c" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of acquisition-related consideration payable and operating lease liabilities approximate fair value based on interest rates available for debt with similar terms at March&#160;31, 2021 and December&#160;31, 2020. Money market funds and short-term investments are measured at fair value on a recurring basis. Our contingent consideration liabilities are measured at fair value on a recurring basis based primarily on significant inputs not observable in the market.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="ib40c7b71e7524d90ad22489fe9a2617c" continuedAt="i4f7553da60f9490aa921a44c99ba74c1"><ix:continuation id="ia64008539d864fd4861e3a94fba9669c"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1- Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3- Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios.</span></div></ix:continuation><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODU_de387dd5-d569-48d6-8121-0a22ec54be5e" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease contracts do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We do not have lease agreements that contain non-lease components, which generally would be accounted for separately.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of our international subsidiaries is generally their local currency. We translate these subsidiaries&#8217; financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholders&#8217; equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i4f7553da60f9490aa921a44c99ba74c1"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODk_d9053f99-adc5-4ec8-a868-a759881cfdc7" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting pronouncements adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for income taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We adopted ASU 2019-12 as of January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for convertible instruments</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting For Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The new standard also simplifies the diluted net income per share calculation in certain areas and is effective for annual and interim periods beginning after December 15, 2021. We are currently evaluating the impact this standard will have on our consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNDEwMw_6239a9dc-f43d-4236-a657-1be5403fcb6a" continuedAt="i1b86f06f437543678228fe11e1b85aa8" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="i1b86f06f437543678228fe11e1b85aa8" continuedAt="i75fcc895b9a14e50ac5b24b9f30916a4"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business acquisitions discussed below are included in our results of operations from their respective dates of acquisition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Able Health, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, we acquired Able Health, Inc. (Able Health)</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a leading software-as-a-service provider of quality and regulatory measurement tracking and reporting to healthcare providers and risk-bearing entities, in a transaction accounted for as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business combination</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The acquisition consideration transferred was  $<ix:nonFraction unitRef="usd" contextRef="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzQw_1ab4bd79-b7f3-4f7f-8d7e-4f3a544fcac5">21.5</ix:nonFraction> million and was comprised of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzkw_16df6e65-3e21-4616-9358-c61665e831eb">15.2</ix:nonFraction> million, Health Catalyst common shares with a fair value of $<ix:nonFraction unitRef="usd" contextRef="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNDQ1_f2806c90-c354-4738-bfd5-e15a2775fb7d">3.3</ix:nonFraction> million, and contingent consideration based on achievement of Able Health specified incremental customer billings for the year ending December 31, 2020, with an initial fair value of $<ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNjIz_565c4f15-e8e8-4150-afad-2c713da16aee">3.0</ix:nonFraction> million. The acquisition consideration is subject to certain working capital escrow adjustments. The purchase resulted in Health Catalyst acquiring <ix:nonFraction unitRef="number" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNzY2_3d025b54-380d-45e4-8f82-9881e12cbf3c">100</ix:nonFraction>% ownership in Able Health.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional <ix:nonFraction unitRef="shares" contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221" decimals="INF" format="ixt:numdotdecimal" name="hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfOTE3_e8ae07a1-db0f-4399-a0a0-9b7adbf58fe6">179,392</ix:nonFraction> shares of our common stock subject to restriction agreements, or restricted shares, were issued pursuant to the terms of the acquisition agreement and <ix:nonFraction unitRef="shares" contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA3MQ_591e6356-8993-46d1-b136-4b86fb2ac557">60,000</ix:nonFraction> restricted stock units were issued in connection with the acquisition agreement. The value of these restricted shares and restricted stock units is recognized as post-combination stock-based compensation expense over their respective vesting terms. The vesting of the restricted shares was subject to <ix:nonNumeric contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDU3NA_ee80d7e3-1228-4fcd-952f-7d4438587ab0">one year</ix:nonNumeric> of continuous service by the applicable team members and fully vested on the <ix:nonNumeric contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDYwMQ_f7da5cf8-38c5-4b5a-aa66-2713e3537781">one-year</ix:nonNumeric> anniversary of the acquisition closing date. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he service-based condition for the restricted stock units issued pursuant to the terms of the acquisition agreement is satisfied over&#160;<ix:nonNumeric contextRef="ib3a602fe1da24b898d87f5aa96f55e7e_D20200221-20200221" format="ixt-sec:durwordsen" name="hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTY1NQ_083239fe-581a-4464-b269-9962b5679259">two years</ix:nonNumeric> with a <ix:nonFraction unitRef="number" contextRef="ie9a6f3c1d5434096a8602552e27ccd8b_D20200221-20200221" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTY2NQ_a5a4ef34-a92c-4684-87f2-6a49c1107192">50</ix:nonFraction>% cliff vesting period of <ix:nonNumeric contextRef="ie9a6f3c1d5434096a8602552e27ccd8b_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTY5Mg_46946ac8-4787-47c6-bbf3-cef7bc3c0904">one year</ix:nonNumeric> and ratable quarterly vesting thereafter.</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 12 for additional details related to our stock-based compensation.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNDEwNA_dae21645-e943-4432-9fa8-30d4ef763e00" continuedAt="ied4c6581d4ae456883f2c16c71bef873" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Able Health (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMS0xLTEtMS0w_6399de63-cc43-4325-812b-2f69c9bf75ef">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMi0xLTEtMS0w_0d55e2f1-3507-4623-90a5-27d72af58c61">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d21b8b985b74d238f472e4e71050a30_I20200221" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMy0xLTEtMS0w_a356a19a-e5fa-4fd7-be89-e0fbfb872fb3">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7ca50433dfa41afaba5f4dbfd9c4080_I20200221" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfNC0xLTEtMS0w_0ee0975c-9e77-4770-af3a-7b3d0ac066ca">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7f7a67b58b4ab7b21087c875b742aa_I20200221" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfNS0xLTEtMS0w_bf864931-b06d-4d94-9516-3cdb49a23ea3">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfNi0xLTEtMS0w_f81d989d-a7cb-480a-9b26-414023825d48">8,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" name="hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfOC0xLTEtMS0w_02f244f5-776a-4c79-a702-9b2fb7f43afe">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfOS0xLTEtMS0w_81278f7b-2728-4745-b4b9-d28912ab37a0">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTAtMS0xLTEtMA_1a45cffd-d5cc-4155-adeb-4bcf8787ccf8">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTEtMS0xLTEtMA_57a41169-3bcc-4a22-b625-35d466210e24">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTItMS0xLTEtMA_8cdb93f2-25d0-48b6-bf2b-9ef9ed35e0e8">6,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTMtMS0xLTEtMA_77a62e45-8579-47be-bea6-39b019d9dbe0">14,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTQtMS0xLTEtMA_c1dc0b82-73a2-4263-9de4-5488261ce886">21,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include customer relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="i6d0acf0e57514eba9c3147edf4b9b2f3_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzE0Nw_6b692048-50a6-433f-a60a-8a2f16f71fdb">six years</ix:nonNumeric>, <ix:nonNumeric contextRef="if9289e7751f54283a46cb7fb7436a914_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzE1MQ_4929d34c-3025-46c1-93f4-0e5141748b57">three years</ix:nonNumeric>, and <ix:nonNumeric contextRef="ie6bea69d2c8a4cbdb35a5f22ae1b2948_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzE1OQ_22fa7061-3e00-4398-8cfc-cd0dd0f3832c">two years</ix:nonNumeric>, respectively. The resulting goodwill from the Able Health acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i75fcc895b9a14e50ac5b24b9f30916a4" continuedAt="ic553c172fad14ac78f6da19570b149f0"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthfinch, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2020, we acquired Healthfinch, Inc. (Healthfinch), which provides a workflow integration engine delivering insights and analytics into electronic medical record (EMR) workflows to automate physicians&#8217; ability to close patient care gaps in real-time, in a transaction accounted for as a business combination.  We believe this acquisition will strengthen our existing population health capabilities. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition consideration transferred was $<ix:nonFraction unitRef="usd" contextRef="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDMyMg_bc823be4-cbc3-4ec9-8099-df25dba72cc5">50.5</ix:nonFraction> million and was comprised of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net cash consideration of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDMzOQ_c6400299-fea7-4e3b-8710-260a84da03a4">16.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Health Catalyst common shares with a fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDM1NQ_3b9e731f-71ad-43ce-abb3-1187b6d541f9">27.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and contingent consideration based on certain earn-out performance targets for Healthfinch during an earn-out period that ends on July&#160;31, 2021, with an initial fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDQyOQ_41050748-4c60-45d4-b2f5-020fde90cf95">5.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purchase resulted in Health Catalyst acquiring <ix:nonFraction unitRef="number" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDUxMA_a211f774-64ab-4043-96c9-18b34ec5a552">100</ix:nonFraction>% ownership in Healthfinch. </span></div><ix:continuation id="ied4c6581d4ae456883f2c16c71bef873" continuedAt="i6f3d5a253e8f41fe9b6fed169f0b0197"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Healthfinch (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMS0xLTEtMS0zNDI_5ab4a405-39c0-47e3-825d-9b3343b5374e">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMi0xLTEtMS0zNDI_0eea6996-c097-462e-a65a-5d4f084bd33f">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdbb8be29c94abbbe84a2dad772a00d_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMy0xLTEtMS0zNDI_289bb04a-005e-4910-8c05-d28025425f9c">8,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contract backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498f4874d4104d52939aa8749d65159d_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfNC0xLTEtMS0zNDI_876e248a-972d-4c2e-8a1f-96680f7ab1ab">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a417b5d4b4461bb7ff7bef53ae612f_I20200731" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfNS0xLTEtMS0zNDI_5e7a36ac-7537-406d-9036-bcbe0fa47954">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfNi0xLTEtMS0zNDI_b38e519f-50e4-4b9d-a7d5-8e2def6beb5c">20,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" name="hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfOC0xLTEtMS0zNDI_f923ffc4-0657-4daf-a026-7274f2bbe54a">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfOS0xLTEtMS0zNDI_2740a48b-312c-4f46-8d2b-47f8a603571e">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTAtMS0xLTEtMzQy_e4b13c67-6baf-45b7-ac5b-46267abda798">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTEtMS0xLTEtMzQy_1be8cf4a-0d2c-4b8c-8ce1-5bf483f529c4">17,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTItMS0xLTEtMzQy_77efa7c4-0f17-44de-8587-7db16b68c7d5">32,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTMtMS0xLTEtMzQy_ad1ad774-1e1d-4dde-a388-140e7f4ec805">50,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include customer relationships and contract backlog, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="i34094f2ce17c4b68b9c7f3e2545dfc9d_D20200731-20200731" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY1MA_79db9053-a467-4120-9f64-e27dc8e2ca8a">seven years</ix:nonNumeric>, <ix:nonNumeric contextRef="i1734d7abc4744d5683af026b80bc322e_D20200731-20200731" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY2Ng_b1fe733a-22a6-4582-9d8d-a0ed12bfd07f">three years</ix:nonNumeric>, and <ix:nonNumeric contextRef="ica753ecaab5f4745ad630406fcb5ecf9_D20200731-20200731" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY3OA_4424c23d-e8ed-4ee2-9b47-b9fca199094b">two years</ix:nonNumeric>, respectively. The resulting goodwill from the Healthfinch acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. </span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="ic553c172fad14ac78f6da19570b149f0" continuedAt="i7fb86668f16f462d95cbe39c95f8d341"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vitalware, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;1, 2020, we acquired Vitalware, LLC (Vitalware)</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a provider of revenue workflow optimization and analytics SaaS technology solutions to healthcare organizations, in a transaction accounted for as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business combination</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Vitalware&#8217;s flagship offering is a chargemaster management solution that delivers results for the complex regulatory and compliance functions needed by healthcare provider systems. Additionally, Vitalware brings to bear newer product suites to help health systems capture lost revenue and to support compliance with expanding pricing transparency regulation. The acquisition consideration transferred was $<ix:nonFraction unitRef="usd" contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDUzMg_5747d678-e726-4147-b994-bdc01b24be85">119.2</ix:nonFraction> million and was comprised of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net cash consideration of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDU0OA_ef262bf7-cf8e-47b5-837c-38909d02df1b">69.6</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Health Catalyst common shares with a fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDU2NA_7bd1c6c2-6e41-4a58-b10d-7c6faa180059">41.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and contingent consideration based on certain earn-out performance targets for Vitalware during an earn-out period that ended on March&#160;31, 2021, with an initial fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDU3OQ_c35e05c8-81c7-4520-b69b-1d29ce1923cb">8.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purchase resulted in Health Catalyst acquiring <ix:nonFraction unitRef="number" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDUyOA_99971272-36e0-4d05-84e7-262a5a6467e8">100</ix:nonFraction>% ownership in Vitalware.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional <ix:nonFraction unitRef="shares" contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901" decimals="INF" format="ixt:numdotdecimal" name="hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDYyMg_38ef34f8-9fec-4555-b476-1d6f7ded736a">203,997</ix:nonFraction> shares of our common stock subject to a restriction agreement, or restricted shares, were issued pursuant to the terms of the acquisition agreement. The value of these restricted shares is recognized as post-combination stock-based compensation expense on a straight-line basis over the <ix:nonNumeric contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDU2NA_3fdf1e9b-788e-4101-b23f-fb9808ec0ff1">12</ix:nonNumeric>-month vesting term. <ix:nonFraction unitRef="number" contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDYyOA_38ae2045-2330-431a-b5a7-3e96bbcabf52">75</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of these restricted shares will vest on a monthly basis over a term of approximately <ix:nonNumeric contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDUzMw_fccdab13-5111-46a9-9ec3-ea31259bb602">one year</ix:nonNumeric> with the remaining <ix:nonFraction unitRef="number" contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDYzNA_46f87dcb-c87f-4813-bc8c-99ceb4fec8bb">25</ix:nonFraction>% vesting on the <ix:nonNumeric contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDU0OA_11b6ab9f-63bb-4dc0-a247-62fc304020f5">one year</ix:nonNumeric> anniversary of the acquisition closing date.</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 12 for additional details related to our stock-based compensation.</span></div><ix:continuation id="i6f3d5a253e8f41fe9b6fed169f0b0197"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Vitalware (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMS0xLTEtMS0zNDI_55bc76c8-dada-4356-9837-a05c53d9427b">3,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMi0xLTEtMS0zNDI_8ee6421a-2b93-4d80-89fa-134cd529ccfc">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c0e7f496834c03a071df11af262227_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMy0xLTEtMS0zNDI_1e4a17ac-3577-48d7-ab3f-cdbea8129eff">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contract backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae6e93b2b18426481d9a6a8da986dc3_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfNC0xLTEtMS0zNDI_eadb6747-f8e1-41d7-b650-f142ade2655d">43,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d756d95f7c48f0b87b33dc8c7a743e_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfNS0xLTEtMS0zNDI_2796c075-95be-4b22-b6fa-e7700f81d0bc">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfNi0xLTEtMS0zNDI_a24a7c93-f257-4199-90b0-fe2466901cf3">66,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" name="hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfOC0xLTEtMS0zNDI_2c037d4e-5599-42b6-b386-a8bd02edb880">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfOS0xLTEtMS0zNDI_36f76b18-1717-4e13-8702-aa42f960d885">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTAtMS0xLTEtMzQy_7ec701d9-ae22-444a-97b4-89a72a3def51">3,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTEtMS0xLTEtMzQy_3851cfc0-1945-4327-8168-97c94de32070">62,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTItMS0xLTEtMzQy_656d815c-a471-42d0-bdbc-ac24cff11b40">56,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271ede7abee462eba0b2b698342faae_I20200901" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTMtMS0xLTEtMzQy_619df8a5-6288-4d94-a5d2-8dce1f2ee1d7">119,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets were valued utilizing an income approach, and include customer relationships, contract backlog, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="ie0aa3a878073450c89d3c4a52f80971f_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY5OA_0efebc79-4848-4584-bdef-f18d98307522">seven years</ix:nonNumeric>, <ix:nonNumeric contextRef="ia3be332fe9194ef58f9aceef7fcef46e_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcxMA_ce475947-237a-4379-9f42-bf57d666698d">two years</ix:nonNumeric>, <ix:nonNumeric contextRef="if53b8b11a34f4165a0b32d5030e61aaf_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcyMw_0e23ec03-a504-43dc-9df8-95826f8f2f14">four years</ix:nonNumeric>, and for trademarks <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcyOQ_4220c2f0-de6b-4637-b12c-d886b4eb2b01">two</span> to <ix:nonNumeric contextRef="i52203ce0773e4de29d77d41ca3e6ed52_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDc0Mg_ece3d11c-973f-43e1-b057-fa8c947dbed1">five years</ix:nonNumeric>, respectively. The resulting goodwill from the Vitalware acquisition was fully allocated to the technology reporting unit and is deductible for income tax purposes.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i7fb86668f16f462d95cbe39c95f8d341"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Pro Forma Financial Information</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxNzU1OA_357a14d9-0a18-4cb7-ab38-fd26c7c00242" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our unaudited pro forma combined results of operations for the years ended December&#160;31, 2020 and 2019 as if the acquisitions of Able Health, Healthfinch, and Vitalware had taken place on January 1, 2019:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pro forma revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563042bec9ce44faad7f33151e649064_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMi0xLTEtMS00MzU3_10b0a1cc-cc38-40db-9538-2bcb8d6259b8">209,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMi0zLTEtMS00MzU3_806e8046-7d5a-4d12-86b2-892f1aec8d67">173,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i563042bec9ce44faad7f33151e649064_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMy0xLTEtMS00MzU3_d0b962ee-cce1-4564-8a34-2acd780ececc">124,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMy0zLTEtMS00MzU3_0a43b4df-e9ff-4f75-b77f-0b956f7f8d5d">90,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma information is not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2019 or to project potential results as of any future date or for any future periods. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma adjustments are based upon available information and certain assumptions that we believe are reasonable. The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma revenues or net loss, as applicable, are attributable to fair value adjustments to deferred revenues, amortization of acquired intangible assets, acquisition-related income tax considerations, and acquisition transaction costs that had a net impact on the pro forma combined net loss of $<ix:nonFraction unitRef="usd" contextRef="i345542d87cc5467f82f4b9ffbcd77517_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNjA0NzMxMzk3Mjk5MQ_186151e8-416c-4faf-9818-a271ebc2c086">9.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a9284427b4344e99bd6a68791952947_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNjA0NzMxMzk3Mjk5OQ_e8ce6106-b9be-4746-9952-fd60014d3480">30.8</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_49"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMjk4_a5830b1e-74cb-45d7-ac4c-96e74f70c72b" continuedAt="i193f3d265f9b4c2893a72ac5f2f7d3b7" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="i193f3d265f9b4c2893a72ac5f2f7d3b7" continuedAt="i4a76987e6a0b445893114531f86e6d53"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMjk3_6dbef86f-bce8-4782-8259-eeff8169ae1e" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Health Catalyst&#8217;s revenue disaggregated by type of arrangement (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurring technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a82e47b69b4d3eb01ecc169fcbbdff_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMi0xLTEtMS0w_73c82d1a-caed-4b7c-8a38-dfe952dde9f7">33,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5b2b2f3eb34e66b9f15ef94b7f93d3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMi0zLTEtMS0w_ec9ebfba-087b-496c-86c1-a31cca6e6256">24,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time technology (i.e., perpetual license)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072686e691b043fc99a5001437848336_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0xLTEtMS00NDAx_a5a69d47-736d-413e-abd0-9f5346c2a7da">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica63ebc6345a4c4e9bf1f23e7fa538d2_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0zLTEtMS00NDAx_ca019107-7165-41e9-b72f-fb8111e965dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMy0xLTEtMS0w_a02de694-a399-4a4c-b85c-02b9218fd770">22,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMy0zLTEtMS0w_604ec4b5-abfd-4877-9e37-708317c3ea46">20,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0xLTEtMS0w_a2edca17-df27-4179-8cb1-bc0d7eda35b7">55,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0zLTEtMS0w_f9526429-a78d-474a-b4b1-5a47f55f662d">45,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, <ix:nonFraction unitRef="number" contextRef="i2b5ac1f2270243679239715132a65f39_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMTky_99f3a6fb-78d3-496f-869c-3ebe2362d176">99.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7dba3e825a6d4aa18b1576f50bc30986_D20200101-20200331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMTk5_5a202718-2bd2-4ac4-a732-f18e382340ed">99.9</ix:nonFraction>%, respectively, of revenue was related to contracts with customers located in the United States.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfOTMy_a7e70527-b710-4a7a-bead-6341c2e92054" continuedAt="i1a16d5945ead491488083607cd58dc33" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i1a16d5945ead491488083607cd58dc33"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in <ix:nonFraction unitRef="segment" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNjY_e2e5788f-da1d-456b-81eb-ad8238f5dee8"><ix:nonFraction unitRef="segment" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNjY_e8a6a151-0dff-4bed-b859-4b73136ff381">two</ix:nonFraction></ix:nonFraction> operating segments that also represent our reporting units. Our reporting units are organized based on our technology and professional services. We have not incurred any goodwill impairment charges.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfOTMz_0b039a84-930a-465f-8e9c-f13b03d255d8" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill by reporting unit is as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c750b2d03c4e43bd847dd5399458fa_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMi0xLTEtMS0w_efe97f54-735b-415a-8812-386d1ff23679">107,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffad74837e64a998ce0d0e6a9d0363c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMi0zLTEtMS0w_8ecbd953-379d-4a86-9c92-1c2e33c64d1e">107,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc1260ae65e4a948c0c470387cf66e8_I20210331" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMy0xLTEtMS0w_c232049a-3cac-4d27-8d04-032fee93ef94">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcd127174c94e03ada02115a901ebb6_I20201231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMy0zLTEtMS0w_3a9c0706-9bac-4a73-95a2-ca3cf8c64856">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfNC0xLTEtMS0w_72198e85-8a3e-4294-8631-80d5d503a03a">107,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfNC0zLTEtMS0w_94a5e29e-3bf7-4444-9d62-fda48c511c8b">107,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="i2ccafaa1a0774d209106f34ceff38387"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db85473fe074ce1a8b9d070f8da1259_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMS0xLTEtMS0w_9c452212-f254-44d5-b75a-8c0a487521fd">69,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6db85473fe074ce1a8b9d070f8da1259_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMS0zLTEtMS0w_67c5890b-b736-4350-b114-fc801deae3c9">28,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db85473fe074ce1a8b9d070f8da1259_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMS01LTEtMS0w_2db7982c-7fa3-41f1-94b7-c176217ff865">41,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f9ad5e961945caa4d034f51243794e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMi0xLTEtMS0w_04949e20-04c1-40c0-8e6b-41a569c33ac5">57,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f9ad5e961945caa4d034f51243794e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMi0zLTEtMS0w_15278575-c3c1-4227-8004-de9d66e8d848">10,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f9ad5e961945caa4d034f51243794e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMi01LTEtMS0w_9730d8f9-3c72-4109-8f19-ec01de40f454">47,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260812b8834d48928c9d06e77dee395b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMy0xLTEtMS0w_25f52c85-6afb-4fca-b70f-34e72fddf864">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i260812b8834d48928c9d06e77dee395b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMy0zLTEtMS0w_62002419-ae75-4fc2-85a7-9c5708a4a3f3">5,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260812b8834d48928c9d06e77dee395b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMy01LTEtMS0w_e93a5664-f389-461a-9c4e-f0feb616f456">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNC0xLTEtMS0w_1d54a6b2-5233-47e0-b5a5-6efe7e72f274">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNC0zLTEtMS0w_2f4eaa44-8640-41cd-a803-dc1795cd1f14">393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNC01LTEtMS0w_e2c50107-d1bf-4f1b-b079-52e4afe7acb4">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNS0xLTEtMS0w_0c5a1e14-6847-4429-bd55-133924bb99f9">136,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNS0zLTEtMS0w_6e27741d-2785-48b8-a9e2-866a116a5d2c">44,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNS01LTEtMS0w_02a3e3b7-4aad-4c14-865f-d6585db2b16d">91,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d7975897fb4234a03bea31f1b463be_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMS0xLTEtMS0w_abb6c886-d3c1-4deb-8843-64d9ba2eecee">69,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55d7975897fb4234a03bea31f1b463be_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMS0zLTEtMS0w_7d9b5a62-9307-4082-93da-86a92e192f43">25,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d7975897fb4234a03bea31f1b463be_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMS01LTEtMS0w_4ff9621e-ebfa-437d-a64e-94680fca254f">44,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb53d4219524c099358c824a99b0cab_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMi0xLTEtMS0w_82f41292-a0fa-4417-9c8c-faa17c6f55cb">57,764</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfb53d4219524c099358c824a99b0cab_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMi0zLTEtMS0w_e30b9df4-a547-426d-9580-24c6cb402212">7,482</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb53d4219524c099358c824a99b0cab_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMi01LTEtMS0w_5af66b88-c56a-4a81-b07f-a6759faf04e3">50,282</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9514dc5706d84f94969cf5c1179a4865_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMy0xLTEtMS0w_6c8cb888-4ad0-4d1c-b2ca-51ee6ca3d699">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9514dc5706d84f94969cf5c1179a4865_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMy0zLTEtMS0w_5aff3cc3-8342-4062-a804-a53ee29ea98f">4,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9514dc5706d84f94969cf5c1179a4865_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMy01LTEtMS0w_9eae2cc7-d771-4fd0-be81-f50e8b3ad639">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa77551a95d4af6815afe266a065d63_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNC0xLTEtMS0w_b4d15f36-ebf5-4c8e-97bd-5b53767ac729">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fa77551a95d4af6815afe266a065d63_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNC0zLTEtMS0w_e21c4e48-ebe0-4ba3-a71c-2d275b183eac">241</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa77551a95d4af6815afe266a065d63_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNC01LTEtMS0w_6f1bed6f-32fe-4f65-8a17-d850ab1e33bd">1,459</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNS0xLTEtMS0w_149352f2-2170-4020-a6e1-4d65024fe783">136,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNS0zLTEtMS0w_017de2de-9d8a-4cd6-a02b-8ae26b6af840">37,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNS01LTEtMS0w_2a46b28f-9e00-45f3-bc0a-1be3c5c75f2c">98,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of acquired intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNzI2_32cbd1c6-d2f1-42ca-a4f9-253b674dcb35">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNzMz_c08e725e-60b8-4939-9d4a-50426bb5356f">2.2</ix:nonFraction> million for the three months ended March&#160;31, 2021, and&#160;2020, respectively. Amortization expense for intangible assets is included in depreciation and amortization in our condensed consolidated statements of operations.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfMzk0_24394df7-3cf1-422a-8ee1-1f8c5b377ca9" continuedAt="id1b13e105bf141bfadfc6b68387d3a9e" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="id1b13e105bf141bfadfc6b68387d3a9e"><ix:continuation id="iaac51503c4a042578773ad335d549736"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983abe9c75604218bf9215278d6c8786_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMi0xLTEtMS0w_e0790768-b200-4d48-a26a-c30bdf50007a">9,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10e2819b49b48ebaeb218115ba93d2b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMi0zLTEtMS0w_14376025-fb80-4162-b08c-eb7c67ab6f20">8,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83e5abba43a418b8748534d60c48c2b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMy0xLTEtMS0w_75e5d213-7409-4440-909a-be7158d01222">10,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb60e336f0d243aeb3c25066686e0e13_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMy0zLTEtMS0w_8b9a5fb4-74f3-44ec-a275-087bc99dfc20">8,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630a4b7ddb6454bb0fd041f7d7959a9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNC0xLTEtMS0w_f6e999b3-cb56-426e-81e8-5aea515af0f4">3,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f14648338143b69e420b0bcff04694_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNC0zLTEtMS0w_d5cbb531-faa5-4ee9-b083-7838f92ec077">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7a206018584742a08cdb6786414f22_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNS0xLTEtMS0w_d04c9a4c-4e6c-4a38-ac65-aff63e34d73d">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50a93f231d04a3c92f044e1aead7038_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNS0zLTEtMS0w_73589262-4366-4bb7-89db-e910b7f75d6c">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9f4a66d37c421d9e84a17684b6e893_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNi0xLTEtMS0w_3deb3d4e-38b2-44f3-bed2-06a3be1b3417">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0db9e7d9d0645fe9a0dd92a5549d8ee_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNi0zLTEtMS0w_75b306f4-3a2e-49bc-a73a-c9f5241d1608">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital lease equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i977516e22f8e4f18a06347de98aabdba_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNy0xLTEtMS0w_bde673d7-9b4d-4b04-954e-0a204f53f4e3">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88139ab53d0d484f97717e145bade887_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNy0zLTEtMS0w_f41399b8-9988-450a-9850-b357445eb135">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOC0xLTEtMS0w_9ffe84e0-a9f7-44b7-872f-41db678ba1af">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOC0zLTEtMS0w_10dea531-26dc-4f1d-8d2d-bf96462806f2">22,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOS0xLTEtMS0w_2dd7ae26-0607-4a86-89e1-b181c1ad10fc">10,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOS0zLTEtMS0w_9acee7b0-ecb1-4046-8bac-1ea06fbe077e">10,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMTAtMS0xLTEtMA_f2727dbb-bd7a-457b-b098-13f7768b209f">18,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMTAtMy0xLTEtMA_6bb4be94-dbf6-4be8-b1ca-db8b3d01a29c">12,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-lived assets are located in the United States. Depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfMTg0_3ae7d623-fa30-4c9c-9ce8-9b12236c5114">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfMTkx_07c39c1e-8ad5-422b-a2ec-5081a2f7c53f">0.7</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively. Depreciation expense includes amortization of assets recorded under a capital lease and the amortization of capitalized internal-use software costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalized $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzY2Ng_89549ee3-6983-44ca-98ee-e7e07b2fa415">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c0efcef22664d14815854888bb21e26_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzY4MQ_19895255-78fd-4974-a8a2-41756a9e3174">0.1</ix:nonFraction> million of internal-use software costs for the three months ended March&#160;31, 2021 and 2020, respectively. We incurred $<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzY5Ng_62c022da-d1a8-4f48-ba05-0786eaa6b823">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzcxMQ_36604489-9987-47b8-9d37-a7cc5000ee8f">0.1</ix:nonFraction> million of capitalized internal-use software cost amortization expense for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_58"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfMjAwNA_82754616-4a67-4900-9155-f73ad275cb95" continuedAt="i453dab5809c242128b39b403dc5bda22" escape="true">Short-term Investments</ix:nonNumeric></span></div><ix:continuation id="i453dab5809c242128b39b403dc5bda22" continuedAt="i93f54fe2d5d647d8a25c8177eb278971"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale. Available-for-sale securities are recorded on our condensed consolidated balance sheets at fair market value and any unrealized gains or losses are reported as part of other comprehensive loss on our condensed consolidated statements of comprehensive loss. We determine realized gains or losses on the sales of investments through the specific identification method and record such gains or losses as part of interest and other expense, net on our condensed consolidated statements of operations. We did not have any material realized gains or losses on investments during the three months ended March&#160;31, 2021 and 2020. We measure the fair value of investments on a recurring basis. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables related to our available-for-sale securities of $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfOTMw_2be894d3-3da4-4025-839f-4cd99a0e2ff2">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfOTM3_5eef2d2d-eada-41f7-8a57-fb6acdca17e8">0.5</ix:nonFraction> million as of March&#160;31, 2021 and December&#160;31, 2020 were included within prepaid expenses and other assets on our condensed consolidated balance sheets. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i93f54fe2d5d647d8a25c8177eb278971"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfMjAwNQ_774acfd2-163b-4d05-af0e-b22e19f640a7" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of March&#160;31, 2021:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS0xLTEtMS0w_7ac4be3b-8554-4f25-88ea-374eaf58d673">125,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS0zLTEtMS0w_6d192ae0-fc29-4fdd-8e84-cb9e16a74e31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS01LTEtMS0w_6f2b5395-fdc5-4071-a73c-f16e80dfde4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS03LTEtMS0w_ad98af1d-e712-4919-8eef-d9d46a720ab5">125,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8030fbd94c4883ab8884ca9b7948c1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS05LTEtMS0w_32cc0648-eb97-4f6c-a9b2-95d14b32a1c1">125,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541592340c83428bbdf196bbddcb23a3_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS0xMS0xLTEtMA_729057b3-76b8-4c1d-a638-eb1724855875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi0xLTEtMS0w_dae18ad4-d4ea-4299-a121-af928bd59027">49,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi0zLTEtMS0w_5d90c4d0-fab9-476c-91ff-d286b3500f4c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi01LTEtMS0w_da7cca8e-c20b-44cc-b610-7e5be52092a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi03LTEtMS0w_c2335b7e-c34a-4010-8854-69259c4bc872">49,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426a8994b6c940268705dd62cb41316b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi05LTEtMS0w_f74e35bd-0457-44f1-b7c6-866164af0e84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c3e9e5c69d458f81c897663c923806_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi0xMS0xLTEtMA_086a09c9-c9e9-4d3b-b2ea-95ba3f50ae89">49,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy0xLTEtMS0w_a8c2524b-f012-4575-ba4f-05439f64b3ad">57,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy0zLTEtMS0w_6ecc0614-2b5f-47f7-974a-596fe1fe927a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy01LTEtMS0w_d0ba5b86-c8ed-4206-b852-67e879c7bed4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy03LTEtMS0w_ac0e1d6e-922f-47ba-a37f-aa645744888c">57,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3505f155dd9c49eeaf5dce4bd2bad37d_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy05LTEtMS0w_0985bc45-1150-40d2-8bfd-667ca2a2f9d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifddc111015e24dd5a3690fdb5f45cc03_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy0xMS0xLTEtMA_743dace8-0624-4038-bba9-3a8a7850a1d4">57,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC0xLTEtMS0w_5bc46470-df9a-4a3d-8854-0af3a2b4328b">27,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC0zLTEtMS0w_51f3ba71-ebd1-4c16-b05d-3a7d774c3a12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC01LTEtMS0w_13b1e888-bd61-4c8a-9911-534170f42c0f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC03LTEtMS0w_08896600-307a-4268-b2ea-1c817f654a3d">27,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87ff6778e0941aea98e91250fcb83cc_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC05LTEtMS0w_f46d5451-a6fd-4589-aa74-62c40602e9ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1af733c21c145808c8ce5cf39e9aa92_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC0xMS0xLTEtMA_722426e1-fa23-43f9-9af1-02b1c46810bd">27,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi0xLTEtMS0w_c7dd2cd3-babc-40b0-bf55-13febd1f287c">259,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi0zLTEtMS0w_0a25b6f1-c756-4048-8bb5-fe7c53ba41b9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi01LTEtMS0w_d8f79f99-6623-4a35-9ce5-4de8ea3a9fdd">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi03LTEtMS0w_78427771-03a9-45f9-be18-177ead69bc6b">259,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9cf71f707df4212a1eab4e8b98af652_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi05LTEtMS0w_e89ed1b0-5d7b-4c09-82e5-513b50bb71f0">125,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d92a783fa4d4b9e8f5c6ddb9773b7ef_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi0xMS0xLTEtMA_f13b56c5-f2af-44be-9da2-3ce86f376352">133,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of December&#160;31, 2020:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS0xLTEtMS0w_0d730461-09e4-4427-98a9-211fa7badf55">79,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS0zLTEtMS0w_25484fe6-65e3-4833-b117-bacbbeb7c87b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS01LTEtMS0w_10291a9a-203f-43dc-8cb3-4f19dfcd5c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS03LTEtMS0w_405c1c84-513f-4809-afa2-3f5066b58474">79,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f8b60d964c412f8bf1c17763bd40bf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS05LTEtMS0w_79165715-2f02-4556-a071-7f4010b6f0f5">79,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i935fba8f21d64ab0a83a3fc3303e30db_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS0xMS0xLTEtMA_4564a8d5-3fe2-4ad3-8175-3571a14e4620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi0xLTEtMS0w_5cf974c4-21af-48bb-870a-3946c0171081">59,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi0zLTEtMS0w_8958e0d7-b88a-45d0-9a34-5c5a8a15c4fc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi01LTEtMS0w_455e886e-5d9b-4720-9a4a-ed95014f0d7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi03LTEtMS0w_64af694d-084b-4191-a2c0-367e71052796">59,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c52c70966543f9b9649f46f30a1296_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi05LTEtMS0w_e6b1616b-1c2d-42e0-8730-f22c871ac318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5d15f13d5b4999b2da4743f59a762c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi0xMS0xLTEtMA_888ac6cd-1857-404a-aa8d-d5f273c0c0dd">59,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy0xLTEtMS0w_02f54115-6b4b-4a4b-ac7b-53e2403ffbe3">68,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy0zLTEtMS0w_cd371a1e-0cfe-494b-a194-b66015162916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy01LTEtMS0w_17dbac73-0886-4817-a563-19f46f47a303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy03LTEtMS0w_108cc01b-1aaf-4fbb-916d-b210f533e5c0">68,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f143d773b74a2c97d01a880e1b5979_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy05LTEtMS0w_b3768227-d501-48ff-9ec3-84be9b7b60ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9a993228ca419ab4f241d7af9bb937_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy0xMS0xLTEtMA_6457c01f-8ad6-4671-a132-081aea938fd0">68,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC0xLTEtMS0w_7fb5b4aa-a264-41c8-937a-f0e474acb29b">48,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC0zLTEtMS0w_48d05ea5-c412-4e6a-99a9-4a50f3c9e7ca">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC01LTEtMS0w_b6f353d8-6b32-493c-874c-221d54678bfc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC03LTEtMS0w_90fdfbc8-34f3-4480-9600-d9d554158bcd">48,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ca7f15ccff44c6bb539eb829a8c5a2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC05LTEtMS0w_7a2c2542-e3bf-4ccd-af99-3efb832cd1c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ae121e125f4a669af32cafe299e72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC0xMS0xLTEtMA_7899e3f2-fc38-402f-b0b9-b99b2ecb0672">48,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS0xLTEtMS0w_38f9e254-6a81-4042-96fe-3e486104a1ec">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS0zLTEtMS0w_7018f2c9-a639-48f2-9794-d403d4c40546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS01LTEtMS0w_19cc4aaa-fe27-4d8c-b22d-8d7c67616976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS03LTEtMS0w_84f3b68f-be4a-4654-b7d0-4554045aa945">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8206db89dd9e4111863cf8b116f25dc4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS05LTEtMS0w_13489fb6-4f8c-4793-ba16-72d26ea08e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cb4a7b357a4575b5c1f13edf15b3a8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS0xMS0xLTEtMA_df7375d6-07b9-42d6-ac2e-07340ec310d7">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi0xLTEtMS0w_e3d3bd95-b206-4b32-8a91-b797a29628de">258,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi0zLTEtMS0w_aa0f9f2e-33f8-4f41-82de-d85ba2a1b1c5">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi01LTEtMS0w_612e005f-b77d-4c3d-8d2e-ce8c1ecf2ae6">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi03LTEtMS0w_5cc207cb-94c9-4665-bdcf-e29304ea3a26">258,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66d1b79d4394e83b7b2d962f19c40a0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi05LTEtMS0w_69bc1e40-67dd-4cb1-901e-e0321d1da96c">79,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978e872b2ba845f49001cc6325ebd9fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi0xMS0xLTEtMA_efafe41e-74ac-47b6-a956-e8e2d085555c">178,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis we evaluate unrealized losses on our available-for-sale debt securities and the related accrued interest receivables to determine whether a decline in the fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors. We do not intend to sell investments that are in an unrealized loss position and it is not likely that we will be required to sell any investments before recovery of their amortized cost basis. As of March&#160;31, 2021 and December&#160;31, 2020, there were no material unrealized losses due to credit-related factors.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_61"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMjE1MQ_77636d8e-391f-425f-a744-db43355ab7fd" continuedAt="i94022485cd3a4d4e9a49a924b1361b08" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i94022485cd3a4d4e9a49a924b1361b08" continuedAt="i0b3bb0034b3e4d9ba25fb5997716769c"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMjE1Mw_69715eb1-0ec4-41c2-8ea7-5b5d11e5f398" continuedAt="i793971e6bb0043d78cb402bd26a66b32" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78fe06353da4595b8d88460f552d5b0_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi0xLTEtMS0w_84e09ceb-a095-45c7-ad5a-acab5289a445">125,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91927ae09dc04b33b971594d8bc54b89_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi0zLTEtMS0w_04247311-01b2-4fe9-98df-abed13d82627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4b7862118b4131ac5f06f5aa47e163_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi01LTEtMS0w_5df79a46-6746-4276-be44-bf9899a1fecc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi03LTEtMS0w_d457850b-06d0-4f7b-8d98-d69620b4e953">125,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed91e357c7f439bad5f2441be2f3393_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy0xLTEtMS0w_849264c5-bd84-4c43-b173-88b70cbf3217">49,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebd1cdc445047d992d3cf7740678f7e_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy0zLTEtMS0w_e9aab9f4-ff3c-4409-8829-7b85349643c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide03cc507eb84e43996d3b6131c163af_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy01LTEtMS0w_1ca7aee9-f890-4be7-aca8-30e572b8a3b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56d22cf25cf4054b9132b3db37d4f5a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy03LTEtMS0w_fa4e3442-7077-4f27-9646-7f485088f12a">49,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab672b01fe5742f2aa363490a53f34e5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC0xLTEtMS0w_09f00359-5aed-4f61-a31e-db75d7344d5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4186455850234995a3fefd4e16a396f4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC0zLTEtMS0w_b19527d6-8380-4b3f-b928-b1df2893a630">57,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1976d6b0d3d4e46ad2266bf99b8e8e7_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC01LTEtMS0w_802788d6-30ec-43fd-ae1f-a3a9a167d237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660b0d75067a411f95ef76e0a4f14bcf_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC03LTEtMS0w_c7534335-19d8-4d14-bc97-23217139bd14">57,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5d27da05ef4dd6820a8bd484966fad_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS0xLTEtMS0w_efde2335-296b-460b-8c5d-ca65f03f64e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dbc4d8aea34408bcdeadf087d32dfe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS0zLTEtMS0w_ed649d53-fcd9-4879-ba66-13936ebde8b7">27,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfcdb2b7b1549cab39eebc5d9febb7e_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS01LTEtMS0w_d6ea510f-27cb-4259-84ef-5dfe3d3efeaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3baad2ca5dec4ecb9082b1a396901a60_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS03LTEtMS0w_d260df67-0bbe-4fc0-95db-6dfd55519539">27,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78fe06353da4595b8d88460f552d5b0_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy0xLTEtMS0w_9f0159f2-9471-4159-b9f9-ba97cd0a8bdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91927ae09dc04b33b971594d8bc54b89_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy0zLTEtMS0w_58799220-d6a4-4157-90e1-cb9c41b36a84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a4b7862118b4131ac5f06f5aa47e163_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy01LTEtMS0w_ca81d550-62b2-4526-806e-be6a1433fea4">32,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy03LTEtMS0w_2103bab5-acb8-486c-a563-fc8de1e60b0d">32,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78fe06353da4595b8d88460f552d5b0_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC0xLTEtMS0w_fbcd5f52-cf13-4014-b921-378bc5c663f3">174,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91927ae09dc04b33b971594d8bc54b89_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC0zLTEtMS0w_0f1e761e-1694-46ee-aaac-7963d77ce660">84,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a4b7862118b4131ac5f06f5aa47e163_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC01LTEtMS0w_35be0997-3d5b-464e-b2f1-478a1480f79b">32,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC03LTEtMS0w_a97b3a27-5347-4dbd-b683-93822899ffe0">226,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i0b3bb0034b3e4d9ba25fb5997716769c" continuedAt="idf6d1e10fcaa49a3b7d17cb4a2a7098e"><ix:continuation id="i793971e6bb0043d78cb402bd26a66b32"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8799ab7618024c44bc02cda2b7c017c3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi0xLTEtMS0w_ecbcf7bc-8659-4064-9fe0-30b5af435e4b">79,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1265ad6d0a51472194b6f09102f17989_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi0zLTEtMS0w_d5000a7e-9452-46a5-ad59-534b967b71b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3257c2bc0d064887835ed5bd428b3341_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi01LTEtMS0w_d0832e4f-2708-4f82-919b-7a3e03424ace">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi03LTEtMS0w_9ffd6d94-ea77-47c8-9b5a-974ceb8b1add">79,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2569064bb5554bff8a5d048551e515ef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy0xLTEtMS0w_fa10d487-bd71-4864-8a6a-42ed5ecbb8fc">59,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161a412a8549477d870aa84d7450f380_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy0zLTEtMS0w_fe8ffdab-d701-4d16-8abc-59d1f0163c50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i527bc64f624c453d86a9fc398fa02162_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy01LTEtMS0w_bf2c8c2d-480c-460d-aac6-dd39d1ba1b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c8d4d672174b0eaf8590b94b667b03_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy03LTEtMS0w_c5781d19-f0b8-491a-bdb3-4ca956acf504">59,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78034192027744038e8701e5a608c7d4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC0xLTEtMS0w_057d4308-ad79-4db2-abbc-51c2a0b007ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id682c7555ec54d519592bb14ada245af_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC0zLTEtMS0w_b067bbea-656a-4c4c-9a46-c6bc73ba18ff">68,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f4f44ee228e4ea0ba64867556b0a8ac_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC01LTEtMS0w_690c4697-09c5-4ba9-bdc2-e4d3989919d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c3845f6f18439d8fb05984c62fff97_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC03LTEtMS0w_d66e7f7e-6b88-4d6e-b4a0-c1ef783dcc91">68,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26633d8bfcfd430fb29e89e97d45eb1a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS0xLTEtMS0w_35f4f697-847f-4fe3-ab2f-e232d3fb5c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5961bc6e1d4847d1aa04aa5a147ce0a1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS0zLTEtMS0w_dd7e214b-ce0e-46da-bb61-7da13861c685">48,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd7c0f92f7040fa9ad243c1f7fbaa69_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS01LTEtMS0w_83fe3917-da29-4237-b5a3-d282695f221c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bbfddff2d48ce808eae7321a3d727_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS03LTEtMS0w_568e9444-1764-4783-945d-613b1fb212de">48,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80924d762aae4accb35feb372dd0973d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi0xLTEtMS0w_a2cb2611-3ebf-4df6-8683-5b1f02557d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd307786e34047c1a07fb54bd6b2b8d2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi0zLTEtMS0w_e9938132-dad6-445c-9be9-1a9857d46b05">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969f245e87394c10994db7d2a6a77fb4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi01LTEtMS0w_59149d40-81dd-4619-8725-80fff176b4ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed4a348fb3e4251a45ae70c403a2faf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi03LTEtMS0w_0ab74336-287c-46d5-9b82-18857d71c486">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8799ab7618024c44bc02cda2b7c017c3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0xLTEtMS02MTM_f137d7ae-4da6-4efa-b25d-3531b6c4d9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1265ad6d0a51472194b6f09102f17989_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0zLTEtMS02MTM_085b8183-d000-490e-a4cc-15ad4887a10f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3257c2bc0d064887835ed5bd428b3341_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy01LTEtMS02MTM_b618e686-8584-4ebb-b229-9ff4a9e2f58a">31,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy03LTEtMS02MTM_1fb12e32-6f31-4de3-b666-a9d8c4cb5dab">31,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8799ab7618024c44bc02cda2b7c017c3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0xLTEtMS0w_58062670-0efc-4223-9ab6-d6eb43c2b6c3">138,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1265ad6d0a51472194b6f09102f17989_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0zLTEtMS0w_6eddbb4b-cc35-4401-b272-5bc5f7da3b95">119,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3257c2bc0d064887835ed5bd428b3341_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy01LTEtMS0w_5a76d6bf-4415-4187-8146-43e8b7eacfcc">31,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy03LTEtMS0w_cdc00e9d-3307-4af6-b806-7b3f8c4608dd">227,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1 and Level 2 during the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2021, the estimated fair value of the our convertible senior notes, with aggregate principal totaling&#160;$<ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzNjU1OA_e6bb892c-750b-4908-956d-2cb6282d6a7b">230.0</ix:nonFraction> million,&#160;was&#160;$<ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzMDU5NQ_3b293c7d-dc63-4555-9aec-8e30e4dc44e4">391.3</ix:nonFraction> million. We estimate the fair value based on quoted market prices in an inactive market on the last trading day of the reporting period (Level 2). These convertible senior notes are recorded at face value less unamortized debt discount and transaction costs on our consolidated balance sheets. Refer to&#160;Note 9 &#8212;Convertible Senior Notes for further information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 fair value measurements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Healthfinch acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Healthfinch during an earn-out period that ends on July&#160;31, 2021. The Healthfinch contingent consideration will be paid in a combination of cash and shares of our common stock in the same proportion as the initial acquisition consideration. The Vitalware acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Vitalware during an earn-out period that ended on March&#160;31, 2021. The Vitalware contingent consideration is capped at $<ix:nonFraction unitRef="shares" contextRef="if709f4c82b2c40929782386201a2329e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzNjU0NA_680c0110-b72a-4ccd-81a0-523eb960f886">30.0</ix:nonFraction> million and will be paid in a combination of approximately <ix:nonFraction unitRef="number" contextRef="icf8b76871176404b8081eb0c5b32f0ba_I20210331" decimals="INF" name="hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfNDM5ODA0NjUxOTg5Mw_d91bd0f7-ec6d-43aa-babb-9e04e798fcdb">50</ix:nonFraction>% cash and <ix:nonFraction unitRef="number" contextRef="icf8b76871176404b8081eb0c5b32f0ba_I20210331" decimals="INF" name="hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfNDM5ODA0NjUxOTg5OA_e8a8648b-a035-4891-ba1e-a1f4323d510a">50</ix:nonFraction>% in shares of our common stock. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value the expected contingent consideration and the corresponding liabilities using the Monte Carlo valuation method based on estimates of potential pay-out scenarios. The resulting contingent consideration liabilities are categorized as Level 3 fair value measurements and are remeasured as of each reporting period. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of the revenue-based earn-out contingent consideration liabilities is approximately $<ix:nonFraction unitRef="usd" contextRef="i2ed47da29f5f4158b9f99d94735bcba3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="hcat:FairValueMeasurementAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzNjEzNQ_d6599f05-b285-4c96-9dd1-1a9e45ed93f8">32.5</ix:nonFraction> million based on a point estimate of our internal forecasting of the ultimate earn-outs that will be earned and our common stock price as of March&#160;31, 2021. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfNDM5ODA0NjUxOTg5MQ_e2659f4f-c0a7-4747-a6b0-68dc4f35ed02" continuedAt="i6cd8ac08a3a347d6b788a63a9da62d96" escape="true">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs as of March&#160;31, 2021:</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="i6cd8ac08a3a347d6b788a63a9da62d96"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation Method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market Price of Revenue Risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Price Volatility</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue-based earn-out liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" name="hcat:FairValueMeasurementAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS00LTEtMS02NjI_7d162fa0-8e1b-44e6-b403-b9f253999e97">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">million</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86af83c7eb5046eda62a9143eb75002f_I20210331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS02LTEtMS02NjI_192a0dcd-af20-42a2-8f43-fede9392462c">3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdc9d82578fd4a2b800c586e00deda04_I20210331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS04LTEtMS02NjI_d3d6e4c9-b306-498b-87f2-abdb792d4883">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6c816c8bd444ca6b6af6a54d8586515_I20210331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS0xMC0xLTEtNjYy_c810f735-6e4c-4112-8202-925d3180e811">41</ix:nonFraction>%</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Able Health acquisition consideration included an initial estimate for contingent consideration for shares of our common stock if certain incremental billing targets for Able Health were met during an earn-out period that ended on December 31, 2020.  This Able Health earn-out contingent consideration liability was settled during the three months ended March&#160;31, 2021.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="idf6d1e10fcaa49a3b7d17cb4a2a7098e"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMjE1NA_0d6cffba-b259-4374-8afc-a6dbe61980cd" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530512a1ce4642378115de9c7b137ee4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfMS0xLTEtMS0w_12fd75ae-f86c-400c-b20d-509477477677">31,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddeb3efca1a047968b5e37ad4c74a3e8_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfMi0xLTEtMS0w_44a88571-7512-4efe-a783-587a27f6b260">1,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeb3efca1a047968b5e37ad4c74a3e8_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfMy0xLTEtMS0w_3e84b578-b2dd-4505-b82f-31af0e758341">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636c7efe46af4879a27c31281770fbe6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfNC0xLTEtMS0w_0ca05a7e-8873-4de7-a4a6-06444ceb1abb">32,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_64"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RleHRyZWdpb246MjU4ZDhjZjhiMWY3NDQzMDg2NDc0ZjdjNjFiZGVmNTVfMTA5_c366a4a8-16a4-4693-8359-5ffda8662caf" continuedAt="i2a8cb517ac2f4d429a3e90c47264ef6a" escape="true">Accrued liabilities</ix:nonNumeric></span></div><ix:continuation id="i2a8cb517ac2f4d429a3e90c47264ef6a"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RleHRyZWdpb246MjU4ZDhjZjhiMWY3NDQzMDg2NDc0ZjdjNjFiZGVmNTVfMTEw_aef9c94a-d992-41ba-8bc5-277218db7bdf" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMi0xLTEtMS0w_233b402e-7df1-4760-be19-cb176cde9b94">7,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMi0zLTEtMS0w_7ecaba84-87e9-4774-9d4a-439249faef69">9,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMy0xLTEtMS0w_40b3ccbe-5a1e-404e-82d1-0f8141b59b22">5,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMy0zLTEtMS0w_c62f66cd-e3fc-47d2-81de-2d763c5d0d3c">6,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfNC0xLTEtMS0w_4a4a4562-23cc-453d-9c80-c7543463cd1c">12,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="-3" format="ixt:numdotdecimal" name="hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfNC0zLTEtMS0w_7e96ba23-fc18-43e1-b8bb-2bde0700ed77">16,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_67"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMzExMQ_dcaa5d30-5d88-41f1-aecf-c24283c8ed15" continuedAt="i05b38fa7fa3043a4bd9e856662ea7681" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="i05b38fa7fa3043a4bd9e856662ea7681" continuedAt="i7c5f229df87a42c88c4ad6a54c0a8b3b"><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;14, 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="-5" format="ixt:numdotdecimal" name="hcat:DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjI4OQ_9f8029ac-10ce-413b-b26f-b1647651fd3d">230.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMwMA_23997327-4eeb-4441-a477-f1efb6493088">2.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the Notes), in a private placement to qualified institutional buyers exempt from registration under the Securities Act (the Note Offering). The net proceeds from the issuance of the Notes were approximately $<ix:nonFraction unitRef="usd" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMxNw_5ed6b8df-a6cb-4469-b528-fdee31ff0c3e">222.5</ix:nonFraction>&#160;million, after deducting the initial purchasers&#8217; discounts and offering expenses payable by us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are governed by an indenture (the Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of <ix:nonFraction unitRef="number" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMyOA_23997327-4eeb-4441-a477-f1efb6493088">2.50</ix:nonFraction>% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Indenture does not contain any financial or operating covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the Notes prior to April 20, 2023. On or after April 20, 2023, we may redeem, for cash, all or a portion of the Notes, at our option, if the last reported sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM0NQ_9e7bba04-acd3-4da9-bada-22c18f6aad31">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="day" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMzMw_aff400f4-b8f5-46fc-a1ed-240c06af921d">20</ix:nonFraction> trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any <ix:nonFraction unitRef="day" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMzOA_8cf7439d-0ad8-4d2e-b7e6-2e6debe1476b">30</ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM1Mg_af571837-5c0a-4067-9c03-c6055938b523">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i7c5f229df87a42c88c4ad6a54c0a8b3b" continuedAt="i18258ee49b7b4de4bcd7e4ad42d81ca9"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes have an initial conversion rate of 32.6797 shares of our common stock per $<ix:nonFraction unitRef="usd" contextRef="i0e584e43e4fa4dfe91200285e31ccff9_I20200414" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM3MQ_71b38535-8058-4b67-9210-5a9616cd5113">1,000</ix:nonFraction> principal amount of Notes (which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM4MA_6dd1c479-68eb-4451-b3bd-9de2f259107d">30.60</ix:nonFraction> per share of our common stock). Following certain corporate events that occur prior to the maturity date, we will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event. Additionally, upon the occurrence of a corporate event that constitutes a &#8220;fundamental change&#8221; per the Indenture, holders of the Notes may require the Company to repurchase for cash all or a portion of their Notes at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM4Nw_af571837-5c0a-4067-9c03-c6055938b523">100</ix:nonFraction>% of the principal amount of the Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes may convert all or any portion of their Notes at any time prior to the close of business on October 14, 2024, in integral multiples of $<ix:nonFraction unitRef="usd" contextRef="i0e584e43e4fa4dfe91200285e31ccff9_I20200414" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM5Ng_71b38535-8058-4b67-9210-5a9616cd5113">1,000</ix:nonFraction> principal amount, only under the following circumstances:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During any calendar quarter commencing after the calendar quarter ended on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of our common stock for at least <ix:nonFraction unitRef="day" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQwMQ_aff400f4-b8f5-46fc-a1ed-240c06af921d">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQwNg_8cf7439d-0ad8-4d2e-b7e6-2e6debe1476b">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQxMw_9e7bba04-acd3-4da9-bada-22c18f6aad31">130</ix:nonFraction>% of the conversion price on each applicable trading day;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the <ix:nonFraction unitRef="day" contextRef="i9e636533f649460881507b118b35238e_D20200414-20200414" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTUyNQ_f8a3b570-e935-4682-9560-fc7734e1bc2f">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="i9e636533f649460881507b118b35238e_D20200414-20200414" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTUzNA_962b1006-20f1-4c4d-83a9-004ba8d56eb1">five</ix:nonFraction> consecutive trading day period (the measurement period) in which the trading price as defined in the Indenture per $<ix:nonFraction unitRef="usd" contextRef="i0e584e43e4fa4dfe91200285e31ccff9_I20200414" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQyMg_71b38535-8058-4b67-9210-5a9616cd5113">1,000</ix:nonFraction> principal amount of Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i9e636533f649460881507b118b35238e_D20200414-20200414" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMzg0ODI5MDcyNTc4NQ_f32e9f2b-b6a6-4489-9233-0b4826121511">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we call such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upon the occurrence of specified corporate events described in the Indenture.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing circumstances. Upon conversion, holders will receive cash, shares of our common stock or a combination of cash and shares of common stock, at our election.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For at least <ix:nonFraction unitRef="day" contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTU1MA_5d152980-8c55-4c1f-b273-c654c8b3ca65">twenty</ix:nonFraction> trading days during the period of <ix:nonFraction unitRef="day" contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTU0OQ_dfbbc940-1cb2-4380-83eb-398837e31ec8">thirty</ix:nonFraction> consecutive trading days ended March&#160;31, 2021, the last reported sale price of the Company&#8217;s common stock was equal to or exceeded <ix:nonFraction unitRef="number" contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTU0NA_f4bf3def-489e-4553-87c3-5ab034dc5007">130</ix:nonFraction>% of the conversion price of the Notes on each applicable trading day. As a result, the Notes are convertible at the option of the holders during the fiscal quarter ending June 30, 2021 and are classified as current liabilities on the condensed consolidated balance sheet as of March&#160;31, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Notes as separate liability and equity components. We determined the carrying amount of the liability component as the present value of its cash flows using a discount rate of approximately <ix:nonFraction unitRef="number" contextRef="i3f8bc9199ddd4da18bed3e8e6956e62f_I20200414" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQ3OA_52b793ae-5d0e-438b-898b-4b04dfa7f5da">10</ix:nonFraction>% based on comparable debt transactions for similar companies. The estimated interest rate was applied to the Notes, which resulted in a fair value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="-5" format="ixt:numdotdecimal" name="hcat:ConvertibleDebtLiabilityComponentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQ5NQ_2685ce8c-0d3a-4a92-a6e4-f483cf17bc40">166.7</ix:nonFraction> million upon issuance, calculated as the present value of future contractual payments based on the $<ix:nonFraction unitRef="usd" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjUxMw_1e7c06fc-84f4-4a22-8518-49cb3a124772">230.0</ix:nonFraction> million aggregate principal amount. The excess of the principal amount of the liability component over its carrying amount, or the debt discount, is amortized to interest expense over the term of the Notes using the effective interest method. The $<ix:nonFraction unitRef="usd" contextRef="ic22bcfd28d2944d7a26478fbca019240_I20200414" decimals="-5" format="ixt:numdotdecimal" name="hcat:ConvertibleDebtLiabilityComponentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjUzMA_e66aef2d-b2b0-4c6c-94b6-76f38d0cb99b">63.3</ix:nonFraction> million difference between the gross proceeds received from issuance of the Notes of $<ix:nonFraction unitRef="usd" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU0OA_1e7c06fc-84f4-4a22-8518-49cb3a124772">230.0</ix:nonFraction> million and the estimated fair value of the liability component represents the equity component, or the conversion option, of the Notes and was recorded in additional paid-in capital. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated issuance costs related to the issuance of the Notes to the liability and equity components using the same proportions as the initial carrying value of the Notes. Issuance costs attributable to the liability component were $<ix:nonFraction unitRef="usd" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="-5" format="ixt:numdotdecimal" name="hcat:DebtIssuanceCostGrossLiabilityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU2NA_fdb92ce0-c662-4b78-8db7-fa4fbcc47852">5.5</ix:nonFraction> million and are being amortized to interest expense using the effective interest method over the term of the Notes. Issuance costs attributable to the equity component were $<ix:nonFraction unitRef="usd" contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414" decimals="-5" format="ixt:numdotdecimal" name="hcat:DebtIssuanceCostGrossEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU4MA_1baa31b0-4663-4ae3-8f13-71b4cb56e280">2.1</ix:nonFraction> million and are netted with the equity component of the Notes in stockholders&#8217; equity on the condensed consolidated balance sheets.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i18258ee49b7b4de4bcd7e4ad42d81ca9"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMzg0ODI5MDcyNTc4OQ_878e2ad6-ca0f-46ce-b83e-ebda847c5368" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized related to the Notes was as follows (in thousands):</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmZhMjU2NWViMjA2ZTQzY2JhZDE1M2Q3M2RkZGI5MjE5L3RhYmxlcmFuZ2U6ZmEyNTY1ZWIyMDZlNDNjYmFkMTUzZDczZGRkYjkyMTlfMS0xLTEtMS0yNzkw_4c87b4d4-7a2b-40d0-a033-dab0a941f415">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs and discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmZhMjU2NWViMjA2ZTQzY2JhZDE1M2Q3M2RkZGI5MjE5L3RhYmxlcmFuZ2U6ZmEyNTY1ZWIyMDZlNDNjYmFkMTUzZDczZGRkYjkyMTlfMi0xLTEtMS0yNzkw_2324f319-42eb-4fbb-a1bc-7d29e864a1ea">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmZhMjU2NWViMjA2ZTQzY2JhZDE1M2Q3M2RkZGI5MjE5L3RhYmxlcmFuZ2U6ZmEyNTY1ZWIyMDZlNDNjYmFkMTUzZDczZGRkYjkyMTlfMy0xLTEtMS0yNzkw_827b7d43-0d65-45c5-a08c-e0adf68ba14c">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying value of the liability component of the Notes was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfMS0xLTEtMS03NzI_e6bb892c-750b-4908-956d-2cb6282d6a7b">230,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfMi0xLTEtMS03NzI_40fcbf5f-41df-4a18-a527-94ae1a349945">53,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfMy0xLTEtMS03NzI_1c16053d-27e3-4935-be89-afdb1868e16d">4,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfNC0xLTEtMS03NzI_5a8c2858-74ce-4cfd-827d-64a23c775f12">171,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying value of the equity component of the Notes was as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds allocated to the conversion option (debt discount)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmEyNTgwZWFlMTE1ZTQyZGJhMzllODNjOTU3ODk4OTgxL3RhYmxlcmFuZ2U6YTI1ODBlYWUxMTVlNDJkYmEzOWU4M2M5NTc4OTg5ODFfMS0xLTEtMS03NzI_fef73083-13ec-4d04-944b-417d69199bf4">63,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:DebtIssuanceCostsGrossEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmEyNTgwZWFlMTE1ZTQyZGJhMzllODNjOTU3ODk4OTgxL3RhYmxlcmFuZ2U6YTI1ODBlYWUxMTVlNDJkYmEzOWU4M2M5NTc4OTg5ODFfMi0xLTEtMS03NzI_b6755762-393d-461a-b859-0e5d7375eb56">2,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmEyNTgwZWFlMTE1ZTQyZGJhMzllODNjOTU3ODk4OTgxL3RhYmxlcmFuZ2U6YTI1ODBlYWUxMTVlNDJkYmEzOWU4M2M5NTc4OTg5ODFfMy0xLTEtMS03NzI_ac8bd7c4-2e64-4e3c-93be-70b862264316">61,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the closing price of our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfNjA0NzMxMzk4MzAyOA_14ddd06e-e91c-4121-bb11-cf94aa14925e">46.77</ix:nonFraction> on March&#160;31, 2021, the if-converted value of the Notes was $<ix:nonFraction unitRef="usd" contextRef="i4882e61e1b5b46ba931866b40710101e_D20210331-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfNjA0NzMxMzk4MzA4MA_3afa4161-210f-4831-b0b7-d077441cae7e">121.5</ix:nonFraction> million more than their respective principal amount.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Calls</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (Base Capped Calls) with certain option counterparties. In addition, in connection with the initial purchasers&#8217; exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used approximately $<ix:nonFraction unitRef="usd" contextRef="id441c0a6737547208b92c291c8d51e05_D20200409-20200409" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeCostOfHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU5OQ_285b8ef6-1812-4398-a8bb-738800ce5c14">21.7</ix:nonFraction> million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $<ix:nonFraction unitRef="usdPerInstrument" contextRef="i6e1056545f074e48880fc579da87512f_I20200408" decimals="2" name="us-gaap:DerivativeCapPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjYwNQ_6d10cb06-2981-4214-b6e2-7f96c083d9dc">42.00</ix:nonFraction> per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. As the Capped Call transactions are considered indexed to our own stock and are considered equity classified, they will be recorded in stockholders&#8217; equity and will not be accounted for as derivatives. The cost incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital on our condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfMTk2NQ_98658639-cbcf-4baf-8220-09c6a1962f90" continuedAt="iccea52e290924e5b8d2ce85790f05744" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="iccea52e290924e5b8d2ce85790f05744"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has the authority, without further action by our stockholders, to issue up to <ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjk2_40873a04-528f-4f8b-a23f-7f41bbd22523">25,000,000</ix:nonFraction> shares of preferred stock in one or more series and to fix the rights, preferences, and privileges thereof, including voting rights. As of March&#160;31, 2021 and December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_19f9e269-3302-4a3b-a7e6-726e2fd2c953"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_577bcd0a-61b2-4106-949b-1ec9cc481a29"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_82aa8ff2-4dcb-4d67-b91d-b7fd95da5756"><ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_8b598304-d23f-42ef-b711-998f43515253">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of this preferred stock were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had <ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTMy_b54df50c-f832-415c-a91f-e4537b4832db"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTMy_eca3437d-48e3-4121-937d-b93cdc154106">500,000,000</ix:nonFraction></ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTQ1_144370c4-4655-4855-b599-54988cf964d2"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTQ1_75a44192-12d3-4df3-be57-6ece519cea88">0.001</ix:nonFraction></ix:nonFraction> par value common stock authorized, of which <ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTky_3cddaf69-36e6-453a-9e11-da1454485ec5"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTky_b2294517-5e38-4ef6-93ee-0349a3025eb6">44,454,783</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTk5_8c7d1aff-1117-43a8-9a91-78a02215ca37"><ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTk5_9c24c043-3455-4dac-96db-69e2442478a1">43,709,237</ix:nonFraction></ix:nonFraction> shares were legally issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The shares legally issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020 included <ix:nonFraction unitRef="shares" contextRef="ib8c6064e783e4b6499fe9fac50aae475_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzA5MQ_550bbd73-70e9-48f6-b7fa-32393fae828d"><ix:nonFraction unitRef="shares" contextRef="ib8c6064e783e4b6499fe9fac50aae475_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzA5MQ_9e2b6088-9262-4ab9-898c-fda8236b3136">114,747</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i6e4af7b7557540d99e4a0928fd4dcef7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzEwMQ_c8c00475-55c2-4c23-9814-e7334b1941e8"><ix:nonFraction unitRef="shares" contextRef="i6e4af7b7557540d99e4a0928fd4dcef7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzEwMQ_ebf862d7-d3c5-48d4-a0f8-617c5ee899e0">332,389</ix:nonFraction></ix:nonFraction> shares, respectively, issued pursuant to the Able Health and Vitalware acquisition agreements, which are subject to a restriction agreement and were unvested, and as such, for accounting purposes they were not considered to be outstanding common stock shares.  Each share of common stock has the right to <ix:nonFraction unitRef="vote" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="hcat:StockholdersVote" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfMjc0ODc3OTA3NDM2NQ_ac84f441-b1f4-494d-a31b-c649e2a7d659">one</ix:nonFraction> vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on our common stock through March&#160;31, 2021.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_76"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfNzQx_05384eb3-88e8-4268-aec5-9ecd86568c5d" continuedAt="id0a38d8e7b724eebb5633977a00ffcfa" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="id0a38d8e7b724eebb5633977a00ffcfa" continuedAt="iaf4f9349a16944d7926402974c81beb3"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfNzQy_2ec137c5-1cfb-4d10-8787-1a57c09e7411" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfMy0xLTEtMS0w_71a4cc05-8c71-4b42-af16-6a938627d2b3">28,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfMy0zLTEtMS0w_186448d9-140e-454b-951a-03fbed0438de">17,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in calculating net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNS0xLTEtMS0w_9bf36f43-ba0c-4114-a876-ceb319208159">43,870,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNS0zLTEtMS0w_afcf88fa-1bc4-4bb9-9eaa-455aba9fbdb4">37,108,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNi0xLTEtMS0w_69cff9f0-bc1a-4368-8c24-feadb8da596e">0.65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNi0zLTEtMS0w_40f82c6e-9388-4afc-947e-770b732b2fa6">0.47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, we incurred net losses and, therefore, the effect of our stock options, restricted stock units, performance-based restricted stock units, convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed or shares issued under our employee stock purchase plan were not included in the calculation of diluted net loss per share as the effect would be anti-dilutive. </span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="iaf4f9349a16944d7926402974c81beb3"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfNzQw_4787c799-f010-4ac4-a0d2-66b27a90286b" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains share totals with a potentially dilutive impact:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf3d7414d599440ab6623f14616c362b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfMy0xLTEtMS0w_791af5cb-1e85-484b-b231-97bb3bd45131">3,344,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb8e3c8002b8497680d01206475b3c70_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfMy0zLTEtMS0w_ec51c823-8c0c-4fdb-b1a7-986cad5cefd5">6,640,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i889328385548411faaca4f9d1d75a560_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0xLTEtMS0w_ec083885-5bd8-4b6b-824a-c4120641fd62">2,937,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cbf6d87e70d4690bbb117a5330e5f92_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0zLTEtMS0w_fcd23704-467e-4970-93f9-88a8ae5a152a">2,145,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c57c1ec8b584886bb5787b258ab2310_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0xLTEtMS00NDEx_7a8df350-c5c6-4a3e-92db-d417fc92c41d">307,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82a09a657dd645c4af6df61e20653b67_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0zLTEtMS00NDEx_f7031ad7-eb77-4e2d-a13b-0dd4c25ab561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares related to convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9a14d8fc64c4c19a75623ef092ff461_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0xLTEtMS0yOTI4_ce7b0694-ad66-4c30-92b4-d2457bf20b39">2,768,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i793d72c883b8430fa8d9b3446ef17c9f_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0zLTEtMS0yOTI4_331efd4d-85c4-4fbd-a0a8-541f1f15e16d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable as acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf5b95cb131b4027a016c3b12f265779_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0xLTEtMS0yOTI4_4d3057e1-33ff-4d0e-8bbe-1deb48ffbecc">344,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5291fdd2f49c42f288d38b74d791754d_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0zLTEtMS0yOTI4_341005ab-bfab-4488-a319-12b8f08ae516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13c02d79a3e94b378178e4a644ab9142_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0xLTEtMS0w_e63cd0cd-baf7-4c43-9ad8-3fcec738e6a5">72,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i174b5dc836864ffb956e769476edb3fc_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0zLTEtMS0w_34576a8e-67d6-4020-8b8b-a40553620e01">87,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a1ea5338944dbc8ab0f9476e6f521e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNi0xLTEtMS0w_1b0cad02-b2a0-4939-ac8d-021f8041a14f">114,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c17e8c4ebc4427892a4e5cc329075de_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNi0zLTEtMS0w_225bc4c4-30fe-4c71-a592-6c41c143d9fe">179,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfOC0xLTEtMS0w_c0d42306-314e-41a7-84c9-4c351f52ea3e">9,889,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfOC0zLTEtMS0w_2e6246f9-3bad-44c8-bfbb-9558d9f83471">9,053,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion spread of the Notes will have a potentially dilutive impact when the average market price of our common stock for a given period exceeds the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfMjc0ODc3OTA3MTMwNQ_26f6c08b-ee7f-426a-8bb5-706a26f0c53d">30.60</ix:nonFraction> per share. The shares related to the Notes in the table above are calculated based on the average market price of our common stock for the three months ended March&#160;31, 2021. Capped Calls are excluded from the calculation of diluted earnings per share, as they would be antidilutive.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares issuable as acquisition-related contingent consideration in the table above are calculated based on the earn-out achieved and the estimated amount of shares that would be issuable if the contingent consideration liabilities from the acquisitions of Healthfinch and Vitalware were to be settled as of March&#160;31, 2021.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_79"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MTg_c490bf73-6101-4b6e-b34c-f52dab87926f" continuedAt="ie68deb4646cd41c5a49c81448301a2dc" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><ix:continuation id="ie68deb4646cd41c5a49c81448301a2dc" continuedAt="i50058862f0874ab18319c8d4e272e11d"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, our board of directors adopted the Health Catalyst, Inc. 2011 Stock Incentive Plan (2011 Plan), which provided for the direct award, sale of shares, and granting of RSUs and options for our common stock to our directors, team members, or consultants.  In connection with our IPO, our board of directors adopted the 2019 Stock Option and Incentive Plan (2019 Plan). The 2019 Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce, including the grant of incentive and nonstatutory stock options, restricted and unrestricted stock, RSUs, and stock appreciation rights to our directors, team members, or consultants.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initially reserved <ix:nonFraction unitRef="shares" contextRef="ic77eedb5e34f4c26abf4a65346e4650a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzc5_2df6e3b1-aa84-4574-aab7-8dc4f982a7f5">2,756,607</ix:nonFraction> shares of our common stock (<ix:nonFraction unitRef="shares" contextRef="ib9191a8e792e492088d4538b45dbd969_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODEw_8442db05-d7d2-4d4e-b267-d7d33dc634de">2,500,000</ix:nonFraction> under the 2019 Plan and <ix:nonFraction unitRef="shares" contextRef="i783ec453ce724eff8223cbd8f18bb73c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODM3_99099803-a0b2-4e6a-bf33-1ce2a676bc88">256,607</ix:nonFraction> shares under the 2011 Plan that were available immediately prior to the IPO registration date). The 2019 Plan provides that the number of shares reserved available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2020, by <ix:nonFraction unitRef="number" contextRef="i783ec453ce724eff8223cbd8f18bb73c_D20210101-20210331" decimals="INF" name="hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTEwOQ_3bfdd777-f058-41f9-87cf-7bd2f92feaf6">5</ix:nonFraction>% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. As of January&#160;1, 2021, there were an additional <ix:nonFraction unitRef="shares" contextRef="idbb8e56635cb40dd9af2d7d512c81522_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTMyMg_5fb6e9c0-1d3b-4de3-87ec-9accabc323ec">2,185,461</ix:nonFraction> shares reserved for issuance under the 2019 Plan.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i9c0228f5aacd43abb6861e9102c54c52_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQwMw_76d94ffc-076b-45f8-8751-919faf6b96c7">15,294,920</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i168ea8840cfb452e9329f1c8021d7a0d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQxMA_ec1e2844-3660-42e4-8e05-6e2b95e37043">13,109,459</ix:nonFraction> shares authorized for grant, respectively, and <ix:nonFraction unitRef="shares" contextRef="i9c0228f5aacd43abb6861e9102c54c52_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQ2MA_a34f5611-159c-464e-a0e4-cb0883215701">3,086,399</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i168ea8840cfb452e9329f1c8021d7a0d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQ2Nw_afa9b961-4882-4710-b715-e1b1d17a2e14">2,481,818</ix:nonFraction> shares available for grant, respectively, under the 2019 Plan and 2011 Plan (collectively the Stock Incentive Plan). All options were granted with an exercise price determined by the board of directors that was equal to the estimated fair value of our common stock at the date of grant, based on the information known on the date of grant. Subject to certain exceptions defined in the Stock Incentive Plan related to an employee&#8217;s termination, options generally expire on the tenth anniversary of the applicable grant date.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i50058862f0874ab18319c8d4e272e11d" continuedAt="i842acc4b2623473f98b0df6d8c7e76b2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options, which vest in accordance with service schedules, is estimated on the date of grant using the Black-Scholes option pricing model. The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MjM_a35f5487-87ba-4d57-9da9-41bfff0acb8b" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our consolidated statements of operations (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMi0xLTEtMS0w_82dc9c77-9d38-46bc-8a99-59d17d89a329">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84298c0178544899bc7be2bae525267e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMi0zLTEtMS0w_3a0f73ff-7a13-4249-afca-84056eeb1cc3">2,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMy0xLTEtMS0w_dd7320a4-97d5-4281-bb35-1b1446a3f644">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b2602642784525904168a8fa8633ce_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMy0zLTEtMS0w_bd111847-ac6b-42d5-861b-19e6e906d3bc">5,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0xLTEtMS0zNjQ2_4942902b-17a4-4d39-9ae7-e78f6d9a584c">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2299b3cd854c339e305d26f3393657_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0zLTEtMS0zNjQ2_eafa9320-7a7c-4079-b8f6-6f8c2f7fea2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0xLTEtMS0w_3671ffc9-da3c-4552-b3c8-ec85ab412ae1">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0zLTEtMS0w_b73ab68e-1197-4df3-aca7-3e703e2bd4fc">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a1e6a0de294ea8abee4a1b9871700e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNS0xLTEtMS0w_1ca3ff3f-9808-42b1-bb25-5645f597caa2">2,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53167a60f2a467d9c28ab7387d78e93_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNS0zLTEtMS0w_f3299947-10a5-4ada-9078-69ff1235dd44">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNi0xLTEtMS0w_e0d97a8c-11b1-489b-b789-a4b81d2aca7e">13,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNi0zLTEtMS0w_73bb7470-bc22-4542-b29c-aa6ce0b9edcf">8,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83724b12cbb24c4a98f79788141daf04_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMi0xLTEtMS0w_d3889e90-05cb-4c0a-8d5f-5abb5dafc909">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a3def7806461eb26ce54d85a9d12d_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMi0zLTEtMS0w_ec037700-4600-4d32-bd51-8dcb5814a782">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29571c06d3a343e6ad4d8056a8d1af33_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMy0xLTEtMS0w_25365f35-b31f-4019-9f25-e2df0ed3b6d8">4,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13592f0c308d4c3ca5b28589349e0918_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMy0zLTEtMS0w_261487c0-ca53-49cb-9db1-9a0cdca96de6">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b84aed76ed431793822e4580b8f1d3_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNC0xLTEtMS0w_2bc50b03-fcb3-4838-9ebf-39479b779696">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8b3f6fdec2a4b278368ed19a4a95efa_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNC0zLTEtMS0w_671daac2-6fcc-4ecf-97ec-4a1d955cddef">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28f76181b1848d096ea303063c91539_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNS0xLTEtMS0w_e13edad3-4186-4888-8c12-9ee972988f93">4,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6253c82367944772a2bf9c34f8b31715_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNS0zLTEtMS0w_f2ac1c29-6168-47cc-a06c-940e538bbac7">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNi0xLTEtMS0w_f78b3df9-a9e2-4dd6-aa3a-d9d63946d44c">13,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNi0zLTEtMS0w_fb4bea87-34e0-4326-80ba-b9bf2e804887">8,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ1NQ_e7fed99e-1718-4d0b-8b54-65579a3bd5a2"><ix:nonFraction unitRef="shares" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ1NQ_f8faa859-9b3d-4559-8f15-687bbd1b1d58">no</ix:nonFraction></ix:nonFraction> stock options granted during the three months ended March 31, 2021 or 2020. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MTk_bf823b4b-e4ae-40f2-a3ff-a46142087838" continuedAt="ib8eccc373d6e4e0bbd1bf6e709949831" escape="true">A summary of the share option activity under the 2019 Plan for the three months ended March 31, 2021, is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="ib8eccc373d6e4e0bbd1bf6e709949831"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Time-Based Option Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMS0xLTEtMS0w_9619c106-571f-445a-a38d-634c3e01c365">3,892,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMS0zLTEtMS0w_c8294604-f7f8-4d93-9bea-9e25a5a091c8">11.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMi0xLTEtMS0w_fe1fe0bf-4533-4378-b45e-1b6a320f15df">537,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMi0zLTEtMS0w_1adab9d9-2710-4ad8-8e19-ca71d1d3487a">12.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMy0xLTEtMS0w_730f3e49-3276-4f5e-af0b-f202af06d611">11,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMy0zLTEtMS0w_e804752e-5385-4040-9089-318e757c4c85">11.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC0xLTEtMS0w_fe42b8d5-56e3-4946-b232-57bb6ce6f116">3,344,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC0zLTEtMS0w_1c83204d-3ead-4562-96cf-77eebb25140c">11.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC01LTEtMS0w_664ce422-653e-41e0-95cc-c8c7fd919f07">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC03LTEtMS0w_3d841190-ae29-4092-a64f-9fbf6df22356">117,946,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS0xLTEtMS0w_c355c83a-2043-43cb-a41c-856c4369d4e5">3,344,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS0zLTEtMS0w_053ef00a-caca-4b2a-92c6-3c240817eb19">11.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS01LTEtMS0w_e914f6f5-aba2-4180-abcd-4103b47374e9">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS03LTEtMS0w_eb544948-22d4-4723-a296-57dbc2141e52">117,946,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi0xLTEtMS0w_61ddfb45-c28f-46e3-b22f-4f7d74431669">1,715,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi0zLTEtMS0w_4a6134bc-5405-4ab5-af52-2e06903d67aa">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi01LTEtMS0w_c3951eb7-72f5-4cd2-9781-ff265e9f365d">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi03LTEtMS0w_b7354e08-2845-4ac7-a9f9-b8f473dbd663">62,231,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised was $<ix:nonFraction unitRef="usd" contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNTc3Mw_13348fbb-2fee-49ed-b52f-f0c5b9e1f388">18.7</ix:nonFraction> million for the three months ended March&#160;31, 2021. The total grant-date fair value of stock options vested during the three months ended March&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNTg5NA_4fa8756a-77f9-4c8d-bfef-b6ae660e6d5c">1.8</ix:nonFraction> million. As of March&#160;31, 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="i9ba12a4c71464ef789bdd7bf566ab6c4_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNTkyMg_0b812c24-f73a-409f-9de1-d4f9bb18c0b4">6.3</ix:nonFraction> million of unrecognized compensation expense related to our stock options is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA2NA_f85b59f4-78b1-4d47-9d66-9d2b313e26ae">1.4</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i842acc4b2623473f98b0df6d8c7e76b2" continuedAt="id9d76af59c6c4772b8e948c9b0b20f89"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (RSUs)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service-based condition for RSUs is generally satisfied over&#160;<ix:nonNumeric contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjM4NA_b38f42c2-7860-4848-9d94-abdefad151b3">four years</ix:nonNumeric> with a <ix:nonFraction unitRef="number" contextRef="i8c65b644a90a47f8b4b906e0790b6239_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjM5NA_3b81a005-e673-44b3-8f36-eafab54807b5">25</ix:nonFraction>% cliff vesting period of <ix:nonNumeric contextRef="i8c65b644a90a47f8b4b906e0790b6239_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjQyMQ_e3c94937-9b1a-4299-aa39-9dba74396bb4">one year</ix:nonNumeric> and ratable quarterly vesting thereafter. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MjA_cbf1e43b-efb5-4eaa-bfeb-2367cf8b3008" continuedAt="i6902e8527c744481aad7a34e77ced6db" escape="true">The following table sets forth the outstanding RSUs and related activity for the&#160;three months ended March&#160;31, 2021:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i6902e8527c744481aad7a34e77ced6db" continuedAt="i9f019dacea0746338ee2a4475d49ac32"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic980a4f37e8843bda75a71bcff67a580_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMS0xLTEtMS0w_158fd243-de04-46c2-a5cf-11d99cc5188e">1,839,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic980a4f37e8843bda75a71bcff67a580_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMS0zLTEtMS0w_b3a33c7a-aecc-4491-8722-dcc63a629aa2">34.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMi0xLTEtMS0w_96bfb245-322b-4cd5-8b11-83a7837f460f">1,329,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMi0zLTEtMS0w_d679cba2-c4cb-43cf-bb0b-16bb292644cc">49.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0xLTEtMS0zNzcw_e46d28b3-2360-46b7-9117-e9cbabbeb892">186,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0zLTEtMS0zNzcw_b39c5b6e-abb1-418e-901a-79a545f2ff83">33.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0xLTEtMS0w_c16450cc-e728-49a4-beb3-8ca8ab32ade3">45,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0zLTEtMS0w_bc3af1b1-51c8-4d0c-a607-6b147f7901fd">35.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i631a418618034b708e3ac39665cd5ccc_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfNC0xLTEtMS0w_cf981588-d3e6-439c-9043-afcce86b4660">2,937,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i631a418618034b708e3ac39665cd5ccc_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfNC0zLTEtMS0w_dac86009-a658-490e-a431-e7ce9786c39c">41.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i631a418618034b708e3ac39665cd5ccc_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjU4Ng_4f3090d5-3cfe-4821-809c-a26d68df1720">114.1</ix:nonFraction> million of unrecognized stock-based compensation expense related to outstanding RSUs expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjczNg_40e5c046-7cba-416c-be4e-f246eef1dfc1">3.2</ix:nonNumeric> years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units (PRSUs)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we granted PRSUs to all employees that included both service conditions and performance conditions related to company-wide goals. These PRSUs will vest to the extent the applicable performance conditions are achieved for the year ended December 31, 2021, and if the individual employee continues to provide services to us through the vesting date of March 1, 2022. The number of PRSUs that will ultimately vest from the 2021 PRSU grants can range from <ix:nonFraction unitRef="number" contextRef="ie966431602dc412e8b09acdcfbeffb3e_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQzNQ_fd40296b-3e56-4481-90b5-065fe702f687">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4dfe9f7c1913433fbc1d1265932b61f7_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ0MA_82b72204-6bba-4a1c-a827-9ad99c8bd971">100</ix:nonFraction>% of the original amount granted depending on our performance during 2021 against the pre-established targets. We also granted additional executive PRSUs based on the same performance conditions described above, but with an extended <ix:nonNumeric contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ1NA_07a1ca59-c549-4bab-84de-d0add2d8b70c">four-year</ix:nonNumeric> service condition whereby one quarter of such shares will vest on March 1, 2022, and the remainder in quarterly installments thereafter.</span></div><ix:continuation id="i9f019dacea0746338ee2a4475d49ac32"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding PRSUs, including executive PRSUs, and related activity for the&#160;three months ended March&#160;31, 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:69.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0de8ec0b76746a1957ad2b58eb7edac_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMi0xLTEtMS00NDIw_064de450-4cc0-4efc-ae30-5cd939a0887e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0de8ec0b76746a1957ad2b58eb7edac_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMi0zLTEtMS00NDIw_c77e4fa1-77ed-4e97-b4bd-2e29045e6d26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMy0xLTEtMS00NDIw_17965eed-04a9-46cf-8809-ea8408a49229">313,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMy0zLTEtMS00NDIw_ae2276a1-10cd-4c95-bd49-89fead2b4b39">49.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSUs forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNS0xLTEtMS00NDIw_b1929d24-e000-482b-9d8b-25b2a91d67a3">5,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNS0zLTEtMS00NDIw_ae851a5c-284d-4139-b3c3-82b544740b95">49.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ad286f2178249fba783e6f88e35ca81_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNi0xLTEtMS00NDIw_dfb906c1-d6ac-4527-af99-9e16f14e61cd">307,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ad286f2178249fba783e6f88e35ca81_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNi0zLTEtMS00NDIw_c38e434d-1295-4a0b-b569-24a63f0a6c10">49.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i6b97cd002a914ee3aa2c282be09d867b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk4Mzk4NQ_07c1d133-a458-4844-b912-95d2dcda7984">10.3</ix:nonFraction> million of unrecognized stock-based compensation expense related to outstanding PRSUs expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="ie7a1e6a0de294ea8abee4a1b9871700e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk4Mzk4OQ_72dfc396-a359-488f-a716-502b67ffde00">1.0</ix:nonNumeric> year.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="id9d76af59c6c4772b8e948c9b0b20f89" continuedAt="i0ebfaa1efad24e10ab28a144b4e9d9fe"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO in July 2019, our board of directors adopted the ESPP and a total of <ix:nonFraction unitRef="shares" contextRef="iedce8ff10cd94af1a1617e8a8e551070_I20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjg1OA_391f3b03-bfb4-4120-80f5-27f41f008c69">750,000</ix:nonFraction> shares of common stock were initially reserved for issuance under the ESPP. The number of shares of common stock available for issuance under the ESPP will be increased on the first day of each calendar year beginning January 1, 2020 and each year thereafter until the ESPP terminates. The number of shares of common stock reserved and available for issuance under the ESPP shall be cumulatively increased by the least of (i) <ix:nonFraction unitRef="shares" contextRef="i51f5fbd68ddc4421b8d0bc58f849fac7_D20190701-20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzI4Nw_ec27ced4-4d64-4dca-b031-532ceb086169">750,000</ix:nonFraction> shares, (ii) <ix:nonFraction unitRef="number" contextRef="i51f5fbd68ddc4421b8d0bc58f849fac7_D20190701-20190731" decimals="INF" format="ixt-sec:numwordsen" name="hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzMwMw_ec8da0ba-61c0-4276-bf53-aaee01de82f4">one</ix:nonFraction> percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of common stock as determined by the ESPP Administrator. As of January&#160;1, 2021, the number of shares of common stock available for issuance under the ESPP increased by <ix:nonFraction unitRef="shares" contextRef="i95c99dfaa5084f8b99fb2b86c782d222_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzU0Mg_d9c7671b-9a6d-4418-9cd4-d1a3cc7b54f7">437,092</ix:nonFraction> shares. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP generally provides for <ix:nonNumeric contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" format="ixt-sec:durwordsen" name="hcat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcwOTQzNg_420a90e0-b53f-4666-b3bd-444138e3f55a">six-month</ix:nonNumeric> offering periods, the exception being the first offering period. The offering periods generally start on the first trading day after June 30 and December 31 of each year. The ESPP permits participants to elect to purchase shares of common stock through fixed percentage contributions from eligible compensation during each offering period, not to exceed <ix:nonFraction unitRef="number" contextRef="i13867759ede9429292155333cf98aa5a_I20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzk4Ng_8d3861fb-cd1d-4c2f-b94e-d7215d10afe4">15</ix:nonFraction>% of the eligible compensation a participant receives during an offering period or accrue at a rate which exceeds $<ix:nonFraction unitRef="usd" contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODEwMQ_1d788995-bc08-4b67-be4f-604c836d58fa">25,000</ix:nonFraction> of the fair value of the stock (determined on the option grant date(s)) for each calendar year. A participant may purchase the lowest of (a) a number of shares of common stock determined by dividing such participant&#8217;s accumulated payroll deductions on the exercise date by the option price, (b) <ix:nonFraction unitRef="shares" contextRef="i13867759ede9429292155333cf98aa5a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODM5OQ_03ddb6cb-912f-4991-94d3-8667e4c054f4">2,500</ix:nonFraction> shares; or (c) such other lesser maximum number of shares as shall have been established by the Administrator in advance of the offering period. Amounts deducted and accumulated by the participant will be used to purchase shares of common stock at the end of each offering period. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of the shares will be <ix:nonFraction unitRef="number" contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODcyNA_cef0935b-6300-47a2-841e-434edb8ea86a">85</ix:nonFraction>% of the lower of the fair value of common stock on the first trading day of each offering period or on the purchase date, except for the first offering period, for which the purchase price will be <ix:nonFraction unitRef="number" contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODkyMw_ee7c0355-0426-46ec-a358-70a3c937612a">85</ix:nonFraction>% of the lower of (i) the IPO price or (ii) the fair value of common stock on the purchase date. Participants may end their participation at any time during an offering period and will be paid their accumulated contributions that have not been used to purchase shares of common stock. Participation ends automatically upon termination of employment.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MjY_cbbd27fa-067e-4ce5-906d-6c7d2c0f3525" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMi0xLTEtMS0w_0e8b1f95-9ed5-417e-aed6-e7f998e8917c">40.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMi0zLTEtMS0yOTk2_61bf9a25-7aad-484d-bbfc-338c79ffdc6b">54.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMy0xLTEtMS0w_d8cf6ab3-9ac6-4a1d-9556-981be98a2e75">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMy0zLTEtMS0yOTk2_0b7abd93-d9ff-4907-9d33-715caf5a4793">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNC0xLTEtMS0w_d3035434-1fbd-40b3-a32d-eed42c796a5a">0.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNC0zLTEtMS0yOTk2_8cd5d8c5-0ab0-42ec-a538-70da2a1a3621">1.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNS0xLTEtMS0w_bf8e88d2-2a3c-4767-9e4c-0184cdb09e06">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNS0zLTEtMS0yOTk2_2d790899-b43b-4b4b-8ed9-5020fb8e96a6">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, a total of <ix:nonFraction unitRef="shares" contextRef="i13867759ede9429292155333cf98aa5a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTQ4Mg_d49a9745-c9dc-43af-882c-3dc290783c9a">72,892</ix:nonFraction> shares were issuable to employees based on ESPP contribution elections and unrecognized ESPP compensation cost was $<ix:nonFraction unitRef="usd" contextRef="i13867759ede9429292155333cf98aa5a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTYwMA_c0913d92-0b2d-4271-acbc-ea476f6a2211">0.4</ix:nonFraction> million, which is expected to be recognized over the remaining portion of the current offering period during the three months ending June 30, 2021. As of March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i13867759ede9429292155333cf98aa5a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTc0Mw_c083d5cc-0aef-4f81-89b7-7123bc6ac8d5">1,245,652</ix:nonFraction> shares are available for future issuance under the ESPP.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i0ebfaa1efad24e10ab28a144b4e9d9fe"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Shares</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Able Health acquisition that closed on February 21, 2020, <ix:nonFraction unitRef="shares" contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221" decimals="INF" format="ixt:numdotdecimal" name="hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTg5NA_e8ae07a1-db0f-4399-a0a0-9b7adbf58fe6">179,392</ix:nonFraction> shares of our common stock were issued pursuant to the terms of the acquisition agreement and are a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares were subject to <ix:nonNumeric contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTAxMTI_aa2f0b25-84b6-4081-bf26-f2a5dd73937b">one year</ix:nonNumeric> of continuous service by the applicable team members and vested fully during the three months ended March&#160;31, 2021 on the <ix:nonNumeric contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcwOTQ0OQ_f924b7ab-4e79-4fd2-aaa7-52045372db8b">one-year</ix:nonNumeric> anniversary of the acquisition closing date.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vitalware acquisition that closed on September 1, 2020, <ix:nonFraction unitRef="shares" contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901" decimals="INF" format="ixt:numdotdecimal" name="hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2ODk5OA_a0261f4f-634a-473a-b21b-7971ac6ef04a">203,997</ix:nonFraction> shares of our common stock were issued pursuant to the terms of the acquisition agreement and are a stock-based compensation arrangement subject to a restriction agreement. <ix:nonFraction unitRef="number" contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2OTAyMQ_900791e0-b350-4eff-8d65-07b45f51829d">75</ix:nonFraction>% of these restricted shares will vest on a monthly basis over a term of approximately <ix:nonNumeric contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcyNzkzMw_e5dd2f7f-2863-485c-8e24-e68ba3639ea0">one year</ix:nonNumeric> with the remaining <ix:nonFraction unitRef="number" contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2OTAyNw_d703c08d-bd3e-4a4f-aa9e-24adf4c561c7">25</ix:nonFraction>% vesting on the <ix:nonNumeric contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcyNzkyMA_85a2b244-4025-42d0-a8d3-43cb1509ffc3">one-year</ix:nonNumeric> anniversary of the acquisition closing date. As of March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="icf8b76871176404b8081eb0c5b32f0ba_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2OTAzNg_d1bfeac7-46c5-4e0b-a116-c34df1ced97d">89,250</ix:nonFraction> of these restricted shares had vested. As of March&#160;31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i63d5a2a619c74cd49c4313f5d1b1c0f3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTAyNjE_ea07c67f-153f-42ee-8d2f-3d2225cddfa0">2.8</ix:nonFraction> million of unrecognized stock-based compensation expense related to outstanding restricted shares expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i0fbb179f359b4f038e44fe90cd706e8a_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MTQ_47a2bc1e-b0db-40b7-b545-f32a2c04a146">0.4</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_85"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfMjczOA_483d3da2-85e5-4e1a-b800-437ea110637c" continuedAt="i890bff0e2bbc43a280a10adf85cfb7e5" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i890bff0e2bbc43a280a10adf85cfb7e5"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, we update our estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, we make a cumulative adjustment in such period. The quarterly tax provision and the estimate of our annual effective tax rate are subject to variation due to several factors, including variability in our loss before income taxes, the mix of jurisdictions to which such income or loss relates, changes in how we conduct business, and tax law developments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;three months ended March&#160;31, 2021 and 2020, our estimated effective tax rate was (<ix:nonFraction unitRef="number" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfNzUx_f564cb5a-d799-447c-9c29-7c5b371ea561">0.4</ix:nonFraction>)% and <ix:nonFraction unitRef="number" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfNzU4_e6adf7c8-337c-40d2-82c6-4a1bec618cd4">6.6</ix:nonFraction>%, respectively. The variations between our estimated effective tax rate and the U.S. statutory rate are&#160;primarily due to our full valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all available evidence to evaluate the recovery of deferred tax assets, including historical levels of income, legislative developments, and risks associated with estimates of future taxable income. We have provided a full valuation allowance for our net deferred tax assets as of March&#160;31, 2021 and December&#160;31, 2020, due to the uncertainty surrounding the future realization of such assets and the cumulative losses we have generated.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we have a full valuation allowance on net deferred tax assets, our income tax provision for the three months ended March 31, 2021 consists primarily of minimal state and foreign income taxes. The income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfMTM1OQ_525fddf0-bee4-4321-afe7-0688641034c0">1.2</ix:nonFraction> million recorded for the three months ended March 31, 2020, is primarily related to the discrete deferred tax benefit attributable to the release of a portion of the valuation allowance during the quarter. The release of valuation allowance is attributable to the acquisition of Able Health, which resulted in deferred tax liabilities that, upon acquisition, allowed us to recognize certain deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfMTczNw_0bc1dd66-10b6-4803-bdd7-b710dde9d0af">1.3</ix:nonFraction> million that had previously been offset by a valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions when it is more likely than not, based on the technical merits, that the position will be sustained upon examination.  We believe that we have provided adequate reserves for income tax uncertainties in all open tax years.  We do not anticipate material changes in the total amount of our unrecognized tax benefits within 12 months of the reporting date.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted and signed into U.S. law to provide economic relief to individuals and businesses facing economic hardship as a result of the COVID-19 pandemic. On March 11, 2021, the American Rescue Plan Act of 2021 (ARPA) was enacted and signed into U.S. law to provide additional economic stimulus and tax credits. Changes in tax laws or rates are accounted for in the period of enactment. We are continuing to analyze these legislative developments and believe that the income tax provisions of the CARES Act and ARPA do not have a significant impact on our current taxes, deferred taxes, or uncertain tax positions.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_88"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84OC9mcmFnOjhhYWQyYmI4MDlhNjQyMDQ5NDFjODhhNjcxMmJjMjNkL3RleHRyZWdpb246OGFhZDJiYjgwOWE2NDIwNDk0MWM4OGE2NzEyYmMyM2RfMTkzNw_314b429c-aa30-4224-98cc-ef12a721ad70" continuedAt="i7b1dfecbe6d042a0bce511429a85e9de" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i7b1dfecbe6d042a0bce511429a85e9de"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings from time to time that arise in the normal course of business. As of March&#160;31, 2021 and December&#160;31, 2020, there were no significant outstanding claims against us.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_91"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:continuation id="i4a76987e6a0b445893114531f86e6d53" continuedAt="i80bf8849443d40d8b8c17ad789db79e3">Deferred Revenue and Performance Obligations</ix:continuation></span></div><ix:continuation id="i80bf8849443d40d8b8c17ad789db79e3" continuedAt="i25ee4512f73542a6ac7ba91c56ddb642"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized.&#160;For the three months ended March&#160;31, 2021 and 2020, <ix:nonFraction unitRef="number" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="2" name="hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMTkw_1f2c5125-95a6-4459-8ed7-c4388a08ff97">42</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="2" name="hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMTk3_dbc4a3e6-1d4c-4ed0-a29b-fac40afdbf8c">33</ix:nonFraction>%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i25ee4512f73542a6ac7ba91c56ddb642">Most of our technology and professional services contracts have up to a <ix:nonNumeric contextRef="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331" format="ixt-sec:durwordsen" name="hcat:DeferredRevenueArrangementForServiceContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMzg0ODI5MDY5ODA3OQ_edb39cb8-afc2-44c8-8811-c29acf021f2c">three-year</ix:nonNumeric> term, of which the vast majority are terminable after <ix:nonNumeric contextRef="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331" format="ixt-sec:durwordsen" name="hcat:DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNTEy_bbb7d39f-02f5-4d51-8040-2410eedb2d5b">one year</ix:nonNumeric> upon <ix:nonNumeric contextRef="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331" format="ixt-sec:durday" name="hcat:DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNTIx_92f14b64-1706-4852-82e1-4034601c61b1">90</ix:nonNumeric> days&#8217; notice. For arrangements that do not allow the customer to cancel within one year or less, we expect to recognize $<ix:nonFraction unitRef="usd" contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNjM5_7e4010f1-087f-4a2f-b7d7-9147ddc9909b">79.6</ix:nonFraction> million of revenue on unsatisfied performance obligations as of March&#160;31, 2021. We expect to recognize approximately <ix:nonFraction unitRef="number" contextRef="i0653e44dccde41d79e0c4dcca4805fd7_I20210331" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNzM5_21496521-b95f-44e2-81c0-becbe830112d">75</ix:nonFraction>% of the remaining performance obligations over the next <ix:nonNumeric contextRef="i0653e44dccde41d79e0c4dcca4805fd7_I20210331" format="ixt-sec:durmonth" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMjc0ODc3OTA3MTEzNw_09365ad4-ec6b-4d24-ba3f-eae75fee52c5">24</ix:nonNumeric> months, with the balance recognized thereafter.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_97"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTA0NQ_b98b306e-fa90-44d0-829b-89cb15f4319b" continuedAt="i03d77f8dad10492f9ee67b4574e05bd0" escape="true">Related Parties</ix:nonNumeric></span></div><ix:continuation id="i03d77f8dad10492f9ee67b4574e05bd0"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into arrangements with a customer, Mass General Brigham (formerly Partners Healthcare), where, at that time, a member of the customer&#8217;s management was a member of our board of directors. He resigned from his executive position with our customer on March 31, 2021 and remains on staff. He served on our board of directors from January 2018 to May 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from this related party of $<ix:nonFraction unitRef="usd" contextRef="i3448fe61af4c4aacaf336c73188b521b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMzIy_51f738d9-96af-4638-b70d-44e4d4937812">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i64b094898f5e4db7b34432cbd11ef1b0_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMzI5_747f1a12-2365-40b0-a357-cb6844970e03">0.7</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, we had receivables from this related party of $<ix:nonFraction unitRef="usd" contextRef="i2374c5eff6d04980b4a36a67bb87de2d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNDQ3_257dd4a6-1c54-4cda-995d-19a6639b645f">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7ad4008f49a049feb88a7b75269882ef_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNDU0_25354b87-414f-4b34-8016-760a130a5411">0.6</ix:nonFraction> million, respectively, and deferred revenue with this related party of $<ix:nonFraction unitRef="usd" contextRef="i2374c5eff6d04980b4a36a67bb87de2d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNTIw_4912f4b1-82a2-4351-9730-624047003640">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7ad4008f49a049feb88a7b75269882ef_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNTI3_0c3c10d7-f348-444f-be6e-27e83c0cdbbc">0.7</ix:nonFraction> million, respectively. We also had acquisition-related consideration payable to this related party for a prior year asset acquisition, of which the final $<ix:nonFraction unitRef="usd" contextRef="ib54854387397459a8c725ddfa3ed8859_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTY0OTI2NzQ0MzAzNg_fef4d6cd-23a7-4f1f-942b-fe4a965986ff">1.2</ix:nonFraction> million was paid during the year ended December 31, 2020.  This asset acquisition occurred prior to this entity becoming a related party. There was <ix:nonFraction unitRef="usd" contextRef="i7ad4008f49a049feb88a7b75269882ef_I20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTY0OTI2NzQ0MzA0NA_6a9dbf5c-60bc-4d20-acf1-502d49aad4ff"><ix:nonFraction unitRef="usd" contextRef="i2374c5eff6d04980b4a36a67bb87de2d_I20210331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTY0OTI2NzQ0MzA0NA_7ab0ae4f-7d6a-4df4-9317-653451d946cd">no</ix:nonFraction></ix:nonFraction> acquisition-related consideration payable to this related party as of March&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into revenue arrangements with customers that are also our investors. None of these customers hold a significant amount of ownership in our equity interests.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CATALYST, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzEzODY_daf6678b-194b-4970-bc4e-e12111a8df62" continuedAt="iff32b4c4520d40b6aa0fa287441e3736" escape="true">Segments</ix:nonNumeric></span></div><ix:continuation id="iff32b4c4520d40b6aa0fa287441e3736"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in <ix:nonFraction unitRef="segment" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzQ1_af22bf15-61d2-4e83-9c4e-9459d52dddf6"><ix:nonFraction unitRef="segment" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzQ1_cc6c8d86-f503-437c-a266-c86ae786b35d">two</ix:nonFraction></ix:nonFraction> operating segments that also represent our reportable segments. Our business is organized based on our technology offerings and professional services. Accordingly, our segments are:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Technology - Our technology segment (Technology) includes our data platform, analytics applications and support services. Technology generates revenues primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Professional Services - Our professional services segment (Professional Services) is generally the combination of data and analytics, domain expertise, outsourcing, and implementation services to deliver expertise to our customers to more fully configure and utilize the benefits of our Technology offerings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and cost of revenues generally are directly attributed to our segments. All segment revenues are from our external customers. Asset and other balance sheet information at the segment level is not reported to our Chief Operating Decision Maker.</span></div><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzEzODc_2a1f251a-8d91-4825-86d8-13ded05aaaf0" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and Adjusted Gross Profit for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c95150cded4d7da0ed5115a50de8ca_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzMtMS0xLTEtMA_d9704eba-ade6-4dcc-8563-b3576927f01c">33,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375d7f606b334e22897257297115deeb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzMtMy0xLTEtMA_489429df-4fbc-48e6-8a54-759d759e6c0b">24,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f46ff336b1840e7b034030cf5eae332_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzQtMS0xLTEtMA_3955890c-4550-4842-a9a6-c6a0d2146ab0">22,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4830aba629412daaa0cc0a46d3c18e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzQtMy0xLTEtMA_11f6a327-1b2c-4e8b-97f7-c9c0a304beb0">20,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzUtMS0xLTEtMA_446bef58-8575-4caa-9887-c9b88b249552">55,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzUtMy0xLTEtMA_b45ec4a5-e05c-49b9-9f2f-458897816d90">45,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzEzODg_c43d6d9d-9f49-439a-a496-0141d7ab4afd" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Gross Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285babe5ab964ef29cef5180c50abd82_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzMtMS0xLTEtMA_5e253d42-2625-416c-b622-b812bc989eb9">23,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c07cafe2db4a11803bb4bf98296039_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzMtMy0xLTEtMA_03c92e7a-d6b3-44b4-87ce-e25de364ed68">16,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49eeee1198d4d19aadbc2d7fd7450bb_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzQtMS0xLTEtMA_b3e3d4ed-ca22-44d0-ab84-febc5d07b074">6,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4814ebae7b6547faaa86c64eccc633f1_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzQtMy0xLTEtMA_a1b2d0ed-3886-459b-9400-67db4f9ad9ef">5,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments Adjusted Gross Profit</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35f3002cf13457c85971a5a2c22d04e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzUtMS0xLTEtMA_49fedd5a-eba5-4e5b-8031-bc9bb0e49177">30,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib160b8d6aaec4f898595c6488b4def77_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzUtMy0xLTEtMA_826acb20-2ed3-4b3c-a3a5-301a1bc05021">22,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Adjusted Gross Profit reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzctMS0xLTEtMA_30f79c38-a7fb-4cd7-a9f2-55f6a67840fe">1,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzctMy0xLTEtMA_e762dbbb-69d3-4226-a679-66e0680d376b">992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less other reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEwLTEtMS0xLTA_47a54f2c-a71a-42e7-840a-bae6a8ddecd4">15,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEwLTMtMS0xLTA_bbc8d8f5-c418-4853-8a20-2297630f19b4">13,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzExLTEtMS0xLTA_3363df49-0ad9-4518-aa59-3758cc576a8d">14,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzExLTMtMS0xLTA_9950296f-bdb4-46c1-be56-59f787a5913d">13,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEyLTEtMS0xLTA_ae63fe3d-a788-4241-8074-b426b2333d80">15,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEyLTMtMS0xLTA_1949898d-8aad-4a5a-a45b-4ec1b09a2526">9,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEzLTEtMS0xLTA_83d49ac8-ba2b-4bd3-9a1d-3371d881ee5b">7,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEzLTMtMS0xLTA_c60448fb-a340-4ab7-af70-ccbade565c4a">2,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="hcat:InterestAndOtherExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE1LTEtMS0xLTA_df07c757-0f92-4bcf-9b70-9995689b9682">3,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331" decimals="-3" name="hcat:InterestAndOtherExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE1LTMtMS0xLTA_fec38111-7527-419b-b756-ffc45f0fa8d8">621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE2LTEtMS0xLTA_e1f2fd26-c7c7-421a-9b85-4d68ae1eb38b">28,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE2LTMtMS0xLTA_39aa4cf2-f406-4c5b-945a-f37cef4cb431">18,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements, the accompanying notes, and other financial information included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results could differ materially from those forward-looking statements below. Factors that could cause or contribute to those differences include, but are not limited to, those identified below and those discussed in &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-looking Statements.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_109"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Our customers, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. We envision a future where all healthcare decisions are data informed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights from the three months ended March&#160;31, 2021 included:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized total revenue of $55.8 million and $45.1 million for the three months ended March 31, 2021 and 2020, respectively. The growth in revenue was primarily due to revenue from new customers, including customers of our recently acquired entities, and existing customers paying higher technology access fees from contractual, annual escalators.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We incurred net losses of $(28.4) million and $(17.5) million for the three months ended March 31, 2021 and 2020, respectively. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Adjusted EBITDA was $(0.8) million and $(6.0) million for the three months ended March 31, 2021 and 2020, respectively. See &#8220;Key Financial Metrics&#8212;Reconciliation of Non-GAAP Financial Measures&#8221; for more information about this financial measure, including the limitations of such measure and a reconciliation to the most directly comparable measure calculated in accordance with GAAP.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Key Factors Affecting Our Performance&#8221; for more information about important opportunities and challenges related to our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a global pandemic. This pandemic, which has continued to spread, and the related adverse public health developments, including orders to shelter-in-place, travel restrictions, and mandated business closures, have adversely affected workforces, organizations, governments, customers, economies, and financial markets globally. It has also disrupted the normal operations of many businesses, including ours. COVID-19 has disrupted and we believe will continue to disrupt the normal operations of our customers, which are primarily healthcare providers. Given the unknown timeline and the near-term uncertainty of COVID-19 on our business, there continues to be uncertainty as to the extent to which the global COVID-19 pandemic may adversely impact our business operations, financial performance, and results of operations at this time. The ongoing COVID-19 surge, coupled alongside vaccine rollout logistics, likely indicate that our country and national healthcare system will be under some amount of continued strain over the coming months. Nevertheless, we continue to be encouraged as we witness meaningful evidence that the healthcare provider ecosystem is significantly better equipped and prepared to respond to the ongoing pandemic, including through its treatment efficacy, supply chain logistics, capacity planning, and broader operational optimization. Lastly, we are encouraged by the pace of the vaccine rollout efforts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are fortunate to have a highly recurring revenue model in which greater than 90% of our revenue is recurring in nature. As such, we expect that the near-term impact of COVID-19 on our total revenue will be relatively muted, as evidenced by our revenue performance for the three months ended March 31, 2021 and year ended December&#160;31, 2020. Additionally, we benefit from a high level of technology revenue predictability, especially our DOS subscription customers that typically have built-in, contractual technology revenue escalators. We also have developed a number of technology and services solutions designed specifically to support healthcare providers during the COVID-19 pandemic. Importantly, since the onset of the COVID-19 pandemic, our customers&#8217; overall usage of our data platform has increased meaningfully. Additionally, we have seen usage of our COVID-19-specific products shift from those focused on COVID-19 preparedness to those focused on financial recovery and planning analytics in areas such as elective procedures, ambulatory care, revenue cycle, and vaccine distribution and delivery. Given these factors, we have seen minimal impact on our technology dollar-based retention as a result of COVID-19 and would anticipate similar dynamics moving forward.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any negative impact to Q1 2021 total revenue caused by the COVID-19 pandemic has also resulted in a negative impact to our Q1 2021 Adjusted EBITDA. We have and continue to plan to partially offset any negative total revenue impact through cost containment efforts, resulting in less of a negative Adjusted EBITDA impact compared to the negative total revenue impact.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Importantly, in our response to the COVID-19 pandemic, we remain centrally committed to our more than 1,000 team members, ensuring they stay at the center of the Health Catalyst Flywheel. As such, any cost containment efforts implemented will have a bias towards non-headcount related items.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we get through the COVID-19 pandemic and healthcare organizations' operations begin to normalize, we continue to be optimistic that the pandemic will serve as an overall medium-to-long term tailwind in the industry&#8217;s adoption of data and analytics.  At the health system level, we are seeing meaningful evidence that COVID-19 is highlighting the need for a commercial-grade data and analytics solution to replace patchwork homegrown systems.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Metrics</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review a number of metrics, including the following key financial metrics, to manage our business and evaluate our operating performance compared to that of other companies in our industry:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Technology Gross Profit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Technology Gross Margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Professional Services Gross Profit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Professional Services Gross Margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Adjusted Gross Profit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Adjusted Gross Margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the key metrics set forth in the preceding table to help us evaluate trends, establish budgets, measure the effectiveness and efficiency of our operations, and determine employee incentives. Adjusted Gross Profit measures, Adjusted Gross Margin measures, and Adjusted EBITDA are non-GAAP financial measures, which we discuss in more detail below.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reconciliation of Non-GAAP&#160;Financial Measures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our results determined in accordance with GAAP, we believe certain non-GAAP measures, including Adjusted Gross Profit measures, Adjusted Gross Margin measures, and Adjusted EBITDA, are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted&#160;Gross Profit and&#160;Adjusted&#160;Gross Margin</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted&#160;Gross Profit is a&#160;non-GAAP&#160;financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization and excluding stock-based compensation. We define&#160;Adjusted&#160;Gross Margin as our&#160;Adjusted&#160;Gross Profit divided by our revenue. We believe&#160;Adjusted&#160;Gross Profit and&#160;Adjusted&#160;Gross Margin are useful to investors as they eliminate the impact of certain&#160;non-cash&#160;expenses and allow a direct comparison of these measures between periods without the impact of&#160;non-cash&#160;expenses and certain other non-recurring operating expenses. We present both of these measures for our technology and professional services business. We believe these&#160;non-GAAP&#160;measures are useful in evaluating our operating performance compared to that of other companies in our industry, as these metrics generally eliminate the effects of certain items that may vary from company to company for reasons unrelated to overall profitability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See above for information regarding the limitations of using our Adjusted Gross Profit and Adjusted Gross Margin as financial measures. The following is a reconciliation of our Adjusted Gross Profit to revenue, the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Professional Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Gross Profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,388&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Professional Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Gross Profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Technology Gross Margin remained consistent at 69% for both of the three months ended March 31, 2021 and 2020. We expect Adjusted Technology Gross Margin to fluctuate and potentially decline in the near term, primarily due to additional costs associated with transitioning customers from on-premise and our managed data centers to third-party hosted data centers with Microsoft Azure, where we incur additional hosting costs. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Professional Services Gross Margin increased from 25% for the three months ended March 31, 2020 to 31% for the three months ended March 31, 2021, due primarily to a change in the mix of professional services we provided and higher utilization rates. Our professional services are comprised of data and analytics services, domain expertise services, outsourcing services, and implementation services. The majority of our professional services revenue is generated from data and analytic services and domain expertise services, which are the highest gross margin professional services we provide. The delivery mix among all of our services in a given period can lead to fluctuations in our Adjusted Professional Services Gross Margin. Adjusted Professional Services Gross Margin may fluctuate on a quarterly basis and will likely decline in the near term due to changes in the mix of services we provide and the amount of operational overhead required to deliver our services.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted EBITDA</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for interest and other expense, net, loss on debt extinguishment, income tax provision (benefit), depreciation and amortization, stock-based compensation, acquisition transaction costs, and change in fair value of contingent consideration liabilities when they are incurred. We view acquisition-related expenses when applicable, such as transaction costs and changes in the fair value of contingent consideration liabilities that are directly related to business combinations as events that are not necessarily reflective of operational performance during a period. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance. We believe Adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See above for information regarding the limitations of using our Adjusted EBITDA as a financial measure.  The following is a reconciliation of our Adjusted EBITDA to net loss, the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,971)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Acquisition transaction costs relate to legal, diligence, valuation, and other third-party fees incurred as part of acquisitions. For additional details refer to Note 2 in our condensed consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The change in fair value of contingent consideration liability relates to changes in the estimated fair value of shares of our common stock that will be issued if certain performance targets for Able Health, Healthfinch, and Vitalware are met during the respective earn-out periods. For additional details refer to Note 7 in our condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Factors Affecting Our Performance</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future growth, success, and performance are dependent on many factors, including those set forth below. While these factors present significant opportunities for us, they also represent the challenges that we must successfully address in order to grow our business and improve our results of operations.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Impact of COVID-19 pandemic. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has adversely affected workforces, organizations, governments, customers, economies, and financial markets globally, leading to an economic downturn and increased market volatility. It has also disrupted the normal operations of many businesses, including ours. This outbreak, as well as intensified measures undertaken to contain the spread of COVID-19, could decrease healthcare industry spending, adversely affect demand for our technology and services, cause one or more of our customers to file for bankruptcy protection or go out of business, cause one or more of our customers to fail to renew, terminate, or renegotiate their contracts, affect the ability of our sales team to travel to potential customers and the ability of our professional services teams to conduct in-person services and trainings, impact expected spending from new customers, negatively impact collections of accounts receivable, and harm our business, results of operations, and financial condition. It is not possible for us to predict the duration or magnitude of the adverse results of the outbreak and its effects on our business, results of operations, or financial condition at this time.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Add new customers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to increase our customer base will enable us to drive growth. Our potential customer base is generally in the early stages of data and analytics adoption and maturity. We expect to further penetrate the market over time as potential customers invest in commercial data and analytics solutions. As one of the first data platform and analytics vendors focused specifically on healthcare organizations, we have an early-mover advantage and strong brand awareness. Our customers are large, complex organizations who typically have long procurement cycles which may lead to declines in the pace of our new customer additions.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Leverage recent product and services offerings to drive expansion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to expand within our customer base will enable us to drive growth. Over the last three years, we have developed and deployed several new analytics applications including CORUS, Touchstone, Patient Safety Monitor, Population Builder, and others. Because we are in the early stages of certain of our applications&#8217; lifecycles and maturity, we do not have enough information to know the impact on revenue growth by upselling these applications and associated services to current and new customers.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Impact of acquisitions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have acquired multiple companies over the last few years, including the Medicity acquisition in June 2018, the Able Health acquisition in February 2020, the Healthfinch acquisition in July 2020, and the Vitalware acquisition in September 2020. The historical and go-forward revenue growth profiles of these businesses may vary from our core DOS Subscription Customers, thus impacting our overall growth rate. Specifically, Medicity customers have generated a lower Dollar-based Retention Rate than DOS Subscription Customers and we expect flat to declining revenue from Medicity customers in the foreseeable future. If our cross-sell efforts and technology integration strategies are successful related to the recent acquisitions, this could offset revenue declines from Medicity customers. As we integrate the teams acquired via our recent acquisitions, we have also incurred integration-related costs and duplicative costs that could impact our operating cost profile in the near-term.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Changing revenue mix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology and professional services offerings have materially different gross margin profiles. While our professional services offerings help our customers achieve measurable improvements and make them stickier, they have lower gross margins than our technology revenue. For the three months ended March 31, 2021, our technology revenue and professional services revenue represented 61% and 39% of total revenue, respectively. Changes in our revenue mix between the two offerings would impact future Total Adjusted Gross Margin. Furthermore, changes within the types of professional services we offer over time can have a material impact on our Adjusted Professional Services Gross Margin, impacting our future Total Adjusted Gross Margin. See &#8220;Key Financial Metrics&#8212;Reconciliation of Non-GAAP Financial Measures&#8221; for more information. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Transitions to Microsoft Azure as DOS hosting provider. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur hosting fees related to providing DOS through a cloud-based environment hosted by Microsoft Azure. We also operate a private data center where we host DOS for certain customers and we maintain a small number of customers that have deployed DOS on-premise. We are in the process of transitioning customers we host in our private data center and who deployed DOS on-premise to Azure-hosted environments. The Azure cloud provides customers with more advanced DOS product functionality and a more seamless customer experience; however, hosting customers in Azure is more costly to us than our private data center on a per-customer basis. This transition will result in higher cost of technology revenue and provide a headwind against increases in Adjusted Technology Gross Margin.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_121"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Acquisitions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Able Health, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, we acquired Able Health, Inc. (Able Health), a leading software-as-a-service provider of quality and regulatory measurement tracking and reporting to healthcare providers and risk-bearing entities, in a transaction accounted for as a business combination. We believe this acquisition will strengthen Health Catalyst&#8217;s Quality and Regulatory Measures capabilities. The acquisition consideration transferred was $21.5 million and was comprised of net cash consideration of $15.2 million, Health Catalyst common shares with a fair value of $3.3 million, and contingent consideration based on achievement of Able Health specified incremental customer billings for the year ended December 31, 2020, which had an initial estimated fair value of $3.0 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Able Health. The Able Health contingent consideration liability was settled during the three months ended March 31, 2021. For additional details refer to Note 7 in our condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthfinch, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, we acquired Healthfinch, Inc. (Healthfinch), which provides a workflow integration engine delivering insights and analytics into EMR workflows to automate physicians&#8217; ability to close patient care gaps in real-time, in a transaction accounted for as a business combination. We believe this acquisition will strengthen our existing population health capabilities. The acquisition consideration transferred was $50.5 million and was comprised of net cash consideration of $16.9 million, Health Catalyst common shares with a fair value of $27.8 million, and contingent consideration based on certain earn-out performance targets for Healthfinch during an earn-out period that ends on July 31, 2021, which had an initial estimated fair value of $5.8 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Healthfinch.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vitalware, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we acquired Vitalware, LLC (Vitalware), a provider of revenue workflow optimization and analytics SaaS technology solutions to healthcare organizations, in a transaction accounted for as a business combination. Vitalware&#8217;s flagship offering is a chargemaster management solution that delivers analytics for the complex regulatory and compliance functions needed by healthcare provider systems. Additionally, Vitalware brings to bear newer product suites to help health systems capture lost revenue and to support compliance with expanding pricing transparency regulation. The acquisition consideration transferred was $119.2 million and was comprised of net cash consideration of $69.6 million, Health Catalyst common shares with a fair value of $41.3 million, and contingent consideration based on certain earn-out performance targets for Vitalware during an earn-out period that ended on March 31, 2021, which had an initial estimated fair value of $8.3 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Vitalware. We have initiated the earn-out settlement process and anticipate that we will finalize the earn-out payment amount and distribution terms, and formally settle the contingent consideration liability associated with the Vitalware acquisition during the three months ended June 30, 2021. We currently anticipate that we will pay approximately $15.0 million in cash and issue approximately 309,458 shares of our common stock to settle this contingent consideration liability. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenue from sales of technology and professional services. For the three months ended March 31, 2021 and 2020, technology represented 61% and 55% of total revenue, respectively, and professional services represented 39% and 45%, of total revenue, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Technology revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Technology revenue primarily consists of subscription fees charged to customers for access to use our data platform and analytics applications. We provide customers access to our technology through either an all-access or limited-access, modular subscription. Most of our subscription contracts are cloud-based and have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#8217; notice. A majority of our DOS Subscription Customers access our technology through all-access subscriptions, which in the vast majority of cases have built-in annual escalators for technology access fees. Also included in technology revenue is the maintenance and support we provide, which generally includes updates and support services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Professional services revenue primarily includes analytics services, domain expertise services, outsourcing services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our customers on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our customers.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of customer billings in advance of revenue being recognized from our technology and professional services arrangements. We primarily invoice our customers for technology arrangements annually or quarterly in advance. Amounts anticipated to be recognized within one year of the balance sheet date are recorded as deferred revenue and the remaining portion is recorded as deferred revenue, net of current portion on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of revenue, excluding depreciation and amortization</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of technology revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, contractor costs, and salary and related personnel costs for our cloud services and support teams.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect cost of technology revenue to increase in absolute dollars as we transition customers to third-party hosted data centers with Microsoft Azure and increase headcount to accommodate growth, we anticipate cost of technology revenue as a percentage of technology revenue will generally decrease over the long term. We expect cost of technology revenue as a percentage of technology revenue to fluctuate and potentially increase in the near term, primarily due to additional costs associated with transitioning customers from on-premise and our managed data centers to Microsoft Azure. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of professional services revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cost of professional services revenue consists primarily of costs related to delivering our team&#8217;s expertise in analytics, strategic advisory, improvement, and implementation services. These costs primarily include salary and related personnel costs, travel-related costs, and outside contractor costs. We expect cost of professional services revenue to increase in absolute dollars as we increase headcount to accommodate growth.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and marketing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sales and marketing expenses primarily include salary and related personnel costs for our sales, marketing, and account management teams, lead generation, marketing events, including our Healthcare Analytics Summit, marketing programs, and outside contractor costs associated with the sale and marketing of our offerings. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to invest in sales and marketing to grow our customer base, expand in new markets, and increase our brand awareness. The trend and timing of sales and marketing expenses will depend in part on the timing of our expansion into new markets and marketing campaigns. We expect that sales and marketing expenses will increase in absolute dollars in future periods, but decrease as a percentage of our revenue over the long term. Our sales and marketing expenses may fluctuate as a percentage of our revenue from period to period due to the timing and extent of these expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development expenses primarily include salary and related personnel costs for our data platform and analytics applications teams, subscriptions, and outside contractor costs associated with the development of products. We have developed an open, flexible, and scalable data platform. We plan to continue to invest in research and development to develop new solutions and enhance our applications library. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that research and development expenses will increase in absolute dollars in future periods, but decrease as a percentage of our revenue over the long term. Our research and development expenses may fluctuate as a percentage of our revenue from period to period due to the timing and extent of these expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;General and administrative expenses primarily include salary and related personnel costs for our legal, finance, people operations, IT, and other administrative teams, including certain executives. General and administrative expenses also include facilities, subscriptions, corporate insurance, outside legal, accounting, directors&#8217; fees, and the change in fair value of contingent consideration liabilities. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses to increase in absolute dollars for the foreseeable future, but decrease as a percentage of our revenue over the long term. Our general and administrative expenses may fluctuate as a percentage of our revenue from period to period due to the timing and extent of these expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expenses are primarily attributable to our capital investment and consist of fixed asset depreciation, amortization of intangibles considered to have definite lives, and amortization of capitalized internal-use software costs.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and other expense, net</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other expense, net primarily consists of interest expense partially offset by income from our investment holdings. Interest expense in the current year is primarily attributable to the Notes and in prior years was primarily attributable to our now extinguished term loan and imputed interest on acquisition-related consideration payable. It also includes the amortization of discounts on debt and amortization of deferred financing costs related to our various debt arrangements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax provision (benefit)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) consists of U.S. federal, state, and foreign income taxes. Because of the uncertainty of the realization of the deferred tax assets, we have a full valuation allowance for our net deferred tax assets, including net operating loss carryforwards (NOLs) and tax credits related primarily to research and development.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had federal and state NOLs of $419.6&#160;million and $334.6&#160;million, respectively, which will begin to expire for federal and state tax purposes in 2032 and 2023, respectively. Our existing NOLs may be subject to limitations arising from ownership changes and, if we undergo an ownership change in the future, our ability to utilize our NOLs and tax credits could be further limited by Sections&#160;382 and 383 of the Code. Future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections&#160;382 and 383 of the Code. Our NOLs and tax credits may also be limited under similar provisions of state law.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted and signed into U.S. law to provide economic relief to individuals and businesses facing economic hardship as a result of the COVID-19 pandemic. On March 11, 2021, the American Rescue Plan Act of 2021 (ARPA) was enacted and signed into U.S. law to provide additional economic stimulus and tax credits. Changes in tax laws or rates are accounted for in the period of enactment. We are continuing to analyze these legislative developments and believe that the income tax provisions of the CARES Act and ARPA do not have a significant impact on our current taxes, deferred taxes, or uncertain tax positions. The CARES Act also provides for the deferral of an employer&#8217;s portion of social security payroll taxes for the remainder of 2020. Under the CARES Act, half of the deferred amount will have to be paid in each of December 2021 and December 2022. We began deferring the social security payroll tax match in April 2020.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our consolidated results of operations data and such data as a percentage of total revenue for each of the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue, excluding depreciation and amortization shown below:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue, excluding depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,317)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,726)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,370)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,490)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes stock-based compensation expense, as follows:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock-Based Compensation Expense:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue, excluding depreciation and amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes acquisition transaction costs, as follows:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition transaction costs:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes the change in fair value of contingent consideration liability, as follows:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in fair value of contingent consideration liability:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue, excluding depreciation and amortization shown below:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue, excluding depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_127"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of the Three Months Ended March 31, 2021 and 2020 </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $55.8 million for the three months ended March 31, 2021, compared to $45.1 million for the three months ended March 31, 2020, an increase of $10.7 million, or 24%. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology revenue was $33.8 million, or 61% of total revenue, for the three months ended March 31, 2021, compared to $24.7 million, or 55% of total revenue, for the three months ended March 31, 2020. The technology revenue growth was primarily from new DOS Subscription Customers, acquired technology customers, revenue from existing customers paying higher technology access fees from contractual, annual escalators, and new offerings of expanded support services.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services revenue was $22.0 million, or&#160;39% of total revenue, for the three months ended March 31, 2021, compared to $20.4 million, or 45% of total revenue, for the three months ended March 31, 2020. The professional services revenue growth is primarily due to implementation, analytics, outsourcing, and other improvement services being provided to new DOS Subscription Customers, partially offset by lower professional services dollar-based retention relative to historical performance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of revenue, excluding depreciation and amortization</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue, excluding depreciation and amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue, excluding depreciation and amortization</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of technology revenue, excluding depreciation and amortization, was $10.8 million for the three months ended March 31, 2021, compared to $7.9 million for the three months ended March 31, 2020, an increase of $2.9 million, or 37%. The increase in cost of technology revenue was primarily due to $1.7 million in increased cloud computing and hosting costs largely from the expanded use of Microsoft Azure to serve existing and new customers and an increase of $0.8 million in salary and related personnel costs from an increase in cloud services and support headcount.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of professional services revenue was $16.5 million for the three months ended March 31, 2021, compared to $16.2 million for the three months ended March 31, 2020, an increase of $0.4 million, or 2%. This increase was primarily due to a $0.3 million increase in salary and related personnel costs from additional professional services headcount and additional stock-based compensation of $0.6 million, partially offset by a decrease in travel-related expenses of $0.6 million due to the impact of COVID-19 related travel restrictions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and marketing</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses were $15.7 million for the three months ended March 31, 2021, compared to $13.5 million for the three months ended March 31, 2020, an increase of $2.2 million, or 16%. The increase was primarily due to a $1.6 million increase in stock-based compensation and a $1.2 million increase in salary and related personnel costs from additional headcount, including new team members added as part of our 2020 acquisitions, partially offset by a decrease in travel-related expenses of $0.8 million due to the impact of COVID-19 related travel restrictions.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense as a percentage of total revenue decreased from 30% in the three months ended March 31, 2020 to 28% in the three months ended March 31, 2021. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $14.3 million for the three months ended March 31, 2021, compared to $13.1 million for the three months ended March 31, 2020, an increase of $1.3 million, or 10%. The increase was primarily due to an increase of $0.4 million in stock-based compensation and an increase of $0.7 million in salary and related personnel costs from additional development team headcount, including new team members added as part of our 2020 acquisitions.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense as a percentage of revenue decreased from 29% in the three months ended March 31, 2020 to 26% in the three months ended March 31, 2021. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $15.0 million for the three months ended March 31, 2021, compared to $9.7 million for the three months ended March 31, 2020, an increase of $5.3 million, or&#160;55%. The increase was primarily due to increases of $2.5 million in change in fair value of contingent consideration liabilities, $1.9 million in stock-based compensation, and $1.1 million in salary and related personnel costs from additional headcount,  including new team members added as part of our 2020 acquisitions, partially offset by a decrease of $0.9 million in acquisition-related costs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense as a percentage of revenue increased from 22% in the three months ended March 31, 2020 to 27% in the three months ended March 31, 2021.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses were $7.8 million for the three months ended March 31, 2021, compared to $2.9 million for the three months ended March 31, 2020, an increase of $4.9 million, or&#160;172%. This increase was primarily due to the amortization of acquired intangible assets resulting from our 2020 business combinations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense as a percentage of revenue increased from 6% in the three months ended March 31, 2020 to 14% in the three months ended March 31, 2021.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other expense, net</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(834)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other expense, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,952)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,331)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other expense, net increased $3.3 million, or 536%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. This change is primarily due to an increase in non-cash interest expense of $2.6 million from the amortization of debt issuance costs and discounts related to our Notes Offering that occurred in April 2020. There was also a decrease in interest income of $0.8 million due to lower market interest rates.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax provision (benefit)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Not meaningful.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision consists of current and deferred taxes for U.S. federal, state, and foreign income taxes. As we have a full valuation allowance on deferred tax assets, our income tax provision typically consists primarily of minimal state and foreign income taxes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit of $1.2 million recorded for the three months ended March 31, 2020 is primarily related to the discrete deferred tax benefit attributable to the release of a portion of the valuation allowance during the quarter. The release of valuation allowance is attributable to the acquisition of Able Health, which resulted in deferred tax liabilities that, upon acquisition, allowed us to recognize certain deferred tax assets of approximately $1.3 million that had previously been offset by a valuation allowance.</span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_130"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had cash, cash equivalents, and short-term investments of $266.4 million, which were held for working capital and other general corporate purposes, which may include potential acquisitions and strategic transactions. Our cash equivalents and short-term investments are comprised primarily of money market funds, U.S. treasury notes, commercial paper, corporate bonds, and asset-backed securities. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have financed our operations primarily from the proceeds we received through private sales of equity securities, payments received from customers under technology and professional services arrangements, borrowings under our loan and security agreements, our 2019 IPO, an our 2020 offering of convertible senior notes. Our future capital requirements will depend on many factors, including our pace of new customer growth and expanded customer relationships, technology and professional services renewal activity, and the timing and extent of spend to support the expansion of sales, marketing, development, and acquisition-related activities. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us, or at all. If we are unable to raise additional capital when desired, our business, results of operations, and financial condition would be adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2020, we issued $230.0&#160;million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025 (the Notes), pursuant to an Indenture dated April 14, 2020, with U.S. Bank National Association, as trustee, in a private offering to qualified institutional buyers. We received net proceeds from the Notes of  $222.5&#160;million, after deducting the initial purchasers&#8217; discounts and offering expenses payable by us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior, unsecured obligations and will accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Notes are convertible into cash, shares of our common stock, or a combination of cash and shares of our common stock, with the form of consideration determined at our election. The conversion rate is initially 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Calls</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (the Base Capped Calls) with certain financial institutions, or option counterparties. In addition, in connection with the initial purchasers&#8217; exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (the Additional Capped Calls, and, together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. We used approximately $21.6 million of the net proceeds from the Note Offering to pay the option premium cost of the Capped Calls. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9 of our condensed consolidated financial statements for additional details regarding the private offering of the Notes and the Capped Calls.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash, cash equivalents and marketable securities  will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months, though we may require additional capital resources in the future.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest source of operating cash flows is cash collections from our customers for technology and professional services arrangements. Our primary uses of cash from operating activities are for employee-related expenses, marketing expenses, and technology costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, net cash used in operating activities was $3.1 million, which included a net loss of $28.4 million. Non-cash adjustments primarily consisted of $7.8 million in depreciation and amortization of property, equipment, and intangible assets, $13.5 million in stock-based compensation, $2.2 million in change in fair value of contingent consideration liabilities, and $2.9 million in amortization of debt discount and issuance costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2020, net cash used in operating activities was $16.8 million, which included a net loss of $17.5 million. Non-cash adjustments primarily consisted of $2.9 million in depreciation and amortization of property, equipment, and intangible assets, $8.7 million in stock-based compensation, the $0.4 million change in fair value of contingent consideration liability, and the $1.3 million deferred tax benefit.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March 31, 2021 of $37.4 million was primarily due to $53.2 million provided from the sale and maturity of short-term investments, reduced by $8.6 million in purchases of short-term investments, and $6.4 million in purchases of property, equipment, and intangible assets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March 31, 2020 of $50.1 million was primarily due to $66.7 million provided from the sale and maturity of short-term investments, reduced by the net cash consideration used to acquire Able Health of $15.2 million, and $1.3 million in purchases of property, equipment, and intangible assets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March 31, 2021 of $6.4 million was primarily the result of $6.5 million in stock option exercise proceeds and $1.3 million in proceeds from our ESPP, reduced by the $1.4 million in payments of acquisition-related obligations. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March 31, 2020 of $9.6 million was primarily the result of  $9.0 million in stock option exercise proceeds and $1.3 million in proceeds from our ESPP, reduced by $0.7 million in payments of acquisition-related obligations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_133"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the contractual obligations as disclosed in our Annual Report on Form 10-K, filed with the SEC on February 25, 2021. Refer to &#8220;Note 9&#8212;Convertible Senior Notes" and "Note 14&#8212;Commitments and Contingencies" of our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information regarding our commitments and contractual obligations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_136"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance&#160;Sheet Arrangements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating&#160;off-balance&#160;sheet arrangements or other contractually narrow or limited purposes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_139"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. Critical accounting policies and estimates are those that we consider critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. We will continue to actively monitor the impact of the COVID-19 pandemic and other factors on expected credit losses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates as previously disclosed in our Annual Report on Form 10-K, filed with the SEC on February 25, 2021. See &#8220;Note 1&#8212;Description of Business and Summary of Significant Accounting Policies&#8221; of our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information regarding the Company's significant accounting policies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_145"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 1&#8212;Description of Business and Summary of Significant Accounting Policies&#8221; to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information regarding recently issued accounting pronouncements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_148"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;Quantitative and Qualitative Disclosures about Market Risk&#160;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to certain market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates but may include foreign currency exchange risk and inflation in the future.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents, and short-term investments of $266.4 million as of March&#160;31, 2021, which are held for working capital purposes. We do not make investments for trading or speculative purposes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and short-term investments are subject to market risk due to changes in factors such as interest rates, market liquidity, and credit ratings. Fixed rate securities may have their market value adversely affected due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fluctuate due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates or other factors. However, because we classify our investments as &#8220;available for sale,&#8221; no gains or losses are recognized due to changes in interest rates unless such securities are sold prior to maturity or declines in fair value are determined to result in a loss from deterioration in credit quality.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, a hypothetical 100 basis point change in interest rates would not have had a material impact on the value of our cash equivalents or investment portfolio. Fluctuations in the value of our cash equivalents and investment portfolio caused by a change in interest rates (gains or losses on the carrying value) are recorded in other comprehensive income and are realized only if we sell the underlying securities prior to maturity, or otherwise recognized in our condensed consolidated statement of operations, if an investment in an available-for-sale debt security is in a loss position and the loss is attributable to a decline in credit quality.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting currency is the U.S. dollar, and the functional currency of our subsidiaries is typically their local currency. Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Singapore Dollar. Due to the relatively small size of our international operations to date, our foreign currency exposure has been fairly limited and thus we have not instituted a hedging program. We are considering the costs and benefits of initiating such a program and may in the future hedge balances and transactions denominated in currencies other than the U.S. dollar as we expand international operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, our international sales contracts are generally denominated in U.S. dollars, while our international operating expenses are often denominated in local currencies. In the future, an increasing portion of our international sales contracts may be denominated in local currencies. Additionally, as we expand our international operations a larger portion of our operating expenses will be denominated in local currencies. Therefore, fluctuations in the value of the U.S. dollar and foreign currencies may affect our results of operations when translated into U.S. dollars.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation has had a material effect on our business, results of operations, or financial condition. Nonetheless, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs. Our inability or failure to do so could harm our business, results of operations, or financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_151"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a&#8211;15(e) and Rule 15d&#8211;15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of&#160;March&#160;31, 2021. Based on the evaluation of our disclosure controls and procedures as of&#160;March&#160;31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are currently working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the effects that the COVID-19 pandemic may have on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_157"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;Legal Proceedings</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, from time to time, subject to legal proceedings and claims arising from the normal course of business activities, and an unfavorable resolution of any of these matters could materially affect our future business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future litigation may be necessary, among other things, to defend ourselves or our users by determining the scope, enforceability, and validity of third-party proprietary rights or to establish our proprietary rights. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_160"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, in addition to the other information contained in this Quarterly Report on Form 10-Q, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Industry</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We operate in a highly competitive industry, and if we are not able to compete effectively, our business and results of operations will be harmed.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for healthcare solutions is intensely competitive. We compete across various segments within the healthcare market, including with respect to data analytics and technology platforms, healthcare consulting, care management and coordination, population health management, and health information exchange.  Competition in our market involves rapidly changing technologies, evolving regulatory requirements and industry expectations, frequent new product introductions, and changes in customer requirements. If we are unable to keep pace with the evolving needs of our customers and continue to develop and introduce new applications and services in a timely and efficient manner, demand for our Solution may be reduced and our business and results of operations will be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from industry-agnostic analytics companies and EHR companies, such as Epic Systems and Cerner.  We also compete with other large, well-financed, and technologically sophisticated entities.  Some of our current large competitors, such as Optum Analytics and IBM, have greater name recognition, longer operating histories, significantly greater resources than we do, and/or more established distribution networks and relationships with healthcare providers.  As a result, our current and potential competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements. In addition, current and potential competitors have established, and may in the future establish, cooperative relationships with vendors of complementary products, or services to increase the availability of their products or services to the marketplace. Current or future competitors may consolidate to improve the breadth of their products, directly competing with our Solution. Accordingly, new competitors may emerge that have greater market share, larger customer bases, greater breadth and volume of data, more widely adopted proprietary technologies, broader offerings, greater marketing expertise, greater financial resources, and larger sales forces than we have, which could put us at a competitive disadvantage. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in light of these advantages, even if our Solution is more effective than the product or service offerings of our competitors, current or potential customers might select competitive products and services in lieu of purchasing our Solution.  We face competition from niche vendors, who offer stand-alone products and services, and from existing enterprise vendors, including those currently focused on software products, which have information systems in place with customers in our target markets. These existing enterprise vendors may now, or in the future, offer or promise products or services with less functionality than our Solution, but offer ease of integration with existing systems and that leverage existing vendor relationships.  Increased competition is likely to result in pricing pressures, which could negatively impact our sales, profitability, or market share.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient engagement, population health, and care coordination services face competition from a wide variety of market participants. For example, certain health systems have developed their own population health and care coordination systems. If we fail to distinguish our offerings from the other options available to healthcare providers, the demand for and market share of those offerings may decrease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Changes in the healthcare industry could affect the demand for our Solution, cause our existing contracts to be terminated, and negatively impact the process of negotiating future contracts.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the healthcare industry evolves, changes in our customer and vendor bases may reduce the demand for our Solution, result in the termination of existing contracts or certain services provided under existing contracts, and make it more difficult to negotiate new contracts on terms that are acceptable to us. For example, the increasing market share of EHR companies in data analytic services at hospital systems may cause our existing customers to terminate contracts with us in order to engage EHR companies to provide these services. Similarly, customer and vendor consolidation results in fewer, larger entities with increased bargaining power and the ability to demand terms that are unfavorable to us. If these trends continue, we cannot assure you that we will be able to continue to maintain or expand our customer base, negotiate contracts with acceptable terms, or maintain our current pricing structure, and our revenue may decrease.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General reductions in expenditures by healthcare organizations, or reductions in such expenditures within market segments that we serve, could have similar impacts with regard to our Solution. Such reductions may result from, among other things, reduced governmental funding for healthcare; a decrease in the number of, or the market exclusivity available to, new drugs coming to market; or adverse changes in business or economic conditions affecting healthcare payors or providers, the pharmaceutical industry, or other healthcare companies that purchase our services (e.g., changes in the design of health plans). In addition, changes in government regulation of the healthcare industry could potentially negatively impact our existing and future contracts. Any of these changes could reduce the purchase of our Solution by such customers, reducing our revenue and possibly requiring us to materially revise our offerings. In addition, our customers&#8217; expectations regarding pending or potential industry developments may also affect their budgeting processes and spending plans with respect to our Solution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The recent global coronavirus (COVID-19) outbreak could harm our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a global pandemic. This pandemic, which has continued to spread, and the related adverse public health developments, including orders to shelter-in-place, travel restrictions, and mandated business closures, have adversely affected workforces, organizations, governments, customers, economies, and financial markets globally, leading to an economic downturn and increased market volatility. It has also disrupted the normal operations of many businesses, including ours. This outbreak, as well as intensified measures undertaken to contain the spread of COVID-19, could decrease healthcare industry spending, adversely affect demand for our technology and services, cause one or more of our customers to file for bankruptcy protection or go out of business, cause one or more of our customers to fail to renew, terminate, or renegotiate their contracts, affect the ability of our sales team to travel to potential customers and the ability of our professional services teams to conduct in-person services and trainings, impact expected spending from new customers, negatively impact collections of accounts receivable, and harm our business, results of operations, and financial condition. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the sales cycle for a new customer of our technology and services, which has averaged approximately one year, could lengthen, resulting in a potentially longer delay between increasing operating expenses and the generation of corresponding revenue, if any. We cannot predict with any certainty whether and to what degree the disruption caused by the COVID-19 pandemic and reactions thereto will continue and expect to face difficulty accurately predicting our internal financial forecasts. The outbreak also presents challenges as our entire workforce is currently working remotely and shifting to assisting new and existing customers who are also generally working remotely. It is not possible for us to predict the duration or magnitude of the adverse results of the outbreak and its effects on our business, results of operations, or financial condition at this time.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">We may be unable to successfully execute on our growth initiatives, business strategies, or operating plans.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continually executing a number of growth initiatives, strategies, and operating plans designed to enhance our business. For example, we recently expanded our data analytics services into the payor and life sciences markets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to successfully complete these growth initiatives, strategies, and operating plans and realize all of the benefits, including growth targets and cost savings, that we expect to achieve or it may be more costly to do so than we anticipate. A variety of factors could cause us not to realize some or all of the expected benefits. These factors include, among others, delays in the anticipated timing of activities related to such growth initiatives, strategies, and operating plans, increased difficulty and cost in implementing these efforts, including difficulties in complying with new regulatory requirements and the incurrence of other unexpected costs associated with operating the business. Moreover, our continued implementation of these programs may disrupt our operations and performance. As a result, we cannot assure you that we will realize these benefits. If, for any reason, the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies, and operating plans adversely affect our operations or cost more or take longer to effectuate than we expect, or if our assumptions prove inaccurate, our business, financial condition, and results of operations may be materially adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">If we fail to provide effective professional services and high-quality customer support, our business and reputation would suffer.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our professional services and high-quality, ongoing customer support are important to the successful marketing and sale of our products and services and for the renewal of existing customer agreements. Providing these services and support requires that our professional services and support personnel have healthcare, technical, and other knowledge and expertise, making it difficult for us to hire qualified personnel and scale our professional services and support operations. The demand on our customer support organization will increase as we expand our business and pursue new customers, and such increased support could require us to devote significant development services and support personnel, which could strain our team and infrastructure and reduce our profit margins. If we do not help our customers quickly resolve any post-implementation issues and provide effective ongoing customer support, our ability to sell additional products and services to existing and future customers could suffer and our reputation would be harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales cycles can be long and unpredictable, and our sales efforts require a considerable investment of time and expense. If our sales cycle lengthens or we invest substantial resources pursuing unsuccessful sales opportunities, our results of operations and growth would be harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales process entails planning discussions with prospective customers, analyzing their existing solutions and identifying how these potential customers can use and benefit from our Solution. The sales cycle for a new customer, from the time of prospect qualification to the completion of the first sale, has averaged approximately one year and in some cases has exceeded two years. We spend substantial time, effort and money in our sales efforts without any assurance that our efforts will result in the sale of our Solution. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our sales cycle and timing of sales can vary substantially from customer to customer because of various factors, including the discretionary nature of potential customers&#8217; purchasing and budget decisions, the announcement or planned introduction of new analytics applications or services by us or our competitors, and the purchasing approval processes of potential customers. If our sales cycle lengthens or we invest substantial resources pursuing unsuccessful sales opportunities, our results of operations and growth would be harmed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Our DOS platform or our analytics applications may not operate properly, which could damage our reputation, give rise to claims against us, or divert application of our resources from other purposes, any of which could harm our business and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary software development is time-consuming, expensive, and complex. Unforeseen difficulties can arise. We may encounter technical obstacles, and it is possible that we will discover additional problems that prevent our applications from operating properly. If our systems do not function reliably or fail to meet user or customer expectations in terms of performance, customers could assert liability claims against us or attempt to cancel their contracts with us, and members could choose to terminate their use of our Solution. This could damage our reputation and impair our ability to attract or retain customers and members. Information services as complex as those we offer have, in the past, contained, and may in the future develop or contain, undetected defects, vulnerabilities, or errors. We cannot be assured that material performance problems or defects in our software will not arise in the future. Errors may result from sources beyond our control, including the receipt, entry, or interpretation of patient information; the interface of our software with legacy systems that we did not develop; or errors in data provided by third parties. Despite testing, defects or errors may arise in our existing or new software or service processes following introduction to the market.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers rely on our Solution to collect, manage, and report clinical, financial, and operational data, and to provide timely and accurate information regarding medical treatment and care delivery patterns. They may have a greater sensitivity to service errors and security vulnerabilities than customers of software products in general.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinicians may also rely on our predictive models for care delivery prioritization, and to inform treatment protocols.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limitations of liability and disclaimers that purport to limit our liability for damages related to defects in our software or content which we may include in our subscription and services agreements may not be enforced by a court or other tribunal or otherwise effectively protect us from related claims. In most cases, we maintain liability insurance coverage, including coverage for errors and omissions. However, it is possible that claims could exceed the amount of our applicable insurance coverage or that this coverage may not continue to be available on acceptable terms or insufficient amounts.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of this, defects, vulnerabilities, and errors and any failure by us to identify and address them could result in loss of revenue or market share; liability to customers, members, their patients, or others; failure to achieve market acceptance or expansion; diversion of development and management resources; delays in the introduction of new services; injury to our reputation; and increased service and maintenance costs. Defects, vulnerabilities, or errors in our software and service processes might discourage existing or potential customers or members from purchasing services from us. Correction of defects, vulnerabilities, or errors could prove to be impossible or impractical. The costs incurred in correcting any defects, vulnerabilities, or errors or in responding to resulting claims or liability may be substantial and could adversely affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing customers and to our ability to attract new customers. The promotion of our brands may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. Our marketing activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our results of operations could be harmed. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our customers, or any adverse publicity surrounding one of our investors or customers, could make it substantially more difficult for us to attract new customers. If we do not successfully maintain and enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with customers, which would harm our business, results of operations, and financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not continue to innovate and provide services that are useful to customers and users, we may not remain competitive, and our revenue and results of operations could suffer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for healthcare in the United States is in the early stages of structural change and is rapidly evolving toward a more value-based care model. Our success depends on our ability to keep pace with technological developments, satisfy increasingly sophisticated customer and user requirements, and sustain market acceptance. Our future financial performance will depend in part on growth in this market and on our ability to adapt to emerging demands of this market, including adapting to the ways our customers or users access and use our Solution. Although we have built eight new software analytics applications in the last three years, we may not be able to sustain this rate of innovation. Our competitors are constantly developing products and services that may become more efficient or appealing to our customers or users. As a result, we must continue to invest significant resources in research and development in order to enhance our existing services and introduce new high-quality services and applications that customers will want, while offering our Solution at competitive prices. If we are unable to predict user preferences or industry changes, or if we are unable to modify our Solution on a timely or cost-effective basis, we may lose customers and users. Our results of operations would also suffer if our innovations are not responsive to the needs of our customers, are not appropriately timed with market opportunity, or are not effectively brought to market, including as the result of delayed releases or releases that are ineffective or have errors or defects. As technology continues to develop, our competitors may be able to offer results that are, or that are perceived to be, substantially similar to, or better than, those generated by our Solution. This may force us to compete on additional service attributes and to expend significant resources in order to remain competitive.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected if our customers are not satisfied with our Solution.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on customer satisfaction to succeed with respect to our cloud-based solutions. Our sales organization is dependent on the quality of our offerings, our business reputation, and the strong recommendations from existing customers. If our cloud-based software does not function reliably or fails to meet customer expectations in terms of performance and availability, customers could assert claims against us or terminate their contracts with us or publish negative feedback. This could damage our reputation and impair our ability to attract or retain customers. Furthermore, we provide professional services to customers to support their use of our applications and to achieve measurable clinical, financial, and operational improvements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to maintain high-quality professional services, or a market perception that we do not maintain high-quality professional services, could harm our reputation, adversely affect our ability to sell our Solution to existing and prospective customers, and harm our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our existing customers do not continue or renew their contracts with us, renew at lower fee levels or decline to purchase additional technology and services from us, it could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to derive a significant portion of our revenue from the renewal of existing customer contracts and sales of additional technology and services to existing customers. As part of our growth strategy, for instance, we have recently focused on expanding our Solution among current customers. As a result, selling additional technology and services is critical to our future business, revenue growth, and results of operations. Factors that may affect our ability to sell additional technology and services include, but are not limited to, the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price, performance, and functionality of our Solution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, price, performance, and functionality of competing solutions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and sell complementary technology and services;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the stability, performance, and security of our hosting infrastructure and hosting services;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continuously deliver measurable improvements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">health systems&#8217; demand for professional services to augment their internal data analytics function;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in healthcare laws, regulations, or trends; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the business environment of our customers and, in particular, headcount reductions by our customers; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into subscription contracts with our customers for access to our Solution. Many of these contracts have initial terms of one to three years. Most of our customers have no obligation to renew their subscriptions for our Solution after the initial term expires. Although we have long-term contracts with many customers, these contracts may be terminated by the customer before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. For example, after a specified period, certain of these contracts are terminable for convenience by our customers, subject to providing us with prior notice. Certain of our contracts may be terminated by the customer immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the customer if we lose applicable third-party licenses, go bankrupt, or lose our liability insurance. If any of our contracts with our customers are terminated, we may not be able to recover all fees due under the terminated contract and we will lose future revenue from that customer, which may adversely affect our results of operations. We expect that future contracts will contain similar provisions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our customers may negotiate terms less advantageous to us upon renewal, which may reduce our revenue from these customers. Our future results of operations also depend, in part, on our ability to upgrade and enhance our Solution. If our customers fail to renew their contracts, renew their contracts upon less favorable terms, or at lower fee levels or fail to purchase new technology and services from us, our revenue may decline or our future revenue growth may be constrained.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations have in the past fluctuated and may continue to fluctuate significantly, and if we fail to meet the expectations of analysts or investors, our stock price and the value of an investment in our common stock could decline substantially.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are likely to fluctuate, and if we fail to meet or exceed the expectations of securities analysts or investors, the trading price of our common stock could decline. Moreover, our stock price may be based on expectations of our future performance that may be unrealistic or that may not be met. Some of the factors that could cause our revenue and results of operations to fluctuate from quarter to quarter include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our Solution achieves or maintains market acceptance;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to introduce new applications, updates, and enhancements to our existing applications on a timely basis;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new competitors and the introduction of enhanced products and services from new or existing competitors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the length of our contracting and implementation cycles and our fulfillment periods for our Solution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mix of revenue generated from professional services as compared to technology subscriptions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the financial condition of our current and future customers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in customer budgets and procurement policies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations or marketing strategies;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19 on our customers, partners and business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of our investment in research and development activities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of our investment in sales and marketing activities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technical difficulties or interruptions to our DOS platform or analytics applications;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire and retain qualified personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the regulatory environment related to healthcare;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory compliance costs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, size, and integration success of potential future acquisitions; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen legal expenses, including litigation and settlement costs; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">buying patterns of our customers and the related seasonality impacts on our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these factors are not within our control, and the occurrence of one or more of them might cause our results of operations to vary widely. As such, we believe that quarter-to-quarter comparisons of our revenue and results of operations may not be meaningful and should not be relied upon as an indication of future performance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our operating expense is relatively fixed in nature in the short term, and planned expenditures are based in part on expectations regarding future revenue and profitability. Accordingly, unexpected revenue shortfalls, lower-than-expected revenue increases as a result of planned expenditures, and longer-than-expected impact on profitability and margins as a result of planned expenditures may decrease our gross margins and profitability and could cause significant changes in our results of operations from quarter to quarter. In addition, our future quarterly results of operations may fluctuate and may not meet the expectations of securities analysts or investors. If this occurs, the trading price of our common stock could fall substantially, either suddenly or over time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our pricing may change over time and our ability to efficiently price our Solution will affect our results of operations and our ability to attract or retain customers.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we have adjusted our prices as a result of offering new applications and services and customer demand. In the fourth quarter of 2018, we began to introduce new pricing for our Solution to new customers, the full effect of which we expect would be realized in future years. While we determined these prices based on prior experience and feedback from customers, our assessments may not be accurate and we could be underpricing or overpricing our Solution, which may require us to continue to adjust our pricing model. Furthermore, as our applications and services change, then we may need to, or choose to, revise our pricing as our prior experience in those areas will be limited. For example, we introduced our subscription model in 2015, and we may need to continually refine our pricing model.  Such changes to our pricing model or our inability to efficiently price our Solution could harm our business, results of operations, and financial condition and impact our ability to predict our future performance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Solution fails to provide accurate and timely information, or if our content or any other element of our Solution is associated with faulty clinical decisions or treatment, we could have liability to customers, members, clinicians, or patients, which could adversely affect our results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our applications, content, and services may be used by customers to support clinical decision-making by providers and interpret information about patient medical histories, treatment plans, medical conditions, and the use of particular medications. If our applications, content, or services are associated with faulty clinical decisions or treatment, then customers or their patients could assert claims against us that could result in substantial costs to us, harm our reputation in the industry, and cause demand for our Solution to decline.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our analytics services may be used by our customers to inform clinical decision-making, provide access to patient medical histories, and assist in creating patient treatment plans.  Therefore, if data analyses are presented incorrectly in our applications or they are incomplete, or if we make mistakes in the capture or input of these data, adverse consequences, including death, may occur and give rise to product liability, medical malpractice liability, and other claims against us by customers, clinicians, patients, or others. We often have little control over data accuracy, yet a court or government agency may take the position that our storage and display of health information exposes us to personal injury liability or other liability for wrongful delivery or handling of healthcare services or erroneous health information.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical guidelines, algorithms, and protocols may be viewed as providing healthcare professionals with guidance on care management, care coordination, or treatment decisions. If our content, or content we obtain from third parties, contains inaccuracies, or we introduce inaccuracies in the process of implementing third-party content, it is possible that patients, physicians, consumers, the providers of the third-party content, or others may sue us if they are harmed as a result of such inaccuracies. We cannot assure you that our software development, editorial, and other quality control procedures will be sufficient to ensure that there are no errors or omissions in any particular content or our software or algorithms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assertion of such claims and ensuing litigation, regardless of its outcome, could result in substantial cost to us, divert management&#8217;s attention from operations, damage our reputation, and decrease market acceptance of our Solution. We attempt to limit by contract our liability for damages, have our customers assume responsibility for clinical treatment, diagnoses, medical oversight, and dosing decisions, and require that our customers assume responsibility for medical care and approve key algorithms, clinical guidelines, clinical protocols, and data. Despite these precautions, the allocations of responsibility and limitations of liability set forth in our contracts may not be enforceable, be binding upon patients, or otherwise protect us from liability for damages. Furthermore, general liability and errors and omissions insurance coverage and medical malpractice liability coverage may not continue to be available on acceptable terms or may not be available in sufficient amounts to cover one or more large claims against us. In addition, the insurer might disclaim coverage as to any future claim. One or more large claims could exceed our available insurance coverage.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, they could materially adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we carry insurance covering medical malpractice claims in amounts that we believe are appropriate in light of the risks attendant to our business, successful medical liability claims could result in substantial damage awards that exceed the limits of our insurance coverage.  In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our Solution. As a result, adequate professional liability insurance may not be available to our providers or to us in the future at acceptable costs or at all.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us and divert the attention of our management and our providers from our operations, which could have a material adverse effect on our business, financial condition, and results of operations. In addition, any claims may adversely affect our business or reputation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">We derive a significant portion of our revenue from our largest customers. The loss, termination, or renegotiation of any contract could negatively impact our results.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have relied on a limited number of customers for a significant portion of our total revenue and accounts receivable. Our three largest customers during 2020 comprised 5.6%, 4.6%, and 3.9% of our revenue, or 14.1% in the aggregate. Our three largest customers during 2019 comprised 4.6%, 3.6%, and 3.6% of our revenue, or 11.8% in the aggregate. The sudden loss of any of our largest customers or the renegotiation of any of our largest customer contracts could adversely affect our results of operations. In the ordinary course of business, we engage in active discussions and renegotiations with our customers in respect of the solutions we provide and the terms of our customer agreements, including our fees. As our customers&#8217; businesses respond to market dynamics and financial pressures, and as our customers make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, we expect that certain of our customers will, from time to time, seek to restructure their agreements with us. In the ordinary course, we renegotiate the terms of our agreements with our customers in connection with renewals or extensions of these agreements. These discussions and future discussions could result in reductions to the fees and changes to the scope of services contemplated by our original customer contracts and consequently could negatively impact our revenue, business, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a limited number of customers for a significant portion of our revenue, we depend on the creditworthiness of these customers. Our customers are subject to a number of risks including reductions in payment rates from governmental payors, higher than expected healthcare costs, and lack of predictability of financial results when entering new lines of business. If the financial condition of our customers declines, our credit risk could increase. Should one or more of our significant customers declare bankruptcy, be declared insolvent, or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenue, the collectability of our accounts receivable, and affect our bad debt reserves and net income.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Because we generally recognize technology and professional services revenue ratably over the term of the contract for our services, a significant downturn in our business may not be reflected immediately in our results of operations, which increases the difficulty of evaluating our future financial performance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally recognize technology and professional services revenue ratably over the term of a contract. As a result, a substantial portion of our revenue is generated from contracts entered into during prior periods. Consequently, a decline in new contracts in any quarter may not affect our results of operations in that quarter but could reduce our revenue in future quarters. Additionally, the timing of renewals or non-renewals of a contract during any quarter may only affect our financial performance in future quarters. For example, the non-renewal of a subscription agreement late in a quarter will have minimal impact on revenue for that quarter but will reduce our revenue in future quarters. Accordingly, the effect of significant declines in sales may not be reflected in our short-term results of operations, which would make these reported results less indicative of our future financial results. By contrast, a non-renewal occurring early in a quarter may have a significant negative impact on revenue for that quarter and we may not be able to offset a decline in revenue due to non-renewal with revenue from new contracts entered into in the same quarter. In addition, we may be unable to quickly adjust our costs in response to reduced revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">If we are unable to implement and maintain effective internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal controls over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal controls over financial reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to provide an annual management report on the effectiveness of our internal control over financial reporting. Many of the internal controls we have implemented pursuant to the Sarbanes-Oxley Act are process controls with respect to which a material weakness may be found whether or not any error has been identified in our reported financial statements. This may be confusing to investors and result in damage to our reputation, which may harm our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the proper design and assessment of internal controls over financial reporting are subject to varying interpretations, and, as a result, application in practice may evolve over time as new guidance is provided by regulatory and governing bodies and as common practices evolve. This could result in continuing uncertainty regarding the proper design and assessment of internal controls over financial reporting and higher costs necessitated by ongoing revisions to internal controls. We must continue to monitor and assess our internal control over financial reporting. If in the future we have any material weaknesses, we may not detect errors on a timely basis and our financial statements may be materially misstated. Additionally, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, are unable to assert that our internal controls over financial reporting are effective, identify material weaknesses in our internal controls over financial reporting, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our common stock could be adversely affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future litigation against us could be costly and time-consuming to defend and could result in additional liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients or vendors of our customers, or stockholders. Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert management&#8217;s attention and resources, which may seriously harm our business, overall financial condition, and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby reducing our results of operations and resulting in a reduction in the trading price of our stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Changes in accounting principles may cause previously unanticipated fluctuations in our financial results, and the implementation of such changes may impact our ability to meet our financial reporting obligations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare our financial statements in accordance with U.S. GAAP which are subject to interpretation or changes by the Financial Accounting Standards Board (FASB), the SEC, and other various bodies formed to promulgate and interpret appropriate accounting principles. New accounting pronouncements and changes in accounting principles have occurred in the past and are expected to occur in the future which may have a significant effect on our financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any difficulties in implementation of changes in accounting principles, including the ability to modify our accounting systems, could cause us to fail to meet our financial reporting obligations, which could result in regulatory discipline and harm investors&#8217; confidence in us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Economic uncertainties or downturns in the general economy or the industries in which our customers operate could disproportionately affect the demand for our Solution and negatively impact our results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General worldwide economic conditions have experienced significant downturns during the last ten or more years, and market volatility and uncertainty remain widespread, making it potentially very difficult for our customers and us to accurately forecast and plan future business activities. During challenging economic times, our customers may have difficulty gaining timely access to sufficient credit or obtaining credit on reasonable terms, which could impair their ability to make timely payments to us and adversely affect our revenue. If that were to occur, our financial results could be harmed. Further, challenging economic conditions may impair the ability of our customers to pay for the applications and services they already have purchased from us and, as a result, our write-offs of accounts receivable could increase. We cannot predict the timing, strength, or duration of any economic slowdown or recovery. If the condition of the general economy or markets in which we operate worsens, our business could be harmed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire other companies or technologies, which could divert our management&#8217;s attention, result in dilution to our stockholders, and otherwise disrupt our operations and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have an adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to acquire or invest in businesses, applications, and services, or technologies that we believe could complement or expand our Solution, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. We have in the past and may in the future have difficulty integrating acquired businesses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, during 2020 we acquired Able Health, Healthfinch, and Vitalware, all of which we are in the process of integrating with our other services. We may have difficulty cross-selling our Solution to acquired customers, and we may have difficulty integrating, or incur integration-related costs associated with, newly acquired team members.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations, and technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including, but not limited to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">inability to integrate or benefit from acquired technologies or services in a profitable manner;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">unanticipated costs or liabilities associated with the acquisition;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">difficulty integrating the accounting systems, operations, and personnel of the acquired business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">difficulty converting the customers of the acquired business onto our platform and contract terms, including disparities in the revenue, licensing, support, or professional services model of the acquired company;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">diversion of management&#8217;s attention from other business concerns;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">adverse effects on our existing business relationships with business partners and customers as a result of the acquisition;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">the potential loss of key employees;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">use of resources that are needed in other parts of our business; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">use of substantial portions of our available cash to consummate the acquisition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our results of operations based on this impairment assessment process, which could adversely affect our results of operations. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our results of operations. In addition, if an acquired business fails to meet our expectations, our business, financial condition, and results of operations may suffer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the anticipated benefit of any acquisition may not materialize or may be prohibited by contractual obligations we may enter into in the future with lenders or other third parties. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities, or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future acquisitions, or the effect that any such transactions might have on our results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Because competition for our target employees is intense, we may not be able to attract and retain the highly skilled employees we need to support our continued growth.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To continue to execute on our growth plan, we must attract and retain highly qualified personnel. Competition for such personnel is intense, especially for senior sales executives and software engineers with high levels of experience in designing and developing applications and consulting and analytics services. We may not be successful in attracting and retaining qualified personnel. We have from time to time in the past experienced, and we expect to continue to experience in the future, difficulty in hiring and retaining highly skilled employees with appropriate qualifications. In addition, our search for replacements for departed employees may cause uncertainty regarding the future of our business, impact employee hiring and retention, and adversely impact our revenue, results of operations, and financial condition. Many of the companies with which we compete for experienced personnel have greater resources than we have. In addition, in making employment decisions, particularly in the Internet and high-technology industries, job candidates often consider the value of the equity awards they may receive in connection with their employment. Volatility in the price of our stock or failure to obtain stockholder approval for increases in the number of shares available for grant under our equity plans may, therefore, adversely affect our ability to attract or retain key employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends largely upon the continued services of our key executive officers and recruitment of additional highly skilled employees. From time to time, there may be changes in our senior management team resulting from the hiring or departure of executives, which could disrupt our business. Several of our senior leaders are active members of the Church of Jesus Christ of Latter-Day Saints.  There is a risk that in the future, one or more of these individuals could receive a call to serve in a full-time capacity for the church.  This has already occurred with one of the two co-founders of our company, Steven Barlow, who in November 2016 was called to serve from June 2017 to June 2020 in a full-time capacity.  At the time of his call, he was serving as the President of our professional services organization and was one of the most senior leaders of our company.  In connection with this call to serve, Mr. Barlow took a leave-of-absence from his company responsibilities in March 2017 and returned from his leave of absence in August 2020. Hiring executives with needed skills or the replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competition for qualified management in our industry is intense. Many of the companies with which we compete for management personnel have greater financial and other resources than we do. We have not entered into term-based employment agreements with our executive officers. All of our employees are &#8220;at-will&#8221; employees, and their employment can be terminated by us or them at any time, for any reason. The departure of key personnel could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. In addition, volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart. If we are not able to retain any of our key management personnel, our business could be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity, and teamwork fostered by our culture, which could harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our corporate culture has been an important contributor to our success, which we believe fosters innovation, teamwork, and passion for providing high levels of customer satisfaction. Most of our employees have been with us for fewer than three years as a result of our rapid growth. As we continue to grow, we must effectively integrate, develop, and motivate a growing number of new employees. As a result, we may find it difficult to maintain our corporate culture, which could limit our ability to innovate and operate effectively. Any failure to preserve our culture could also negatively affect our ability to retain and recruit personnel, maintain our performance, or execute on our business strategy.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">If we fail to effectively manage our growth and organizational change, our business and results of operations could be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced, and may continue to experience, rapid growth and organizational change, which has placed, and may continue to place, significant demands on our management, operational, and financial resources. In addition, if we fail to successfully integrate new team members, it could harm our culture. We must continue to maintain, and may need to enhance, our information technology infrastructure and financial and accounting systems and controls, as well as manage expanded operations in geographically distributed locations, which will place additional demands on our resources and operations. We also must attract, train, and retain a significant number of qualified sales and marketing personnel, professional services personnel, software engineers, technical personnel, service offering personnel, and management personnel. This will require us to invest in and commit significant financial, operational, and management resources to grow and change in these areas without undermining the corporate culture that has been critical to our growth so far.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve the benefits anticipated from these investments, or if the realization of these benefits is delayed, our results of operations may be adversely affected. If we fail to provide effective customer training on our Solution and high-quality customer support, our business and reputation could suffer. Failure to manage our growth effectively could lead us to over-invest or under-invest in technology and operations; result in weaknesses in our infrastructure, systems, or controls; give rise to operational mistakes, losses, or loss of productivity or business opportunities; reduce customer or user satisfaction; limit our ability to respond to competitive pressures; and result in loss of team members and reduced productivity of remaining team members. Our growth could require significant capital expenditures and may divert financial resources and management attention from other projects, such as the development of new or enhanced services or the acquisition of suitable businesses or technologies. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our revenue could decline or may grow more slowly than expected, and we may be unable to implement our business strategy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not grow at the rates we historically have achieved or at all, even if our key metrics may indicate growth.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant growth in the last five years. Future revenue may not grow at these same rates or may decline. Our future growth will depend, in part, on our ability to grow our revenue from existing customers, to complete sales to potential future customers, to expand our customer and member bases, to develop new solutions, and to expand internationally. We can provide no assurances that we will be successful in executing on these growth strategies or that we will continue to grow our revenue or to generate net income. Our historical results may not be indicative of future performance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute on our existing sales pipeline, create additional sales pipelines, and expand our customer base depends on, among other things, the attractiveness of our Solution relative to those offered by our competitors, our ability to demonstrate the value of our existing and future services, and our ability to attract and retain a sufficient number of qualified sales and marketing leadership and support personnel. In addition, our existing customers may be slower to adopt our Solution than we currently anticipate, which could adversely affect our results of operations and growth prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">The estimates of market opportunity and forecasts of market growth included herein may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market opportunity estimates and growth forecasts included herein are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimates and forecasts included herein relating to the size and expected growth of our target market may prove to be inaccurate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the markets in which we compete meet the size estimates and growth forecasts included herein, our business may not grow at similar rates, or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Data and Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Our Solution is dependent on our ability to source data from third parties, and such third parties could take steps to block our access to data, which could impair our ability to provide our Solution or limit the effectiveness of our Solution.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data platform requires us to source data from multiple clinical, financial, and operational data sources, which sources are also typically third-party vendors of our customers.  The functioning of our analytics applications and our ability to perform analytics services is predicated on our ability to establish interfaces that download the relevant data from these source systems on a repeated basis and in a reliable manner.  We may encounter vendors that engage in information blocking practices that may inhibit our ability to access the relevant data on behalf of customers. Further, on May 1, 2020, the Office of the National Coordinator and the Centers for Medicare and Medicaid Services finalized and published complementary new rules to support access, exchange, and use of electronic health information (EHI), referred to as the Final Rule. The Final Rule is intended to clarify provisions of the 21st Century Cures Act regarding interoperability and information blocking, and, subject to the interpretations of the Final Rule, and exceptions to what constitutes information blocking, may create significant new requirements for healthcare industry participants. The Final Rule requires certain electronic health record technology to incorporate standardized application programming interfaces (APIs) to allow individuals to securely and easily access structured EHI using smartphone applications. The Final Rule also implements provisions of the 21st Century Cures Act requiring that patients be provided with electronic access to all of their EHI (structured and/or unstructured) at no cost. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the Final Rule also implements the information blocking provisions of the 21st Century Cures Act, subject to eight exceptions that will not be considered information blocking as long as specific conditions are met. The impact of the Final Rule on our business is unclear at this time, due to, among other things, uncertainty regarding the interpretation of safe harbors and exceptions to the Final Rule by industry participants and regulators.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Final Rule focuses on health plans, payors, and healthcare providers and proposes measures to enable patients to move from health plan to health plan, provider to provider, and have both their clinical and administrative information travel with them. It is unclear whether the Final Rule may benefit us in that certain EHR vendors will no longer be permitted to interfere with our attempts at integration, but the rules may also make it easier for other similar companies to enter the market, creating increased competition, and reducing our market share.  It is unclear at this time what the costs of compliance with the proposed rules, if adopted, would be, and what additional risks there may be to our business. If we face limitations on the development of data interfaces and other information blocking practices, our data access and ability to download relevant data may be limited, which could adversely affect our ability to provide our Solution as effectively as possible.  Any steps we take to enforce the anti-information blocking provisions of the 21st Century Cures Act could be costly, could distract management attention from the business, and could have uncertain results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure by our customers to obtain proper permissions and waivers may result in claims against us or may limit or prevent our use of data, which could harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our customers to provide necessary notices and to obtain necessary permissions and waivers for use and disclosure of the information that we receive, and we require contractual assurances from them that they have done so and will do so. If they do not obtain necessary permissions and waivers, then our use and disclosure of information that we receive from them or on their behalf may be restricted or prohibited by state, federal or international privacy or data protection laws, or other related privacy and data protection laws. This could impair our functions, processes, and databases that reflect, contain, or are based upon such data and may prevent the use of such data, including our ability to provide such data to third parties that are incorporated into our service offerings. Furthermore, this may cause us to breach obligations to third parties to whom we may provide such data, such as third-party service or technology providers that are incorporated into our service offerings. In addition, this could interfere with or prevent data sourcing, data analyses, or limit other data-driven activities that benefit us. Moreover, we may be subject to claims, civil and/or criminal liability or government or state attorneys general investigations for use or disclosure of information by reason of lack of valid notice, permission, or waiver. These claims, liabilities or government or state attorneys general investigations could subject us to unexpected costs and adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">If our security measures are breached or unauthorized access to customer data is otherwise obtained, our Solution may be perceived as not being secure, customers may reduce the use of or stop using our Solution, and we may incur significant liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Solution involves the storage and transmission of our customers&#8217; proprietary information, including personal or identifying information regarding patients and their protected health information (PHI). Despite the implementation of security measures, our internal computer systems and those of our customers, contractors, consultants and collaborators are vulnerable to damage from cyberattacks, &#8220;phishing&#8221; attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Because the techniques used to obtain unauthorized access or sabotage systems change frequently and generally are not identified until they are launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Moreover, the detection, prevention, and remediation of known or unknown security vulnerabilities, including those arising from third-party hardware or software, may result in additional direct or indirect costs and management time. As a result, unauthorized access or security breaches as a result of third-party action, employee error, malfeasance, or otherwise could result in the loss or inappropriate use of information, litigation, indemnity obligations, damage to our reputation, and other liability such as government or state Attorney General investigations. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these issues could adversely affect our ability to attract new customers, cause existing customers to elect to not renew their subscriptions, result in reputational damage, or subject us to third-party lawsuits, regulatory fines, mandatory disclosures, or other action or liability, which could adversely affect our results of operations. Our general liability insurance may not be adequate to cover all potential claims to which we are exposed and may not be adequate to indemnify us for liability that may be imposed or the losses associated with such events, and in any case, such insurance may not cover all of the specific costs, expenses, and losses we could incur in responding to and remediating a security breach. A security breach of another significant provider of cloud-based solutions may also negatively impact the demand for our Solution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party providers, including Microsoft Azure, for computing infrastructure, network connectivity, and other technology-related services needed to deliver our Solution. Any disruption in the services provided by such third-party providers could adversely affect our business and subject us to liability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DOS platform and analytics applications are hosted from and use computing infrastructure provided by third parties, including Microsoft Azure and Flexential, and other computing infrastructure service providers. We have migrated and expect to continue to migrate a significant portion of our computing infrastructure needs to Microsoft Azure. We have made and expect to continue to make substantial investments in transitioning customers from our own managed data center to Microsoft Azure. We anticipate that this transition will increase the cost of hosting our technology and negatively impact our technology gross margin. We currently expect our planned transitions to be substantially complete by the end of 2022. Such migrations are risky and may cause disruptions to our Solution, service outages, downtime, or other problems and may increase our costs.  Despite precautions taken during such transitions, any unsuccessful transition of technology may impair customers&#8217; use of our technology which may cause greater costs or downtime and which may lead to, among other things, customer dissatisfaction and non-renewals.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our computing infrastructure service providers have no obligation to renew their agreements with us on commercially reasonable terms or at all. If we are unable to renew these agreements on commercially reasonable terms, or if one of our computing infrastructure service providers is acquired, we may be required to transition to a new provider and we may incur significant costs and possible service interruption in connection with doing so.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Problems faced by our computing infrastructure service providers, including those operated by Microsoft, could adversely affect the experience of our customers. Microsoft Azure has also had and may in the future experience significant service outages. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if our computing infrastructure service providers are unable to keep up with our growing needs for capacity, this could have an adverse effect on our business. For example, a rapid expansion of our business could affect our service levels or cause our third-party hosted systems to fail. Our agreements with third-party computing infrastructure service providers may not entitle us to service level credits that correspond with those we offer to our customers.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes in third-party service levels at our computing infrastructure service providers, or any related disruptions or performance problems with our Solution, could adversely affect our reputation and may damage our customers&#8217; stored files, result in lengthy interruptions in our services, or result in potential losses of customer data. Interruptions in our services might reduce our revenue, cause us to issue refunds to customers for prepaid and unused subscriptions, subject us to service level credit claims and potential liability, allow our customers to terminate their contracts with us, or adversely affect our renewal rates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties, and our own systems for providing services to our users, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation, potentially require us to issue credits to our customers, and negatively impact our relationships with users or customers, adversely affecting our brand and our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the services we provide from our offices, we serve our customers primarily from third-party data-hosting facilities. These facilities are vulnerable to damage or interruption from earthquakes, floods, fires, power loss, telecommunications failures, and similar events. They are also subject to break-ins, sabotage, intentional acts of vandalism, and similar misconduct. Their systems and servers could also be subject to hacking, spamming, ransomware, computer viruses or other malicious software, denial of service attacks, service disruptions, including the inability to process certain transactions, phishing attacks and unauthorized access attempts, including third parties gaining access to users&#8217; accounts using stolen or inferred credentials or other means, and may use such access to prevent use of users&#8217; accounts. Despite precautions taken at these facilities, the occurrence of a natural disaster or an act of terrorism, a decision to close the facilities without adequate notice, or other unanticipated problems at two or more of the facilities could result in lengthy interruptions in our services. Even with our disaster recovery arrangements, our services could be interrupted.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to deliver our Internet- and telecommunications-based services is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity, and security for providing reliable Internet access and services and reliable mobile device, telephone, facsimile, and pager systems, all at a predictable and reasonable cost. We have experienced and expect that we will experience interruptions and delays in services and availability from time to time. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on internal systems as well as third-party vendors, including data center, bandwidth, and telecommunications equipment or service providers, to provide our services. We do not maintain redundant systems or facilities for some of these services. In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could negatively impact our relationship with users or customers. To operate without interruption, both we and our service providers must guard against:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage from fire, power loss, and other natural disasters;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">communications failures;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">software and hardware errors, failures, and crashes;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">security breaches, computer viruses, ransomware, and similar disruptive problems; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other potential interruptions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption in the network access, telecommunications, or co-location services provided by these third-party providers or any failure of or by these third-party providers or our own systems to handle the current or higher volume of use could significantly harm our business. We exercise limited control over these third-party vendors, which increases our vulnerability to problems with the services they provide. Any errors, failures, interruptions, or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with users and customers, adversely affect our brands and business, and expose us to third-party liabilities. The insurance coverage under our policies may not be adequate to compensate us for all losses that may occur. In addition, we cannot provide assurance that we will continue to be able to obtain adequate insurance coverage at an acceptable cost.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reliability and performance of the Internet may be harmed by increased usage or by denial-of-service attacks. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage as well as the availability of the Internet to us for delivery of our Internet-based services. We typically provide service level commitments under our customer contracts. If we fail to meet these contractual commitments, we could be obligated to provide credits or refunds for prepaid amounts related to unused subscription services or face contract terminations, which could adversely affect our results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, recent changes in law could impact the cost and availability of necessary Internet infrastructure. Increased costs and/or decreased availability would negatively affect our results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution utilizes open-source software, and any failure to comply with the terms of one or more of these open-source licenses could adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use software modules licensed to us by third-party authors under &#8220;open-source&#8221; licenses in our Solution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some open-source licenses contain affirmative obligations or restrictive terms that could adversely impact our business, such as restrictions on commercialization or obligations to make available modified or derivative works of certain open-source code.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to combine our proprietary software with certain open-source software subject to these licenses in a certain manner, we could, under certain open-source licenses, be required to release or otherwise make available the source code to our proprietary software to the public. This would allow our competitors to create similar products with lower development effort and time and ultimately could result in a loss of product sales for us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we employ practices designed to manage our compliance with open-source licenses and protect our proprietary source code, we may inadvertently use open-source software in a manner we do not intend and that could expose us to claims for breach of contract and intellectual property infringement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are held to have breached the terms of an open-source software license, we could be required to, among other things, seek licenses from third parties to continue offering our products on terms that are not economically feasible, pay damages to third parties, to re-engineer our products, to discontinue the sale of our products if re-engineering cannot be accomplished on a timely basis, or to make generally available, in source code form, a portion of our proprietary code, any of which could adversely affect our business, results of operations, and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of many open-source licenses have not been interpreted by U.S. courts, and, as a result, there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to commercialize our Solution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We employ third-party licensed software and software components for use in or with our Solution, and the inability to maintain these licenses or the presence of errors in the software we license could limit the functionality of our Solution and result in increased costs or reduced service levels, which would adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software applications might incorporate or interact with certain third-party software and software components (other than open-source software), such as data visualization software, obtained under licenses from other companies. We pay these third parties a license fee or royalty payment. We anticipate that we will continue to use such third-party software in the future. Although we believe that there are commercially reasonable alternatives to the third-party software we currently make available, this may not always be the case, or it may be difficult or costly to replace. Furthermore, these third parties may increase the price for licensing their software, which could negatively impact our results of operations. Our use of additional or alternative third-party software could require customers to enter into license agreements with third parties. In addition, if the third-party software we make available has errors or otherwise malfunctions, or if the third-party terminates its agreement with us, the functionality of our Solution may be negatively impacted and our business may suffer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a limited number of customers for a significant portion of our revenue, we depend on the creditworthiness of these customers. Our customers are subject to a number of risks including reductions in payment rates from governmental payors, higher than expected healthcare costs, and lack of predictability of financial results when entering new lines of business. If the financial condition of our customers declines, our credit risk could increase. Should one or more of our significant customers declare bankruptcy, be declared insolvent, or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenue, the collectability of our accounts receivable, and affect our bad debt reserves and net income.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure to protect our intellectual property rights could impair our ability to protect our proprietary technology and our brand.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success and ability to compete depend in part upon our intellectual property. As of December 31, 2020, we had filed applications for a number of patents, and we have eleven issued U.S., two issued Canadian patents, one issued Great Britain patent, and one issued European patent, as well as two patent applications pending in the United States and two patent applications pending in Canada. We also had twenty-seven registered trademarks in the United States, Canada, and China. We also rely on copyright and trademark laws, trade secret protection, and confidentiality or license agreements with our employees, customers, partners, and others to protect our intellectual property rights. However, the steps we take to protect our intellectual property rights may be inadequate.  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, other parties, including our competitors, may independently develop similar technology, duplicate our services, or design around our intellectual property and, in such cases, we may not be able to assert our intellectual property rights against such parties. Further, our contractual arrangements may not effectively prevent disclosure of our confidential information or provide an adequate remedy in the event of unauthorized disclosure of our confidential information, and we may be unable to detect the unauthorized use of, or take appropriate steps to enforce, our intellectual property rights.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make business decisions about when to seek patent protection for a particular technology and when to rely upon trade secret protection, and the approach we select may ultimately prove to be inadequate.  Even in cases where we seek patent protection, there is no assurance that the resulting patents will effectively protect every significant feature of our Solution, technology, or proprietary information, or provide us with any competitive advantages. Moreover, we cannot guarantee that any of our pending patent applications will issue or be approved. The United States Patent and Trademark Office and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process and after a patent has issued. There are situations in which noncompliance can result in abandonment or lapse of the patent, or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs, our competitors might be able to enter the market, which would have a material adverse effect on our business. Effective trademark, copyright, patent, and trade secret protection may not be available in every country in which we conduct business. Further, intellectual property law, including statutory and case law, particularly in the United States, is constantly developing, and any changes in the law could make it harder for us to enforce our rights.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect our intellectual property rights, we may be required to spend significant resources to monitor and protect these rights. Litigation brought to protect and enforce our intellectual property rights could be costly, time-consuming, and distracting to management and could result in the impairment or loss of portions of our intellectual property. Furthermore, our efforts to enforce our intellectual property rights may be met with defenses, counterclaims, and countersuits attacking the validity and enforceability of our intellectual property rights. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse determination of any litigation proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Negative publicity related to a decision by us to initiate such enforcement actions against a customer or former customer, regardless of its accuracy, may adversely impact our other customer relationships or prospective customer relationships, harm our brand and business, and could cause the market price of our common stock to decline. Our failure to secure, protect, and enforce our intellectual property rights could adversely affect our brand and our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be sued by third parties for alleged infringement of their proprietary rights or misappropriation of intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is considerable patent and other intellectual property development activity in our industry. Our future success depends in part on not infringing upon the intellectual property rights of others.  Our competitors, as well as a number of other entities and individuals, including so-called non-practicing entities (NPEs), may own or claim to own intellectual property relating to our Solution. From time to time, third parties may claim that we are infringing upon their intellectual property rights or that we have misappropriated their intellectual property. For example, in some cases, very broad patents are granted that may be interpreted as covering a wide field of healthcare data storage and analytics solutions or machine learning and predictive modeling methods in healthcare. As competition in our market grows, the possibility of patent infringement, trademark infringement, and other intellectual property claims against us increases. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect others to claim that our Solution and underlying technology infringe or violate their intellectual property rights. In a patent infringement claim against us, we may assert, as a defense, that we do not infringe the relevant patent claims, that the patent is invalid or both. The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted patents. However, we could be unsuccessful in advancing non-infringement and/or invalidity arguments in our defense. In the United States, issued patents enjoy a presumption of validity, and the party challenging the validity of a patent claim must present clear and convincing evidence of invalidity, which is a high burden of proof. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unaware of the intellectual property rights that others may claim cover some or all of our technology or services. Because patent applications can take years to issue and are often afforded confidentiality for some period of time there may currently be pending applications, unknown to us, that later result in issued patents that could cover one or more aspects of our technology and services. Any claims or litigation could cause us to incur significant expenses and, whether or not successfully asserted against us, could require that we pay substantial damages, ongoing royalty or license payments, or settlement fees, prevent us from offering our Solution or using certain technologies, require us to re-engineer all or a portion of our platform, or require that we comply with other unfavorable terms. We may also be obligated to indemnify our customers or business partners or pay substantial settlement costs, including royalty payments, in connection with any such claim or litigation and to obtain licenses, modify applications, or refund fees, which could be costly. Even if we were to prevail in such a dispute, any litigation regarding our intellectual property could be costly and time-consuming and divert the attention of our management and key personnel from our business operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Governmental Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Healthcare and Data Privacy and Security Regulation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Health Information Privacy and Security Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There are numerous federal and state laws and regulations that govern the privacy and security of health information. In particular, the federal Health Insurance Portability and Accountability Act of 1992 (HIPAA) imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of PHI. By processing and maintaining PHI on behalf of our covered entity customers, we are a HIPAA business associate and are required to enter into business associate agreements (BAAs) with our covered entity clients to safeguard PHI, as well as BAAs with our subcontractors that access or otherwise process PHI on our behalf.  </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to adequately address the business risks created by HIPAA implementation. Furthermore, we are unable to predict what changes to HIPAA or other laws or regulations might be made in the future or how those changes could affect our business or the costs of compliance. We are unable to predict what, if any, impact the changes in such standards will have on our compliance costs or our Solution. Penalties for failure to comply with a requirement of HIPAA vary significantly depending on the nature of violation and could include civil monetary or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. Certain states have also adopted privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our analytics applications, for example one of our benchmarking applications, require that we obtain permissions consistent with HIPAA to provide &#8220;data aggregation services&#8221; and the right to create de-identified information and to use and disclose such de-identified information. We will also require large sets of de-identified information to enable us to continue to develop machine learning algorithms that enhance our Solution. If we are unable to secure these rights in customer BAAs or as a result of any future changes to HIPAA or other applicable laws, we may face limitations on the use of PHI and our ability to use de-identified information that could negatively affect the scope of our Solution as well as impair our ability to provide upgrades and enhancements to our Solution. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource important aspects of the storage and transmission of customer and member information, and thus rely on third parties to manage functions that have material cyber&#8209;security risks. We attempt to address these risks by requiring outsourcing subcontractors who handle customer information to sign BAAs contractually requiring those subcontractors to adequately safeguard PHI in a similar manner that applies to us and in some cases by requiring such outsourcing subcontractors to undergo third&#8209;party security examinations as well as to protect the confidentiality of other sensitive customer information. In addition, we periodically hire third&#8209;party security experts to assess and test our security measures. However, we cannot be assured that these contractual measures and other safeguards will adequately protect us from the risks associated with the storage and transmission of customer proprietary information and PHI.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Protection Regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Federal and state government bodies and agencies have adopted or are considering adopting laws and regulations regarding the collection, use, and dissemination of data, and the presentation of website or other electronic content, which may require compliance with certain standards for notice, choice, security, and access. California adopted the California Consumer Privacy Act (CCPA), which went into effect on January 1, 2020. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the state of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Additionally, the CPRA recently passed in California. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. If we fail to comply with any of these privacy laws that apply to us, and are subject to the aforementioned penalties, our business and financial results could be adversely affected.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">General Data Protection Regulation (GDPR) and Foreign Data Privacy Protection Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, many foreign governments have established or are in the process of establishing privacy and data security legal frameworks governing the collection, use and disclosure of personal information obtained from their residents. For example, in the European Union (EU), the GDPR went into effect on May 25, 2018. If we or our vendors fail to comply with the applicable EU privacy laws, we could be subject to government enforcement actions and significant penalties against us. GDPR introduced new data protection requirements in the EU relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the documentation we must retain, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. GDPR has increased our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place mechanisms to ensure compliance with GDPR. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the GDPR increases the scrutiny of transfers of personal data from the European Economic Area (EEA) to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws; in July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield and imposing further restrictions on use of the standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data protection authorities of the different EU member states may also interpret GDPR differently, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data in the EU. Any failure by us to comply with GDPR could result in proceedings or actions against us by governmental entities or others, which may subject us to significant penalties and negative publicity, require us to change our business practices, and increase our costs and severely disrupt our business. From January 1, 2021, we may be subject to the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and UK Trade and Cooperation Agreement, ending June 30, 2021 at the latest, while the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the UK long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Canadian Data Privacy Protection Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Similarly, Canada&#8217;s Personal Information and Protection of Electronic Documents Act provides Canadian residents with privacy protections in regard to transactions with businesses and organizations in the private sector and sets out ground rules for how private-sector organizations may collect, use, and disclose personal information in the course of commercial activities. Foreign governments may attempt to apply such laws extraterritorially or through treaties or other arrangements with U.S. governmental entities. Other jurisdictions besides the EU and Canada are similarly introducing or enhancing laws and regulations relating to privacy and data security, which enhances risks relating to compliance with such laws. Furthermore, as we enter into business arrangements in countries outside of the United States, we will need to be prepared to comply with applicable local privacy laws. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of personal data, such as healthcare data or other sensitive information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions that we operate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that the privacy policies and other statements regarding our practices will be found sufficient to protect us from liability or adverse publicity relating to the privacy and security of personal information. There is ongoing concern from privacy advocates, regulators, and others regarding data protection and privacy issues, and the number of jurisdictions with data protection and privacy laws has been increasing. Also, there are ongoing public policy discussions regarding whether the standards for de-identified, anonymous, or pseudonymized health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. We expect that there will continue to be new proposed laws, regulations, and industry standards concerning privacy, data protection, and information security in the United States, including the CCPA, and we cannot yet determine the impact such laws, regulations, and standards may have on our business. Future laws, regulations, standards, and other obligations, and changes in the interpretation of existing laws, regulations, standards, and other obligations could impair our or our customers&#8217; ability to collect, use, or disclose information relating to consumers, which could decrease demand for our Solutions, increase our costs, and impair our ability to maintain and grow our customer base and increase our revenue. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or perceived failure by us to comply with international, federal or state laws or regulations, industry standards, or other legal obligations, or any actual or suspected security incident, whether or not resulting in unauthorized access to, or acquisition, release, or transfer of personally identifiable information or other data, may result in governmental enforcement actions and prosecutions, private litigation, fines, and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse effect on our reputation and business. We may be unable to make such changes and modifications in a commercially reasonable manner or at all, and our ability to develop new products and features could be limited. Any of these developments could harm our business, financial condition, and results of operations. Privacy and data security concerns, whether valid or not valid, may inhibit market adoption of our platform.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many healthcare laws are complex, and their application to specific services and relationships may not be clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate the data analytics and improvement services that we provide, and these laws and regulations may be applied to our Solution in ways that we do not anticipate, particularly as we develop and release new and more sophisticated solutions. Our failure to accurately anticipate the application of these laws and regulations, or our other failure to comply with them, could create significant liability for us, result in adverse publicity, and negatively affect our business. Some of the risks we face or may face from healthcare regulation are described below.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal Anti-Kickback Statute prohibits, among other things, the offering, paying, soliciting, or receiving anything of value, directly or indirectly, for the referral of patients covered by Medicare, Medicaid, and other federal healthcare programs or the leasing, purchasing, ordering, or arranging for or recommending the lease, purchase, or order of any item, good, facility, or service covered by these programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.  Some enforcement activities focus on below or above market payments for federally reimbursable healthcare items or services as evidence of the intent to provide a kickback.  Many states also have similar anti-kickback laws that are not necessarily limited to items or services for which payment is made by a federal healthcare program.  Moreover, both federal and state laws prohibit bribery and similar behavior.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe we directly order or provide healthcare services that are reimbursable by Medicare, Medicaid or other third-party payors or submit claims or receive reimbursement from any such payor. However, nonetheless, in addition to direct enforcement action against us, if our advisory services or Solutions offered to customers are associated with action by customers that is determined or alleged to be in violation of these laws and regulations, it is possible that an enforcement agency would also try to hold us liable. There are also numerous federal and state laws that prohibit the submission of false information, or the failure to disclose information, in connection with submission and payment of claims for health care items and services by health care providers. For example, the federal civil False Claims Act prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA also created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.  Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any determination by a court or regulatory agency that we or any of our customers, vendors or partners have violated these laws could subject us to significant civil or criminal penalties, invalidate all or portions of some of our customer contracts, require us to change or terminate some portions of our business, require us to refund portions of our services fees, subject us to additional reporting requirements and oversight under a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, cause us to be disqualified from serving customers doing business with government payors, and have an adverse effect on our business. Our customers&#8217; failure to comply with these laws and regulations in connection with our services could result in substantial liability (including, but not limited to, criminal liability), adversely affect demand for our Solution, and force us to expend significant capital, research and development, and other resources to address the failure.  Even an unsuccessful challenge by regulatory authorities of our activities could result in adverse publicity and could require a costly response from us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our arrangements with physicians and other health care professionals are found to constitute the improper rendering of professional medical services or fee splitting under applicable state laws, our business, financial condition and our ability to operate in those states could be adversely impacted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ and contract with physicians and other licensed health care professionals who assist our customers with the customers&#8217; care coordination, care management, population health management, and patient safety activities.  Although we do not intend to provide medical care, treatment, or advice, our relationships with such health care professionals may implicate certain state laws in the United States in which we operate that generally prohibit non-professional entities from providing licensed medical services, exercising control over licensed physicians or other licensed health care professionals or engaging in certain practices such as fee-splitting with such licensed professionals. There can be no assurance that these laws will be interpreted in a manner consistent with our practices or that other laws or regulations will not be enacted in the future that could have a material and adverse effect on our business, financial condition and results of operations. Regulatory authorities, state boards of medicine, state attorneys general and other parties may assert that we are engaged in the provision of professional medical services, and/or that our arrangements with our affiliated physicians and other licensed health care professionals constitute unlawful fee-splitting. If a jurisdiction&#8217;s prohibition on the corporate practice of medicine or fee-splitting is interpreted in a manner that is inconsistent with our practices, we may be required to restructure or terminate some portions of our business, require us to refund portions of our services fees, and have an adverse effect on our business. Even an unsuccessful challenge by regulatory authorities of our activities could result in adverse publicity and could require a costly response from us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may modify its enforcement policies with respect to medical software products, and our products may become subject to extensive regulatory requirements, which may increase the cost of conducting, or otherwise harm, our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may regulate medical or health-related software, including machine learning functionality and predictive algorithms, if such software falls within the definition of a &#8220;medical device&#8221; under the Federal Food, Drug, and Cosmetic Act (FDCA). Medical devices are subject to extensive and rigorous regulation by the FDA and by other federal, state and local authorities. The FDCA and related regulations govern the conditions of safety, efficacy, clearance, approval, manufacturing, quality system requirements, labeling, packaging, distribution, storage, recordkeeping, reporting, marketing, advertising, and promotion of medical devices. However, historically, the FDA has exercised enforcement discretion for certain low-risk software products, and has issued several guidance documents outlining its approach to the regulation of software as a medical device. In addition, the 21st Century Cures Act amended the FDCA to exclude from the definition of &#8220;medical device&#8221; certain medical-related software, including software used for administrative support functions at a healthcare facility, software intended for maintaining or encouraging a healthy lifestyle, software designed to store electronic health records, software for transferring, storing, or displaying medical device data or in vitro diagnostic data, and certain clinical decision support software. Accordingly, we believe our currently marketed products are not currently regulated by the FDA as medical devices, or that our products are otherwise subject to FDA&#8217;s current enforcement discretion policies applicable to software products. However, there is a risk that the FDA could disagree with our determination, or that the FDA could alter its enforcement discretion policies, and in each case, subject our software to more stringent medical device regulations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that any of our current or future analytics applications are regulated as medical devices, we would become subject to various requirements under the FDCA and the FDA&#8217;s implementing regulations. If this occurs, we may be required to cease marketing or to recall our product until we obtain the requisite clearances or approvals, which would entail significant cost and could harm our business. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our  failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, or comparable state or foreign regulatory authorities, including: untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties, recalls, termination of distribution, administrative detentions, seizure of our products, operating restrictions, partial suspension or total shutdown of production, delays in or refusal to grant clearances or approvals, prohibitions on sales of our products,  and criminal prosecution. Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial condition and results of operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare regulatory and political framework is uncertain and evolving.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing and new laws and regulations affecting the healthcare industry, or changes to existing laws and regulations could create unexpected liabilities for us, cause us to incur additional costs, and/or restrict our operations.  Reforming the healthcare industry has been a priority for U.S. politicians, and key members of the legislative and executive branches have proposed a wide variety of potential changes and policy goals. Certain changes to laws impacting our industry, or perceived intentions to do so, could affect our business and results of operations. By way of example, in March 2010, the Affordable Care Act (ACA) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers and has significantly impacted our industry and, to some degree, our business. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA.  The U.S. Supreme Court is currently reviewing the constitutionality of the ACA in its entirety, although it is unclear when or how the Supreme Court will rule.  We anticipate that new cost containment measures or other healthcare reforms will continue to be implemented at both the federal and state level, any of which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the particular nature of certain services we provide or the manner in which we provide them, we may be subject to additional government regulation and foreign government regulation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our Solution is primarily subject to government regulations pertaining to healthcare, certain aspects of our Solution may require us to comply with regulatory schema from other areas. Examples of such regulatory schema include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Antitrust Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our national cloud-based network allows us access to cost and pricing data for a large number of providers in most regional markets, as well as to the contracted rates for third-party payors. To the extent that our Solution enables providers to compare their cost and pricing data with those of their competitors, those providers could collude to increase the pricing for their services, to reduce the compensation they pay their employees, or to collectively negotiate agreements with third parties. Similarly, if payors are able to compare their contracted rates of payment to providers, those payors may seek to reduce the amounts they might otherwise pay. Such actions may be deemed to be anti-competitive and a violation of federal antitrust laws. To the extent that we are deemed to have enabled such activities, we could be subject to fines and penalties imposed by the U.S. Department of Justice or the FTC and be required to curtail or terminate the services that permitted such collusion.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Corrupt Practices Act (FCPA) and Foreign Anti-Bribery Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The FCPA makes it illegal for U.S. persons, including U.S. companies, and their subsidiaries, directors, officers, employees, and agents, to promise, authorize or make any corrupt payment, or otherwise provide anything of value, directly or indirectly, to any foreign official, any foreign political party or party official, or candidate for foreign political office to obtain or retain business.  </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the FCPA can also result in violations of other U.S. laws, including anti-money laundering, mail and wire fraud, and conspiracy laws.  There are severe penalties for violating the FCPA.  In addition, the Company may also be subject to other non-U.S. anti-corruption or anti-bribery laws, such as the U.K. Bribery Act 2010.  If our employees, contractors, vendors, or partners fail to comply with the FCPA and/or foreign anti-bribery laws, we may be subject to penalties or sanctions, and our ability to develop new prospects and retain existing customers could be adversely affected.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Economic Sanctions and Export Controls</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Economic and trade sanctions programs that are administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control prohibit or restrict transactions to or from, and dealings with specified countries and territories, their governments, and in certain circumstances, with individuals and entities that are specially designated nationals of those countries, and other sanctioned persons, including narcotics traffickers and terrorists or terrorist organizations. As federal, state and foreign legislative regulatory scrutiny and enforcement actions in these areas increase, we expect our costs to comply with these requirements will increase as well. Failure to comply with any of these requirements could result in the limitation, suspension or termination of our services, imposition of significant civil and criminal penalties, including fines, and/or the seizure and/or forfeiture of our assets.  Further, our Solution incorporates encryption technology. This encryption technology may be exported from the United States only with the required export authorizations, including by a license, a license exception or other appropriate government authorizations. Such solutions may also be subject to certain regulatory reporting requirements. Various countries also regulate the import of certain encryption technology, including through import permitting and licensing requirements, and have enacted laws that could limit our customers&#8217; ability to import our Solution into those countries. Governmental regulation of encryption technology and of exports and imports of encryption products, or our failure to obtain required approval for our Solution, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the provision of our Solution, including with respect to new applications, may delay the introduction of our Solution in various markets or, in some cases, prevent the provision of our Solution to some countries altogether.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory Certification</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We must obtain certification from governmental agencies, such as the Agency for Healthcare Research and Quality to sell certain of our analytics applications and services in the United States.  We cannot be certain that our Solution will continue to meet these standards.  The failure to comply with these certification requirements could result in the loss of certification, which could restrict our Solution offerings and cause us to lose customers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Internet Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Our business could be adversely impacted by changes in laws and regulations related to the Internet or changes in access to the Internet generally.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of our business depends upon the continued use of the Internet as a primary medium for communication, business applications, and commerce. Federal or state government bodies or agencies have in the past adopted, and may in the future adopt, laws or regulations affecting the use of the Internet as a commercial medium.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislators, regulators, or government bodies or agencies may also make legal or regulatory changes or interpret or apply existing laws or regulations that relate to the use of the Internet in new and materially different ways. Changes in these laws, regulations or interpretations could require us to modify our platform in order to comply with these changes, to incur substantial additional costs or divert resources that could otherwise be deployed to grow our business, or expose us to unanticipated civil or criminal liability, among other things.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government agencies and private organizations have imposed, and may in the future impose, additional taxes, fees or other charges for accessing the Internet or commerce conducted via the Internet.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internet access is frequently provided by companies that have significant market power and could take actions that degrade, disrupt or increase the cost of our customers&#8217; use of our platform, which could negatively impact our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net neutrality rules, which were designed to ensure that all online content is treated the same by Internet service providers and other companies that provide broadband services were repealed by the Federal Communications Commission effective June 2018.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repeal of the net neutrality rules could force us to incur greater operating expenses or our customers&#8217; use of our platform could be adversely affected, either of which could harm our business and results of operations. These developments could limit the growth of Internet-related commerce or communications generally or result in reductions in the demand for Internet-based platforms and services such as ours, increased costs to us or the disruption of our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as the Internet continues to experience growth in the numbers of users, frequency of use and amount of data transmitted, the use of the Internet as a business tool could be adversely affected due to delays in the development or adoption of new standards and protocols to handle increased demands of Internet activity, security, reliability, cost, ease-of-use, accessibility, and quality of service. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of the Internet and its acceptance as a business tool has been adversely affected by &#8220;viruses,&#8221; &#8220;worms,&#8221; and similar malicious programs and the Internet has experienced a variety of outages and other delays as a result of damage to portions of its infrastructure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the use of the Internet generally, or our platform specifically, is adversely affected by these or other issues, we could be forced to incur substantial costs, demand for our platform could decline, and our results of operations and financial condition could be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Tax Regulation</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value-added or similar transactional taxes, and we could be subject to liability with respect to past or future sales, which could adversely affect our results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not collect sales and use, value-added, and similar transactional taxes in all jurisdictions in which we have sales, based on our belief that such taxes are not applicable or that we are not required to collect such taxes with respect to the jurisdiction. Sales and use, value-added, and similar tax laws and rates vary greatly by jurisdiction. Certain jurisdictions in which we do not collect such taxes may assert that such taxes are applicable, which could result in tax assessments, penalties, and interest, and we may be required to collect such taxes in the future. Such tax assessments, penalties, interest or future requirements, increase in tax rates, or a combination of the foregoing may result in an increase in our sales and similar transactional taxes, increase administrative burdens or costs, or otherwise adversely affect our business, results of operations, or financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unanticipated changes in our effective tax rate and additional tax liabilities, including as a result of our international operations or implementation of new tax rules, could harm our future results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the United States and are expanding into various foreign jurisdictions that are subject to income tax. Our domestic and international tax liabilities are subject to the allocation of expenses in differing jurisdictions and complex transfer pricing regulations administered by taxing authorities in various jurisdictions. Tax rates in the jurisdictions in which we operate may change as a result of factors outside of our control or relevant taxing authorities may disagree with our determinations as to the income and expenses attributable to specific jurisdictions. In addition, changes in tax and trade laws, treaties or regulations, or their interpretation or enforcement, have become more unpredictable and may become more stringent, which could materially adversely affect our tax position. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forecasting our estimated annual effective tax rate is complex and subject to uncertainty, and there may be material differences between our forecasted and actual effective tax rate. Our effective tax rate could be adversely affected by changes in the mix of earnings and losses in countries with differing statutory tax rates, certain non-deductible expenses, the valuation of deferred tax assets and liabilities, adjustments to income taxes upon finalization of tax returns, changes in available tax attributes, decision to repatriate non-U.S. earnings for which we have not previously provided for U.S. taxes, and changes in federal, state, or international tax laws and accounting principles. Finally, we may be subject to income tax audits throughout the world. An adverse resolution of one or more uncertain tax positions in any period could have a material impact on our results of operations or financial condition for that period.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and December&#160;31, 2019, we had net operating loss (NOL) carryforwards for federal income tax purposes of approximately $419.6 million and $269.1 million, respectively, and state income tax purposes of approximately $334.6 million and $215.2 million, respectively, which may be available to offset taxable income in the future, and which expire in various years beginning in 2032 for federal purposes if not utilized. The state NOLs will expire depending upon the various rules in the states in which we operate. A lack of future taxable income would adversely affect our ability to utilize these NOLs before they expire. In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the Code) a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section 382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre-change NOLs to offset its future taxable income. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience a future ownership change under Section 382 of the Code that could affect our ability to utilize the NOLs to offset our income. Furthermore, our ability to utilize NOLs of companies that we have acquired or may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state income tax purposes. Certain provisions of the Tax Act (as defined below), as amended by the CARES Act, also limit the use of NOLs, as discussed further below. For these reasons, we may not be able to utilize a material portion of our NOLs, even if we attain profitability, which could potentially result in increased future tax liability to us and could adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive tax reform legislation could adversely affect our business and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law. The Tax Act contains, among other things, significant changes to corporate taxation, including (i) a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, (ii) a limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(increased to 50% by the CARES Act for taxable years beginning in 2019 and 2020), (iii) a limitation of the deduction for NOLs in taxable years beginning after December 31, 2020 to 80% of current year taxable income in respect of NOLs generated during or after 2018 and elimination of net operating loss carrybacks for NOLs arising in tax years ending after December 31, 2020, (iv) a one-time tax on offshore earnings at reduced rates regardless of whether they are repatriated, (v) immediate deductions for certain new investments instead of deductions for depreciation expense over time, and (vi) a modification or repeal of many business deductions and credits. For federal NOLs arising in tax years beginning after December 31, 2017, the Tax Act (as modified by the CARES Act) limits a taxpayer&#8217;s ability to utilize federal NOL carryforwards in taxable years beginning after December 31, 2020 to 80% of taxable income. In addition, federal NOLs arising in tax years ending after December 31, 2017 can be carried forward indefinitely, but carryback of federal NOLs arising in tax years ending after December 31, 2020 is generally prohibited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. We will continue to examine the impact the Tax Act and CARES Act may have on our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Our Outstanding Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our Notes may require a significant amount of cash, and we may not have sufficient cash or the ability to raise the funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes as required.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2020, we issued $230.0 million in aggregate principal amount of 2.50% Convertible Senior Notes (the Notes) due 2025, pursuant to an Indenture dated April 14, 2020, with U.S. Bank National Association, as trustee, in a private offering to qualified institutional buyers (the Note Offering). We received net proceeds from the Notes of $222.5 million, after deducting the initial purchasers&#8217; discounts and offering expenses payable by us. The Notes are governed by an indenture (the Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Indenture does not contain any financial covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries. A holder may convert all or any portion of its Notes, at its option, subject to certain conditions and during certain periods, into cash, shares of our common stock or a combination of cash and shares of our common stock, with the form of consideration determined at our election. Noteholders will have the right to require us to repurchase all or a portion of their notes at 100% of the principal amount of Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date, upon the occurrence of certain events. The conversion rate is initially 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock). If the Notes have not previously been converted, redeemed or repurchased, we will be required to repay the Notes in cash at maturity.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make required cash payments in connection with redemptions or conversions of the Notes, repurchase the Notes upon the occurrence of certain events, or to repay or refinance the Notes at maturity will depend on market conditions and our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. We also may not use the cash proceeds we raised through the issuance of the Notes in an optimally productive and profitable manner. Since inception, our business has generated net losses, and we may continue to incur significant losses. As a result, we may not have enough available cash or be able to obtain financing at the time we are required to repurchase or repay the Notes or pay cash with respect to Notes being converted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to repurchase or to pay cash upon conversion or at maturity of the Notes may be limited by law or regulatory authority or by other agreements governing our future indebtedness. Our failure to repurchase Notes upon the occurrence of certain events or to pay cash upon conversion or at maturity of the Notes as required by the Indenture would constitute a default under the Indenture. A default under the Indenture or the occurrence of certain events that allow Noteholders to require repurchase could also lead to a default under agreements governing our future indebtedness and could have a material adverse effect on our business, results of operations, and financial condition. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or to pay cash upon conversion or at maturity of the Notes.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to counterparty risk with respect to the Capped Calls.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Notes, we entered into the Capped Calls with certain option counterparties. We used approximately $21.6 million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. The option counterparties are financial institutions or affiliates of financial institutions, and we will be subject to the risk that one or more of such option counterparties may default under the Capped Calls. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to the credit risk of the option counterparties will not be secured by any collateral. If any option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the Capped Calls. Our exposure will depend on many factors but, generally, the increase in our exposure will be correlated to the increase in our common stock market price and in the volatility of the market price of our common stock. In addition, upon a default by any option counterparty, we may suffer adverse tax consequences and dilution with respect to our common stock. We can provide no assurance as to the financial stability or viability of any option counterparty.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Capped Calls may affect the value of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Notes, we entered into the Capped Calls with the option counterparties. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the Notes. This activity could cause or avoid an increase or a decrease in the market price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility by subjecting us to customary affirmative and negative covenants, indemnification provisions, and events of default. Further, if we are liquidated, the lender&#8217;s rights to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. Any declaration by a lender of an event of default could significantly harm our business and prospects and could cause the price of our common shares to decline. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history in an evolving industry which makes it difficult to evaluate our current business future prospects and increases the risk of your investment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched operations in 2008 and we acquired Medicity, Able Health, Healthfinch and Vitalware in June 2018, February 2020, July 2020 and September 2020, respectively. Our limited operating history, in particular with respect to the businesses we acquired in 2020, makes it difficult to effectively assess or forecast our future prospects. You should consider our business and prospects in light of the risks and difficulties we encounter or may encounter. These risks and difficulties include our ability to cost-effectively acquire new customers and retain existing customers, maintain the quality of our technology infrastructure that can efficiently and reliably handle the requirements of our customers and the deployment of new features and solutions and successfully compete with other companies that are currently in, or may enter, the healthcare solution space. Additional risks include our ability to effectively manage growth, achieve synergies, responsibly use the data that customers share with us, process, store, protect, and use personal data in compliance with governmental regulation, contractual obligations, and other legal obligations related to privacy and security and avoid interruptions or disruptions in our service or slower than expected load times for our platform. If we fail to address the risks and difficulties that we face, including those associated with the challenges listed above, our business and our results of operations will be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced significant net losses since inception, we expect to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain profitability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses in the past, including net losses of $115.0 million and $60.1 million in the years ended December 31, 2020 and 2019, respectively. We had an accumulated deficit of $725.7 million as of December 31, 2020. We expect our costs will increase over time as we continue to invest to grow our business and build relationships with customers, develop our platform, develop new solutions, and operate as a public company. These efforts may prove to be more expensive than we currently anticipate, and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may need to raise additional capital through equity and debt financings in order to fund our operations. To date, we have financed our operations principally from the sale of redeemable convertible preferred stock, revenue from sales of our Solution and the incurrence of indebtedness.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also fail to improve the gross margins of our business. If we are unable to effectively manage these risks and difficulties as we encounter them, our business, financial condition, and results of operations would be adversely affected. Our failure to achieve or maintain profitability could negatively impact the value of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile and may decline regardless of our operating performance, and you may lose all or part of your investments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets and/or publicly-listed technology companies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our net revenue or other operating metrics;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the financial projections we provide to the public or our failure to meet these projections;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of securities analysts to initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our company, or our failure to meet the estimates or the expectations of investors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economy as a whole and market conditions in our industry;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rumors and market speculation involving us or other companies in our industry;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant innovations, acquisitions, strategic partnerships, joint ventures, or capital commitments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new laws or regulations or new interpretations of existing laws or regulations applicable to our business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lawsuits threatened or filed against us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruitment or departure of key personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, including those resulting from war, incidents of terrorism, or responses to these events; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of contractual lock-up or market standoff agreements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, extreme price and volume fluctuations in the stock markets have affected and continue to affect many technology companies&#8217; stock prices. Often, their stock prices have fluctuated in ways unrelated or disproportionate to the companies&#8217; operating performance. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business, and harm our business. Moreover, because of these fluctuations, comparing our results of operations on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our net revenue or results of operations fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated net revenue or earnings forecasts that we may provide.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our common stock and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock could be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us on a regular basis, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our management has broad discretion in the use of proceeds from our IPO and the Note Offering and our use may not produce a positive rate of return.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal purposes of our IPO were to increase our capitalization and financial flexibility, create a public market for our stock and thereby enable access to the public equity markets by our employees and stockholders, obtain additional capital, and strengthen our position in the healthcare data analytics applications and services market. We used a portion of the Note Offering proceeds to pay the cost of the capped call transactions related thereto and to prepay in full all outstanding indebtedness under our credit agreement with OrbiMed. We cannot specify with certainty our plans for the use of the net proceeds we received from these offerings. However, we intend to use the net proceeds we received from our IPO for working capital and other general corporate purposes. We may also use a portion of the net proceeds from these offerings for the acquisition of, or investment in, technologies, solutions or businesses that complement our business. Our management has broad discretion over the specific use of the net proceeds we received in these offerings and might not be able to obtain a significant return, if any, on investment of these net proceeds. Investors will need to rely upon the judgment of our management with respect to the use of proceeds. If we do not use the net proceeds that we received in our IPO and the Note Offering effectively, our business, results of operations, and financial condition could be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors, and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products, or technologies and issue equity securities to pay for any such acquisition or investment, such as our issuance of equity securities in connection with our acquisitions of Able Health, Healthfinch, and Vitalware in February 2020, July 2020, and September 2020, respectively. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per-share value of our common stock to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934 (the Exchange Act), the listing standards of Nasdaq&#160;and other applicable securities rules and regulations. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming, and costly, and place significant strain on our personnel, systems, and resources. For example, the Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and results of operations. As a result of the complexity involved in complying with the rules and regulations applicable to public companies, our management&#8217;s attention may be diverted from other business concerns, which could harm our business, results of operations, and financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have already hired additional employees to assist us in complying with these requirements, we may need to hire more employees in the future or engage outside consultants, which will increase our operating expenses. In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time-consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to invest substantial resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from business operations to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that being a public company and these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of disclosure of information in filings required of a public company, our business and financial condition is more visible, which may result in an increased risk of threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The individuals who now constitute our senior management team have limited experience managing a publicly-traded company and limited experience complying with the increasingly complex laws pertaining to public companies. Our senior management team may not successfully or efficiently manage our transition to a public company that is subject to significant regulatory oversight and reporting obligations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock and, consequently, the ability of common stockholders to achieve a return on investment will depend on appreciation, if any, in the price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid any dividends on our capital stock. We intend to retain any earnings to finance the operation and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. In addition, the terms of any future credit facility or financing we obtain may contain, terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, common stockholders may only receive a return on investment if the market price of our common stock increases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">We could be subject to securities class action litigation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because technology and healthcare technology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;text-decoration:underline">Risks Related to Our Charter and Bylaws</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current board of directors, and limit the market price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws, include provisions that:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our board of directors is classified into three classes of directors with staggered three-year terms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit the board of directors to establish the number of directors and fill any vacancies and newly-created directorships;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require super-majority voting to amend some provisions in our amended and restated certificate of incorporation and amended and restated bylaws;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights plan;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that only a majority of our board of directors will be authorized to call a special meeting of stockholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the board of directors is expressly authorized to make, alter, or repeal our bylaws; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Section 203 of the Delaware General Corporation Law may discourage, delay, or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide, to the fullest extent permitted by law, that a state or federal court located within the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal affairs doctrine.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Nothing in our amended and restated bylaws precludes stockholders that assert claims under the Securities Act or the Exchange Act from bringing such claims in state or federal court, subject to applicable law. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provision which will be contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</span></div><div id="i697ec2deca434bfbba4eea21a51f5e11_163"></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference from Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference from Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-q12021xcertific.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-q12021xcertific.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-q12021xcertific.htm">Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#94;&#160;&#160;&#160;&#160;The certifications attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Health Catalyst, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i697ec2deca434bfbba4eea21a51f5e11_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:6.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bryan Hunt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May&#160;6, 2021</span></div></td></tr><tr style="height:24pt"><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryan Hunt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-q12021xcertific.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if64b9a505b3c4ab8911fe32f62eb2e0f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a)&#160;OR 15d-14(a)&#160;OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Burton, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Health Catalyst, Inc.&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 6, 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Burton</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Burton</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-q12021xcertific.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id6b13cf5f6c44c6bbf4d926e3b863edc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a)&#160;OR 15d-14(a)&#160;OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Bryan Hunt, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Health Catalyst, Inc.&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 6, 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bryan Hunt</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryan Hunt</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-q12021xcertific.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i34250e3ea9a9413688514c2f3c8e6080_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit&#160;32.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Daniel Burton, Chief Executive Officer of Health Catalyst, Inc. (the &#8220;Company&#8221;), and Bryan Hunt, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarterly period ended March 31, 2021, to which this Certification is attached as Exhibit&#160;32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange Act&#59; and</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Date&#58; May 6, 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Burton</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Burton</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bryan Hunt</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryan Hunt</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>hcat-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ac4f3b8b-712a-43a6-9f81-b9cf5889a679,g:b64543c5-cb81-4282-9510-d3dfb10c5ee8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:hcat="http://www.healthcatalyst.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.healthcatalyst.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hcat-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hcat-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hcat-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hcat-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.healthcatalyst.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails">
        <link:definition>2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails">
        <link:definition>2406403 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails">
        <link:definition>2407404 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.healthcatalyst.com/role/BusinessCombinations">
        <link:definition>2108102 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsTables">
        <link:definition>2309302 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>2410405 - Disclosure - Business Combinations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2411406 - Disclosure - Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsUnauditedProFormaFinancialInformationDetails" roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails">
        <link:definition>2412407 - Disclosure - Business Combinations - Unaudited Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.healthcatalyst.com/role/Revenue">
        <link:definition>2113103 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.healthcatalyst.com/role/RevenueTables">
        <link:definition>2314303 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" roleURI="http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails">
        <link:definition>2415408 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/RevenueNarrativeDetails">
        <link:definition>2416409 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets">
        <link:definition>2117104 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2318304 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2419410 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails">
        <link:definition>2420411 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2421412 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.healthcatalyst.com/role/PropertyandEquipment">
        <link:definition>2122105 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentTables">
        <link:definition>2323305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentComponentsofPropertyandEquipmentDetails" roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails">
        <link:definition>2424413 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2425414 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestments" roleURI="http://www.healthcatalyst.com/role/ShorttermInvestments">
        <link:definition>2126106 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsTables" roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsTables">
        <link:definition>2327306 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsDetails" roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails">
        <link:definition>2428415 - Disclosure - Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstruments">
        <link:definition>2129107 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2330307 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2431416 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails" roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails">
        <link:definition>2432417 - Disclosure - Fair Value of Financial Instruments - Contingent Consideration Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails">
        <link:definition>2433418 - Disclosure - Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accruedliabilities" roleURI="http://www.healthcatalyst.com/role/Accruedliabilities">
        <link:definition>2134108 - Disclosure - Accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedliabilitiesTables" roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesTables">
        <link:definition>2335308 - Disclosure - Accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedliabilitiesDetails" roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesDetails">
        <link:definition>2436419 - Disclosure - Accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotes">
        <link:definition>2137109 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2338309 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails">
        <link:definition>2439420 - Disclosure - Convertible Senior Notes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesInterestExpenseDetails" roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails">
        <link:definition>2440421 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails" roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails">
        <link:definition>2441422 - Disclosure - Convertible Senior Notes - Net Carrying Value Of the Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails" roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails">
        <link:definition>2442423 - Disclosure - Convertible Senior Notes - Net Carrying Value Of the Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.healthcatalyst.com/role/StockholdersEquity">
        <link:definition>2143110 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2444424 - Disclosure - Stockholders&#8217; Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.healthcatalyst.com/role/NetLossPerShare">
        <link:definition>2145111 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.healthcatalyst.com/role/NetLossPerShareTables">
        <link:definition>2346310 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails">
        <link:definition>2447425 - Disclosure - Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails">
        <link:definition>2448426 - Disclosure - Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.healthcatalyst.com/role/StockBasedCompensation">
        <link:definition>2149112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationTables">
        <link:definition>2350311 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2451427 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails">
        <link:definition>2452428 - Disclosure - Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2453429 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2454430 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails">
        <link:definition>2455431 - Disclosure - Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.healthcatalyst.com/role/IncomeTaxes">
        <link:definition>2156113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.healthcatalyst.com/role/IncomeTaxesDetails">
        <link:definition>2457432 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.healthcatalyst.com/role/CommitmentsandContingencies">
        <link:definition>2158114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueandPerformanceObligations" roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations">
        <link:definition>2159115 - Disclosure - Deferred Revenue and Performance Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueandPerformanceObligationsNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails">
        <link:definition>2460433 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueandPerformanceObligationsNarrativeDetails_1" roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails_1">
        <link:definition>2460433 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails" roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails">
        <link:definition>2461434 - Disclosure - Deferred Revenue and Performance Obligations - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1" roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1">
        <link:definition>2461434 - Disclosure - Deferred Revenue and Performance Obligations - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.healthcatalyst.com/role/RelatedParties">
        <link:definition>2162116 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesDetails" roleURI="http://www.healthcatalyst.com/role/RelatedPartiesDetails">
        <link:definition>2463435 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.healthcatalyst.com/role/Segments">
        <link:definition>2164117 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.healthcatalyst.com/role/SegmentsTables">
        <link:definition>2365312 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.healthcatalyst.com/role/SegmentsNarrativeDetails">
        <link:definition>2466436 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsScheduledofSegmentRevenueDetails" roleURI="http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails">
        <link:definition>2467437 - Disclosure - Segments - Scheduled of Segment Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsScheduleofSegmentAdjustedGrossProfitDetails" roleURI="http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails">
        <link:definition>2468438 - Disclosure - Segments - Schedule of Segment Adjusted Gross Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="hcat_TechnologyMember" abstract="true" name="TechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="hcat_BusinessCombinationConsiderationPayableCurrent" abstract="false" name="BusinessCombinationConsiderationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_RevenueFromSubscriptionContractTermofContract" abstract="false" name="RevenueFromSubscriptionContractTermofContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_DebtInstrumentConvertibleThresholdTypeDomain" abstract="true" name="DebtInstrumentConvertibleThresholdTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod" abstract="false" name="RevenueFromSubscriptionsContractAllowedTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="hcat_OneTimeTechnologyMember" abstract="true" name="OneTimeTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" abstract="false" name="BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_LessOtherReconcilingItemsAbstract" abstract="true" name="LessOtherReconcilingItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="hcat_DebtIssuanceCostsGrossEquityComponent" abstract="false" name="DebtIssuanceCostsGrossEquityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" abstract="false" name="NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination" abstract="false" name="RevenueFromSubscriptionsContractNoticeRequiredForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="hcat_CappedCallMember" abstract="true" name="CappedCallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_ShortTermMarketableSecurityMember" abstract="true" name="ShortTermMarketableSecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_DebtInstrumentConvertibleThresholdTypeAxis" abstract="true" name="DebtInstrumentConvertibleThresholdTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="hcat_InterestAndOtherExpenseNet" abstract="false" name="InterestAndOtherExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_DebtIssuanceCostGrossEquityComponent" abstract="false" name="DebtIssuanceCostGrossEquityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember" abstract="true" name="DebtInstrumentConvertibleSalePriceOfStockThresholdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_SeniorNotesDue2025Member" abstract="true" name="SeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" abstract="false" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_DebtIssuanceCostGrossLiabilityComponent" abstract="false" name="DebtIssuanceCostGrossLiabilityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" abstract="false" name="DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_FairValueMeasurementAggregateIntrinsicValue" abstract="false" name="FairValueMeasurementAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_TechnologyAndProfessionalServicesMember" abstract="true" name="TechnologyAndProfessionalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_CustomerRelationshipsAndContractsMember" abstract="true" name="CustomerRelationshipsAndContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_LessAdjustedGrossProfitreconcilingitemsAbstract" abstract="true" name="LessAdjustedGrossProfitreconcilingitemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" abstract="false" name="NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_AbleHealthIncMember" abstract="true" name="AbleHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_StockIncentivePlan2011Member" abstract="true" name="StockIncentivePlan2011Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_AssetsHeldUnderFinanceLeasesMember" abstract="true" name="AssetsHeldUnderFinanceLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure" abstract="false" name="ConvertibleDebtLiabilityComponentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_CommissionPaymentEstimatedBenefitPeriod" abstract="false" name="CommissionPaymentEstimatedBenefitPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_MeasurementInputRevenueVolatilityMember" abstract="true" name="MeasurementInputRevenueVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" abstract="false" name="DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" abstract="false" name="DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_StockholdersVote" abstract="false" name="StockholdersVote" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="hcat_CapitalizedOfInternalUseSoftware" abstract="false" name="CapitalizedOfInternalUseSoftware" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_VitalwareLLCMember" abstract="true" name="VitalwareLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_MeasurementInputMarketPriceOfRevenueRiskMember" abstract="true" name="MeasurementInputMarketPriceOfRevenueRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_RestrictedSharesPursuantToAcquisitionAgreementMember" abstract="true" name="RestrictedSharesPursuantToAcquisitionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hcat_ContractBacklogsMember" abstract="true" name="ContractBacklogsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_RecurringTechnologyMember" abstract="true" name="RecurringTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" abstract="true" name="ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="hcat_DeferredRevenueArrangementForServiceContractTerm" abstract="false" name="DeferredRevenueArrangementForServiceContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_StockIncentivePlan2019Member" abstract="true" name="StockIncentivePlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_HealthfinchIncMember" abstract="true" name="HealthfinchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" abstract="false" name="BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hcat_AcquisitionRelatedFairValueAdjustmentsMember" abstract="true" name="AcquisitionRelatedFairValueAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="hcat_ProfessionalServicesMember" abstract="true" name="ProfessionalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>hcat-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ac4f3b8b-712a-43a6-9f81-b9cf5889a679,g:b64543c5-cb81-4282-9510-d3dfb10c5ee8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CoverPage" xlink:type="simple" xlink:href="hcat-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_63b05495-bd93-479c-9024-cd17090681e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_63b05495-bd93-479c-9024-cd17090681e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_51018625-32cb-4a2e-afde-84fcfb8e3663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_51018625-32cb-4a2e-afde-84fcfb8e3663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0cb9a584-558a-4e4a-9ef6-2b9ede602e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0cb9a584-558a-4e4a-9ef6-2b9ede602e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_521b35ae-e586-4d29-8297-a8fdb77f6fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:to="loc_us-gaap_AccountsPayableCurrent_521b35ae-e586-4d29-8297-a8fdb77f6fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_fd6c8a65-4499-4101-8a55-8ce6a2681966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:to="loc_us-gaap_SeniorNotes_fd6c8a65-4499-4101-8a55-8ce6a2681966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationPayableCurrent_f32965d6-62d0-4733-950b-f32d5b5684a9" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:to="loc_hcat_BusinessCombinationConsiderationPayableCurrent_f32965d6-62d0-4733-950b-f32d5b5684a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_c782a1cf-814b-409d-9353-294952c21c33" xlink:href="hcat-20210331.xsd#hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf438a0e-e085-4844-8014-62f46d8b1428" xlink:to="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_c782a1cf-814b-409d-9353-294952c21c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4789d823-db13-4d38-b595-2c5cdb4cd899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d77fd0dd-9137-4898-aa9c-151e88723e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4789d823-db13-4d38-b595-2c5cdb4cd899" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d77fd0dd-9137-4898-aa9c-151e88723e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c5b2af85-46af-4b0a-aca6-d12db1ab30e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4789d823-db13-4d38-b595-2c5cdb4cd899" xlink:to="loc_us-gaap_LiabilitiesCurrent_c5b2af85-46af-4b0a-aca6-d12db1ab30e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_884cc0bb-888a-4e60-8183-ea3bd7b28610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4789d823-db13-4d38-b595-2c5cdb4cd899" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_884cc0bb-888a-4e60-8183-ea3bd7b28610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3f8e567e-e7bb-4edf-b285-3ea0ffe37ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4789d823-db13-4d38-b595-2c5cdb4cd899" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3f8e567e-e7bb-4edf-b285-3ea0ffe37ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42fc145e-1683-4a70-a6d9-3f9029276603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4789d823-db13-4d38-b595-2c5cdb4cd899" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42fc145e-1683-4a70-a6d9-3f9029276603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e313a090-39da-4358-ba79-4a515e789792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4789d823-db13-4d38-b595-2c5cdb4cd899" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e313a090-39da-4358-ba79-4a515e789792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2a58974b-58f4-4065-98ab-7d1dfdf8f2de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_569a6b90-903e-4670-9260-f98056a3d1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a58974b-58f4-4065-98ab-7d1dfdf8f2de" xlink:to="loc_us-gaap_AssetsCurrent_569a6b90-903e-4670-9260-f98056a3d1cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_130b105e-7df3-4d2e-ad72-e7b51181ca70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a58974b-58f4-4065-98ab-7d1dfdf8f2de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_130b105e-7df3-4d2e-ad72-e7b51181ca70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d5edc9a7-cc6a-49af-a6ec-a8319e549d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a58974b-58f4-4065-98ab-7d1dfdf8f2de" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d5edc9a7-cc6a-49af-a6ec-a8319e549d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c8ba8fa-0dda-4766-b6ec-862c00268085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a58974b-58f4-4065-98ab-7d1dfdf8f2de" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c8ba8fa-0dda-4766-b6ec-862c00268085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b084d80e-cf3a-4d2e-996b-483745e8d2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a58974b-58f4-4065-98ab-7d1dfdf8f2de" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b084d80e-cf3a-4d2e-996b-483745e8d2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_009ab203-f87e-49e6-a2b2-e6d40fe2d6da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a58974b-58f4-4065-98ab-7d1dfdf8f2de" xlink:to="loc_us-gaap_Goodwill_009ab203-f87e-49e6-a2b2-e6d40fe2d6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_765fb9ae-a358-487d-aaf7-8cbc89c06889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b0c99565-d18f-4e81-8fab-2a95ea481d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_765fb9ae-a358-487d-aaf7-8cbc89c06889" xlink:to="loc_us-gaap_Liabilities_b0c99565-d18f-4e81-8fab-2a95ea481d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b098238f-0d0d-4c7e-9177-7541801b0cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_765fb9ae-a358-487d-aaf7-8cbc89c06889" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b098238f-0d0d-4c7e-9177-7541801b0cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6a93e859-19db-416e-8a0a-02475e85273b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_765fb9ae-a358-487d-aaf7-8cbc89c06889" xlink:to="loc_us-gaap_StockholdersEquity_6a93e859-19db-416e-8a0a-02475e85273b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3cf519aa-be93-49bd-97bd-24e4432a9a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c930a72f-82a4-432d-a11f-96188665334a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3cf519aa-be93-49bd-97bd-24e4432a9a6b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c930a72f-82a4-432d-a11f-96188665334a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_57e6098c-a999-48ab-b4cb-50998569b978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3cf519aa-be93-49bd-97bd-24e4432a9a6b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_57e6098c-a999-48ab-b4cb-50998569b978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_50969c43-adcd-4838-87c1-5e997b527645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3cf519aa-be93-49bd-97bd-24e4432a9a6b" xlink:to="loc_us-gaap_CommonStockValue_50969c43-adcd-4838-87c1-5e997b527645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df596fa9-ba69-428f-92a5-51e300ba8e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3cf519aa-be93-49bd-97bd-24e4432a9a6b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df596fa9-ba69-428f-92a5-51e300ba8e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_239b5a16-bcb2-4603-99ed-db8b810fd702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3cf519aa-be93-49bd-97bd-24e4432a9a6b" xlink:to="loc_us-gaap_PreferredStockValue_239b5a16-bcb2-4603-99ed-db8b810fd702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_01c34d90-4c4c-4a4e-b286-22de4e87813e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_2aa01521-8237-46fd-ad9b-8ea49ea527e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_01c34d90-4c4c-4a4e-b286-22de4e87813e" xlink:to="loc_us-gaap_ShortTermInvestments_2aa01521-8237-46fd-ad9b-8ea49ea527e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5729438d-5e77-42e4-b59a-55e6f4ad9dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_01c34d90-4c4c-4a4e-b286-22de4e87813e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5729438d-5e77-42e4-b59a-55e6f4ad9dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67ae937d-1e0e-4446-ac5c-619f190e54c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_01c34d90-4c4c-4a4e-b286-22de4e87813e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67ae937d-1e0e-4446-ac5c-619f190e54c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23c39ca0-38f9-41e4-a146-a3d82bdb35c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_01c34d90-4c4c-4a4e-b286-22de4e87813e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23c39ca0-38f9-41e4-a146-a3d82bdb35c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55be20ca-840d-41ef-96ef-e72a907215ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_da09fb47-12e0-4952-b862-8f634c83eae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_55be20ca-840d-41ef-96ef-e72a907215ee" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_da09fb47-12e0-4952-b862-8f634c83eae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fbe13fd9-975e-491d-aa3a-c76d32e46ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_55be20ca-840d-41ef-96ef-e72a907215ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fbe13fd9-975e-491d-aa3a-c76d32e46ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_56336b4e-923b-4b89-915d-3158d48947fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b10c7b20-9952-405f-9856-cbb299742454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_56336b4e-923b-4b89-915d-3158d48947fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_b10c7b20-9952-405f-9856-cbb299742454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_InterestAndOtherExpenseNet_3bfe38da-6d40-4539-aa86-4d409e318dbc" xlink:href="hcat-20210331.xsd#hcat_InterestAndOtherExpenseNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_56336b4e-923b-4b89-915d-3158d48947fe" xlink:to="loc_hcat_InterestAndOtherExpenseNet_3bfe38da-6d40-4539-aa86-4d409e318dbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_85a111b5-2ae1-4696-9592-f952191abb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_74e6ac26-d1f3-4602-ac03-5ae5736cb6fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_85a111b5-2ae1-4696-9592-f952191abb15" xlink:to="loc_us-gaap_SellingAndMarketingExpense_74e6ac26-d1f3-4602-ac03-5ae5736cb6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7a599756-a964-4b7e-aea9-17f334ed9bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_85a111b5-2ae1-4696-9592-f952191abb15" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7a599756-a964-4b7e-aea9-17f334ed9bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1d1c7b7c-1590-4f38-bf48-8dcd75d3eaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_85a111b5-2ae1-4696-9592-f952191abb15" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1d1c7b7c-1590-4f38-bf48-8dcd75d3eaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d7952b0c-0a0d-4272-bb79-33793c275219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_85a111b5-2ae1-4696-9592-f952191abb15" xlink:to="loc_us-gaap_DepreciationAndAmortization_d7952b0c-0a0d-4272-bb79-33793c275219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a58265a5-4d69-46f7-bc85-5e88e3425d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_059a127a-d431-4c6e-bbd0-a89d19f99188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a58265a5-4d69-46f7-bc85-5e88e3425d97" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_059a127a-d431-4c6e-bbd0-a89d19f99188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f9470efb-d1c0-4d58-ae2b-b73c059aed18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a58265a5-4d69-46f7-bc85-5e88e3425d97" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f9470efb-d1c0-4d58-ae2b-b73c059aed18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4f47722c-a541-4de8-a836-3f05f6192368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a58265a5-4d69-46f7-bc85-5e88e3425d97" xlink:to="loc_us-gaap_OperatingExpenses_4f47722c-a541-4de8-a836-3f05f6192368" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd89733-f9f6-4b79-9212-c4fa9c3f9d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c89ab34e-ab57-46e9-9f01-c7616f5aa224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd89733-f9f6-4b79-9212-c4fa9c3f9d9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c89ab34e-ab57-46e9-9f01-c7616f5aa224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9ac31e1c-edb0-4d53-9e75-e2257bf225ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd89733-f9f6-4b79-9212-c4fa9c3f9d9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9ac31e1c-edb0-4d53-9e75-e2257bf225ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0938ce7f-f662-4eff-88ba-def1a2e89db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd89733-f9f6-4b79-9212-c4fa9c3f9d9f" xlink:to="loc_us-gaap_NetIncomeLoss_0938ce7f-f662-4eff-88ba-def1a2e89db0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_33796df0-891c-47c2-b606-27a19b3b7947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e04ce463-3aae-43bf-9e64-30576e9ed2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_33796df0-891c-47c2-b606-27a19b3b7947" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e04ce463-3aae-43bf-9e64-30576e9ed2b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce257a41-7a02-4e65-ab62-ecaba1536f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_33796df0-891c-47c2-b606-27a19b3b7947" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce257a41-7a02-4e65-ab62-ecaba1536f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_474dd5af-0b44-4784-b6e2-f588d0c3d919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_33796df0-891c-47c2-b606-27a19b3b7947" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_474dd5af-0b44-4784-b6e2-f588d0c3d919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8985f3ff-50a9-4bfb-b6fc-5922a9a41c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_33796df0-891c-47c2-b606-27a19b3b7947" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8985f3ff-50a9-4bfb-b6fc-5922a9a41c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_1e266dac-52fe-4151-877b-2525fbbf1e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_1e266dac-52fe-4151-877b-2525fbbf1e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInOperatingLeaseLiabilities_9f7c4789-d766-4981-a962-505c1a23ce77" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_hcat_IncreaseDecreaseInOperatingLeaseLiabilities_9f7c4789-d766-4981-a962-505c1a23ce77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_25090e71-2dfc-4ca2-8c00-d3e4ee637bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_ShareBasedCompensation_25090e71-2dfc-4ca2-8c00-d3e4ee637bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_f5b6665b-73c8-4e46-b0e4-0da5501ab919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_f5b6665b-73c8-4e46-b0e4-0da5501ab919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0d2f1d0-bd94-4584-a016-7e0d71b69d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0d2f1d0-bd94-4584-a016-7e0d71b69d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_9bbdfe9c-f7f2-4790-921e-d26578270e89" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_9bbdfe9c-f7f2-4790-921e-d26578270e89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_a2e312dc-b22c-408e-891c-a80b02bd2746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_a2e312dc-b22c-408e-891c-a80b02bd2746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de448333-0efc-47a2-a28d-93e4d4117db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_NetIncomeLoss_de448333-0efc-47a2-a28d-93e4d4117db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c63ee5ce-e29e-41ca-a4ad-e020450ccaed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c63ee5ce-e29e-41ca-a4ad-e020450ccaed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ca4f4fe7-ba85-4124-a777-8cb7eab89e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ca4f4fe7-ba85-4124-a777-8cb7eab89e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities_93285d15-5218-47b7-b691-363784cd4886" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities_93285d15-5218-47b7-b691-363784cd4886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4a0f7281-8e67-46f8-9b77-039ebd19b718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4a0f7281-8e67-46f8-9b77-039ebd19b718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7c04a9b7-c118-4b32-9b58-947857476c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7c04a9b7-c118-4b32-9b58-947857476c26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8741171-2bb2-48ca-8836-2c50cfd59360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8741171-2bb2-48ca-8836-2c50cfd59360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_db38f7b3-a33c-4624-94d4-40fb11e5cef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_DepreciationAndAmortization_db38f7b3-a33c-4624-94d4-40fb11e5cef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_66967585-e4f2-4d8f-9b86-5d58bf4d0a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff1cc6d9-7175-433e-bb54-f71c1675a143" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_66967585-e4f2-4d8f-9b86-5d58bf4d0a2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18719f5d-333f-4160-a766-3aa86204e1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d34ac878-d11e-4272-ac16-58a7b7940178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18719f5d-333f-4160-a766-3aa86204e1bf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d34ac878-d11e-4272-ac16-58a7b7940178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4a6c9105-1bd9-483c-9bad-ba6930250b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18719f5d-333f-4160-a766-3aa86204e1bf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4a6c9105-1bd9-483c-9bad-ba6930250b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c9736ce2-7294-49b6-a353-43cae0bcf2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18719f5d-333f-4160-a766-3aa86204e1bf" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c9736ce2-7294-49b6-a353-43cae0bcf2b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c8c4dac0-1f50-430b-a3c3-be2678771c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c8c4dac0-1f50-430b-a3c3-be2678771c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4d8b95e3-5394-4220-bede-9f8d3ef14173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4d8b95e3-5394-4220-bede-9f8d3ef14173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CapitalizedOfInternalUseSoftware_790d78b6-7dc7-4c29-895b-250cf998b245" xlink:href="hcat-20210331.xsd#hcat_CapitalizedOfInternalUseSoftware"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:to="loc_hcat_CapitalizedOfInternalUseSoftware_790d78b6-7dc7-4c29-895b-250cf998b245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f4f80a45-c959-4024-a486-23164f32f535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f4f80a45-c959-4024-a486-23164f32f535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_909fcc33-0759-40f3-9cbb-04499657ea13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_909fcc33-0759-40f3-9cbb-04499657ea13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_39090da4-cf71-4fa4-9a11-7eafa9e3f518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_39090da4-cf71-4fa4-9a11-7eafa9e3f518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67178ffb-df2c-41e4-a5b7-b292eff779c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae0337e5-3ff4-4ec5-a89b-5c24ca335e21" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67178ffb-df2c-41e4-a5b7-b292eff779c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinations" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinations"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_79813966-39cf-48be-80ea-1ddbc9950c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_786d343a-c05c-4388-aebc-ed674deb692f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_79813966-39cf-48be-80ea-1ddbc9950c34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_786d343a-c05c-4388-aebc-ed674deb692f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_87f1408e-71c4-41e3-b69b-92664605cc0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_79813966-39cf-48be-80ea-1ddbc9950c34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_87f1408e-71c4-41e3-b69b-92664605cc0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c202bdde-4d58-4135-8a01-c3168aa87b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_79813966-39cf-48be-80ea-1ddbc9950c34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c202bdde-4d58-4135-8a01-c3168aa87b00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9fab0c22-0c4c-436f-b308-5227a246781b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eb9b574f-bbdf-419d-b392-1e5850c53146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9fab0c22-0c4c-436f-b308-5227a246781b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eb9b574f-bbdf-419d-b392-1e5850c53146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cafaa414-28a7-440a-bc95-3c0bf5e2ec67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9fab0c22-0c4c-436f-b308-5227a246781b" xlink:to="loc_us-gaap_Goodwill_cafaa414-28a7-440a-bc95-3c0bf5e2ec67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5770d60f-cdf2-4637-bc85-4a72b2e24e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a2146702-b743-4640-ac14-42e5af5892c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5770d60f-cdf2-4637-bc85-4a72b2e24e52" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a2146702-b743-4640-ac14-42e5af5892c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_5e87c2df-c0d2-41cc-810a-a6fb3a400b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5770d60f-cdf2-4637-bc85-4a72b2e24e52" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_5e87c2df-c0d2-41cc-810a-a6fb3a400b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9616d8fc-386e-4f5b-97df-540ed6582064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_c3889eec-1a48-4168-9ba6-08bdc9a89107" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9616d8fc-386e-4f5b-97df-540ed6582064" xlink:to="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_c3889eec-1a48-4168-9ba6-08bdc9a89107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_fd4265f8-e7cd-43cd-b277-d60ad5e2ed2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9616d8fc-386e-4f5b-97df-540ed6582064" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_fd4265f8-e7cd-43cd-b277-d60ad5e2ed2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d0d1b42f-b65b-42a3-89db-b08cd0f7549c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9616d8fc-386e-4f5b-97df-540ed6582064" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d0d1b42f-b65b-42a3-89db-b08cd0f7549c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsUnauditedProFormaFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Revenue" xlink:type="simple" xlink:href="hcat-20210331.xsd#Revenue"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/Revenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/RevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/RevenueNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a79874a3-2fee-4a29-91c0-9e1966df49d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f9ca527-d26d-4fbc-b155-8f86647a6005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a79874a3-2fee-4a29-91c0-9e1966df49d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f9ca527-d26d-4fbc-b155-8f86647a6005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d73dfef0-cf7f-4db6-9c97-ce22e0bd7a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a79874a3-2fee-4a29-91c0-9e1966df49d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d73dfef0-cf7f-4db6-9c97-ce22e0bd7a0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7efbc6bd-0e16-4eab-bb12-09b58823dcea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_09de9dda-92d9-4076-ace2-936dcfc1b54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7efbc6bd-0e16-4eab-bb12-09b58823dcea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_09de9dda-92d9-4076-ace2-936dcfc1b54d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dfb71976-567d-43ae-90e4-ed5b83a21949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7efbc6bd-0e16-4eab-bb12-09b58823dcea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dfb71976-567d-43ae-90e4-ed5b83a21949" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestments"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_34a71045-f09f-4bda-b30d-c87c24c829b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3a3611a0-eaf7-45ed-813b-61594920806d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_34a71045-f09f-4bda-b30d-c87c24c829b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3a3611a0-eaf7-45ed-813b-61594920806d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06bd2511-3251-465f-a3ba-937dcc79f723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_34a71045-f09f-4bda-b30d-c87c24c829b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06bd2511-3251-465f-a3ba-937dcc79f723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd2a3371-fb91-40fe-b046-005c0f011e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_34a71045-f09f-4bda-b30d-c87c24c829b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd2a3371-fb91-40fe-b046-005c0f011e96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_29aff95c-5b2d-43a5-9da6-f327d8070f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc1e1436-75a9-4189-909b-d0d96a5d1f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_29aff95c-5b2d-43a5-9da6-f327d8070f27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc1e1436-75a9-4189-909b-d0d96a5d1f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fda44964-b054-4137-815e-f4bd73819b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_29aff95c-5b2d-43a5-9da6-f327d8070f27" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fda44964-b054-4137-815e-f4bd73819b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f8acca25-d08b-487d-b52f-b31a5d88de81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_29aff95c-5b2d-43a5-9da6-f327d8070f27" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f8acca25-d08b-487d-b52f-b31a5d88de81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Accruedliabilities" xlink:type="simple" xlink:href="hcat-20210331.xsd#Accruedliabilities"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/Accruedliabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#AccruedliabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/AccruedliabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#AccruedliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/AccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_42148371-1cfa-4397-9888-71c375704926" xlink:href="hcat-20210331.xsd#hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_445cc584-5007-4256-9818-9e8ece970f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_42148371-1cfa-4397-9888-71c375704926" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_445cc584-5007-4256-9818-9e8ece970f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f4e2758a-cdea-4904-990f-a5c9114ef121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_42148371-1cfa-4397-9888-71c375704926" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f4e2758a-cdea-4904-990f-a5c9114ef121" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotes"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1ccc456c-d60c-4915-9423-35e9ea411086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ffa5ae61-7240-4875-8386-4174fac35fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_1ccc456c-d60c-4915-9423-35e9ea411086" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ffa5ae61-7240-4875-8386-4174fac35fe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_484a1eb2-c46c-435b-8a76-84b9c1e86bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_1ccc456c-d60c-4915-9423-35e9ea411086" xlink:to="loc_us-gaap_InterestExpenseDebt_484a1eb2-c46c-435b-8a76-84b9c1e86bf2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e6be7200-1602-4fa3-9827-7b5997de35cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1d8debea-ab30-4fc8-ba87-dbdcb1aa773b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e6be7200-1602-4fa3-9827-7b5997de35cd" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1d8debea-ab30-4fc8-ba87-dbdcb1aa773b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_0f60ab4c-297c-4dc6-b0dd-3477dcd4d2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e6be7200-1602-4fa3-9827-7b5997de35cd" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_0f60ab4c-297c-4dc6-b0dd-3477dcd4d2b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5554873f-da22-4578-a9bd-bd8c2ed49429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e6be7200-1602-4fa3-9827-7b5997de35cd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5554873f-da22-4578-a9bd-bd8c2ed49429" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_565a723f-d96f-47d4-b6d5-2f6a313322d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_8cb65bf1-4f64-43b1-add0-f46ebb9d82fc" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_565a723f-d96f-47d4-b6d5-2f6a313322d6" xlink:to="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_8cb65bf1-4f64-43b1-add0-f46ebb9d82fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostsGrossEquityComponent_be4682c9-7511-4bfc-918e-0e36566565af" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostsGrossEquityComponent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_565a723f-d96f-47d4-b6d5-2f6a313322d6" xlink:to="loc_hcat_DebtIssuanceCostsGrossEquityComponent_be4682c9-7511-4bfc-918e-0e36566565af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockholdersEquity" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShare" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/IncomeTaxes" xlink:type="simple" xlink:href="hcat-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="hcat-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligations"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails_1" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsNarrativeDetails_1"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RelatedParties" xlink:type="simple" xlink:href="hcat-20210331.xsd#RelatedParties"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/RelatedParties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RelatedPartiesDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/RelatedPartiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Segments" xlink:type="simple" xlink:href="hcat-20210331.xsd#Segments"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/Segments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsTables"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsScheduledofSegmentRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsScheduleofSegmentAdjustedGrossProfitDetails"/>
  <link:calculationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b185346c-5c37-425b-ad02-e71abbb30130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b185346c-5c37-425b-ad02-e71abbb30130" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a1ddedd8-db4e-4cb3-bfa1-48bf03f64e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:to="loc_us-gaap_DepreciationAndAmortization_a1ddedd8-db4e-4cb3-bfa1-48bf03f64e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ccf73030-0d67-4686-8303-05851462b1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:to="loc_us-gaap_GrossProfit_ccf73030-0d67-4686-8303-05851462b1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3a5bbdf-8d6c-4db3-bd56-a49c898813e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3a5bbdf-8d6c-4db3-bd56-a49c898813e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_InterestAndOtherExpenseNet_c1f22d40-07e3-4c6e-b9be-77a3f8b464ac" xlink:href="hcat-20210331.xsd#hcat_InterestAndOtherExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:to="loc_hcat_InterestAndOtherExpenseNet_c1f22d40-07e3-4c6e-b9be-77a3f8b464ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_e52fd6f1-7b94-4d5d-b70a-f1650e9409e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:to="loc_us-gaap_SellingAndMarketingExpense_e52fd6f1-7b94-4d5d-b70a-f1650e9409e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2a8efc20-9117-4868-9fa3-d61acddd7396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_560f36cc-5325-4423-8150-9433961c2f57" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2a8efc20-9117-4868-9fa3-d61acddd7396" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>hcat-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ac4f3b8b-712a-43a6-9f81-b9cf5889a679,g:b64543c5-cb81-4282-9510-d3dfb10c5ee8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CoverPage" xlink:type="simple" xlink:href="hcat-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CoverPage" xlink:type="extended" id="i7f2549c8a8f24bd9adeb7880eb4c0f49_CoverPage"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="if31a4a2d546f4198809f90e5e3e35db0_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="id721fc5e358d43e7bea31e95b99f1e43_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="id9eaa00a3a4a4bef83ed5c532115a6fe_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d5d80884-b22f-4909-b0e6-972f26ddb791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_RevenuesAbstract_d5d80884-b22f-4909-b0e6-972f26ddb791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_992b830c-f3dd-4264-97de-2c97cb9a8c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d5d80884-b22f-4909-b0e6-972f26ddb791" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_992b830c-f3dd-4264-97de-2c97cb9a8c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_e86101ca-1e8b-44f1-901c-b551c2c406c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_CostOfRevenueAbstract_e86101ca-1e8b-44f1-901c-b551c2c406c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_8607c377-74c3-4ee3-8c62-fc1c2802d990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e86101ca-1e8b-44f1-901c-b551c2c406c9" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_8607c377-74c3-4ee3-8c62-fc1c2802d990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6d4a61f7-0b58-4b52-a72d-05a33471bd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6d4a61f7-0b58-4b52-a72d-05a33471bd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_47798463-d2ec-40c3-9ce9-8b5a06acfc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_47798463-d2ec-40c3-9ce9-8b5a06acfc10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d83006d3-ff94-48e5-ba60-1cd71e74fc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d83006d3-ff94-48e5-ba60-1cd71e74fc3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5b9d393b-2eea-4331-b902-98d907bd6398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_DepreciationAndAmortization_5b9d393b-2eea-4331-b902-98d907bd6398" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fb7fcb9d-1786-433c-952d-f8f403b658f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_OperatingExpenses_fb7fcb9d-1786-433c-952d-f8f403b658f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4b5c04a9-6361-484a-9b29-de578f7d7c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_OperatingIncomeLoss_4b5c04a9-6361-484a-9b29-de578f7d7c39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_InterestAndOtherExpenseNet_56bdde73-08e7-4756-94cc-f9aa0916958c" xlink:href="hcat-20210331.xsd#hcat_InterestAndOtherExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_hcat_InterestAndOtherExpenseNet_56bdde73-08e7-4756-94cc-f9aa0916958c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_265dc167-47ce-4180-ab7d-098b9685e632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_265dc167-47ce-4180-ab7d-098b9685e632" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6668dd24-9498-45a0-b27e-5337253a22a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6668dd24-9498-45a0-b27e-5337253a22a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2f6e770-1e38-4696-9805-2fc81497df12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_NetIncomeLoss_b2f6e770-1e38-4696-9805-2fc81497df12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e9e3699a-4be1-48b4-816a-d65469b772bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_EarningsPerShareBasic_e9e3699a-4be1-48b4-816a-d65469b772bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f4732beb-115e-45f2-be21-49bfee20fecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f4732beb-115e-45f2-be21-49bfee20fecf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7388f06-166c-4a73-add3-55adb94df44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7388f06-166c-4a73-add3-55adb94df44b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bfe0d22e-0d19-4e73-a511-640f4b55d77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bfe0d22e-0d19-4e73-a511-640f4b55d77d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b10ab96-8144-4de7-ad2d-d92996fd1bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_StatementTable_8b10ab96-8144-4de7-ad2d-d92996fd1bc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe517421-9295-4e5e-bb76-0e7cd94ed911" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8b10ab96-8144-4de7-ad2d-d92996fd1bc4" xlink:to="loc_srt_ProductOrServiceAxis_fe517421-9295-4e5e-bb76-0e7cd94ed911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe517421-9295-4e5e-bb76-0e7cd94ed911_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe517421-9295-4e5e-bb76-0e7cd94ed911" xlink:to="loc_srt_ProductsAndServicesDomain_fe517421-9295-4e5e-bb76-0e7cd94ed911_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe517421-9295-4e5e-bb76-0e7cd94ed911" xlink:to="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_42e73dc8-3127-45a5-a488-7ca517eed4f9" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:to="loc_hcat_TechnologyMember_42e73dc8-3127-45a5-a488-7ca517eed4f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_581b29d0-a29f-4efd-a2b5-fb618344d78d" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:to="loc_hcat_ProfessionalServicesMember_581b29d0-a29f-4efd-a2b5-fb618344d78d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i23101fd591c444cd98f4d4c6aad5a149_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="if532242abfd642bd945abdafa91c0aae_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_20fb0dd3-f54f-4282-9640-9579f39335f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_20fb0dd3-f54f-4282-9640-9579f39335f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6455980b-0a28-45d8-8c6a-cb293de09afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6455980b-0a28-45d8-8c6a-cb293de09afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_87d639ad-ca42-407c-b973-c006816aca7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_87d639ad-ca42-407c-b973-c006816aca7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_706053dd-be5b-44af-abcf-c260d54f2877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3b6b64c9-89b2-4a20-8308-678c89da8ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cf9e44c2-819e-42f8-925e-a728dd9137bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_SharesOutstanding_cf9e44c2-819e-42f8-925e-a728dd9137bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14df82a0-ea1e-4b2b-956d-9bf69ea45a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockholdersEquity_14df82a0-ea1e-4b2b-956d-9bf69ea45a8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_528305af-7bc6-4791-8d3a-ca55f5420db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_528305af-7bc6-4791-8d3a-ca55f5420db9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa580747-4770-47ac-b5ad-3196b1fb5f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa580747-4770-47ac-b5ad-3196b1fb5f1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_044c3bfa-d3a2-4d18-8855-06aa6600d4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_044c3bfa-d3a2-4d18-8855-06aa6600d4aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07249f0-fb72-43b9-92b9-2b21ae114756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07249f0-fb72-43b9-92b9-2b21ae114756" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares_b4137a0c-bb4d-4cb7-ad22-c1c8875c7f30" xlink:href="hcat-20210331.xsd#hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares_b4137a0c-bb4d-4cb7-ad22-c1c8875c7f30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_392fcfa9-7043-4dfa-923c-8a3e8ba3516d" xlink:href="hcat-20210331.xsd#hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_392fcfa9-7043-4dfa-923c-8a3e8ba3516d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b16f2c5d-d366-40f0-8ba8-5954c1c75611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b16f2c5d-d366-40f0-8ba8-5954c1c75611" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_93f0991e-a5e7-47ee-aa69-4b46cda72689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_93f0991e-a5e7-47ee-aa69-4b46cda72689" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_248c9f89-6079-4743-8a28-f9821e9dc82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_NetIncomeLoss_248c9f89-6079-4743-8a28-f9821e9dc82f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_443ccd0a-eeb6-4747-b097-c9e9f7f03956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_443ccd0a-eeb6-4747-b097-c9e9f7f03956" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4d740d75-9f34-4f65-9717-082664a7756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d05db12-46f6-4191-a602-7e18f0707383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:to="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4d79fe61-da14-493f-a9cf-9f6b186335a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4d79fe61-da14-493f-a9cf-9f6b186335a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4d79fe61-da14-493f-a9cf-9f6b186335a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4d79fe61-da14-493f-a9cf-9f6b186335a8" xlink:to="loc_us-gaap_EquityComponentDomain_4d79fe61-da14-493f-a9cf-9f6b186335a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4d79fe61-da14-493f-a9cf-9f6b186335a8" xlink:to="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f882c7af-64cd-4c31-a3ac-1da596e11471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_CommonStockMember_f882c7af-64cd-4c31-a3ac-1da596e11471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d0c74342-23a4-463d-9a67-892f97615ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d0c74342-23a4-463d-9a67-892f97615ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8fbec919-48f0-4138-bf1e-2aea9c1b5ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_RetainedEarningsMember_8fbec919-48f0-4138-bf1e-2aea9c1b5ea8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_185b353f-86a7-4982-8feb-9f4dce99dc84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_185b353f-86a7-4982-8feb-9f4dce99dc84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_796f5fa7-55cc-40f9-88c5-b36d2060edb9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_796f5fa7-55cc-40f9-88c5-b36d2060edb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_796f5fa7-55cc-40f9-88c5-b36d2060edb9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_796f5fa7-55cc-40f9-88c5-b36d2060edb9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_796f5fa7-55cc-40f9-88c5-b36d2060edb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a7d000d3-5026-40ea-9306-e961853a5118" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_796f5fa7-55cc-40f9-88c5-b36d2060edb9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a7d000d3-5026-40ea-9306-e961853a5118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_13fb59c1-54ba-411b-99dd-e673163d61f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a7d000d3-5026-40ea-9306-e961853a5118" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_13fb59c1-54ba-411b-99dd-e673163d61f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i7f479d31dcbe423d859df13e31ad1002_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="id4f9ad52509649989be67cd413b3350c_DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ia0f1d0a27c6a480484dc20b6a6f79d83_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i80e3ba71f2f04419924e47e65e289f47_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="iff8d08669c354862b220eaa28b01c3aa_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" xlink:type="extended" id="i80ce4ea9de634f07af2714535d0914a3_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" xlink:type="extended" id="ice063a91fdb04b18b571fe3e12168027_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d2b472e-0b8b-4bac-bc65-5231b6dccebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bed0dbdc-20fe-4c88-95b2-b1b444f2c3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d2b472e-0b8b-4bac-bc65-5231b6dccebb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bed0dbdc-20fe-4c88-95b2-b1b444f2c3eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d2b472e-0b8b-4bac-bc65-5231b6dccebb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_eefa017d-2da0-48c1-8244-ae22fc37cf9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_ComputerEquipmentMember_eefa017d-2da0-48c1-8244-ae22fc37cf9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_76b7d2f5-fe28-4e54-a57a-f0e56cf599b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_76b7d2f5-fe28-4e54-a57a-f0e56cf599b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c7ac65b2-ac3d-4c88-90ad-d563b4fdd565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c7ac65b2-ac3d-4c88-90ad-d563b4fdd565" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_c705e9b1-25a1-4462-878f-4a96992fb1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_c705e9b1-25a1-4462-878f-4a96992fb1bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25036da0-b721-4d88-9abf-4f50e2ba4a2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:to="loc_srt_RangeAxis_25036da0-b721-4d88-9abf-4f50e2ba4a2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25036da0-b721-4d88-9abf-4f50e2ba4a2f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_25036da0-b721-4d88-9abf-4f50e2ba4a2f" xlink:to="loc_srt_RangeMember_25036da0-b721-4d88-9abf-4f50e2ba4a2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_25036da0-b721-4d88-9abf-4f50e2ba4a2f" xlink:to="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ede7bc0d-3daa-4d9e-99d9-d215f8e347ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:to="loc_srt_MinimumMember_ede7bc0d-3daa-4d9e-99d9-d215f8e347ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_852c271f-c6be-40d3-9468-e011b44a051e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:to="loc_srt_MaximumMember_852c271f-c6be-40d3-9468-e011b44a051e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" xlink:type="extended" id="i36bb3d227f1347a18832dac93242bb68_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fb6e2e4-90e7-4e4c-8fae-59e24fdbf13e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_79484bb0-c7db-4ef4-9297-04bf829daaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fb6e2e4-90e7-4e4c-8fae-59e24fdbf13e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_79484bb0-c7db-4ef4-9297-04bf829daaa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fb6e2e4-90e7-4e4c-8fae-59e24fdbf13e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aaee8ed1-fd13-4c79-9375-79cc0740d2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aaee8ed1-fd13-4c79-9375-79cc0740d2f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aaee8ed1-fd13-4c79-9375-79cc0740d2f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aaee8ed1-fd13-4c79-9375-79cc0740d2f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aaee8ed1-fd13-4c79-9375-79cc0740d2f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aaee8ed1-fd13-4c79-9375-79cc0740d2f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_35986f66-eb7d-461b-9747-d43ee8d03414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_35986f66-eb7d-461b-9747-d43ee8d03414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CustomerRelationshipsAndContractsMember_385f8701-07c2-4e9a-9afe-4b505e1c3502" xlink:href="hcat-20210331.xsd#hcat_CustomerRelationshipsAndContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_hcat_CustomerRelationshipsAndContractsMember_385f8701-07c2-4e9a-9afe-4b505e1c3502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2ffe3f90-15d8-44eb-8206-df7390826666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2ffe3f90-15d8-44eb-8206-df7390826666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_cb9219db-63d0-4040-9332-b1041ee20227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_us-gaap_TrademarksMember_cb9219db-63d0-4040-9332-b1041ee20227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b42abe5e-a56f-46bc-8e00-78782c2620df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:to="loc_srt_RangeAxis_b42abe5e-a56f-46bc-8e00-78782c2620df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b42abe5e-a56f-46bc-8e00-78782c2620df_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b42abe5e-a56f-46bc-8e00-78782c2620df" xlink:to="loc_srt_RangeMember_b42abe5e-a56f-46bc-8e00-78782c2620df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b42abe5e-a56f-46bc-8e00-78782c2620df" xlink:to="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07cd9e57-b189-4d8f-8a27-a925a11440f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:to="loc_srt_MinimumMember_07cd9e57-b189-4d8f-8a27-a925a11440f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bcce8844-8f2a-4629-9717-2c5a413727c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:to="loc_srt_MaximumMember_bcce8844-8f2a-4629-9717-2c5a413727c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinations" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinations"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinations" xlink:type="extended" id="i626c9dc2c5c14ab8b3d1f0526c136822_BusinessCombinations"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsTables" xlink:type="extended" id="ie43de64c0c184caab11a52f954522a5b_BusinessCombinationsTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended" id="i26e9122e465f407da761419c149773e9_BusinessCombinationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6394907-4c3e-4894-b9a3-e15a9d9b9770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6394907-4c3e-4894-b9a3-e15a9d9b9770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4d3e4c15-1985-4758-aa10-411e9283d8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4d3e4c15-1985-4758-aa10-411e9283d8f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c3b8197f-98c4-4cde-85f4-89abce37407c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c3b8197f-98c4-4cde-85f4-89abce37407c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_adefbf12-d8eb-4f2b-98d6-02385ee68506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_adefbf12-d8eb-4f2b-98d6-02385ee68506" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c836f42b-3aea-44c0-9d28-8951eb6ed464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c836f42b-3aea-44c0-9d28-8951eb6ed464" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_573278c7-c484-4e74-8161-2d7a9956d97a" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_573278c7-c484-4e74-8161-2d7a9956d97a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_540f9a8b-bb21-4609-9178-6f212656d1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_540f9a8b-bb21-4609-9178-6f212656d1cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_132e1d0c-01d9-45cf-a7fe-e05a79a04849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_132e1d0c-01d9-45cf-a7fe-e05a79a04849" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod_07aeeea5-5553-4091-bd52-f8588b4803dc" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod_07aeeea5-5553-4091-bd52-f8588b4803dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a10cc65e-451d-41db-8e07-8ebfc19e14a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a10cc65e-451d-41db-8e07-8ebfc19e14a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e77feb21-ad52-4396-8ce2-266b898037ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e77feb21-ad52-4396-8ce2-266b898037ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_774c7218-4fae-4fdf-94cd-ede043769b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_774c7218-4fae-4fdf-94cd-ede043769b24" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c2a9a43-e122-46d1-9519-deac227057e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c2a9a43-e122-46d1-9519-deac227057e7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b42bf034-3214-498f-adc9-5e40f03bea74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b42bf034-3214-498f-adc9-5e40f03bea74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b42bf034-3214-498f-adc9-5e40f03bea74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b42bf034-3214-498f-adc9-5e40f03bea74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b42bf034-3214-498f-adc9-5e40f03bea74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b42bf034-3214-498f-adc9-5e40f03bea74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f80cb87c-3170-4927-9a5d-fd8db417439c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f80cb87c-3170-4927-9a5d-fd8db417439c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a5b6a8fb-4eef-4f4c-8594-b9163c449685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a5b6a8fb-4eef-4f4c-8594-b9163c449685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_917c29f4-1a96-4a8b-ad73-c703b7507077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_us-gaap_TrademarksMember_917c29f4-1a96-4a8b-ad73-c703b7507077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContractBacklogsMember_c8e9b05f-047a-4dc2-b4ba-10f296496bd0" xlink:href="hcat-20210331.xsd#hcat_ContractBacklogsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_hcat_ContractBacklogsMember_c8e9b05f-047a-4dc2-b4ba-10f296496bd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_d428d6ff-bec8-49ef-952d-d9a7ce700a7f" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:to="loc_hcat_AbleHealthIncMember_d428d6ff-bec8-49ef-952d-d9a7ce700a7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_HealthfinchIncMember_b0822f3b-28dd-48a5-bbcb-4a83de458ce0" xlink:href="hcat-20210331.xsd#hcat_HealthfinchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:to="loc_hcat_HealthfinchIncMember_b0822f3b-28dd-48a5-bbcb-4a83de458ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_37a16a07-f1ae-443d-a08d-08bf4b126b58" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:to="loc_hcat_VitalwareLLCMember_37a16a07-f1ae-443d-a08d-08bf4b126b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_244f17af-76b9-43c0-a5b7-92ae4fc05e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_VestingAxis_244f17af-76b9-43c0-a5b7-92ae4fc05e45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_244f17af-76b9-43c0-a5b7-92ae4fc05e45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_244f17af-76b9-43c0-a5b7-92ae4fc05e45" xlink:to="loc_us-gaap_VestingDomain_244f17af-76b9-43c0-a5b7-92ae4fc05e45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a1a09c8e-eb76-4a98-bb51-85c1dc048590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_244f17af-76b9-43c0-a5b7-92ae4fc05e45" xlink:to="loc_us-gaap_VestingDomain_a1a09c8e-eb76-4a98-bb51-85c1dc048590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61a5a0d8-359a-4bcb-88dd-4660650a191b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a1a09c8e-eb76-4a98-bb51-85c1dc048590" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61a5a0d8-359a-4bcb-88dd-4660650a191b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_680ecd50-0f7f-4664-ac4f-7a41e164cb38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_srt_RangeAxis_680ecd50-0f7f-4664-ac4f-7a41e164cb38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_680ecd50-0f7f-4664-ac4f-7a41e164cb38_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_680ecd50-0f7f-4664-ac4f-7a41e164cb38" xlink:to="loc_srt_RangeMember_680ecd50-0f7f-4664-ac4f-7a41e164cb38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_680ecd50-0f7f-4664-ac4f-7a41e164cb38" xlink:to="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98ef7952-8e19-4272-8aa6-112f383840ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:to="loc_srt_MaximumMember_98ef7952-8e19-4272-8aa6-112f383840ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_af37365e-4c5b-45dd-89d7-55f2a097b53e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:to="loc_srt_MinimumMember_af37365e-4c5b-45dd-89d7-55f2a097b53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73814f68-1b8e-4c27-8744-72fd020649e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_AwardTypeAxis_73814f68-1b8e-4c27-8744-72fd020649e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73814f68-1b8e-4c27-8744-72fd020649e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_73814f68-1b8e-4c27-8744-72fd020649e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73814f68-1b8e-4c27-8744-72fd020649e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_73814f68-1b8e-4c27-8744-72fd020649e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_341d4c90-eadc-48f2-9671-bd49c7a347f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:to="loc_us-gaap_RestrictedStockMember_341d4c90-eadc-48f2-9671-bd49c7a347f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember_d75c30f0-6226-4531-b6df-0c43c5517ba4" xlink:href="hcat-20210331.xsd#hcat_RestrictedSharesPursuantToAcquisitionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:to="loc_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember_d75c30f0-6226-4531-b6df-0c43c5517ba4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="id2f6596c51ba453fba473bc6f7b398a2_BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9749de2a-3c92-4578-9491-32dac2f4da73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9749de2a-3c92-4578-9491-32dac2f4da73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_526329cd-f002-480a-a308-0228fd3a5782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_526329cd-f002-480a-a308-0228fd3a5782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f1e2217-49e9-4703-b374-5f20402e5428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f1e2217-49e9-4703-b374-5f20402e5428" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f76f5c5f-99fc-4e13-91d3-c78fffd59264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f76f5c5f-99fc-4e13-91d3-c78fffd59264" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_efb01cf4-dda8-4ab4-b8e5-4d3651e321b2" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:to="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_efb01cf4-dda8-4ab4-b8e5-4d3651e321b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_e4a8d0c8-e76c-440f-8035-3f9402a78a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_e4a8d0c8-e76c-440f-8035-3f9402a78a94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dead52b5-d814-4b76-b905-aed5fb294e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dead52b5-d814-4b76-b905-aed5fb294e15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_821bb5f5-8e4a-4fd2-a946-a67d7d2b1e89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_821bb5f5-8e4a-4fd2-a946-a67d7d2b1e89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e17b3e-3bfd-451b-831d-34474d163d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e17b3e-3bfd-451b-831d-34474d163d7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12630e07-f57c-4d79-831e-f861e1246dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_Goodwill_12630e07-f57c-4d79-831e-f861e1246dac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6820a0d8-5c14-4d37-a28a-c44b3757712b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6820a0d8-5c14-4d37-a28a-c44b3757712b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79b8715e-cb65-415c-93fc-16507b5034bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79b8715e-cb65-415c-93fc-16507b5034bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79b8715e-cb65-415c-93fc-16507b5034bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79b8715e-cb65-415c-93fc-16507b5034bb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79b8715e-cb65-415c-93fc-16507b5034bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79b8715e-cb65-415c-93fc-16507b5034bb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_e59a5c0a-f0cf-4a4a-98d9-b85ee06e6bde" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:to="loc_hcat_AbleHealthIncMember_e59a5c0a-f0cf-4a4a-98d9-b85ee06e6bde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_HealthfinchIncMember_00a93a3c-1357-4695-af1d-aa5c265fe101" xlink:href="hcat-20210331.xsd#hcat_HealthfinchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:to="loc_hcat_HealthfinchIncMember_00a93a3c-1357-4695-af1d-aa5c265fe101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_9a6bd9c9-b79d-461d-b00c-c6920950d923" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:to="loc_hcat_VitalwareLLCMember_9a6bd9c9-b79d-461d-b00c-c6920950d923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc3dca7a-5488-4c26-af9c-ae8bf792067c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc3dca7a-5488-4c26-af9c-ae8bf792067c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc3dca7a-5488-4c26-af9c-ae8bf792067c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc3dca7a-5488-4c26-af9c-ae8bf792067c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc3dca7a-5488-4c26-af9c-ae8bf792067c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc3dca7a-5488-4c26-af9c-ae8bf792067c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d17afdfb-e1fa-4a85-9ce5-dce20a06a996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d17afdfb-e1fa-4a85-9ce5-dce20a06a996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_fa1b044a-200d-46a7-900e-f0b0c4a47c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:to="loc_us-gaap_CustomerRelationshipsMember_fa1b044a-200d-46a7-900e-f0b0c4a47c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0c96bd55-9cc4-4cc4-b654-ee971b80f7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:to="loc_us-gaap_TrademarksMember_0c96bd55-9cc4-4cc4-b654-ee971b80f7d1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsUnauditedProFormaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" xlink:type="extended" id="ied2c966444af4d3ba3ad0541fa8a9405_BusinessCombinationsUnauditedProFormaFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1246bfdb-c499-4273-be7c-adbf5f3b319c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1246bfdb-c499-4273-be7c-adbf5f3b319c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75b0015c-2216-407d-a21a-60f64a067bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75b0015c-2216-407d-a21a-60f64a067bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc081ac1-ff2d-4fef-ad51-085087dde400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:to="loc_us-gaap_ProfitLoss_cc081ac1-ff2d-4fef-ad51-085087dde400" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_568ea576-c38e-496e-b087-57b2e1339ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_568ea576-c38e-496e-b087-57b2e1339ece" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_9770929e-0c02-4591-942f-37fc29ddbf76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_568ea576-c38e-496e-b087-57b2e1339ece" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_9770929e-0c02-4591-942f-37fc29ddbf76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_9770929e-0c02-4591-942f-37fc29ddbf76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_9770929e-0c02-4591-942f-37fc29ddbf76" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_9770929e-0c02-4591-942f-37fc29ddbf76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_825e2f7a-437a-4a82-b5c0-75ce054687a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_9770929e-0c02-4591-942f-37fc29ddbf76" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_825e2f7a-437a-4a82-b5c0-75ce054687a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AcquisitionRelatedFairValueAdjustmentsMember_328e60d4-38d9-410d-bff9-fbf03186812f" xlink:href="hcat-20210331.xsd#hcat_AcquisitionRelatedFairValueAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_825e2f7a-437a-4a82-b5c0-75ce054687a1" xlink:to="loc_hcat_AcquisitionRelatedFairValueAdjustmentsMember_328e60d4-38d9-410d-bff9-fbf03186812f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Revenue" xlink:type="simple" xlink:href="hcat-20210331.xsd#Revenue"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/Revenue" xlink:type="extended" id="iff2b4186a00b4a729ff1e8618233ce7e_Revenue"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/RevenueTables" xlink:type="extended" id="ia80a3562ccf440a49ab2fccb6a2a7583_RevenueTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" xlink:type="extended" id="i1bd4ea0bb6c0458e96b7d6b3e00cf582_RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_abd2711e-ee42-4109-a3b2-2fc934b3b6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb916aff-cf7e-4223-b7d5-f7a3a7e198b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_abd2711e-ee42-4109-a3b2-2fc934b3b6b9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb916aff-cf7e-4223-b7d5-f7a3a7e198b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_385bf143-1d48-4ee8-a973-3e9c8fc8c5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_abd2711e-ee42-4109-a3b2-2fc934b3b6b9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_385bf143-1d48-4ee8-a973-3e9c8fc8c5bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f348395f-af8a-48d6-a155-0afa3c4291c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_385bf143-1d48-4ee8-a973-3e9c8fc8c5bf" xlink:to="loc_srt_ProductOrServiceAxis_f348395f-af8a-48d6-a155-0afa3c4291c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f348395f-af8a-48d6-a155-0afa3c4291c2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f348395f-af8a-48d6-a155-0afa3c4291c2" xlink:to="loc_srt_ProductsAndServicesDomain_f348395f-af8a-48d6-a155-0afa3c4291c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f348395f-af8a-48d6-a155-0afa3c4291c2" xlink:to="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RecurringTechnologyMember_dc210911-414d-437b-99eb-4d029f7fd404" xlink:href="hcat-20210331.xsd#hcat_RecurringTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:to="loc_hcat_RecurringTechnologyMember_dc210911-414d-437b-99eb-4d029f7fd404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_OneTimeTechnologyMember_656cd9b5-0deb-45e5-a4aa-fcdb0f1cba9c" xlink:href="hcat-20210331.xsd#hcat_OneTimeTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:to="loc_hcat_OneTimeTechnologyMember_656cd9b5-0deb-45e5-a4aa-fcdb0f1cba9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_8436f6d6-9bcf-4b85-98d6-eb208c0806f7" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:to="loc_hcat_ProfessionalServicesMember_8436f6d6-9bcf-4b85-98d6-eb208c0806f7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/RevenueNarrativeDetails" xlink:type="extended" id="iff1d3ef734a5490d81fb01dab8262248_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_099339ee-7f79-4e1a-a004-0c6688c673fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7941d5e8-1b81-4f61-86f6-69bf14f3bee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_099339ee-7f79-4e1a-a004-0c6688c673fb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7941d5e8-1b81-4f61-86f6-69bf14f3bee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_099339ee-7f79-4e1a-a004-0c6688c673fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_12694aee-d564-4a4e-b77e-6d81ca39bd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_12694aee-d564-4a4e-b77e-6d81ca39bd16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_12694aee-d564-4a4e-b77e-6d81ca39bd16_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12694aee-d564-4a4e-b77e-6d81ca39bd16" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_12694aee-d564-4a4e-b77e-6d81ca39bd16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e01fc064-8fe0-494a-b5a2-d57b8a40e63d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12694aee-d564-4a4e-b77e-6d81ca39bd16" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e01fc064-8fe0-494a-b5a2-d57b8a40e63d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_c9a64405-f273-46ca-b73f-8c2f0ec379e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e01fc064-8fe0-494a-b5a2-d57b8a40e63d" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_c9a64405-f273-46ca-b73f-8c2f0ec379e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712f1b77-0bfb-44f3-b6b3-5894c1da9ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712f1b77-0bfb-44f3-b6b3-5894c1da9ded" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_712f1b77-0bfb-44f3-b6b3-5894c1da9ded_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712f1b77-0bfb-44f3-b6b3-5894c1da9ded" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_712f1b77-0bfb-44f3-b6b3-5894c1da9ded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_532d7e18-2a92-4dbe-aaab-fc38c393a081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712f1b77-0bfb-44f3-b6b3-5894c1da9ded" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_532d7e18-2a92-4dbe-aaab-fc38c393a081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_0481a2d2-1f7d-4a01-82ac-50430e81c19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_532d7e18-2a92-4dbe-aaab-fc38c393a081" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_0481a2d2-1f7d-4a01-82ac-50430e81c19e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd277a87-a7b2-48f4-a979-024786b8207c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:to="loc_srt_StatementGeographicalAxis_bd277a87-a7b2-48f4-a979-024786b8207c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bd277a87-a7b2-48f4-a979-024786b8207c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bd277a87-a7b2-48f4-a979-024786b8207c" xlink:to="loc_srt_SegmentGeographicalDomain_bd277a87-a7b2-48f4-a979-024786b8207c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bf31d1be-1182-4933-a54f-c2b44e6b9f23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bd277a87-a7b2-48f4-a979-024786b8207c" xlink:to="loc_srt_SegmentGeographicalDomain_bf31d1be-1182-4933-a54f-c2b44e6b9f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_422f91ed-2a5c-4f08-8090-65ec499d4586" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_bf31d1be-1182-4933-a54f-c2b44e6b9f23" xlink:to="loc_country_US_422f91ed-2a5c-4f08-8090-65ec499d4586" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets" xlink:type="extended" id="i27d6b6eafc9c4b19817ed56daf1e54ba_GoodwillandIntangibleAssets"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended" id="i13e89c0a9af7461aa52aff6cdbf045b8_GoodwillandIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i3c051a5c0f1e4ce6bfb15014b1f80091_GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" xlink:type="extended" id="i1d6457e011824ceda383ca8cb090aee3_GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4caa20a8-b495-4174-bd42-c0f4672e6261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bed484f2-3c3c-4728-be23-0cc787ec33a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4caa20a8-b495-4174-bd42-c0f4672e6261" xlink:to="loc_us-gaap_Goodwill_bed484f2-3c3c-4728-be23-0cc787ec33a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c3532de7-caf3-4da7-b8f0-6df4acec038f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_4caa20a8-b495-4174-bd42-c0f4672e6261" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c3532de7-caf3-4da7-b8f0-6df4acec038f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d58a1f67-36b4-4621-a4f8-e3d21cd6611a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c3532de7-caf3-4da7-b8f0-6df4acec038f" xlink:to="loc_us-gaap_ReportingUnitAxis_d58a1f67-36b4-4621-a4f8-e3d21cd6611a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d58a1f67-36b4-4621-a4f8-e3d21cd6611a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_d58a1f67-36b4-4621-a4f8-e3d21cd6611a" xlink:to="loc_us-gaap_ReportingUnitDomain_d58a1f67-36b4-4621-a4f8-e3d21cd6611a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_d58a1f67-36b4-4621-a4f8-e3d21cd6611a" xlink:to="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_a6680a73-97d3-422c-95f1-4f3f3a577bcd" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:to="loc_hcat_TechnologyMember_a6680a73-97d3-422c-95f1-4f3f3a577bcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_308d294f-2bea-4af1-ad5b-22e76c103d04" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:to="loc_hcat_ProfessionalServicesMember_308d294f-2bea-4af1-ad5b-22e76c103d04" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="if56c452f812a483d9d090ca3d045e139_GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8236cf2d-757e-43e7-a993-763ca34f79cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8236cf2d-757e-43e7-a993-763ca34f79cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9c27ad41-65f4-440b-a424-0ac5d8e19a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9c27ad41-65f4-440b-a424-0ac5d8e19a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fde7bd7e-dd68-4b1e-8d80-fd27d4b9a768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fde7bd7e-dd68-4b1e-8d80-fd27d4b9a768" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9741b7e-4c5d-40a3-892f-c8cf4900a7f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9741b7e-4c5d-40a3-892f-c8cf4900a7f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_05ea6393-f727-4cab-8422-d691b49a0276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9741b7e-4c5d-40a3-892f-c8cf4900a7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_05ea6393-f727-4cab-8422-d691b49a0276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_05ea6393-f727-4cab-8422-d691b49a0276_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_05ea6393-f727-4cab-8422-d691b49a0276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_05ea6393-f727-4cab-8422-d691b49a0276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_05ea6393-f727-4cab-8422-d691b49a0276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1f9ac17b-fd2b-4a6f-894b-33b3ffd8e1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1f9ac17b-fd2b-4a6f-894b-33b3ffd8e1a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CustomerRelationshipsAndContractsMember_4d13e055-f57c-49f7-9e10-80e3bfe81bb8" xlink:href="hcat-20210331.xsd#hcat_CustomerRelationshipsAndContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_hcat_CustomerRelationshipsAndContractsMember_4d13e055-f57c-49f7-9e10-80e3bfe81bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_cde82975-83fd-49d8-906b-b2dcc04307f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_cde82975-83fd-49d8-906b-b2dcc04307f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_f4ad8a0f-731e-42b2-9c82-e5d70924ceeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_us-gaap_TrademarksMember_f4ad8a0f-731e-42b2-9c82-e5d70924ceeb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipment" xlink:type="extended" id="ideb13760e656452fb6406138845862c0_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentTables" xlink:type="extended" id="ib8b76bd9e9144fe89b8029e4d8c7f2f8_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended" id="i82909ebb20764a9b9b1ebfbbe1668837_PropertyandEquipmentComponentsofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3c86891a-f625-47ab-98b4-cf0538dfbe34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3c86891a-f625-47ab-98b4-cf0538dfbe34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9f3d076f-8147-473c-9501-a0a114ea56a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9f3d076f-8147-473c-9501-a0a114ea56a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f92a2a05-6ccd-4adc-9340-0e765314692b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f92a2a05-6ccd-4adc-9340-0e765314692b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03ce0ea8-f5c5-446b-9395-d6f769b8aa68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03ce0ea8-f5c5-446b-9395-d6f769b8aa68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aadebe43-3291-47d1-b1e7-4331ca9c8d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03ce0ea8-f5c5-446b-9395-d6f769b8aa68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aadebe43-3291-47d1-b1e7-4331ca9c8d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aadebe43-3291-47d1-b1e7-4331ca9c8d9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aadebe43-3291-47d1-b1e7-4331ca9c8d9c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aadebe43-3291-47d1-b1e7-4331ca9c8d9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aadebe43-3291-47d1-b1e7-4331ca9c8d9c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8739875b-0398-4b05-93ea-38cd71f986d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_ComputerEquipmentMember_8739875b-0398-4b05-93ea-38cd71f986d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b6be0f65-6ff9-43c6-9504-417d552b27ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b6be0f65-6ff9-43c6-9504-417d552b27ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e0ca0a74-64e1-4213-a82f-7ccaef041a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e0ca0a74-64e1-4213-a82f-7ccaef041a69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_8b5f1792-d219-4dd7-8ef7-e3a1b0483bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_8b5f1792-d219-4dd7-8ef7-e3a1b0483bac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d20245ce-e558-44c7-97c4-24e06737f6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d20245ce-e558-44c7-97c4-24e06737f6e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AssetsHeldUnderFinanceLeasesMember_25fa63f5-c821-44ec-b8ce-c71e030937ed" xlink:href="hcat-20210331.xsd#hcat_AssetsHeldUnderFinanceLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_hcat_AssetsHeldUnderFinanceLeasesMember_25fa63f5-c821-44ec-b8ce-c71e030937ed" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="icf8c82f4a78540dc826ee8a0956e61c2_PropertyandEquipmentNarrativeDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestments"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestments" xlink:type="extended" id="ibc107a742d5848cfa6b34e4ba630e5f6_ShorttermInvestments"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestmentsTables" xlink:type="extended" id="i486e493e6f00488d8288e940e451e7d1_ShorttermInvestmentsTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails" xlink:type="extended" id="i1d01695c17754abd9e5da689a097a749_ShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a39e7edf-4751-48b5-ab4c-cacbc5b9e2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a39e7edf-4751-48b5-ab4c-cacbc5b9e2bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38a78db6-c3ff-483e-a749-47798c8be005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38a78db6-c3ff-483e-a749-47798c8be005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63baa26f-1b1c-455e-b7fd-ebab6c8e5b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63baa26f-1b1c-455e-b7fd-ebab6c8e5b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c50c3887-3c5a-45f1-a78b-09fd83c06a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c50c3887-3c5a-45f1-a78b-09fd83c06a8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cdea0802-5c5f-442a-b70a-9fcdfdb429c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cdea0802-5c5f-442a-b70a-9fcdfdb429c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cdea0802-5c5f-442a-b70a-9fcdfdb429c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cdea0802-5c5f-442a-b70a-9fcdfdb429c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cdea0802-5c5f-442a-b70a-9fcdfdb429c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cdea0802-5c5f-442a-b70a-9fcdfdb429c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_64c9747f-5785-433f-9b66-c120123e67ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:to="loc_us-gaap_CashEquivalentsMember_64c9747f-5785-433f-9b66-c120123e67ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShortTermMarketableSecurityMember_9bacbb58-3e03-479a-a4dc-9f6105b5b3ac" xlink:href="hcat-20210331.xsd#hcat_ShortTermMarketableSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:to="loc_hcat_ShortTermMarketableSecurityMember_9bacbb58-3e03-479a-a4dc-9f6105b5b3ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a6c08664-671e-4151-80d0-54a1839d55a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a6c08664-671e-4151-80d0-54a1839d55a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6c08664-671e-4151-80d0-54a1839d55a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6c08664-671e-4151-80d0-54a1839d55a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6c08664-671e-4151-80d0-54a1839d55a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6c08664-671e-4151-80d0-54a1839d55a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5cc93437-5db9-45fa-8b1d-f942a6e17065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5cc93437-5db9-45fa-8b1d-f942a6e17065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b809bd6b-d3ca-4960-8ca5-97d929d721ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b809bd6b-d3ca-4960-8ca5-97d929d721ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2f619d91-d1df-48dc-89f5-192156143033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_CommercialPaperMember_2f619d91-d1df-48dc-89f5-192156143033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_9238f04c-fbe6-4964-a0f1-7211420d79b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_9238f04c-fbe6-4964-a0f1-7211420d79b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_552c1b04-7ea8-43f0-a9a2-f5fdfb90739e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_552c1b04-7ea8-43f0-a9a2-f5fdfb90739e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstruments" xlink:type="extended" id="ifd79b6b6e15742e0b2dfda02a4520705_FairValueofFinancialInstruments"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended" id="id3342848d6a8442fb770008948ad790a_FairValueofFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="iec78810f0351492a871625b86415c129_FairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cdf032-70af-4df7-900d-244533dcc9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cdf032-70af-4df7-900d-244533dcc9f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b9835ec-cbb8-447c-a6f4-afff0ccd5122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b9835ec-cbb8-447c-a6f4-afff0ccd5122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_263597cd-f434-4b03-8087-86ea9a82cdbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_263597cd-f434-4b03-8087-86ea9a82cdbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_710f2c0f-c967-4a7d-87b1-4e7bf4d677e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_FairValueNetAssetLiability_710f2c0f-c967-4a7d-87b1-4e7bf4d677e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_bebb68eb-cfe9-406b-8a22-1a7b67176e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_bebb68eb-cfe9-406b-8a22-1a7b67176e90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fa522e5f-774e-4dd2-a86f-662f77fb20a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fa522e5f-774e-4dd2-a86f-662f77fb20a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability_121d4f43-d31d-49d3-a27e-6af712e193ad" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability_121d4f43-d31d-49d3-a27e-6af712e193ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash_a706de65-3da4-4bbe-8cdc-cba23e0ead64" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash_a706de65-3da4-4bbe-8cdc-cba23e0ead64" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares_f6ca138a-225b-4674-8fa7-3ae103efa925" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares_f6ca138a-225b-4674-8fa7-3ae103efa925" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_d48347ec-8dbd-4b36-88e6-cd916a3f7c32" xlink:href="hcat-20210331.xsd#hcat_FairValueMeasurementAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_d48347ec-8dbd-4b36-88e6-cd916a3f7c32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_68d1e620-c064-4932-962c-17888bc546be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_68d1e620-c064-4932-962c-17888bc546be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_68d1e620-c064-4932-962c-17888bc546be_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_68d1e620-c064-4932-962c-17888bc546be" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_68d1e620-c064-4932-962c-17888bc546be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b48af50-a808-41ab-8b84-42907be4f248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_68d1e620-c064-4932-962c-17888bc546be" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b48af50-a808-41ab-8b84-42907be4f248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_671f5d71-7eb8-4f2a-a1a7-77684b98a544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b48af50-a808-41ab-8b84-42907be4f248" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_671f5d71-7eb8-4f2a-a1a7-77684b98a544" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f907616-b5c7-4ef8-87dd-08e2b7027075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f907616-b5c7-4ef8-87dd-08e2b7027075" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f907616-b5c7-4ef8-87dd-08e2b7027075_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f907616-b5c7-4ef8-87dd-08e2b7027075" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f907616-b5c7-4ef8-87dd-08e2b7027075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f907616-b5c7-4ef8-87dd-08e2b7027075" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d75c7df9-c1c5-46f7-a94d-18733412bb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d75c7df9-c1c5-46f7-a94d-18733412bb06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9463cab8-d524-4935-b657-3b2d06f5cd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_CommercialPaperMember_9463cab8-d524-4935-b657-3b2d06f5cd8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e50a84bb-68d2-4eb5-8063-bf0eb5aedfce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e50a84bb-68d2-4eb5-8063-bf0eb5aedfce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7ed27178-c45e-4e9f-b7f3-070c077d9f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7ed27178-c45e-4e9f-b7f3-070c077d9f85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3997c030-b4cf-4ec6-a82e-a9056ec4406d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3997c030-b4cf-4ec6-a82e-a9056ec4406d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3997c030-b4cf-4ec6-a82e-a9056ec4406d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3997c030-b4cf-4ec6-a82e-a9056ec4406d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3997c030-b4cf-4ec6-a82e-a9056ec4406d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3997c030-b4cf-4ec6-a82e-a9056ec4406d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cfd37c87-d016-404c-9ee8-316d68b45ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cfd37c87-d016-404c-9ee8-316d68b45ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56512ebf-553e-4f1b-b54f-bad6e2673ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56512ebf-553e-4f1b-b54f-bad6e2673ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e03c0a6b-ee63-4eea-96be-b61b853385b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e03c0a6b-ee63-4eea-96be-b61b853385b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d05423b4-bee6-471d-b8c1-37433824a30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d05423b4-bee6-471d-b8c1-37433824a30d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05423b4-bee6-471d-b8c1-37433824a30d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d05423b4-bee6-471d-b8c1-37433824a30d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05423b4-bee6-471d-b8c1-37433824a30d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_564a44e7-c803-480d-b3ac-b151f7fd83d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d05423b4-bee6-471d-b8c1-37433824a30d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_564a44e7-c803-480d-b3ac-b151f7fd83d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_dcf3bc5e-3f54-4b55-a433-ea4f40636565" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_564a44e7-c803-480d-b3ac-b151f7fd83d1" xlink:to="loc_hcat_VitalwareLLCMember_dcf3bc5e-3f54-4b55-a433-ea4f40636565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_36677f69-bee3-4723-b099-7af2ee172735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_36677f69-bee3-4723-b099-7af2ee172735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_44ec5379-cdc6-472a-867a-b0f4b44866a3" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_36677f69-bee3-4723-b099-7af2ee172735" xlink:to="loc_hcat_SeniorNotesDue2025Member_44ec5379-cdc6-472a-867a-b0f4b44866a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cfc1d66a-c0cb-4e37-8f5b-f68d42b7d5ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cfc1d66a-c0cb-4e37-8f5b-f68d42b7d5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_76688ded-2ddf-49ab-b51f-7834927f9b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cfc1d66a-c0cb-4e37-8f5b-f68d42b7d5ce" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_76688ded-2ddf-49ab-b51f-7834927f9b00" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails" xlink:type="extended" id="id73f99510096438b9c00caf0b9eabb59_FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_453dcb2a-bb52-4347-93c4-f67eb61bc61d" xlink:href="hcat-20210331.xsd#hcat_FairValueMeasurementAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:to="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_453dcb2a-bb52-4347-93c4-f67eb61bc61d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4a45d82c-064f-4ba4-913c-67f7e520bec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4a45d82c-064f-4ba4-913c-67f7e520bec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f7a3e6bb-8b26-4fd5-8b19-07564c426c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f7a3e6bb-8b26-4fd5-8b19-07564c426c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f7a3e6bb-8b26-4fd5-8b19-07564c426c56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f7a3e6bb-8b26-4fd5-8b19-07564c426c56" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f7a3e6bb-8b26-4fd5-8b19-07564c426c56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f7a3e6bb-8b26-4fd5-8b19-07564c426c56" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_MeasurementInputMarketPriceOfRevenueRiskMember_f7c5cb78-741a-450c-a0cf-cc9edaf780eb" xlink:href="hcat-20210331.xsd#hcat_MeasurementInputMarketPriceOfRevenueRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:to="loc_hcat_MeasurementInputMarketPriceOfRevenueRiskMember_f7c5cb78-741a-450c-a0cf-cc9edaf780eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_MeasurementInputRevenueVolatilityMember_86395260-ccdc-443d-a392-562a22eb3b0d" xlink:href="hcat-20210331.xsd#hcat_MeasurementInputRevenueVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:to="loc_hcat_MeasurementInputRevenueVolatilityMember_86395260-ccdc-443d-a392-562a22eb3b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_91db8c73-579e-4f51-8b76-700e35558d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_91db8c73-579e-4f51-8b76-700e35558d51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d3ae620-330a-444a-b6e8-a3dda49d3a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d3ae620-330a-444a-b6e8-a3dda49d3a40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ae620-330a-444a-b6e8-a3dda49d3a40_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d3ae620-330a-444a-b6e8-a3dda49d3a40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ae620-330a-444a-b6e8-a3dda49d3a40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee9e3f1f-2252-439a-83de-bf4005d489ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d3ae620-330a-444a-b6e8-a3dda49d3a40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee9e3f1f-2252-439a-83de-bf4005d489ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e04aef5d-78a1-4524-8323-efdc6d7c113c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee9e3f1f-2252-439a-83de-bf4005d489ba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e04aef5d-78a1-4524-8323-efdc6d7c113c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_530c464c-0b63-461c-a9a8-15f0b12b6440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:to="loc_srt_RangeAxis_530c464c-0b63-461c-a9a8-15f0b12b6440" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_530c464c-0b63-461c-a9a8-15f0b12b6440_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_530c464c-0b63-461c-a9a8-15f0b12b6440" xlink:to="loc_srt_RangeMember_530c464c-0b63-461c-a9a8-15f0b12b6440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_530c464c-0b63-461c-a9a8-15f0b12b6440" xlink:to="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_046be5a9-168e-4672-ad87-cc65c742bff7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:to="loc_srt_MinimumMember_046be5a9-168e-4672-ad87-cc65c742bff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a7556ea-5217-46e5-a39a-9f6d650f4640" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:to="loc_srt_MaximumMember_0a7556ea-5217-46e5-a39a-9f6d650f4640" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" xlink:type="extended" id="ibcad20a4f8b946a59044db4f8f2b41dd_FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a0eb812-1044-4b4c-a211-13ed2f3c9255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a0eb812-1044-4b4c-a211-13ed2f3c9255" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_33d097ae-8561-409e-9858-2d100c95f686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_33d097ae-8561-409e-9858-2d100c95f686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_3a9c747a-ec77-4923-bcf9-0d99c2e68e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_3a9c747a-ec77-4923-bcf9-0d99c2e68e61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0cccae5-1fff-43eb-8d1c-78c27e4074d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0cccae5-1fff-43eb-8d1c-78c27e4074d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e2895dfc-8539-4fe0-95d2-b80d96d8c202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc06c012-ee5c-4e7d-b632-7a70ac42bb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a0eb812-1044-4b4c-a211-13ed2f3c9255" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc06c012-ee5c-4e7d-b632-7a70ac42bb14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc06c012-ee5c-4e7d-b632-7a70ac42bb14" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6582e6fe-83ed-443a-9fb9-e27f6e29152c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6582e6fe-83ed-443a-9fb9-e27f6e29152c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContingentConsiderationMember_29030e50-c022-4f9e-9c18-0f6b5476335b" xlink:href="hcat-20210331.xsd#hcat_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6582e6fe-83ed-443a-9fb9-e27f6e29152c" xlink:to="loc_hcat_ContingentConsiderationMember_29030e50-c022-4f9e-9c18-0f6b5476335b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Accruedliabilities" xlink:type="simple" xlink:href="hcat-20210331.xsd#Accruedliabilities"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/Accruedliabilities" xlink:type="extended" id="i55b1085a8d9b4173830785769aed0cff_Accruedliabilities"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#AccruedliabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/AccruedliabilitiesTables" xlink:type="extended" id="iaba0eec4e00a490eb7d9d0b4a376abc4_AccruedliabilitiesTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#AccruedliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/AccruedliabilitiesDetails" xlink:type="extended" id="i474e072f0f1845f49a7a1b6b180fb1fb_AccruedliabilitiesDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotes"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotes" xlink:type="extended" id="iba2ba529832d4b2487a4b8567472bc4f_ConvertibleSeniorNotes"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables" xlink:type="extended" id="id2044faf1aa449bfbe26bfdab938e2b0_ConvertibleSeniorNotesTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended" id="i6458047c12564abb902abea1b7562957_ConvertibleSeniorNotesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_37887a15-4733-4b37-ac16-00c233cca85f" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_37887a15-4733-4b37-ac16-00c233cca85f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bfd1244e-3084-4b2b-b36c-1573e340cfb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bfd1244e-3084-4b2b-b36c-1573e340cfb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_63a207d6-355a-4f01-bf84-e7fa23f4f07d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_63a207d6-355a-4f01-bf84-e7fa23f4f07d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eeb58a0a-baee-4dba-a8aa-fe22f05e0902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eeb58a0a-baee-4dba-a8aa-fe22f05e0902" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_482db184-fd5b-4ecc-a7ee-d5c3c5deebc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_482db184-fd5b-4ecc-a7ee-d5c3c5deebc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c61ac26f-bb9f-457a-b356-9fc7e32ad2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c61ac26f-bb9f-457a-b356-9fc7e32ad2d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_cc8e16a1-48dc-4125-a693-149de1fbfc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_cc8e16a1-48dc-4125-a693-149de1fbfc47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c01f3080-6541-42cb-97a5-23a32362d97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c01f3080-6541-42cb-97a5-23a32362d97f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_33c5b627-b3b4-4bad-9d9c-7c4eec09e83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_33c5b627-b3b4-4bad-9d9c-7c4eec09e83a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ce1d11af-9cd5-45e2-bb69-25e2d97f8f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ce1d11af-9cd5-45e2-bb69-25e2d97f8f05" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_059659d3-1332-485a-ba2a-afa9f6483e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_059659d3-1332-485a-ba2a-afa9f6483e14" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure_9b45889d-868f-49b5-b93b-5565c85d889c" xlink:href="hcat-20210331.xsd#hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure_9b45889d-868f-49b5-b93b-5565c85d889c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostGrossLiabilityComponent_df50b3c5-fd2a-436a-a3b3-00fb3a78f93f" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostGrossLiabilityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_DebtIssuanceCostGrossLiabilityComponent_df50b3c5-fd2a-436a-a3b3-00fb3a78f93f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostGrossEquityComponent_030a43ce-8a92-42ed-80c3-d7e279cb87fa" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostGrossEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_DebtIssuanceCostGrossEquityComponent_030a43ce-8a92-42ed-80c3-d7e279cb87fa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6e66d779-80c4-4d51-8fa1-43b9f202d1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_SharePrice_6e66d779-80c4-4d51-8fa1-43b9f202d1f8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_69aeb682-9afd-4a81-9c6e-e524474c3fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_69aeb682-9afd-4a81-9c6e-e524474c3fbf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCostOfHedge_e7af59ea-49ae-4fbd-a928-23d1a9770ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCostOfHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DerivativeCostOfHedge_e7af59ea-49ae-4fbd-a928-23d1a9770ddc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapPrice_3a99d24c-a6b2-4a35-9b52-342b120637cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCapPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DerivativeCapPrice_3a99d24c-a6b2-4a35-9b52-342b120637cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d9558a79-14bd-4faf-b60b-824cd8a10584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d9558a79-14bd-4faf-b60b-824cd8a10584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_9764a733-fd2c-4123-8252-cb82236217cb" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9558a79-14bd-4faf-b60b-824cd8a10584" xlink:to="loc_hcat_SeniorNotesDue2025Member_9764a733-fd2c-4123-8252-cb82236217cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_232ad869-a49d-4207-a0a4-97c615bb37ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_232ad869-a49d-4207-a0a4-97c615bb37ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_232ad869-a49d-4207-a0a4-97c615bb37ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_232ad869-a49d-4207-a0a4-97c615bb37ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_232ad869-a49d-4207-a0a4-97c615bb37ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_07107e27-f02d-4b55-83b5-43e551b8fecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_232ad869-a49d-4207-a0a4-97c615bb37ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_07107e27-f02d-4b55-83b5-43e551b8fecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_b7dfe22d-0be6-4557-8b70-2e6cbef798d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_07107e27-f02d-4b55-83b5-43e551b8fecf" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_b7dfe22d-0be6-4557-8b70-2e6cbef798d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis_e6aed120-8209-4837-a920-c2d9505d2cf4" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleThresholdTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis_e6aed120-8209-4837-a920-c2d9505d2cf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_e6aed120-8209-4837-a920-c2d9505d2cf4_default" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleThresholdTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis_e6aed120-8209-4837-a920-c2d9505d2cf4" xlink:to="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_e6aed120-8209-4837-a920-c2d9505d2cf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_3f0b0810-dc23-4241-be02-dbc92b77bb0e" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleThresholdTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis_e6aed120-8209-4837-a920-c2d9505d2cf4" xlink:to="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_3f0b0810-dc23-4241-be02-dbc92b77bb0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember_41b276be-7cf1-468d-be7a-1616b6d32dec" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_3f0b0810-dc23-4241-be02-dbc92b77bb0e" xlink:to="loc_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember_41b276be-7cf1-468d-be7a-1616b6d32dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1f61f284-62ea-452b-8e23-33f8b65cb6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1f61f284-62ea-452b-8e23-33f8b65cb6cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1f61f284-62ea-452b-8e23-33f8b65cb6cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1f61f284-62ea-452b-8e23-33f8b65cb6cc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1f61f284-62ea-452b-8e23-33f8b65cb6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b88fb905-5b8e-4a8c-87e5-4e141c676d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1f61f284-62ea-452b-8e23-33f8b65cb6cc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b88fb905-5b8e-4a8c-87e5-4e141c676d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d4f266b6-830e-4a5f-b139-3836c2715ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b88fb905-5b8e-4a8c-87e5-4e141c676d0b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d4f266b6-830e-4a5f-b139-3836c2715ff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d7e476ad-f079-4e0c-9699-5199a82f1bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d7e476ad-f079-4e0c-9699-5199a82f1bb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d7e476ad-f079-4e0c-9699-5199a82f1bb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d7e476ad-f079-4e0c-9699-5199a82f1bb3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d7e476ad-f079-4e0c-9699-5199a82f1bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3a081301-51d2-40b4-b496-8d59773fead6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d7e476ad-f079-4e0c-9699-5199a82f1bb3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3a081301-51d2-40b4-b496-8d59773fead6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2bde823f-a35b-435c-bf4c-3b1fbd7ef3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3a081301-51d2-40b4-b496-8d59773fead6" xlink:to="loc_us-gaap_CashFlowHedgingMember_2bde823f-a35b-435c-bf4c-3b1fbd7ef3a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3bd092d0-7fff-4e09-af0e-752d7ebdf68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3bd092d0-7fff-4e09-af0e-752d7ebdf68f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3bd092d0-7fff-4e09-af0e-752d7ebdf68f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3bd092d0-7fff-4e09-af0e-752d7ebdf68f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3bd092d0-7fff-4e09-af0e-752d7ebdf68f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e04a68df-b57b-4936-9f78-3ac88d834922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3bd092d0-7fff-4e09-af0e-752d7ebdf68f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e04a68df-b57b-4936-9f78-3ac88d834922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CappedCallMember_461981fd-ab4f-4f38-858c-289dd65335c8" xlink:href="hcat-20210331.xsd#hcat_CappedCallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e04a68df-b57b-4936-9f78-3ac88d834922" xlink:to="loc_hcat_CappedCallMember_461981fd-ab4f-4f38-858c-289dd65335c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ed9f7099-62be-44a2-bda6-e20be81fb678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_HedgingDesignationAxis_ed9f7099-62be-44a2-bda6-e20be81fb678" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ed9f7099-62be-44a2-bda6-e20be81fb678_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ed9f7099-62be-44a2-bda6-e20be81fb678" xlink:to="loc_us-gaap_HedgingDesignationDomain_ed9f7099-62be-44a2-bda6-e20be81fb678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_89689342-fc3a-47f0-abdb-fbfc705d67d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ed9f7099-62be-44a2-bda6-e20be81fb678" xlink:to="loc_us-gaap_HedgingDesignationDomain_89689342-fc3a-47f0-abdb-fbfc705d67d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d36f890b-31f4-4e9b-86bb-ed7a668d2710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_89689342-fc3a-47f0-abdb-fbfc705d67d1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d36f890b-31f4-4e9b-86bb-ed7a668d2710" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended" id="if5155187e89a4fba83104e4560328079_ConvertibleSeniorNotesInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_fd2d04aa-3069-4bbc-8c99-21807addac24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:to="loc_us-gaap_InterestExpenseDebt_fd2d04aa-3069-4bbc-8c99-21807addac24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b41358d1-58b3-4958-80cd-7fdbbd71ec6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b41358d1-58b3-4958-80cd-7fdbbd71ec6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_429d48e5-5c91-4c21-8e19-d0e2bafa240b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:to="loc_us-gaap_InterestExpense_429d48e5-5c91-4c21-8e19-d0e2bafa240b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:to="loc_us-gaap_DebtInstrumentAxis_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f2bbe12-9796-44f6-b416-2be969aceb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f2bbe12-9796-44f6-b416-2be969aceb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_ff395745-3910-4fb0-b5bf-4ace81abcc02" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f2bbe12-9796-44f6-b416-2be969aceb14" xlink:to="loc_hcat_SeniorNotesDue2025Member_ff395745-3910-4fb0-b5bf-4ace81abcc02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3c880ebe-2e87-436e-9a23-493ad89a72c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3c880ebe-2e87-436e-9a23-493ad89a72c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3c880ebe-2e87-436e-9a23-493ad89a72c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c880ebe-2e87-436e-9a23-493ad89a72c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3c880ebe-2e87-436e-9a23-493ad89a72c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8b46edf-ca93-41b0-aed5-724514f025cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c880ebe-2e87-436e-9a23-493ad89a72c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8b46edf-ca93-41b0-aed5-724514f025cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_d60cf683-5af0-4141-b973-5889665ab56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8b46edf-ca93-41b0-aed5-724514f025cc" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_d60cf683-5af0-4141-b973-5889665ab56f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails" xlink:type="extended" id="i4e01213889814a9fbbafc97c54c48a51_ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_92d33239-0902-4322-96ea-c5997a879146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_92d33239-0902-4322-96ea-c5997a879146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_34f09e39-21e0-4846-92ae-333ab8ae2e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_34f09e39-21e0-4846-92ae-333ab8ae2e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8738f36e-a13a-49be-b21f-6b9fbceb2037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8738f36e-a13a-49be-b21f-6b9fbceb2037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1dd7e383-4bb7-4e85-90ac-388a65ca3222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_LongTermDebt_1dd7e383-4bb7-4e85-90ac-388a65ca3222" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7942acb-8b98-4462-9342-3452bee3b27d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7942acb-8b98-4462-9342-3452bee3b27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_c170d22f-1a55-44eb-99f4-c79a93b454d3" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7942acb-8b98-4462-9342-3452bee3b27d" xlink:to="loc_hcat_SeniorNotesDue2025Member_c170d22f-1a55-44eb-99f4-c79a93b454d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a049d3b0-5fd2-49c3-b17c-84a55aef75db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a049d3b0-5fd2-49c3-b17c-84a55aef75db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a049d3b0-5fd2-49c3-b17c-84a55aef75db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a049d3b0-5fd2-49c3-b17c-84a55aef75db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a049d3b0-5fd2-49c3-b17c-84a55aef75db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_daaf0f07-f09c-4ef8-83b6-f15d7aad3698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a049d3b0-5fd2-49c3-b17c-84a55aef75db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_daaf0f07-f09c-4ef8-83b6-f15d7aad3698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_eb345965-8ea4-4151-a2dd-9e8d48913a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_daaf0f07-f09c-4ef8-83b6-f15d7aad3698" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_eb345965-8ea4-4151-a2dd-9e8d48913a12" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails" xlink:type="extended" id="i0398c72ba40a4c0eb9f412a1301cb1fd_ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_7ae948f4-65bc-4af5-a05f-c3b8ed56e625" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:to="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_7ae948f4-65bc-4af5-a05f-c3b8ed56e625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostsGrossEquityComponent_53988dc7-dccd-4810-ac09-da623f061236" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostsGrossEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:to="loc_hcat_DebtIssuanceCostsGrossEquityComponent_53988dc7-dccd-4810-ac09-da623f061236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1296400c-9eac-44d8-b27d-b22a96e1c584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1296400c-9eac-44d8-b27d-b22a96e1c584" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ccfbe000-7c3c-4515-ac7f-54f59541014b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:to="loc_us-gaap_DebtInstrumentAxis_ccfbe000-7c3c-4515-ac7f-54f59541014b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ccfbe000-7c3c-4515-ac7f-54f59541014b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ccfbe000-7c3c-4515-ac7f-54f59541014b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ccfbe000-7c3c-4515-ac7f-54f59541014b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbb49fa8-8b99-47c9-b241-24a080201378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ccfbe000-7c3c-4515-ac7f-54f59541014b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbb49fa8-8b99-47c9-b241-24a080201378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_01eef18b-a38c-4a13-9586-92e16c3ab9c6" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbb49fa8-8b99-47c9-b241-24a080201378" xlink:to="loc_hcat_SeniorNotesDue2025Member_01eef18b-a38c-4a13-9586-92e16c3ab9c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_241a42a7-568e-43fb-a76b-5a775cbc7842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_241a42a7-568e-43fb-a76b-5a775cbc7842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_241a42a7-568e-43fb-a76b-5a775cbc7842_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_241a42a7-568e-43fb-a76b-5a775cbc7842" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_241a42a7-568e-43fb-a76b-5a775cbc7842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ad222dcf-200d-44f3-82c5-e141d9e3e7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_241a42a7-568e-43fb-a76b-5a775cbc7842" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ad222dcf-200d-44f3-82c5-e141d9e3e7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_310a8d9a-d04c-4f5d-b850-46d0a35cfb16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ad222dcf-200d-44f3-82c5-e141d9e3e7ba" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_310a8d9a-d04c-4f5d-b850-46d0a35cfb16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockholdersEquity" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockholdersEquity" xlink:type="extended" id="ia69d424664a44ffd8e9cec947e61c3a6_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i4ed63011028b435daf3f7c7f14060082_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bc23615e-b8cc-4cbf-98d7-54a385f255c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bc23615e-b8cc-4cbf-98d7-54a385f255c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_da305198-ee17-493f-9a0d-53182a741578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_PreferredStockSharesIssued_da305198-ee17-493f-9a0d-53182a741578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5b8c2742-c6c8-4532-a309-86a480029613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5b8c2742-c6c8-4532-a309-86a480029613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_59bac105-2dc4-4d1c-844c-7a13b5ecc408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_59bac105-2dc4-4d1c-844c-7a13b5ecc408" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cda31834-0fed-4f02-a55c-6ba997c1d871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cda31834-0fed-4f02-a55c-6ba997c1d871" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_71f3851d-c70b-4794-8e6e-a05a8f17c9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_SharesIssued_71f3851d-c70b-4794-8e6e-a05a8f17c9ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4a4ba909-6be8-4f2b-9d21-235a82227736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_SharesOutstanding_4a4ba909-6be8-4f2b-9d21-235a82227736" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockholdersVote_94104c66-6a03-4876-b8e9-afa6adf0a98e" xlink:href="hcat-20210331.xsd#hcat_StockholdersVote"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_hcat_StockholdersVote_94104c66-6a03-4876-b8e9-afa6adf0a98e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:href="hcat-20210331.xsd#hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20082877-58a1-4c1e-ad9c-ef38d208a646" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:to="loc_srt_CounterpartyNameAxis_20082877-58a1-4c1e-ad9c-ef38d208a646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20082877-58a1-4c1e-ad9c-ef38d208a646_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_20082877-58a1-4c1e-ad9c-ef38d208a646" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20082877-58a1-4c1e-ad9c-ef38d208a646_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95e9dd81-ceb5-4c55-a675-5d7ad7bc8ee1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_20082877-58a1-4c1e-ad9c-ef38d208a646" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95e9dd81-ceb5-4c55-a675-5d7ad7bc8ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_9d9974a8-5371-4491-b7fd-3ecaf378d8dc" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95e9dd81-ceb5-4c55-a675-5d7ad7bc8ee1" xlink:to="loc_hcat_VitalwareLLCMember_9d9974a8-5371-4491-b7fd-3ecaf378d8dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0eb962c5-fe9a-45ee-a88d-4a0eef6451db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0eb962c5-fe9a-45ee-a88d-4a0eef6451db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0eb962c5-fe9a-45ee-a88d-4a0eef6451db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0eb962c5-fe9a-45ee-a88d-4a0eef6451db" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0eb962c5-fe9a-45ee-a88d-4a0eef6451db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cf79ff6-0c48-4b57-af81-a721f36a846e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0eb962c5-fe9a-45ee-a88d-4a0eef6451db" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cf79ff6-0c48-4b57-af81-a721f36a846e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_c53abaf8-52f8-4755-bc60-671cbac7a0d2" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cf79ff6-0c48-4b57-af81-a721f36a846e" xlink:to="loc_hcat_AbleHealthIncMember_c53abaf8-52f8-4755-bc60-671cbac7a0d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShare" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShare" xlink:type="extended" id="ifc5c31fac0984e3c9fe4fccbffb03453_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareTables" xlink:type="extended" id="i338a1fd789dd45ca97900f5c866c6260_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="extended" id="i8f430b540bb7430fbe326d45d57f47e4_NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" xlink:type="extended" id="iab7a8820dcb24cb9ad385d9e284f3603_NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cbe2d06-1720-4483-b6d3-d25dddac6c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cbe2d06-1720-4483-b6d3-d25dddac6c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e3cef11e-080f-4902-8cd6-04d526249e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e3cef11e-080f-4902-8cd6-04d526249e66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c442b699-258d-4415-bd61-ab67dd9d4aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c442b699-258d-4415-bd61-ab67dd9d4aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c442b699-258d-4415-bd61-ab67dd9d4aaf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c442b699-258d-4415-bd61-ab67dd9d4aaf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c442b699-258d-4415-bd61-ab67dd9d4aaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c442b699-258d-4415-bd61-ab67dd9d4aaf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_220c5222-28a7-4702-84fb-dc72da354783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_EmployeeStockOptionMember_220c5222-28a7-4702-84fb-dc72da354783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_671e7571-a142-46cd-957f-ff13e6d9e327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_671e7571-a142-46cd-957f-ff13e6d9e327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_19ec0d77-26db-4d4f-b466-e3d07d4b8f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_19ec0d77-26db-4d4f-b466-e3d07d4b8f1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_472b5f3d-6367-442d-94c4-ae8e3ebc1c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_SeniorNotesMember_472b5f3d-6367-442d-94c4-ae8e3ebc1c5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContingentConsiderationMember_3fd0dced-a706-4fa3-92c0-bb55bf772784" xlink:href="hcat-20210331.xsd#hcat_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_hcat_ContingentConsiderationMember_3fd0dced-a706-4fa3-92c0-bb55bf772784" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8e93ab60-a3db-4a43-a3b1-f5305d093bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_EmployeeStockMember_8e93ab60-a3db-4a43-a3b1-f5305d093bdc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3d4938b4-fce4-4767-880c-67f6888641b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_RestrictedStockMember_3d4938b4-fce4-4767-880c-67f6888641b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5fc92530-c4d5-403f-aa1f-a1c54b033f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_5fc92530-c4d5-403f-aa1f-a1c54b033f59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5fc92530-c4d5-403f-aa1f-a1c54b033f59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5fc92530-c4d5-403f-aa1f-a1c54b033f59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5fc92530-c4d5-403f-aa1f-a1c54b033f59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72c19558-5ac1-432b-97be-82da90a40576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5fc92530-c4d5-403f-aa1f-a1c54b033f59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72c19558-5ac1-432b-97be-82da90a40576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_a7c9a0a0-9fe7-4a45-9692-821b9df0dcaa" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72c19558-5ac1-432b-97be-82da90a40576" xlink:to="loc_hcat_SeniorNotesDue2025Member_a7c9a0a0-9fe7-4a45-9692-821b9df0dcaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_00dd97e8-7274-46b9-bc13-1b08d6c20d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_00dd97e8-7274-46b9-bc13-1b08d6c20d0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00dd97e8-7274-46b9-bc13-1b08d6c20d0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_00dd97e8-7274-46b9-bc13-1b08d6c20d0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00dd97e8-7274-46b9-bc13-1b08d6c20d0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3f313040-96c3-4529-b07e-e447c6e76f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_00dd97e8-7274-46b9-bc13-1b08d6c20d0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3f313040-96c3-4529-b07e-e447c6e76f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_77531448-dec4-4761-a1a5-4d1cdde130f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3f313040-96c3-4529-b07e-e447c6e76f9c" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_77531448-dec4-4761-a1a5-4d1cdde130f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensation" xlink:type="extended" id="if4367c92b4c74de5921e83cbb5cb9de8_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationTables" xlink:type="extended" id="i9f331bee2c64421b95bc513a1dcbd9d4_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ic5d2406a5d77452995a5fcdac78ab71b_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05144a4c-9883-48c9-9fa4-34aee1920d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05144a4c-9883-48c9-9fa4-34aee1920d11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_63bfcec7-0cff-4792-9fc4-82f79663acf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_63bfcec7-0cff-4792-9fc4-82f79663acf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares_c4839d9a-42c2-4e5d-9630-2fb0e5aa0c17" xlink:href="hcat-20210331.xsd#hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares_c4839d9a-42c2-4e5d-9630-2fb0e5aa0c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_597b37c1-c769-476b-bafc-ff9169a80613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_597b37c1-c769-476b-bafc-ff9169a80613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_423f3b3e-f9e7-43d2-bc7a-6e32aa7033f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_423f3b3e-f9e7-43d2-bc7a-6e32aa7033f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_82b81a64-2087-47ca-ac85-471c71622aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_82b81a64-2087-47ca-ac85-471c71622aa4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14046bf4-3244-4f25-8b7f-b00fe7b9d63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14046bf4-3244-4f25-8b7f-b00fe7b9d63c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_510f6873-90f6-46ce-b4c0-248bc7cdd3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_510f6873-90f6-46ce-b4c0-248bc7cdd3dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae810d50-8057-4dab-a9f4-5fb0530be1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae810d50-8057-4dab-a9f4-5fb0530be1d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_71283223-99e7-4f68-a28a-d6dc5f8f145a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_71283223-99e7-4f68-a28a-d6dc5f8f145a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_44f922a5-17cb-4920-984e-c3f4ba840590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_44f922a5-17cb-4920-984e-c3f4ba840590" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5f9ff9a8-d468-457d-bf2d-dd1da5d148a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5f9ff9a8-d468-457d-bf2d-dd1da5d148a7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_1d74cf90-0eae-4b36-bcdb-e4daba807e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_1d74cf90-0eae-4b36-bcdb-e4daba807e27" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_d8c3ca69-7bea-4d7f-a7e8-a08181bb8cf3" xlink:href="hcat-20210331.xsd#hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_d8c3ca69-7bea-4d7f-a7e8-a08181bb8cf3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e37351a3-1bab-47d3-b7a2-973bef5163e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e37351a3-1bab-47d3-b7a2-973bef5163e7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee_ff2b60a9-6aba-4f60-87b3-044affc4e32d" xlink:href="hcat-20210331.xsd#hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee_ff2b60a9-6aba-4f60-87b3-044affc4e32d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed_ed536ab2-8e2d-4df5-9f76-348445ee7561" xlink:href="hcat-20210331.xsd#hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed_ed536ab2-8e2d-4df5-9f76-348445ee7561" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2d4b9867-04b3-4098-8e13-0b99a654a164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2d4b9867-04b3-4098-8e13-0b99a654a164" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_78e7c3ec-8a4f-442f-89d7-0bff21883962" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_78e7c3ec-8a4f-442f-89d7-0bff21883962" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3dc2bc58-7ae1-416b-b70c-4a9b37736413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3dc2bc58-7ae1-416b-b70c-4a9b37736413" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_21c479cc-0c5b-43e3-85a1-67b1052d2180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_PlanNameAxis_21c479cc-0c5b-43e3-85a1-67b1052d2180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_21c479cc-0c5b-43e3-85a1-67b1052d2180_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_21c479cc-0c5b-43e3-85a1-67b1052d2180" xlink:to="loc_us-gaap_PlanNameDomain_21c479cc-0c5b-43e3-85a1-67b1052d2180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_21c479cc-0c5b-43e3-85a1-67b1052d2180" xlink:to="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlanMember_7bcee816-f38f-43f1-aee5-2dfb73e2335f" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:to="loc_hcat_StockIncentivePlanMember_7bcee816-f38f-43f1-aee5-2dfb73e2335f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlan2011Member_eb2a74f1-8718-42ce-b051-a092745b9832" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlan2011Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:to="loc_hcat_StockIncentivePlan2011Member_eb2a74f1-8718-42ce-b051-a092745b9832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlan2019Member_5ee22682-0005-42fc-bd20-0bbc91948368" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:to="loc_hcat_StockIncentivePlan2019Member_5ee22682-0005-42fc-bd20-0bbc91948368" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_766f608d-3486-404c-8069-4c131f7bc972" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:to="loc_hcat_AbleHealthIncMember_766f608d-3486-404c-8069-4c131f7bc972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_498c1a97-930f-49aa-b21b-7ad7a7a20670" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:to="loc_hcat_VitalwareLLCMember_498c1a97-930f-49aa-b21b-7ad7a7a20670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3c7068ed-401b-4d90-bade-133691d079dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_AwardTypeAxis_3c7068ed-401b-4d90-bade-133691d079dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c7068ed-401b-4d90-bade-133691d079dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3c7068ed-401b-4d90-bade-133691d079dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c7068ed-401b-4d90-bade-133691d079dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3c7068ed-401b-4d90-bade-133691d079dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8cd825a8-a916-4c05-b647-83108c2e6dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8cd825a8-a916-4c05-b647-83108c2e6dd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_72ae7561-21ec-4aa2-afa7-5b3c10523f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_72ae7561-21ec-4aa2-afa7-5b3c10523f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_2b0066bd-22e9-4db1-ae6e-81558828dac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_2b0066bd-22e9-4db1-ae6e-81558828dac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c13757eb-2f0b-4a5b-a143-08891c77625c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_RestrictedStockMember_c13757eb-2f0b-4a5b-a143-08891c77625c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_72082887-2f7a-4f00-bb07-e8f681118560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_EmployeeStockMember_72082887-2f7a-4f00-bb07-e8f681118560" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6b64738c-eeb8-4fa2-8bec-09a84c5ea609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_VestingAxis_6b64738c-eeb8-4fa2-8bec-09a84c5ea609" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6b64738c-eeb8-4fa2-8bec-09a84c5ea609_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_6b64738c-eeb8-4fa2-8bec-09a84c5ea609" xlink:to="loc_us-gaap_VestingDomain_6b64738c-eeb8-4fa2-8bec-09a84c5ea609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6ee7c414-f603-42c8-94d0-f9040a219431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_6b64738c-eeb8-4fa2-8bec-09a84c5ea609" xlink:to="loc_us-gaap_VestingDomain_6ee7c414-f603-42c8-94d0-f9040a219431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b368c651-1fe8-4e99-9d4f-89f6b00bc2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6ee7c414-f603-42c8-94d0-f9040a219431" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b368c651-1fe8-4e99-9d4f-89f6b00bc2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d92445a-4be3-48fc-8f90-7692c5d74ba9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_srt_RangeAxis_2d92445a-4be3-48fc-8f90-7692c5d74ba9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d92445a-4be3-48fc-8f90-7692c5d74ba9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2d92445a-4be3-48fc-8f90-7692c5d74ba9" xlink:to="loc_srt_RangeMember_2d92445a-4be3-48fc-8f90-7692c5d74ba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2d92445a-4be3-48fc-8f90-7692c5d74ba9" xlink:to="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87818b17-f575-49d1-a52a-efdb25774d63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:to="loc_srt_MinimumMember_87818b17-f575-49d1-a52a-efdb25774d63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3cbd3c36-f42a-49ce-8e6a-ddbce3a5538f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:to="loc_srt_MaximumMember_3cbd3c36-f42a-49ce-8e6a-ddbce3a5538f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" xlink:type="extended" id="idd7d00fe82be47418cfae1ccb6c06032_StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abbc9231-a541-47f5-ac49-28b5c390a549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_db8633d6-241c-42a4-bf0a-5e37d66e7cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abbc9231-a541-47f5-ac49-28b5c390a549" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_db8633d6-241c-42a4-bf0a-5e37d66e7cb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abbc9231-a541-47f5-ac49-28b5c390a549" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83c72061-02bf-48bb-95c4-b2765a6dc220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:to="loc_us-gaap_AwardTypeAxis_83c72061-02bf-48bb-95c4-b2765a6dc220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83c72061-02bf-48bb-95c4-b2765a6dc220_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_83c72061-02bf-48bb-95c4-b2765a6dc220" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83c72061-02bf-48bb-95c4-b2765a6dc220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_83c72061-02bf-48bb-95c4-b2765a6dc220" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8194554-8d11-4191-acd4-2231f036034a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8194554-8d11-4191-acd4-2231f036034a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_76d60eb1-cf6a-41cf-af64-8ab59287efa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_76d60eb1-cf6a-41cf-af64-8ab59287efa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_05f803ca-3aad-47b7-af6d-fa5e822c7516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_05f803ca-3aad-47b7-af6d-fa5e822c7516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_06cf2830-9262-4aa8-8134-de15410c5572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_EmployeeStockMember_06cf2830-9262-4aa8-8134-de15410c5572" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_77879ff6-3246-48c8-8c20-7bbce4949e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_RestrictedStockMember_77879ff6-3246-48c8-8c20-7bbce4949e8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f67672c0-9a03-4b94-be6a-32ba56af769a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_CostOfSalesMember_f67672c0-9a03-4b94-be6a-32ba56af769a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_a7f10356-0308-480b-a723-dd581f19738d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_a7f10356-0308-480b-a723-dd581f19738d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_efaded06-405f-48b3-b22b-b54dcdd7dd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_efaded06-405f-48b3-b22b-b54dcdd7dd8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f1874118-90da-4b11-8328-0dab9ce21592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f1874118-90da-4b11-8328-0dab9ce21592" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i5b028f97817349eda27729dc6883147a_StockBasedCompensationStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="iaa12240c84e642698975cbb5b4b467b1_StockBasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_643a1b0f-e0e0-4965-b9e6-cbc7dc14b7da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_643a1b0f-e0e0-4965-b9e6-cbc7dc14b7da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cf6f277-1b61-442f-90ca-b13e5540635d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cf6f277-1b61-442f-90ca-b13e5540635d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6b28c510-9c7d-43a6-a330-932a6caf575f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6b28c510-9c7d-43a6-a330-932a6caf575f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf609039-ab4d-40e1-bada-f0b084be2136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf609039-ab4d-40e1-bada-f0b084be2136" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_657ab502-3fea-4768-bac9-d67b196b1476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_843c9e2c-ea8d-40ba-9b6d-42c481169b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_843c9e2c-ea8d-40ba-9b6d-42c481169b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5ec78b58-3ea8-4835-a6d7-da51664848c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5ec78b58-3ea8-4835-a6d7-da51664848c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0fb0aefd-4a3a-4811-b2cf-80635237bf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0fb0aefd-4a3a-4811-b2cf-80635237bf15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1456df53-6a08-492d-a7ac-216082e248b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1456df53-6a08-492d-a7ac-216082e248b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa25d6f9-ba24-482c-978f-ae816fcbf4df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b828d774-5a57-40bb-a652-3dac0131be13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b828d774-5a57-40bb-a652-3dac0131be13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57e05c61-fbb4-4c80-bd02-0c4fc4de451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b828d774-5a57-40bb-a652-3dac0131be13" xlink:to="loc_us-gaap_AwardTypeAxis_57e05c61-fbb4-4c80-bd02-0c4fc4de451b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57e05c61-fbb4-4c80-bd02-0c4fc4de451b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_57e05c61-fbb4-4c80-bd02-0c4fc4de451b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57e05c61-fbb4-4c80-bd02-0c4fc4de451b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_57e05c61-fbb4-4c80-bd02-0c4fc4de451b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_39edb9cc-451f-4a2e-92ff-91421d011a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_39edb9cc-451f-4a2e-92ff-91421d011a1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_f3113698-f297-410c-bb0d-1fb91a43fc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_f3113698-f297-410c-bb0d-1fb91a43fc3e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" xlink:type="extended" id="ic6c967597d6642a386c1347dce787fb5_StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b6c17155-51f8-4ab0-916d-9dcee0ba4bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b6c17155-51f8-4ab0-916d-9dcee0ba4bd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e44825f-2c40-4fbc-8e94-aecc17ec170a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e44825f-2c40-4fbc-8e94-aecc17ec170a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08a8c05e-aead-42b3-b899-126006108d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08a8c05e-aead-42b3-b899-126006108d57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_1086266f-e79b-4db7-87c0-d3a1b93ff02f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_1086266f-e79b-4db7-87c0-d3a1b93ff02f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76e841b7-2991-4880-a321-c62e8ff25abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76e841b7-2991-4880-a321-c62e8ff25abf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f499c8d-7431-45ae-a1e5-10c5ddb051c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76e841b7-2991-4880-a321-c62e8ff25abf" xlink:to="loc_us-gaap_AwardTypeAxis_2f499c8d-7431-45ae-a1e5-10c5ddb051c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f499c8d-7431-45ae-a1e5-10c5ddb051c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2f499c8d-7431-45ae-a1e5-10c5ddb051c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f499c8d-7431-45ae-a1e5-10c5ddb051c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d47d35e-6aa3-4972-8e88-49fbd979f756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2f499c8d-7431-45ae-a1e5-10c5ddb051c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d47d35e-6aa3-4972-8e88-49fbd979f756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0fa2aabb-944f-4806-a577-ea53a0c91c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d47d35e-6aa3-4972-8e88-49fbd979f756" xlink:to="loc_us-gaap_EmployeeStockMember_0fa2aabb-944f-4806-a577-ea53a0c91c1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/IncomeTaxes" xlink:type="simple" xlink:href="hcat-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/IncomeTaxes" xlink:type="extended" id="if474952b2b684b63a4089f23b103ad04_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/IncomeTaxesDetails" xlink:type="extended" id="icd771a88dea04060b71b63bf930bb038_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="hcat-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/CommitmentsandContingencies" xlink:type="extended" id="i5c2bdc02b83c4372812c5f5a86623ac8_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligations"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations" xlink:type="extended" id="iabee578e1c29438db9236b8768c05a63_DeferredRevenueandPerformanceObligations"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" xlink:type="extended" id="i840298d2efd9414cbedf7d996bcda01e_DeferredRevenueandPerformanceObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_4be98025-3fa6-4c4e-93be-9d5e946737b9" xlink:href="hcat-20210331.xsd#hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_4be98025-3fa6-4c4e-93be-9d5e946737b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractTerm_32074d4c-eab9-41e2-bc53-93768f5f7e58" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractTerm_32074d4c-eab9-41e2-bc53-93768f5f7e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_c6a2097c-0746-43fd-a599-26524ff253a1" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_c6a2097c-0746-43fd-a599-26524ff253a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_20fc1c4a-e28c-4dda-a2f0-889832f380ad" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_20fc1c4a-e28c-4dda-a2f0-889832f380ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_023689aa-d736-4f64-b19a-bf1a697fa400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_023689aa-d736-4f64-b19a-bf1a697fa400" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:to="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f30a63b5-7ac4-4b25-9e94-2046909acdf6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:to="loc_srt_ProductsAndServicesDomain_f30a63b5-7ac4-4b25-9e94-2046909acdf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:to="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyAndProfessionalServicesMember_1a13ba64-53d2-4600-8f1c-9d823efca0cc" xlink:href="hcat-20210331.xsd#hcat_TechnologyAndProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:to="loc_hcat_TechnologyAndProfessionalServicesMember_1a13ba64-53d2-4600-8f1c-9d823efca0cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_745c623a-2aae-45aa-87b6-42eabcf4d50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_745c623a-2aae-45aa-87b6-42eabcf4d50f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails_1" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails_1" xlink:type="extended" id="ib10dd9d609a84ef1a68893f9a2e6df91_DeferredRevenueandPerformanceObligationsNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_4be98025-3fa6-4c4e-93be-9d5e946737b9" xlink:href="hcat-20210331.xsd#hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_4be98025-3fa6-4c4e-93be-9d5e946737b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractTerm_32074d4c-eab9-41e2-bc53-93768f5f7e58" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractTerm_32074d4c-eab9-41e2-bc53-93768f5f7e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_c6a2097c-0746-43fd-a599-26524ff253a1" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_c6a2097c-0746-43fd-a599-26524ff253a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_20fc1c4a-e28c-4dda-a2f0-889832f380ad" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_20fc1c4a-e28c-4dda-a2f0-889832f380ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_023689aa-d736-4f64-b19a-bf1a697fa400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_023689aa-d736-4f64-b19a-bf1a697fa400" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:to="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f30a63b5-7ac4-4b25-9e94-2046909acdf6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:to="loc_srt_ProductsAndServicesDomain_f30a63b5-7ac4-4b25-9e94-2046909acdf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:to="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyAndProfessionalServicesMember_1a13ba64-53d2-4600-8f1c-9d823efca0cc" xlink:href="hcat-20210331.xsd#hcat_TechnologyAndProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:to="loc_hcat_TechnologyAndProfessionalServicesMember_1a13ba64-53d2-4600-8f1c-9d823efca0cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails" xlink:type="extended" id="i6226182296d14409bd6b23f5181d5547_DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_54a5a01e-4932-4446-bbd6-d464eaa2a292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_54a5a01e-4932-4446-bbd6-d464eaa2a292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a0db5c75-81b5-45f2-b706-904ecf8362dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a0db5c75-81b5-45f2-b706-904ecf8362dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6102c505-164b-4c66-bdca-f6d132b1d6c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6102c505-164b-4c66-bdca-f6d132b1d6c8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1" xlink:type="extended" id="i214c9a9297e345cb9121ae422cf4912b_DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_54a5a01e-4932-4446-bbd6-d464eaa2a292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_54a5a01e-4932-4446-bbd6-d464eaa2a292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a0db5c75-81b5-45f2-b706-904ecf8362dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a0db5c75-81b5-45f2-b706-904ecf8362dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RelatedParties" xlink:type="simple" xlink:href="hcat-20210331.xsd#RelatedParties"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/RelatedParties" xlink:type="extended" id="i03e8468422cb4c42af2cff827c80e8d9_RelatedParties"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/RelatedPartiesDetails" xlink:type="extended" id="i502e57972aed41f9bb74052209b5d5dc_RelatedPartiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_cecb13a9-4965-4df0-9937-5e4bcaa2dc84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_RevenueFromRelatedParties_cecb13a9-4965-4df0-9937-5e4bcaa2dc84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_cab5220c-92ea-485e-aa55-ac61ee08a279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_DueFromRelatedParties_cab5220c-92ea-485e-aa55-ac61ee08a279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_25856e63-4317-4cd6-b670-6022b7849d39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_25856e63-4317-4cd6-b670-6022b7849d39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_9dc09ad5-0bcc-44b3-8a9f-88f0ca728c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_9dc09ad5-0bcc-44b3-8a9f-88f0ca728c26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e71a7f5e-2a9d-484f-a4e3-0bbc978c8acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e71a7f5e-2a9d-484f-a4e3-0bbc978c8acf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd6a7c81-de12-491d-97c5-b235578f5ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd6a7c81-de12-491d-97c5-b235578f5ce8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_de59a500-d87b-4f97-90a0-f7809ed88044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd6a7c81-de12-491d-97c5-b235578f5ce8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_de59a500-d87b-4f97-90a0-f7809ed88044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_de59a500-d87b-4f97-90a0-f7809ed88044_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_de59a500-d87b-4f97-90a0-f7809ed88044" xlink:to="loc_us-gaap_RelatedPartyDomain_de59a500-d87b-4f97-90a0-f7809ed88044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e41b1e8e-194c-4544-bd28-34052e39412a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_de59a500-d87b-4f97-90a0-f7809ed88044" xlink:to="loc_us-gaap_RelatedPartyDomain_e41b1e8e-194c-4544-bd28-34052e39412a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_9466437e-dae6-4a5b-b41e-e13e27625b15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e41b1e8e-194c-4544-bd28-34052e39412a" xlink:to="loc_srt_DirectorMember_9466437e-dae6-4a5b-b41e-e13e27625b15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Segments" xlink:type="simple" xlink:href="hcat-20210331.xsd#Segments"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/Segments" xlink:type="extended" id="i523b034915e34eb2a55bfae04c4d9aed_Segments"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsTables"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/SegmentsTables" xlink:type="extended" id="ic7f2ddf720344ff4a4a6737aecc31076_SegmentsTables"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/SegmentsNarrativeDetails" xlink:type="extended" id="i3331b81de95549d89ba20e227b90e616_SegmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsScheduledofSegmentRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails" xlink:type="extended" id="i3568c55772344f93bccb859623ef2019_SegmentsScheduledofSegmentRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f09ce44b-7be5-470e-af30-77ed16bfe597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ad0e41c-c89d-48c1-9842-c7e84e66f084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f09ce44b-7be5-470e-af30-77ed16bfe597" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ad0e41c-c89d-48c1-9842-c7e84e66f084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_106ba987-6a50-4f75-870d-3a1b7faedcda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f09ce44b-7be5-470e-af30-77ed16bfe597" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_106ba987-6a50-4f75-870d-3a1b7faedcda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_373360d7-d145-4ae6-89d3-c594adfd4fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_106ba987-6a50-4f75-870d-3a1b7faedcda" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_373360d7-d145-4ae6-89d3-c594adfd4fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_373360d7-d145-4ae6-89d3-c594adfd4fde_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_373360d7-d145-4ae6-89d3-c594adfd4fde" xlink:to="loc_us-gaap_SegmentDomain_373360d7-d145-4ae6-89d3-c594adfd4fde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_373360d7-d145-4ae6-89d3-c594adfd4fde" xlink:to="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_6b44ba13-f459-4b79-9160-bb47e73c82c4" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:to="loc_hcat_TechnologyMember_6b44ba13-f459-4b79-9160-bb47e73c82c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_ffe9d1c6-ee17-4eb8-9745-1c6eec87a97e" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:to="loc_hcat_ProfessionalServicesMember_ffe9d1c6-ee17-4eb8-9745-1c6eec87a97e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsScheduleofSegmentAdjustedGrossProfitDetails"/>
  <link:definitionLink xlink:role="http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" xlink:type="extended" id="i40f7306e6e4b4b03b01aea60c7a300ec_SegmentsScheduleofSegmentAdjustedGrossProfitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_74707b4d-cd36-4200-b9dd-78a64052aaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_us-gaap_GrossProfitAbstract_74707b4d-cd36-4200-b9dd-78a64052aaf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_84d24877-a10e-4a7e-ae5c-8f2406bb5e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GrossProfitAbstract_74707b4d-cd36-4200-b9dd-78a64052aaf5" xlink:to="loc_us-gaap_GrossProfit_84d24877-a10e-4a7e-ae5c-8f2406bb5e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_27e34fd0-ec57-4411-9a3c-79034c4dba68" xlink:href="hcat-20210331.xsd#hcat_LessAdjustedGrossProfitreconcilingitemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_27e34fd0-ec57-4411-9a3c-79034c4dba68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0aad2156-f5c2-4dae-a8c4-602af3a4e0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_27e34fd0-ec57-4411-9a3c-79034c4dba68" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0aad2156-f5c2-4dae-a8c4-602af3a4e0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:href="hcat-20210331.xsd#hcat_LessOtherReconcilingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_cbc6566a-b0f8-4bc0-827d-ea9558bf24ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_cbc6566a-b0f8-4bc0-827d-ea9558bf24ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2861e8f8-48b0-46c3-ae4b-d71aeabeecc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2861e8f8-48b0-46c3-ae4b-d71aeabeecc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9ee7733d-75e0-4ac0-89b9-7292f936140c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9ee7733d-75e0-4ac0-89b9-7292f936140c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1c444b12-9a8b-49bc-9417-4a5fc325d955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_DepreciationAndAmortization_1c444b12-9a8b-49bc-9417-4a5fc325d955" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_InterestAndOtherExpenseNet_d0b6feba-df34-4025-8597-210704d0c0dd" xlink:href="hcat-20210331.xsd#hcat_InterestAndOtherExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_hcat_InterestAndOtherExpenseNet_d0b6feba-df34-4025-8597-210704d0c0dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9c4bfbf5-0588-4af7-9e40-77897006dd5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9c4bfbf5-0588-4af7-9e40-77897006dd5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5f79ae38-ec44-404f-9c89-be2f47fb33e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:to="loc_srt_ConsolidationItemsAxis_5f79ae38-ec44-404f-9c89-be2f47fb33e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5f79ae38-ec44-404f-9c89-be2f47fb33e2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_5f79ae38-ec44-404f-9c89-be2f47fb33e2" xlink:to="loc_srt_ConsolidationItemsDomain_5f79ae38-ec44-404f-9c89-be2f47fb33e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_5f79ae38-ec44-404f-9c89-be2f47fb33e2" xlink:to="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a95717cb-e9bb-4e7b-a6d0-c5f0850898ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:to="loc_us-gaap_OperatingSegmentsMember_a95717cb-e9bb-4e7b-a6d0-c5f0850898ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_288bbb62-a78a-4f69-b8fd-de1b9c451da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_288bbb62-a78a-4f69-b8fd-de1b9c451da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2dd13ed6-a680-4bd8-b029-a45790b5110b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2dd13ed6-a680-4bd8-b029-a45790b5110b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2dd13ed6-a680-4bd8-b029-a45790b5110b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2dd13ed6-a680-4bd8-b029-a45790b5110b" xlink:to="loc_us-gaap_SegmentDomain_2dd13ed6-a680-4bd8-b029-a45790b5110b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2dd13ed6-a680-4bd8-b029-a45790b5110b" xlink:to="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_9261d514-8a80-4b00-9957-e273e0563e7d" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:to="loc_hcat_TechnologyMember_9261d514-8a80-4b00-9957-e273e0563e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_21584411-1eca-49dd-be5d-e750db8f644a" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:to="loc_hcat_ProfessionalServicesMember_21584411-1eca-49dd-be5d-e750db8f644a" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>hcat-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ac4f3b8b-712a-43a6-9f81-b9cf5889a679,g:b64543c5-cb81-4282-9510-d3dfb10c5ee8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_822432dd-fbfc-453f-8012-cde5a4c18afc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de902c69-42da-4982-99ec-0c2cdcdb94e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ef43adc2-354e-4af9-81f7-0f236e6d9421_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a26cb773-ef62-457c-9986-d44d57a38c0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option shares outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f6d77b70-37c9-44f6-9033-e18f5645505e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ec7a0b6e-58a5-40ce-8a7f-a79b1dc87df5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c05b695b-e963-4ae5-821b-2be5ae549f9d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_97911d63-c7c3-47f4-80aa-f898dfe0333c_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_b9567389-9e81-4cb7-94c1-4a0b92c5824c_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_OneTimeTechnologyMember_4817987f-7e6e-412b-9121-4aa75c0c1a09_terseLabel_en-US" xlink:label="lab_hcat_OneTimeTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time technology (i.e., perpetual license)</link:label>
    <link:label id="lab_hcat_OneTimeTechnologyMember_label_en-US" xlink:label="lab_hcat_OneTimeTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Time Technology [Member]</link:label>
    <link:label id="lab_hcat_OneTimeTechnologyMember_documentation_en-US" xlink:label="lab_hcat_OneTimeTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Time Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_OneTimeTechnologyMember" xlink:href="hcat-20210331.xsd#hcat_OneTimeTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_OneTimeTechnologyMember" xlink:to="lab_hcat_OneTimeTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_35a01551-9b45-4857-a43a-94e59dba2769_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_24f44880-ecec-4a19-a901-3a88e0a460e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8ef00e7a-0c9e-43e8-9357-a1fa17c62e11_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3eeb1b8b-23c6-415f-846d-de31e19224cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_215e676a-d6fc-41c6-958d-f89320aa8a9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a7127c78-ffe3-45df-87ae-c7aa71a717c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_32d17413-482a-434d-ae8a-fb73e5322927_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ContractBacklogsMember_8a471e70-4e8e-4f1b-a25a-89809b27d6ff_terseLabel_en-US" xlink:label="lab_hcat_ContractBacklogsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Backlogs</link:label>
    <link:label id="lab_hcat_ContractBacklogsMember_label_en-US" xlink:label="lab_hcat_ContractBacklogsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Backlogs [Member]</link:label>
    <link:label id="lab_hcat_ContractBacklogsMember_documentation_en-US" xlink:label="lab_hcat_ContractBacklogsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Backlogs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContractBacklogsMember" xlink:href="hcat-20210331.xsd#hcat_ContractBacklogsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ContractBacklogsMember" xlink:to="lab_hcat_ContractBacklogsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_539656fe-1cb4-47a9-9341-0e85372b1f95_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_82f252a9-54e5-4d73-ba48-549450a8a64d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_25772fcf-cc8d-4363-97c3-44b5a7a05f06_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a2917466-912e-441d-ae35-743525c26252_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3388b156-b080-432a-9982-dca1edf5a1bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_c807965a-c072-4269-bb85-867065c79271_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_34c02327-2bd7-41e4-a275-a7aaa392fe66_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5b64d946-e0a8-408b-8fe0-fd3d0d5f6506_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_RecurringTechnologyMember_494ea333-14d8-4c9f-ab16-00ff3d05127b_terseLabel_en-US" xlink:label="lab_hcat_RecurringTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring technology</link:label>
    <link:label id="lab_hcat_RecurringTechnologyMember_label_en-US" xlink:label="lab_hcat_RecurringTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring Technology [Member]</link:label>
    <link:label id="lab_hcat_RecurringTechnologyMember_documentation_en-US" xlink:label="lab_hcat_RecurringTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RecurringTechnologyMember" xlink:href="hcat-20210331.xsd#hcat_RecurringTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_RecurringTechnologyMember" xlink:to="lab_hcat_RecurringTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_23e943ac-63e2-4d53-9bf8-0c982b13fed6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_382851d9-b04b-4f1e-b866-4eea1e7f3238_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_22ae67f0-5067-409f-b06a-53aa4564b253_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_ffc101d2-8ec2-41b1-88e1-0b28f66994d1_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d3f16537-f81e-4c80-bd13-a600ca0ff294_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f6d8bd97-ab54-433f-bb30-7b08ab712d6c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding, beginning balance, grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9dcd499f-b53a-4864-b5f9-06a096835170_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding, ending balance, grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c2c24e-5884-4383-b7a2-3edd90a49224_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c5c0136d-1c57-42b8-828c-b2c708398fe3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1f7c0b36-a4ad-4e1e-8367-3e906f282b85_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebfd30fa-68df-47a7-be44-9b5fa0ad699a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2955c1f5-463e-4eca-93f3-7bf3bca3c217_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c2e73c58-72e1-4d79-be02-3d59787dcaca_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_dd681996-6d90-463c-80ac-536c90db0cae_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6b6d9595-2aa3-4905-90f2-622d6065ef60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_771bf2f7-eb39-4903-ae7c-8b34c8be253c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_18a82f8f-bcac-4b3a-9ee0-7e5f9fd7f902_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_575ae6fe-4fd9-4a85-ae48-198b3024a645_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_99205b4c-f830-4254-a870-209224960f3f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_d6aa0f7b-8ec2-49a6-bd79-52639ee386cc_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development cost and internal-use software</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9397395c-f115-4934-bb50-d111ff60181b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0637c210-24cb-4513-9c32-e46e09957db9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_fe6aa557-3cce-487c-91a9-71852ae11598_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_StockIncentivePlanMember_37c8f784-e5ae-4a25-a0b5-21eab3ad33d4_terseLabel_en-US" xlink:label="lab_hcat_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:label id="lab_hcat_StockIncentivePlanMember_label_en-US" xlink:label="lab_hcat_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_hcat_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_hcat_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlanMember" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_StockIncentivePlanMember" xlink:to="lab_hcat_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_634d4d23-28d2-441c-b603-c982d4e89077_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_789773ef-a9ff-4581-a81d-1a2856ee5555_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at January 1, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f39e1aad-0c02-4b2a-a5d8-58141f32ae99_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at March 31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_29567739-e248-461e-babf-5442e67b730f_terseLabel_en-US" xlink:label="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of restricted shares issued (in shares)</link:label>
    <link:label id="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_label_en-US" xlink:label="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares</link:label>
    <link:label id="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_documentation_en-US" xlink:label="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" xlink:to="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed_dada927b-b835-41ce-a470-822e8d44de43_terseLabel_en-US" xlink:label="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator of lowest purchase of a participant (in shares)</link:label>
    <link:label id="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed_label_en-US" xlink:label="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed</link:label>
    <link:label id="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed_documentation_en-US" xlink:label="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" xlink:href="hcat-20210331.xsd#hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" xlink:to="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5d923a90-960a-49e3-bdb7-1f6e00b04f39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_c5dbd881-0111-49a8-89ed-423575a20bfe_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_bab63a18-9591-497e-8990-55614fa47263_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_1b20f4e2-d9a5-4d46-9105-7a34e19d8910_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_79d1385a-810a-4d78-80c3-69e1f204ce99_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 25,000,000 shares authorized as of March&#160;31, 2021 and December&#160;31, 2020; no shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ee5bc8a4-cac5-4b74-bd4f-ecbf0ae35a82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_8bfbcdaa-65bf-4d9c-9d3b-432f1a7112d0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c1d097b4-1284-4d4e-b052-bdeb6e18502c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_dca24ddd-4e46-4cc2-ba0d-69036f0c6cc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05497642-3e0c-418e-aa18-791985e7b2e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award, options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dac35e20-1eec-4477-b72e-c09fb83dbc24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_536cb4aa-d77a-4fe8-9a74-aa8938782ab7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_15e50ee5-cf3f-4fc0-8ac4-8d7c8adfb8c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled/forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_5ff73c13-48ff-472f-a727-0a4999e8124f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue, excluding depreciation and amortization:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_137eb9fb-c893-438f-a87b-6ea798363415_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total grant-date fair value of stock options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_cf26e411-de68-4b15-9313-c21a49ce09a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fcb9e1c7-9bc7-4165-a9af-bf0c0138105c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_5b930b80-e28c-4ad2-a9e4-cb4f5a305207_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe707865-c5a4-417a-929c-865cdf0c3271_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_18f3f380-a4db-4edc-bef4-eadb20761c1e_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reconciling items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f987d3ec-d89f-4d87-af07-b81c0c9e6754_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d85d06da-5dbc-4b13-9e64-80cd679c5553_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_57888314-351a-4fb2-87bc-5ddad067814a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_66259156-6f92-4fb7-9b05-32c9321cbb7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_a5653889-5b65-4eaa-8040-ecb99aa49464_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_14f5398a-98a2-4fa5-83e0-01c91ca7a085_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_4e720849-ff4b-4b21-a238-efd2c9081feb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_57d33048-5a54-4a04-997f-36cf1facdafd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to contracts with customers (percentage)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_eeb0afc3-d961-4ad6-af64-a7b54744e48f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4f857154-bbdd-44c5-97d5-9e4ac2668c4e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_78f51005-47e9-4bcd-8c42-ef3c07e08d3c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_939a1360-3643-4ff9-b6ef-e270b89b9258_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6853048e-7583-4ede-b1de-453723ce7096_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_81ab780a-67e6-4a1d-bb78-3c9730403b3c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for acquisition consideration (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5fff9b8c-2384-43ba-8706-d924cec2ba85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share totals with a potentially dilutive impact</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_18f131c7-3cc9-4677-8b56-14cc62f5e318_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_df62ad12-541f-487d-adbc-258275473e4e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_a3384648-8538-48c4-b886-3b4d8ed09c21_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_ea72d356-3da4-4e51-93e0-bc9fc1cc431b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b2ae0ef-3115-41c4-a981-ec256dff4a77_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_fc6e37d3-ecb1-4005-a093-881b664f59be_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b65b4edb-b569-4226-9065-d7605e89b025_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_e6d7cc22-6327-41bc-88e8-23860d81db4d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Write-offs, net of recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_759d2db6-6014-4612-9e42-93b469fc0b2d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_IncreaseDecreaseInOperatingLeaseLiabilities_69511fa6-e5f4-409a-bdc9-9f30e8af2e14_terseLabel_en-US" xlink:label="lab_hcat_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_hcat_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_hcat_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_hcat_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_hcat_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_hcat_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_a58c4fea-f36a-41c3-a576-0a2cf8e82029_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_8b7c78e3-3a4f-443a-8843-5019f0eff557_terseLabel_en-US" xlink:label="lab_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue recognized was included in deferred revenue (in percentage)</link:label>
    <link:label id="lab_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_label_en-US" xlink:label="lab_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue Recognized, Percentage</link:label>
    <link:label id="lab_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_documentation_en-US" xlink:label="lab_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue Recognized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage" xlink:href="hcat-20210331.xsd#hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage" xlink:to="lab_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_37108b4a-4a91-4b03-aeb8-9241a63dde9d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_b8a0b75b-2801-4cd7-b8f4-f21d78f18da3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_fefff209-6bd8-40f4-8287-a3832c2b7a90_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a9c82c66-eaf4-4e38-9248-1bdc7dbd21d2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2da69995-18df-4a29-8d7f-bad68194cd5e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c405d4f5-2aef-4930-8efa-6d798b03dfce_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_47177076-fb96-465f-80e4-8bedfceb53f5_terseLabel_en-US" xlink:label="lab_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Adjusted Gross Profit reconciling items:</link:label>
    <link:label id="lab_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_label_en-US" xlink:label="lab_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Adjusted Gross Profit reconciling items [Abstract]</link:label>
    <link:label id="lab_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_documentation_en-US" xlink:label="lab_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Adjusted Gross Profit reconciling items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract" xlink:href="hcat-20210331.xsd#hcat_LessAdjustedGrossProfitreconcilingitemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract" xlink:to="lab_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8f539467-e04d-4694-9df6-283ed3c4311f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80d27f64-47d3-41dd-8739-ea614d99b0ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4db8f18e-f8cf-4d4b-8222-06c9b6b187f2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable, weighted average remaining contractual life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_61623d7c-de12-4a5b-a718-b22a5e0ac58f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_MeasurementInputMarketPriceOfRevenueRiskMember_4b7c9864-8f05-4213-af25-459f3fc82b84_terseLabel_en-US" xlink:label="lab_hcat_MeasurementInputMarketPriceOfRevenueRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Market Price Of Revenue Risk</link:label>
    <link:label id="lab_hcat_MeasurementInputMarketPriceOfRevenueRiskMember_label_en-US" xlink:label="lab_hcat_MeasurementInputMarketPriceOfRevenueRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Market Price Of Revenue Risk [Member]</link:label>
    <link:label id="lab_hcat_MeasurementInputMarketPriceOfRevenueRiskMember_documentation_en-US" xlink:label="lab_hcat_MeasurementInputMarketPriceOfRevenueRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Market Price Of Revenue Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_MeasurementInputMarketPriceOfRevenueRiskMember" xlink:href="hcat-20210331.xsd#hcat_MeasurementInputMarketPriceOfRevenueRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_MeasurementInputMarketPriceOfRevenueRiskMember" xlink:to="lab_hcat_MeasurementInputMarketPriceOfRevenueRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a2d5f866-e156-4b01-b212-184b35639e5e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_174fbf00-cbec-4bbd-98d2-052280621a58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the calculation of basic and diluted net loss per share attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_42724bf7-d16f-4bb0-a162-55633ac52796_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44f0f57f-0dba-443c-af76-21651242c18e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fa6f9a19-031a-42e4-b9a5-f75bc3b3eb8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18e1c6f1-5ff8-4ee2-a573-73d9c9f7dd31_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of March&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8bf82061-1098-49c4-8ba3-d2d4e475c81a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dd89b411-a156-4d00-ae82-adc1a5af62b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of recognized identified assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ee630000-f8fd-4fdb-b3d4-f9d7b5232904_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, assets measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ca6bac23-4eb0-43a7-96d8-aee1857e4898_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_455713ba-b9ed-4511-a734-d4265aaa07f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_CappedCallMember_2d37c93c-e12b-4ff1-a70f-1204715f8f18_terseLabel_en-US" xlink:label="lab_hcat_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call</link:label>
    <link:label id="lab_hcat_CappedCallMember_label_en-US" xlink:label="lab_hcat_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call [Member]</link:label>
    <link:label id="lab_hcat_CappedCallMember_documentation_en-US" xlink:label="lab_hcat_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CappedCallMember" xlink:href="hcat-20210331.xsd#hcat_CappedCallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_CappedCallMember" xlink:to="lab_hcat_CappedCallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3771ede8-e590-47b4-8e14-44436cd221d0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e98fb550-1a46-464e-bbbf-1f3beb7185d4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_de1a38d9-f5e1-45df-9d3a-5cea41b53725_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f241e247-0ecc-4afa-88f9-9641c56ae553_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure_742762c9-3d05-4d53-ba23-299b048e711a_terseLabel_en-US" xlink:label="lab_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt liability component fair value disclosure</link:label>
    <link:label id="lab_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure_label_en-US" xlink:label="lab_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Liability Component Fair Value Disclosure</link:label>
    <link:label id="lab_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure_documentation_en-US" xlink:label="lab_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Liability Component Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure" xlink:href="hcat-20210331.xsd#hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure" xlink:to="lab_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_6c587bcc-2790-4c5f-97b6-8871ccf342f6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_71fed3fc-bd94-4cdf-9af7-3a1b7bf4bb97_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software licenses</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_3a61d0e2-963f-42fd-b530-4e31ad06e4d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_da7466e4-588e-4959-a091-3a3bcf761cd1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3251a6ca-4fbf-4f84-b07e-27b7f79a855f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash_538ba0cc-1f3d-4879-85f8-d87e49e17fc7_terseLabel_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid in a combination cash</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash_label_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Cash</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash_documentation_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" xlink:to="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b511693-8dff-4c83-98b8-6b25f61b03d3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0c0068e9-37ac-47e6-9559-e9ee4b785f91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3f0a4db1-0467-42c6-91d1-8c3c1ff64d4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_9ea836e4-137f-408d-aabe-168710e35d63_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from related party</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_dcbdd2e0-c703-4fe3-aa7e-716e0f8bd63f_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares related to convertible senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b62a2c32-0cff-42e5-865e-de5ab0d7e2f2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_14eecafc-ef8e-4e3e-ae4d-a76e9e11ab98_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_505d9181-e1bd-45b9-867c-c8eb20a07008_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a0cb7c9b-a4fb-420c-8c6c-ea323671e264_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6d39ed66-bd64-4a5e-b696-8c2117b20866_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_12868ecb-e795-460a-9c2e-1361be5b5f25_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized as internal-use software</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b32b4a4c-d872-4d37-8fcb-9c1e5c5e8d9d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested award options, unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c995dc6a-5a31-4c00-b5ec-37a345dec5f2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2c930d84-b103-42a3-aff4-257eb58b8ffe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_d4ae99a9-990d-4862-a6e1-614c895f4593_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_728e1c4f-d465-4fd1-bb3e-7a42638c82ae_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022d79e9-4d52-447f-948e-8e5af774744c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_b9d6a44a-5bd4-4c0c-9263-c5125e2c5420_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2e0b2c49-03a5-4120-b755-ff5919d23b1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_57a85303-da61-46b4-b285-daae1903f2b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for settlement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ec7f8313-5d0e-41e6-896a-d9cf142499f7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in connection with acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_36fee42e-1ba9-457e-9140-e6fb7a42ed64_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b7a13db6-ab4e-48c5-b72d-f2a5200f5b62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a56b539a-ce11-4d62-9fc1-867644e6f6e7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_9431042f-3ee6-43af-879f-b0cc8ce15d47_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_a477467f-f274-4487-b7aa-fb619a8380fa_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares_4178a439-adfd-430d-98ce-b8765dedea05_terseLabel_en-US" xlink:label="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase of the number of common stock shares (in percentage)</link:label>
    <link:label id="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares_label_en-US" xlink:label="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares</link:label>
    <link:label id="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares_documentation_en-US" xlink:label="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" xlink:href="hcat-20210331.xsd#hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" xlink:to="lab_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_eb6f174e-a762-4bc3-9920-78071a0a56ec_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_53873dcc-7c9e-45d1-b7ff-b58fb7715e37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_47bef415-83b5-4a8d-86c5-3305d6b9deba_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_8e0e57db-06ba-4326-b0c2-3bb370d784d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_cddead49-78c5-4cd3-919b-4998f577e199_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6f5fa42f-7f54-465e-bc6c-a191c7a0665d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_02334e67-7bab-4e98-a0e2-972d45283218_verboseLabel_en-US" xlink:label="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for settlement of contingent consideration</link:label>
    <link:label id="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_f946c06f-5d50-4721-8404-34f182759b4d_terseLabel_en-US" xlink:label="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for settlement of contingent consideration</link:label>
    <link:label id="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_label_en-US" xlink:label="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability</link:label>
    <link:label id="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_documentation_en-US" xlink:label="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" xlink:href="hcat-20210331.xsd#hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" xlink:to="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c7d7463c-dc87-436f-a6c5-46294fdfd96f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dc52e4ca-7851-459b-9b04-a86ec30a2f68_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c514f68e-ec09-4a56-bdbc-d63bece4d66d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_ba0aa1c1-5464-4c31-889f-d6cdb4c1b1cd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_be73064f-df18-4599-a07b-dc3f619d556a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8df16f39-0119-442e-be3d-9d9b88b1a595_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7bdffbb8-4c4a-4a31-ac4a-3a7e7a1fe63e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5d6cfd6c-5db7-44e5-bb17-aa05e6482aca_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ec354564-a8a1-45de-bf96-b6168ad86b69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_7634e2bd-1e8d-4595-b993-42147a3779e8_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8683c000-0313-43cd-90ed-05a2fd6976ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_cbbf115b-15bb-4e7a-aae3-4673ec6d9333_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5a8fbaaf-e599-47eb-9aba-2eb832b009ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gains (losses) on available for sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8387b31f-56c6-4b75-9460-3fd6b694335f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_c2a97bef-e4f6-4bbe-88ff-753b07150794_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7f017eb-6888-4fbd-bd54-65d3c13abbc2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_29d71f0d-c124-483d-b4ac-764690711034_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_bafa2d74-22a0-4ea2-ab97-2d2f8f50f7ca_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_ea950807-49d8-43d9-bd5a-24f88fb20f18_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f43ca051-f522-4326-9c3a-19bee056a11c_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e5d535f8-0fb7-4a1e-addc-e66978a150df_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_AcquisitionRelatedFairValueAdjustmentsMember_a1e4a2c1-0f2d-4d6f-a6d2-02ed43d78807_terseLabel_en-US" xlink:label="lab_hcat_AcquisitionRelatedFairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Fair Value Adjustments</link:label>
    <link:label id="lab_hcat_AcquisitionRelatedFairValueAdjustmentsMember_label_en-US" xlink:label="lab_hcat_AcquisitionRelatedFairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Fair Value Adjustments [Member]</link:label>
    <link:label id="lab_hcat_AcquisitionRelatedFairValueAdjustmentsMember_documentation_en-US" xlink:label="lab_hcat_AcquisitionRelatedFairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Fair Value Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AcquisitionRelatedFairValueAdjustmentsMember" xlink:href="hcat-20210331.xsd#hcat_AcquisitionRelatedFairValueAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_AcquisitionRelatedFairValueAdjustmentsMember" xlink:to="lab_hcat_AcquisitionRelatedFairValueAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_669f85fd-4356-4492-9406-c882251e23d2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DebtInstrumentConvertibleThresholdTypeAxis_998de4a8-7a26-4100-b040-c35ffdd09b12_terseLabel_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleThresholdTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Type [Axis]</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleThresholdTypeAxis_label_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleThresholdTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Type [Axis]</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleThresholdTypeAxis_documentation_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleThresholdTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleThresholdTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis" xlink:to="lab_hcat_DebtInstrumentConvertibleThresholdTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f579ba42-a3fc-41fa-98cd-bee5e2696bbf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested awards, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e4a93b59-b18a-41e6-847a-f7e9f639b4bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1d80ddf5-d3e0-4f8c-99db-f8c236093ed3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted average remaining contractual life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eb8c626f-06c1-415c-ba1f-8eee5f1520be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_04748aee-86ba-4b44-858f-13dd6a767d34_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19b493e7-5d04-4044-9d8f-aeda95d79c42_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3e787800-0df1-4c30-bd90-5108218e5ac2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ab9db643-3185-405e-a80a-4da721a8c487_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_072c18ef-ce03-4d20-a3b1-705eaa7d24bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f74067c5-0b2e-4002-bb6d-be3961ad42a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PhantomShareUnitsPSUsMember_fe5226c4-5de9-47ef-9b47-85feaf1a3b2b_terseLabel_en-US" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_PhantomShareUnitsPSUsMember_label_en-US" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phantom Share Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PhantomShareUnitsPSUsMember" xlink:to="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_HealthfinchIncMember_d90c9ce8-078e-4857-acce-031ad4214986_terseLabel_en-US" xlink:label="lab_hcat_HealthfinchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthfinch Inc</link:label>
    <link:label id="lab_hcat_HealthfinchIncMember_label_en-US" xlink:label="lab_hcat_HealthfinchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthfinch Inc [Member]</link:label>
    <link:label id="lab_hcat_HealthfinchIncMember_documentation_en-US" xlink:label="lab_hcat_HealthfinchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthfinch Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_HealthfinchIncMember" xlink:href="hcat-20210331.xsd#hcat_HealthfinchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_HealthfinchIncMember" xlink:to="lab_hcat_HealthfinchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2b4876a-4b18-4dec-a662-ee56074ccbdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_fe0c4be5-7e0a-4be7-b7c9-369606383546_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8d4f4ed5-5098-4249-94c8-f6f221d77078_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c0b3844c-7df8-4cf4-ad57-61f4d3c7336e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_247c0f16-7634-4ebc-986d-00d385de7539_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:to="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_8ed34a65-a54a-4247-8538-07e7fa12af19_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_f7e926ff-b389-469a-9b14-bbe61d32195e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5b9f23ce-94b9-406b-806d-9aa68ebdc129_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2aa64048-0ba1-4915-825e-f23f1a34f871_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_06386661-ef3f-4b97-946d-95e17a3487a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0a0c4a2e-068a-444b-acd4-619b0579aafe_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_dc94bac5-ca7d-4b5c-b4b3-69ddd34c4e85_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_74d3badc-6ac3-404d-8f3b-a1475a5d1928_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_daad6c6b-1cca-4a12-a579-a31a70a12ce0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_93ceafe3-4fd3-4364-b44a-385b770f0f16_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_71a6b643-0ca4-47d2-b4f9-dbc06619246e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_bdca1907-fe3e-4007-8879-64b11de1146d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fd8c0ada-2333-4c40-96e6-f379a1d8eae1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f679dad4-c8f7-4a16-8585-d1a6f4d21cb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_daf2795a-da1f-49d5-8147-21497b88a247_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_4c74b3f5-d776-4469-92bc-6fb3b7002bd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e2fa89d2-dc9a-4648-8cb0-d8f5201eeac2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ae8e856-3562-4beb-bf0a-c9ac67f066e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_118a5cf4-3233-405c-8980-051e9c477185_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f80ce9c9-aa95-4097-aca0-3fe4a7e0aca2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2d371c87-389f-47a5-b798-f1e2aed1c0bd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6561739a-051e-4d77-9f6f-736191dc1099_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f8deb4f9-5b33-4123-9545-d56fb21d1b6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of outstanding RSUs and related activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b83d6530-04ee-4a2f-83d0-9da74b3692df_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a1d5dbfb-7ba9-41e2-a29e-9bfce53e4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5555be48-b7f8-4868-b466-e2b5e85068aa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c4a4618f-3204-4b9f-918d-cfc7adc88da0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_df7629ba-d479-4902-b0ab-f3a7c7937e34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_b47a9e3f-e7be-43be-96f5-2c88e60aa8a9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long lived impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_902fb2f4-70e4-465c-b125-68215532f3e3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1dd526a1-fb06-48b8-8e17-934293a4dbb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ac7bba-a4fe-47ef-b9cc-38805d53b835_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_041cc8a0-8bf6-4fec-aae0-5fb0282151f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_df0e6f41-30d0-4013-82dd-19bd181b6b74_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e891f706-d7cf-485b-a60c-cfff201ea649_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_d8f13023-4a51-442b-aa99-38a0b1a6e2bb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_582183d0-3fd9-4fce-9579-28bf4a8df487_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_06d833cd-2324-4599-8e4b-abe2950f40f1_terseLabel_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds allocated to the conversion option (debt discount)</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_label_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Carrying Amount Of Equity Component Gross</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_documentation_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Carrying Amount Of Equity Component Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" xlink:to="lab_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_CommissionPaymentEstimatedBenefitPeriod_a89344e5-9411-4f48-9224-5024c9ad4f64_terseLabel_en-US" xlink:label="lab_hcat_CommissionPaymentEstimatedBenefitPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated period of benefit</link:label>
    <link:label id="lab_hcat_CommissionPaymentEstimatedBenefitPeriod_label_en-US" xlink:label="lab_hcat_CommissionPaymentEstimatedBenefitPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Payment, Estimated Benefit Period</link:label>
    <link:label id="lab_hcat_CommissionPaymentEstimatedBenefitPeriod_documentation_en-US" xlink:label="lab_hcat_CommissionPaymentEstimatedBenefitPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Payment, Estimated Benefit Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CommissionPaymentEstimatedBenefitPeriod" xlink:href="hcat-20210331.xsd#hcat_CommissionPaymentEstimatedBenefitPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_CommissionPaymentEstimatedBenefitPeriod" xlink:to="lab_hcat_CommissionPaymentEstimatedBenefitPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_b360d9fe-baa2-4b83-8c80-ba427bdbf3e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_InterestAndOtherExpenseNet_3a01efee-c57f-42fb-bbfd-178044d0baa6_negatedTerseLabel_en-US" xlink:label="lab_hcat_InterestAndOtherExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other expense, net</link:label>
    <link:label id="lab_hcat_InterestAndOtherExpenseNet_label_en-US" xlink:label="lab_hcat_InterestAndOtherExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Expense, Net</link:label>
    <link:label id="lab_hcat_InterestAndOtherExpenseNet_documentation_en-US" xlink:label="lab_hcat_InterestAndOtherExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_InterestAndOtherExpenseNet" xlink:href="hcat-20210331.xsd#hcat_InterestAndOtherExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_InterestAndOtherExpenseNet" xlink:to="lab_hcat_InterestAndOtherExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e88391f0-78c9-42ff-8821-3c5f102ce1cf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7dd8ce4a-fee4-40b9-9391-b4c63f9b396b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_VitalwareLLCMember_f78a4779-5325-47ee-b844-7eb449a9cf4e_terseLabel_en-US" xlink:label="lab_hcat_VitalwareLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vitalware L L C</link:label>
    <link:label id="lab_hcat_VitalwareLLCMember_label_en-US" xlink:label="lab_hcat_VitalwareLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vitalware L L C [Member]</link:label>
    <link:label id="lab_hcat_VitalwareLLCMember_documentation_en-US" xlink:label="lab_hcat_VitalwareLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vitalware L L C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_VitalwareLLCMember" xlink:to="lab_hcat_VitalwareLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_72af1200-334c-4455-ba45-fcdde8d9b234_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue with related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_18f95a98-4058-4ab9-8e8a-aa8a3141b96b_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6c7655bf-df86-450e-a58b-569570ed6298_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_638c84a6-6952-4535-81f1-d39c45ec5327_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_094326b8-129d-4471-9dcc-1bf41a06592e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_88edd7ac-fcbc-4dd6-9b27-d99162277680_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred contract fulfillment costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ProfessionalServicesMember_b467357f-8e98-4cec-9525-bb8b7b5c27b9_verboseLabel_en-US" xlink:label="lab_hcat_ProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_hcat_ProfessionalServicesMember_f20792f2-f5b2-474d-ad0a-b8d49e435258_terseLabel_en-US" xlink:label="lab_hcat_ProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services</link:label>
    <link:label id="lab_hcat_ProfessionalServicesMember_label_en-US" xlink:label="lab_hcat_ProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services [Member]</link:label>
    <link:label id="lab_hcat_ProfessionalServicesMember_documentation_en-US" xlink:label="lab_hcat_ProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ProfessionalServicesMember" xlink:to="lab_hcat_ProfessionalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_be4a6b8b-7bfb-4da3-888a-961d88566024_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_5dd05669-9a03-41c4-8c8c-d399c4dfae04_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3ae2321a-bfa2-4151-878c-adb6ac55d1b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_97db244e-2c17-4989-b150-a49d0bb7d29d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_9b155aab-7619-4c40-8b1c-8f139cb680b7_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_db41a0c8-e5d3-4146-9f02-4eafef9a9916_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5973990a-5892-4132-b1ff-5999c62a56a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0b764035-0732-4cba-8b43-d4293dc1929a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d64e7041-01e1-4c66-b535-8c226770077a_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_85cfccc6-4fb9-469b-b4c3-87acc7b52909_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_66dcc9eb-0626-4333-b572-e37ee7d4c448_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_cea741ee-1eec-4115-8d8b-d639e017b29b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation (in percentage)</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_b2d92bdd-9ade-44a8-a5de-0faa9060f54d_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board member</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_7dd54fc9-a5cb-48ea-868d-fda3fbe8ae35_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_c2cd96c6-d651-4aaa-81d9-89347680f545_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue disaggregated by type of arrangement</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_7083d5c5-fb18-41d5-b03e-573fd19fe611_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_8006ef9a-416a-4458-bb67-ff50b1944bbb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_36cc5297-e911-44b3-9586-1e739ea39aa2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7899c4a6-5474-45a3-9644-05ca4afeacac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_f23fd61d-6a5a-47f6-aea3-c209adc9c9f7_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5de36744-40ae-415c-9267-b38444b22fcf_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_8df06ffa-3323-45f9-8554-4570116f62b0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCostOfHedge_d2180340-d3bd-4df2-9624-3f616aef6d26_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCostOfHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, cost of hedge</link:label>
    <link:label id="lab_us-gaap_DerivativeCostOfHedge_label_en-US" xlink:label="lab_us-gaap_DerivativeCostOfHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Cost of Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCostOfHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCostOfHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCostOfHedge" xlink:to="lab_us-gaap_DerivativeCostOfHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_d685d7e6-d8de-4056-8df2-7590a63589de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, if-converted value in excess of principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_194a9e86-87a6-4029-bd0e-d48117e56b8e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash equivalents and short-term investments measured at fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_511abdad-c3ca-4d84-a2c8-8e59f0aa4bd4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_dccca91a-0e9d-493a-8cb4-c52589d6f1f2_terseLabel_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowed termination period</link:label>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_label_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement For Service Contract, Allowed Termination Period</link:label>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_documentation_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement For Service Contract, Allowed Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" xlink:to="lab_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_0d34ac56-1d52-4e77-99f8-65975c2ee61c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_e7e64121-dd23-4e59-9316-37776bbe3c72_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c6fc9180-0912-4db6-8dfa-63559cbee8b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_dfb3efa4-ff17-4aa9-a862-134add3de10e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0cb9c50a-1ebc-4fc0-9be2-a6a359b1ff66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_586f8c56-c6fe-4e1e-9e35-562279b1c4db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment discount and premium amortization</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b677544d-57d5-4b87-87c9-b484f990c1e3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_1515d9aa-86b2-4a4e-ac29-d0a21f3dd41b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd7c3f49-1291-4062-b20c-327435d38a33_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b9290206-fdd1-453d-904e-358c4ba3d838_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_afa990cb-5ff8-4717-84c9-5dccfb91e703_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4f8346e2-9c13-4b75-a132-0168177e2d6e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1844083b-9a90-476d-940a-7dab1c057b90_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3fe23a8f-00d1-4914-b893-ecbc48cb91f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6d1b5e12-80bb-4907-9f76-adb848f5f974_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_1f5324d4-c168-484b-811e-15c607e22496_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_b4cbf92f-f2b7-46c1-ad4c-db8419de7638_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b5b696dc-ee90-42f7-b693-e6ffd14b4d06_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_6f97e7a1-78bf-40ab-a0d5-ff34c042a491_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of allowance for accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c3bb5c4c-6cb5-417e-bb81-5871bd42b5da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod_2dbd6103-9b7f-42a9-81be-74817f93fcc9_terseLabel_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription contracts, terminable period</link:label>
    <link:label id="lab_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod_label_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Subscriptions Contract, Allowed Termination Period</link:label>
    <link:label id="lab_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod_documentation_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Subscription Contract, Allowed Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod" xlink:href="hcat-20210331.xsd#hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod" xlink:to="lab_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c75367d2-776e-4d65-a17f-f884553f3ac5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense related to RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_aefa3536-1458-4e9e-9bf1-563e65fd9b58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, liabilities measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0aea271b-b459-4791-abd6-d687fd909b29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_af1187c3-b7a7-4200-ae42-898f52078622_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_0a0bf981-97b1-4e26-b817-d7b061954309_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_84924c3d-a0d4-41b3-9420-e2b63ef0b55b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_de6705eb-5e56-4b22-9835-0d48fc50dea2_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_d37250cc-9f43-4025-b632-7b37af2eb78e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a37b5482-c00d-4a96-823b-e2f2d399b155_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_86d25521-70b2-44d3-9130-baa046146eeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_37e7f2e5-7a13-4bf6-8e7a-201306fe92f6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c73d5bd1-8b01-4bb0-b2d6-9511ce05b2cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077c87dd-c894-4196-a45e-6632cfd60b91_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b195526e-5f8a-4754-87a5-f2dad91574c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_768d60d1-788f-4b9b-9e57-eec52db8e8a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information related to stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a1979003-d722-4438-9d6f-6d694ac6b655_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_3b0e4eca-101c-4e97-b6d0-aa92e31ac08e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e9fa8eeb-3935-499d-921d-84f0d0ac8068_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c5b7adb7-5bc2-41ee-a1aa-010a3553b6f7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_55d68969-9df8-4e96-8c3c-efce1bf502d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f5c333e9-e6e1-4a23-87f1-cbe801944e67_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_8a13325a-08b1-4234-a73f-35c023a6bfa2_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising cost</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_26afc8e2-1b8d-4d9f-836c-8e98a3249726_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment adjusted gross profit</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_62c36c68-15cd-4103-9362-0890ba98febe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_2890889b-4be9-4e78-93a0-1abf53670df0_terseLabel_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notice required for termination</link:label>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_label_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement For Service Contract, Notice Required For Termination</link:label>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_documentation_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement For Service Contract, Notice Required For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" xlink:to="lab_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f3473e80-d72a-44df-808e-c107593bcaa3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_80bac92a-1747-42f7-9f0e-47520ddb42e2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e281ea77-5fbf-470c-9680-321ac2d461b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_5c4c2d9d-27a4-4429-9d73-3190ea0970f7_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_40e5bbd5-0ad2-4118-b861-6dbc88bca252_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_12af2023-4229-43b1-aa42-8699eca25949_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_3cb24977-60c3-4125-b5ae-8b5e29d7c9bb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6f182502-1e87-4f08-916d-c0416c885763_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_c8e215c8-e7e9-4d91-97f2-1853bae8beea_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_0d355bd8-c37f-4ebd-b9f1-69e40e9184ed_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_ca0c0b03-60dd-413b-8609-c0a242775900_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7ce0d699-49dc-4446-a60c-76facc7b80a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ca5362a-5586-4d2e-a0e6-13205aabe8ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_StockholdersVote_058e8e45-6718-4759-9b4c-7cf13ed176cd_terseLabel_en-US" xlink:label="lab_hcat_StockholdersVote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders vote</link:label>
    <link:label id="lab_hcat_StockholdersVote_label_en-US" xlink:label="lab_hcat_StockholdersVote" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Vote</link:label>
    <link:label id="lab_hcat_StockholdersVote_documentation_en-US" xlink:label="lab_hcat_StockholdersVote" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Vote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockholdersVote" xlink:href="hcat-20210331.xsd#hcat_StockholdersVote"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_StockholdersVote" xlink:to="lab_hcat_StockholdersVote" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8904f4d5-e5c7-4a35-9452-7f01cb47e398_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_152dabb1-f8f3-41cc-b9a1-c368c812ae24_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_73de409b-7bc1-4ff0-a003-4cd557dc8e41_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_959fd293-167d-4bba-9be8-05179e7fa9c9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used in calculating net loss per share basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ShortTermMarketableSecurityMember_de41e2d0-0903-46d6-9689-b9e3bf98769d_terseLabel_en-US" xlink:label="lab_hcat_ShortTermMarketableSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_hcat_ShortTermMarketableSecurityMember_label_en-US" xlink:label="lab_hcat_ShortTermMarketableSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Security [Member]</link:label>
    <link:label id="lab_hcat_ShortTermMarketableSecurityMember_documentation_en-US" xlink:label="lab_hcat_ShortTermMarketableSecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Security [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShortTermMarketableSecurityMember" xlink:href="hcat-20210331.xsd#hcat_ShortTermMarketableSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ShortTermMarketableSecurityMember" xlink:to="lab_hcat_ShortTermMarketableSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee_f82adf3e-5868-46b2-94a2-92d513db4d08_terseLabel_en-US" xlink:label="lab_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum purchase value during offering period</link:label>
    <link:label id="lab_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee_label_en-US" xlink:label="lab_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee</link:label>
    <link:label id="lab_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee_documentation_en-US" xlink:label="lab_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" xlink:href="hcat-20210331.xsd#hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" xlink:to="lab_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ccc1a931-4e9f-41c5-9ced-8c77393547f5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (in percentage)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_StockIncentivePlan2019Member_e2d36bf6-8fe7-46f1-82a4-68856631f2b6_terseLabel_en-US" xlink:label="lab_hcat_StockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Incentive Plan</link:label>
    <link:label id="lab_hcat_StockIncentivePlan2019Member_label_en-US" xlink:label="lab_hcat_StockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2019 [Member]</link:label>
    <link:label id="lab_hcat_StockIncentivePlan2019Member_documentation_en-US" xlink:label="lab_hcat_StockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlan2019Member" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_StockIncentivePlan2019Member" xlink:to="lab_hcat_StockIncentivePlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2afef27a-e314-48a8-826e-e1ae4bbb5878_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d11b8e02-f45b-43f5-a58b-20212005269e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cb3bfb14-0ec8-4f37-b88a-464d1ea86375_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_SeniorNotesDue2025Member_54aead43-664c-4267-9876-aedf5a6a5e0b_terseLabel_en-US" xlink:label="lab_hcat_SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2025</link:label>
    <link:label id="lab_hcat_SeniorNotesDue2025Member_label_en-US" xlink:label="lab_hcat_SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_hcat_SeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_hcat_SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_SeniorNotesDue2025Member" xlink:to="lab_hcat_SeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_baf9a700-344e-4331-b09a-18f328635727_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the purchase right for the ESPP option assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_495dd996-cc3a-4681-b5fd-23dc06338485_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_FairValueMeasurementAggregateIntrinsicValue_a42742d3-9531-428c-94ba-e6e288291e42_terseLabel_en-US" xlink:label="lab_hcat_FairValueMeasurementAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_hcat_FairValueMeasurementAggregateIntrinsicValue_label_en-US" xlink:label="lab_hcat_FairValueMeasurementAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Aggregate Intrinsic Value</link:label>
    <link:label id="lab_hcat_FairValueMeasurementAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_hcat_FairValueMeasurementAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_FairValueMeasurementAggregateIntrinsicValue" xlink:href="hcat-20210331.xsd#hcat_FairValueMeasurementAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_FairValueMeasurementAggregateIntrinsicValue" xlink:to="lab_hcat_FairValueMeasurementAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c18fea35-397f-4665-8922-49e50c3c3679_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount borrowed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e1498deb-496c-4fad-af53-c93231462fed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_af1c08b9-0089-4fcb-96e9-749c9448db7a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_81ec92a7-957d-4eb7-9a30-7aa5af1c0b80_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-based earn-out liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_24eb4f56-7b10-49a6-9814-02875c28e15f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill by reporting unit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_0f7c42d3-3948-466a-89a9-e0287b5d611f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DebtInstrumentConvertibleThresholdTypeDomain_ac8c0a79-6811-4f69-8f89-6b32d6474179_terseLabel_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleThresholdTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Type [Domain]</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleThresholdTypeDomain_label_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleThresholdTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Type [Domain]</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleThresholdTypeDomain_documentation_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleThresholdTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleThresholdTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain" xlink:to="lab_hcat_DebtInstrumentConvertibleThresholdTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e9aa0ceb-644d-4e90-a31e-b92768d5b904_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d431a682-84c8-4910-8437-c9e313c5a59a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9a789227-9d55-4020-a434-1b06d0660b69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_617b2012-31c1-4882-bb5a-36e17a60fe3c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_d01498eb-3125-4651-b54c-06543fb5f7a7_terseLabel_en-US" xlink:label="lab_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan period</link:label>
    <link:label id="lab_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_label_en-US" xlink:label="lab_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:label id="lab_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_documentation_en-US" xlink:label="lab_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:href="hcat-20210331.xsd#hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:to="lab_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f196b045-41c4-4043-817e-0a4829de8089_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_3b190a52-aa8c-467c-b1da-18a9a72f4bde_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting standards update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_ed127dde-ed1c-44f8-892d-21e36405ae82_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16b9dbc5-b711-4a87-8d5e-b40fc50708e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_ea040cdc-4c43-4525-81bd-33d69a27bc29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a6eca96c-eed9-47c7-b22e-0bd6b96d8e60_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b3ee034e-9b9e-495e-9d22-ea9731817b8e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_859c84c4-1506-4467-ae2f-d106ee74d751_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47d5d225-34bf-4387-99cc-d80a7349f396_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in months)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_90bfa781-f832-46bb-af49-34c344d58e25_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_bfb6db9d-db91-4f88-a37e-3420584cd80c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_64898506-c7db-43c4-8d4a-10ac87ab80c2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_45a3a403-7dbf-493e-a4d8-97a6f333ce75_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9785a515-0fd0-4bcb-907e-2ff185884654_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5e5df08f-3009-44f5-b1cf-f64c234d713d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_7044d132-e67b-4b71-9f73-9e383c1c94dd_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_3c14d883-8ef3-4588-a268-9a486dbc3cf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1718d574-ecd5-4e13-988a-30ce52d1b1f6_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_2860fa13-597a-427c-aeb0-67b3343a039d_verboseLabel_en-US" xlink:label="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_c280c813-98a9-4e5c-b514-2443955f9cf5_totalLabel_en-US" xlink:label="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities And Employee-Related Liabilities, Current</link:label>
    <link:label id="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities And Employee-Related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:href="hcat-20210331.xsd#hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d508710-3416-4485-820b-61b8c0496694_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_446e0c1b-b88c-43b9-87eb-841944bbd6e9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue remaining performance obligation amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_95dae97d-7508-45a5-8182-e872846fbce6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c932f6ec-1102-472e-b6fb-1f9b221a0799_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_451f8424-14a5-4ed3-8c4a-d17353f7d420_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_AbleHealthIncMember_8c2045c6-2f5e-40a0-a99b-df7943de9168_terseLabel_en-US" xlink:label="lab_hcat_AbleHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Able Health Inc</link:label>
    <link:label id="lab_hcat_AbleHealthIncMember_label_en-US" xlink:label="lab_hcat_AbleHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Able Health Inc [Member]</link:label>
    <link:label id="lab_hcat_AbleHealthIncMember_documentation_en-US" xlink:label="lab_hcat_AbleHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Able Health Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_AbleHealthIncMember" xlink:to="lab_hcat_AbleHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_cea55825-4cf2-4efa-b08a-771a9d8017a7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1041504b-0b2e-4913-a3cc-9ad7a3cbf759_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7d21557b-fec2-4e65-b3e0-1b82ecbf60be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 500,000,000 shares authorized as of March&#160;31, 2021 and December&#160;31, 2020; 44,340,036 and 43,376,848 shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_fe71b581-c15d-4e8e-bc58-d0fa2a16211d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, net, noncurrent</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3e8ff6b1-3fa6-46bf-a03a-a80480caaacb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_17648a6d-dd50-4ee5-b2e7-3839798948d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4cfafb3e-5472-454b-8805-ce8a0a806b93_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_dc68a266-3fcc-426f-a470-ce5f62387975_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_ac2fc31f-666a-4df8-b0bc-fdb9630e5105_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b02e3cff-2e9d-49d9-b7ac-e905ae5ddd9e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option shares vested and exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9c43a680-ffc6-41a7-8ef2-192a5bcb70a0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DebtIssuanceCostsGrossEquityComponent_c6dc9d5b-dc53-4a7a-9cd6-5a333064fc2d_negatedTerseLabel_en-US" xlink:label="lab_hcat_DebtIssuanceCostsGrossEquityComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Issuance costs</link:label>
    <link:label id="lab_hcat_DebtIssuanceCostsGrossEquityComponent_label_en-US" xlink:label="lab_hcat_DebtIssuanceCostsGrossEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Gross Equity Component</link:label>
    <link:label id="lab_hcat_DebtIssuanceCostsGrossEquityComponent_documentation_en-US" xlink:label="lab_hcat_DebtIssuanceCostsGrossEquityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Gross Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostsGrossEquityComponent" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostsGrossEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DebtIssuanceCostsGrossEquityComponent" xlink:to="lab_hcat_DebtIssuanceCostsGrossEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_ffa7ed6f-100f-4d49-aa95-ec55a1387b5f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_175895ba-7054-49f7-981e-98bedd985ddc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_109c440f-4787-416f-9607-8f73a502b12d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_aaa59101-ac92-423d-b894-b7b1f1b3a479_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7fadd2be-66cf-4933-9c94-1c834fc18ab9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3f6ae048-e2c8-423c-a9f6-b8837727767d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fe51a541-282c-47cd-9091-d950de746e48_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod_52f9e9d0-1cac-4986-abcb-8bd7a1831251_terseLabel_en-US" xlink:label="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod_label_en-US" xlink:label="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Stock-based Compensation Shares Issuable, Vesting Period</link:label>
    <link:label id="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod_documentation_en-US" xlink:label="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Stock-based Compensation Shares Issuable, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" xlink:to="lab_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01d488ab-17e0-48b9-bb85-f6e1acdb689d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e836a810-4a6b-4af8-a131-bedebb000854_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_688224d2-46eb-4813-bf2a-8a4f6e793d8f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability_fba9d4ec-34bf-4cca-891b-9661185ff694_terseLabel_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable, contingent consideration (in shares)</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability_label_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Contingent Consideration, Liability</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability_documentation_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" xlink:to="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_TechnologyAndProfessionalServicesMember_8793836c-d9ed-468f-be25-e5471009833a_terseLabel_en-US" xlink:label="lab_hcat_TechnologyAndProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and professional services</link:label>
    <link:label id="lab_hcat_TechnologyAndProfessionalServicesMember_label_en-US" xlink:label="lab_hcat_TechnologyAndProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology And Professional Services [Member]</link:label>
    <link:label id="lab_hcat_TechnologyAndProfessionalServicesMember_documentation_en-US" xlink:label="lab_hcat_TechnologyAndProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology And Professional Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyAndProfessionalServicesMember" xlink:href="hcat-20210331.xsd#hcat_TechnologyAndProfessionalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_TechnologyAndProfessionalServicesMember" xlink:to="lab_hcat_TechnologyAndProfessionalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_MeasurementInputRevenueVolatilityMember_c7928cf3-0cf8-4d6e-ab56-2cb3e2bc0e72_terseLabel_en-US" xlink:label="lab_hcat_MeasurementInputRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Revenue Volatility</link:label>
    <link:label id="lab_hcat_MeasurementInputRevenueVolatilityMember_label_en-US" xlink:label="lab_hcat_MeasurementInputRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Revenue Volatility [Member]</link:label>
    <link:label id="lab_hcat_MeasurementInputRevenueVolatilityMember_documentation_en-US" xlink:label="lab_hcat_MeasurementInputRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Revenue Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_MeasurementInputRevenueVolatilityMember" xlink:href="hcat-20210331.xsd#hcat_MeasurementInputRevenueVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_MeasurementInputRevenueVolatilityMember" xlink:to="lab_hcat_MeasurementInputRevenueVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_19124c38-93cd-440c-8023-530160498ca8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, net</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8b9a0000-5c10-4dcc-acbe-9d2d474b3e64_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_f4fb1e53-b4b2-492c-ad9f-038065189868_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8171c91e-0094-49dd-892b-8b240b0d8787_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_23e86941-5cb7-42ce-bf9c-8d1ed9d5f024_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3a1b8a93-323a-421c-abd1-22e9af6fd73b_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_93cf31c5-987c-4a3e-b965-fe4f627817dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6b1be2dd-1ab8-48f0-adb5-19e9871b51ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_dc3f0e0f-e403-451f-95d8-f80980bc3f85_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1e6a6c8d-f311-4390-a564-b48b65beb295_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_60caf3a5-6717-4a80-9fae-98e6f30e2f35_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_BusinessCombinationConsiderationPayableCurrent_b81ab6f3-8dca-41da-b2f2-d4e1d175a89b_terseLabel_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related consideration payable</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationPayableCurrent_label_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Payable, Current</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationPayableCurrent_documentation_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationPayableCurrent" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_BusinessCombinationConsiderationPayableCurrent" xlink:to="lab_hcat_BusinessCombinationConsiderationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_baf3b792-ffb0-40f5-a6b9-00cf35776e98_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5d2e7814-999a-4716-b615-923225cb848b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_dfd7bd93-7f97-469d-9ce5-a0674cfafa44_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5fabc8a3-c6c5-4221-a04b-ff0be79f2442_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_88bf4cdf-6571-41c9-a619-a6eeb4fdcf4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f87b5adc-405a-415e-8005-75c22029cf58_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7c6a2383-5f40-4f26-a76f-9a5809f6c7e9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefit expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0a1af86-6030-4740-a806-788119dda6c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_f7ca92d7-e7be-4362-8e37-89f7e1f55651_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2a7a6106-27ac-4b48-b2ce-e37187f4ec46_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2c18e707-88c4-489d-9a48-978d36619bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d7636869-d78c-440b-9c27-374d86d22530_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ca95f32f-7038-4d08-a286-f8fa30027ba7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de41ca88-b5b8-4cd6-858c-34b5e6029931_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fee45ea5-4b76-40bc-afee-2475b60f9f56_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_67f9624d-d8c2-4e2a-8754-7285fa1f0a31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a592dad3-bb0b-40e3-9d45-8a65e0963bcd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_a7b03108-5413-442c-816b-d6da12bb81ad_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:to="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ced71ba5-7678-43a0-acc7-6a15c05ce350_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares with a potentially dilutive impact (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_032ebe09-6bf2-4322-9e6f-51ee0c6a2cb1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale and maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_f8630711-2d4a-4d4f-93b7-5ce67aaffd8e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_3fe17457-82be-4d1c-bd2d-6a7df14a6cd3_terseLabel_en-US" xlink:label="lab_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_label_en-US" xlink:label="lab_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Other</link:label>
    <link:label id="lab_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_documentation_en-US" xlink:label="lab_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" xlink:to="lab_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_StockIncentivePlan2011Member_e8859c1d-401f-4039-a0b3-2a7fb8eaae0a_terseLabel_en-US" xlink:label="lab_hcat_StockIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Stock Incentive Plan</link:label>
    <link:label id="lab_hcat_StockIncentivePlan2011Member_label_en-US" xlink:label="lab_hcat_StockIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</link:label>
    <link:label id="lab_hcat_StockIncentivePlan2011Member_documentation_en-US" xlink:label="lab_hcat_StockIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlan2011Member" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlan2011Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_StockIncentivePlan2011Member" xlink:to="lab_hcat_StockIncentivePlan2011Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6d35683c-f0ff-4d9a-8b86-48e3628bb009_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_033ee1d1-891f-4a0a-8aed-c0a243d6ec4e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_TechnologyMember_220540b1-7d4b-4a6a-917f-4cad90bffbd3_verboseLabel_en-US" xlink:label="lab_hcat_TechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_hcat_TechnologyMember_0f2c0a66-39ed-49c7-b148-de3d028d15ee_terseLabel_en-US" xlink:label="lab_hcat_TechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_hcat_TechnologyMember_label_en-US" xlink:label="lab_hcat_TechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology [Member]</link:label>
    <link:label id="lab_hcat_TechnologyMember_documentation_en-US" xlink:label="lab_hcat_TechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_TechnologyMember" xlink:to="lab_hcat_TechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_7d099f48-bade-477c-8a9b-73f2c2bdfb2a_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0d219b8e-d86d-4d6a-902f-b439acfcbe88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a8bfabfd-84ba-40b9-b070-9bf14645dfc2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2a94370b-f3b0-4fc6-b1af-dbfc081405bb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2fa897c6-f239-4992-85dc-1513b2f3a7d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6ba5071f-560b-47f7-b109-f38786290e3a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e39a18bd-7020-47ea-a39d-87c8bc8fa9a9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_eb0c8203-148e-48dc-9697-1e1ae68c7dbf_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e6a609ae-07f4-4492-b2b7-b22eef24877b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dbd06dec-b854-423d-b136-b55d986d0251_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9fe9c175-5239-48ba-839c-0da9eddbdc44_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember_0b2b9c65-7754-475b-a3aa-34348612748e_terseLabel_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Sale Price Of Stock Threshold</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember_label_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Sale Price Of Stock Threshold [Member]</link:label>
    <link:label id="lab_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember_documentation_en-US" xlink:label="lab_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Sale Price Of Stock Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember" xlink:to="lab_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_7651f06a-e098-4fba-9b50-2d59f80a0bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for expected credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Loss, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:to="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c4f0dd49-be5b-4240-8e4a-6b0fdd7ca4e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_AssetsHeldUnderFinanceLeasesMember_0a09b70c-13c7-4029-8f40-c709019136db_terseLabel_en-US" xlink:label="lab_hcat_AssetsHeldUnderFinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital lease equipment</link:label>
    <link:label id="lab_hcat_AssetsHeldUnderFinanceLeasesMember_label_en-US" xlink:label="lab_hcat_AssetsHeldUnderFinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held Under Finance Leases [Member]</link:label>
    <link:label id="lab_hcat_AssetsHeldUnderFinanceLeasesMember_documentation_en-US" xlink:label="lab_hcat_AssetsHeldUnderFinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held Under Finance Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AssetsHeldUnderFinanceLeasesMember" xlink:href="hcat-20210331.xsd#hcat_AssetsHeldUnderFinanceLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_AssetsHeldUnderFinanceLeasesMember" xlink:to="lab_hcat_AssetsHeldUnderFinanceLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_CustomerRelationshipsAndContractsMember_34487281-b312-4e26-93eb-569761c6cfb4_verboseLabel_en-US" xlink:label="lab_hcat_CustomerRelationshipsAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and contracts</link:label>
    <link:label id="lab_hcat_CustomerRelationshipsAndContractsMember_52a1c071-7313-44c9-90f6-fc96bcbf70de_terseLabel_en-US" xlink:label="lab_hcat_CustomerRelationshipsAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and contracts</link:label>
    <link:label id="lab_hcat_CustomerRelationshipsAndContractsMember_label_en-US" xlink:label="lab_hcat_CustomerRelationshipsAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships And Contracts [Member]</link:label>
    <link:label id="lab_hcat_CustomerRelationshipsAndContractsMember_documentation_en-US" xlink:label="lab_hcat_CustomerRelationshipsAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships And Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CustomerRelationshipsAndContractsMember" xlink:href="hcat-20210331.xsd#hcat_CustomerRelationshipsAndContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_CustomerRelationshipsAndContractsMember" xlink:to="lab_hcat_CustomerRelationshipsAndContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9cbdc55d-ff81-478d-ad50-1cb02b762229_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_16c7a37f-2f2d-426f-b6a1-9f7016a64648_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ff9c0a1d-e87d-4412-8878-57b39fa44056_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_51c4e964-2e0f-48a7-8e9d-b70dcc56379b_terseLabel_en-US" xlink:label="lab_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]</link:label>
    <link:label id="lab_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_label_en-US" xlink:label="lab_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]</link:label>
    <link:label id="lab_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_documentation_en-US" xlink:label="lab_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" xlink:href="hcat-20210331.xsd#hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" xlink:to="lab_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DebtIssuanceCostGrossEquityComponent_2a03dbac-f4a5-444f-9b79-fcad85af7205_terseLabel_en-US" xlink:label="lab_hcat_DebtIssuanceCostGrossEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost gross equity component</link:label>
    <link:label id="lab_hcat_DebtIssuanceCostGrossEquityComponent_label_en-US" xlink:label="lab_hcat_DebtIssuanceCostGrossEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DebtIssuance Cost Gross Equity Component</link:label>
    <link:label id="lab_hcat_DebtIssuanceCostGrossEquityComponent_documentation_en-US" xlink:label="lab_hcat_DebtIssuanceCostGrossEquityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DebtIssuance Cost Gross Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostGrossEquityComponent" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostGrossEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DebtIssuanceCostGrossEquityComponent" xlink:to="lab_hcat_DebtIssuanceCostGrossEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_78f13c4e-43ae-4e0c-8d11-b145a32a6961_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d980325f-232c-4b71-af22-58cb806145d5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_73f53a15-9d50-43ae-8551-65c5794ba917_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_7ce9bc25-7c50-47a0-9ddd-5ad42f85cc5b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_62081be2-95d1-43d6-9d7c-2fd69b7088d7_negatedTerseLabel_en-US" xlink:label="lab_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Assets</link:label>
    <link:label id="lab_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a8818eb5-8cce-4fe3-8c51-7f732ccc7106_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_56ef2f3e-9813-48ab-9583-86dca834ebbf_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technologies</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_e4f3773a-9e7c-4a8e-bd88-65b768c857d7_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technologies</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f294a0bb-ff5e-4763-9d73-5c18d475f90d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Option Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a9bcec10-13f7-4be9-b8fc-025a4049161c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_dbd21dab-dd6b-4821-b94f-23ec01a26ada_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized internal-use software costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_431de0ac-5829-4aff-b413-c75b69f568e2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_403e7370-d91d-4398-82ec-951074cd0fbd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_849b543d-4049-4937-93ba-7cf0a70e519b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP share increase in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_RevenueFromSubscriptionContractTermofContract_1af9f79e-4100-493c-aecb-18c1ad8918ef_terseLabel_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionContractTermofContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription contract, term</link:label>
    <link:label id="lab_hcat_RevenueFromSubscriptionContractTermofContract_label_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionContractTermofContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Subscription Contract, Term of Contract</link:label>
    <link:label id="lab_hcat_RevenueFromSubscriptionContractTermofContract_documentation_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionContractTermofContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Subscription Contract, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RevenueFromSubscriptionContractTermofContract" xlink:href="hcat-20210331.xsd#hcat_RevenueFromSubscriptionContractTermofContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_RevenueFromSubscriptionContractTermofContract" xlink:to="lab_hcat_RevenueFromSubscriptionContractTermofContract" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares_9d135383-20b6-49a1-885e-814031be7c3a_terseLabel_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid in a combination shares</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares_label_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Shares</link:label>
    <link:label id="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares_documentation_en-US" xlink:label="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" xlink:to="lab_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3775327b-15bd-4c01-bba0-f21e8b26362b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_64777bb6-bc85-4a17-b12d-ada590515c10_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination_0cb405ca-349e-4338-837a-98af569abfa4_terseLabel_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription contracts, days notice of termination</link:label>
    <link:label id="lab_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination_label_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Subscriptions Contract, Notice Required For Termination</link:label>
    <link:label id="lab_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination_documentation_en-US" xlink:label="lab_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Subscriptions Contract, Notice Required For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination" xlink:href="hcat-20210331.xsd#hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination" xlink:to="lab_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_933d65de-50ef-4cde-8a6a-e78f4fc4a929_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_18196674-e743-4f3d-aee0-b94da3a64749_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_323789b6-51be-436d-bcfe-3256f13dd8a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_04849bfa-6771-43a3-80ea-ed568bb0b95d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_04beaf30-4d76-41c5-a08c-4715180872b8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfitAbstract_f13c1229-d3fa-4d0a-a2db-5f2451430d42_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfitAbstract_label_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfitAbstract" xlink:to="lab_us-gaap_GrossProfitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a225457b-82ee-4c26-9697-defc62e42a95_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_LessOtherReconcilingItemsAbstract_4c0ddb28-9625-4ed5-a275-9fcb59abbead_terseLabel_en-US" xlink:label="lab_hcat_LessOtherReconcilingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less other reconciling items:</link:label>
    <link:label id="lab_hcat_LessOtherReconcilingItemsAbstract_label_en-US" xlink:label="lab_hcat_LessOtherReconcilingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Other Reconciling Items [Abstract]</link:label>
    <link:label id="lab_hcat_LessOtherReconcilingItemsAbstract_documentation_en-US" xlink:label="lab_hcat_LessOtherReconcilingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Other Reconciling Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_LessOtherReconcilingItemsAbstract" xlink:href="hcat-20210331.xsd#hcat_LessOtherReconcilingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract" xlink:to="lab_hcat_LessOtherReconcilingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_be0a178a-45a0-4afe-a36c-e5c1fa4ea13c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, net, current</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0c9bcee4-cf7e-483d-b76a-d256490f07cb_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related consideration payable to related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_bf29799c-e65a-4e67-9384-b2b4395e91fe_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2c90acde-dbe4-4436-8aae-fc02ded6fb7e_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_51c5f1a1-fbda-4279-8b80-ee2a9d06a671_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_03bc8ac7-79e2-424b-8f82-5530bb62e29a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, measurement input</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_feb781b4-0505-4eb6-bce3-51bb85d2b2f5_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_e072efd6-c030-4a15-b244-2c237ab73e9f_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_ContingentConsiderationMember_fc1e040e-5418-47fc-a416-319a6cac83ca_terseLabel_en-US" xlink:label="lab_hcat_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable as acquisition-related contingent consideration</link:label>
    <link:label id="lab_hcat_ContingentConsiderationMember_label_en-US" xlink:label="lab_hcat_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_hcat_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_hcat_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContingentConsiderationMember" xlink:href="hcat-20210331.xsd#hcat_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_ContingentConsiderationMember" xlink:to="lab_hcat_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd4933df-ad4a-4393-af91-3973483ae9ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bcddc70b-f255-47d1-ba61-8730726c57fb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_CapitalizedOfInternalUseSoftware_c4747d48-48ae-44ad-9248-7de2178634c9_negatedTerseLabel_en-US" xlink:label="lab_hcat_CapitalizedOfInternalUseSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization of internal-use software</link:label>
    <link:label id="lab_hcat_CapitalizedOfInternalUseSoftware_label_en-US" xlink:label="lab_hcat_CapitalizedOfInternalUseSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Of Internal Use Software</link:label>
    <link:label id="lab_hcat_CapitalizedOfInternalUseSoftware_documentation_en-US" xlink:label="lab_hcat_CapitalizedOfInternalUseSoftware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Of Internal Use Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CapitalizedOfInternalUseSoftware" xlink:href="hcat-20210331.xsd#hcat_CapitalizedOfInternalUseSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_CapitalizedOfInternalUseSoftware" xlink:to="lab_hcat_CapitalizedOfInternalUseSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0b086aed-4ce7-4ad9-87bb-d876b20207be_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_11b84df0-3556-40c3-bd53-1938b5ec009d_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_d3c22f7f-bb46-4d93-b5a9-e75ad429e8ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis rate (in percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_0578347e-5e76-4f79-9409-0d6c95a2495a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c9b021af-7d4d-4463-8cca-444a9310c170_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_eb225edf-ac92-44fc-b097-cd9ff313833d_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provision for expected credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6cd8d938-b004-4bca-b555-210ef4cba3eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_30ee3ef0-cc79-4c03-bbfd-6beee5bd2bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled accounts receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a6b6271e-64d9-4d1a-a7c3-7765f5ba579c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option shares vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a5d80956-4593-4abc-be00-ba7cc7d1245c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2d896d18-2898-4696-9945-02b65deb4a15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_75abcb8b-654b-4904-b2fe-1b971d74bde4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c8c3512-eb1f-47fe-b335-fc2702269fdf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0667037a-c911-4a3f-8e5e-e5389c09c1ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_33aff122-e388-4b9f-9316-f2f11f4d8546_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DebtIssuanceCostGrossLiabilityComponent_46ac4e7a-1be4-4f56-9a0c-0de9830ecc8d_terseLabel_en-US" xlink:label="lab_hcat_DebtIssuanceCostGrossLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost gross liability component</link:label>
    <link:label id="lab_hcat_DebtIssuanceCostGrossLiabilityComponent_label_en-US" xlink:label="lab_hcat_DebtIssuanceCostGrossLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost Gross Liability Component</link:label>
    <link:label id="lab_hcat_DebtIssuanceCostGrossLiabilityComponent_documentation_en-US" xlink:label="lab_hcat_DebtIssuanceCostGrossLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost Gross Liability Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostGrossLiabilityComponent" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostGrossLiabilityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DebtIssuanceCostGrossLiabilityComponent" xlink:to="lab_hcat_DebtIssuanceCostGrossLiabilityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bb21d9b4-373a-4123-9d82-60d0321f0690_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d03e0737-323d-41e9-a2b5-1c1cac3b3c65_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f9d31b9f-6216-477a-84d6-6c999190fc9d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d90f943d-268d-4d3b-954b-757134700235_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f7d2a1a5-9d5b-47c0-af5b-a71feb13fba9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e049c26-1109-4c85-a42a-27acf5cabee2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_c36bbc75-f2cb-4eb1-9bc5-c8fc6c7e60df_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities_cfa0251c-176f-43d8-a3e3-ca8824906ba2_terseLabel_en-US" xlink:label="lab_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities, and other liabilities</link:label>
    <link:label id="lab_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities</link:label>
    <link:label id="lab_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities_documentation_en-US" xlink:label="lab_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_b04191c0-3ece-453f-84b9-1dc0fc8c99db_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_70ffb1c5-5be4-446a-8c85-51abdf22fc07_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_0a8376e2-06e4-4215-ad7d-9f8bed33884b_terseLabel_en-US" xlink:label="lab_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:label id="lab_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_documentation_en-US" xlink:label="lab_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:href="hcat-20210331.xsd#hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f9cbfa6b-3ca0-4156-a8f6-07a6a36c128f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_4d19b605-4265-4221-b5da-bcee48775f92_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue and Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares_142d30d6-e219-43de-998f-97c6265b3a3d_terseLabel_en-US" xlink:label="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for settlement of contingent consideration (in shares)</link:label>
    <link:label id="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares_label_en-US" xlink:label="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability, Shares</link:label>
    <link:label id="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares_documentation_en-US" xlink:label="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" xlink:href="hcat-20210331.xsd#hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" xlink:to="lab_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d49b2217-6a24-42a4-a257-b7659de8b49b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_be507ab5-708d-4ba4-9306-cd71990590a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1d3875c2-500b-43b9-90e6-c2668253d4be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e6473d21-2e18-4853-ab40-f072f5ada4b3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55e269a8-5b38-42d0-8a20-d741f08d6147_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3daf609-bc8a-42ac-bd23-36259bce764f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ba768eca-d06b-4f3c-aef3-fe755f959ffa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_124a2baa-a58e-4f01-a6f4-c5db4c42d838_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_693fe014-211b-4f80-887b-0618c1af21e7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_80186318-369a-4ce5-912e-4d1e4a9af3d4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_dda29191-7473-4ed4-838a-c9c4895c8801_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Summary</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_603247a4-fa8a-4615-830c-507b3c1d6d7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_9b1ae570-a23c-4b1e-8911-ff1a4af8dd7d_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_19a4136a-ee16-449a-a0b9-0546a0d710be_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_3ce1d2b1-9666-4ec4-9edb-f9481c0c384b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued in acquisition, at fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_833be6dd-98f3-42b7-981f-368f0c3cce32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest in year one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_906305a2-d6f7-4160-9dda-8bfdfe6791a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercised in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2ebaa168-0385-489a-828f-bb05dc11dab0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities measured on recurring basis, unobservable input reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_925b6e7c-8ea9-458c-bd3b-ffebe0346cde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_99e79059-0b03-4784-b355-c3896c6aab09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_21657399-d245-4fa6-ad82-645a1e9c54c6_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d45be387-66bf-4ef8-9e79-e76650c08803_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_fc066ab3-fb78-4759-90e9-a3c1d7874d23_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9768b592-aafd-45ec-9487-c233949b97fc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b9ebed09-0dc9-4288-88df-ee1e4664cc47_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0d3bea4a-c57e-41fc-8a69-4297e7a1ac64_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember_d17d6dcc-136e-4997-bb1f-dd3f3ef18d24_terseLabel_en-US" xlink:label="lab_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Shares Pursuant To Acquisition Agreement</link:label>
    <link:label id="lab_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember_label_en-US" xlink:label="lab_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Shares Pursuant To Acquisition Agreement [Member]</link:label>
    <link:label id="lab_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember_documentation_en-US" xlink:label="lab_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Shares Pursuant To Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember" xlink:href="hcat-20210331.xsd#hcat_RestrictedSharesPursuantToAcquisitionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember" xlink:to="lab_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2cdd57fa-5084-4d64-874f-68216b21696a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93a7f364-d588-4953-a772-09d437ba0a2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_4612dbba-1fb2-40d0-bbc3-79fc4778a051_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pro forma revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d6e928d9-4c23-4024-8778-a517e2bd2b1a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7d9f83e2-e158-4521-8cef-a49164170c56_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ebbdbafb-ecff-4fd4-b891-201d12f509a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCapPrice_fc71e91e-4a83-4daf-9731-e3fbb4b12b58_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCapPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DerivativeCapPrice_label_en-US" xlink:label="lab_us-gaap_DerivativeCapPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Cap Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapPrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCapPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCapPrice" xlink:to="lab_us-gaap_DerivativeCapPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_be6ebe7d-9bbf-4930-9d16-33b67eac6372_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ff8fa37e-1d09-41b6-840d-ea4b86d5e493_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e25afcfc-49c0-408e-8d21-d8b9c1b49377_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d03d3b65-f9c3-4931-bb8a-8c9f35b908e6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ca368ce8-f597-451f-8b90-eadbce26f91d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_9b1eb3e6-1db9-4277-9ce0-7cfd468a33c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2a134db5-d239-4350-9eb4-21baff4c35f8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9346e215-f2a0-4df1-90f5-21e44f579e6e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_362d9872-c22d-45a5-acff-d9ca4daf02a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9eca5591-9bae-4dca-9b9b-13d99292537a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option shares outstanding, weighted average remaining contractual life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6627494d-22f1-405d-842f-d212b7ff2e67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_a571cef9-5abd-443d-970b-991330766dd6_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_b1d94934-6e74-4806-ab78-c1c0393ddd63_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0909f3b-cc26-4c03-83ca-a84b92f2b0d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7bc66575-fb49-4305-a235-70abb89c8c7d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_8e92e3da-30d0-4b76-9ffe-8965e758d0db_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62e567d3-98e3-41d5-8f81-24814c5bc5d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c9f69f53-ba3b-4d3f-890a-7b44accd99c4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_88e30cda-3726-41c4-8f62-5f9bed9b6b42_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_4ae6ac04-8c80-4bfc-907b-2ae8ce13d0a5_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_53c60159-2723-448d-8fd6-535d538c6908_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractTerm_66d01baf-d874-47e5-85e2-e3055177ce5b_terseLabel_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service contract term</link:label>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractTerm_label_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement For Service Contract, Term</link:label>
    <link:label id="lab_hcat_DeferredRevenueArrangementForServiceContractTerm_documentation_en-US" xlink:label="lab_hcat_DeferredRevenueArrangementForServiceContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement For Service Contract, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractTerm" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hcat_DeferredRevenueArrangementForServiceContractTerm" xlink:to="lab_hcat_DeferredRevenueArrangementForServiceContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4d2e2ffc-727d-41bc-8b1e-e430c30556f8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_db86547a-8c1b-455e-a7c8-b985f7391701_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d31e4cda-7790-49b1-90f8-9bba347191a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_717bbc95-1815-4bd5-9e03-3be007eef5d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5e490d54-6b17-4137-bbee-a8aa98e9a0ff_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c67dd2c7-fc15-4a16-b6c3-4f8a333a6fb8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting pronouncements adopted and recent accounting pronouncements not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_0b1c2843-6459-4b6f-9f3c-f4c68e819a4b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9a61af0c-24e9-45ca-9bc4-663efe61a305_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_b985f6e7-b91d-4ad0-b522-0cd35ea52d3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>hcat-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ac4f3b8b-712a-43a6-9f81-b9cf5889a679,g:b64543c5-cb81-4282-9510-d3dfb10c5ee8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CoverPage" xlink:type="simple" xlink:href="hcat-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_eff8d7f1-1a23-4b6b-95f2-3cf1e4eedd4a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_DocumentType_eff8d7f1-1a23-4b6b-95f2-3cf1e4eedd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_af77ca2e-e35e-4728-9078-125272877ff9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_DocumentQuarterlyReport_af77ca2e-e35e-4728-9078-125272877ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_41dd4860-dca8-4ee7-90a9-be46694cdd7f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_DocumentPeriodEndDate_41dd4860-dca8-4ee7-90a9-be46694cdd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bcd23739-725a-4209-a73e-a168806ffb5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_DocumentTransitionReport_bcd23739-725a-4209-a73e-a168806ffb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c681e0d-5ab9-4e9b-87b7-bceecbaa959b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityFileNumber_4c681e0d-5ab9-4e9b-87b7-bceecbaa959b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5390f1ad-7f24-465a-a814-a408c07e16df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityRegistrantName_5390f1ad-7f24-465a-a814-a408c07e16df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bdb6f9ef-907c-4c20-9d18-65217fcc36fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bdb6f9ef-907c-4c20-9d18-65217fcc36fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_10b2febf-a6f6-4e0a-b97e-b034ef7d6821" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityTaxIdentificationNumber_10b2febf-a6f6-4e0a-b97e-b034ef7d6821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f3c89783-28a4-4453-b22e-ab2dbe1077d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityAddressAddressLine1_f3c89783-28a4-4453-b22e-ab2dbe1077d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b97d3d2b-cca4-41cd-8744-09987250a08e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityAddressCityOrTown_b97d3d2b-cca4-41cd-8744-09987250a08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f8d8e070-0dba-4bce-9372-fbe8131f7669" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityAddressStateOrProvince_f8d8e070-0dba-4bce-9372-fbe8131f7669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fd4efb2e-2054-48c7-a444-a9e716507a7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityAddressPostalZipCode_fd4efb2e-2054-48c7-a444-a9e716507a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a1d53fac-da19-434c-8e5c-5085f991d5ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_CityAreaCode_a1d53fac-da19-434c-8e5c-5085f991d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5b5e5fe6-08cb-4dbd-af96-1f0f78093b7f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_LocalPhoneNumber_5b5e5fe6-08cb-4dbd-af96-1f0f78093b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ce71558e-f0d7-4a13-a13f-d7225d1ed2cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_Security12bTitle_ce71558e-f0d7-4a13-a13f-d7225d1ed2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e785fae5-d1ff-496b-9f93-7145084ac667" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_TradingSymbol_e785fae5-d1ff-496b-9f93-7145084ac667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_66320032-52c6-477d-9df7-42f5a8b23944" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_SecurityExchangeName_66320032-52c6-477d-9df7-42f5a8b23944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bc92ed06-fefc-4a52-adaf-abf4fb32693a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityCurrentReportingStatus_bc92ed06-fefc-4a52-adaf-abf4fb32693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_35400950-aa09-4af3-bed3-1bfaf7659653" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityInteractiveDataCurrent_35400950-aa09-4af3-bed3-1bfaf7659653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d8710aae-e1c5-4e7b-8662-f62f81a6d3ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityFilerCategory_d8710aae-e1c5-4e7b-8662-f62f81a6d3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3114f786-1137-4235-a174-bc486d7d8664" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityEmergingGrowthCompany_3114f786-1137-4235-a174-bc486d7d8664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_606051ff-a295-487d-bd9e-9dcfafdf10fb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntitySmallBusiness_606051ff-a295-487d-bd9e-9dcfafdf10fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fe324812-7513-4bef-96de-796da03d493b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityShellCompany_fe324812-7513-4bef-96de-796da03d493b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_522b89d7-ba8a-403b-9396-aae26cfab28d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_522b89d7-ba8a-403b-9396-aae26cfab28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_19092ab4-c222-4725-a841-ed88a672e256" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_EntityCentralIndexKey_19092ab4-c222-4725-a841-ed88a672e256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_31297724-a27f-4d43-8835-9034ff4e86e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_CurrentFiscalYearEndDate_31297724-a27f-4d43-8835-9034ff4e86e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4b4b778e-aafa-401c-ae7a-950ffaddaa68" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_DocumentFiscalYearFocus_4b4b778e-aafa-401c-ae7a-950ffaddaa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b0eb0111-bc7f-46f0-988f-2cb748d3b508" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b0eb0111-bc7f-46f0-988f-2cb748d3b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2eda63c1-4444-42b4-8f96-bd80a0934780" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11f782a6-b558-458a-a886-05479a9b722c" xlink:to="loc_dei_AmendmentFlag_2eda63c1-4444-42b4-8f96-bd80a0934780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1afb1f74-bee4-4caa-8446-de787dd8e583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1afb1f74-bee4-4caa-8446-de787dd8e583" xlink:to="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bbfdd4a6-011d-4ffe-a3ff-61344919a2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bbfdd4a6-011d-4ffe-a3ff-61344919a2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d84808d8-cd14-43e9-a0c5-2cd7ecbeea14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bbfdd4a6-011d-4ffe-a3ff-61344919a2be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d84808d8-cd14-43e9-a0c5-2cd7ecbeea14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_528611b6-3966-4703-988a-f7dab4083dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bbfdd4a6-011d-4ffe-a3ff-61344919a2be" xlink:to="loc_us-gaap_ShortTermInvestments_528611b6-3966-4703-988a-f7dab4083dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e84a2cfa-1abc-4453-a03a-65e9da9e1d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bbfdd4a6-011d-4ffe-a3ff-61344919a2be" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e84a2cfa-1abc-4453-a03a-65e9da9e1d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_183bbb41-b157-4b94-ac5e-43cdaadaf0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bbfdd4a6-011d-4ffe-a3ff-61344919a2be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_183bbb41-b157-4b94-ac5e-43cdaadaf0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9af16ce-3fd0-4c3e-85f8-aeb9854d5348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bbfdd4a6-011d-4ffe-a3ff-61344919a2be" xlink:to="loc_us-gaap_AssetsCurrent_e9af16ce-3fd0-4c3e-85f8-aeb9854d5348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_930a7fac-09f6-4269-9dfc-8947aa76a80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_930a7fac-09f6-4269-9dfc-8947aa76a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7b7dfda7-2fce-4aa5-93c1-a024ed4b403c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7b7dfda7-2fce-4aa5-93c1-a024ed4b403c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_243d08c7-cf27-47c2-aecc-22950c1a5e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_243d08c7-cf27-47c2-aecc-22950c1a5e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_45964afa-324d-4029-b2da-47f4585bca1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:to="loc_us-gaap_Goodwill_45964afa-324d-4029-b2da-47f4585bca1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bf58b7b5-1122-4b27-8a27-2a186c71e85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bf58b7b5-1122-4b27-8a27-2a186c71e85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_aa97b2f7-9202-410c-8bc4-1c1c72325d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bdba06f-e14c-42b8-a7f8-18f61224d53b" xlink:to="loc_us-gaap_Assets_aa97b2f7-9202-410c-8bc4-1c1c72325d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1afb1f74-bee4-4caa-8446-de787dd8e583" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c1005146-660d-464a-9f59-ec555433e496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_us-gaap_AccountsPayableCurrent_c1005146-660d-464a-9f59-ec555433e496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_0b030c97-5eea-4803-973b-9fab96c46196" xlink:href="hcat-20210331.xsd#hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_0b030c97-5eea-4803-973b-9fab96c46196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7d7432d6-eb2b-44fb-a34c-02f687e96b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7d7432d6-eb2b-44fb-a34c-02f687e96b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_616ee1a0-9ef9-4e74-b29a-9ee9a73f9029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_616ee1a0-9ef9-4e74-b29a-9ee9a73f9029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_596e033f-391d-4b19-a896-12a7e890e211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_596e033f-391d-4b19-a896-12a7e890e211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationPayableCurrent_0f1f2aa3-b6af-4c12-a55f-3fae0f7c03c9" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_hcat_BusinessCombinationConsiderationPayableCurrent_0f1f2aa3-b6af-4c12-a55f-3fae0f7c03c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_9a3488e5-9b08-49aa-886a-ccb31ef96e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_us-gaap_SeniorNotes_9a3488e5-9b08-49aa-886a-ccb31ef96e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c9cb0929-6f97-4d46-85d5-b621bf1a1f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9bcca18f-a85b-4614-979a-ec86bc091a43" xlink:to="loc_us-gaap_LiabilitiesCurrent_c9cb0929-6f97-4d46-85d5-b621bf1a1f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a2567d24-d588-4e57-bd36-e488b83840d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a2567d24-d588-4e57-bd36-e488b83840d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ead84977-ccb1-406a-9350-b07bc3a1f64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ead84977-ccb1-406a-9350-b07bc3a1f64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f8248a2-033e-4c01-b159-819d24f5f778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f8248a2-033e-4c01-b159-819d24f5f778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a31a3db2-a15c-4c2f-aa4b-99cf98186ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a31a3db2-a15c-4c2f-aa4b-99cf98186ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a2ff181c-de9d-4d49-bedc-c0a382d7bd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a2ff181c-de9d-4d49-bedc-c0a382d7bd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a7e92040-15d0-47ab-943b-00d5fd60c6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_Liabilities_a7e92040-15d0-47ab-943b-00d5fd60c6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_95e16b55-471c-4c54-814d-130b67874eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_95e16b55-471c-4c54-814d-130b67874eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_facf67b8-d491-40da-b4f0-a7ff34e5e42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:to="loc_us-gaap_PreferredStockValue_facf67b8-d491-40da-b4f0-a7ff34e5e42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9edb2dc2-9af4-4a8c-8fc9-22e46842089a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:to="loc_us-gaap_CommonStockValue_9edb2dc2-9af4-4a8c-8fc9-22e46842089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4624a213-cd64-4fe6-98ca-4225ab7ae18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4624a213-cd64-4fe6-98ca-4225ab7ae18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_17691681-e0e4-4b48-ad85-433520400fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_17691681-e0e4-4b48-ad85-433520400fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_be26296d-835f-486b-b70c-6e10158a8298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_be26296d-835f-486b-b70c-6e10158a8298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36d8524e-3af4-49ee-bacc-abbdbd9d9579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_91ce4d4d-7b88-4b2e-b229-05bdb077c3cd" xlink:to="loc_us-gaap_StockholdersEquity_36d8524e-3af4-49ee-bacc-abbdbd9d9579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58ea1672-ccab-4336-8ba6-24861bb1ccf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b31f02e-e19c-4ad4-acd7-f14291ed71d2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_58ea1672-ccab-4336-8ba6-24861bb1ccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_237c0831-7a65-44bc-b03e-b2670c23a9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_237c0831-7a65-44bc-b03e-b2670c23a9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4bb1af30-ded8-4453-adeb-21316732a7ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4bb1af30-ded8-4453-adeb-21316732a7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f9131461-9e5d-4698-bfc4-e08141d4c7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f9131461-9e5d-4698-bfc4-e08141d4c7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_de885dd6-0cbd-4aae-ac7e-4677253427e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_de885dd6-0cbd-4aae-ac7e-4677253427e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0549fadc-31cc-4e19-a0b1-3a8ce9c313d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0549fadc-31cc-4e19-a0b1-3a8ce9c313d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dad78f82-a475-43b6-bb27-919e29193011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dad78f82-a475-43b6-bb27-919e29193011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d1fc3eb3-030c-40c7-ad31-c7eb7d0dcb24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_CommonStockSharesIssued_d1fc3eb3-030c-40c7-ad31-c7eb7d0dcb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2e372f0b-70b3-4d2b-9941-2809e1ddcf2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abfec1fb-b1bf-4a42-b7ae-0cbdd6de60bc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2e372f0b-70b3-4d2b-9941-2809e1ddcf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ad1dd1c5-f24d-45be-ba8d-26e3d4d84095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b10ab96-8144-4de7-ad2d-d92996fd1bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad1dd1c5-f24d-45be-ba8d-26e3d4d84095" xlink:to="loc_us-gaap_StatementTable_8b10ab96-8144-4de7-ad2d-d92996fd1bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe517421-9295-4e5e-bb76-0e7cd94ed911" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b10ab96-8144-4de7-ad2d-d92996fd1bc4" xlink:to="loc_srt_ProductOrServiceAxis_fe517421-9295-4e5e-bb76-0e7cd94ed911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe517421-9295-4e5e-bb76-0e7cd94ed911" xlink:to="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_42e73dc8-3127-45a5-a488-7ca517eed4f9" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:to="loc_hcat_TechnologyMember_42e73dc8-3127-45a5-a488-7ca517eed4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_581b29d0-a29f-4efd-a2b5-fb618344d78d" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_457d7901-ce31-4cb0-82ee-dffbdac9eea6" xlink:to="loc_hcat_ProfessionalServicesMember_581b29d0-a29f-4efd-a2b5-fb618344d78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b10ab96-8144-4de7-ad2d-d92996fd1bc4" xlink:to="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d5d80884-b22f-4909-b0e6-972f26ddb791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_RevenuesAbstract_d5d80884-b22f-4909-b0e6-972f26ddb791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_992b830c-f3dd-4264-97de-2c97cb9a8c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d5d80884-b22f-4909-b0e6-972f26ddb791" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_992b830c-f3dd-4264-97de-2c97cb9a8c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_e86101ca-1e8b-44f1-901c-b551c2c406c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_CostOfRevenueAbstract_e86101ca-1e8b-44f1-901c-b551c2c406c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_8607c377-74c3-4ee3-8c62-fc1c2802d990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e86101ca-1e8b-44f1-901c-b551c2c406c9" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_8607c377-74c3-4ee3-8c62-fc1c2802d990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6d4a61f7-0b58-4b52-a72d-05a33471bd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6d4a61f7-0b58-4b52-a72d-05a33471bd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_47798463-d2ec-40c3-9ce9-8b5a06acfc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_47798463-d2ec-40c3-9ce9-8b5a06acfc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d83006d3-ff94-48e5-ba60-1cd71e74fc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d83006d3-ff94-48e5-ba60-1cd71e74fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5b9d393b-2eea-4331-b902-98d907bd6398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_DepreciationAndAmortization_5b9d393b-2eea-4331-b902-98d907bd6398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fb7fcb9d-1786-433c-952d-f8f403b658f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27a2d5e9-662f-4b4b-a626-07846ccb9986" xlink:to="loc_us-gaap_OperatingExpenses_fb7fcb9d-1786-433c-952d-f8f403b658f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4b5c04a9-6361-484a-9b29-de578f7d7c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_OperatingIncomeLoss_4b5c04a9-6361-484a-9b29-de578f7d7c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_InterestAndOtherExpenseNet_56bdde73-08e7-4756-94cc-f9aa0916958c" xlink:href="hcat-20210331.xsd#hcat_InterestAndOtherExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_hcat_InterestAndOtherExpenseNet_56bdde73-08e7-4756-94cc-f9aa0916958c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_265dc167-47ce-4180-ab7d-098b9685e632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_265dc167-47ce-4180-ab7d-098b9685e632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6668dd24-9498-45a0-b27e-5337253a22a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6668dd24-9498-45a0-b27e-5337253a22a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2f6e770-1e38-4696-9805-2fc81497df12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_NetIncomeLoss_b2f6e770-1e38-4696-9805-2fc81497df12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e9e3699a-4be1-48b4-816a-d65469b772bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_EarningsPerShareBasic_e9e3699a-4be1-48b4-816a-d65469b772bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f4732beb-115e-45f2-be21-49bfee20fecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f4732beb-115e-45f2-be21-49bfee20fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7388f06-166c-4a73-add3-55adb94df44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7388f06-166c-4a73-add3-55adb94df44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bfe0d22e-0d19-4e73-a511-640f4b55d77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a1e0375-901a-4fc7-85e0-a4b3e7950504" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bfe0d22e-0d19-4e73-a511-640f4b55d77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f2fa560-04da-4ab1-b1c9-e0b37ddea7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_40d2d224-e259-4468-8304-3a6bdd79bc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f2fa560-04da-4ab1-b1c9-e0b37ddea7b0" xlink:to="loc_us-gaap_NetIncomeLoss_40d2d224-e259-4468-8304-3a6bdd79bc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_167d7648-bf04-43ac-b271-cb8cecd56aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f2fa560-04da-4ab1-b1c9-e0b37ddea7b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_167d7648-bf04-43ac-b271-cb8cecd56aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8fe274bc-96d1-4fa3-b1a6-1c1df3389efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_167d7648-bf04-43ac-b271-cb8cecd56aa6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8fe274bc-96d1-4fa3-b1a6-1c1df3389efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d2a828b5-3360-4272-bfd2-70ea7fbfb570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_167d7648-bf04-43ac-b271-cb8cecd56aa6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d2a828b5-3360-4272-bfd2-70ea7fbfb570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4dc13248-c5c1-4d6b-8731-38a2c5a09964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f2fa560-04da-4ab1-b1c9-e0b37ddea7b0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4dc13248-c5c1-4d6b-8731-38a2c5a09964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c94462b9-b96a-4f0e-a6cc-51f3ab907943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c94462b9-b96a-4f0e-a6cc-51f3ab907943" xlink:to="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4d79fe61-da14-493f-a9cf-9f6b186335a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4d79fe61-da14-493f-a9cf-9f6b186335a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4d79fe61-da14-493f-a9cf-9f6b186335a8" xlink:to="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f882c7af-64cd-4c31-a3ac-1da596e11471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_CommonStockMember_f882c7af-64cd-4c31-a3ac-1da596e11471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d0c74342-23a4-463d-9a67-892f97615ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d0c74342-23a4-463d-9a67-892f97615ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8fbec919-48f0-4138-bf1e-2aea9c1b5ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_RetainedEarningsMember_8fbec919-48f0-4138-bf1e-2aea9c1b5ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_185b353f-86a7-4982-8feb-9f4dce99dc84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d787d755-7b89-4d81-80ad-7cb891cfaa6d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_185b353f-86a7-4982-8feb-9f4dce99dc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_796f5fa7-55cc-40f9-88c5-b36d2060edb9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_796f5fa7-55cc-40f9-88c5-b36d2060edb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a7d000d3-5026-40ea-9306-e961853a5118" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_796f5fa7-55cc-40f9-88c5-b36d2060edb9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a7d000d3-5026-40ea-9306-e961853a5118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_13fb59c1-54ba-411b-99dd-e673163d61f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a7d000d3-5026-40ea-9306-e961853a5118" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_13fb59c1-54ba-411b-99dd-e673163d61f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4470a355-1800-46f6-abfa-76315fa715ea" xlink:to="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_20fb0dd3-f54f-4282-9640-9579f39335f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_20fb0dd3-f54f-4282-9640-9579f39335f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6455980b-0a28-45d8-8c6a-cb293de09afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6455980b-0a28-45d8-8c6a-cb293de09afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_87d639ad-ca42-407c-b973-c006816aca7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_87d639ad-ca42-407c-b973-c006816aca7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_706053dd-be5b-44af-abcf-c260d54f2877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_706053dd-be5b-44af-abcf-c260d54f2877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3b6b64c9-89b2-4a20-8308-678c89da8ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b6a897e8-69d2-4155-a4ff-9b622468a83e" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3b6b64c9-89b2-4a20-8308-678c89da8ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cfd85be-ca2b-4f78-9911-7615503931e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cf9e44c2-819e-42f8-925e-a728dd9137bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_SharesOutstanding_cf9e44c2-819e-42f8-925e-a728dd9137bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14df82a0-ea1e-4b2b-956d-9bf69ea45a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockholdersEquity_14df82a0-ea1e-4b2b-956d-9bf69ea45a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_528305af-7bc6-4791-8d3a-ca55f5420db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_528305af-7bc6-4791-8d3a-ca55f5420db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa580747-4770-47ac-b5ad-3196b1fb5f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa580747-4770-47ac-b5ad-3196b1fb5f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_044c3bfa-d3a2-4d18-8855-06aa6600d4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_044c3bfa-d3a2-4d18-8855-06aa6600d4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07249f0-fb72-43b9-92b9-2b21ae114756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07249f0-fb72-43b9-92b9-2b21ae114756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares_b4137a0c-bb4d-4cb7-ad22-c1c8875c7f30" xlink:href="hcat-20210331.xsd#hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares_b4137a0c-bb4d-4cb7-ad22-c1c8875c7f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_392fcfa9-7043-4dfa-923c-8a3e8ba3516d" xlink:href="hcat-20210331.xsd#hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_392fcfa9-7043-4dfa-923c-8a3e8ba3516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b16f2c5d-d366-40f0-8ba8-5954c1c75611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b16f2c5d-d366-40f0-8ba8-5954c1c75611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_93f0991e-a5e7-47ee-aa69-4b46cda72689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_93f0991e-a5e7-47ee-aa69-4b46cda72689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_248c9f89-6079-4743-8a28-f9821e9dc82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_NetIncomeLoss_248c9f89-6079-4743-8a28-f9821e9dc82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_443ccd0a-eeb6-4747-b097-c9e9f7f03956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_443ccd0a-eeb6-4747-b097-c9e9f7f03956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4d740d75-9f34-4f65-9717-082664a7756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_SharesOutstanding_4d740d75-9f34-4f65-9717-082664a7756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d05db12-46f6-4191-a602-7e18f0707383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c91bbbde-ea9d-44f4-8c64-b3e4b255d18f" xlink:to="loc_us-gaap_StockholdersEquity_1d05db12-46f6-4191-a602-7e18f0707383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="hcat-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d70d3620-c646-42ad-8d92-b2bb2820efa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d70d3620-c646-42ad-8d92-b2bb2820efa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_09581826-c3b4-4ddb-bb9a-0b9cebe49700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d70d3620-c646-42ad-8d92-b2bb2820efa6" xlink:to="loc_us-gaap_NetIncomeLoss_09581826-c3b4-4ddb-bb9a-0b9cebe49700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d70d3620-c646-42ad-8d92-b2bb2820efa6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e5392881-32d5-488e-ab8f-73eefa3feb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_DepreciationAndAmortization_e5392881-32d5-488e-ab8f-73eefa3feb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d4211121-e0f5-4785-ac9b-54b15f73ebe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d4211121-e0f5-4785-ac9b-54b15f73ebe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_12ec1b85-7026-4d49-bbe9-fc3ee03fdfe9" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_12ec1b85-7026-4d49-bbe9-fc3ee03fdfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9b21a12e-1824-451e-a1dd-92a75ab40a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9b21a12e-1824-451e-a1dd-92a75ab40a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_ee47cbc4-32f1-41bf-97fd-ee36b7cee08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_ee47cbc4-32f1-41bf-97fd-ee36b7cee08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2285bb13-3115-4e16-bbc3-610e40a5e25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_ShareBasedCompensation_2285bb13-3115-4e16-bbc3-610e40a5e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aad23f4c-7419-4102-aebc-82d98790cbe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aad23f4c-7419-4102-aebc-82d98790cbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_83e9dc69-f765-4e96-bb31-036507ece29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_83e9dc69-f765-4e96-bb31-036507ece29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_534211dd-f419-4463-a97a-1bc6d394f3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_534211dd-f419-4463-a97a-1bc6d394f3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_37065784-ab1a-49f7-90be-cb05c3ea77bd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b21eda3b-24fb-441b-9dbb-198e8df83241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b21eda3b-24fb-441b-9dbb-198e8df83241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_86e191ef-455e-46fd-848e-6214f84dca01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_86e191ef-455e-46fd-848e-6214f84dca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c9ab4211-7a73-4cc9-b2ac-c282c3fa660f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c9ab4211-7a73-4cc9-b2ac-c282c3fa660f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities_a0cb7d30-26c2-46c0-b134-1c1ddaf61f2c" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:to="loc_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities_a0cb7d30-26c2-46c0-b134-1c1ddaf61f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f6428c32-36a9-4ef8-9f2c-2f5d8f2f675b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f6428c32-36a9-4ef8-9f2c-2f5d8f2f675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_IncreaseDecreaseInOperatingLeaseLiabilities_5552a24f-a138-4aac-a787-58ec94d0ce20" xlink:href="hcat-20210331.xsd#hcat_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6cf54b10-408d-4e66-8c36-0a81ddcf253c" xlink:to="loc_hcat_IncreaseDecreaseInOperatingLeaseLiabilities_5552a24f-a138-4aac-a787-58ec94d0ce20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_297e1a8b-c65a-45a1-abb6-16f6caf9287d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d70d3620-c646-42ad-8d92-b2bb2820efa6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_297e1a8b-c65a-45a1-abb6-16f6caf9287d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_96f17277-dece-4562-a934-002ae9c0cacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_96f17277-dece-4562-a934-002ae9c0cacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CapitalizedOfInternalUseSoftware_75b18a53-0752-4938-9914-639d636719fe" xlink:href="hcat-20210331.xsd#hcat_CapitalizedOfInternalUseSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_hcat_CapitalizedOfInternalUseSoftware_75b18a53-0752-4938-9914-639d636719fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d16efdf5-d6cf-4443-b39c-77e8a54aae7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d16efdf5-d6cf-4443-b39c-77e8a54aae7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_77ec8924-1f47-4f7f-ba5b-e469b46fc076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_77ec8924-1f47-4f7f-ba5b-e469b46fc076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_fabb1ff3-9f00-4aa4-b69b-ee4f08425561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_fabb1ff3-9f00-4aa4-b69b-ee4f08425561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88fd43c0-d5f7-448f-9dd0-dfe1e28e298e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88fd43c0-d5f7-448f-9dd0-dfe1e28e298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_57720c4d-d336-49d1-a35a-762e7c5c88af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_57720c4d-d336-49d1-a35a-762e7c5c88af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72ab81d4-acf8-4993-8ac4-0863ea8010dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_900d0926-c36e-41e4-962e-0a2e19237899" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72ab81d4-acf8-4993-8ac4-0863ea8010dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abc1a769-9005-41d9-8477-922c79a20880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abc1a769-9005-41d9-8477-922c79a20880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a1da088c-a09e-4845-9793-cf7395ea64f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abc1a769-9005-41d9-8477-922c79a20880" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a1da088c-a09e-4845-9793-cf7395ea64f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_cec737d8-d843-418c-9380-20bfaf8363f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abc1a769-9005-41d9-8477-922c79a20880" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_cec737d8-d843-418c-9380-20bfaf8363f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_06f59e10-8c9f-4309-8035-c44087c721c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abc1a769-9005-41d9-8477-922c79a20880" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_06f59e10-8c9f-4309-8035-c44087c721c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9cc96e45-47d8-413b-9251-4264a0d594d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abc1a769-9005-41d9-8477-922c79a20880" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9cc96e45-47d8-413b-9251-4264a0d594d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd1971a-60ab-426d-aa39-7a956935ea50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd1971a-60ab-426d-aa39-7a956935ea50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c2dae0c-9fd3-4c7a-b049-1564af8a2bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c2dae0c-9fd3-4c7a-b049-1564af8a2bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34cda922-a795-4605-927e-14238dee0463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34cda922-a795-4605-927e-14238dee0463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d933ce4-2223-4399-a74a-d75b0328fd5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d933ce4-2223-4399-a74a-d75b0328fd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ae89a6b-89cc-4a89-9c8c-72dc69f8486f" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aca7f6bc-3403-4329-8801-01b5e38a3276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aca7f6bc-3403-4329-8801-01b5e38a3276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_e23dda9e-7489-45e3-bcd5-49b5e0468f6c" xlink:href="hcat-20210331.xsd#hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:to="loc_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability_e23dda9e-7489-45e3-bcd5-49b5e0468f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ce119ded-2c6c-4c23-b5f2-bed1a2be586f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ce119ded-2c6c-4c23-b5f2-bed1a2be586f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_0df584c5-d082-473a-b359-5254f00bf03c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_0df584c5-d082-473a-b359-5254f00bf03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_0bf7b775-0b54-4a74-b138-9524727a646c" xlink:href="hcat-20210331.xsd#hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:to="loc_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_0bf7b775-0b54-4a74-b138-9524727a646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_25715826-5c2a-43ae-9334-8afb9497dc16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4619589f-914d-4272-b350-51c157f348b9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_25715826-5c2a-43ae-9334-8afb9497dc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8cc28df2-1466-4fcf-8cf3-89469385274b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_bb2bcac9-780a-42f8-8f94-349a7984c800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cc28df2-1466-4fcf-8cf3-89469385274b" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_bb2bcac9-780a-42f8-8f94-349a7984c800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6340d9ad-af6b-4722-a4da-f6656da17d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6340d9ad-af6b-4722-a4da-f6656da17d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f784b8bb-f02d-4aa3-a724-839895079923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f784b8bb-f02d-4aa3-a724-839895079923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d24e1b3b-a296-4b08-8303-2a3b97c5b828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d24e1b3b-a296-4b08-8303-2a3b97c5b828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_da461db7-7c6a-4d6e-80a9-a35112a015df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_UseOfEstimates_da461db7-7c6a-4d6e-80a9-a35112a015df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_fea8a564-1870-43b4-b8cf-18900cfa2532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_fea8a564-1870-43b4-b8cf-18900cfa2532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_80e52c7e-da5e-4cdf-ab6f-5be2dbb2ac26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_80e52c7e-da5e-4cdf-ab6f-5be2dbb2ac26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_eb3cc265-22ba-4190-8ef4-c1e3b98ca55e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_eb3cc265-22ba-4190-8ef4-c1e3b98ca55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3cb90682-24d5-452f-b669-116ecc745ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3cb90682-24d5-452f-b669-116ecc745ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_381e7d6d-fb5a-4a1b-9070-4d488a2b4a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_381e7d6d-fb5a-4a1b-9070-4d488a2b4a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9728bb58-f0c2-470a-9ebe-991852f4c892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9728bb58-f0c2-470a-9ebe-991852f4c892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5568db2c-d80c-4306-8ca2-bcf9884fbcb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5568db2c-d80c-4306-8ca2-bcf9884fbcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_206d73dd-7df4-4ca4-9ea6-b444245da234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_206d73dd-7df4-4ca4-9ea6-b444245da234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_bc71881d-adb5-4126-9b8f-dcd47753bd02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_bc71881d-adb5-4126-9b8f-dcd47753bd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_8956c523-a00a-4fe6-ab26-e660d8a6a116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_8956c523-a00a-4fe6-ab26-e660d8a6a116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_9f70e28f-e614-494d-9d32-e498c0d01938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_9f70e28f-e614-494d-9d32-e498c0d01938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_db511c99-1bc5-483f-ac5b-964ecb938c73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_db511c99-1bc5-483f-ac5b-964ecb938c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a8df387f-e2b8-4d27-9c9e-9224ee99b81b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a8df387f-e2b8-4d27-9c9e-9224ee99b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c8f0db26-9b6e-4aa2-b389-2256dc812a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c8f0db26-9b6e-4aa2-b389-2256dc812a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_539a7078-e4c9-4b9a-b239-1995a1125f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_539a7078-e4c9-4b9a-b239-1995a1125f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_430044f9-4c6c-4fea-be25-33ad4b2b0891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_430044f9-4c6c-4fea-be25-33ad4b2b0891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d8388a75-0906-4fca-a7e2-5a0458cba153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adcac87-7857-4629-acbd-cbe457a55a7c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d8388a75-0906-4fca-a7e2-5a0458cba153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0f9b39e0-43c7-41ac-8a81-695269d75866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_19df1b5a-b839-4131-a3ad-f2c056b6e5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f9b39e0-43c7-41ac-8a81-695269d75866" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_19df1b5a-b839-4131-a3ad-f2c056b6e5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0e571faa-e9a1-4179-84a0-a56a5ed39cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f9b39e0-43c7-41ac-8a81-695269d75866" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0e571faa-e9a1-4179-84a0-a56a5ed39cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c1975606-2e01-465b-9280-390797a33adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f9b39e0-43c7-41ac-8a81-695269d75866" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c1975606-2e01-465b-9280-390797a33adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e4fb8481-7c8f-4515-a7dd-b387793b7b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e4fb8481-7c8f-4515-a7dd-b387793b7b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5ffb5104-6345-473b-811e-e2154ee98b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_NumberOfReportableSegments_5ffb5104-6345-473b-811e-e2154ee98b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RevenueFromSubscriptionContractTermofContract_14e4d3be-54ba-46c6-999b-6b9a2228a915" xlink:href="hcat-20210331.xsd#hcat_RevenueFromSubscriptionContractTermofContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_hcat_RevenueFromSubscriptionContractTermofContract_14e4d3be-54ba-46c6-999b-6b9a2228a915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod_628e8661-edeb-4187-b133-cc8a1d5dbf41" xlink:href="hcat-20210331.xsd#hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod_628e8661-edeb-4187-b133-cc8a1d5dbf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination_1d75f265-d309-4ba3-b8bd-70c668d8b68f" xlink:href="hcat-20210331.xsd#hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination_1d75f265-d309-4ba3-b8bd-70c668d8b68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0b679626-e78e-4b25-b68a-9f2e6d0a5e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0b679626-e78e-4b25-b68a-9f2e6d0a5e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cdd8e0c6-181e-43d5-87db-0ef3049ec7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cdd8e0c6-181e-43d5-87db-0ef3049ec7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_90627f7e-9e66-49e2-aa41-eabd78314d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_90627f7e-9e66-49e2-aa41-eabd78314d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_9dfbb631-c813-49b9-b655-d7b36c962fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_9dfbb631-c813-49b9-b655-d7b36c962fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_90083b86-5be9-4235-a315-e94905035d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_90083b86-5be9-4235-a315-e94905035d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CommissionPaymentEstimatedBenefitPeriod_ef33902c-e558-49d8-ac51-06d2940a0382" xlink:href="hcat-20210331.xsd#hcat_CommissionPaymentEstimatedBenefitPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_hcat_CommissionPaymentEstimatedBenefitPeriod_ef33902c-e558-49d8-ac51-06d2940a0382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_18ec40b7-5b3f-44e7-a96d-e62084ec2418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_CapitalizedContractCostNet_18ec40b7-5b3f-44e7-a96d-e62084ec2418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2d48b36d-e2de-4abb-9b06-70034d345e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2d48b36d-e2de-4abb-9b06-70034d345e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6c94c52a-565b-48d3-8815-cd913bb90ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6c94c52a-565b-48d3-8815-cd913bb90ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_374a4c97-4873-4ed2-bf89-4314bc23ba5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_374a4c97-4873-4ed2-bf89-4314bc23ba5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_b96aefe7-818a-4745-96fe-c3514b23bee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_AdvertisingExpense_b96aefe7-818a-4745-96fe-c3514b23bee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5537ce3c-2123-4ffb-843f-8d463b8ccb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd50b94-6323-4a82-bf5d-77b0c943c617" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5537ce3c-2123-4ffb-843f-8d463b8ccb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5a5e56ae-30da-403d-bd22-a0e6f4217f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_074d4e72-bce6-4b15-97b6-a2dccb25b016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a5e56ae-30da-403d-bd22-a0e6f4217f1d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_074d4e72-bce6-4b15-97b6-a2dccb25b016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6cbc7657-d18f-49e3-b739-224861ac6d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a5e56ae-30da-403d-bd22-a0e6f4217f1d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6cbc7657-d18f-49e3-b739-224861ac6d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c3a93783-d947-45a5-bbe2-517f85cdbe33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a5e56ae-30da-403d-bd22-a0e6f4217f1d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c3a93783-d947-45a5-bbe2-517f85cdbe33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_70f516ac-a6b5-4ee7-964d-54cb34193eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a5e56ae-30da-403d-bd22-a0e6f4217f1d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_70f516ac-a6b5-4ee7-964d-54cb34193eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_638a750d-be28-42dd-bdde-343c77b79f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_638a750d-be28-42dd-bdde-343c77b79f12" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb8d7328-fcd0-4fab-a7c0-8a9a298faf05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_eefa017d-2da0-48c1-8244-ae22fc37cf9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_ComputerEquipmentMember_eefa017d-2da0-48c1-8244-ae22fc37cf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_76b7d2f5-fe28-4e54-a57a-f0e56cf599b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_76b7d2f5-fe28-4e54-a57a-f0e56cf599b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c7ac65b2-ac3d-4c88-90ad-d563b4fdd565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c7ac65b2-ac3d-4c88-90ad-d563b4fdd565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_c705e9b1-25a1-4462-878f-4a96992fb1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d13ae01-a3eb-402c-a5a7-cd1cd40653d2" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_c705e9b1-25a1-4462-878f-4a96992fb1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25036da0-b721-4d88-9abf-4f50e2ba4a2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:to="loc_srt_RangeAxis_25036da0-b721-4d88-9abf-4f50e2ba4a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_25036da0-b721-4d88-9abf-4f50e2ba4a2f" xlink:to="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ede7bc0d-3daa-4d9e-99d9-d215f8e347ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:to="loc_srt_MinimumMember_ede7bc0d-3daa-4d9e-99d9-d215f8e347ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_852c271f-c6be-40d3-9468-e011b44a051e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_96114021-f2b2-470d-931f-920ec9fd2d23" xlink:to="loc_srt_MaximumMember_852c271f-c6be-40d3-9468-e011b44a051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d2b472e-0b8b-4bac-bc65-5231b6dccebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5befa015-15f9-4a5b-b4d7-db8756352ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d2b472e-0b8b-4bac-bc65-5231b6dccebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bed0dbdc-20fe-4c88-95b2-b1b444f2c3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d2b472e-0b8b-4bac-bc65-5231b6dccebb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bed0dbdc-20fe-4c88-95b2-b1b444f2c3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9b304952-f5fa-4a79-be38-0fe226bbbe36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b304952-f5fa-4a79-be38-0fe226bbbe36" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aaee8ed1-fd13-4c79-9375-79cc0740d2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aaee8ed1-fd13-4c79-9375-79cc0740d2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aaee8ed1-fd13-4c79-9375-79cc0740d2f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_35986f66-eb7d-461b-9747-d43ee8d03414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_35986f66-eb7d-461b-9747-d43ee8d03414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CustomerRelationshipsAndContractsMember_385f8701-07c2-4e9a-9afe-4b505e1c3502" xlink:href="hcat-20210331.xsd#hcat_CustomerRelationshipsAndContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_hcat_CustomerRelationshipsAndContractsMember_385f8701-07c2-4e9a-9afe-4b505e1c3502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2ffe3f90-15d8-44eb-8206-df7390826666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2ffe3f90-15d8-44eb-8206-df7390826666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_cb9219db-63d0-4040-9332-b1041ee20227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7996068f-a2f3-4f62-b57d-b1588ea6d9b7" xlink:to="loc_us-gaap_TrademarksMember_cb9219db-63d0-4040-9332-b1041ee20227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b42abe5e-a56f-46bc-8e00-78782c2620df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:to="loc_srt_RangeAxis_b42abe5e-a56f-46bc-8e00-78782c2620df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b42abe5e-a56f-46bc-8e00-78782c2620df" xlink:to="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07cd9e57-b189-4d8f-8a27-a925a11440f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:to="loc_srt_MinimumMember_07cd9e57-b189-4d8f-8a27-a925a11440f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bcce8844-8f2a-4629-9717-2c5a413727c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b869e1a8-8bf1-4351-b985-ec7da2a49a3f" xlink:to="loc_srt_MaximumMember_bcce8844-8f2a-4629-9717-2c5a413727c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fb6e2e4-90e7-4e4c-8fae-59e24fdbf13e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_974d395c-fc8a-4d83-adfc-a0824ddd3505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fb6e2e4-90e7-4e4c-8fae-59e24fdbf13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_79484bb0-c7db-4ef4-9297-04bf829daaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fb6e2e4-90e7-4e4c-8fae-59e24fdbf13e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_79484bb0-c7db-4ef4-9297-04bf829daaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinations" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8a2aea1f-a1a5-45e3-97d9-d67bff4a247a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_2d07a1e5-b348-478c-9ab9-f14c8f7a2858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8a2aea1f-a1a5-45e3-97d9-d67bff4a247a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_2d07a1e5-b348-478c-9ab9-f14c8f7a2858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2c09f417-299f-453c-b836-5d3f0beb837e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_78de2c6c-ccef-4dae-9074-4062ba84ec90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2c09f417-299f-453c-b836-5d3f0beb837e" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_78de2c6c-ccef-4dae-9074-4062ba84ec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e56d9f9a-091d-40d3-8062-6e3da1cd6522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2c09f417-299f-453c-b836-5d3f0beb837e" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e56d9f9a-091d-40d3-8062-6e3da1cd6522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_40861840-d50a-491f-88b4-19df65dd6308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_40861840-d50a-491f-88b4-19df65dd6308" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b42bf034-3214-498f-adc9-5e40f03bea74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b42bf034-3214-498f-adc9-5e40f03bea74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b42bf034-3214-498f-adc9-5e40f03bea74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f80cb87c-3170-4927-9a5d-fd8db417439c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f80cb87c-3170-4927-9a5d-fd8db417439c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a5b6a8fb-4eef-4f4c-8594-b9163c449685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a5b6a8fb-4eef-4f4c-8594-b9163c449685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_917c29f4-1a96-4a8b-ad73-c703b7507077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_us-gaap_TrademarksMember_917c29f4-1a96-4a8b-ad73-c703b7507077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContractBacklogsMember_c8e9b05f-047a-4dc2-b4ba-10f296496bd0" xlink:href="hcat-20210331.xsd#hcat_ContractBacklogsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85b9ae4b-456b-4625-a572-eb0364e89ce6" xlink:to="loc_hcat_ContractBacklogsMember_c8e9b05f-047a-4dc2-b4ba-10f296496bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ecf56aa-f7ca-4176-91a3-341ec9ab1e74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_d428d6ff-bec8-49ef-952d-d9a7ce700a7f" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:to="loc_hcat_AbleHealthIncMember_d428d6ff-bec8-49ef-952d-d9a7ce700a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_HealthfinchIncMember_b0822f3b-28dd-48a5-bbcb-4a83de458ce0" xlink:href="hcat-20210331.xsd#hcat_HealthfinchIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:to="loc_hcat_HealthfinchIncMember_b0822f3b-28dd-48a5-bbcb-4a83de458ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_37a16a07-f1ae-443d-a08d-08bf4b126b58" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_930f33c1-d6c2-4e30-be41-a1bc624ed9b2" xlink:to="loc_hcat_VitalwareLLCMember_37a16a07-f1ae-443d-a08d-08bf4b126b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_244f17af-76b9-43c0-a5b7-92ae4fc05e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_VestingAxis_244f17af-76b9-43c0-a5b7-92ae4fc05e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a1a09c8e-eb76-4a98-bb51-85c1dc048590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_244f17af-76b9-43c0-a5b7-92ae4fc05e45" xlink:to="loc_us-gaap_VestingDomain_a1a09c8e-eb76-4a98-bb51-85c1dc048590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61a5a0d8-359a-4bcb-88dd-4660650a191b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a1a09c8e-eb76-4a98-bb51-85c1dc048590" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61a5a0d8-359a-4bcb-88dd-4660650a191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_680ecd50-0f7f-4664-ac4f-7a41e164cb38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_srt_RangeAxis_680ecd50-0f7f-4664-ac4f-7a41e164cb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_680ecd50-0f7f-4664-ac4f-7a41e164cb38" xlink:to="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98ef7952-8e19-4272-8aa6-112f383840ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:to="loc_srt_MaximumMember_98ef7952-8e19-4272-8aa6-112f383840ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_af37365e-4c5b-45dd-89d7-55f2a097b53e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb97bfc6-11c6-4548-be74-10b87a08040c" xlink:to="loc_srt_MinimumMember_af37365e-4c5b-45dd-89d7-55f2a097b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73814f68-1b8e-4c27-8744-72fd020649e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_AwardTypeAxis_73814f68-1b8e-4c27-8744-72fd020649e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_73814f68-1b8e-4c27-8744-72fd020649e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_341d4c90-eadc-48f2-9671-bd49c7a347f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:to="loc_us-gaap_RestrictedStockMember_341d4c90-eadc-48f2-9671-bd49c7a347f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember_d75c30f0-6226-4531-b6df-0c43c5517ba4" xlink:href="hcat-20210331.xsd#hcat_RestrictedSharesPursuantToAcquisitionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98530b4-80ae-406b-9222-dd2897fbb155" xlink:to="loc_hcat_RestrictedSharesPursuantToAcquisitionAgreementMember_d75c30f0-6226-4531-b6df-0c43c5517ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_882d2f48-edcd-4e06-a1be-cc9be4714088" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6394907-4c3e-4894-b9a3-e15a9d9b9770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6394907-4c3e-4894-b9a3-e15a9d9b9770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4d3e4c15-1985-4758-aa10-411e9283d8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4d3e4c15-1985-4758-aa10-411e9283d8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c3b8197f-98c4-4cde-85f4-89abce37407c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c3b8197f-98c4-4cde-85f4-89abce37407c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_adefbf12-d8eb-4f2b-98d6-02385ee68506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_adefbf12-d8eb-4f2b-98d6-02385ee68506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c836f42b-3aea-44c0-9d28-8951eb6ed464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c836f42b-3aea-44c0-9d28-8951eb6ed464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_573278c7-c484-4e74-8161-2d7a9956d97a" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_573278c7-c484-4e74-8161-2d7a9956d97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_540f9a8b-bb21-4609-9178-6f212656d1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_540f9a8b-bb21-4609-9178-6f212656d1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_132e1d0c-01d9-45cf-a7fe-e05a79a04849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_132e1d0c-01d9-45cf-a7fe-e05a79a04849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod_07aeeea5-5553-4091-bd52-f8588b4803dc" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod_07aeeea5-5553-4091-bd52-f8588b4803dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a10cc65e-451d-41db-8e07-8ebfc19e14a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a10cc65e-451d-41db-8e07-8ebfc19e14a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e77feb21-ad52-4396-8ce2-266b898037ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e77feb21-ad52-4396-8ce2-266b898037ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_774c7218-4fae-4fdf-94cd-ede043769b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_774c7218-4fae-4fdf-94cd-ede043769b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c2a9a43-e122-46d1-9519-deac227057e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2fe2a010-fb13-468f-b7ac-e66f843a8675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c2a9a43-e122-46d1-9519-deac227057e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cfb516c7-60b2-4618-af6b-335e0b1f8f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cfb516c7-60b2-4618-af6b-335e0b1f8f00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79b8715e-cb65-415c-93fc-16507b5034bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79b8715e-cb65-415c-93fc-16507b5034bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79b8715e-cb65-415c-93fc-16507b5034bb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_e59a5c0a-f0cf-4a4a-98d9-b85ee06e6bde" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:to="loc_hcat_AbleHealthIncMember_e59a5c0a-f0cf-4a4a-98d9-b85ee06e6bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_HealthfinchIncMember_00a93a3c-1357-4695-af1d-aa5c265fe101" xlink:href="hcat-20210331.xsd#hcat_HealthfinchIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:to="loc_hcat_HealthfinchIncMember_00a93a3c-1357-4695-af1d-aa5c265fe101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_9a6bd9c9-b79d-461d-b00c-c6920950d923" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62cf23be-26f6-4ffe-a330-ccf4305918a9" xlink:to="loc_hcat_VitalwareLLCMember_9a6bd9c9-b79d-461d-b00c-c6920950d923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc3dca7a-5488-4c26-af9c-ae8bf792067c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc3dca7a-5488-4c26-af9c-ae8bf792067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc3dca7a-5488-4c26-af9c-ae8bf792067c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d17afdfb-e1fa-4a85-9ce5-dce20a06a996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d17afdfb-e1fa-4a85-9ce5-dce20a06a996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_fa1b044a-200d-46a7-900e-f0b0c4a47c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:to="loc_us-gaap_CustomerRelationshipsMember_fa1b044a-200d-46a7-900e-f0b0c4a47c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0c96bd55-9cc4-4cc4-b654-ee971b80f7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bcbc3e87-6524-4c65-8606-c9857623cc93" xlink:to="loc_us-gaap_TrademarksMember_0c96bd55-9cc4-4cc4-b654-ee971b80f7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf62daeb-6143-41ac-ba91-36d4150d5962" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9749de2a-3c92-4578-9491-32dac2f4da73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9749de2a-3c92-4578-9491-32dac2f4da73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_526329cd-f002-480a-a308-0228fd3a5782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_526329cd-f002-480a-a308-0228fd3a5782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f1e2217-49e9-4703-b374-5f20402e5428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f1e2217-49e9-4703-b374-5f20402e5428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f76f5c5f-99fc-4e13-91d3-c78fffd59264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_a9e9ff64-13d1-43d4-863d-3be8d6ef08d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f76f5c5f-99fc-4e13-91d3-c78fffd59264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_efb01cf4-dda8-4ab4-b8e5-4d3651e321b2" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:to="loc_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther_efb01cf4-dda8-4ab4-b8e5-4d3651e321b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_e4a8d0c8-e76c-440f-8035-3f9402a78a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_e4a8d0c8-e76c-440f-8035-3f9402a78a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dead52b5-d814-4b76-b905-aed5fb294e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_dfd75f37-9519-4ebd-9d58-80fe49cff762" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dead52b5-d814-4b76-b905-aed5fb294e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_821bb5f5-8e4a-4fd2-a946-a67d7d2b1e89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_821bb5f5-8e4a-4fd2-a946-a67d7d2b1e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e17b3e-3bfd-451b-831d-34474d163d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e17b3e-3bfd-451b-831d-34474d163d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12630e07-f57c-4d79-831e-f861e1246dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_Goodwill_12630e07-f57c-4d79-831e-f861e1246dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6820a0d8-5c14-4d37-a28a-c44b3757712b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54a23646-47ef-47aa-83fd-b3ab224a4d86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6820a0d8-5c14-4d37-a28a-c44b3757712b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#BusinessCombinationsUnauditedProFormaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8cf54e12-7391-49c9-bec5-163c1e8dd12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_568ea576-c38e-496e-b087-57b2e1339ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8cf54e12-7391-49c9-bec5-163c1e8dd12c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_568ea576-c38e-496e-b087-57b2e1339ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_9770929e-0c02-4591-942f-37fc29ddbf76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_568ea576-c38e-496e-b087-57b2e1339ece" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_9770929e-0c02-4591-942f-37fc29ddbf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_825e2f7a-437a-4a82-b5c0-75ce054687a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_9770929e-0c02-4591-942f-37fc29ddbf76" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_825e2f7a-437a-4a82-b5c0-75ce054687a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AcquisitionRelatedFairValueAdjustmentsMember_328e60d4-38d9-410d-bff9-fbf03186812f" xlink:href="hcat-20210331.xsd#hcat_AcquisitionRelatedFairValueAdjustmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_825e2f7a-437a-4a82-b5c0-75ce054687a1" xlink:to="loc_hcat_AcquisitionRelatedFairValueAdjustmentsMember_328e60d4-38d9-410d-bff9-fbf03186812f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_568ea576-c38e-496e-b087-57b2e1339ece" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1246bfdb-c499-4273-be7c-adbf5f3b319c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1246bfdb-c499-4273-be7c-adbf5f3b319c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75b0015c-2216-407d-a21a-60f64a067bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75b0015c-2216-407d-a21a-60f64a067bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc081ac1-ff2d-4fef-ad51-085087dde400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1102e699-092d-4d46-91a0-1f987028f7bd" xlink:to="loc_us-gaap_ProfitLoss_cc081ac1-ff2d-4fef-ad51-085087dde400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Revenue" xlink:type="simple" xlink:href="hcat-20210331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_42e6db8a-d198-4e8b-8089-56d0f05b4e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d9b7d53e-6d24-48d7-818b-1c62e1e1ebe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_42e6db8a-d198-4e8b-8089-56d0f05b4e12" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d9b7d53e-6d24-48d7-818b-1c62e1e1ebe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a238faa-67f5-4ab7-9e78-5dc1ddba2487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_de4e99e0-a4fa-41a9-8fe2-18bd9cbd51b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a238faa-67f5-4ab7-9e78-5dc1ddba2487" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_de4e99e0-a4fa-41a9-8fe2-18bd9cbd51b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8507a695-06cd-44c0-bbdc-75ee53e493de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_385bf143-1d48-4ee8-a973-3e9c8fc8c5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8507a695-06cd-44c0-bbdc-75ee53e493de" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_385bf143-1d48-4ee8-a973-3e9c8fc8c5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f348395f-af8a-48d6-a155-0afa3c4291c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_385bf143-1d48-4ee8-a973-3e9c8fc8c5bf" xlink:to="loc_srt_ProductOrServiceAxis_f348395f-af8a-48d6-a155-0afa3c4291c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f348395f-af8a-48d6-a155-0afa3c4291c2" xlink:to="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_RecurringTechnologyMember_dc210911-414d-437b-99eb-4d029f7fd404" xlink:href="hcat-20210331.xsd#hcat_RecurringTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:to="loc_hcat_RecurringTechnologyMember_dc210911-414d-437b-99eb-4d029f7fd404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_OneTimeTechnologyMember_656cd9b5-0deb-45e5-a4aa-fcdb0f1cba9c" xlink:href="hcat-20210331.xsd#hcat_OneTimeTechnologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:to="loc_hcat_OneTimeTechnologyMember_656cd9b5-0deb-45e5-a4aa-fcdb0f1cba9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_8436f6d6-9bcf-4b85-98d6-eb208c0806f7" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb859702-52b5-4e06-8206-fc2c3f11be9b" xlink:to="loc_hcat_ProfessionalServicesMember_8436f6d6-9bcf-4b85-98d6-eb208c0806f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_abd2711e-ee42-4109-a3b2-2fc934b3b6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_385bf143-1d48-4ee8-a973-3e9c8fc8c5bf" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_abd2711e-ee42-4109-a3b2-2fc934b3b6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb916aff-cf7e-4223-b7d5-f7a3a7e198b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_abd2711e-ee42-4109-a3b2-2fc934b3b6b9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb916aff-cf7e-4223-b7d5-f7a3a7e198b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f87c90dc-fcb4-49ce-9601-308ca8b4b531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f87c90dc-fcb4-49ce-9601-308ca8b4b531" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_12694aee-d564-4a4e-b77e-6d81ca39bd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_12694aee-d564-4a4e-b77e-6d81ca39bd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e01fc064-8fe0-494a-b5a2-d57b8a40e63d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12694aee-d564-4a4e-b77e-6d81ca39bd16" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e01fc064-8fe0-494a-b5a2-d57b8a40e63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_c9a64405-f273-46ca-b73f-8c2f0ec379e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e01fc064-8fe0-494a-b5a2-d57b8a40e63d" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_c9a64405-f273-46ca-b73f-8c2f0ec379e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712f1b77-0bfb-44f3-b6b3-5894c1da9ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712f1b77-0bfb-44f3-b6b3-5894c1da9ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_532d7e18-2a92-4dbe-aaab-fc38c393a081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712f1b77-0bfb-44f3-b6b3-5894c1da9ded" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_532d7e18-2a92-4dbe-aaab-fc38c393a081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_0481a2d2-1f7d-4a01-82ac-50430e81c19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_532d7e18-2a92-4dbe-aaab-fc38c393a081" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_0481a2d2-1f7d-4a01-82ac-50430e81c19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd277a87-a7b2-48f4-a979-024786b8207c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:to="loc_srt_StatementGeographicalAxis_bd277a87-a7b2-48f4-a979-024786b8207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bf31d1be-1182-4933-a54f-c2b44e6b9f23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bd277a87-a7b2-48f4-a979-024786b8207c" xlink:to="loc_srt_SegmentGeographicalDomain_bf31d1be-1182-4933-a54f-c2b44e6b9f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_422f91ed-2a5c-4f08-8090-65ec499d4586" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_bf31d1be-1182-4933-a54f-c2b44e6b9f23" xlink:to="loc_country_US_422f91ed-2a5c-4f08-8090-65ec499d4586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_099339ee-7f79-4e1a-a004-0c6688c673fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eb558c94-af89-4eef-b2d8-a4d79457875b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_099339ee-7f79-4e1a-a004-0c6688c673fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7941d5e8-1b81-4f61-86f6-69bf14f3bee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_099339ee-7f79-4e1a-a004-0c6688c673fb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7941d5e8-1b81-4f61-86f6-69bf14f3bee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb96081a-bd28-4aa7-b9c2-0b24e65dde95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_66f80652-1f7b-40ff-982e-dc8ad72f8beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb96081a-bd28-4aa7-b9c2-0b24e65dde95" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_66f80652-1f7b-40ff-982e-dc8ad72f8beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4c8e35a8-8da4-48ec-9817-5a271667bcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_9cc21ca5-70b2-4f57-9679-ceb0529f3271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4c8e35a8-8da4-48ec-9817-5a271667bcf3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_9cc21ca5-70b2-4f57-9679-ceb0529f3271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_923054cd-ec98-43d2-bf52-b8da81a6bf75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4c8e35a8-8da4-48ec-9817-5a271667bcf3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_923054cd-ec98-43d2-bf52-b8da81a6bf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eec2aec2-f176-4b7c-b239-d215c6a43fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a0954de3-8dfa-4a4a-b566-2f04be76fef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eec2aec2-f176-4b7c-b239-d215c6a43fd8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a0954de3-8dfa-4a4a-b566-2f04be76fef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_3ee6d8af-05db-4d21-bd74-197d3c274195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eec2aec2-f176-4b7c-b239-d215c6a43fd8" xlink:to="loc_us-gaap_NumberOfReportingUnits_3ee6d8af-05db-4d21-bd74-197d3c274195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d81d3725-2a7c-4933-8663-f586a075290b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eec2aec2-f176-4b7c-b239-d215c6a43fd8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d81d3725-2a7c-4933-8663-f586a075290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c462e97-1fba-400b-84d0-32dbed3b13a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c3532de7-caf3-4da7-b8f0-6df4acec038f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c462e97-1fba-400b-84d0-32dbed3b13a5" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c3532de7-caf3-4da7-b8f0-6df4acec038f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d58a1f67-36b4-4621-a4f8-e3d21cd6611a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c3532de7-caf3-4da7-b8f0-6df4acec038f" xlink:to="loc_us-gaap_ReportingUnitAxis_d58a1f67-36b4-4621-a4f8-e3d21cd6611a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_d58a1f67-36b4-4621-a4f8-e3d21cd6611a" xlink:to="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_a6680a73-97d3-422c-95f1-4f3f3a577bcd" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:to="loc_hcat_TechnologyMember_a6680a73-97d3-422c-95f1-4f3f3a577bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_308d294f-2bea-4af1-ad5b-22e76c103d04" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_9b942ec7-fb12-4574-a903-ad1df93dc30c" xlink:to="loc_hcat_ProfessionalServicesMember_308d294f-2bea-4af1-ad5b-22e76c103d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4caa20a8-b495-4174-bd42-c0f4672e6261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c3532de7-caf3-4da7-b8f0-6df4acec038f" xlink:to="loc_us-gaap_GoodwillLineItems_4caa20a8-b495-4174-bd42-c0f4672e6261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bed484f2-3c3c-4728-be23-0cc787ec33a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4caa20a8-b495-4174-bd42-c0f4672e6261" xlink:to="loc_us-gaap_Goodwill_bed484f2-3c3c-4728-be23-0cc787ec33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3a1cfdd0-e2cb-4883-8732-18b07d9ed1f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9741b7e-4c5d-40a3-892f-c8cf4900a7f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3a1cfdd0-e2cb-4883-8732-18b07d9ed1f3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9741b7e-4c5d-40a3-892f-c8cf4900a7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_05ea6393-f727-4cab-8422-d691b49a0276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9741b7e-4c5d-40a3-892f-c8cf4900a7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_05ea6393-f727-4cab-8422-d691b49a0276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_05ea6393-f727-4cab-8422-d691b49a0276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1f9ac17b-fd2b-4a6f-894b-33b3ffd8e1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1f9ac17b-fd2b-4a6f-894b-33b3ffd8e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CustomerRelationshipsAndContractsMember_4d13e055-f57c-49f7-9e10-80e3bfe81bb8" xlink:href="hcat-20210331.xsd#hcat_CustomerRelationshipsAndContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_hcat_CustomerRelationshipsAndContractsMember_4d13e055-f57c-49f7-9e10-80e3bfe81bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_cde82975-83fd-49d8-906b-b2dcc04307f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_cde82975-83fd-49d8-906b-b2dcc04307f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_f4ad8a0f-731e-42b2-9c82-e5d70924ceeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f65c6539-f70f-4dd9-af52-21f6b008ecd1" xlink:to="loc_us-gaap_TrademarksMember_f4ad8a0f-731e-42b2-9c82-e5d70924ceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9741b7e-4c5d-40a3-892f-c8cf4900a7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8236cf2d-757e-43e7-a993-763ca34f79cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8236cf2d-757e-43e7-a993-763ca34f79cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9c27ad41-65f4-440b-a424-0ac5d8e19a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9c27ad41-65f4-440b-a424-0ac5d8e19a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fde7bd7e-dd68-4b1e-8d80-fd27d4b9a768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_938e9194-b7ed-48d6-ba7c-42675eb85471" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fde7bd7e-dd68-4b1e-8d80-fd27d4b9a768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85129a3b-a957-423d-a0fa-563233995737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9908d8ad-50dd-4e28-bc0c-8a82be392b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85129a3b-a957-423d-a0fa-563233995737" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9908d8ad-50dd-4e28-bc0c-8a82be392b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6befb048-696d-4fa3-ab8b-addddfa781c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4b603ca9-1f3f-45a1-a40f-3f652f10e74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6befb048-696d-4fa3-ab8b-addddfa781c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4b603ca9-1f3f-45a1-a40f-3f652f10e74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b258379e-94f2-4e98-9347-1124f754b779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03ce0ea8-f5c5-446b-9395-d6f769b8aa68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b258379e-94f2-4e98-9347-1124f754b779" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03ce0ea8-f5c5-446b-9395-d6f769b8aa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aadebe43-3291-47d1-b1e7-4331ca9c8d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03ce0ea8-f5c5-446b-9395-d6f769b8aa68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aadebe43-3291-47d1-b1e7-4331ca9c8d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aadebe43-3291-47d1-b1e7-4331ca9c8d9c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8739875b-0398-4b05-93ea-38cd71f986d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_ComputerEquipmentMember_8739875b-0398-4b05-93ea-38cd71f986d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b6be0f65-6ff9-43c6-9504-417d552b27ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b6be0f65-6ff9-43c6-9504-417d552b27ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e0ca0a74-64e1-4213-a82f-7ccaef041a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e0ca0a74-64e1-4213-a82f-7ccaef041a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_8b5f1792-d219-4dd7-8ef7-e3a1b0483bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_8b5f1792-d219-4dd7-8ef7-e3a1b0483bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d20245ce-e558-44c7-97c4-24e06737f6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d20245ce-e558-44c7-97c4-24e06737f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AssetsHeldUnderFinanceLeasesMember_25fa63f5-c821-44ec-b8ce-c71e030937ed" xlink:href="hcat-20210331.xsd#hcat_AssetsHeldUnderFinanceLeasesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcf61aa2-a7e6-4e4e-ab7d-e50f1c90c776" xlink:to="loc_hcat_AssetsHeldUnderFinanceLeasesMember_25fa63f5-c821-44ec-b8ce-c71e030937ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03ce0ea8-f5c5-446b-9395-d6f769b8aa68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3c86891a-f625-47ab-98b4-cf0538dfbe34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3c86891a-f625-47ab-98b4-cf0538dfbe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9f3d076f-8147-473c-9501-a0a114ea56a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9f3d076f-8147-473c-9501-a0a114ea56a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f92a2a05-6ccd-4adc-9340-0e765314692b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7b6f9ca-41fa-4c1c-a42a-711d6fb9279d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f92a2a05-6ccd-4adc-9340-0e765314692b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bb803b5b-d8b2-40ea-9cf1-f84788dbba5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3ea91814-2e67-4a12-b7e0-a8d1e52d1313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bb803b5b-d8b2-40ea-9cf1-f84788dbba5e" xlink:to="loc_us-gaap_Depreciation_3ea91814-2e67-4a12-b7e0-a8d1e52d1313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_e504cd9e-108f-4b0a-b5f6-0951e55308e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bb803b5b-d8b2-40ea-9cf1-f84788dbba5e" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_e504cd9e-108f-4b0a-b5f6-0951e55308e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_03110eb2-1dc3-47b9-89ff-338643f20afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bb803b5b-d8b2-40ea-9cf1-f84788dbba5e" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_03110eb2-1dc3-47b9-89ff-338643f20afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestments"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3bc0388-2b5b-469b-bce3-563a1256be48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_679467d2-f02a-4bd4-8cbc-b517ff7a12e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3bc0388-2b5b-469b-bce3-563a1256be48" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_679467d2-f02a-4bd4-8cbc-b517ff7a12e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a914abb9-bafb-4de5-9860-d342fc7d3914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0db89e6b-4b07-49c5-b3bd-84346ee5c7db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a914abb9-bafb-4de5-9860-d342fc7d3914" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0db89e6b-4b07-49c5-b3bd-84346ee5c7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b8f639b5-9ede-4c2f-b9d5-2c8539106c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_5082e88a-eb50-4191-86cd-b048f9307cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b8f639b5-9ede-4c2f-b9d5-2c8539106c98" xlink:to="loc_us-gaap_InterestReceivable_5082e88a-eb50-4191-86cd-b048f9307cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b8f639b5-9ede-4c2f-b9d5-2c8539106c98" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cdea0802-5c5f-442a-b70a-9fcdfdb429c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cdea0802-5c5f-442a-b70a-9fcdfdb429c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cdea0802-5c5f-442a-b70a-9fcdfdb429c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_64c9747f-5785-433f-9b66-c120123e67ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:to="loc_us-gaap_CashEquivalentsMember_64c9747f-5785-433f-9b66-c120123e67ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShortTermMarketableSecurityMember_9bacbb58-3e03-479a-a4dc-9f6105b5b3ac" xlink:href="hcat-20210331.xsd#hcat_ShortTermMarketableSecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d3a29d1e-951d-42b6-8e3b-8a903c7452dd" xlink:to="loc_hcat_ShortTermMarketableSecurityMember_9bacbb58-3e03-479a-a4dc-9f6105b5b3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a6c08664-671e-4151-80d0-54a1839d55a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a6c08664-671e-4151-80d0-54a1839d55a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6c08664-671e-4151-80d0-54a1839d55a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5cc93437-5db9-45fa-8b1d-f942a6e17065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5cc93437-5db9-45fa-8b1d-f942a6e17065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b809bd6b-d3ca-4960-8ca5-97d929d721ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b809bd6b-d3ca-4960-8ca5-97d929d721ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2f619d91-d1df-48dc-89f5-192156143033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_CommercialPaperMember_2f619d91-d1df-48dc-89f5-192156143033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_9238f04c-fbe6-4964-a0f1-7211420d79b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_9238f04c-fbe6-4964-a0f1-7211420d79b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_552c1b04-7ea8-43f0-a9a2-f5fdfb90739e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8705fb88-5504-4ca1-bf77-06f6fb61e6c5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_552c1b04-7ea8-43f0-a9a2-f5fdfb90739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_85bab328-098e-4629-8963-ba5936a3ca88" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a39e7edf-4751-48b5-ab4c-cacbc5b9e2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a39e7edf-4751-48b5-ab4c-cacbc5b9e2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38a78db6-c3ff-483e-a749-47798c8be005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38a78db6-c3ff-483e-a749-47798c8be005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63baa26f-1b1c-455e-b7fd-ebab6c8e5b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63baa26f-1b1c-455e-b7fd-ebab6c8e5b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c50c3887-3c5a-45f1-a78b-09fd83c06a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2cf6e98f-616c-43bb-a934-13aa6e9da8eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c50c3887-3c5a-45f1-a78b-09fd83c06a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33f2dff4-94c8-43cd-b172-095267efab38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5882b583-5e45-473c-894a-6a492302e136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33f2dff4-94c8-43cd-b172-095267efab38" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5882b583-5e45-473c-894a-6a492302e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b85b60cd-3789-424d-b6ae-636d6942ce0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_cf0deec0-e84a-4113-919b-7934baab4bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b85b60cd-3789-424d-b6ae-636d6942ce0d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_cf0deec0-e84a-4113-919b-7934baab4bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6e0fe2ac-0f0a-4a82-993d-457b74bcf361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b85b60cd-3789-424d-b6ae-636d6942ce0d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6e0fe2ac-0f0a-4a82-993d-457b74bcf361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a8a50a30-ddc9-4614-a254-d4d38acff50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b85b60cd-3789-424d-b6ae-636d6942ce0d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a8a50a30-ddc9-4614-a254-d4d38acff50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5d39d2e2-8e57-48e0-9d08-1e86619550de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5d39d2e2-8e57-48e0-9d08-1e86619550de" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_68d1e620-c064-4932-962c-17888bc546be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_68d1e620-c064-4932-962c-17888bc546be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b48af50-a808-41ab-8b84-42907be4f248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_68d1e620-c064-4932-962c-17888bc546be" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b48af50-a808-41ab-8b84-42907be4f248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_671f5d71-7eb8-4f2a-a1a7-77684b98a544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b48af50-a808-41ab-8b84-42907be4f248" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_671f5d71-7eb8-4f2a-a1a7-77684b98a544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f907616-b5c7-4ef8-87dd-08e2b7027075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f907616-b5c7-4ef8-87dd-08e2b7027075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f907616-b5c7-4ef8-87dd-08e2b7027075" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d75c7df9-c1c5-46f7-a94d-18733412bb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d75c7df9-c1c5-46f7-a94d-18733412bb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9463cab8-d524-4935-b657-3b2d06f5cd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_CommercialPaperMember_9463cab8-d524-4935-b657-3b2d06f5cd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e50a84bb-68d2-4eb5-8063-bf0eb5aedfce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e50a84bb-68d2-4eb5-8063-bf0eb5aedfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7ed27178-c45e-4e9f-b7f3-070c077d9f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c2a9bca-86a8-48f1-aab2-994d2eb98e93" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7ed27178-c45e-4e9f-b7f3-070c077d9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3997c030-b4cf-4ec6-a82e-a9056ec4406d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3997c030-b4cf-4ec6-a82e-a9056ec4406d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3997c030-b4cf-4ec6-a82e-a9056ec4406d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cfd37c87-d016-404c-9ee8-316d68b45ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cfd37c87-d016-404c-9ee8-316d68b45ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56512ebf-553e-4f1b-b54f-bad6e2673ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56512ebf-553e-4f1b-b54f-bad6e2673ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e03c0a6b-ee63-4eea-96be-b61b853385b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9f7676-5791-421a-b627-b391f0c74f7b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e03c0a6b-ee63-4eea-96be-b61b853385b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d05423b4-bee6-471d-b8c1-37433824a30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d05423b4-bee6-471d-b8c1-37433824a30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_564a44e7-c803-480d-b3ac-b151f7fd83d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d05423b4-bee6-471d-b8c1-37433824a30d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_564a44e7-c803-480d-b3ac-b151f7fd83d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_dcf3bc5e-3f54-4b55-a433-ea4f40636565" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_564a44e7-c803-480d-b3ac-b151f7fd83d1" xlink:to="loc_hcat_VitalwareLLCMember_dcf3bc5e-3f54-4b55-a433-ea4f40636565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_36677f69-bee3-4723-b099-7af2ee172735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d0336ef-35ba-49a8-b4b4-abacfb04c0a6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_36677f69-bee3-4723-b099-7af2ee172735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_44ec5379-cdc6-472a-867a-b0f4b44866a3" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_36677f69-bee3-4723-b099-7af2ee172735" xlink:to="loc_hcat_SeniorNotesDue2025Member_44ec5379-cdc6-472a-867a-b0f4b44866a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cfc1d66a-c0cb-4e37-8f5b-f68d42b7d5ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69f6b82d-f8ad-4bfa-b14a-5d2fa2ee96bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cfc1d66a-c0cb-4e37-8f5b-f68d42b7d5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_76688ded-2ddf-49ab-b51f-7834927f9b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cfc1d66a-c0cb-4e37-8f5b-f68d42b7d5ce" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_76688ded-2ddf-49ab-b51f-7834927f9b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_943625ad-69ea-48bf-a84e-4eb59b8ba8ac" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cdf032-70af-4df7-900d-244533dcc9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cdf032-70af-4df7-900d-244533dcc9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b9835ec-cbb8-447c-a6f4-afff0ccd5122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b9835ec-cbb8-447c-a6f4-afff0ccd5122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_263597cd-f434-4b03-8087-86ea9a82cdbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_263597cd-f434-4b03-8087-86ea9a82cdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_710f2c0f-c967-4a7d-87b1-4e7bf4d677e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_FairValueNetAssetLiability_710f2c0f-c967-4a7d-87b1-4e7bf4d677e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_bebb68eb-cfe9-406b-8a22-1a7b67176e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_bebb68eb-cfe9-406b-8a22-1a7b67176e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fa522e5f-774e-4dd2-a86f-662f77fb20a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fa522e5f-774e-4dd2-a86f-662f77fb20a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability_121d4f43-d31d-49d3-a27e-6af712e193ad" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability_121d4f43-d31d-49d3-a27e-6af712e193ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash_a706de65-3da4-4bbe-8cdc-cba23e0ead64" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash_a706de65-3da4-4bbe-8cdc-cba23e0ead64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares_f6ca138a-225b-4674-8fa7-3ae103efa925" xlink:href="hcat-20210331.xsd#hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares_f6ca138a-225b-4674-8fa7-3ae103efa925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_d48347ec-8dbd-4b36-88e6-cd916a3f7c32" xlink:href="hcat-20210331.xsd#hcat_FairValueMeasurementAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_416ff8d2-f858-4550-b979-838ead0be28b" xlink:to="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_d48347ec-8dbd-4b36-88e6-cd916a3f7c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_438c0294-8240-4d2a-b0ff-5ac24bf9fc36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_438c0294-8240-4d2a-b0ff-5ac24bf9fc36" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f7a3e6bb-8b26-4fd5-8b19-07564c426c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f7a3e6bb-8b26-4fd5-8b19-07564c426c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f7a3e6bb-8b26-4fd5-8b19-07564c426c56" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_MeasurementInputMarketPriceOfRevenueRiskMember_f7c5cb78-741a-450c-a0cf-cc9edaf780eb" xlink:href="hcat-20210331.xsd#hcat_MeasurementInputMarketPriceOfRevenueRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:to="loc_hcat_MeasurementInputMarketPriceOfRevenueRiskMember_f7c5cb78-741a-450c-a0cf-cc9edaf780eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_MeasurementInputRevenueVolatilityMember_86395260-ccdc-443d-a392-562a22eb3b0d" xlink:href="hcat-20210331.xsd#hcat_MeasurementInputRevenueVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:to="loc_hcat_MeasurementInputRevenueVolatilityMember_86395260-ccdc-443d-a392-562a22eb3b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_91db8c73-579e-4f51-8b76-700e35558d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e20985c4-acdf-4aad-a2c5-e2026b366a05" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_91db8c73-579e-4f51-8b76-700e35558d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d3ae620-330a-444a-b6e8-a3dda49d3a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d3ae620-330a-444a-b6e8-a3dda49d3a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee9e3f1f-2252-439a-83de-bf4005d489ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d3ae620-330a-444a-b6e8-a3dda49d3a40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee9e3f1f-2252-439a-83de-bf4005d489ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e04aef5d-78a1-4524-8323-efdc6d7c113c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee9e3f1f-2252-439a-83de-bf4005d489ba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e04aef5d-78a1-4524-8323-efdc6d7c113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_530c464c-0b63-461c-a9a8-15f0b12b6440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:to="loc_srt_RangeAxis_530c464c-0b63-461c-a9a8-15f0b12b6440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_530c464c-0b63-461c-a9a8-15f0b12b6440" xlink:to="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_046be5a9-168e-4672-ad87-cc65c742bff7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:to="loc_srt_MinimumMember_046be5a9-168e-4672-ad87-cc65c742bff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a7556ea-5217-46e5-a39a-9f6d650f4640" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a795e841-514d-46ab-8f66-865e1b899f67" xlink:to="loc_srt_MaximumMember_0a7556ea-5217-46e5-a39a-9f6d650f4640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4d04ed2f-e8f5-456a-a96f-aa73a4074858" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_453dcb2a-bb52-4347-93c4-f67eb61bc61d" xlink:href="hcat-20210331.xsd#hcat_FairValueMeasurementAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:to="loc_hcat_FairValueMeasurementAggregateIntrinsicValue_453dcb2a-bb52-4347-93c4-f67eb61bc61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4a45d82c-064f-4ba4-913c-67f7e520bec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_19363171-8719-44b2-b87b-74d4490e5d9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4a45d82c-064f-4ba4-913c-67f7e520bec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aea454b2-816a-43d4-aaf5-12485a2a216a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc06c012-ee5c-4e7d-b632-7a70ac42bb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aea454b2-816a-43d4-aaf5-12485a2a216a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc06c012-ee5c-4e7d-b632-7a70ac42bb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc06c012-ee5c-4e7d-b632-7a70ac42bb14" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6582e6fe-83ed-443a-9fb9-e27f6e29152c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4c29f213-a6ad-4bd1-bf3b-aec24e19abfe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6582e6fe-83ed-443a-9fb9-e27f6e29152c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContingentConsiderationMember_29030e50-c022-4f9e-9c18-0f6b5476335b" xlink:href="hcat-20210331.xsd#hcat_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6582e6fe-83ed-443a-9fb9-e27f6e29152c" xlink:to="loc_hcat_ContingentConsiderationMember_29030e50-c022-4f9e-9c18-0f6b5476335b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a0eb812-1044-4b4c-a211-13ed2f3c9255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc06c012-ee5c-4e7d-b632-7a70ac42bb14" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a0eb812-1044-4b4c-a211-13ed2f3c9255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a0eb812-1044-4b4c-a211-13ed2f3c9255" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_33d097ae-8561-409e-9858-2d100c95f686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_33d097ae-8561-409e-9858-2d100c95f686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_3a9c747a-ec77-4923-bcf9-0d99c2e68e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_3a9c747a-ec77-4923-bcf9-0d99c2e68e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0cccae5-1fff-43eb-8d1c-78c27e4074d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0cccae5-1fff-43eb-8d1c-78c27e4074d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e2895dfc-8539-4fe0-95d2-b80d96d8c202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd4becbe-3a03-462b-8657-ca7e048147be" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e2895dfc-8539-4fe0-95d2-b80d96d8c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Accruedliabilities" xlink:type="simple" xlink:href="hcat-20210331.xsd#Accruedliabilities"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/Accruedliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9c0ced3f-b0a7-466a-b7a4-a9b025dd54ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7bdb875f-7988-4009-b10c-6c693df22566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9c0ced3f-b0a7-466a-b7a4-a9b025dd54ad" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7bdb875f-7988-4009-b10c-6c693df22566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#AccruedliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/AccruedliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_877b095e-e090-4715-ad3c-724835056c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dd055dbb-83f6-43a0-8a74-01c5ea208116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_877b095e-e090-4715-ad3c-724835056c26" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dd055dbb-83f6-43a0-8a74-01c5ea208116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/AccruedliabilitiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#AccruedliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/AccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dbb444ab-2616-42a1-8677-b2bc7defb05f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dac0ae37-04dd-4d2e-b651-65a8add8e8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb444ab-2616-42a1-8677-b2bc7defb05f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dac0ae37-04dd-4d2e-b651-65a8add8e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bae6ed5b-7c2a-4db8-864e-167711f76256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb444ab-2616-42a1-8677-b2bc7defb05f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bae6ed5b-7c2a-4db8-864e-167711f76256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_b4ad475a-2e50-4e53-a320-00623d0dcb20" xlink:href="hcat-20210331.xsd#hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb444ab-2616-42a1-8677-b2bc7defb05f" xlink:to="loc_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_b4ad475a-2e50-4e53-a320-00623d0dcb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c5b59904-f97e-4f25-95bb-f90ac96eadcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f805160d-53d7-41bd-9aef-02a01f2e7799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5b59904-f97e-4f25-95bb-f90ac96eadcf" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f805160d-53d7-41bd-9aef-02a01f2e7799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_352cf84d-07ad-4446-894c-be975eac4255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_e26b8e9d-234a-4cb5-b921-0bcd25f22dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_352cf84d-07ad-4446-894c-be975eac4255" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_e26b8e9d-234a-4cb5-b921-0bcd25f22dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2afdac82-7303-42e8-a55e-d5c52b62636d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2afdac82-7303-42e8-a55e-d5c52b62636d" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d9558a79-14bd-4faf-b60b-824cd8a10584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b6ff8c4-8deb-4ea1-909e-06793ad1fdd0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d9558a79-14bd-4faf-b60b-824cd8a10584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_9764a733-fd2c-4123-8252-cb82236217cb" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9558a79-14bd-4faf-b60b-824cd8a10584" xlink:to="loc_hcat_SeniorNotesDue2025Member_9764a733-fd2c-4123-8252-cb82236217cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_232ad869-a49d-4207-a0a4-97c615bb37ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_232ad869-a49d-4207-a0a4-97c615bb37ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_07107e27-f02d-4b55-83b5-43e551b8fecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_232ad869-a49d-4207-a0a4-97c615bb37ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_07107e27-f02d-4b55-83b5-43e551b8fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_b7dfe22d-0be6-4557-8b70-2e6cbef798d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_07107e27-f02d-4b55-83b5-43e551b8fecf" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_b7dfe22d-0be6-4557-8b70-2e6cbef798d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis_e6aed120-8209-4837-a920-c2d9505d2cf4" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleThresholdTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis_e6aed120-8209-4837-a920-c2d9505d2cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_3f0b0810-dc23-4241-be02-dbc92b77bb0e" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleThresholdTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_DebtInstrumentConvertibleThresholdTypeAxis_e6aed120-8209-4837-a920-c2d9505d2cf4" xlink:to="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_3f0b0810-dc23-4241-be02-dbc92b77bb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember_41b276be-7cf1-468d-be7a-1616b6d32dec" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_DebtInstrumentConvertibleThresholdTypeDomain_3f0b0810-dc23-4241-be02-dbc92b77bb0e" xlink:to="loc_hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember_41b276be-7cf1-468d-be7a-1616b6d32dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1f61f284-62ea-452b-8e23-33f8b65cb6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1f61f284-62ea-452b-8e23-33f8b65cb6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b88fb905-5b8e-4a8c-87e5-4e141c676d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1f61f284-62ea-452b-8e23-33f8b65cb6cc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b88fb905-5b8e-4a8c-87e5-4e141c676d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d4f266b6-830e-4a5f-b139-3836c2715ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b88fb905-5b8e-4a8c-87e5-4e141c676d0b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d4f266b6-830e-4a5f-b139-3836c2715ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d7e476ad-f079-4e0c-9699-5199a82f1bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d7e476ad-f079-4e0c-9699-5199a82f1bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3a081301-51d2-40b4-b496-8d59773fead6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d7e476ad-f079-4e0c-9699-5199a82f1bb3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3a081301-51d2-40b4-b496-8d59773fead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2bde823f-a35b-435c-bf4c-3b1fbd7ef3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3a081301-51d2-40b4-b496-8d59773fead6" xlink:to="loc_us-gaap_CashFlowHedgingMember_2bde823f-a35b-435c-bf4c-3b1fbd7ef3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3bd092d0-7fff-4e09-af0e-752d7ebdf68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3bd092d0-7fff-4e09-af0e-752d7ebdf68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e04a68df-b57b-4936-9f78-3ac88d834922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3bd092d0-7fff-4e09-af0e-752d7ebdf68f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e04a68df-b57b-4936-9f78-3ac88d834922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_CappedCallMember_461981fd-ab4f-4f38-858c-289dd65335c8" xlink:href="hcat-20210331.xsd#hcat_CappedCallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e04a68df-b57b-4936-9f78-3ac88d834922" xlink:to="loc_hcat_CappedCallMember_461981fd-ab4f-4f38-858c-289dd65335c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ed9f7099-62be-44a2-bda6-e20be81fb678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_HedgingDesignationAxis_ed9f7099-62be-44a2-bda6-e20be81fb678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_89689342-fc3a-47f0-abdb-fbfc705d67d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ed9f7099-62be-44a2-bda6-e20be81fb678" xlink:to="loc_us-gaap_HedgingDesignationDomain_89689342-fc3a-47f0-abdb-fbfc705d67d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d36f890b-31f4-4e9b-86bb-ed7a668d2710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_89689342-fc3a-47f0-abdb-fbfc705d67d1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d36f890b-31f4-4e9b-86bb-ed7a668d2710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_462435aa-5e18-41d3-952e-06d4672ac262" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_37887a15-4733-4b37-ac16-00c233cca85f" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_37887a15-4733-4b37-ac16-00c233cca85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bfd1244e-3084-4b2b-b36c-1573e340cfb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bfd1244e-3084-4b2b-b36c-1573e340cfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_63a207d6-355a-4f01-bf84-e7fa23f4f07d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_63a207d6-355a-4f01-bf84-e7fa23f4f07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eeb58a0a-baee-4dba-a8aa-fe22f05e0902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eeb58a0a-baee-4dba-a8aa-fe22f05e0902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_482db184-fd5b-4ecc-a7ee-d5c3c5deebc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_482db184-fd5b-4ecc-a7ee-d5c3c5deebc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c61ac26f-bb9f-457a-b356-9fc7e32ad2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c61ac26f-bb9f-457a-b356-9fc7e32ad2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_cc8e16a1-48dc-4125-a693-149de1fbfc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_cc8e16a1-48dc-4125-a693-149de1fbfc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c01f3080-6541-42cb-97a5-23a32362d97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c01f3080-6541-42cb-97a5-23a32362d97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_33c5b627-b3b4-4bad-9d9c-7c4eec09e83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_33c5b627-b3b4-4bad-9d9c-7c4eec09e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ce1d11af-9cd5-45e2-bb69-25e2d97f8f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ce1d11af-9cd5-45e2-bb69-25e2d97f8f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_059659d3-1332-485a-ba2a-afa9f6483e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_059659d3-1332-485a-ba2a-afa9f6483e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure_9b45889d-868f-49b5-b93b-5565c85d889c" xlink:href="hcat-20210331.xsd#hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure_9b45889d-868f-49b5-b93b-5565c85d889c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostGrossLiabilityComponent_df50b3c5-fd2a-436a-a3b3-00fb3a78f93f" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostGrossLiabilityComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_DebtIssuanceCostGrossLiabilityComponent_df50b3c5-fd2a-436a-a3b3-00fb3a78f93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostGrossEquityComponent_030a43ce-8a92-42ed-80c3-d7e279cb87fa" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostGrossEquityComponent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_hcat_DebtIssuanceCostGrossEquityComponent_030a43ce-8a92-42ed-80c3-d7e279cb87fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6e66d779-80c4-4d51-8fa1-43b9f202d1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_SharePrice_6e66d779-80c4-4d51-8fa1-43b9f202d1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_69aeb682-9afd-4a81-9c6e-e524474c3fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_69aeb682-9afd-4a81-9c6e-e524474c3fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCostOfHedge_e7af59ea-49ae-4fbd-a928-23d1a9770ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCostOfHedge"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DerivativeCostOfHedge_e7af59ea-49ae-4fbd-a928-23d1a9770ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapPrice_3a99d24c-a6b2-4a35-9b52-342b120637cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCapPrice"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67695ca-fca0-497a-9f55-d646581a1a37" xlink:to="loc_us-gaap_DerivativeCapPrice_3a99d24c-a6b2-4a35-9b52-342b120637cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8e9b038-6481-424d-81cf-2ca3c7f7874a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8e9b038-6481-424d-81cf-2ca3c7f7874a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:to="loc_us-gaap_DebtInstrumentAxis_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f2bbe12-9796-44f6-b416-2be969aceb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a67e0f9a-cff6-498b-ad2e-a7926c4c9f33" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f2bbe12-9796-44f6-b416-2be969aceb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_ff395745-3910-4fb0-b5bf-4ace81abcc02" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f2bbe12-9796-44f6-b416-2be969aceb14" xlink:to="loc_hcat_SeniorNotesDue2025Member_ff395745-3910-4fb0-b5bf-4ace81abcc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3c880ebe-2e87-436e-9a23-493ad89a72c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3c880ebe-2e87-436e-9a23-493ad89a72c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8b46edf-ca93-41b0-aed5-724514f025cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c880ebe-2e87-436e-9a23-493ad89a72c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8b46edf-ca93-41b0-aed5-724514f025cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_d60cf683-5af0-4141-b973-5889665ab56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8b46edf-ca93-41b0-aed5-724514f025cc" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_d60cf683-5af0-4141-b973-5889665ab56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5e131ba7-7bf1-4e6a-a5c8-b9cc0ab0678f" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_fd2d04aa-3069-4bbc-8c99-21807addac24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:to="loc_us-gaap_InterestExpenseDebt_fd2d04aa-3069-4bbc-8c99-21807addac24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b41358d1-58b3-4958-80cd-7fdbbd71ec6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b41358d1-58b3-4958-80cd-7fdbbd71ec6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_429d48e5-5c91-4c21-8e19-d0e2bafa240b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0e35c9f8-043d-45ad-bb1d-47d6cb9bc85a" xlink:to="loc_us-gaap_InterestExpense_429d48e5-5c91-4c21-8e19-d0e2bafa240b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_13e861dd-7b7a-46f8-8e35-e582e1d2e3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_13e861dd-7b7a-46f8-8e35-e582e1d2e3e9" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7942acb-8b98-4462-9342-3452bee3b27d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a6d45f9-c8b9-4a7f-ad6c-a6e81906b31a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7942acb-8b98-4462-9342-3452bee3b27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_c170d22f-1a55-44eb-99f4-c79a93b454d3" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7942acb-8b98-4462-9342-3452bee3b27d" xlink:to="loc_hcat_SeniorNotesDue2025Member_c170d22f-1a55-44eb-99f4-c79a93b454d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a049d3b0-5fd2-49c3-b17c-84a55aef75db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a049d3b0-5fd2-49c3-b17c-84a55aef75db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_daaf0f07-f09c-4ef8-83b6-f15d7aad3698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a049d3b0-5fd2-49c3-b17c-84a55aef75db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_daaf0f07-f09c-4ef8-83b6-f15d7aad3698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_eb345965-8ea4-4151-a2dd-9e8d48913a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_daaf0f07-f09c-4ef8-83b6-f15d7aad3698" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_eb345965-8ea4-4151-a2dd-9e8d48913a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_261fe069-11da-455b-aaae-3bc40e6217b8" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_92d33239-0902-4322-96ea-c5997a879146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_92d33239-0902-4322-96ea-c5997a879146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_34f09e39-21e0-4846-92ae-333ab8ae2e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_34f09e39-21e0-4846-92ae-333ab8ae2e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8738f36e-a13a-49be-b21f-6b9fbceb2037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8738f36e-a13a-49be-b21f-6b9fbceb2037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1dd7e383-4bb7-4e85-90ac-388a65ca3222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abe417f2-9e9c-49aa-9497-0b0b88116bb6" xlink:to="loc_us-gaap_LongTermDebt_1dd7e383-4bb7-4e85-90ac-388a65ca3222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1928a580-b29e-4158-aa87-52d9c2eb19fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1928a580-b29e-4158-aa87-52d9c2eb19fd" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ccfbe000-7c3c-4515-ac7f-54f59541014b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:to="loc_us-gaap_DebtInstrumentAxis_ccfbe000-7c3c-4515-ac7f-54f59541014b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbb49fa8-8b99-47c9-b241-24a080201378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ccfbe000-7c3c-4515-ac7f-54f59541014b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbb49fa8-8b99-47c9-b241-24a080201378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_01eef18b-a38c-4a13-9586-92e16c3ab9c6" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbb49fa8-8b99-47c9-b241-24a080201378" xlink:to="loc_hcat_SeniorNotesDue2025Member_01eef18b-a38c-4a13-9586-92e16c3ab9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_241a42a7-568e-43fb-a76b-5a775cbc7842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_241a42a7-568e-43fb-a76b-5a775cbc7842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ad222dcf-200d-44f3-82c5-e141d9e3e7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_241a42a7-568e-43fb-a76b-5a775cbc7842" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ad222dcf-200d-44f3-82c5-e141d9e3e7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_310a8d9a-d04c-4f5d-b850-46d0a35cfb16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ad222dcf-200d-44f3-82c5-e141d9e3e7ba" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_310a8d9a-d04c-4f5d-b850-46d0a35cfb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0771c256-aac0-431b-aceb-18848b78babd" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_7ae948f4-65bc-4af5-a05f-c3b8ed56e625" xlink:href="hcat-20210331.xsd#hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:to="loc_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross_7ae948f4-65bc-4af5-a05f-c3b8ed56e625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DebtIssuanceCostsGrossEquityComponent_53988dc7-dccd-4810-ac09-da623f061236" xlink:href="hcat-20210331.xsd#hcat_DebtIssuanceCostsGrossEquityComponent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:to="loc_hcat_DebtIssuanceCostsGrossEquityComponent_53988dc7-dccd-4810-ac09-da623f061236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1296400c-9eac-44d8-b27d-b22a96e1c584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1e425b32-f7a2-4ef1-8939-549e6dc215b6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1296400c-9eac-44d8-b27d-b22a96e1c584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockholdersEquity" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e05cb195-e4c8-4671-9729-b208c34adc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_19b74c5b-387b-4157-9286-dac96c4d6435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e05cb195-e4c8-4671-9729-b208c34adc02" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_19b74c5b-387b-4157-9286-dac96c4d6435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_788fa0a1-f48c-44ac-8a7a-5937c665628c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:href="hcat-20210331.xsd#hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_788fa0a1-f48c-44ac-8a7a-5937c665628c" xlink:to="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20082877-58a1-4c1e-ad9c-ef38d208a646" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:to="loc_srt_CounterpartyNameAxis_20082877-58a1-4c1e-ad9c-ef38d208a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95e9dd81-ceb5-4c55-a675-5d7ad7bc8ee1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_20082877-58a1-4c1e-ad9c-ef38d208a646" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95e9dd81-ceb5-4c55-a675-5d7ad7bc8ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_9d9974a8-5371-4491-b7fd-3ecaf378d8dc" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95e9dd81-ceb5-4c55-a675-5d7ad7bc8ee1" xlink:to="loc_hcat_VitalwareLLCMember_9d9974a8-5371-4491-b7fd-3ecaf378d8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0eb962c5-fe9a-45ee-a88d-4a0eef6451db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0eb962c5-fe9a-45ee-a88d-4a0eef6451db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cf79ff6-0c48-4b57-af81-a721f36a846e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0eb962c5-fe9a-45ee-a88d-4a0eef6451db" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cf79ff6-0c48-4b57-af81-a721f36a846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_c53abaf8-52f8-4755-bc60-671cbac7a0d2" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cf79ff6-0c48-4b57-af81-a721f36a846e" xlink:to="loc_hcat_AbleHealthIncMember_c53abaf8-52f8-4755-bc60-671cbac7a0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable_1a808c06-3021-4baf-912b-95c9c420d96a" xlink:to="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bc23615e-b8cc-4cbf-98d7-54a385f255c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bc23615e-b8cc-4cbf-98d7-54a385f255c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_da305198-ee17-493f-9a0d-53182a741578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_PreferredStockSharesIssued_da305198-ee17-493f-9a0d-53182a741578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5b8c2742-c6c8-4532-a309-86a480029613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5b8c2742-c6c8-4532-a309-86a480029613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_59bac105-2dc4-4d1c-844c-7a13b5ecc408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_59bac105-2dc4-4d1c-844c-7a13b5ecc408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cda31834-0fed-4f02-a55c-6ba997c1d871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cda31834-0fed-4f02-a55c-6ba997c1d871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_71f3851d-c70b-4794-8e6e-a05a8f17c9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_SharesIssued_71f3851d-c70b-4794-8e6e-a05a8f17c9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4a4ba909-6be8-4f2b-9d21-235a82227736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_us-gaap_SharesOutstanding_4a4ba909-6be8-4f2b-9d21-235a82227736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockholdersVote_94104c66-6a03-4876-b8e9-afa6adf0a98e" xlink:href="hcat-20210331.xsd#hcat_StockholdersVote"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0209966f-8b3f-4f11-b262-c1be307e6380" xlink:to="loc_hcat_StockholdersVote_94104c66-6a03-4876-b8e9-afa6adf0a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShare" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d892853a-2c0a-4b2b-9074-9dfd2a5bd20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_faa7f536-0744-469d-abca-d0c3378cf078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d892853a-2c0a-4b2b-9074-9dfd2a5bd20d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_faa7f536-0744-469d-abca-d0c3378cf078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a3154e81-ca0e-4dfc-87de-b7a61f5c34e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bf0f1a6a-269b-4c71-8e54-3508f77c73d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a3154e81-ca0e-4dfc-87de-b7a61f5c34e6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bf0f1a6a-269b-4c71-8e54-3508f77c73d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f2635704-0678-4dc2-ab99-f32259f2e6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a3154e81-ca0e-4dfc-87de-b7a61f5c34e6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f2635704-0678-4dc2-ab99-f32259f2e6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0a72016f-58d2-4f85-8946-a1adca422c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ff913cd8-13d1-48aa-b0f7-5a5e3269558a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a72016f-58d2-4f85-8946-a1adca422c9f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ff913cd8-13d1-48aa-b0f7-5a5e3269558a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2d25429a-b2a6-49a7-9133-00551555bf03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ff913cd8-13d1-48aa-b0f7-5a5e3269558a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2d25429a-b2a6-49a7-9133-00551555bf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ad6f02de-2e0e-4a49-9f23-48bcfcb20ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a72016f-58d2-4f85-8946-a1adca422c9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ad6f02de-2e0e-4a49-9f23-48bcfcb20ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1f4c56bc-89fe-4022-b75f-d9568a1beaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ad6f02de-2e0e-4a49-9f23-48bcfcb20ead" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1f4c56bc-89fe-4022-b75f-d9568a1beaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_f6938e5c-decf-41a4-bf9e-ba41e4420619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a72016f-58d2-4f85-8946-a1adca422c9f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_f6938e5c-decf-41a4-bf9e-ba41e4420619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e5c5d01e-fc3e-47e7-84c4-c550f0d63d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5c5d01e-fc3e-47e7-84c4-c550f0d63d96" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c442b699-258d-4415-bd61-ab67dd9d4aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c442b699-258d-4415-bd61-ab67dd9d4aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c442b699-258d-4415-bd61-ab67dd9d4aaf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_220c5222-28a7-4702-84fb-dc72da354783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_EmployeeStockOptionMember_220c5222-28a7-4702-84fb-dc72da354783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_671e7571-a142-46cd-957f-ff13e6d9e327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_671e7571-a142-46cd-957f-ff13e6d9e327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_19ec0d77-26db-4d4f-b466-e3d07d4b8f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_19ec0d77-26db-4d4f-b466-e3d07d4b8f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_472b5f3d-6367-442d-94c4-ae8e3ebc1c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_SeniorNotesMember_472b5f3d-6367-442d-94c4-ae8e3ebc1c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContingentConsiderationMember_3fd0dced-a706-4fa3-92c0-bb55bf772784" xlink:href="hcat-20210331.xsd#hcat_ContingentConsiderationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_hcat_ContingentConsiderationMember_3fd0dced-a706-4fa3-92c0-bb55bf772784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8e93ab60-a3db-4a43-a3b1-f5305d093bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_EmployeeStockMember_8e93ab60-a3db-4a43-a3b1-f5305d093bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3d4938b4-fce4-4767-880c-67f6888641b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad90ce1-578e-4cee-9d54-0e3191532135" xlink:to="loc_us-gaap_RestrictedStockMember_3d4938b4-fce4-4767-880c-67f6888641b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5fc92530-c4d5-403f-aa1f-a1c54b033f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_5fc92530-c4d5-403f-aa1f-a1c54b033f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72c19558-5ac1-432b-97be-82da90a40576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5fc92530-c4d5-403f-aa1f-a1c54b033f59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72c19558-5ac1-432b-97be-82da90a40576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SeniorNotesDue2025Member_a7c9a0a0-9fe7-4a45-9692-821b9df0dcaa" xlink:href="hcat-20210331.xsd#hcat_SeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72c19558-5ac1-432b-97be-82da90a40576" xlink:to="loc_hcat_SeniorNotesDue2025Member_a7c9a0a0-9fe7-4a45-9692-821b9df0dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_00dd97e8-7274-46b9-bc13-1b08d6c20d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_00dd97e8-7274-46b9-bc13-1b08d6c20d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3f313040-96c3-4529-b07e-e447c6e76f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_00dd97e8-7274-46b9-bc13-1b08d6c20d0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3f313040-96c3-4529-b07e-e447c6e76f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_77531448-dec4-4761-a1a5-4d1cdde130f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3f313040-96c3-4529-b07e-e447c6e76f9c" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_77531448-dec4-4761-a1a5-4d1cdde130f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a3bf9cb-d29a-41d2-895d-257f3eff19e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cbe2d06-1720-4483-b6d3-d25dddac6c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cbe2d06-1720-4483-b6d3-d25dddac6c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e3cef11e-080f-4902-8cd6-04d526249e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5dc83f-18b2-4125-b081-407a45a97c92" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e3cef11e-080f-4902-8cd6-04d526249e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04bf13e8-75c9-4de7-86e5-6030c58040f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d96db96c-29b8-4ea7-a66a-cf93584e0211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04bf13e8-75c9-4de7-86e5-6030c58040f3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d96db96c-29b8-4ea7-a66a-cf93584e0211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_357c8494-ab59-4090-b6f6-a838496ce88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_7717514f-77aa-48cc-aeae-726d4a40815e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_357c8494-ab59-4090-b6f6-a838496ce88f" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_7717514f-77aa-48cc-aeae-726d4a40815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9ccc5eb7-c929-4215-94fa-3b6a09a2d44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_357c8494-ab59-4090-b6f6-a838496ce88f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9ccc5eb7-c929-4215-94fa-3b6a09a2d44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_51d90818-c0c3-4d55-80e9-8a2897396a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_357c8494-ab59-4090-b6f6-a838496ce88f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_51d90818-c0c3-4d55-80e9-8a2897396a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ea11df6a-4ec2-4050-bee3-53184cb4443c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_357c8494-ab59-4090-b6f6-a838496ce88f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ea11df6a-4ec2-4050-bee3-53184cb4443c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7380f39-a71c-4fb9-bad4-01e44ce0d894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7380f39-a71c-4fb9-bad4-01e44ce0d894" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_21c479cc-0c5b-43e3-85a1-67b1052d2180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_PlanNameAxis_21c479cc-0c5b-43e3-85a1-67b1052d2180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_21c479cc-0c5b-43e3-85a1-67b1052d2180" xlink:to="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlanMember_7bcee816-f38f-43f1-aee5-2dfb73e2335f" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:to="loc_hcat_StockIncentivePlanMember_7bcee816-f38f-43f1-aee5-2dfb73e2335f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlan2011Member_eb2a74f1-8718-42ce-b051-a092745b9832" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlan2011Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:to="loc_hcat_StockIncentivePlan2011Member_eb2a74f1-8718-42ce-b051-a092745b9832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_StockIncentivePlan2019Member_5ee22682-0005-42fc-bd20-0bbc91948368" xlink:href="hcat-20210331.xsd#hcat_StockIncentivePlan2019Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_556c07e7-cb66-4417-88b7-68d7b638aca4" xlink:to="loc_hcat_StockIncentivePlan2019Member_5ee22682-0005-42fc-bd20-0bbc91948368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_70f1c697-af4f-4e8b-8ecd-0bc36e7b0888" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_AbleHealthIncMember_766f608d-3486-404c-8069-4c131f7bc972" xlink:href="hcat-20210331.xsd#hcat_AbleHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:to="loc_hcat_AbleHealthIncMember_766f608d-3486-404c-8069-4c131f7bc972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_VitalwareLLCMember_498c1a97-930f-49aa-b21b-7ad7a7a20670" xlink:href="hcat-20210331.xsd#hcat_VitalwareLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd0746da-9892-4771-a1f7-52649d0542b1" xlink:to="loc_hcat_VitalwareLLCMember_498c1a97-930f-49aa-b21b-7ad7a7a20670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3c7068ed-401b-4d90-bade-133691d079dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_AwardTypeAxis_3c7068ed-401b-4d90-bade-133691d079dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3c7068ed-401b-4d90-bade-133691d079dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8cd825a8-a916-4c05-b647-83108c2e6dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8cd825a8-a916-4c05-b647-83108c2e6dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_72ae7561-21ec-4aa2-afa7-5b3c10523f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_72ae7561-21ec-4aa2-afa7-5b3c10523f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_2b0066bd-22e9-4db1-ae6e-81558828dac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_2b0066bd-22e9-4db1-ae6e-81558828dac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c13757eb-2f0b-4a5b-a143-08891c77625c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_RestrictedStockMember_c13757eb-2f0b-4a5b-a143-08891c77625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_72082887-2f7a-4f00-bb07-e8f681118560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc0dcf5-bc60-4f00-9983-6424bd619d23" xlink:to="loc_us-gaap_EmployeeStockMember_72082887-2f7a-4f00-bb07-e8f681118560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6b64738c-eeb8-4fa2-8bec-09a84c5ea609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_VestingAxis_6b64738c-eeb8-4fa2-8bec-09a84c5ea609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6ee7c414-f603-42c8-94d0-f9040a219431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_6b64738c-eeb8-4fa2-8bec-09a84c5ea609" xlink:to="loc_us-gaap_VestingDomain_6ee7c414-f603-42c8-94d0-f9040a219431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b368c651-1fe8-4e99-9d4f-89f6b00bc2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6ee7c414-f603-42c8-94d0-f9040a219431" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b368c651-1fe8-4e99-9d4f-89f6b00bc2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d92445a-4be3-48fc-8f90-7692c5d74ba9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_srt_RangeAxis_2d92445a-4be3-48fc-8f90-7692c5d74ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2d92445a-4be3-48fc-8f90-7692c5d74ba9" xlink:to="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87818b17-f575-49d1-a52a-efdb25774d63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:to="loc_srt_MinimumMember_87818b17-f575-49d1-a52a-efdb25774d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3cbd3c36-f42a-49ce-8e6a-ddbce3a5538f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e092cce-3dcf-4f73-8a0e-23e998d7be03" xlink:to="loc_srt_MaximumMember_3cbd3c36-f42a-49ce-8e6a-ddbce3a5538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7fd1713-9e62-4d99-b335-614fdff1cb07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05144a4c-9883-48c9-9fa4-34aee1920d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05144a4c-9883-48c9-9fa4-34aee1920d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_63bfcec7-0cff-4792-9fc4-82f79663acf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_63bfcec7-0cff-4792-9fc4-82f79663acf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares_c4839d9a-42c2-4e5d-9630-2fb0e5aa0c17" xlink:href="hcat-20210331.xsd#hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares_c4839d9a-42c2-4e5d-9630-2fb0e5aa0c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_597b37c1-c769-476b-bafc-ff9169a80613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_597b37c1-c769-476b-bafc-ff9169a80613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_423f3b3e-f9e7-43d2-bc7a-6e32aa7033f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_423f3b3e-f9e7-43d2-bc7a-6e32aa7033f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_82b81a64-2087-47ca-ac85-471c71622aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_82b81a64-2087-47ca-ac85-471c71622aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14046bf4-3244-4f25-8b7f-b00fe7b9d63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14046bf4-3244-4f25-8b7f-b00fe7b9d63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_510f6873-90f6-46ce-b4c0-248bc7cdd3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_510f6873-90f6-46ce-b4c0-248bc7cdd3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae810d50-8057-4dab-a9f4-5fb0530be1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae810d50-8057-4dab-a9f4-5fb0530be1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_71283223-99e7-4f68-a28a-d6dc5f8f145a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_71283223-99e7-4f68-a28a-d6dc5f8f145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_44f922a5-17cb-4920-984e-c3f4ba840590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_44f922a5-17cb-4920-984e-c3f4ba840590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5f9ff9a8-d468-457d-bf2d-dd1da5d148a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5f9ff9a8-d468-457d-bf2d-dd1da5d148a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_1d74cf90-0eae-4b36-bcdb-e4daba807e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_1d74cf90-0eae-4b36-bcdb-e4daba807e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_d8c3ca69-7bea-4d7f-a7e8-a08181bb8cf3" xlink:href="hcat-20210331.xsd#hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_d8c3ca69-7bea-4d7f-a7e8-a08181bb8cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e37351a3-1bab-47d3-b7a2-973bef5163e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e37351a3-1bab-47d3-b7a2-973bef5163e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee_ff2b60a9-6aba-4f60-87b3-044affc4e32d" xlink:href="hcat-20210331.xsd#hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee_ff2b60a9-6aba-4f60-87b3-044affc4e32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed_ed536ab2-8e2d-4df5-9f76-348445ee7561" xlink:href="hcat-20210331.xsd#hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed_ed536ab2-8e2d-4df5-9f76-348445ee7561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2d4b9867-04b3-4098-8e13-0b99a654a164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2d4b9867-04b3-4098-8e13-0b99a654a164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_78e7c3ec-8a4f-442f-89d7-0bff21883962" xlink:href="hcat-20210331.xsd#hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares_78e7c3ec-8a4f-442f-89d7-0bff21883962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3dc2bc58-7ae1-416b-b70c-4a9b37736413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a84eccc-cee2-4cac-8769-bb8b65e0cd30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3dc2bc58-7ae1-416b-b70c-4a9b37736413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ee607eb-44c8-4a41-9229-627c535989f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ee607eb-44c8-4a41-9229-627c535989f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83c72061-02bf-48bb-95c4-b2765a6dc220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:to="loc_us-gaap_AwardTypeAxis_83c72061-02bf-48bb-95c4-b2765a6dc220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_83c72061-02bf-48bb-95c4-b2765a6dc220" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8194554-8d11-4191-acd4-2231f036034a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8194554-8d11-4191-acd4-2231f036034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_76d60eb1-cf6a-41cf-af64-8ab59287efa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_76d60eb1-cf6a-41cf-af64-8ab59287efa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_05f803ca-3aad-47b7-af6d-fa5e822c7516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_05f803ca-3aad-47b7-af6d-fa5e822c7516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_06cf2830-9262-4aa8-8134-de15410c5572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_EmployeeStockMember_06cf2830-9262-4aa8-8134-de15410c5572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_77879ff6-3246-48c8-8c20-7bbce4949e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a477adb-7987-4423-add2-f35fa266218e" xlink:to="loc_us-gaap_RestrictedStockMember_77879ff6-3246-48c8-8c20-7bbce4949e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d2f47340-d0ed-4f34-b48d-b9f63d9ba2d2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f67672c0-9a03-4b94-be6a-32ba56af769a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_CostOfSalesMember_f67672c0-9a03-4b94-be6a-32ba56af769a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_a7f10356-0308-480b-a723-dd581f19738d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_a7f10356-0308-480b-a723-dd581f19738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_efaded06-405f-48b3-b22b-b54dcdd7dd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_efaded06-405f-48b3-b22b-b54dcdd7dd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f1874118-90da-4b11-8328-0dab9ce21592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea5f7ae-99fb-43cc-992f-b226fcfcb284" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f1874118-90da-4b11-8328-0dab9ce21592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abbc9231-a541-47f5-ac49-28b5c390a549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95846f48-50fe-474b-98d3-44f47b02f8ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abbc9231-a541-47f5-ac49-28b5c390a549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_db8633d6-241c-42a4-bf0a-5e37d66e7cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abbc9231-a541-47f5-ac49-28b5c390a549" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_db8633d6-241c-42a4-bf0a-5e37d66e7cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_02918e82-d982-4468-92f6-ae8d7abb3d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_02918e82-d982-4468-92f6-ae8d7abb3d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39c7d8ce-919e-4d9b-b13e-2d489d9c73cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_02918e82-d982-4468-92f6-ae8d7abb3d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39c7d8ce-919e-4d9b-b13e-2d489d9c73cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c58e30e5-11b8-4564-aa86-33b09fea12c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_02918e82-d982-4468-92f6-ae8d7abb3d1a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c58e30e5-11b8-4564-aa86-33b09fea12c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_080accde-bd9e-49ea-8315-37267fafcf1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_02918e82-d982-4468-92f6-ae8d7abb3d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_080accde-bd9e-49ea-8315-37267fafcf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4aa09319-1075-4458-be18-6426c87d21f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_02918e82-d982-4468-92f6-ae8d7abb3d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4aa09319-1075-4458-be18-6426c87d21f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_979c3079-ed33-49bf-8a57-5c8ad516d83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_979c3079-ed33-49bf-8a57-5c8ad516d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e7a6a4f7-a8e9-4381-8ae5-85f7356ea9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e7a6a4f7-a8e9-4381-8ae5-85f7356ea9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ed145b1a-87f8-4e1e-9a95-c9fc443b39f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ed145b1a-87f8-4e1e-9a95-c9fc443b39f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df128f64-1d86-486c-b1b1-ff62ae7f50f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ed145b1a-87f8-4e1e-9a95-c9fc443b39f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df128f64-1d86-486c-b1b1-ff62ae7f50f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f52c2c09-2f5a-4741-b490-45e3f189be13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ed145b1a-87f8-4e1e-9a95-c9fc443b39f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f52c2c09-2f5a-4741-b490-45e3f189be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_20df397d-3481-4e7a-857b-a664dfe82c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ed145b1a-87f8-4e1e-9a95-c9fc443b39f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_20df397d-3481-4e7a-857b-a664dfe82c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1acad12c-2ebb-4574-b489-b56916a7899c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ed145b1a-87f8-4e1e-9a95-c9fc443b39f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1acad12c-2ebb-4574-b489-b56916a7899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c3073147-129e-4e6e-b1db-18eb9def1b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c3073147-129e-4e6e-b1db-18eb9def1b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8465beff-33a1-4c61-9e0b-d63f14e7991d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8465beff-33a1-4c61-9e0b-d63f14e7991d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cd1abde8-720a-4d1f-a12c-13ad2df31675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cd1abde8-720a-4d1f-a12c-13ad2df31675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8f956993-f27f-4312-aa3c-81fc630271a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8f956993-f27f-4312-aa3c-81fc630271a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_52feaff9-c991-4bfa-81be-d01731cd6623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_52feaff9-c991-4bfa-81be-d01731cd6623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_08e6a774-332f-471c-8b28-5cc17981ae1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_08e6a774-332f-471c-8b28-5cc17981ae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a707322f-6a35-4d64-ac11-7744e8d13f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a707322f-6a35-4d64-ac11-7744e8d13f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76188504-af55-4748-8e72-17692e648da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_354a7441-39c7-471d-9aed-c5ef5aa1be89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76188504-af55-4748-8e72-17692e648da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c7fd369-7daa-42c9-91aa-fb646a12fb95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b828d774-5a57-40bb-a652-3dac0131be13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c7fd369-7daa-42c9-91aa-fb646a12fb95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b828d774-5a57-40bb-a652-3dac0131be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57e05c61-fbb4-4c80-bd02-0c4fc4de451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b828d774-5a57-40bb-a652-3dac0131be13" xlink:to="loc_us-gaap_AwardTypeAxis_57e05c61-fbb4-4c80-bd02-0c4fc4de451b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_57e05c61-fbb4-4c80-bd02-0c4fc4de451b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_39edb9cc-451f-4a2e-92ff-91421d011a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_39edb9cc-451f-4a2e-92ff-91421d011a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_f3113698-f297-410c-bb0d-1fb91a43fc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ed86066-b5c4-4370-bb0e-552bd376565c" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_f3113698-f297-410c-bb0d-1fb91a43fc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b828d774-5a57-40bb-a652-3dac0131be13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_643a1b0f-e0e0-4965-b9e6-cbc7dc14b7da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_643a1b0f-e0e0-4965-b9e6-cbc7dc14b7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cf6f277-1b61-442f-90ca-b13e5540635d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cf6f277-1b61-442f-90ca-b13e5540635d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6b28c510-9c7d-43a6-a330-932a6caf575f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6b28c510-9c7d-43a6-a330-932a6caf575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf609039-ab4d-40e1-bada-f0b084be2136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf609039-ab4d-40e1-bada-f0b084be2136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_657ab502-3fea-4768-bac9-d67b196b1476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74d76ed8-9451-4a83-a0b0-51c22b7eafa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_657ab502-3fea-4768-bac9-d67b196b1476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d758a4-a0f8-4f69-9ced-ee2770b2db9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_843c9e2c-ea8d-40ba-9b6d-42c481169b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_843c9e2c-ea8d-40ba-9b6d-42c481169b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5ec78b58-3ea8-4835-a6d7-da51664848c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5ec78b58-3ea8-4835-a6d7-da51664848c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0fb0aefd-4a3a-4811-b2cf-80635237bf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0fb0aefd-4a3a-4811-b2cf-80635237bf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1456df53-6a08-492d-a7ac-216082e248b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1456df53-6a08-492d-a7ac-216082e248b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa25d6f9-ba24-482c-978f-ae816fcbf4df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce9d84a9-9a66-406c-8eb4-3ffa0be5924c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa25d6f9-ba24-482c-978f-ae816fcbf4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03b05006-9af6-4e55-bdd3-d9885f8e0ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76e841b7-2991-4880-a321-c62e8ff25abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03b05006-9af6-4e55-bdd3-d9885f8e0ece" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76e841b7-2991-4880-a321-c62e8ff25abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f499c8d-7431-45ae-a1e5-10c5ddb051c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76e841b7-2991-4880-a321-c62e8ff25abf" xlink:to="loc_us-gaap_AwardTypeAxis_2f499c8d-7431-45ae-a1e5-10c5ddb051c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d47d35e-6aa3-4972-8e88-49fbd979f756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2f499c8d-7431-45ae-a1e5-10c5ddb051c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d47d35e-6aa3-4972-8e88-49fbd979f756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0fa2aabb-944f-4806-a577-ea53a0c91c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d47d35e-6aa3-4972-8e88-49fbd979f756" xlink:to="loc_us-gaap_EmployeeStockMember_0fa2aabb-944f-4806-a577-ea53a0c91c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76e841b7-2991-4880-a321-c62e8ff25abf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b6c17155-51f8-4ab0-916d-9dcee0ba4bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b6c17155-51f8-4ab0-916d-9dcee0ba4bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e44825f-2c40-4fbc-8e94-aecc17ec170a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e44825f-2c40-4fbc-8e94-aecc17ec170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08a8c05e-aead-42b3-b899-126006108d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08a8c05e-aead-42b3-b899-126006108d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_1086266f-e79b-4db7-87c0-d3a1b93ff02f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ee0d38b-a63d-4b98-adfd-110c319e3afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_1086266f-e79b-4db7-87c0-d3a1b93ff02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/IncomeTaxes" xlink:type="simple" xlink:href="hcat-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_34d14cac-a645-4812-8cfd-b2f87ddc33a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b197b534-5de8-4c83-9148-5772db43cdba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34d14cac-a645-4812-8cfd-b2f87ddc33a7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b197b534-5de8-4c83-9148-5772db43cdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16cac1d5-5a5f-4b81-b84a-28598c9e2c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7ba4b3-c3b9-4d29-8d50-72d9580d1851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16cac1d5-5a5f-4b81-b84a-28598c9e2c89" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7ba4b3-c3b9-4d29-8d50-72d9580d1851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fc2de90a-de67-41e2-9e28-b7bc543ede64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16cac1d5-5a5f-4b81-b84a-28598c9e2c89" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fc2de90a-de67-41e2-9e28-b7bc543ede64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_63c3bfed-d73e-401c-9b6e-c4beec8a57a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16cac1d5-5a5f-4b81-b84a-28598c9e2c89" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_63c3bfed-d73e-401c-9b6e-c4beec8a57a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="hcat-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6be200f5-2c88-465f-99f1-f8b6c290d940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9dbe9ed7-c3d9-46aa-baa0-4b1af5d53c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6be200f5-2c88-465f-99f1-f8b6c290d940" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9dbe9ed7-c3d9-46aa-baa0-4b1af5d53c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligations"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_35e3c057-f2c5-47ad-af72-15cc8463369f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3a9262aa-937f-4511-ae6c-2d6acdb8a067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_35e3c057-f2c5-47ad-af72-15cc8463369f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3a9262aa-937f-4511-ae6c-2d6acdb8a067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c449e17a-6f48-4f6d-82c2-3a8a08ff1f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c449e17a-6f48-4f6d-82c2-3a8a08ff1f4f" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:to="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f30a63b5-7ac4-4b25-9e94-2046909acdf6" xlink:to="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyAndProfessionalServicesMember_1a13ba64-53d2-4600-8f1c-9d823efca0cc" xlink:href="hcat-20210331.xsd#hcat_TechnologyAndProfessionalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b391f6d6-9010-4406-9fc7-7052d022086f" xlink:to="loc_hcat_TechnologyAndProfessionalServicesMember_1a13ba64-53d2-4600-8f1c-9d823efca0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_745c623a-2aae-45aa-87b6-42eabcf4d50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_745c623a-2aae-45aa-87b6-42eabcf4d50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_9a95b0ec-0c12-4186-9701-24882924723d" xlink:to="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_4be98025-3fa6-4c4e-93be-9d5e946737b9" xlink:href="hcat-20210331.xsd#hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage_4be98025-3fa6-4c4e-93be-9d5e946737b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractTerm_32074d4c-eab9-41e2-bc53-93768f5f7e58" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractTerm_32074d4c-eab9-41e2-bc53-93768f5f7e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_c6a2097c-0746-43fd-a599-26524ff253a1" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod_c6a2097c-0746-43fd-a599-26524ff253a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_20fc1c4a-e28c-4dda-a2f0-889832f380ad" xlink:href="hcat-20210331.xsd#hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination_20fc1c4a-e28c-4dda-a2f0-889832f380ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_023689aa-d736-4f64-b19a-bf1a697fa400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_e805915f-70e9-4dad-abd9-681da1acb9dc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_023689aa-d736-4f64-b19a-bf1a697fa400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails_1" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_421e6970-bbe9-4693-97af-a659796eaaab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_421e6970-bbe9-4693-97af-a659796eaaab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6102c505-164b-4c66-bdca-f6d132b1d6c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6102c505-164b-4c66-bdca-f6d132b1d6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_7791afa5-87e7-4036-84ba-192aeb4dab72" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_54a5a01e-4932-4446-bbd6-d464eaa2a292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_54a5a01e-4932-4446-bbd6-d464eaa2a292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a0db5c75-81b5-45f2-b706-904ecf8362dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e72963fb-79c4-4194-8b0f-1a5da6b12ce4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a0db5c75-81b5-45f2-b706-904ecf8362dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="hcat-20210331.xsd#DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RelatedParties" xlink:type="simple" xlink:href="hcat-20210331.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4862487d-abef-4e80-a6e9-46416162f94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_fbc9a138-6751-4c26-b386-3625b3713740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4862487d-abef-4e80-a6e9-46416162f94a" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_fbc9a138-6751-4c26-b386-3625b3713740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#RelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/RelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_26cba02b-ede5-4649-b7e1-222f4bc36898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd6a7c81-de12-491d-97c5-b235578f5ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_26cba02b-ede5-4649-b7e1-222f4bc36898" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd6a7c81-de12-491d-97c5-b235578f5ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_de59a500-d87b-4f97-90a0-f7809ed88044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd6a7c81-de12-491d-97c5-b235578f5ce8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_de59a500-d87b-4f97-90a0-f7809ed88044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e41b1e8e-194c-4544-bd28-34052e39412a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_de59a500-d87b-4f97-90a0-f7809ed88044" xlink:to="loc_us-gaap_RelatedPartyDomain_e41b1e8e-194c-4544-bd28-34052e39412a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_9466437e-dae6-4a5b-b41e-e13e27625b15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e41b1e8e-194c-4544-bd28-34052e39412a" xlink:to="loc_srt_DirectorMember_9466437e-dae6-4a5b-b41e-e13e27625b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd6a7c81-de12-491d-97c5-b235578f5ce8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_cecb13a9-4965-4df0-9937-5e4bcaa2dc84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_RevenueFromRelatedParties_cecb13a9-4965-4df0-9937-5e4bcaa2dc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_cab5220c-92ea-485e-aa55-ac61ee08a279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_DueFromRelatedParties_cab5220c-92ea-485e-aa55-ac61ee08a279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_25856e63-4317-4cd6-b670-6022b7849d39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_25856e63-4317-4cd6-b670-6022b7849d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_9dc09ad5-0bcc-44b3-8a9f-88f0ca728c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_9dc09ad5-0bcc-44b3-8a9f-88f0ca728c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e71a7f5e-2a9d-484f-a4e3-0bbc978c8acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_664a2fd7-42e6-4a67-a0d8-cfb44812108b" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e71a7f5e-2a9d-484f-a4e3-0bbc978c8acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/Segments" xlink:type="simple" xlink:href="hcat-20210331.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_32250f59-2baf-4128-8144-eccab5ded3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5f5d43c8-8b11-4acc-8f02-c1cdadda74d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_32250f59-2baf-4128-8144-eccab5ded3ff" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5f5d43c8-8b11-4acc-8f02-c1cdadda74d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsTables" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f49f4498-9171-49b0-ab48-0e76fbd56044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1c5692d2-b92d-49ee-9adb-a0b49c117925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f49f4498-9171-49b0-ab48-0e76fbd56044" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1c5692d2-b92d-49ee-9adb-a0b49c117925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a953723d-6f19-4fd8-a980-fda8410944d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f49f4498-9171-49b0-ab48-0e76fbd56044" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a953723d-6f19-4fd8-a980-fda8410944d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_987a198d-6967-4a15-bfc5-d5837c9f0c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_143d5574-9e4b-4dff-99b7-22d35d54b522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_987a198d-6967-4a15-bfc5-d5837c9f0c57" xlink:to="loc_us-gaap_NumberOfOperatingSegments_143d5574-9e4b-4dff-99b7-22d35d54b522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_482e6e99-586f-46d2-92d9-8e8aa60a6555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_987a198d-6967-4a15-bfc5-d5837c9f0c57" xlink:to="loc_us-gaap_NumberOfReportableSegments_482e6e99-586f-46d2-92d9-8e8aa60a6555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsScheduledofSegmentRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7d90d209-74a5-42ce-a9f2-e375ec1e38b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_106ba987-6a50-4f75-870d-3a1b7faedcda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7d90d209-74a5-42ce-a9f2-e375ec1e38b1" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_106ba987-6a50-4f75-870d-3a1b7faedcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_373360d7-d145-4ae6-89d3-c594adfd4fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_106ba987-6a50-4f75-870d-3a1b7faedcda" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_373360d7-d145-4ae6-89d3-c594adfd4fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_373360d7-d145-4ae6-89d3-c594adfd4fde" xlink:to="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_6b44ba13-f459-4b79-9160-bb47e73c82c4" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:to="loc_hcat_TechnologyMember_6b44ba13-f459-4b79-9160-bb47e73c82c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_ffe9d1c6-ee17-4eb8-9745-1c6eec87a97e" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7f40d5ff-376c-45a2-9791-a03cf8912720" xlink:to="loc_hcat_ProfessionalServicesMember_ffe9d1c6-ee17-4eb8-9745-1c6eec87a97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f09ce44b-7be5-470e-af30-77ed16bfe597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_106ba987-6a50-4f75-870d-3a1b7faedcda" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f09ce44b-7be5-470e-af30-77ed16bfe597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ad0e41c-c89d-48c1-9842-c7e84e66f084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f09ce44b-7be5-470e-af30-77ed16bfe597" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ad0e41c-c89d-48c1-9842-c7e84e66f084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" xlink:type="simple" xlink:href="hcat-20210331.xsd#SegmentsScheduleofSegmentAdjustedGrossProfitDetails"/>
  <link:presentationLink xlink:role="http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_74104fd9-2b25-4baf-a24b-e41ba282bc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_74104fd9-2b25-4baf-a24b-e41ba282bc3f" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5f79ae38-ec44-404f-9c89-be2f47fb33e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:to="loc_srt_ConsolidationItemsAxis_5f79ae38-ec44-404f-9c89-be2f47fb33e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_5f79ae38-ec44-404f-9c89-be2f47fb33e2" xlink:to="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a95717cb-e9bb-4e7b-a6d0-c5f0850898ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:to="loc_us-gaap_OperatingSegmentsMember_a95717cb-e9bb-4e7b-a6d0-c5f0850898ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_288bbb62-a78a-4f69-b8fd-de1b9c451da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e0782184-b47e-4f7b-84b7-23f17b701263" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_288bbb62-a78a-4f69-b8fd-de1b9c451da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2dd13ed6-a680-4bd8-b029-a45790b5110b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2dd13ed6-a680-4bd8-b029-a45790b5110b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2dd13ed6-a680-4bd8-b029-a45790b5110b" xlink:to="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_TechnologyMember_9261d514-8a80-4b00-9957-e273e0563e7d" xlink:href="hcat-20210331.xsd#hcat_TechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:to="loc_hcat_TechnologyMember_9261d514-8a80-4b00-9957-e273e0563e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_ProfessionalServicesMember_21584411-1eca-49dd-be5d-e750db8f644a" xlink:href="hcat-20210331.xsd#hcat_ProfessionalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_82833f57-e897-4677-bef6-1f050d08b3a2" xlink:to="loc_hcat_ProfessionalServicesMember_21584411-1eca-49dd-be5d-e750db8f644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_cfd9cb49-791e-4bc2-9025-3b2eeabf47ea" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_74707b4d-cd36-4200-b9dd-78a64052aaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_us-gaap_GrossProfitAbstract_74707b4d-cd36-4200-b9dd-78a64052aaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_84d24877-a10e-4a7e-ae5c-8f2406bb5e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GrossProfitAbstract_74707b4d-cd36-4200-b9dd-78a64052aaf5" xlink:to="loc_us-gaap_GrossProfit_84d24877-a10e-4a7e-ae5c-8f2406bb5e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_27e34fd0-ec57-4411-9a3c-79034c4dba68" xlink:href="hcat-20210331.xsd#hcat_LessAdjustedGrossProfitreconcilingitemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_27e34fd0-ec57-4411-9a3c-79034c4dba68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0aad2156-f5c2-4dae-a8c4-602af3a4e0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract_27e34fd0-ec57-4411-9a3c-79034c4dba68" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0aad2156-f5c2-4dae-a8c4-602af3a4e0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:href="hcat-20210331.xsd#hcat_LessOtherReconcilingItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_cbc6566a-b0f8-4bc0-827d-ea9558bf24ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_cbc6566a-b0f8-4bc0-827d-ea9558bf24ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2861e8f8-48b0-46c3-ae4b-d71aeabeecc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2861e8f8-48b0-46c3-ae4b-d71aeabeecc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9ee7733d-75e0-4ac0-89b9-7292f936140c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9ee7733d-75e0-4ac0-89b9-7292f936140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1c444b12-9a8b-49bc-9417-4a5fc325d955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_us-gaap_DepreciationAndAmortization_1c444b12-9a8b-49bc-9417-4a5fc325d955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hcat_InterestAndOtherExpenseNet_d0b6feba-df34-4025-8597-210704d0c0dd" xlink:href="hcat-20210331.xsd#hcat_InterestAndOtherExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hcat_LessOtherReconcilingItemsAbstract_3aba7051-842c-4522-9a40-42da1d370c8d" xlink:to="loc_hcat_InterestAndOtherExpenseNet_d0b6feba-df34-4025-8597-210704d0c0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9c4bfbf5-0588-4af7-9e40-77897006dd5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_a09ede81-bddf-4bc4-9889-19b474bd96a3" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9c4bfbf5-0588-4af7-9e40-77897006dd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>hcat-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:hcat="http://www.healthcatalyst.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hcat-20210331.xsd" xlink:type="simple"/>
    <context id="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie345a5d82c04411d88183387ca0f2e03_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4dfda2f92ed340caa2877a927d22e736_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6bb236a6d7f468880b49898be6fc30a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5ece495212884ea7a688a503a845633c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia4ed21d069e44040883da517205949ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if13411e0950346e18adca59be7a3a6e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id239684cf62a40bd84edbe1e1929f0b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5246542574fd40a6acee46eddd59f600_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i067e0e6900304a738394616a183db02f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica0e3333f61a401497d1869d991e2376_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6b73d6b0c08b416fa95d0ffafd4a69be_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ice27b80f156b4c7c97e4c9714bf0a308_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i87e366123354486cababd5831e94051e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i183085abd0424ba1b6749e0788cec760_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icd2d729e83a74d25a64ee4134008cfca_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i384152dcce9849d1bba93e9d52950c6b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ffb26487eb34a6cad9855d641b8a555_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f406e1ada1b4b7fa1d2e0eb11b7bd16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32bab634e2c04ca8a0b8272bce5cc112_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf1c0fd3c5bb4f7490e1619c30315164_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i63dae0960a21470cadf5c35381490d80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73bfc66cbfc34ae8a0fa31cc621730d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i67e743d83b6e43f6a07eaae2dd2b103a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib2ee6ea456694392b6844031fc89de02_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9c0efcef22664d14815854888bb21e26_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i386ccc1569bb40d885c8301f5452d4c9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7c0cec055bcd4b89865d64d93fd1adbc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i963ff9fa8e4f417285df70d02db0ce49_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8a78b3ee92264aa6b424fb238b67d7f4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0b1145c0be2f4abd984b071985b91ff7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i570b1a58613c45b78737719cc3a0796e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8806568ffc14910a88f456175540071_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib98e1d9087f64f35abf0c9c0b35b25ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2eb546857cc494fa9f8c061084c10cc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7625b67853714c90870b7c5404d9bcbb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic1895ebcf2194a20ae75e64ba8b210ad_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1c6b011b06cd4b56805334a4b840ea06_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib11cd2ccbecf4ec4889f63e8c0bdbfe6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23793db4aa3a4118a87890e37cc5f76a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5eec362ff8b44eebbb405af5d1e31e89_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaa2ec48709a149158db346873042cfa2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3d455966ff3546f28112a01f67004be8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i19090821c190424ca2b60933a320196d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i752e657a7ed54158a466343124496aef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98f9fd2755be4ddca2dadbcf036fe11c_D20190710-20190710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <startDate>2019-07-10</startDate>
            <endDate>2019-07-10</endDate>
        </period>
    </context>
    <context id="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="ib3a602fe1da24b898d87f5aa96f55e7e_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hcat:RestrictedSharesPursuantToAcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="ie9a6f3c1d5434096a8602552e27ccd8b_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hcat:RestrictedSharesPursuantToAcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="i2d21b8b985b74d238f472e4e71050a30_I20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="ib7ca50433dfa41afaba5f4dbfd9c4080_I20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="ice7f7a67b58b4ab7b21087c875b742aa_I20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="i6d0acf0e57514eba9c3147edf4b9b2f3_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="if9289e7751f54283a46cb7fb7436a914_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="ie6bea69d2c8a4cbdb35a5f22ae1b2948_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ib2cff5f451304355a1795c9ec977b1b3_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i0bdbb8be29c94abbbe84a2dad772a00d_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i498f4874d4104d52939aa8749d65159d_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i51a417b5d4b4461bb7ff7bef53ae612f_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i34094f2ce17c4b68b9c7f3e2545dfc9d_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i1734d7abc4744d5683af026b80bc322e_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ica753ecaab5f4745ad630406fcb5ecf9_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:HealthfinchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i2cd704a45bb3466b99382868818856b6_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i0271ede7abee462eba0b2b698342faae_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="id10adc4ae8854029957496d9f5339693_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i59c0e7f496834c03a071df11af262227_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="i8ae6e93b2b18426481d9a6a8da986dc3_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="if5d756d95f7c48f0b87b33dc8c7a743e_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="ie0aa3a878073450c89d3c4a52f80971f_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="ia3be332fe9194ef58f9aceef7fcef46e_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:ContractBacklogsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="if53b8b11a34f4165a0b32d5030e61aaf_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="ifb69fcbcfa3c445cae93cdcd8e8f89e1_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i52203ce0773e4de29d77d41ca3e6ed52_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i563042bec9ce44faad7f33151e649064_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i345542d87cc5467f82f4b9ffbcd77517_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">hcat:AcquisitionRelatedFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a9284427b4344e99bd6a68791952947_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">hcat:AcquisitionRelatedFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04a82e47b69b4d3eb01ecc169fcbbdff_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:RecurringTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a5b2b2f3eb34e66b9f15ef94b7f93d3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:RecurringTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i072686e691b043fc99a5001437848336_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:OneTimeTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica63ebc6345a4c4e9bf1f23e7fa538d2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:OneTimeTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2b5ac1f2270243679239715132a65f39_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7dba3e825a6d4aa18b1576f50bc30986_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id3c750b2d03c4e43bd847dd5399458fa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6ffad74837e64a998ce0d0e6a9d0363c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdc1260ae65e4a948c0c470387cf66e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9fcd127174c94e03ada02115a901ebb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6db85473fe074ce1a8b9d070f8da1259_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i17f9ad5e961945caa4d034f51243794e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i260812b8834d48928c9d06e77dee395b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i55d7975897fb4234a03bea31f1b463be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfb53d4219524c099358c824a99b0cab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hcat:CustomerRelationshipsAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9514dc5706d84f94969cf5c1179a4865_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fa77551a95d4af6815afe266a065d63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i983abe9c75604218bf9215278d6c8786_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie10e2819b49b48ebaeb218115ba93d2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if83e5abba43a418b8748534d60c48c2b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb60e336f0d243aeb3c25066686e0e13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib630a4b7ddb6454bb0fd041f7d7959a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic1f14648338143b69e420b0bcff04694_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d7a206018584742a08cdb6786414f22_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib50a93f231d04a3c92f044e1aead7038_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b9f4a66d37c421d9e84a17684b6e893_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0db9e7d9d0645fe9a0dd92a5549d8ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i977516e22f8e4f18a06347de98aabdba_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hcat:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88139ab53d0d484f97717e145bade887_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hcat:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieb8030fbd94c4883ab8884ca9b7948c1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i541592340c83428bbdf196bbddcb23a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i426a8994b6c940268705dd62cb41316b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie7c3e9e5c69d458f81c897663c923806_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if016bb5751394439b838dd7a5e32d9e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3505f155dd9c49eeaf5dce4bd2bad37d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifddc111015e24dd5a3690fdb5f45cc03_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i12990573c5334556ae9ffecfcdd78f8b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib87ff6778e0941aea98e91250fcb83cc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib1af733c21c145808c8ce5cf39e9aa92_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id9cf71f707df4212a1eab4e8b98af652_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9d92a783fa4d4b9e8f5c6ddb9773b7ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iccf00f0e3ce94b20aa839b353e220099_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89f8b60d964c412f8bf1c17763bd40bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i935fba8f21d64ab0a83a3fc3303e30db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifaaece3cffb845d288b5e4226bc51516_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00c52c70966543f9b9649f46f30a1296_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife5d15f13d5b4999b2da4743f59a762c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae6d29b54640446d8d61a7b0cbdb303b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26f143d773b74a2c97d01a880e1b5979_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f9a993228ca419ab4f241d7af9bb937_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80ca7f15ccff44c6bb539eb829a8c5a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0ae121e125f4a669af32cafe299e72b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54312b9eac0b49b2837ad56f42f14a85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8206db89dd9e4111863cf8b116f25dc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95cb4a7b357a4575b5c1f13edf15b3a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if66d1b79d4394e83b7b2d962f19c40a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i978e872b2ba845f49001cc6325ebd9fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hcat:ShortTermMarketableSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id78fe06353da4595b8d88460f552d5b0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i91927ae09dc04b33b971594d8bc54b89_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a4b7862118b4131ac5f06f5aa47e163_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibed91e357c7f439bad5f2441be2f3393_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibebd1cdc445047d992d3cf7740678f7e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ide03cc507eb84e43996d3b6131c163af_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic56d22cf25cf4054b9132b3db37d4f5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iab672b01fe5742f2aa363490a53f34e5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4186455850234995a3fefd4e16a396f4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib1976d6b0d3d4e46ad2266bf99b8e8e7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i660b0d75067a411f95ef76e0a4f14bcf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb5d27da05ef4dd6820a8bd484966fad_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i66dbc4d8aea34408bcdeadf087d32dfe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iebfcdb2b7b1549cab39eebc5d9febb7e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3baad2ca5dec4ecb9082b1a396901a60_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8799ab7618024c44bc02cda2b7c017c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1265ad6d0a51472194b6f09102f17989_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3257c2bc0d064887835ed5bd428b3341_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2569064bb5554bff8a5d048551e515ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i161a412a8549477d870aa84d7450f380_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i527bc64f624c453d86a9fc398fa02162_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13c8d4d672174b0eaf8590b94b667b03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78034192027744038e8701e5a608c7d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id682c7555ec54d519592bb14ada245af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f4f44ee228e4ea0ba64867556b0a8ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4c3845f6f18439d8fb05984c62fff97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26633d8bfcfd430fb29e89e97d45eb1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5961bc6e1d4847d1aa04aa5a147ce0a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafd7c0f92f7040fa9ad243c1f7fbaa69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if49bbfddff2d48ce808eae7321a3d727_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80924d762aae4accb35feb372dd0973d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd307786e34047c1a07fb54bd6b2b8d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i969f245e87394c10994db7d2a6a77fb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ed4a348fb3e4251a45ae70c403a2faf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59fcfef1efb441dea240055b2986ee9d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if709f4c82b2c40929782386201a2329e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf8b76871176404b8081eb0c5b32f0ba_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2ed47da29f5f4158b9f99d94735bcba3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86af83c7eb5046eda62a9143eb75002f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hcat:MeasurementInputMarketPriceOfRevenueRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icdc9d82578fd4a2b800c586e00deda04_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hcat:MeasurementInputRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic6c816c8bd444ca6b6af6a54d8586515_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i530512a1ce4642378115de9c7b137ee4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddeb3efca1a047968b5e37ad4c74a3e8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i636c7efe46af4879a27c31281770fbe6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i98c1bd93b08e4ba5b807d436d71276d1_I20200414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="i23059744db234f77ac69c30533821763_D20200414-20200414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-14</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="i0e584e43e4fa4dfe91200285e31ccff9_I20200414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="i9e636533f649460881507b118b35238e_D20200414-20200414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hcat:DebtInstrumentConvertibleThresholdTypeAxis">hcat:DebtInstrumentConvertibleSalePriceOfStockThresholdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-14</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3f8bc9199ddd4da18bed3e8e6956e62f_I20200414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="ic22bcfd28d2944d7a26478fbca019240_I20200414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="i4882e61e1b5b46ba931866b40710101e_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hcat:SeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id441c0a6737547208b92c291c8d51e05_D20200409-20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hcat:CappedCallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-09</endDate>
        </period>
    </context>
    <context id="i6e1056545f074e48880fc579da87512f_I20200408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hcat:CappedCallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-08</instant>
        </period>
    </context>
    <context id="ib8c6064e783e4b6499fe9fac50aae475_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6e4af7b7557540d99e4a0928fd4dcef7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:AbleHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf3d7414d599440ab6623f14616c362b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idb8e3c8002b8497680d01206475b3c70_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i889328385548411faaca4f9d1d75a560_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0cbf6d87e70d4690bbb117a5330e5f92_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5c57c1ec8b584886bb5787b258ab2310_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82a09a657dd645c4af6df61e20653b67_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic9a14d8fc64c4c19a75623ef092ff461_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i793d72c883b8430fa8d9b3446ef17c9f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idf5b95cb131b4027a016c3b12f265779_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5291fdd2f49c42f288d38b74d791754d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hcat:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i13c02d79a3e94b378178e4a644ab9142_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i174b5dc836864ffb956e769476edb3fc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i38a1ea5338944dbc8ab0f9476e6f521e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c17e8c4ebc4427892a4e5cc329075de_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic77eedb5e34f4c26abf4a65346e4650a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib9191a8e792e492088d4538b45dbd969_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i783ec453ce724eff8223cbd8f18bb73c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idbb8e56635cb40dd9af2d7d512c81522_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9c0228f5aacd43abb6861e9102c54c52_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i168ea8840cfb452e9329f1c8021d7a0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hcat:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i84298c0178544899bc7be2bae525267e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i639974b37d9546128e75e5929286a25e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6b2602642784525904168a8fa8633ce_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iee2299b3cd854c339e305d26f3393657_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie7a1e6a0de294ea8abee4a1b9871700e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib53167a60f2a467d9c28ab7387d78e93_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i83724b12cbb24c4a98f79788141daf04_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibd9a3def7806461eb26ce54d85a9d12d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i29571c06d3a343e6ad4d8056a8d1af33_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i13592f0c308d4c3ca5b28589349e0918_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i12b84aed76ed431793822e4580b8f1d3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie8b3f6fdec2a4b278368ed19a4a95efa_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if28f76181b1848d096ea303063c91539_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6253c82367944772a2bf9c34f8b31715_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9ba12a4c71464ef789bdd7bf566ab6c4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c65b644a90a47f8b4b906e0790b6239_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic980a4f37e8843bda75a71bcff67a580_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i631a418618034b708e3ac39665cd5ccc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie966431602dc412e8b09acdcfbeffb3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4dfe9f7c1913433fbc1d1265932b61f7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib0de8ec0b76746a1957ad2b58eb7edac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ad286f2178249fba783e6f88e35ca81_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b97cd002a914ee3aa2c282be09d867b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iedce8ff10cd94af1a1617e8a8e551070_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i51f5fbd68ddc4421b8d0bc58f849fac7_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i95c99dfaa5084f8b99fb2b86c782d222_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i13867759ede9429292155333cf98aa5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i63d5a2a619c74cd49c4313f5d1b1c0f3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0fbb179f359b4f038e44fe90cd706e8a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hcat:VitalwareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hcat:TechnologyAndProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0653e44dccde41d79e0c4dcca4805fd7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3448fe61af4c4aacaf336c73188b521b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i64b094898f5e4db7b34432cbd11ef1b0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2374c5eff6d04980b4a36a67bb87de2d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7ad4008f49a049feb88a7b75269882ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib54854387397459a8c725ddfa3ed8859_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72c95150cded4d7da0ed5115a50de8ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i375d7f606b334e22897257297115deeb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6f46ff336b1840e7b034030cf5eae332_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1e4830aba629412daaa0cc0a46d3c18e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i285babe5ab964ef29cef5180c50abd82_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i74c07cafe2db4a11803bb4bf98296039_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if49eeee1198d4d19aadbc2d7fd7450bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4814ebae7b6547faaa86c64eccc633f1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hcat:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic35f3002cf13457c85971a5a2c22d04e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib160b8d6aaec4f898595c6488b4def77_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636422</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>hcat:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>hcat:day</measure>
    </unit>
    <unit id="usdPerInstrument">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>hcat:instrument</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="vote">
        <measure>hcat:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF8yLTEtMS0xLTA_540d52e3-21e4-4e70-84d1-36aec1c27ba6">0001636422</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF8zLTEtMS0xLTA_91c7747f-f944-4371-b509-038bbb33a498">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF80LTEtMS0xLTA_70c7273e-baec-48f5-955a-dfd550ed7159">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF81LTEtMS0xLTA_ae78f65c-c4fe-45de-bb30-02e493b49239">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80L2ZyYWc6ZDhkNzIzYTA5MDUyNDNlNWI4NmFiMzRhNjVlNjczODMvdGFibGU6OWY4MWY0M2RkNTUyNGMzNWI2ODM5YmNkZDBjNGQ0ZDAvdGFibGVyYW5nZTo5ZjgxZjQzZGQ1NTI0YzM1YjY4MzliY2RkMGM0ZDRkMF82LTEtMS0xLTA_f930a23a-ec45-4fa3-8bfd-196ce846311e">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNC0wLTEtMS0w_514a1d19-4d44-47e5-a039-9bdfa2a97ce4">us-gaap:AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i98f9fd2755be4ddca2dadbcf036fe11c_D20190710-20190710"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80MC9mcmFnOjg3OTBhYTgyM2U4MzQ4ZmQ4YjYyNjU2NDY0ZDhiZTZlL3RleHRyZWdpb246ODc5MGFhODIzZTgzNDhmZDhiNjI2NTY0NjRkOGJlNmVfMjYx_a464ec8d-3abf-479e-9bfe-bae5aa44af13"
      unitRef="number">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifb69fcbcfa3c445cae93cdcd8e8f89e1_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcyOQ_4220c2f0-de6b-4637-b12c-d886b4eb2b01">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"
      decimals="8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xNTkyL2ZyYWc6NzU1MWNkYjA2NTNmNGY5ZWE2N2JiNmFjMGUyZjkzNTgvdGV4dHJlZ2lvbjo3NTUxY2RiMDY1M2Y0ZjllYTY3YmI2YWMwZTJmOTM1OF8yNzQ4Nzc5MDY5NDg1_9bc5e7a4-3fbe-4526-ac30-7f540d9587ba"
      unitRef="shares">0.00326797</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <dei:DocumentType
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk2_abdc4ca5-634a-49bb-8bd8-13bdbf3ab284">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk3_7503474c-0155-4c9f-add8-e258314fa710">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yNjg_7c0b6106-f292-4413-aaf0-b608a10576fe">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjg5_6936cc8b-e76e-4506-9dcc-c7df6b6944b4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk4_b4ea1693-6ba6-4dc8-aa7a-abd5e99bcb8b">001-38993</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjkx_ad615cee-90b7-490d-af9c-5a2dde48f44e">HEALTH CATALYST, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ODM2M2VjYjExZDM4NDFiNGJlZDE1YjQ2NzgyOThmMDQvdGFibGVyYW5nZTo4MzYzZWNiMTFkMzg0MWI0YmVkMTViNDY3ODI5OGYwNF8wLTAtMS0xLTA_650db3de-90c1-4f03-aa0e-1b8337367cbc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ODM2M2VjYjExZDM4NDFiNGJlZDE1YjQ2NzgyOThmMDQvdGFibGVyYW5nZTo4MzYzZWNiMTFkMzg0MWI0YmVkMTViNDY3ODI5OGYwNF8wLTItMS0xLTA_21ea549d-6c05-4c8f-bb8b-9961cecd8537">45-3337483</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk5_1fa336b6-f5a6-4e6f-ae55-88bbad2c1ebd">10897 South River Front Parkway #300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjg4_05e0308c-74d5-45c6-950b-31fad458962d">South Jordan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjky_5e1093d6-a9bb-49ac-bfdd-c72e5d17c0b4">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjkw_e68d4e52-9769-43fc-89b3-8ba003a63825">84095</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMzAw_b86d4232-860a-4fb1-9eeb-c45dcccf9cdd">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMzAx_63ddea76-5e67-47bd-8dc1-d6fd0b247ecd">708-6800</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ZmFmNjEyYjZhZGIzNDM0NWFhZGQzNDIzZTA0NWM0YTUvdGFibGVyYW5nZTpmYWY2MTJiNmFkYjM0MzQ1YWFkZDM0MjNlMDQ1YzRhNV8xLTAtMS0xLTA_7a47a76a-9242-4591-bcb7-e6dfd9c51e28">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ZmFmNjEyYjZhZGIzNDM0NWFhZGQzNDIzZTA0NWM0YTUvdGFibGVyYW5nZTpmYWY2MTJiNmFkYjM0MzQ1YWFkZDM0MjNlMDQ1YzRhNV8xLTItMS0xLTA_b319bcfc-2f91-491e-930b-e443531c308f">HCAT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6ZmFmNjEyYjZhZGIzNDM0NWFhZGQzNDIzZTA0NWM0YTUvdGFibGVyYW5nZTpmYWY2MTJiNmFkYjM0MzQ1YWFkZDM0MjNlMDQ1YzRhNV8xLTQtMS0xLTA_006a09fa-187d-4704-86cb-bd5f5afd9be8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjkz_ae209c52-39bb-4cfe-b3f5-95bc05f72f86">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjk0_c4b2421d-f906-4829-b654-449b4f3e5140">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6NTM5ZDdjZWIxNWUzNDU1Mzk1NTU5ZmQxMjM2Njg0MTMvdGFibGVyYW5nZTo1MzlkN2NlYjE1ZTM0NTUzOTU1NTlmZDEyMzY2ODQxM18wLTAtMS0xLTUyOTk_978c1b57-e267-4039-b4e5-84b736a701f9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6NTM5ZDdjZWIxNWUzNDU1Mzk1NTU5ZmQxMjM2Njg0MTMvdGFibGVyYW5nZTo1MzlkN2NlYjE1ZTM0NTUzOTU1NTlmZDEyMzY2ODQxM18wLTUtMS0xLTA_970dec15-5599-4c84-b3fe-b0cc49395285">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGFibGU6NTM5ZDdjZWIxNWUzNDU1Mzk1NTU5ZmQxMjM2Njg0MTMvdGFibGVyYW5nZTo1MzlkN2NlYjE1ZTM0NTUzOTU1NTlmZDEyMzY2ODQxM18xLTMtMS0xLTA_0c373aab-dd78-4ebc-81c7-e19eb1acdb29">false</dei:EntitySmallBusiness>
    <dei:EntityShellCompany
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMzAy_d66240c1-a9f0-4d46-a262-26b3e05cbfb9">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie345a5d82c04411d88183387ca0f2e03_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xL2ZyYWc6ZmJjMjkwMTRiNmZhNGRmN2IyOGM2NTViNWQ4YTE1MGQvdGV4dHJlZ2lvbjpmYmMyOTAxNGI2ZmE0ZGY3YjI4YzY1NWI1ZDhhMTUwZF8yMjQ4_6d85b448-19b5-447e-9c25-54f106fac2f1"
      unitRef="shares">44520749</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNS0xLTEtMS0w_b50635e9-78b7-43bb-9f54-566012e99ce1"
      unitRef="usd">132627000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNS0zLTEtMS0w_bb3b36b2-e062-4dd6-94f0-ba40e1799379"
      unitRef="usd">91954000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNi0xLTEtMS0w_f88e6615-8212-425b-a657-224cacfca293"
      unitRef="usd">133807000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNi0zLTEtMS0w_90de1d55-0d15-4f8e-97b9-da5f54eead96"
      unitRef="usd">178917000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0xLTEtMS0w_192c6583-7c7a-4592-b6e3-8000c933980e"
      unitRef="usd">45905000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0zLTEtMS0w_1ca04824-0b8b-4f86-8c91-006a1433b454"
      unitRef="usd">48296000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfOS0xLTEtMS0w_ccbecfec-b3c5-49b3-9f62-eb7c2e37a915"
      unitRef="usd">12404000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfOS0zLTEtMS0w_ffc38493-6d99-496d-96a8-47d7edc56bfc"
      unitRef="usd">10632000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTAtMS0xLTEtMA_de6ec829-4034-42dc-9471-76417562aabc"
      unitRef="usd">324743000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTAtMy0xLTEtMA_9b57883d-56e7-4a45-9593-6f4f0888e5ba"
      unitRef="usd">329799000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTEtMS0xLTEtMA_0f60ce02-b999-4e13-a4fa-e23c3452075c"
      unitRef="usd">18653000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTEtMy0xLTEtMA_2d82f770-b494-44ff-a19e-d687585572cf"
      unitRef="usd">12863000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTItMS0xLTEtMA_58efa802-7b35-488e-8313-fe0db2ea1ae2"
      unitRef="usd">91840000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTItMy0xLTEtMA_7ab2c670-180b-4586-9c26-84bb27fc88f9"
      unitRef="usd">98921000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTMtMS0xLTEtMA_9d25535e-2dfd-4ef2-8981-3d721c6dc6e1"
      unitRef="usd">24093000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTMtMy0xLTEtMA_988cb6c7-04b1-424a-97f2-7d1b07a88c15"
      unitRef="usd">24729000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTQtMS0xLTEtMA_b577d6cf-45ef-476b-a41d-5e24149b6cc4"
      unitRef="usd">107822000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTQtMy0xLTEtMA_56a3bcaf-3a1c-4cc8-8c60-1f6f102abf44"
      unitRef="usd">107822000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTUtMS0xLTEtMA_870efd2f-59e9-4c1f-b458-8084371d70e5"
      unitRef="usd">4068000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTUtMy0xLTEtMA_61b6e812-b560-4888-94df-3b0affeb4951"
      unitRef="usd">3606000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTYtMS0xLTEtMA_e71ac941-0cfd-4de9-aff2-f1dc71b5721b"
      unitRef="usd">571219000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTYtMy0xLTEtMA_3ad8eb9b-e634-44cb-ae35-ccb020f4cfc0"
      unitRef="usd">577740000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTktMS0xLTEtMA_e4a87a38-a763-493c-87da-0e3e3ea1ef6d"
      unitRef="usd">4626000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMTktMy0xLTEtMA_2b1a310c-ef7b-4a07-8f51-16b6de8e537a"
      unitRef="usd">5332000</us-gaap:AccountsPayableCurrent>
    <hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjAtMS0xLTEtMA_56504df1-dd77-4399-9e9d-ad2d203abc37"
      unitRef="usd">12946000</hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjAtMy0xLTEtMA_3179af3c-7d71-4d06-abab-4354d57feb06"
      unitRef="usd">16510000</hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMA_93c76e98-5e07-47cd-8681-684959c98a3f"
      unitRef="usd">51634000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtMA_faba9f23-af9a-40a1-8681-f0f00c33ad42"
      unitRef="usd">47145000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMA_c2a4f2ab-e07d-4cc8-8874-a228dc62e4ec"
      unitRef="usd">2454000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMA_9ac31a09-0310-4b18-8d46-ffa3279d6ffb"
      unitRef="usd">2622000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMTc1Mg_64b96fdc-a4dc-4a11-af33-af22bf4934f1"
      unitRef="usd">15902000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtODY_447ee5d4-d113-499e-9d74-4e83ac4bebda"
      unitRef="usd">14427000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <hcat:BusinessCombinationConsiderationPayableCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMzc3Ng_183754e7-e126-4bbc-8a62-dd5bcff30a7e"
      unitRef="usd">0</hcat:BusinessCombinationConsiderationPayableCurrent>
    <hcat:BusinessCombinationConsiderationPayableCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMzc3Ng_eda0e928-76c1-4314-a439-b53de6ab4a91"
      unitRef="usd">2000000</hcat:BusinessCombinationConsiderationPayableCurrent>
    <us-gaap:SeniorNotes
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMjE2OA_aac87365-2731-4f35-8754-ee32d919c3dc"
      unitRef="usd">171864000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMjE2OA_a78ac591-5ec8-4a6d-8b19-214f0383dea8"
      unitRef="usd">0</us-gaap:SeniorNotes>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjQtMS0xLTEtMA_ddbdfff4-1b65-4043-b7d2-bc5056e1edd5"
      unitRef="usd">259426000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjQtMy0xLTEtMA_649ca2a4-1d6c-4c3e-8e1a-10c1a9f9e518"
      unitRef="usd">88036000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjUtMS0xLTEtMA_e674c900-f1e1-483e-ac47-3233ba6ccc2e"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjUtMy0xLTEtMA_3396274d-9131-493f-8a58-b2eb5307f53c"
      unitRef="usd">168994000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjctMS0xLTEtMA_0d9d5b57-2485-4917-ba90-d7c2b3bc10a4"
      unitRef="usd">1135000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjctMy0xLTEtMA_7118b3eb-21b8-4fc3-a50f-0f2aef5dee64"
      unitRef="usd">1878000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjgtMS0xLTEtMA_9926cd7a-fede-4900-b76b-08c005fe5dcf"
      unitRef="usd">23083000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjgtMy0xLTEtMA_3f9c757f-9267-4945-8dce-73c1565045b6"
      unitRef="usd">23669000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjktMS0xLTEtMA_a7602ec0-df4b-4eb6-83ae-8a32bc2d14d6"
      unitRef="usd">16509000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjktMy0xLTEtMA_99ee6dba-754e-491e-a2c1-bb38cf60b344"
      unitRef="usd">16837000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzAtMS0xLTEtMA_59d2a691-8f5f-4a26-880c-a51ecea4464e"
      unitRef="usd">2230000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzAtMy0xLTEtMA_422b939f-439b-44a9-beea-08f75c48d7ae"
      unitRef="usd">2227000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzEtMS0xLTEtMA_216c28a0-3b63-40ea-a74b-e9a4a0fbd866"
      unitRef="usd">302383000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzEtMy0xLTEtMA_9d241295-87eb-46fe-a84d-ffbe4772097c"
      unitRef="usd">301641000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzMtMS0xLTEtMA_1c4db66f-b2a0-4e25-b21f-94e844138f2f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzMtMy0xLTEtMA_8baa4806-f138-4c64-982c-50fc8b9e6a25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzIy_e62c20e4-4e1f-479e-b946-7e4a45530765"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzIy_eb83875b-e9c6-4510-895f-5b0701a626ef"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzQ2_28d15594-c717-4e35-bb8a-13c94101b638"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzQ2_6663a610-5c8f-4a30-a0f1-d72adb476b9b"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_0c53de0b-4410-4ce2-a71d-8e8dbced1ac3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_703b8d6f-fe13-4af5-b70a-cf50df56d7ff"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_b3c9123c-73b4-4403-a25c-b11ed3d5000f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTYzZjgxMDdmODQxMDQ4NjA2OGE4MjVhZDllZGNkXzg0_fd76fd1e-0587-4e69-8c6f-6c9cedba5961"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMS0xLTEtMA_1fcdca86-f84e-47c6-88df-265f339b81d1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzYtMy0xLTEtMA_151fbde0-1dcf-4c81-81e1-700357eef71f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzE5_527f6a7d-9fc4-46a5-92ae-e811ebd5c2ce"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzE5_ae0e041f-9c4a-4e52-a5a7-53366cdb0332"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzQz_0f82f015-13f8-468b-bf4c-81b4aea9df1f"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzQz_40e2c7a0-0210-49d4-8555-38b8ceeef210"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzgx_2c16805d-4c13-4af5-bc00-3031390cc85d"
      unitRef="shares">44340036</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzgx_683b5fcc-3b73-4eed-ad48-e8df788f0f55"
      unitRef="shares">44340036</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzg4_93723e6e-dd64-4bd6-ad40-ddb8f24a95b4"
      unitRef="shares">43376848</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjZkNWIyZDM0Y2M5NjQ2ZjU4MGIyZjBiZDY4ZmRlNzcyXzg4_b1829130-589b-4fb9-b5af-fc89a650bd35"
      unitRef="shares">43376848</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMS0xLTEtMA_ed1ed45f-893e-427e-abe7-be7076d6ae64"
      unitRef="usd">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzctMy0xLTEtMA_e1090f6e-46a7-4f92-9162-c0af37a532c7"
      unitRef="usd">43000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzgtMS0xLTEtMA_bb40f879-c333-4f6c-ac17-c556dd4563db"
      unitRef="usd">1022781000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzgtMy0xLTEtMA_9c70937a-4875-4bf2-88a0-8a502087b306"
      unitRef="usd">1001645000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzktMS0xLTEtMA_38d08591-f99d-434c-bfdb-62c497a994ce"
      unitRef="usd">-754020000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMzktMy0xLTEtMA_67b08a80-f18a-4ce6-b87f-f13ba7c1e909"
      unitRef="usd">-725650000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDAtMS0xLTEtMA_51d88a08-7316-426d-b7f0-2133582439f8"
      unitRef="usd">31000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDAtMy0xLTEtMA_4bfbd9f1-7b71-4625-adbd-f6c6c893ddd6"
      unitRef="usd">61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDEtMS0xLTEtMA_3adb8458-0f06-49d9-81b3-a9fb906a885e"
      unitRef="usd">268836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDEtMy0xLTEtMA_b5654968-774e-4a17-a72d-ac14170446ee"
      unitRef="usd">276099000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDItMS0xLTEtMA_7241fb35-805f-4db0-8b73-e6077517bf4b"
      unitRef="usd">571219000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNDItMy0xLTEtMA_e292e75a-bf88-446d-920f-7a867951d9b2"
      unitRef="usd">577740000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dfda2f92ed340caa2877a927d22e736_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0xLTEtMS0w_6112616b-0505-4343-83e3-ce6afd1552ae"
      unitRef="usd">33839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6bb236a6d7f468880b49898be6fc30a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0zLTEtMS0w_00c50cdd-e9cd-4b76-8678-954a4470c020"
      unitRef="usd">24699000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0xLTEtMS0w_7250e1a3-5ba0-475a-9ed5-653c3392b0eb"
      unitRef="usd">22007000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0zLTEtMS0w_09b64410-8c75-432e-ae83-490ea8a3e660"
      unitRef="usd">20417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0xLTEtMS0w_955fb2f4-dfae-45bb-a8cd-b520deef26f2"
      unitRef="usd">55846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0zLTEtMS0w_4b09ec26-7fc3-4a32-b1cf-74667c274ce0"
      unitRef="usd">45116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i4dfda2f92ed340caa2877a927d22e736_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNy0xLTEtMS0w_19bb15d4-5894-4fbf-9ed2-1cccaf101408"
      unitRef="usd">10825000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ib6bb236a6d7f468880b49898be6fc30a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNy0zLTEtMS0w_6acb084a-b960-4f0f-986d-857c858993be"
      unitRef="usd">7906000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOC0xLTEtMS0w_2dbe6c04-2ed6-4bf0-b455-80e94dc42fd2"
      unitRef="usd">16513000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOC0zLTEtMS0w_bb4044d1-7018-48d5-bfcc-ab23ca467e01"
      unitRef="usd">16162000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOS0xLTEtMS0w_e547c30c-6b26-4cfa-9601-91b8d6125728"
      unitRef="usd">27338000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfOS0zLTEtMS0w_f96c8382-ef3e-450e-9df1-96f6375980e4"
      unitRef="usd">24068000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTEtMS0xLTEtMA_aba4019e-9b31-4ae5-8438-a6ffcf827d00"
      unitRef="usd">15651000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTEtMy0xLTEtMA_56ee9b16-dd2f-47a1-9bd7-64b0a200321e"
      unitRef="usd">13487000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTItMS0xLTEtMA_ec42e67e-c96b-4379-9e5a-073ce3d1a40b"
      unitRef="usd">14345000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTItMy0xLTEtMA_48e3f0e5-946a-4c71-a466-8e5c3d3f6efd"
      unitRef="usd">13088000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTMtMS0xLTEtMA_c428c74a-2406-45e7-bcdb-4b5becd31bc0"
      unitRef="usd">15015000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTMtMy0xLTEtMA_385f856e-0614-4c5e-9578-ab650ba3248a"
      unitRef="usd">9701000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTQtMS0xLTEtMA_ecd43f4d-c3ba-4f33-ab1d-8bbf8db77ced"
      unitRef="usd">7814000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTQtMy0xLTEtMA_b4126e4f-91b0-4654-bd13-a25fcd1f8273"
      unitRef="usd">2877000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTUtMS0xLTEtMA_908af329-850b-4af5-af70-b00039ead566"
      unitRef="usd">52825000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTUtMy0xLTEtMA_31ba5b2c-4a1a-41d3-a9f8-cd0487b4b4c8"
      unitRef="usd">39153000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTYtMS0xLTEtMA_a5e93077-61dd-4c3b-8ae6-4e15542cfc2e"
      unitRef="usd">-24317000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTYtMy0xLTEtMA_6e0fa8fb-f312-45e4-afd6-671d18899b9c"
      unitRef="usd">-18105000</us-gaap:OperatingIncomeLoss>
    <hcat:InterestAndOtherExpenseNet
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTgtMS0xLTEtMA_5ec5ac4f-cb09-4697-b897-f59b7f0baa29"
      unitRef="usd">3952000</hcat:InterestAndOtherExpenseNet>
    <hcat:InterestAndOtherExpenseNet
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTgtMy0xLTEtMA_f3ad7781-ab05-4b71-8d27-8429ffdd16a0"
      unitRef="usd">621000</hcat:InterestAndOtherExpenseNet>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTktMS0xLTEtMA_e221707e-22f7-4812-8e2e-396a216a2565"
      unitRef="usd">-28269000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMTktMy0xLTEtMA_7e6e5e4b-7099-4e2b-a580-4fca5cb9f1d1"
      unitRef="usd">-18726000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjAtMS0xLTEtMA_ab9a519a-c3ad-467e-a62c-60a4267d29ec"
      unitRef="usd">101000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjAtMy0xLTEtMA_35493b04-c1e1-4d9f-b879-a143d97e137f"
      unitRef="usd">-1236000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjEtMS0xLTEtMA_75463e45-424b-4c88-a4ae-4de8b9aab4cb"
      unitRef="usd">-28370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjEtMy0xLTEtMA_160bdefa-e4bf-4788-81b9-b01d1a62084a"
      unitRef="usd">-17490000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMS0xLTEtMA_a870d792-9456-428e-9c57-2ef5e315f1e4"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMS0xLTEtMA_f5a84a91-9521-42a0-af51-ea6ddf0c00e0"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMy0xLTEtMA_9137fca9-972f-45c4-90d9-676a3d5732e0"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjQtMy0xLTEtMA_b09071f6-7392-40e3-a2be-64d34594d665"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMS0xLTEtMA_a61385a8-884f-43cb-bf7b-6bea063929c0"
      unitRef="shares">43870000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMS0xLTEtMA_fa25db98-d07b-44ec-be63-7f5e4b97fddd"
      unitRef="shares">43870000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMy0xLTEtMA_874147d6-d8d1-4c96-98a1-bd7b3b511e89"
      unitRef="shares">37109000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMjUtMy0xLTEtMA_d038a766-e57e-4517-a882-f5a7bcad54c0"
      unitRef="shares">37109000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfMi0xLTEtMS0w_2db7b7ad-5727-4070-b0a5-2aeb2b8bf90e"
      unitRef="usd">-28370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfMi0zLTEtMS0w_6cf4cd8a-22ca-4937-8ae7-95c597c67b4d"
      unitRef="usd">-17490000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNS0xLTEtMS0w_502adfcc-47d7-4397-84a0-317431d770e9"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNS0zLTEtMS0w_19654083-ffd6-4658-8f5c-cf89007b7568"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNi0xLTEtMS0w_23280af4-622e-4c02-bf26-a98a96c47b9b"
      unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNi0zLTEtMS0w_7a24df67-fead-4916-a6f5-9ed9a0ef06f6"
      unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNy0xLTEtMS0w_e7159caa-9389-460d-8ede-c6d1370087fc"
      unitRef="usd">-28400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yNS9mcmFnOmMyN2IxMjgxOWI2NzRiZmViNTc5NTBkNzI2YmUyMzk3L3RhYmxlOmM3ZWM0NDZiNTg1NDRmZGM5YmYyZWVkZGJjNWY5ZWVkL3RhYmxlcmFuZ2U6YzdlYzQ0NmI1ODU0NGZkYzliZjJlZWRkYmM1ZjllZWRfNy0zLTEtMS0w_91bc5417-461c-412a-a3b5-1d2ec56a6535"
      unitRef="usd">-17523000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xLTEtMS0w_82053c54-afb7-4630-aa07-7bbc8c6bff74"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0zLTEtMS0w_498c9211-4974-4a0f-ab0d-0ec5195aa5c3"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ia4ed21d069e44040883da517205949ae_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy02LTEtMS0w_0b890daa-1415-45e4-87b9-73487061b39a"
      unitRef="shares">43376848</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia4ed21d069e44040883da517205949ae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy04LTEtMS0w_28c3afa6-8e3c-4b6f-9145-0651b2d10420"
      unitRef="usd">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if13411e0950346e18adca59be7a3a6e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xMC0xLTEtMA_7a2e5eff-e28e-4ad0-bf6b-097ec3ce9f52"
      unitRef="usd">1001645000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id239684cf62a40bd84edbe1e1929f0b3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xMi0xLTEtMA_203e0283-97c6-4cca-bd72-3601ef26f68a"
      unitRef="usd">-725650000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5246542574fd40a6acee46eddd59f600_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xNC0xLTEtMA_f2076191-ae54-4499-8acc-f2ab8a09ef8b"
      unitRef="usd">61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMy0xNi0xLTEtMA_66956c7e-ad77-4749-b893-4a0b38a2341a"
      unitRef="usd">276099000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNC02LTEtMS0w_c96428f0-6818-46ce-8f32-2b8cfdc1ed42"
      unitRef="shares">403971</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS02LTEtMS0w_92ecb139-2f9a-4331-bfda-d8437669c7db"
      unitRef="shares">537889</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS04LTEtMS0w_0de71b03-028d-4da4-a38c-23ab07e63be0"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i067e0e6900304a738394616a183db02f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS0xMC0xLTEtMA_281d8fa0-0453-4500-9b29-740957081e8f"
      unitRef="usd">6487000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNS0xNi0xLTEtMA_de3bb6d2-aabb-4ba4-9a22-49981cf88741"
      unitRef="usd">6488000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i067e0e6900304a738394616a183db02f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNi0xMC0xLTEtMA_116bea7a-b466-4963-9694-16a2b9a1b40c"
      unitRef="usd">13640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNi0xNi0xLTEtMA_56bd9edb-bc42-4ba9-ba91-9f13e83172b1"
      unitRef="usd">13640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares
      contextRef="i8e4c639b4574467f8580e5725b320b97_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNy02LTEtMS0w_555eacea-ea51-4fa5-8176-de6860fcb9d0"
      unitRef="shares">21328</hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares>
    <hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
      contextRef="i067e0e6900304a738394616a183db02f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNy0xMC0xLTEtMA_a491be19-90fe-4b34-a238-375fa82f34a3"
      unitRef="usd">1009000</hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability>
    <hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfNy0xNi0xLTEtMA_882cd35b-b142-4366-bca2-27bf378f2c85"
      unitRef="usd">1009000</hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability>
    <us-gaap:NetIncomeLoss
      contextRef="ica0e3333f61a401497d1869d991e2376_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOC0xMi0xLTEtMA_857798b0-1379-4695-89cc-3833311436e8"
      unitRef="usd">-28370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOC0xNi0xLTEtMA_846b70ed-396b-491d-a61f-35bada95b3bb"
      unitRef="usd">-28370000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b73d6b0c08b416fa95d0ffafd4a69be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOS0xNC0xLTEtMA_87fb7dde-1474-4807-8413-7fda3599dac0"
      unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfOS0xNi0xLTEtMA_d7bb1b8a-12fa-45e9-8d5b-f4b4eb5e0d11"
      unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMS0xLTEtMA_c7736913-7cb6-4259-93e6-44da89d44f74"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMy0xLTEtMA_6cfa2e0f-61a3-429e-80f6-6ef56b8540b6"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ice27b80f156b4c7c97e4c9714bf0a308_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtNi0xLTEtMA_525b4a74-160d-4c23-98c2-330c6084cf09"
      unitRef="shares">44340036</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ice27b80f156b4c7c97e4c9714bf0a308_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtOC0xLTEtMA_8a3ad012-37bf-46b9-87c9-9644c2431800"
      unitRef="usd">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87e366123354486cababd5831e94051e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTAtMS0xLTA_07f77da1-4aba-4296-b1cd-915546d77554"
      unitRef="usd">1022781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i183085abd0424ba1b6749e0788cec760_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTItMS0xLTA_3a8d21ee-e4c4-49dc-88ea-c5ad02009492"
      unitRef="usd">-754020000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd2d729e83a74d25a64ee4134008cfca_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTQtMS0xLTA_b92993e6-d417-4673-b26e-b3bbb2342074"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjQ5Yjk0MjU5MjA1ZjRkZmFhN2UwYzBjYjc4YzNmMDVjL3RhYmxlcmFuZ2U6NDliOTQyNTkyMDVmNGRmYWE3ZTBjMGNiNzhjM2YwNWNfMTAtMTYtMS0xLTA_d016d4b7-e5cc-4ff0-9ea7-5d8f11fc6715"
      unitRef="usd">268836000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xLTEtMS0w_ed535a6c-7555-487b-a198-6cea286c7715"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0zLTEtMS0w_4a653f5a-c5dd-4c16-a52f-7f43d3d9f5d4"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i6ffb26487eb34a6cad9855d641b8a555_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy02LTEtMS0w_5d4d7d5a-1a9d-4ee1-90e2-086059600acf"
      unitRef="shares">36678854</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6ffb26487eb34a6cad9855d641b8a555_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy04LTEtMS0w_044c8944-9b38-4e4b-807f-97c227c824e5"
      unitRef="usd">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f406e1ada1b4b7fa1d2e0eb11b7bd16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xMC0xLTEtMA_971d0af0-6d64-4a90-ae5d-5add89aef96a"
      unitRef="usd">811049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32bab634e2c04ca8a0b8272bce5cc112_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xMi0xLTEtMA_1a922072-fd7a-4a8e-96c9-31a75c082a66"
      unitRef="usd">-610514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf1c0fd3c5bb4f7490e1619c30315164_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xNC0xLTEtMA_3cc18227-1f93-4264-8286-04074f2fcaaa"
      unitRef="usd">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMy0xNi0xLTEtMA_5b70fb74-d609-4bca-bb73-66b3b314d742"
      unitRef="usd">200644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63dae0960a21470cadf5c35381490d80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNC0xMi0xLTEtMA_d31f9f64-85a0-4f02-aec1-00d7b551278c"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73bfc66cbfc34ae8a0fa31cc621730d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNC0xNi0xLTEtMA_e97fc4f3-e9ce-42b2-bd39-29d2a0c49004"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS02LTEtMS0w_e02d2d3f-c7af-4525-9173-e0af0b04a13e"
      unitRef="shares">1048760</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS04LTEtMS0w_ceb166cb-59a0-463f-a867-e00335b3f0c1"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS0xMC0xLTEtMA_25e9954e-2246-4401-8e56-f1bb9e5eb9ff"
      unitRef="usd">9045000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNS0xNi0xLTEtMA_b5b1b3bd-4658-4f99-8862-24ef5ecbd15d"
      unitRef="usd">9046000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNi0xMC0xLTEtMA_ed7ec787-6b19-460a-824c-12173b31f089"
      unitRef="usd">8741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNi0xNi0xLTEtMA_5eae75ed-a13a-408e-93f1-ce7e4c05e7e9"
      unitRef="usd">8741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i0e99b61941fc4c00bfbacdd2443ecef2_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNy02LTEtMS0w_939e954b-f953-4727-accf-048ab589a251"
      unitRef="shares">110662</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i9c17cf21bc314e88aba6f7b84b415075_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNy0xMC0xLTEtMA_4b92961f-71ac-4452-bc58-d5ee2909e313"
      unitRef="usd">3332000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfNy0xNi0xLTEtMA_f92e97ab-31be-4844-bec9-401fda4a54ef"
      unitRef="usd">3332000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NetIncomeLoss
      contextRef="i67e743d83b6e43f6a07eaae2dd2b103a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOC0xMi0xLTEtMA_b1a742c8-998f-4122-a00c-85b705404189"
      unitRef="usd">-17490000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOC0xNi0xLTEtMA_b06f10eb-347b-40ca-b16f-539910f944dc"
      unitRef="usd">-17490000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib2ee6ea456694392b6844031fc89de02_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOS0xNC0xLTEtMA_c65a2936-32a3-4684-b633-73f221bfcd59"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfOS0xNi0xLTEtMA_00fc5fb8-6ae3-4f4a-acc0-f0423ba92a5f"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9c0efcef22664d14815854888bb21e26_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMS0xLTEtMA_cf4de4fe-abe7-4720-8595-ef3a935924ff"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9c0efcef22664d14815854888bb21e26_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMy0xLTEtMA_d4ea54f9-50f5-4eea-8ba7-d0251af81afe"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i386ccc1569bb40d885c8301f5452d4c9_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtNi0xLTEtMA_9968e8ea-3b20-40de-9c00-123514a0c814"
      unitRef="shares">37838276</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i386ccc1569bb40d885c8301f5452d4c9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtOC0xLTEtMA_bb90fd41-7a0a-4af9-bc1a-6e1c949d4805"
      unitRef="usd">38000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c0cec055bcd4b89865d64d93fd1adbc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTAtMS0xLTA_464f1d6b-583d-4796-bf96-b08f52cb494a"
      unitRef="usd">832167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i963ff9fa8e4f417285df70d02db0ce49_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTItMS0xLTA_d4d2c02e-84d7-46f1-a672-cb7c134ab475"
      unitRef="usd">-628123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a78b3ee92264aa6b424fb238b67d7f4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTQtMS0xLTA_9e56a297-9165-4062-90df-fcb58e7bc485"
      unitRef="usd">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c0efcef22664d14815854888bb21e26_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yOC9mcmFnOjhhMzhhOTI3YjJkNDRkZTZhMjA4ZjAxOTI4M2M3Y2M0L3RhYmxlOjEyYzNjZTdmMWJiZTQxZmU4ZTZjNzc1MDhlOWIxYzJmL3RhYmxlcmFuZ2U6MTJjM2NlN2YxYmJlNDFmZThlNmM3NzUwOGU5YjFjMmZfMTAtMTYtMS0xLTA_226c2363-4c25-4f8d-a74c-70e32efd85dd"
      unitRef="usd">204121000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMy0xLTEtMS0w_6452b4a2-2f3f-43f5-9885-d5def4dd7f09"
      unitRef="usd">-28370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMy0zLTEtMS0w_fce9cdde-c55f-49c8-9590-4ec4dc9315e1"
      unitRef="usd">-17490000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNS0xLTEtMS0w_c6fd2ce8-8a9e-482d-8770-c99de24b397c"
      unitRef="usd">7814000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNS0zLTEtMS0w_23fb42cd-68a3-4d10-84db-5543ca40c8ca"
      unitRef="usd">2877000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNy0xLTEtMS0w_99b9eee7-9332-44e1-9025-d182d92ba53e"
      unitRef="usd">2870000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNy0zLTEtMS0w_79668bec-a03c-4504-9ac6-a09650c33b23"
      unitRef="usd">285000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <hcat:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0xLTEtMS0xNTg4_78e68d3c-d3ff-446a-b6ec-39a81c45c9ee"
      unitRef="usd">-965000</hcat:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <hcat:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0zLTEtMS0xNTg4_7fdfdb9e-57fe-4a79-bebf-82ec91980fdb"
      unitRef="usd">-741000</hcat:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0xLTEtMS0w_6cee2d9a-9704-47c1-a015-0242b737fbb8"
      unitRef="usd">-417000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfOC0zLTEtMS0w_1c85160f-97f7-45fc-8014-649093d1f18d"
      unitRef="usd">6000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMS0xLTEtMjI1OA_8f60c815-2313-4a50-88ea-16fbb42b30a7"
      unitRef="usd">300000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMy0xLTEtMjI1OA_0f447f07-fd20-4e53-84bb-266db1759239"
      unitRef="usd">51000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ShareBasedCompensation
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMS0xLTEtMA_798ed17e-1f44-4ca4-ad63-a72e7663eeb8"
      unitRef="usd">13510000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTAtMy0xLTEtMA_79c70004-add4-43d3-a0e1-016a4c71affe"
      unitRef="usd">8741000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTEtMS0xLTEtMA_873e6f57-564a-4156-9f34-12d0cc7b4e58"
      unitRef="usd">2000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTEtMy0xLTEtMA_52ceb64f-a484-4811-9a90-ab87aa3266a9"
      unitRef="usd">-1280000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTItMS0xLTEtMA_2f293806-f534-4666-b7c3-46219c31591c"
      unitRef="usd">2156000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTItMy0xLTEtMA_fc0f54c9-9f42-4c66-88d4-5173c0d8c48b"
      unitRef="usd">-359000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTMtMS0xLTEtMA_db47c74d-df3d-4325-a2a4-3da9375142f1"
      unitRef="usd">-34000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTMtMy0xLTEtMA_20b43872-e35c-4995-b5a2-e6b2dd7d8750"
      unitRef="usd">-4000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTUtMS0xLTEtMA_94d24fc9-36bf-415b-84c4-5f65cd2b4810"
      unitRef="usd">-2090000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTUtMy0xLTEtMA_26176dba-0767-40f6-b4cc-e75f52bdda7c"
      unitRef="usd">7335000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTYtMS0xLTEtMA_1d537614-44fb-46ee-b029-cce1f9e9f50b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTYtMy0xLTEtMA_f0abb830-6da6-46d4-bac2-aa4cba78cc3a"
      unitRef="usd">-444000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTctMS0xLTEtMA_b89fd568-2d0d-4c39-8882-d7e36e90f183"
      unitRef="usd">2173000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTctMy0xLTEtMA_c0e842e4-fff6-4c04-b2e6-f29aed79302e"
      unitRef="usd">2244000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <hcat:IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTktMS0xLTEtMA_3194299c-3bac-4c2d-a38d-18f18cd73a6a"
      unitRef="usd">-5352000</hcat:IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities>
    <hcat:IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMTktMy0xLTEtMA_a52ba284-b2c0-4cbe-891f-8948879333c0"
      unitRef="usd">-4283000</hcat:IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjAtMS0xLTEtMA_71994f0e-7887-4166-94eb-e2132903408e"
      unitRef="usd">3745000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjAtMy0xLTEtMA_8c96700b-5067-4db6-8284-52a85660399d"
      unitRef="usd">3936000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <hcat:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjEtMS0xLTEtMA_4a310056-b48d-40d8-aaa4-a72c689f2919"
      unitRef="usd">-1083000</hcat:IncreaseDecreaseInOperatingLeaseLiabilities>
    <hcat:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjEtMy0xLTEtMA_91bf07cd-b956-49d7-8795-d0b7b91ea6c7"
      unitRef="usd">-843000</hcat:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjItMS0xLTEtMA_223f45d6-3dce-441b-b1a1-020021f3acd5"
      unitRef="usd">-3143000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjItMy0xLTEtMA_d42b3ae0-8049-453f-b2d5-422aba72c9f8"
      unitRef="usd">-16769000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjUtMS0xLTEtMA_0350d5a5-7ca9-48af-843f-d2311534db0f"
      unitRef="usd">5882000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjUtMy0xLTEtMA_abb208d0-5358-4afd-97a1-937ee06d3107"
      unitRef="usd">428000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <hcat:CapitalizedOfInternalUseSoftware
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMS0xLTEtMjI0MQ_97fc9370-93a2-4aa5-8533-39243275b017"
      unitRef="usd">887000</hcat:CapitalizedOfInternalUseSoftware>
    <hcat:CapitalizedOfInternalUseSoftware
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMy0xLTEtMjI0MQ_036f2a87-fbed-4aad-8d14-3e262032039c"
      unitRef="usd">78000</hcat:CapitalizedOfInternalUseSoftware>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMS0xLTEtMA_b5c3aacd-2ac8-47ce-98cf-289f2efd0f03"
      unitRef="usd">6000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjYtMy0xLTEtMA_3c1d2deb-106b-41af-9c4a-bbb7a1380cd0"
      unitRef="usd">6000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjctMS0xLTEtMA_9e1e7abd-3276-4b71-a151-dd87a59d4e4d"
      unitRef="usd">8621000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjctMy0xLTEtMA_6bc1a163-d4de-4929-8eb4-bb30964b5976"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjgtMS0xLTEtMA_100376dc-09b4-4cd0-aacf-a5f03e329448"
      unitRef="usd">53240000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjgtMy0xLTEtMA_ffecd9e6-6d21-4807-8d7a-053a118055b4"
      unitRef="usd">66653000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjktMS0xLTEtMA_29ecb259-1cc0-4ad7-a786-066e81d54373"
      unitRef="usd">480000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMjktMy0xLTEtMA_52b6b083-e71a-4059-a1d3-9d2f2a59f480"
      unitRef="usd">758000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzAtMS0xLTEtMA_d98e0a25-6c7e-4320-826c-9d8ef5b38a87"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzAtMy0xLTEtMA_f3c422d8-68af-4ca2-b048-963a3db72bc5"
      unitRef="usd">15249000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzEtMS0xLTEtMA_91b84633-6cc7-4b0e-a0e0-9894eb7d7c52"
      unitRef="usd">37376000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzEtMy0xLTEtMA_768ca4e6-983e-499b-810a-bad3651b27be"
      unitRef="usd">50146000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzUtMS0xLTEtMA_9eda1283-ee75-4894-82fd-8f51e0572ff3"
      unitRef="usd">6488000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzUtMy0xLTEtMA_6ba2449f-3d61-4c8e-8489-10eb8164ecbb"
      unitRef="usd">9046000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzYtMS0xLTEtMA_4a41894c-68d6-44ce-8841-d36ff00f49ef"
      unitRef="usd">1349000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzYtMy0xLTEtMA_86b88d78-4435-4b7f-90b3-d30e393c9084"
      unitRef="usd">1289000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzktMS0xLTEtMA_6a877569-265f-4f49-ae4e-eb6419b592bd"
      unitRef="usd">1391000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfMzktMy0xLTEtMA_8fa7bde7-6f65-4a3c-baa8-2d5cfbade2db"
      unitRef="usd">748000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDEtMS0xLTEtMA_7f07f1be-e93b-45ff-9b2f-9fd49bbeaa79"
      unitRef="usd">6446000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDEtMy0xLTEtMA_d853c1bf-3e7b-401a-9131-b54fdf144fe1"
      unitRef="usd">9587000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDItMS0xLTEtMA_1ff92bbd-cabf-4064-939a-e5a5a4d09e49"
      unitRef="usd">-6000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDItMy0xLTEtMA_a0c9c990-49de-4fa8-8190-55183017c63b"
      unitRef="usd">-31000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDMtMS0xLTEtMA_38e77bcb-0eb7-4ce6-b18c-086561776937"
      unitRef="usd">40673000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDMtMy0xLTEtMA_c18220c8-2666-4311-b82f-86921b00895e"
      unitRef="usd">42933000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDUtMS0xLTEtMA_26718ec6-c744-4f31-8b6f-2e97a72824d2"
      unitRef="usd">91954000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i384152dcce9849d1bba93e9d52950c6b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDUtMy0xLTEtMA_58fa4b92-25f8-4582-af8a-ce5a56c2d97a"
      unitRef="usd">18032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDYtMS0xLTEtMA_66076a58-83df-4280-9ed6-492224842794"
      unitRef="usd">132627000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c0efcef22664d14815854888bb21e26_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDYtMy0xLTEtMA_a2730c16-51c7-4176-b543-b965c8030d3b"
      unitRef="usd">60965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMS0xLTEtMjI3Mw_5bfd2e9e-c780-4ba1-9a1f-f722bec2b3c5"
      unitRef="usd">1816000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMy0xLTEtMjI3Mw_6d320f64-dc12-4319-84fd-ed4c9758a1a1"
      unitRef="usd">77000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMS0xLTEtMA_524bf377-83e2-416d-af35-3fd234dd1d53"
      unitRef="usd">1009000</hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability>
    <hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNDktMy0xLTEtMA_48829510-5893-4205-8461-a7b0719b9e17"
      unitRef="usd">0</hcat:NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMS0xLTEtMjI4OA_6c78ed95-3194-40fd-b321-5802aba58b80"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMy0xLTEtMjI4OA_ffbabae2-f633-43a3-b2bd-f66a2630cfe9"
      unitRef="usd">3332000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTItMS0xLTEtMjI5NQ_710c5532-1d36-4903-ac06-2628cfcdfa6b"
      unitRef="usd">130000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTItMy0xLTEtMjI5NQ_e083eec2-f6d0-4b00-b518-9f14d13d5807"
      unitRef="usd">0</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <hcat:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTAtMS0xLTEtMA_8cd94bad-3cf4-4b3c-8ae3-b56ce0768f84"
      unitRef="usd">0</hcat:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities>
    <hcat:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTAtMy0xLTEtMA_15878176-9b61-4935-9590-82a1b2264fcc"
      unitRef="usd">427000</hcat:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMS0xLTEtMA_fdfad0e9-2618-4796-b448-22c7d66f8ca2"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zMS9mcmFnOmNjNDFkZGU0Y2ZhNjRlMTNhYzRhZTIyOTc0ZTY3YTM3L3RhYmxlOmE4ZjA3MDQ3NGU4MzRmZDE4YTc4YWE2ZmE2MTA3MWRkL3RhYmxlcmFuZ2U6YThmMDcwNDc0ZTgzNGZkMThhNzhhYTZmYTYxMDcxZGRfNTEtMy0xLTEtMA_80d70535-4e8e-4ae6-ad66-a8f92b50fe67"
      unitRef="usd">132000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODY_a5574a09-cf4f-4e09-8185-2946201013ab">Description of Business and Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Catalyst, Inc. (Health Catalyst) was incorporated under the laws of Delaware in September 2011. We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Our customers, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts on the condensed consolidated statements of cash flows have been reclassified to conform to the current year presentation. A reclassification was made to separately present the non-cash operating lease expense as a non-cash reconciling adjustment from net loss and the change in the operating lease liabilities due to cash payments as a change in operating assets and liabilities. This net change is not material and does not affect previously reported net cash used in operating activities in the condensed consolidated statements of cash flows. This reclassification had no effect on our other condensed consolidated financial statements for the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interim Unaudited Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accompanying interim condensed consolidated balance sheet as of&#160;March&#160;31, 2021, the interim condensed consolidated statements of operations for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020, our interim condensed consolidated statements of stockholders' equity for the&#160;three months ended March&#160;31, 2021 and 2020, and our interim condensed consolidated statements of cash flows for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020&#160;are unaudited. Our condensed consolidated balance sheet as of&#160;December&#160;31, 2020&#160;was derived from audited financial statements, but does not include all disclosures required by GAAP. Our interim unaudited condensed consolidated financial statements have been prepared on a basis consistent with our annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company's financial position, its operations and cash flows for the periods presented. The historical results are not necessarily indicative of future results, and the results of operations for the&#160;three months ended March&#160;31, 2021&#160;are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (the CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as the effect is antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We derive our revenues primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Determination of the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Recognition of revenue when, or as, we satisfy the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue net of any taxes collected from customers and subsequently remitted to governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Technology revenue primarily consists of subscription fees charged to customers for access to use our technology. We provide customers access to our technology through either an all-access or limited-access, modular subscription. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our subscription arrangements are cloud-based and do not provide customers the right to take possession of the technology or contain a significant penalty if the customer were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the customer. Most of our subscription contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#x2019; notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subscriptions that allow the customer to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the customer. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have certain perpetual license arrangements. Revenue from these arrangements is recognized at a point in time upon delivery of the software. Technology revenue also includes maintenance and support revenue which generally includes bug fixes, updates, and support services. Revenue related to maintenance and support is recognized over the contract term beginning on the date that the service is made available to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Professional&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional services revenue primarily includes data and analytics services, domain expertise services, outsourcing services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our customers on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our customer. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the &#x201c;right to invoice&#x201d; practical expedient. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include customer demographics and the types of users. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we use the residual estimation method due to a limited number of standalone transactions and/or prices that are highly variable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Variable consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into at-risk and shared savings arrangements with certain customers whereby we receive variable consideration based on the achievement of measurable improvements which may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets resulting from services performed prior to invoicing customers are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of March&#160;31, 2021 and December&#160;31, 2020, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $1.3 million and $1.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the customer. As of March&#160;31, 2021 and December&#160;31, 2020, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.8 million and $49.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize sales commissions and associated fringe costs, such as payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with customers, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the customer contract. As of March&#160;31, 2021 and December&#160;31, 2020, $0.7&#160;million and $0.5 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and were included in prepaid expenses and other assets on the consolidated balance sheets. As of March&#160;31, 2021 and December&#160;31, 2020, the remaining $1.9&#160;million and $1.4 million, respectively, of deferred contract acquisition costs were included in non-current other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average customer life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average customer life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs is included within sales and marketing expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. As of March&#160;31, 2021 and December&#160;31, 2020, $0.5&#160;million and $0.5&#160;million, respectively, of deferred fulfillment costs were included in prepaid expenses and other assets on the condensed consolidated balance sheets. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of revenue, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue excludes costs related to depreciation and amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, the establishment of specific reserves for customers in an adverse financial condition, and our expectations of changes in macro-economic conditions, including the current COVID-19 pandemic, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses on Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Write-offs, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of lease term or estimated useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized internal-use software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset in the asset group. If the carrying amount of the asset group exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets. We did not incur any long-lived impairment charges for the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include developed technologies, customer relationships, customer contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets&#x2019; estimated useful lives. The estimated useful life of each asset category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, customer relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually or more frequently if indicators of impairment are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;present or circumstances suggest that impairment may exist. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value. There was no impairment of goodwill for the three months ended March&#160;31, 2021 and 2020.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the customer-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for customer relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of assets acquired and liabilities assumed in a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2020, we expensed $0.9 million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our consolidated statements of operations. No such costs were incurred or recorded for the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements. We value the expected contingent consideration and the corresponding liabilities using a probability model such as the Monte Carlo method based on estimates of potential pay-out scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes to the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All advertising costs are expensed as incurred. We recorded advertising costs of&#160;$0.4 million&#160;and&#160;$0.6 million&#160;for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Development costs and internal-use software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our customers on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. Our standard stock-based awards vest solely on a service-based condition. &#160;For these awards, we recognize stock-based compensation expense on a straight-line basis over the vesting period. Awards that contain both service-based and performance conditions are recognized using the accelerated attribution method once the performance condition is probable of occurring. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because we have NOLs. Significant judgment is required to evaluate uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of acquisition-related consideration payable and operating lease liabilities approximate fair value based on interest rates available for debt with similar terms at March&#160;31, 2021 and December&#160;31, 2020. Money market funds and short-term investments are measured at fair value on a recurring basis. Our contingent consideration liabilities are measured at fair value on a recurring basis based primarily on significant inputs not observable in the market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1- Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3- Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease contracts do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We do not have lease agreements that contain non-lease components, which generally would be accounted for separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of our international subsidiaries is generally their local currency. We translate these subsidiaries&#x2019; financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholders&#x2019; equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting pronouncements adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We adopted ASU 2019-12 as of January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for convertible instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40)&#x2014;Accounting For Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The new standard also simplifies the diluted net income per share calculation in certain areas and is effective for annual and interim periods beginning after December 15, 2021. We are currently evaluating the impact this standard will have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDI_c0886998-c48a-451b-85d6-2e20d529c089">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDM5ODA0NjU2ODM1Nw_20a2a629-f35e-4094-99d5-cf45bc5f3d27">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts on the condensed consolidated statements of cash flows have been reclassified to conform to the current year presentation. A reclassification was made to separately present the non-cash operating lease expense as a non-cash reconciling adjustment from net loss and the change in the operating lease liabilities due to cash payments as a change in operating assets and liabilities. This net change is not material and does not affect previously reported net cash used in operating activities in the condensed consolidated statements of cash flows. This reclassification had no effect on our other condensed consolidated financial statements for the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTM_e72efbc0-05fb-47fa-b2b9-10acde7223ba">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTA_25b78627-8157-4fd7-b8be-22caa0430bb1">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODc_b4cfbde9-39d3-420d-bfe2-eb4da28a5103">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (the CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDg3MQ_ad21cd3d-26ce-4d4e-86b1-1555162000da"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDg3MQ_fdb6f94d-5bdc-4501-ab80-92dcf0755994"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODI_06660096-5dab-43f1-b9dc-67f510525e73">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as the effect is antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTc_965cbeeb-acd5-484a-b598-531b175bf7ea">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We derive our revenues primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Determination of the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Recognition of revenue when, or as, we satisfy the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue net of any taxes collected from customers and subsequently remitted to governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Technology revenue primarily consists of subscription fees charged to customers for access to use our technology. We provide customers access to our technology through either an all-access or limited-access, modular subscription. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our subscription arrangements are cloud-based and do not provide customers the right to take possession of the technology or contain a significant penalty if the customer were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the customer. Most of our subscription contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#x2019; notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subscriptions that allow the customer to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the customer. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have certain perpetual license arrangements. Revenue from these arrangements is recognized at a point in time upon delivery of the software. Technology revenue also includes maintenance and support revenue which generally includes bug fixes, updates, and support services. Revenue related to maintenance and support is recognized over the contract term beginning on the date that the service is made available to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Professional&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional services revenue primarily includes data and analytics services, domain expertise services, outsourcing services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our customers on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our customer. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the &#x201c;right to invoice&#x201d; practical expedient. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include customer demographics and the types of users. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we use the residual estimation method due to a limited number of standalone transactions and/or prices that are highly variable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Variable consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into at-risk and shared savings arrangements with certain customers whereby we receive variable consideration based on the achievement of measurable improvements which may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets resulting from services performed prior to invoicing customers are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of March&#160;31, 2021 and December&#160;31, 2020, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $1.3 million and $1.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the customer. As of March&#160;31, 2021 and December&#160;31, 2020, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.8 million and $49.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize sales commissions and associated fringe costs, such as payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with customers, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the customer contract. As of March&#160;31, 2021 and December&#160;31, 2020, $0.7&#160;million and $0.5 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and were included in prepaid expenses and other assets on the consolidated balance sheets. As of March&#160;31, 2021 and December&#160;31, 2020, the remaining $1.9&#160;million and $1.4 million, respectively, of deferred contract acquisition costs were included in non-current other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average customer life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average customer life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs is included within sales and marketing expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. As of March&#160;31, 2021 and December&#160;31, 2020, $0.5&#160;million and $0.5&#160;million, respectively, of deferred fulfillment costs were included in prepaid expenses and other assets on the condensed consolidated balance sheets. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of revenue, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue excludes costs related to depreciation and amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <hcat:RevenueFromSubscriptionContractTermofContract
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEyNw_2c4f1630-afec-48d2-a6e7-17a06a0ada91">P3Y</hcat:RevenueFromSubscriptionContractTermofContract>
    <hcat:RevenueFromSubscriptionsContractAllowedTerminationPeriod
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEwNQ_7ec520c6-13a5-47b8-a131-f15590743bc5">P1Y</hcat:RevenueFromSubscriptionsContractAllowedTerminationPeriod>
    <hcat:RevenueFromSubscriptionsContractNoticeRequiredForTermination
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEyMA_318d5004-cf0d-4808-8548-a16ff98b66ae">P90D</hcat:RevenueFromSubscriptionsContractNoticeRequiredForTermination>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI1NDA_a5d956e1-635a-4288-8cb2-92025e30c49c"
      unitRef="usd">1300000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI1NDc_331938cc-8004-4e5c-a7ab-11da2836aab3"
      unitRef="usd">1600000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI4OTU_7b67c3d4-60b1-41aa-8b70-725f3abb07fe"
      unitRef="usd">52800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTI5MDI_dde3fd94-81da-4ef9-a05d-9c8ae6399665"
      unitRef="usd">49000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTc2NA_431bbfef-d4bb-476b-8e36-d8e062d48ab0"
      unitRef="usd">700000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNjA0NzMxNDAxMjIyNw_43d56344-46ae-429e-b04f-8010c24ce5b9"
      unitRef="usd">500000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDM5ODA0NjU2ODM2OA_61ec3e26-d15b-45c8-80af-630fbaa1587e">P12M</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTgwNQ_de35a621-f6a5-4722-ad01-500c92ee0bfd"
      unitRef="usd">1900000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNjA0NzMxNDAxMjMzMA_ba6fb3c5-d773-4a48-b1ed-b753c55028f3"
      unitRef="usd">1400000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <hcat:CommissionPaymentEstimatedBenefitPeriod
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMjc0ODc3OTE0MTEyOA_dcd18ec0-a491-4594-ad01-5589fb15d378">P4Y</hcat:CommissionPaymentEstimatedBenefitPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTg0MQ_0046d832-d251-4272-9309-06f464fdc7e7"
      unitRef="usd">500000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTA5OTUxMTY2OTgzMw_d5ef1842-4f96-4dba-9eba-58e99f03545a"
      unitRef="usd">500000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTQ_f7f5c4f2-a67c-4a41-b2e3-b914ddd56ee1">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDY_d9d0bd3e-01b4-4f1f-9c1c-e105d07b65ba">Short-term investmentsOur investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTg_a0c205ba-0fb1-4abc-a684-3ea7ce6756f4">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, the establishment of specific reserves for customers in an adverse financial condition, and our expectations of changes in macro-economic conditions, including the current COVID-19 pandemic, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNDM5ODA0NjU2ODM2MA_f466b63b-4b74-417a-9c5a-6bf12f2eb82e">We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses on Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Write-offs, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfMS0xLTEtMS0yMTY_bbf09629-b407-4ad4-a49e-f2ba1899538d"
      unitRef="usd">1200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfMi0xLTEtMS0yMjA_615f39a8-f268-461f-9709-183017f238f2"
      unitRef="usd">300000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfMy0xLTEtMS0yMjA_8865d27c-bb3d-4e3a-a943-0339c868b8a9"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjVmZjBmYWYzZjIyNTQ2M2NiNDU4YTQ1ZjY0NTIxZWZhL3RhYmxlcmFuZ2U6NWZmMGZhZjNmMjI1NDYzY2I0NThhNDVmNjQ1MjFlZmFfNC0xLTEtMS0yMTY_9f8e9629-50ef-4a6e-9fa3-c80de458a225"
      unitRef="usd">1500000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDc_dbe202fd-1a41-4745-a03c-c1476681650b">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of lease term or estimated useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized internal-use software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset in the asset group. If the carrying amount of the asset group exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTU_4242d26d-a57c-476e-bd8f-87aa8e7ea69f">The estimated useful life of each asset category is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of lease term or estimated useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized internal-use software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized internal-use software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital lease equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0b1145c0be2f4abd984b071985b91ff7_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMC0xLTEtMS0wL3RleHRyZWdpb246ZTY5OTc2NzBhMjRmNDQxZWE2ODJhNGE5ODkxODA2NzNfNA_68500de2-682b-4a41-b3d2-efb7ef05835c">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i570b1a58613c45b78737719cc3a0796e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMC0xLTEtMS0wL3RleHRyZWdpb246ZTY5OTc2NzBhMjRmNDQxZWE2ODJhNGE5ODkxODA2NzNfNw_a26e9e95-583d-4580-9888-14f93cde0093">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic8806568ffc14910a88f456175540071_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMS0xLTEtMS0w_11c46ca4-db9f-4d07-bc8b-5e66f28dcbde">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib98e1d9087f64f35abf0c9c0b35b25ed_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMy0xLTEtMS0wL3RleHRyZWdpb246MmQyZDEwNjk5ZWM3NDNmYWJmNzVjMTA5YTA4ZjNkNmZfNA_1b4d62a6-0f2c-4100-a530-7f52b2bbc3fb">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia2eb546857cc494fa9f8c061084c10cc_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfMy0xLTEtMS0wL3RleHRyZWdpb246MmQyZDEwNjk5ZWM3NDNmYWJmNzVjMTA5YTA4ZjNkNmZfNw_5ac198dc-e934-4233-a1cf-0197ab3fbaa6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7625b67853714c90870b7c5404d9bcbb_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfNC0xLTEtMS0wL3RleHRyZWdpb246ZjZjNjM5NjRlYTUwNDkzYjg1ZTI5ODkwOTM2OThlMDdfNjA0NzMxMzk1Mjc4Mg_fba784c7-f5ce-45c5-acfe-c398c88fba5d">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic1895ebcf2194a20ae75e64ba8b210ad_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOmRmMDM3M2UwZDllNjQ3ZTlhYzQxMDJjZWI0YjQxOGQ2L3RhYmxlcmFuZ2U6ZGYwMzczZTBkOWU2NDdlOWFjNDEwMmNlYjRiNDE4ZDZfNC0xLTEtMS0wL3RleHRyZWdpb246ZjZjNjM5NjRlYTUwNDkzYjg1ZTI5ODkwOTM2OThlMDdfNjA0NzMxMzk1Mjc4Ng_c63db072-4a70-4ae3-93f8-fbecd4931b37">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTY1MDI_12f38767-6abe-4169-b700-ac037765a5b1"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTY1MDI_4b566f9c-c5d9-406c-8876-3545cb2d3c9f"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDQ_1d98623a-f937-4e2b-9215-5f7967dd86ca">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include developed technologies, customer relationships, customer contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets&#x2019; estimated useful lives. The estimated useful life of each asset category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTk_e8700d29-0230-49bd-912b-1a007a1574ea">The estimated useful life of each asset category is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1c6b011b06cd4b56805334a4b840ea06_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMC0xLTEtMS0wL3RleHRyZWdpb246ZDM3OTQyNzFjOTEzNGY0NzlhYjRmZjNmNDlkNTcyMWVfNA_901d1d76-4b6d-4066-9f67-183307c88c76">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib11cd2ccbecf4ec4889f63e8c0bdbfe6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMC0xLTEtMS0wL3RleHRyZWdpb246ZDM3OTQyNzFjOTEzNGY0NzlhYjRmZjNmNDlkNTcyMWVfNw_0639091f-a7c4-4076-80e7-559cda70d819">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i23793db4aa3a4118a87890e37cc5f76a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMS0xLTEtMS0wL3RleHRyZWdpb246MmU1OGMyYmFjZmFhNDc5ZjljZjQ2NzkwZjhlMDBiYzVfMTA5OTUxMTYyNzc4Mw_88dd8f42-02ac-42dd-9755-082682f8f10e">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5eec362ff8b44eebbb405af5d1e31e89_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMS0xLTEtMS0wL3RleHRyZWdpb246MmU1OGMyYmFjZmFhNDc5ZjljZjQ2NzkwZjhlMDBiYzVfMTA5OTUxMTYyNzc5Mg_b3f85cbd-56f5-4a98-b546-c983cab3889c">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iaa2ec48709a149158db346873042cfa2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMi0xLTEtMS0wL3RleHRyZWdpb246ZGEwZTM3NjVmZGMwNDI2OTg0Yjk2NDZlNTY2ZmExZGJfNA_06f7fa71-9729-4f98-a2bf-f973de512fa4">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3d455966ff3546f28112a01f67004be8_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMi0xLTEtMS0wL3RleHRyZWdpb246ZGEwZTM3NjVmZGMwNDI2OTg0Yjk2NDZlNTY2ZmExZGJfNw_3d812076-3a9e-456b-a5a9-a0d6e207d92c">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i19090821c190424ca2b60933a320196d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMy0xLTEtMS0wL3RleHRyZWdpb246ZjM5OGNmZWEwMGRmNGQwZTgwZjk4MmE1YzgyNTU3NTJfMTA5OTUxMTYyNzc4Ng_99d3372a-572f-4353-92bf-d594585be4a4">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i752e657a7ed54158a466343124496aef_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RhYmxlOjlmZWRkZjc1OTVmNjQ0OTZiNDQxYWM0MzJiNjBjZGMyL3RhYmxlcmFuZ2U6OWZlZGRmNzU5NWY2NDQ5NmI0NDFhYzQzMmI2MGNkYzJfMy0xLTEtMS0wL3RleHRyZWdpb246ZjM5OGNmZWEwMGRmNGQwZTgwZjk4MmE1YzgyNTU3NTJfMTA5OTUxMTYyNzc5MA_fb7f700d-aa98-4b79-87b3-5d2903fcf857">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODE_3127c281-5a73-4bbb-9e6e-2fee698c4e21">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, customer relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually or more frequently if indicators of impairment are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;present or circumstances suggest that impairment may exist. &lt;/span&gt;&lt;/div&gt;Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTgwMTc_1ee0afa8-4bca-419f-9e34-0b148e2fcdac"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTgwMTc_fe0f71a9-4f7a-458f-8970-a183c84db58c"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDU_591c56f5-6e22-4654-b33c-4b17b8bb5333">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the customer-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for customer relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of assets acquired and liabilities assumed in a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2020, we expensed $0.9 million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our consolidated statements of operations. No such costs were incurred or recorded for the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements. We value the expected contingent consideration and the corresponding liabilities using a probability model such as the Monte Carlo method based on estimates of potential pay-out scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.&lt;/span&gt;&lt;/div&gt;The portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes to the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfNjA0NzMxNDAxODE2Ng_2a44a045-377f-40b4-aa82-9c797ea5aae9"
      unitRef="usd">900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTI_94b243d4-0e24-4143-816f-75e883bfafb3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;costs&lt;/span&gt;All advertising costs are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTg0OTA_05728347-b8ba-423d-8ae5-94340ff4b412"
      unitRef="usd">400000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMTg0OTc_fab4fb24-0c2b-4fea-802a-37801927f5e7"
      unitRef="usd">600000</us-gaap:AdvertisingExpense>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDA_637e1a8c-6572-420e-a8a5-2dd7201d2166">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Development costs and internal-use software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our customers on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life.&lt;/span&gt;&lt;/div&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3OTY_6b7760f2-8bce-4ceb-8773-b79c5d9856f7">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. Our standard stock-based awards vest solely on a service-based condition. &#160;For these awards, we recognize stock-based compensation expense on a straight-line basis over the vesting period. Awards that contain both service-based and performance conditions are recognized using the accelerated attribution method once the performance condition is probable of occurring. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI4MDE_a1ee936b-5037-4959-b9d0-55d9d6895531">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because we have NOLs. Significant judgment is required to evaluate uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODg_060ae7d8-d6e1-46e1-9fec-f901b75baa45">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of acquisition-related consideration payable and operating lease liabilities approximate fair value based on interest rates available for debt with similar terms at March&#160;31, 2021 and December&#160;31, 2020. Money market funds and short-term investments are measured at fair value on a recurring basis. Our contingent consideration liabilities are measured at fair value on a recurring basis based primarily on significant inputs not observable in the market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1- Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3- Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODU_de387dd5-d569-48d6-8121-0a22ec54be5e">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease contracts do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We do not have lease agreements that contain non-lease components, which generally would be accounted for separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of our international subsidiaries is generally their local currency. We translate these subsidiaries&#x2019; financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholders&#x2019; equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8zNy9mcmFnOjhjN2YyMWRiNmU4YjRiODNhZDQ3ZTMxMGU5YzNkNGUxL3RleHRyZWdpb246OGM3ZjIxZGI2ZThiNGI4M2FkNDdlMzEwZTljM2Q0ZTFfMzI3ODk_d9053f99-adc5-4ec8-a868-a759881cfdc7">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting pronouncements adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We adopted ASU 2019-12 as of January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for convertible instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40)&#x2014;Accounting For Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The new standard also simplifies the diluted net income per share calculation in certain areas and is effective for annual and interim periods beginning after December 15, 2021. We are currently evaluating the impact this standard will have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNDEwMw_6239a9dc-f43d-4236-a657-1be5403fcb6a">Business Combinations&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The business acquisitions discussed below are included in our results of operations from their respective dates of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Able Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 21, 2020, we acquired Able Health, Inc. (Able Health)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a leading software-as-a-service provider of quality and regulatory measurement tracking and reporting to healthcare providers and risk-bearing entities, in a transaction accounted for as a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;business combination&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The acquisition consideration transferred was  $21.5 million and was comprised of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; net cash consideration of $15.2 million, Health Catalyst common shares with a fair value of $3.3 million, and contingent consideration based on achievement of Able Health specified incremental customer billings for the year ending December 31, 2020, with an initial fair value of $3.0 million. The acquisition consideration is subject to certain working capital escrow adjustments. The purchase resulted in Health Catalyst acquiring 100% ownership in Able Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An additional 179,392 shares of our common stock subject to restriction agreements, or restricted shares, were issued pursuant to the terms of the acquisition agreement and 60,000 restricted stock units were issued in connection with the acquisition agreement. The value of these restricted shares and restricted stock units is recognized as post-combination stock-based compensation expense over their respective vesting terms. The vesting of the restricted shares was subject to one year of continuous service by the applicable team members and fully vested on the one-year anniversary of the acquisition closing date. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he service-based condition for the restricted stock units issued pursuant to the terms of the acquisition agreement is satisfied over&#160;two years with a 50% cliff vesting period of one year and ratable quarterly vesting thereafter.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Refer to Note 12 for additional details related to our stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Able Health (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include customer relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of six years, three years, and two years, respectively. The resulting goodwill from the Able Health acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Healthfinch, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;31, 2020, we acquired Healthfinch, Inc. (Healthfinch), which provides a workflow integration engine delivering insights and analytics into electronic medical record (EMR) workflows to automate physicians&#x2019; ability to close patient care gaps in real-time, in a transaction accounted for as a business combination.  We believe this acquisition will strengthen our existing population health capabilities. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition consideration transferred was $50.5 million and was comprised of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; net cash consideration of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Health Catalyst common shares with a fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$27.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and contingent consideration based on certain earn-out performance targets for Healthfinch during an earn-out period that ends on July&#160;31, 2021, with an initial fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The purchase resulted in Health Catalyst acquiring 100% ownership in Healthfinch. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Healthfinch (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contract backlog&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include customer relationships and contract backlog, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, three years, and two years, respectively. The resulting goodwill from the Healthfinch acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vitalware, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;1, 2020, we acquired Vitalware, LLC (Vitalware)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a provider of revenue workflow optimization and analytics SaaS technology solutions to healthcare organizations, in a transaction accounted for as a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;business combination&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Vitalware&#x2019;s flagship offering is a chargemaster management solution that delivers results for the complex regulatory and compliance functions needed by healthcare provider systems. Additionally, Vitalware brings to bear newer product suites to help health systems capture lost revenue and to support compliance with expanding pricing transparency regulation. The acquisition consideration transferred was $119.2 million and was comprised of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; net cash consideration of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$69.6 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Health Catalyst common shares with a fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$41.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and contingent consideration based on certain earn-out performance targets for Vitalware during an earn-out period that ended on March&#160;31, 2021, with an initial fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$8.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The purchase resulted in Health Catalyst acquiring 100% ownership in Vitalware.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An additional 203,997 shares of our common stock subject to a restriction agreement, or restricted shares, were issued pursuant to the terms of the acquisition agreement. The value of these restricted shares is recognized as post-combination stock-based compensation expense on a straight-line basis over the 12-month vesting term. 75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of these restricted shares will vest on a monthly basis over a term of approximately one year with the remaining 25% vesting on the one year anniversary of the acquisition closing date.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Refer to Note 12 for additional details related to our stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Vitalware (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contract backlog&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquired intangible assets were valued utilizing an income approach, and include customer relationships, contract backlog, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, two years, four years, and for trademarks &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcyOQ_4220c2f0-de6b-4637-b12c-d886b4eb2b01"&gt;two&lt;/span&gt; to five years, respectively. The resulting goodwill from the Vitalware acquisition was fully allocated to the technology reporting unit and is deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Pro Forma Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects our unaudited pro forma combined results of operations for the years ended December&#160;31, 2020 and 2019 as if the acquisitions of Able Health, Healthfinch, and Vitalware had taken place on January 1, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pro forma revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma information is not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2019 or to project potential results as of any future date or for any future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pro forma adjustments are based upon available information and certain assumptions that we believe are reasonable. The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma revenues or net loss, as applicable, are attributable to fair value adjustments to deferred revenues, amortization of acquired intangible assets, acquisition-related income tax considerations, and acquisition transaction costs that had a net impact on the pro forma combined net loss of $9.5 million and $30.8 million for the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzQw_1ab4bd79-b7f3-4f7f-8d7e-4f3a544fcac5"
      unitRef="usd">21500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzkw_16df6e65-3e21-4616-9358-c61665e831eb"
      unitRef="usd">15200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNDQ1_f2806c90-c354-4738-bfd5-e15a2775fb7d"
      unitRef="usd">3300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNjIz_565c4f15-e8e8-4150-afad-2c713da16aee"
      unitRef="usd">3000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNzY2_3d025b54-380d-45e4-8f82-9881e12cbf3c"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares
      contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfOTE3_e8ae07a1-db0f-4399-a0a0-9b7adbf58fe6"
      unitRef="shares">179392</hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA3MQ_591e6356-8993-46d1-b136-4b86fb2ac557"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDU3NA_ee80d7e3-1228-4fcd-952f-7d4438587ab0">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDYwMQ_f7da5cf8-38c5-4b5a-aa66-2713e3537781">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod
      contextRef="ib3a602fe1da24b898d87f5aa96f55e7e_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTY1NQ_083239fe-581a-4464-b269-9962b5679259">P2Y</hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie9a6f3c1d5434096a8602552e27ccd8b_D20200221-20200221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTY2NQ_a5a4ef34-a92c-4684-87f2-6a49c1107192"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ie9a6f3c1d5434096a8602552e27ccd8b_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTY5Mg_46946ac8-4787-47c6-bbf3-cef7bc3c0904">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNDEwNA_dae21645-e943-4432-9fa8-30d4ef763e00">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Able Health (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Healthfinch (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contract backlog&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Vitalware (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contract backlog&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMS0xLTEtMS0w_6399de63-cc43-4325-812b-2f69c9bf75ef"
      unitRef="usd">633000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMi0xLTEtMS0w_0d55e2f1-3507-4623-90a5-27d72af58c61"
      unitRef="usd">57000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i2d21b8b985b74d238f472e4e71050a30_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMy0xLTEtMS0w_a356a19a-e5fa-4fd7-be89-e0fbfb872fb3"
      unitRef="usd">7500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib7ca50433dfa41afaba5f4dbfd9c4080_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfNC0xLTEtMS0w_0ee0975c-9e77-4770-af3a-7b3d0ac066ca"
      unitRef="usd">600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ice7f7a67b58b4ab7b21087c875b742aa_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfNS0xLTEtMS0w_bf864931-b06d-4d94-9516-3cdb49a23ea3"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfNi0xLTEtMS0w_f81d989d-a7cb-480a-9b26-414023825d48"
      unitRef="usd">8890000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfOC0xLTEtMS0w_02f244f5-776a-4c79-a702-9b2fb7f43afe"
      unitRef="usd">91000</hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfOS0xLTEtMS0w_81278f7b-2728-4745-b4b9-d28912ab37a0"
      unitRef="usd">762000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTAtMS0xLTEtMA_1a45cffd-d5cc-4155-adeb-4bcf8787ccf8"
      unitRef="usd">1280000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTEtMS0xLTEtMA_57a41169-3bcc-4a22-b625-35d466210e24"
      unitRef="usd">2133000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTItMS0xLTEtMA_8cdb93f2-25d0-48b6-bf2b-9ef9ed35e0e8"
      unitRef="usd">6757000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTMtMS0xLTEtMA_77a62e45-8579-47be-bea6-39b019d9dbe0"
      unitRef="usd">14725000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjNkMjUxNmE0OTk0OTQxZmJiZTYyN2YzNDQxMjE5YWVmL3RhYmxlcmFuZ2U6M2QyNTE2YTQ5OTQ5NDFmYmJlNjI3ZjM0NDEyMTlhZWZfMTQtMS0xLTEtMA_c1dc0b82-73a2-4263-9de4-5488261ce886"
      unitRef="usd">21482000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6d0acf0e57514eba9c3147edf4b9b2f3_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzE0Nw_6b692048-50a6-433f-a60a-8a2f16f71fdb">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if9289e7751f54283a46cb7fb7436a914_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzE1MQ_4929d34c-3025-46c1-93f4-0e5141748b57">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie6bea69d2c8a4cbdb35a5f22ae1b2948_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzE1OQ_22fa7061-3e00-4398-8cfc-cd0dd0f3832c">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDMyMg_bc823be4-cbc3-4ec9-8099-df25dba72cc5"
      unitRef="usd">50500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDMzOQ_c6400299-fea7-4e3b-8710-260a84da03a4"
      unitRef="usd">16900000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i9979e0cd6b304ac9a56363789316f1f8_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDM1NQ_3b9e731f-71ad-43ce-abb3-1187b6d541f9"
      unitRef="usd">27800000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDQyOQ_41050748-4c60-45d4-b2f5-020fde90cf95"
      unitRef="usd">5800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDUxMA_a211f774-64ab-4043-96c9-18b34ec5a552"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMS0xLTEtMS0zNDI_5ab4a405-39c0-47e3-825d-9b3343b5374e"
      unitRef="usd">1408000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMi0xLTEtMS0zNDI_0eea6996-c097-462e-a65a-5d4f084bd33f"
      unitRef="usd">347000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i0bdbb8be29c94abbbe84a2dad772a00d_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMy0xLTEtMS0zNDI_289bb04a-005e-4910-8c05-d28025425f9c"
      unitRef="usd">8100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i498f4874d4104d52939aa8749d65159d_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfNC0xLTEtMS0zNDI_876e248a-972d-4c2e-8a1f-96680f7ab1ab"
      unitRef="usd">10000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i51a417b5d4b4461bb7ff7bef53ae612f_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfNS0xLTEtMS0zNDI_5e7a36ac-7537-406d-9036-bcbe0fa47954"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfNi0xLTEtMS0zNDI_b38e519f-50e4-4b9d-a7d5-8e2def6beb5c"
      unitRef="usd">20055000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfOC0xLTEtMS0zNDI_f923ffc4-0657-4daf-a026-7274f2bbe54a"
      unitRef="usd">408000</hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfOS0xLTEtMS0zNDI_2740a48b-312c-4f46-8d2b-47f8a603571e"
      unitRef="usd">2100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTAtMS0xLTEtMzQy_e4b13c67-6baf-45b7-ac5b-46267abda798"
      unitRef="usd">2508000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTEtMS0xLTEtMzQy_1be8cf4a-0d2c-4b8c-8ce1-5bf483f529c4"
      unitRef="usd">17547000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTItMS0xLTEtMzQy_77efa7c4-0f17-44de-8587-7db16b68c7d5"
      unitRef="usd">32960000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib2cff5f451304355a1795c9ec977b1b3_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOmJiMmQ2YzlkYTE3ODRhM2I5ZjFkOWJjODdiOGQyOGIxL3RhYmxlcmFuZ2U6YmIyZDZjOWRhMTc4NGEzYjlmMWQ5YmM4N2I4ZDI4YjFfMTMtMS0xLTEtMzQy_ad1ad774-1e1d-4dde-a388-140e7f4ec805"
      unitRef="usd">50507000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i34094f2ce17c4b68b9c7f3e2545dfc9d_D20200731-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY1MA_79db9053-a467-4120-9f64-e27dc8e2ca8a">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1734d7abc4744d5683af026b80bc322e_D20200731-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY2Ng_b1fe733a-22a6-4582-9d8d-a0ed12bfd07f">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ica753ecaab5f4745ad630406fcb5ecf9_D20200731-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY3OA_4424c23d-e8ed-4ee2-9b47-b9fca199094b">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDUzMg_5747d678-e726-4147-b994-bdc01b24be85"
      unitRef="usd">119200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDU0OA_ef262bf7-cf8e-47b5-837c-38909d02df1b"
      unitRef="usd">69600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDU2NA_7bd1c6c2-6e41-4a58-b10d-7c6faa180059"
      unitRef="usd">41300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDU3OQ_c35e05c8-81c7-4520-b69b-1d29ce1923cb"
      unitRef="usd">8300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDUyOA_99971272-36e0-4d05-84e7-262a5a6467e8"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares
      contextRef="i2cd704a45bb3466b99382868818856b6_D20200901-20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDYyMg_38ef34f8-9fec-4555-b476-1d6f7ded736a"
      unitRef="shares">203997</hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDU2NA_3fdf1e9b-788e-4101-b23f-fb9808ec0ff1">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDYyOA_38ae2045-2330-431a-b5a7-3e96bbcabf52"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDUzMw_fccdab13-5111-46a9-9ec3-ea31259bb602">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDYzNA_46f87dcb-c87f-4813-bc8c-99ceb4fec8bb"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxMDU0OA_11b6ab9f-63bb-4dc0-a247-62fc304020f5">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMS0xLTEtMS0zNDI_55bc76c8-dada-4356-9837-a05c53d9427b"
      unitRef="usd">3220000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMi0xLTEtMS0zNDI_8ee6421a-2b93-4d80-89fa-134cd529ccfc"
      unitRef="usd">469000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i59c0e7f496834c03a071df11af262227_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMy0xLTEtMS0zNDI_1e4a17ac-3577-48d7-ab3f-cdbea8129eff"
      unitRef="usd">18000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8ae6e93b2b18426481d9a6a8da986dc3_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfNC0xLTEtMS0zNDI_eadb6747-f8e1-41d7-b650-f142ade2655d"
      unitRef="usd">43000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="if5d756d95f7c48f0b87b33dc8c7a743e_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfNS0xLTEtMS0zNDI_2796c075-95be-4b22-b6fa-e7700f81d0bc"
      unitRef="usd">1400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfNi0xLTEtMS0zNDI_a24a7c93-f257-4199-90b0-fe2466901cf3"
      unitRef="usd">66089000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfOC0xLTEtMS0zNDI_2c037d4e-5599-42b6-b386-a8bd02edb880"
      unitRef="usd">766000</hcat:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfOS0xLTEtMS0zNDI_36f76b18-1717-4e13-8702-aa42f960d885"
      unitRef="usd">2589000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTAtMS0xLTEtMzQy_7ec701d9-ae22-444a-97b4-89a72a3def51"
      unitRef="usd">3355000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTEtMS0xLTEtMzQy_3851cfc0-1945-4327-8168-97c94de32070"
      unitRef="usd">62734000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTItMS0xLTEtMzQy_656d815c-a471-42d0-bdbc-ac24cff11b40"
      unitRef="usd">56443000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i0271ede7abee462eba0b2b698342faae_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjA0OWZlNjVlOTg1OTQxNzY4NWZhMjY5NTBjOTdhMDkyL3RhYmxlcmFuZ2U6MDQ5ZmU2NWU5ODU5NDE3Njg1ZmEyNjk1MGM5N2EwOTJfMTMtMS0xLTEtMzQy_619df8a5-6288-4d94-a5d2-8dce1f2ee1d7"
      unitRef="usd">119177000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie0aa3a878073450c89d3c4a52f80971f_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDY5OA_0efebc79-4848-4584-bdef-f18d98307522">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia3be332fe9194ef58f9aceef7fcef46e_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcxMA_ce475947-237a-4379-9f42-bf57d666698d">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if53b8b11a34f4165a0b32d5030e61aaf_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcyMw_0e23ec03-a504-43dc-9df8-95826f8f2f14">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i52203ce0773e4de29d77d41ca3e6ed52_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDc0Mg_ece3d11c-973f-43e1-b057-fa8c947dbed1">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMzg0ODI5MDcxNzU1OA_357a14d9-0a18-4cb7-ab38-fd26c7c00242">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects our unaudited pro forma combined results of operations for the years ended December&#160;31, 2020 and 2019 as if the acquisitions of Able Health, Healthfinch, and Vitalware had taken place on January 1, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pro forma revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i563042bec9ce44faad7f33151e649064_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMi0xLTEtMS00MzU3_10b0a1cc-cc38-40db-9538-2bcb8d6259b8"
      unitRef="usd">209409000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMi0zLTEtMS00MzU3_806e8046-7d5a-4d12-86b2-892f1aec8d67"
      unitRef="usd">173973000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i563042bec9ce44faad7f33151e649064_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMy0xLTEtMS00MzU3_d0b962ee-cce1-4564-8a34-2acd780ececc"
      unitRef="usd">-124485000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="if0f95d17b23f4d0aae45ac128966dc9e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RhYmxlOjJhMTZkNWVmZGE1NjRjZWM4ZTQwMjVjZWNmMTg1Y2QwL3RhYmxlcmFuZ2U6MmExNmQ1ZWZkYTU2NGNlYzhlNDAyNWNlY2YxODVjZDBfMy0zLTEtMS00MzU3_0a43b4df-e9ff-4f75-b77f-0b956f7f8d5d"
      unitRef="usd">-90850000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i345542d87cc5467f82f4b9ffbcd77517_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNjA0NzMxMzk3Mjk5MQ_186151e8-416c-4faf-9818-a271ebc2c086"
      unitRef="usd">9500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9a9284427b4344e99bd6a68791952947_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfNjA0NzMxMzk3Mjk5OQ_e8ce6106-b9be-4746-9952-fd60014d3480"
      unitRef="usd">30800000</us-gaap:ProfitLoss>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMjk4_a5830b1e-74cb-45d7-ac4c-96e74f70c72b">Revenue&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Health Catalyst&#x2019;s revenue disaggregated by type of arrangement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recurring technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One-time technology (i.e., perpetual license)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, 99.9% and 99.9%, respectively, of revenue was related to contracts with customers located in the United States.&lt;/span&gt;&lt;/div&gt;Deferred Revenue and Performance Obligations&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized.&#160;For the three months ended March&#160;31, 2021 and 2020, 42% and 33%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;Most of our technology and professional services contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#x2019; notice. For arrangements that do not allow the customer to cancel within one year or less, we expect to recognize $79.6 million of revenue on unsatisfied performance obligations as of March&#160;31, 2021. We expect to recognize approximately 75% of the remaining performance obligations over the next 24 months, with the balance recognized thereafter.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMjk3_6dbef86f-bce8-4782-8259-eeff8169ae1e">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Health Catalyst&#x2019;s revenue disaggregated by type of arrangement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recurring technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One-time technology (i.e., perpetual license)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04a82e47b69b4d3eb01ecc169fcbbdff_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMi0xLTEtMS0w_73c82d1a-caed-4b7c-8a38-dfe952dde9f7"
      unitRef="usd">33567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a5b2b2f3eb34e66b9f15ef94b7f93d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMi0zLTEtMS0w_ec9ebfba-087b-496c-86c1-a31cca6e6256"
      unitRef="usd">24699000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i072686e691b043fc99a5001437848336_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0xLTEtMS00NDAx_a5a69d47-736d-413e-abd0-9f5346c2a7da"
      unitRef="usd">272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica63ebc6345a4c4e9bf1f23e7fa538d2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0zLTEtMS00NDAx_ca019107-7165-41e9-b72f-fb8111e965dc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfefcc20552b403fad1f5cebb5341876_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMy0xLTEtMS0w_a02de694-a399-4a4c-b85c-02b9218fd770"
      unitRef="usd">22007000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i951e435f5ea44248b319109a4fd485f4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfMy0zLTEtMS0w_604ec4b5-abfd-4877-9e37-708317c3ea46"
      unitRef="usd">20417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0xLTEtMS0w_a2edca17-df27-4179-8cb1-bc0d7eda35b7"
      unitRef="usd">55846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RhYmxlOjA5OGI2ZTI2YzQzNjQ4MjFhNjhjMDljMTFiNjlmNmU2L3RhYmxlcmFuZ2U6MDk4YjZlMjZjNDM2NDgyMWE2OGMwOWMxMWI2OWY2ZTZfNC0zLTEtMS0w_f9526429-a78d-474a-b4b1-5a47f55f662d"
      unitRef="usd">45116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2b5ac1f2270243679239715132a65f39_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMTky_99f3a6fb-78d3-496f-869c-3ebe2362d176"
      unitRef="number">0.999</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7dba3e825a6d4aa18b1576f50bc30986_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80OS9mcmFnOjMyZDhmNDBiYzY1YjRiNmM4NWUyM2I1M2UzNzU3NDhmL3RleHRyZWdpb246MzJkOGY0MGJjNjViNGI2Yzg1ZTIzYjUzZTM3NTc0OGZfMTk5_5a202718-2bd2-4ac4-a732-f18e382340ed"
      unitRef="number">0.999</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfOTMy_a7e70527-b710-4a7a-bead-6341c2e92054">Goodwill and Intangible Assets&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate our business in two operating segments that also represent our reporting units. Our reporting units are organized based on our technology and professional services. We have not incurred any goodwill impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill by reporting unit is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense of acquired intangible assets was $7.1 million and $2.2 million for the three months ended March&#160;31, 2021, and&#160;2020, respectively. Amortization expense for intangible assets is included in depreciation and amortization in our condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNjY_e2e5788f-da1d-456b-81eb-ad8238f5dee8"
      unitRef="segment">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNjY_e8a6a151-0dff-4bed-b859-4b73136ff381"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfOTMz_0b039a84-930a-465f-8e9c-f13b03d255d8">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill by reporting unit is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="id3c750b2d03c4e43bd847dd5399458fa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMi0xLTEtMS0w_efe97f54-735b-415a-8812-386d1ff23679"
      unitRef="usd">107040000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6ffad74837e64a998ce0d0e6a9d0363c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMi0zLTEtMS0w_8ecbd953-379d-4a86-9c92-1c2e33c64d1e"
      unitRef="usd">107040000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibdc1260ae65e4a948c0c470387cf66e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMy0xLTEtMS0w_c232049a-3cac-4d27-8d04-032fee93ef94"
      unitRef="usd">782000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9fcd127174c94e03ada02115a901ebb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfMy0zLTEtMS0w_3a9c0706-9bac-4a73-95a2-ca3cf8c64856"
      unitRef="usd">782000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfNC0xLTEtMS0w_72198e85-8a3e-4294-8631-80d5d503a03a"
      unitRef="usd">107822000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIzMWVjYzJmNWRkZDQxYWY4ODliYTMzOGNlYzI1YWQzL3RhYmxlcmFuZ2U6MjMxZWNjMmY1ZGRkNDFhZjg4OWJhMzM4Y2VjMjVhZDNfNC0zLTEtMS0w_94a5e29e-3bf7-4444-9d62-fda48c511c8b"
      unitRef="usd">107822000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6db85473fe074ce1a8b9d070f8da1259_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMS0xLTEtMS0w_9c452212-f254-44d5-b75a-8c0a487521fd"
      unitRef="usd">69729000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6db85473fe074ce1a8b9d070f8da1259_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMS0zLTEtMS0w_67c5890b-b736-4350-b114-fc801deae3c9"
      unitRef="usd">28676000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6db85473fe074ce1a8b9d070f8da1259_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMS01LTEtMS0w_2db7982c-7fa3-41f1-94b7-c176217ff865"
      unitRef="usd">41053000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i17f9ad5e961945caa4d034f51243794e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMi0xLTEtMS0w_04949e20-04c1-40c0-8e6b-41a569c33ac5"
      unitRef="usd">57764000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i17f9ad5e961945caa4d034f51243794e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMi0zLTEtMS0w_15278575-c3c1-4227-8004-de9d66e8d848"
      unitRef="usd">10520000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i17f9ad5e961945caa4d034f51243794e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMi01LTEtMS0w_9730d8f9-3c72-4109-8f19-ec01de40f454"
      unitRef="usd">47244000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i260812b8834d48928c9d06e77dee395b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMy0xLTEtMS0w_25f52c85-6afb-4fca-b70f-34e72fddf864"
      unitRef="usd">7359000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i260812b8834d48928c9d06e77dee395b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMy0zLTEtMS0w_62002419-ae75-4fc2-85a7-9c5708a4a3f3"
      unitRef="usd">5123000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i260812b8834d48928c9d06e77dee395b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfMy01LTEtMS0w_e93a5664-f389-461a-9c4e-f0feb616f456"
      unitRef="usd">2236000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNC0xLTEtMS0w_1d54a6b2-5233-47e0-b5a5-6efe7e72f274"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNC0zLTEtMS0w_2f4eaa44-8640-41cd-a803-dc1795cd1f14"
      unitRef="usd">393000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8b616c29ad4a44ec9d6cc1b474264a71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNC01LTEtMS0w_e2c50107-d1bf-4f1b-b079-52e4afe7acb4"
      unitRef="usd">1307000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNS0xLTEtMS0w_0c5a1e14-6847-4429-bd55-133924bb99f9"
      unitRef="usd">136552000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNS0zLTEtMS0w_6e27741d-2785-48b8-a9e2-866a116a5d2c"
      unitRef="usd">44712000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjIxZWNmNDliYjRiYTQ0ODE4NTQ5ZTQyNzI0NWNmYTM2L3RhYmxlcmFuZ2U6MjFlY2Y0OWJiNGJhNDQ4MTg1NDllNDI3MjQ1Y2ZhMzZfNS01LTEtMS0w_02a3e3b7-4aad-4c14-865f-d6585db2b16d"
      unitRef="usd">91840000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i55d7975897fb4234a03bea31f1b463be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMS0xLTEtMS0w_abb6c886-d3c1-4deb-8843-64d9ba2eecee"
      unitRef="usd">69729000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i55d7975897fb4234a03bea31f1b463be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMS0zLTEtMS0w_7d9b5a62-9307-4082-93da-86a92e192f43"
      unitRef="usd">25293000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i55d7975897fb4234a03bea31f1b463be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMS01LTEtMS0w_4ff9621e-ebfa-437d-a64e-94680fca254f"
      unitRef="usd">44436000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idfb53d4219524c099358c824a99b0cab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMi0xLTEtMS0w_82f41292-a0fa-4417-9c8c-faa17c6f55cb"
      unitRef="usd">57764000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idfb53d4219524c099358c824a99b0cab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMi0zLTEtMS0w_e30b9df4-a547-426d-9580-24c6cb402212"
      unitRef="usd">7482000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idfb53d4219524c099358c824a99b0cab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMi01LTEtMS0w_5af66b88-c56a-4a81-b07f-a6759faf04e3"
      unitRef="usd">50282000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9514dc5706d84f94969cf5c1179a4865_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMy0xLTEtMS0w_6c8cb888-4ad0-4d1c-b2ca-51ee6ca3d699"
      unitRef="usd">7359000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9514dc5706d84f94969cf5c1179a4865_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMy0zLTEtMS0w_5aff3cc3-8342-4062-a804-a53ee29ea98f"
      unitRef="usd">4615000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9514dc5706d84f94969cf5c1179a4865_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfMy01LTEtMS0w_9eae2cc7-d771-4fd0-be81-f50e8b3ad639"
      unitRef="usd">2744000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3fa77551a95d4af6815afe266a065d63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNC0xLTEtMS0w_b4d15f36-ebf5-4c8e-97bd-5b53767ac729"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3fa77551a95d4af6815afe266a065d63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNC0zLTEtMS0w_e21c4e48-ebe0-4ba3-a71c-2d275b183eac"
      unitRef="usd">241000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3fa77551a95d4af6815afe266a065d63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNC01LTEtMS0w_6f1bed6f-32fe-4f65-8a17-d850ab1e33bd"
      unitRef="usd">1459000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNS0xLTEtMS0w_149352f2-2170-4020-a6e1-4d65024fe783"
      unitRef="usd">136552000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNS0zLTEtMS0w_017de2de-9d8a-4cd6-a02b-8ae26b6af840"
      unitRef="usd">37631000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RhYmxlOjhmMjc4OWE5ZmQ5MzQwZWM5N2JmNmVkODgwMDc3YWI2L3RhYmxlcmFuZ2U6OGYyNzg5YTlmZDkzNDBlYzk3YmY2ZWQ4ODAwNzdhYjZfNS01LTEtMS0w_2a46b28f-9e00-45f3-bc0a-1be3c5c75f2c"
      unitRef="usd">98921000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNzI2_32cbd1c6-d2f1-42ca-a4f9-253b674dcb35"
      unitRef="usd">7100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81Mi9mcmFnOjc0ZmYzZGY1ODcxYzRmOTM5NWYxOWJkYmY5OGNmNDg3L3RleHRyZWdpb246NzRmZjNkZjU4NzFjNGY5Mzk1ZjE5YmRiZjk4Y2Y0ODdfNzMz_c08e725e-60b8-4939-9d4a-50426bb5356f"
      unitRef="usd">2200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfMzk0_24394df7-3cf1-422a-8ee1-1f8c5b377ca9">Property and Equipment&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized internal-use software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital lease equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-lived assets are located in the United States. Depreciation expense totaled $0.7 million and $0.7 million for the three months ended March&#160;31, 2021 and 2020, respectively. Depreciation expense includes amortization of assets recorded under a capital lease and the amortization of capitalized internal-use software costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalized $1.0 million and $0.1 million of internal-use software costs for the three months ended March&#160;31, 2021 and 2020, respectively. We incurred $0.3 million and $0.1 million of capitalized internal-use software cost amortization expense for the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i983abe9c75604218bf9215278d6c8786_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMi0xLTEtMS0w_e0790768-b200-4d48-a26a-c30bdf50007a"
      unitRef="usd">9562000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie10e2819b49b48ebaeb218115ba93d2b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMi0zLTEtMS0w_14376025-fb80-4162-b08c-eb7c67ab6f20"
      unitRef="usd">8576000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if83e5abba43a418b8748534d60c48c2b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMy0xLTEtMS0w_75e5d213-7409-4440-909a-be7158d01222"
      unitRef="usd">10536000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifb60e336f0d243aeb3c25066686e0e13_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMy0zLTEtMS0w_8b9a5fb4-74f3-44ec-a275-087bc99dfc20"
      unitRef="usd">8089000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib630a4b7ddb6454bb0fd041f7d7959a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNC0xLTEtMS0w_f6e999b3-cb56-426e-81e8-5aea515af0f4"
      unitRef="usd">3614000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic1f14648338143b69e420b0bcff04694_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNC0zLTEtMS0w_d5cbb531-faa5-4ee9-b083-7838f92ec077"
      unitRef="usd">1734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6d7a206018584742a08cdb6786414f22_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNS0xLTEtMS0w_d04c9a4c-4e6c-4a38-ac65-aff63e34d73d"
      unitRef="usd">4506000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib50a93f231d04a3c92f044e1aead7038_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNS0zLTEtMS0w_73589262-4366-4bb7-89db-e910b7f75d6c"
      unitRef="usd">3489000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b9f4a66d37c421d9e84a17684b6e893_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNi0xLTEtMS0w_3deb3d4e-38b2-44f3-bed2-06a3be1b3417"
      unitRef="usd">947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie0db9e7d9d0645fe9a0dd92a5549d8ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNi0zLTEtMS0w_75b306f4-3a2e-49bc-a73a-c9f5241d1608"
      unitRef="usd">947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i977516e22f8e4f18a06347de98aabdba_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNy0xLTEtMS0w_bde673d7-9b4d-4b04-954e-0a204f53f4e3"
      unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i88139ab53d0d484f97717e145bade887_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfNy0zLTEtMS0w_f41399b8-9988-450a-9850-b357445eb135"
      unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOC0xLTEtMS0w_9ffe84e0-a9f7-44b7-872f-41db678ba1af"
      unitRef="usd">29202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOC0zLTEtMS0w_10dea531-26dc-4f1d-8d2d-bf96462806f2"
      unitRef="usd">22872000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOS0xLTEtMS0w_2dd7ae26-0607-4a86-89e1-b181c1ad10fc"
      unitRef="usd">10549000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfOS0zLTEtMS0w_9acee7b0-ecb1-4046-8bac-1ea06fbe077e"
      unitRef="usd">10009000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMTAtMS0xLTEtMA_f2727dbb-bd7a-457b-b098-13f7768b209f"
      unitRef="usd">18653000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RhYmxlOmM3NWRmZjNlMjIwYzRmNGZiMWZhY2RhM2VjZWE5ZDVmL3RhYmxlcmFuZ2U6Yzc1ZGZmM2UyMjBjNGY0ZmIxZmFjZGEzZWNlYTlkNWZfMTAtMy0xLTEtMA_6bb4be94-dbf6-4be8-b1ca-db8b3d01a29c"
      unitRef="usd">12863000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfMTg0_3ae7d623-fa30-4c9c-9ce8-9b12236c5114"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfMTkx_07c39c1e-8ad5-422b-a2ec-5081a2f7c53f"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzY2Ng_89549ee3-6983-44ca-98ee-e7e07b2fa415"
      unitRef="usd">1000000.0</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="i9c0efcef22664d14815854888bb21e26_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzY4MQ_19895255-78fd-4974-a8a2-41756a9e3174"
      unitRef="usd">100000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzY5Ng_62c022da-d1a8-4f48-ba05-0786eaa6b823"
      unitRef="usd">300000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81NS9mcmFnOmE1ODFkM2UyNDM0YzQ2ODVhNjJlOTgzMTZlMzlhYjMxL3RleHRyZWdpb246YTU4MWQzZTI0MzRjNDY4NWE2MmU5ODMxNmUzOWFiMzFfNjA0NzMxMzk1MzcxMQ_36604489-9987-47b8-9d37-a7cc5000ee8f"
      unitRef="usd">100000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfMjAwNA_82754616-4a67-4900-9155-f73ad275cb95">Short-term Investments&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale. Available-for-sale securities are recorded on our condensed consolidated balance sheets at fair market value and any unrealized gains or losses are reported as part of other comprehensive loss on our condensed consolidated statements of comprehensive loss. We determine realized gains or losses on the sales of investments through the specific identification method and record such gains or losses as part of interest and other expense, net on our condensed consolidated statements of operations. We did not have any material realized gains or losses on investments during the three months ended March&#160;31, 2021 and 2020. We measure the fair value of investments on a recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables related to our available-for-sale securities of $0.6 million and $0.5 million as of March&#160;31, 2021 and December&#160;31, 2020 were included within prepaid expenses and other assets on our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis we evaluate unrealized losses on our available-for-sale debt securities and the related accrued interest receivables to determine whether a decline in the fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors. We do not intend to sell investments that are in an unrealized loss position and it is not likely that we will be required to sell any investments before recovery of their amortized cost basis. As of March&#160;31, 2021 and December&#160;31, 2020, there were no material unrealized losses due to credit-related factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:InterestReceivable
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfOTMw_2be894d3-3da4-4025-839f-4cd99a0e2ff2"
      unitRef="usd">600000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfOTM3_5eef2d2d-eada-41f7-8a57-fb6acdca17e8"
      unitRef="usd">500000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RleHRyZWdpb246NzU1YmE1Zjk0MjU3NGI3OWExYjU3MTMyNmIwYjk3MzVfMjAwNQ_774acfd2-163b-4d05-af0e-b22e19f640a7">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS0xLTEtMS0w_7ac4be3b-8554-4f25-88ea-374eaf58d673"
      unitRef="usd">125378000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS0zLTEtMS0w_6d192ae0-fc29-4fdd-8e84-cb9e16a74e31"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS01LTEtMS0w_6f2b5395-fdc5-4071-a73c-f16e80dfde4a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ecf10cc4085481ca4cbafb3a5ec3956_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS03LTEtMS0w_ad98af1d-e712-4919-8eef-d9d46a720ab5"
      unitRef="usd">125378000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb8030fbd94c4883ab8884ca9b7948c1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS05LTEtMS0w_32cc0648-eb97-4f6c-a9b2-95d14b32a1c1"
      unitRef="usd">125378000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i541592340c83428bbdf196bbddcb23a3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMS0xMS0xLTEtMA_729057b3-76b8-4c1d-a638-eb1724855875"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi0xLTEtMS0w_dae18ad4-d4ea-4299-a121-af928bd59027"
      unitRef="usd">49123000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi0zLTEtMS0w_5d90c4d0-fab9-476c-91ff-d286b3500f4c"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi01LTEtMS0w_da7cca8e-c20b-44cc-b610-7e5be52092a4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f527cddf90d40a6a583d5ef14ce3acd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi03LTEtMS0w_c2335b7e-c34a-4010-8854-69259c4bc872"
      unitRef="usd">49130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i426a8994b6c940268705dd62cb41316b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi05LTEtMS0w_f74e35bd-0457-44f1-b7c6-866164af0e84"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie7c3e9e5c69d458f81c897663c923806_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMi0xMS0xLTEtMA_086a09c9-c9e9-4d3b-b2ea-95ba3f50ae89"
      unitRef="usd">49130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy0xLTEtMS0w_a8c2524b-f012-4575-ba4f-05439f64b3ad"
      unitRef="usd">57067000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy0zLTEtMS0w_6ecc0614-2b5f-47f7-974a-596fe1fe927a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy01LTEtMS0w_d0ba5b86-c8ed-4206-b852-67e879c7bed4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if016bb5751394439b838dd7a5e32d9e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy03LTEtMS0w_ac0e1d6e-922f-47ba-a37f-aa645744888c"
      unitRef="usd">57067000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3505f155dd9c49eeaf5dce4bd2bad37d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy05LTEtMS0w_0985bc45-1150-40d2-8bfd-667ca2a2f9d0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifddc111015e24dd5a3690fdb5f45cc03_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfMy0xMS0xLTEtMA_743dace8-0624-4038-bba9-3a8a7850a1d4"
      unitRef="usd">57067000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC0xLTEtMS0w_5bc46470-df9a-4a3d-8854-0af3a2b4328b"
      unitRef="usd">27615000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC0zLTEtMS0w_51f3ba71-ebd1-4c16-b05d-3a7d774c3a12"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC01LTEtMS0w_13b1e888-bd61-4c8a-9911-534170f42c0f"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12990573c5334556ae9ffecfcdd78f8b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC03LTEtMS0w_08896600-307a-4268-b2ea-1c817f654a3d"
      unitRef="usd">27610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib87ff6778e0941aea98e91250fcb83cc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC05LTEtMS0w_f46d5451-a6fd-4589-aa74-62c40602e9ac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1af733c21c145808c8ce5cf39e9aa92_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNC0xMS0xLTEtMA_722426e1-fa23-43f9-9af1-02b1c46810bd"
      unitRef="usd">27610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi0xLTEtMS0w_c7dd2cd3-babc-40b0-bf55-13febd1f287c"
      unitRef="usd">259183000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi0zLTEtMS0w_0a25b6f1-c756-4048-8bb5-fe7c53ba41b9"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi01LTEtMS0w_d8f79f99-6623-4a35-9ce5-4de8ea3a9fdd"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi03LTEtMS0w_78427771-03a9-45f9-be18-177ead69bc6b"
      unitRef="usd">259185000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9cf71f707df4212a1eab4e8b98af652_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi05LTEtMS0w_e89ed1b0-5d7b-4c09-82e5-513b50bb71f0"
      unitRef="usd">125378000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d92a783fa4d4b9e8f5c6ddb9773b7ef_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmZhMTZhNjM2NjE0MDQ2NWVhZjJjNTUyYTRmYzgyMzNkL3RhYmxlcmFuZ2U6ZmExNmE2MzY2MTQwNDY1ZWFmMmM1NTJhNGZjODIzM2RfNi0xMS0xLTEtMA_f13b56c5-f2af-44be-9da2-3ce86f376352"
      unitRef="usd">133807000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS0xLTEtMS0w_0d730461-09e4-4427-98a9-211fa7badf55"
      unitRef="usd">79387000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS0zLTEtMS0w_25484fe6-65e3-4833-b117-bacbbeb7c87b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS01LTEtMS0w_10291a9a-203f-43dc-8cb3-4f19dfcd5c4b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccf00f0e3ce94b20aa839b353e220099_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS03LTEtMS0w_405c1c84-513f-4809-afa2-3f5066b58474"
      unitRef="usd">79387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89f8b60d964c412f8bf1c17763bd40bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS05LTEtMS0w_79165715-2f02-4556-a071-7f4010b6f0f5"
      unitRef="usd">79387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i935fba8f21d64ab0a83a3fc3303e30db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMS0xMS0xLTEtMA_4564a8d5-3fe2-4ad3-8175-3571a14e4620"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi0xLTEtMS0w_5cf974c4-21af-48bb-870a-3946c0171081"
      unitRef="usd">59382000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi0zLTEtMS0w_8958e0d7-b88a-45d0-9a34-5c5a8a15c4fc"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi01LTEtMS0w_455e886e-5d9b-4720-9a4a-ed95014f0d7a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifaaece3cffb845d288b5e4226bc51516_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi03LTEtMS0w_64af694d-084b-4191-a2c0-367e71052796"
      unitRef="usd">59389000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00c52c70966543f9b9649f46f30a1296_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi05LTEtMS0w_e6b1616b-1c2d-42e0-8730-f22c871ac318"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife5d15f13d5b4999b2da4743f59a762c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMi0xMS0xLTEtMA_888ac6cd-1857-404a-aa8d-d5f273c0c0dd"
      unitRef="usd">59389000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy0xLTEtMS0w_02f54115-6b4b-4a4b-ac7b-53e2403ffbe3"
      unitRef="usd">68018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy0zLTEtMS0w_cd371a1e-0cfe-494b-a194-b66015162916"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy01LTEtMS0w_17dbac73-0886-4817-a563-19f46f47a303"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae6d29b54640446d8d61a7b0cbdb303b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy03LTEtMS0w_108cc01b-1aaf-4fbb-916d-b210f533e5c0"
      unitRef="usd">68018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26f143d773b74a2c97d01a880e1b5979_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy05LTEtMS0w_b3768227-d501-48ff-9ec3-84be9b7b60ac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f9a993228ca419ab4f241d7af9bb937_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfMy0xMS0xLTEtMA_6457c01f-8ad6-4671-a132-081aea938fd0"
      unitRef="usd">68018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC0xLTEtMS0w_7fb5b4aa-a264-41c8-937a-f0e474acb29b"
      unitRef="usd">48494000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC0zLTEtMS0w_48d05ea5-c412-4e6a-99a9-4a50f3c9e7ca"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC01LTEtMS0w_b6f353d8-6b32-493c-874c-221d54678bfc"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bdab57ed0e94216adfff9b427fcd2f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC03LTEtMS0w_90fdfbc8-34f3-4480-9600-d9d554158bcd"
      unitRef="usd">48501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80ca7f15ccff44c6bb539eb829a8c5a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC05LTEtMS0w_7a2c2542-e3bf-4ccd-af99-3efb832cd1c4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0ae121e125f4a669af32cafe299e72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNC0xMS0xLTEtMA_7899e3f2-fc38-402f-b0b9-b99b2ecb0672"
      unitRef="usd">48501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS0xLTEtMS0w_38f9e254-6a81-4042-96fe-3e486104a1ec"
      unitRef="usd">3009000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS0zLTEtMS0w_7018f2c9-a639-48f2-9794-d403d4c40546"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS01LTEtMS0w_19cc4aaa-fe27-4d8c-b22d-8d7c67616976"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54312b9eac0b49b2837ad56f42f14a85_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS03LTEtMS0w_84f3b68f-be4a-4654-b7d0-4554045aa945"
      unitRef="usd">3009000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8206db89dd9e4111863cf8b116f25dc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS05LTEtMS0w_13489fb6-4f8c-4793-ba16-72d26ea08e3f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95cb4a7b357a4575b5c1f13edf15b3a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNS0xMS0xLTEtMA_df7375d6-07b9-42d6-ac2e-07340ec310d7"
      unitRef="usd">3009000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi0xLTEtMS0w_e3d3bd95-b206-4b32-8a91-b797a29628de"
      unitRef="usd">258290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi0zLTEtMS0w_aa0f9f2e-33f8-4f41-82de-d85ba2a1b1c5"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi01LTEtMS0w_612e005f-b77d-4c3d-8d2e-ce8c1ecf2ae6"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi03LTEtMS0w_5cc207cb-94c9-4665-bdcf-e29304ea3a26"
      unitRef="usd">258304000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if66d1b79d4394e83b7b2d962f19c40a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi05LTEtMS0w_69bc1e40-67dd-4cb1-901e-e0321d1da96c"
      unitRef="usd">79387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i978e872b2ba845f49001cc6325ebd9fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV81OC9mcmFnOjc1NWJhNWY5NDI1NzRiNzlhMWI1NzEzMjZiMGI5NzM1L3RhYmxlOmI1ZTQ2OTRjYmM2NzRhMDdiYzc3MjhiNTUxM2UwMTQ2L3RhYmxlcmFuZ2U6YjVlNDY5NGNiYzY3NGEwN2JjNzcyOGI1NTEzZTAxNDZfNi0xMS0xLTEtMA_efafe41e-74ac-47b6-a956-e8e2d085555c"
      unitRef="usd">178917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMjE1MQ_77636d8e-391f-425f-a744-db43355ab7fd">Fair Value of Financial Instruments&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level 1 and Level 2 during the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;March&#160;31, 2021, the estimated fair value of the our convertible senior notes, with aggregate principal totaling&#160;$230.0 million,&#160;was&#160;$391.3 million. We estimate the fair value based on quoted market prices in an inactive market on the last trading day of the reporting period (Level 2). These convertible senior notes are recorded at face value less unamortized debt discount and transaction costs on our consolidated balance sheets. Refer to&#160;Note 9 &#x2014;Convertible Senior Notes for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Healthfinch acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Healthfinch during an earn-out period that ends on July&#160;31, 2021. The Healthfinch contingent consideration will be paid in a combination of cash and shares of our common stock in the same proportion as the initial acquisition consideration. The Vitalware acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Vitalware during an earn-out period that ended on March&#160;31, 2021. The Vitalware contingent consideration is capped at $30.0 million and will be paid in a combination of approximately 50% cash and 50% in shares of our common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value the expected contingent consideration and the corresponding liabilities using the Monte Carlo valuation method based on estimates of potential pay-out scenarios. The resulting contingent consideration liabilities are categorized as Level 3 fair value measurements and are remeasured as of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of the revenue-based earn-out contingent consideration liabilities is approximately $32.5 million based on a point estimate of our internal forecasting of the ultimate earn-outs that will be earned and our common stock price as of March&#160;31, 2021. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Valuation Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market Price of Revenue Risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Revenue Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stock Price Volatility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue-based earn-out liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Monte Carlo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Able Health acquisition consideration included an initial estimate for contingent consideration for shares of our common stock if certain incremental billing targets for Able Health were met during an earn-out period that ended on December 31, 2020.  This Able Health earn-out contingent consideration liability was settled during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMjE1Mw_69715eb1-0ec4-41c2-8ea7-5b5d11e5f398">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id78fe06353da4595b8d88460f552d5b0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi0xLTEtMS0w_84e09ceb-a095-45c7-ad5a-acab5289a445"
      unitRef="usd">125378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i91927ae09dc04b33b971594d8bc54b89_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi0zLTEtMS0w_04247311-01b2-4fe9-98df-abed13d82627"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3a4b7862118b4131ac5f06f5aa47e163_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi01LTEtMS0w_5df79a46-6746-4276-be44-bf9899a1fecc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMi03LTEtMS0w_d457850b-06d0-4f7b-8d98-d69620b4e953"
      unitRef="usd">125378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibed91e357c7f439bad5f2441be2f3393_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy0xLTEtMS0w_849264c5-bd84-4c43-b173-88b70cbf3217"
      unitRef="usd">49130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibebd1cdc445047d992d3cf7740678f7e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy0zLTEtMS0w_e9aab9f4-ff3c-4409-8829-7b85349643c8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide03cc507eb84e43996d3b6131c163af_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy01LTEtMS0w_1ca7aee9-f890-4be7-aca8-30e572b8a3b4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic56d22cf25cf4054b9132b3db37d4f5a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfMy03LTEtMS0w_fa4e3442-7077-4f27-9646-7f485088f12a"
      unitRef="usd">49130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab672b01fe5742f2aa363490a53f34e5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC0xLTEtMS0w_09f00359-5aed-4f61-a31e-db75d7344d5d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4186455850234995a3fefd4e16a396f4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC0zLTEtMS0w_b19527d6-8380-4b3f-b928-b1df2893a630"
      unitRef="usd">57067000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1976d6b0d3d4e46ad2266bf99b8e8e7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC01LTEtMS0w_802788d6-30ec-43fd-ae1f-a3a9a167d237"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i660b0d75067a411f95ef76e0a4f14bcf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNC03LTEtMS0w_c7534335-19d8-4d14-bc97-23217139bd14"
      unitRef="usd">57067000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb5d27da05ef4dd6820a8bd484966fad_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS0xLTEtMS0w_efde2335-296b-460b-8c5d-ca65f03f64e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66dbc4d8aea34408bcdeadf087d32dfe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS0zLTEtMS0w_ed649d53-fcd9-4879-ba66-13936ebde8b7"
      unitRef="usd">27610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iebfcdb2b7b1549cab39eebc5d9febb7e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS01LTEtMS0w_d6ea510f-27cb-4259-84ef-5dfe3d3efeaf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3baad2ca5dec4ecb9082b1a396901a60_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNS03LTEtMS0w_d260df67-0bbe-4fc0-95db-6dfd55519539"
      unitRef="usd">27610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id78fe06353da4595b8d88460f552d5b0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy0xLTEtMS0w_9f0159f2-9471-4159-b9f9-ba97cd0a8bdd"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i91927ae09dc04b33b971594d8bc54b89_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy0zLTEtMS0w_58799220-d6a4-4157-90e1-cb9c41b36a84"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3a4b7862118b4131ac5f06f5aa47e163_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy01LTEtMS0w_ca81d550-62b2-4526-806e-be6a1433fea4"
      unitRef="usd">32444000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfNy03LTEtMS0w_2103bab5-acb8-486c-a563-fc8de1e60b0d"
      unitRef="usd">32444000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="id78fe06353da4595b8d88460f552d5b0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC0xLTEtMS0w_fbcd5f52-cf13-4014-b921-378bc5c663f3"
      unitRef="usd">174508000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i91927ae09dc04b33b971594d8bc54b89_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC0zLTEtMS0w_0f1e761e-1694-46ee-aaac-7963d77ce660"
      unitRef="usd">84677000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i3a4b7862118b4131ac5f06f5aa47e163_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC01LTEtMS0w_35be0997-3d5b-464e-b2f1-478a1480f79b"
      unitRef="usd">-32444000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i5f0f2b068c1a4fe692be1e115c3a8305_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmQ1ODg0M2Q0MGM0NDRmYmVhMDQzNTc0OWJhYmVlZjAzL3RhYmxlcmFuZ2U6ZDU4ODQzZDQwYzQ0NGZiZWEwNDM1NzQ5YmFiZWVmMDNfOC03LTEtMS0w_a97b3a27-5347-4dbd-b683-93822899ffe0"
      unitRef="usd">226741000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8799ab7618024c44bc02cda2b7c017c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi0xLTEtMS0w_ecbcf7bc-8659-4064-9fe0-30b5af435e4b"
      unitRef="usd">79387000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1265ad6d0a51472194b6f09102f17989_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi0zLTEtMS0w_d5000a7e-9452-46a5-ad59-534b967b71b3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3257c2bc0d064887835ed5bd428b3341_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi01LTEtMS0w_d0832e4f-2708-4f82-919b-7a3e03424ace"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMi03LTEtMS0w_9ffd6d94-ea77-47c8-9b5a-974ceb8b1add"
      unitRef="usd">79387000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2569064bb5554bff8a5d048551e515ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy0xLTEtMS0w_fa10d487-bd71-4864-8a6a-42ed5ecbb8fc"
      unitRef="usd">59389000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i161a412a8549477d870aa84d7450f380_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy0zLTEtMS0w_fe8ffdab-d701-4d16-8abc-59d1f0163c50"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i527bc64f624c453d86a9fc398fa02162_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy01LTEtMS0w_bf2c8c2d-480c-460d-aac6-dd39d1ba1b3c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13c8d4d672174b0eaf8590b94b667b03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfMy03LTEtMS0w_c5781d19-f0b8-491a-bdb3-4ca956acf504"
      unitRef="usd">59389000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78034192027744038e8701e5a608c7d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC0xLTEtMS0w_057d4308-ad79-4db2-abbc-51c2a0b007ce"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id682c7555ec54d519592bb14ada245af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC0zLTEtMS0w_b067bbea-656a-4c4c-9a46-c6bc73ba18ff"
      unitRef="usd">68018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f4f44ee228e4ea0ba64867556b0a8ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC01LTEtMS0w_690c4697-09c5-4ba9-bdc2-e4d3989919d3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4c3845f6f18439d8fb05984c62fff97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNC03LTEtMS0w_d66e7f7e-6b88-4d6e-b4a0-c1ef783dcc91"
      unitRef="usd">68018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26633d8bfcfd430fb29e89e97d45eb1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS0xLTEtMS0w_35f4f697-847f-4fe3-ab2f-e232d3fb5c12"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5961bc6e1d4847d1aa04aa5a147ce0a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS0zLTEtMS0w_dd7e214b-ce0e-46da-bb61-7da13861c685"
      unitRef="usd">48501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iafd7c0f92f7040fa9ad243c1f7fbaa69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS01LTEtMS0w_83fe3917-da29-4237-b5a3-d282695f221c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if49bbfddff2d48ce808eae7321a3d727_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNS03LTEtMS0w_568e9444-1764-4783-945d-613b1fb212de"
      unitRef="usd">48501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80924d762aae4accb35feb372dd0973d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi0xLTEtMS0w_a2cb2611-3ebf-4df6-8683-5b1f02557d34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd307786e34047c1a07fb54bd6b2b8d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi0zLTEtMS0w_e9938132-dad6-445c-9be9-1a9857d46b05"
      unitRef="usd">3009000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i969f245e87394c10994db7d2a6a77fb4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi01LTEtMS0w_59149d40-81dd-4619-8725-80fff176b4ab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ed4a348fb3e4251a45ae70c403a2faf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNi03LTEtMS0w_0ab74336-287c-46d5-9b82-18857d71c486"
      unitRef="usd">3009000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8799ab7618024c44bc02cda2b7c017c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0xLTEtMS02MTM_f137d7ae-4da6-4efa-b25d-3531b6c4d9db"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1265ad6d0a51472194b6f09102f17989_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0zLTEtMS02MTM_085b8183-d000-490e-a4cc-15ad4887a10f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3257c2bc0d064887835ed5bd428b3341_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy01LTEtMS02MTM_b618e686-8584-4ebb-b229-9ff4a9e2f58a"
      unitRef="usd">31264000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy03LTEtMS02MTM_1fb12e32-6f31-4de3-b666-a9d8c4cb5dab"
      unitRef="usd">31264000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i8799ab7618024c44bc02cda2b7c017c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0xLTEtMS0w_58062670-0efc-4223-9ab6-d6eb43c2b6c3"
      unitRef="usd">138776000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i1265ad6d0a51472194b6f09102f17989_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy0zLTEtMS0w_6eddbb4b-cc35-4401-b272-5bc5f7da3b95"
      unitRef="usd">119528000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i3257c2bc0d064887835ed5bd428b3341_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy01LTEtMS0w_5a76d6bf-4415-4187-8146-43e8b7eacfcc"
      unitRef="usd">-31264000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="ic564c4a0c7f64ecbbf80e1d2386111b3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOmZhY2MxNmU1MDIyYzRhMDI4N2FkZDhlODI2MTE5ZTlhL3RhYmxlcmFuZ2U6ZmFjYzE2ZTUwMjJjNGEwMjg3YWRkOGU4MjYxMTllOWFfNy03LTEtMS0w_cdc00e9d-3307-4af6-b806-7b3f8c4608dd"
      unitRef="usd">227040000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzNjU1OA_e6bb892c-750b-4908-956d-2cb6282d6a7b"
      unitRef="usd">230000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzMDU5NQ_3b293c7d-dc63-4555-9aec-8e30e4dc44e4"
      unitRef="usd">391300000</us-gaap:DebtInstrumentFaceAmount>
    <hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability
      contextRef="if709f4c82b2c40929782386201a2329e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzNjU0NA_680c0110-b72a-4ccd-81a0-523eb960f886"
      unitRef="shares">30000000.0</hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability>
    <hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash
      contextRef="icf8b76871176404b8081eb0c5b32f0ba_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfNDM5ODA0NjUxOTg5Mw_d91bd0f7-ec6d-43aa-babb-9e04e798fcdb"
      unitRef="number">0.50</hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash>
    <hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares
      contextRef="icf8b76871176404b8081eb0c5b32f0ba_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfNDM5ODA0NjUxOTg5OA_e8a8648b-a035-4891-ba1e-a1f4323d510a"
      unitRef="number">0.50</hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares>
    <hcat:FairValueMeasurementAggregateIntrinsicValue
      contextRef="i2ed47da29f5f4158b9f99d94735bcba3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMTA5OTUxMTYzNjEzNQ_d6599f05-b285-4c96-9dd1-1a9e45ed93f8"
      unitRef="usd">32500000</hcat:FairValueMeasurementAggregateIntrinsicValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfNDM5ODA0NjUxOTg5MQ_e2659f4f-c0a7-4747-a6b0-68dc4f35ed02">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs as of March&#160;31, 2021:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Valuation Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market Price of Revenue Risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Revenue Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stock Price Volatility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue-based earn-out liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Monte Carlo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Able Health acquisition consideration included an initial estimate for contingent consideration for shares of our common stock if certain incremental billing targets for Able Health were met during an earn-out period that ended on December 31, 2020.  This Able Health earn-out contingent consideration liability was settled during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <hcat:FairValueMeasurementAggregateIntrinsicValue
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS00LTEtMS02NjI_7d162fa0-8e1b-44e6-b403-b9f253999e97"
      unitRef="usd">32400000</hcat:FairValueMeasurementAggregateIntrinsicValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i86af83c7eb5046eda62a9143eb75002f_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS02LTEtMS02NjI_192a0dcd-af20-42a2-8f43-fede9392462c"
      unitRef="number">0.03</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="icdc9d82578fd4a2b800c586e00deda04_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS04LTEtMS02NjI_d3d6e4c9-b306-498b-87f2-abdb792d4883"
      unitRef="number">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic6c816c8bd444ca6b6af6a54d8586515_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjA2ZWI2OTZlZmE2ZDQ0MDNhNzE2OWNhMDEzZDRmYmQ5L3RhYmxlcmFuZ2U6MDZlYjY5NmVmYTZkNDQwM2E3MTY5Y2EwMTNkNGZiZDlfMS0xMC0xLTEtNjYy_c810f735-6e4c-4112-8202-925d3180e811"
      unitRef="number">0.41</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RleHRyZWdpb246ZTZhODNlZDI3ZDQxNDUyYmIzMzIxNDNhZTU1ZTI5ZGVfMjE1NA_0d6cffba-b259-4374-8afc-a6dbe61980cd">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i530512a1ce4642378115de9c7b137ee4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfMS0xLTEtMS0w_12fd75ae-f86c-400c-b20d-509477477677"
      unitRef="usd">31264000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="iddeb3efca1a047968b5e37ad4c74a3e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfMi0xLTEtMS0w_44a88571-7512-4efe-a783-587a27f6b260"
      unitRef="usd">-1009000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="iddeb3efca1a047968b5e37ad4c74a3e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfMy0xLTEtMS0w_3e84b578-b2dd-4505-b82f-31af0e758341"
      unitRef="usd">2156000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i636c7efe46af4879a27c31281770fbe6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82MS9mcmFnOmU2YTgzZWQyN2Q0MTQ1MmJiMzMyMTQzYWU1NWUyOWRlL3RhYmxlOjdkNDZlZGE3YjIwMjRhZjliZjZjYjg3OTk4MTM1ODMxL3RhYmxlcmFuZ2U6N2Q0NmVkYTdiMjAyNGFmOWJmNmNiODc5OTgxMzU4MzFfNC0xLTEtMS0w_0ca05a7e-8873-4de7-a4a6-06444ceb1abb"
      unitRef="usd">32411000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RleHRyZWdpb246MjU4ZDhjZjhiMWY3NDQzMDg2NDc0ZjdjNjFiZGVmNTVfMTA5_c366a4a8-16a4-4693-8359-5ffda8662caf">Accrued liabilities&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefit expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RleHRyZWdpb246MjU4ZDhjZjhiMWY3NDQzMDg2NDc0ZjdjNjFiZGVmNTVfMTEw_aef9c94a-d992-41ba-8bc5-277218db7bdf">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefit expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMi0xLTEtMS0w_233b402e-7df1-4760-be19-cb176cde9b94"
      unitRef="usd">7024000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMi0zLTEtMS0w_7ecaba84-87e9-4774-9d4a-439249faef69"
      unitRef="usd">9838000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMy0xLTEtMS0w_40b3ccbe-5a1e-404e-82d1-0f8141b59b22"
      unitRef="usd">5922000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfMy0zLTEtMS0w_c62f66cd-e3fc-47d2-81de-2d763c5d0d3c"
      unitRef="usd">6672000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfNC0xLTEtMS0w_4a4a4562-23cc-453d-9c80-c7543463cd1c"
      unitRef="usd">12946000</hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82NC9mcmFnOjI1OGQ4Y2Y4YjFmNzQ0MzA4NjQ3NGY3YzYxYmRlZjU1L3RhYmxlOjFmNDdhODM2NWM0NDQ2OTVhMTI4M2NiZWQ0MDdiODFjL3RhYmxlcmFuZ2U6MWY0N2E4MzY1YzQ0NDY5NWExMjgzY2JlZDQwN2I4MWNfNC0zLTEtMS0w_7e96ba23-fc18-43e1-b8bb-2bde0700ed77"
      unitRef="usd">16510000</hcat:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMzExMQ_dcaa5d30-5d88-41f1-aecf-c24283c8ed15">Convertible Senior Notes&lt;div style="margin-bottom:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;14, 2020, we issued $230.0&#160;million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025 (the Notes), in a private placement to qualified institutional buyers exempt from registration under the Securities Act (the Note Offering). The net proceeds from the issuance of the Notes were approximately $222.5&#160;million, after deducting the initial purchasers&#x2019; discounts and offering expenses payable by us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are governed by an indenture (the Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Indenture does not contain any financial or operating covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may not redeem the Notes prior to April 20, 2023. On or after April 20, 2023, we may redeem, for cash, all or a portion of the Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes have an initial conversion rate of 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock). Following certain corporate events that occur prior to the maturity date, we will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event. Additionally, upon the occurrence of a corporate event that constitutes a &#x201c;fundamental change&#x201d; per the Indenture, holders of the Notes may require the Company to repurchase for cash all or a portion of their Notes at a purchase price equal to 100% of the principal amount of the Notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Notes may convert all or any portion of their Notes at any time prior to the close of business on October 14, 2024, in integral multiples of $1,000 principal amount, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;During any calendar quarter commencing after the calendar quarter ended on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;During the five business day period after any five consecutive trading day period (the measurement period) in which the trading price as defined in the Indenture per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;If we call such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Upon the occurrence of specified corporate events described in the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing circumstances. Upon conversion, holders will receive cash, shares of our common stock or a combination of cash and shares of common stock, at our election.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For at least twenty trading days during the period of thirty consecutive trading days ended March&#160;31, 2021, the last reported sale price of the Company&#x2019;s common stock was equal to or exceeded 130% of the conversion price of the Notes on each applicable trading day. As a result, the Notes are convertible at the option of the holders during the fiscal quarter ending June 30, 2021 and are classified as current liabilities on the condensed consolidated balance sheet as of March&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the Notes as separate liability and equity components. We determined the carrying amount of the liability component as the present value of its cash flows using a discount rate of approximately 10% based on comparable debt transactions for similar companies. The estimated interest rate was applied to the Notes, which resulted in a fair value of the liability component of $166.7 million upon issuance, calculated as the present value of future contractual payments based on the $230.0 million aggregate principal amount. The excess of the principal amount of the liability component over its carrying amount, or the debt discount, is amortized to interest expense over the term of the Notes using the effective interest method. The $63.3 million difference between the gross proceeds received from issuance of the Notes of $230.0 million and the estimated fair value of the liability component represents the equity component, or the conversion option, of the Notes and was recorded in additional paid-in capital. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated issuance costs related to the issuance of the Notes to the liability and equity components using the same proportions as the initial carrying value of the Notes. Issuance costs attributable to the liability component were $5.5 million and are being amortized to interest expense using the effective interest method over the term of the Notes. Issuance costs attributable to the equity component were $2.1 million and are netted with the equity component of the Notes in stockholders&#x2019; equity on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized related to the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs and discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying value of the liability component of the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying value of the equity component of the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds allocated to the conversion option (debt discount)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the closing price of our common stock of $46.77 on March&#160;31, 2021, the if-converted value of the Notes was $121.5 million more than their respective principal amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capped Calls&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (Base Capped Calls) with certain option counterparties. In addition, in connection with the initial purchasers&#x2019; exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used approximately $21.7 million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. As the Capped Call transactions are considered indexed to our own stock and are considered equity classified, they will be recorded in stockholders&#x2019; equity and will not be accounted for as derivatives. The cost incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <hcat:DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjI4OQ_9f8029ac-10ce-413b-b26f-b1647651fd3d"
      unitRef="usd">230000000.0</hcat:DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMwMA_23997327-4eeb-4441-a477-f1efb6493088"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMxNw_5ed6b8df-a6cb-4469-b528-fdee31ff0c3e"
      unitRef="usd">222500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMyOA_23997327-4eeb-4441-a477-f1efb6493088"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM0NQ_9e7bba04-acd3-4da9-bada-22c18f6aad31"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMzMw_aff400f4-b8f5-46fc-a1ed-240c06af921d"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjMzOA_8cf7439d-0ad8-4d2e-b7e6-2e6debe1476b"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM1Mg_af571837-5c0a-4067-9c03-c6055938b523"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0e584e43e4fa4dfe91200285e31ccff9_I20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM3MQ_71b38535-8058-4b67-9210-5a9616cd5113"
      unitRef="usd">1000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM4MA_6dd1c479-68eb-4451-b3bd-9de2f259107d"
      unitRef="usdPerShare">30.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM4Nw_af571837-5c0a-4067-9c03-c6055938b523"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0e584e43e4fa4dfe91200285e31ccff9_I20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjM5Ng_71b38535-8058-4b67-9210-5a9616cd5113"
      unitRef="usd">1000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQwMQ_aff400f4-b8f5-46fc-a1ed-240c06af921d"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQwNg_8cf7439d-0ad8-4d2e-b7e6-2e6debe1476b"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i23059744db234f77ac69c30533821763_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQxMw_9e7bba04-acd3-4da9-bada-22c18f6aad31"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i9e636533f649460881507b118b35238e_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTUyNQ_f8a3b570-e935-4682-9560-fc7734e1bc2f"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i9e636533f649460881507b118b35238e_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTUzNA_962b1006-20f1-4c4d-83a9-004ba8d56eb1"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0e584e43e4fa4dfe91200285e31ccff9_I20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQyMg_71b38535-8058-4b67-9210-5a9616cd5113"
      unitRef="usd">1000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i9e636533f649460881507b118b35238e_D20200414-20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMzg0ODI5MDcyNTc4NQ_f32e9f2b-b6a6-4489-9233-0b4826121511"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTU1MA_5d152980-8c55-4c1f-b273-c654c8b3ca65"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTU0OQ_dfbbc940-1cb2-4380-83eb-398837e31ec8"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMjc0ODc3OTEwMTU0NA_f4bf3def-489e-4553-87c3-5ab034dc5007"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i3f8bc9199ddd4da18bed3e8e6956e62f_I20200414"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQ3OA_52b793ae-5d0e-438b-898b-4b04dfa7f5da"
      unitRef="number">0.10</us-gaap:DebtInstrumentMeasurementInput>
    <hcat:ConvertibleDebtLiabilityComponentFairValueDisclosure
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjQ5NQ_2685ce8c-0d3a-4a92-a6e4-f483cf17bc40"
      unitRef="usd">166700000</hcat:ConvertibleDebtLiabilityComponentFairValueDisclosure>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjUxMw_1e7c06fc-84f4-4a22-8518-49cb3a124772"
      unitRef="usd">230000000.0</us-gaap:DebtInstrumentFaceAmount>
    <hcat:ConvertibleDebtLiabilityComponentFairValueDisclosure
      contextRef="ic22bcfd28d2944d7a26478fbca019240_I20200414"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjUzMA_e66aef2d-b2b0-4c6c-94b6-76f38d0cb99b"
      unitRef="usd">63300000</hcat:ConvertibleDebtLiabilityComponentFairValueDisclosure>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU0OA_1e7c06fc-84f4-4a22-8518-49cb3a124772"
      unitRef="usd">230000000.0</us-gaap:DebtInstrumentFaceAmount>
    <hcat:DebtIssuanceCostGrossLiabilityComponent
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU2NA_fdb92ce0-c662-4b78-8db7-fa4fbcc47852"
      unitRef="usd">5500000</hcat:DebtIssuanceCostGrossLiabilityComponent>
    <hcat:DebtIssuanceCostGrossEquityComponent
      contextRef="i98c1bd93b08e4ba5b807d436d71276d1_I20200414"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU4MA_1baa31b0-4663-4ae3-8f13-71b4cb56e280"
      unitRef="usd">2100000</hcat:DebtIssuanceCostGrossEquityComponent>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMzg0ODI5MDcyNTc4OQ_878e2ad6-ca0f-46ce-b83e-ebda847c5368">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized related to the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs and discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying value of the liability component of the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying value of the equity component of the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds allocated to the conversion option (debt discount)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmZhMjU2NWViMjA2ZTQzY2JhZDE1M2Q3M2RkZGI5MjE5L3RhYmxlcmFuZ2U6ZmEyNTY1ZWIyMDZlNDNjYmFkMTUzZDczZGRkYjkyMTlfMS0xLTEtMS0yNzkw_4c87b4d4-7a2b-40d0-a033-dab0a941f415"
      unitRef="usd">1437000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmZhMjU2NWViMjA2ZTQzY2JhZDE1M2Q3M2RkZGI5MjE5L3RhYmxlcmFuZ2U6ZmEyNTY1ZWIyMDZlNDNjYmFkMTUzZDczZGRkYjkyMTlfMi0xLTEtMS0yNzkw_2324f319-42eb-4fbb-a1bc-7d29e864a1ea"
      unitRef="usd">2870000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpense
      contextRef="ibaad3de365a845369ab8d51789f54b13_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmZhMjU2NWViMjA2ZTQzY2JhZDE1M2Q3M2RkZGI5MjE5L3RhYmxlcmFuZ2U6ZmEyNTY1ZWIyMDZlNDNjYmFkMTUzZDczZGRkYjkyMTlfMy0xLTEtMS0yNzkw_827b7d43-0d65-45c5-a08c-e0adf68ba14c"
      unitRef="usd">4307000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfMS0xLTEtMS03NzI_e6bb892c-750b-4908-956d-2cb6282d6a7b"
      unitRef="usd">230000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfMi0xLTEtMS03NzI_40fcbf5f-41df-4a18-a527-94ae1a349945"
      unitRef="usd">53577000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfMy0xLTEtMS03NzI_1c16053d-27e3-4935-be89-afdb1868e16d"
      unitRef="usd">4559000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmQyMjBmMTExNmIzNjQ5NTQ5OTI0MmQyYzk1ZjJmM2Y4L3RhYmxlcmFuZ2U6ZDIyMGYxMTE2YjM2NDk1NDk5MjQyZDJjOTVmMmYzZjhfNC0xLTEtMS03NzI_5a8c2858-74ce-4cfd-827d-64a23c775f12"
      unitRef="usd">171864000</us-gaap:LongTermDebt>
    <hcat:DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmEyNTgwZWFlMTE1ZTQyZGJhMzllODNjOTU3ODk4OTgxL3RhYmxlcmFuZ2U6YTI1ODBlYWUxMTVlNDJkYmEzOWU4M2M5NTc4OTg5ODFfMS0xLTEtMS03NzI_fef73083-13ec-4d04-944b-417d69199bf4"
      unitRef="usd">63270000</hcat:DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross>
    <hcat:DebtIssuanceCostsGrossEquityComponent
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmEyNTgwZWFlMTE1ZTQyZGJhMzllODNjOTU3ODk4OTgxL3RhYmxlcmFuZ2U6YTI1ODBlYWUxMTVlNDJkYmEzOWU4M2M5NTc4OTg5ODFfMi0xLTEtMS03NzI_b6755762-393d-461a-b859-0e5d7375eb56"
      unitRef="usd">2057000</hcat:DebtIssuanceCostsGrossEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RhYmxlOmEyNTgwZWFlMTE1ZTQyZGJhMzllODNjOTU3ODk4OTgxL3RhYmxlcmFuZ2U6YTI1ODBlYWUxMTVlNDJkYmEzOWU4M2M5NTc4OTg5ODFfMy0xLTEtMS03NzI_ac8bd7c4-2e64-4e3c-93be-70b862264316"
      unitRef="usd">61213000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:SharePrice
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfNjA0NzMxMzk4MzAyOA_14ddd06e-e91c-4121-bb11-cf94aa14925e"
      unitRef="usdPerShare">46.77</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i4882e61e1b5b46ba931866b40710101e_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfNjA0NzMxMzk4MzA4MA_3afa4161-210f-4831-b0b7-d077441cae7e"
      unitRef="usd">121500000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DerivativeCostOfHedge
      contextRef="id441c0a6737547208b92c291c8d51e05_D20200409-20200409"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjU5OQ_285b8ef6-1812-4398-a8bb-738800ce5c14"
      unitRef="usd">21700000</us-gaap:DerivativeCostOfHedge>
    <us-gaap:DerivativeCapPrice
      contextRef="i6e1056545f074e48880fc579da87512f_I20200408"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV82Ny9mcmFnOmQwM2VkYzBiODJjMjQ2NGI4MGU3Nzg2YjlhNjFjMzE4L3RleHRyZWdpb246ZDAzZWRjMGI4MmMyNDY0YjgwZTc3ODZiOWE2MWMzMThfMTA5OTUxMTY0NjYwNQ_6d10cb06-2981-4214-b6e2-7f96c083d9dc"
      unitRef="usdPerInstrument">42.00</us-gaap:DerivativeCapPrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfMTk2NQ_98658639-cbcf-4baf-8220-09c6a1962f90">Stockholders&#x2019; Equity&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our board of directors has the authority, without further action by our stockholders, to issue up to 25,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, and privileges thereof, including voting rights. As of March&#160;31, 2021 and December&#160;31, 2020, no shares of this preferred stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had 500,000,000 shares of $0.001 par value common stock authorized, of which 44,454,783 and 43,709,237 shares were legally issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The shares legally issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020 included 114,747 shares and 332,389 shares, respectively, issued pursuant to the Able Health and Vitalware acquisition agreements, which are subject to a restriction agreement and were unvested, and as such, for accounting purposes they were not considered to be outstanding common stock shares.  Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on our common stock through March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjk2_40873a04-528f-4f8b-a23f-7f41bbd22523"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_19f9e269-3302-4a3b-a7e6-726e2fd2c953"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_577bcd0a-61b2-4106-949b-1ec9cc481a29"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_82aa8ff2-4dcb-4d67-b91d-b7fd95da5756"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfODQ5_8b598304-d23f-42ef-b711-998f43515253"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTMy_b54df50c-f832-415c-a91f-e4537b4832db"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTMy_eca3437d-48e3-4121-937d-b93cdc154106"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTQ1_144370c4-4655-4855-b599-54988cf964d2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTQ1_75a44192-12d3-4df3-be57-6ece519cea88"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTky_3cddaf69-36e6-453a-9e11-da1454485ec5"
      unitRef="shares">44454783</us-gaap:SharesIssued>
    <us-gaap:SharesOutstanding
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTky_b2294517-5e38-4ef6-93ee-0349a3025eb6"
      unitRef="shares">44454783</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTk5_8c7d1aff-1117-43a8-9a91-78a02215ca37"
      unitRef="shares">43709237</us-gaap:SharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfOTk5_9c24c043-3455-4dac-96db-69e2442478a1"
      unitRef="shares">43709237</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="ib8c6064e783e4b6499fe9fac50aae475_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzA5MQ_550bbd73-70e9-48f6-b7fa-32393fae828d"
      unitRef="shares">114747</us-gaap:SharesIssued>
    <us-gaap:SharesOutstanding
      contextRef="ib8c6064e783e4b6499fe9fac50aae475_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzA5MQ_9e2b6088-9262-4ab9-898c-fda8236b3136"
      unitRef="shares">114747</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i6e4af7b7557540d99e4a0928fd4dcef7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzEwMQ_c8c00475-55c2-4c23-9814-e7334b1941e8"
      unitRef="shares">332389</us-gaap:SharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="i6e4af7b7557540d99e4a0928fd4dcef7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfNjA0NzMxMzk1NzEwMQ_ebf862d7-d3c5-48d4-a0f8-617c5ee899e0"
      unitRef="shares">332389</us-gaap:SharesIssued>
    <hcat:StockholdersVote
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83MC9mcmFnOjkxMjQ3ZWU3NGY3YjRmNWRhMmI4OTk4ZGNjNWE5MjE0L3RleHRyZWdpb246OTEyNDdlZTc0ZjdiNGY1ZGEyYjg5OThkY2M1YTkyMTRfMjc0ODc3OTA3NDM2NQ_ac84f441-b1f4-494d-a31b-c649e2a7d659"
      unitRef="vote">1</hcat:StockholdersVote>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfNzQx_05384eb3-88e8-4268-aec5-9ecd86568c5d">Net Loss Per Share&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares used in calculating net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,870,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,108,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, we incurred net losses and, therefore, the effect of our stock options, restricted stock units, performance-based restricted stock units, convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed or shares issued under our employee stock purchase plan were not included in the calculation of diluted net loss per share as the effect would be anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table contains share totals with a potentially dilutive impact:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,640,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares related to convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable as acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,889,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,053,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion spread of the Notes will have a potentially dilutive impact when the average market price of our common stock for a given period exceeds the conversion price of $30.60 per share. The shares related to the Notes in the table above are calculated based on the average market price of our common stock for the three months ended March&#160;31, 2021. Capped Calls are excluded from the calculation of diluted earnings per share, as they would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares issuable as acquisition-related contingent consideration in the table above are calculated based on the earn-out achieved and the estimated amount of shares that would be issuable if the contingent consideration liabilities from the acquisitions of Healthfinch and Vitalware were to be settled as of March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfNzQy_2ec137c5-1cfb-4d10-8787-1a57c09e7411">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares used in calculating net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,870,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,108,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfMy0xLTEtMS0w_71a4cc05-8c71-4b42-af16-6a938627d2b3"
      unitRef="usd">-28370000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfMy0zLTEtMS0w_186448d9-140e-454b-951a-03fbed0438de"
      unitRef="usd">-17490000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNS0xLTEtMS0w_9bf36f43-ba0c-4114-a876-ceb319208159"
      unitRef="shares">43870288</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNS0zLTEtMS0w_afcf88fa-1bc4-4bb9-9eaa-455aba9fbdb4"
      unitRef="shares">37108998</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNi0xLTEtMS0w_69cff9f0-bc1a-4368-8c24-feadb8da596e"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOjcwMGRmNDJkZmVjNTQ5NDRiZGQzYzFkMmIzNDdiZDBhL3RhYmxlcmFuZ2U6NzAwZGY0MmRmZWM1NDk0NGJkZDNjMWQyYjM0N2JkMGFfNi0zLTEtMS0w_40f82c6e-9388-4afc-947e-770b732b2fa6"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfNzQw_4787c799-f010-4ac4-a0d2-66b27a90286b">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table contains share totals with a potentially dilutive impact:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,640,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares related to convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable as acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,889,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,053,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf3d7414d599440ab6623f14616c362b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfMy0xLTEtMS0w_791af5cb-1e85-484b-b231-97bb3bd45131"
      unitRef="shares">3344047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idb8e3c8002b8497680d01206475b3c70_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfMy0zLTEtMS0w_ec51c823-8c0c-4fdb-b1a7-986cad5cefd5"
      unitRef="shares">6640662</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i889328385548411faaca4f9d1d75a560_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0xLTEtMS0w_ec083885-5bd8-4b6b-824a-c4120641fd62"
      unitRef="shares">2937690</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0cbf6d87e70d4690bbb117a5330e5f92_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0zLTEtMS0w_fcd23704-467e-4970-93f9-88a8ae5a152a"
      unitRef="shares">2145968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c57c1ec8b584886bb5787b258ab2310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0xLTEtMS00NDEx_7a8df350-c5c6-4a3e-92db-d417fc92c41d"
      unitRef="shares">307859</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82a09a657dd645c4af6df61e20653b67_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0zLTEtMS00NDEx_f7031ad7-eb77-4e2d-a13b-0dd4c25ab561"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic9a14d8fc64c4c19a75623ef092ff461_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0xLTEtMS0yOTI4_ce7b0694-ad66-4c30-92b4-d2457bf20b39"
      unitRef="shares">2768114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i793d72c883b8430fa8d9b3446ef17c9f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNC0zLTEtMS0yOTI4_331efd4d-85c4-4fbd-a0a8-541f1f15e16d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf5b95cb131b4027a016c3b12f265779_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0xLTEtMS0yOTI4_4d3057e1-33ff-4d0e-8bbe-1deb48ffbecc"
      unitRef="shares">344436</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5291fdd2f49c42f288d38b74d791754d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0zLTEtMS0yOTI4_341005ab-bfab-4488-a319-12b8f08ae516"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13c02d79a3e94b378178e4a644ab9142_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0xLTEtMS0w_e63cd0cd-baf7-4c43-9ad8-3fcec738e6a5"
      unitRef="shares">72892</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i174b5dc836864ffb956e769476edb3fc_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNS0zLTEtMS0w_34576a8e-67d6-4020-8b8b-a40553620e01"
      unitRef="shares">87107</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i38a1ea5338944dbc8ab0f9476e6f521e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNi0xLTEtMS0w_1b0cad02-b2a0-4939-ac8d-021f8041a14f"
      unitRef="shares">114747</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c17e8c4ebc4427892a4e5cc329075de_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfNi0zLTEtMS0w_225bc4c4-30fe-4c71-a592-6c41c143d9fe"
      unitRef="shares">179392</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfOC0xLTEtMS0w_c0d42306-314e-41a7-84c9-4c351f52ea3e"
      unitRef="shares">9889785</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RhYmxlOmQ1MjAwNDQ1NjQ0NzRkYWNiZGI3M2QwZDM4MGNlYjkxL3RhYmxlcmFuZ2U6ZDUyMDA0NDU2NDQ3NGRhY2JkYjczZDBkMzgwY2ViOTFfOC0zLTEtMS0w_2e6246f9-3bad-44c8-bfbb-9558d9f83471"
      unitRef="shares">9053129</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i59fcfef1efb441dea240055b2986ee9d_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83Ni9mcmFnOmQ2OTZkNjM5ODJjODRmMWJiYjhlNDk2M2Y3YmZlZjYyL3RleHRyZWdpb246ZDY5NmQ2Mzk4MmM4NGYxYmJiOGU0OTYzZjdiZmVmNjJfMjc0ODc3OTA3MTMwNQ_26f6c08b-ee7f-426a-8bb5-706a26f0c53d"
      unitRef="usdPerShare">30.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MTg_c490bf73-6101-4b6e-b34c-f52dab87926f">Stock-Based Compensation &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2011, our board of directors adopted the Health Catalyst, Inc. 2011 Stock Incentive Plan (2011 Plan), which provided for the direct award, sale of shares, and granting of RSUs and options for our common stock to our directors, team members, or consultants.  In connection with our IPO, our board of directors adopted the 2019 Stock Option and Incentive Plan (2019 Plan). The 2019 Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce, including the grant of incentive and nonstatutory stock options, restricted and unrestricted stock, RSUs, and stock appreciation rights to our directors, team members, or consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have initially reserved 2,756,607 shares of our common stock (2,500,000 under the 2019 Plan and 256,607 shares under the 2011 Plan that were available immediately prior to the IPO registration date). The 2019 Plan provides that the number of shares reserved available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. As of January&#160;1, 2021, there were an additional 2,185,461 shares reserved for issuance under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, there were 15,294,920 and 13,109,459 shares authorized for grant, respectively, and 3,086,399 and 2,481,818 shares available for grant, respectively, under the 2019 Plan and 2011 Plan (collectively the Stock Incentive Plan). All options were granted with an exercise price determined by the board of directors that was equal to the estimated fair value of our common stock at the date of grant, based on the information known on the date of grant. Subject to certain exceptions defined in the Stock Incentive Plan related to an employee&#x2019;s termination, options generally expire on the tenth anniversary of the applicable grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options, which vest in accordance with service schedules, is estimated on the date of grant using the Black-Scholes option pricing model. The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no stock options granted during the three months ended March 31, 2021 or 2020. A summary of the share option activity under the 2019 Plan for the three months ended March 31, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Time-Based Option Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,892,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(537,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,946,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,946,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,231,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised was $18.7 million for the three months ended March&#160;31, 2021. The total grant-date fair value of stock options vested during the three months ended March&#160;31, 2021 was $1.8 million. As of March&#160;31, 2021, approximately $6.3 million of unrecognized compensation expense related to our stock options is expected to be recognized over a remaining weighted-average period of 1.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The service-based condition for RSUs is generally satisfied over&#160;four years with a 25% cliff vesting period of one year and ratable quarterly vesting thereafter. The following table sets forth the outstanding RSUs and related activity for the&#160;three months ended March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, we had $114.1 million of unrecognized stock-based compensation expense related to outstanding RSUs expected to be recognized over a remaining weighted-average period of 3.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based Restricted Stock Units (PRSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, we granted PRSUs to all employees that included both service conditions and performance conditions related to company-wide goals. These PRSUs will vest to the extent the applicable performance conditions are achieved for the year ended December 31, 2021, and if the individual employee continues to provide services to us through the vesting date of March 1, 2022. The number of PRSUs that will ultimately vest from the 2021 PRSU grants can range from 0% to 100% of the original amount granted depending on our performance during 2021 against the pre-established targets. We also granted additional executive PRSUs based on the same performance conditions described above, but with an extended four-year service condition whereby one quarter of such shares will vest on March 1, 2022, and the remainder in quarterly installments thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding PRSUs, including executive PRSUs, and related activity for the&#160;three months ended March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, we had $10.3 million of unrecognized stock-based compensation expense related to outstanding PRSUs expected to be recognized over a remaining weighted-average period of 1.0 year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our IPO in July 2019, our board of directors adopted the ESPP and a total of 750,000 shares of common stock were initially reserved for issuance under the ESPP. The number of shares of common stock available for issuance under the ESPP will be increased on the first day of each calendar year beginning January 1, 2020 and each year thereafter until the ESPP terminates. The number of shares of common stock reserved and available for issuance under the ESPP shall be cumulatively increased by the least of (i) 750,000 shares, (ii) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of common stock as determined by the ESPP Administrator. As of January&#160;1, 2021, the number of shares of common stock available for issuance under the ESPP increased by 437,092 shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP generally provides for six-month offering periods, the exception being the first offering period. The offering periods generally start on the first trading day after June 30 and December 31 of each year. The ESPP permits participants to elect to purchase shares of common stock through fixed percentage contributions from eligible compensation during each offering period, not to exceed 15% of the eligible compensation a participant receives during an offering period or accrue at a rate which exceeds $25,000 of the fair value of the stock (determined on the option grant date(s)) for each calendar year. A participant may purchase the lowest of (a) a number of shares of common stock determined by dividing such participant&#x2019;s accumulated payroll deductions on the exercise date by the option price, (b) 2,500 shares; or (c) such other lesser maximum number of shares as shall have been established by the Administrator in advance of the offering period. Amounts deducted and accumulated by the participant will be used to purchase shares of common stock at the end of each offering period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price of the shares will be 85% of the lower of the fair value of common stock on the first trading day of each offering period or on the purchase date, except for the first offering period, for which the purchase price will be 85% of the lower of (i) the IPO price or (ii) the fair value of common stock on the purchase date. Participants may end their participation at any time during an offering period and will be paid their accumulated contributions that have not been used to purchase shares of common stock. Participation ends automatically upon termination of employment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended March&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, a total of 72,892 shares were issuable to employees based on ESPP contribution elections and unrecognized ESPP compensation cost was $0.4 million, which is expected to be recognized over the remaining portion of the current offering period during the three months ending June 30, 2021. As of March&#160;31, 2021, 1,245,652 shares are available for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Able Health acquisition that closed on February 21, 2020, 179,392 shares of our common stock were issued pursuant to the terms of the acquisition agreement and are a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares were subject to one year of continuous service by the applicable team members and vested fully during the three months ended March&#160;31, 2021 on the one-year anniversary of the acquisition closing date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vitalware acquisition that closed on September 1, 2020, 203,997 shares of our common stock were issued pursuant to the terms of the acquisition agreement and are a stock-based compensation arrangement subject to a restriction agreement. 75% of these restricted shares will vest on a monthly basis over a term of approximately one year with the remaining 25% vesting on the one-year anniversary of the acquisition closing date. As of March&#160;31, 2021, 89,250 of these restricted shares had vested. As of March&#160;31, 2021, we had $2.8 million of unrecognized stock-based compensation expense related to outstanding restricted shares expected to be recognized over a weighted-average period of 0.4 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic77eedb5e34f4c26abf4a65346e4650a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzc5_2df6e3b1-aa84-4574-aab7-8dc4f982a7f5"
      unitRef="shares">2756607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib9191a8e792e492088d4538b45dbd969_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODEw_8442db05-d7d2-4d4e-b267-d7d33dc634de"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i783ec453ce724eff8223cbd8f18bb73c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODM3_99099803-a0b2-4e6a-bf33-1ce2a676bc88"
      unitRef="shares">256607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares
      contextRef="i783ec453ce724eff8223cbd8f18bb73c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTEwOQ_3bfdd777-f058-41f9-87cf-7bd2f92feaf6"
      unitRef="number">0.05</hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idbb8e56635cb40dd9af2d7d512c81522_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTMyMg_5fb6e9c0-1d3b-4de3-87ec-9accabc323ec"
      unitRef="shares">2185461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9c0228f5aacd43abb6861e9102c54c52_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQwMw_76d94ffc-076b-45f8-8751-919faf6b96c7"
      unitRef="shares">15294920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i168ea8840cfb452e9329f1c8021d7a0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQxMA_ec1e2844-3660-42e4-8e05-6e2b95e37043"
      unitRef="shares">13109459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9c0228f5aacd43abb6861e9102c54c52_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQ2MA_a34f5611-159c-464e-a0e4-cb0883215701"
      unitRef="shares">3086399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i168ea8840cfb452e9329f1c8021d7a0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTQ2Nw_afa9b961-4882-4710-b715-e1b1d17a2e14"
      unitRef="shares">2481818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MjM_a35f5487-87ba-4d57-9da9-41bfff0acb8b">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMi0xLTEtMS0w_82dc9c77-9d38-46bc-8a99-59d17d89a329"
      unitRef="usd">1394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84298c0178544899bc7be2bae525267e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMi0zLTEtMS0w_3a0f73ff-7a13-4249-afca-84056eeb1cc3"
      unitRef="usd">2542000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMy0xLTEtMS0w_dd7320a4-97d5-4281-bb35-1b1446a3f644"
      unitRef="usd">8002000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6b2602642784525904168a8fa8633ce_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfMy0zLTEtMS0w_bd111847-ac6b-42d5-861b-19e6e906d3bc"
      unitRef="usd">5117000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0xLTEtMS0zNjQ2_4942902b-17a4-4d39-9ae7-e78f6d9a584c"
      unitRef="usd">1329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee2299b3cd854c339e305d26f3393657_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0zLTEtMS0zNjQ2_eafa9320-7a7c-4079-b8f6-6f8c2f7fea2e"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0xLTEtMS0w_3671ffc9-da3c-4552-b3c8-ec85ab412ae1"
      unitRef="usd">417000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNC0zLTEtMS0w_b73ab68e-1197-4df3-aca7-3e703e2bd4fc"
      unitRef="usd">492000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7a1e6a0de294ea8abee4a1b9871700e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNS0xLTEtMS0w_1ca3ff3f-9808-42b1-bb25-5645f597caa2"
      unitRef="usd">2368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib53167a60f2a467d9c28ab7387d78e93_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNS0zLTEtMS0w_f3299947-10a5-4ada-9078-69ff1235dd44"
      unitRef="usd">590000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNi0xLTEtMS0w_e0d97a8c-11b1-489b-b789-a4b81d2aca7e"
      unitRef="usd">13510000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVjZTIyYTU2YTZhNzQ5ZmNiZWY5OTI2NmEwNzhhMWFhL3RhYmxlcmFuZ2U6ZWNlMjJhNTZhNmE3NDlmY2JlZjk5MjY2YTA3OGExYWFfNi0zLTEtMS0w_73bb7470-bc22-4542-b29c-aa6ce0b9edcf"
      unitRef="usd">8741000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i83724b12cbb24c4a98f79788141daf04_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMi0xLTEtMS0w_d3889e90-05cb-4c0a-8d5f-5abb5dafc909"
      unitRef="usd">1809000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd9a3def7806461eb26ce54d85a9d12d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMi0zLTEtMS0w_ec037700-4600-4d32-bd51-8dcb5814a782"
      unitRef="usd">992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29571c06d3a343e6ad4d8056a8d1af33_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMy0xLTEtMS0w_25365f35-b31f-4019-9f25-e2df0ed3b6d8"
      unitRef="usd">4818000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i13592f0c308d4c3ca5b28589349e0918_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfMy0zLTEtMS0w_261487c0-ca53-49cb-9db1-9a0cdca96de6"
      unitRef="usd">3182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12b84aed76ed431793822e4580b8f1d3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNC0xLTEtMS0w_2bc50b03-fcb3-4838-9ebf-39479b779696"
      unitRef="usd">2257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8b3f6fdec2a4b278368ed19a4a95efa_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNC0zLTEtMS0w_671daac2-6fcc-4ecf-97ec-4a1d955cddef"
      unitRef="usd">1882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if28f76181b1848d096ea303063c91539_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNS0xLTEtMS0w_e13edad3-4186-4888-8c12-9ee972988f93"
      unitRef="usd">4626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6253c82367944772a2bf9c34f8b31715_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNS0zLTEtMS0w_f2ac1c29-6168-47cc-a06c-940e538bbac7"
      unitRef="usd">2685000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNi0xLTEtMS0w_f78b3df9-a9e2-4dd6-aa3a-d9d63946d44c"
      unitRef="usd">13510000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjBmOWM1NTMxZTY1ODQxMTM5YWJhMWI1YjdjYWRmZGJjL3RhYmxlcmFuZ2U6MGY5YzU1MzFlNjU4NDExMzlhYmExYjViN2NhZGZkYmNfNi0zLTEtMS0w_fb4bea87-34e0-4326-80ba-b9bf2e804887"
      unitRef="usd">8741000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ1NQ_e7fed99e-1718-4d0b-8b54-65579a3bd5a2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ1NQ_f8faa859-9b3d-4559-8f15-687bbd1b1d58"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MTk_bf823b4b-e4ae-40f2-a3ff-a46142087838">A summary of the share option activity under the 2019 Plan for the three months ended March 31, 2021, is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Time-Based Option Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,892,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(537,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,946,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,946,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,231,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMS0xLTEtMS0w_9619c106-571f-445a-a38d-634c3e01c365"
      unitRef="shares">3892936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMS0zLTEtMS0w_c8294604-f7f8-4d93-9bea-9e25a5a091c8"
      unitRef="usdPerShare">11.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMi0xLTEtMS0w_fe1fe0bf-4533-4378-b45e-1b6a320f15df"
      unitRef="shares">537889</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMi0zLTEtMS0w_1adab9d9-2710-4ad8-8e19-ca71d1d3487a"
      unitRef="usdPerShare">12.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMy0xLTEtMS0w_730f3e49-3276-4f5e-af0b-f202af06d611"
      unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfMy0zLTEtMS0w_e804752e-5385-4040-9089-318e757c4c85"
      unitRef="usdPerShare">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC0xLTEtMS0w_fe42b8d5-56e3-4946-b232-57bb6ce6f116"
      unitRef="shares">3344047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC0zLTEtMS0w_1c83204d-3ead-4562-96cf-77eebb25140c"
      unitRef="usdPerShare">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC01LTEtMS0w_664ce422-653e-41e0-95cc-c8c7fd919f07">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNC03LTEtMS0w_3d841190-ae29-4092-a64f-9fbf6df22356"
      unitRef="usd">117946252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS0xLTEtMS0w_c355c83a-2043-43cb-a41c-856c4369d4e5"
      unitRef="shares">3344047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS0zLTEtMS0w_053ef00a-caca-4b2a-92c6-3c240817eb19"
      unitRef="usdPerShare">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS01LTEtMS0w_e914f6f5-aba2-4180-abcd-4103b47374e9">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNS03LTEtMS0w_eb544948-22d4-4723-a296-57dbc2141e52"
      unitRef="usd">117946252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi0xLTEtMS0w_61ddfb45-c28f-46e3-b22f-4f7d74431669"
      unitRef="shares">1715358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi0zLTEtMS0w_4a6134bc-5405-4ab5-af52-2e06903d67aa"
      unitRef="usdPerShare">10.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi01LTEtMS0w_c3951eb7-72f5-4cd2-9781-ff265e9f365d">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmFhY2U1NDhkNmFjYjRhYzg4NzBmZjMzM2JkMjJmNDNmL3RhYmxlcmFuZ2U6YWFjZTU0OGQ2YWNiNGFjODg3MGZmMzMzYmQyMmY0M2ZfNi03LTEtMS0w_b7354e08-2845-4ac7-a9f9-b8f473dbd663"
      unitRef="usd">62231385</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNTc3Mw_13348fbb-2fee-49ed-b52f-f0c5b9e1f388"
      unitRef="usd">18700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNTg5NA_4fa8756a-77f9-4c8d-bfef-b6ae660e6d5c"
      unitRef="usd">1800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i9ba12a4c71464ef789bdd7bf566ab6c4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNTkyMg_0b812c24-f73a-409f-9de1-d4f9bb18c0b4"
      unitRef="usd">6300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i609e7d77e1444b4bb0703edeac775a57_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA2NA_f85b59f4-78b1-4d47-9d66-9d2b313e26ae">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjM4NA_b38f42c2-7860-4848-9d94-abdefad151b3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8c65b644a90a47f8b4b906e0790b6239_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjM5NA_3b81a005-e673-44b3-8f36-eafab54807b5"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8c65b644a90a47f8b4b906e0790b6239_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjQyMQ_e3c94937-9b1a-4299-aa39-9dba74396bb4">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MjA_cbf1e43b-efb5-4eaa-bfeb-2367cf8b3008">The following table sets forth the outstanding RSUs and related activity for the&#160;three months ended March&#160;31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding PRSUs, including executive PRSUs, and related activity for the&#160;three months ended March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic980a4f37e8843bda75a71bcff67a580_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMS0xLTEtMS0w_158fd243-de04-46c2-a5cf-11d99cc5188e"
      unitRef="shares">1839998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic980a4f37e8843bda75a71bcff67a580_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMS0zLTEtMS0w_b3a33c7a-aecc-4491-8722-dcc63a629aa2"
      unitRef="usdPerShare">34.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMi0xLTEtMS0w_96bfb245-322b-4cd5-8b11-83a7837f460f"
      unitRef="shares">1329687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMi0zLTEtMS0w_d679cba2-c4cb-43cf-bb0b-16bb292644cc"
      unitRef="usdPerShare">49.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0xLTEtMS0zNzcw_e46d28b3-2360-46b7-9117-e9cbabbeb892"
      unitRef="shares">186329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0zLTEtMS0zNzcw_b39c5b6e-abb1-418e-901a-79a545f2ff83"
      unitRef="usdPerShare">33.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0xLTEtMS0w_c16450cc-e728-49a4-beb3-8ca8ab32ade3"
      unitRef="shares">45666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfMy0zLTEtMS0w_bc3af1b1-51c8-4d0c-a607-6b147f7901fd"
      unitRef="usdPerShare">35.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i631a418618034b708e3ac39665cd5ccc_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfNC0xLTEtMS0w_cf981588-d3e6-439c-9043-afcce86b4660"
      unitRef="shares">2937690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i631a418618034b708e3ac39665cd5ccc_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmVkYWYzYTkwNDVhYzRjNzlhNDU4ZGM4ZmVhNWVmMGYwL3RhYmxlcmFuZ2U6ZWRhZjNhOTA0NWFjNGM3OWE0NThkYzhmZWE1ZWYwZjBfNC0zLTEtMS0w_dac86009-a658-490e-a431-e7ce9786c39c"
      unitRef="usdPerShare">41.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i631a418618034b708e3ac39665cd5ccc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjU4Ng_4f3090d5-3cfe-4821-809c-a26d68df1720"
      unitRef="usd">114100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i639974b37d9546128e75e5929286a25e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjczNg_40e5c046-7cba-416c-be4e-f246eef1dfc1">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie966431602dc412e8b09acdcfbeffb3e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQzNQ_fd40296b-3e56-4481-90b5-065fe702f687"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4dfe9f7c1913433fbc1d1265932b61f7_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ0MA_82b72204-6bba-4a1c-a827-9ad99c8bd971"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMjc0ODc3OTEwMjQ1NA_07a1ca59-c549-4bab-84de-d0add2d8b70c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib0de8ec0b76746a1957ad2b58eb7edac_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMi0xLTEtMS00NDIw_064de450-4cc0-4efc-ae30-5cd939a0887e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib0de8ec0b76746a1957ad2b58eb7edac_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMi0zLTEtMS00NDIw_c77e4fa1-77ed-4e97-b4bd-2e29045e6d26"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMy0xLTEtMS00NDIw_17965eed-04a9-46cf-8809-ea8408a49229"
      unitRef="shares">313322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfMy0zLTEtMS00NDIw_ae2276a1-10cd-4c95-bd49-89fead2b4b39"
      unitRef="usdPerShare">49.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNS0xLTEtMS00NDIw_b1929d24-e000-482b-9d8b-25b2a91d67a3"
      unitRef="shares">5463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iafe8e0e467a6452da290da59b489dd75_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNS0zLTEtMS00NDIw_ae851a5c-284d-4139-b3c3-82b544740b95"
      unitRef="usdPerShare">49.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6ad286f2178249fba783e6f88e35ca81_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNi0xLTEtMS00NDIw_dfb906c1-d6ac-4527-af99-9e16f14e61cd"
      unitRef="shares">307859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6ad286f2178249fba783e6f88e35ca81_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOjYwYWM5YjkyMzk5NDRjOWU5NDdkZDdiNWM2N2NlYTRkL3RhYmxlcmFuZ2U6NjBhYzliOTIzOTk0NGM5ZTk0N2RkN2I1YzY3Y2VhNGRfNi0zLTEtMS00NDIw_c38e434d-1295-4a0b-b569-24a63f0a6c10"
      unitRef="usdPerShare">49.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i6b97cd002a914ee3aa2c282be09d867b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk4Mzk4NQ_07c1d133-a458-4844-b912-95d2dcda7984"
      unitRef="usd">10300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie7a1e6a0de294ea8abee4a1b9871700e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk4Mzk4OQ_72dfc396-a359-488f-a716-502b67ffde00">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iedce8ff10cd94af1a1617e8a8e551070_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjg1OA_391f3b03-bfb4-4120-80f5-27f41f008c69"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="i51f5fbd68ddc4421b8d0bc58f849fac7_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzI4Nw_ec27ced4-4d64-4dca-b031-532ceb086169"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares
      contextRef="i51f5fbd68ddc4421b8d0bc58f849fac7_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzMwMw_ec8da0ba-61c0-4276-bf53-aaee01de82f4"
      unitRef="number">0.01</hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i95c99dfaa5084f8b99fb2b86c782d222_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzU0Mg_d9c7671b-9a6d-4418-9cd4-d1a3cc7b54f7"
      unitRef="shares">437092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <hcat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcwOTQzNg_420a90e0-b53f-4666-b3bd-444138e3f55a">P6M</hcat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i13867759ede9429292155333cf98aa5a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNzk4Ng_8d3861fb-cd1d-4c2f-b94e-d7215d10afe4"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <hcat:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODEwMQ_1d788995-bc08-4b67-be4f-604c836d58fa"
      unitRef="usd">25000000</hcat:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee>
    <hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed
      contextRef="i13867759ede9429292155333cf98aa5a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODM5OQ_03ddb6cb-912f-4991-94d3-8667e4c054f4"
      unitRef="shares">2500</hcat:SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODcyNA_cef0935b-6300-47a2-841e-434edb8ea86a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfODkyMw_ee7c0355-0426-46ec-a358-70a3c937612a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MjY_cbbd27fa-067e-4ce5-906d-6c7d2c0f3525">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended March&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMi0xLTEtMS0w_0e8b1f95-9ed5-417e-aed6-e7f998e8917c"
      unitRef="number">0.404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMi0zLTEtMS0yOTk2_61bf9a25-7aad-484d-bbfc-338c79ffdc6b"
      unitRef="number">0.549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMy0xLTEtMS0w_d8cf6ab3-9ac6-4a1d-9556-981be98a2e75">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfMy0zLTEtMS0yOTk2_0b7abd93-d9ff-4907-9d33-715caf5a4793">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNC0xLTEtMS0w_d3035434-1fbd-40b3-a32d-eed42c796a5a"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNC0zLTEtMS0yOTk2_8cd5d8c5-0ab0-42ec-a538-70da2a1a3621"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNS0xLTEtMS0w_bf8e88d2-2a3c-4767-9e4c-0184cdb09e06"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="i639ff05fe4a64b348fd47412cdd1492f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RhYmxlOmRhNGQxMTA3NThiOTQwYjM5YWY3ZDYxZDRiNDBkOTIxL3RhYmxlcmFuZ2U6ZGE0ZDExMDc1OGI5NDBiMzlhZjdkNjFkNGI0MGQ5MjFfNS0zLTEtMS0yOTk2_2d790899-b43b-4b4b-8ed9-5020fb8e96a6"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i13867759ede9429292155333cf98aa5a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTQ4Mg_d49a9745-c9dc-43af-882c-3dc290783c9a"
      unitRef="shares">72892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i13867759ede9429292155333cf98aa5a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTYwMA_c0913d92-0b2d-4271-acbc-ea476f6a2211"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i13867759ede9429292155333cf98aa5a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTc0Mw_c083d5cc-0aef-4f81-89b7-7123bc6ac8d5"
      unitRef="shares">1245652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares
      contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfOTg5NA_e8ae07a1-db0f-4399-a0a0-9b7adbf58fe6"
      unitRef="shares">179392</hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTAxMTI_aa2f0b25-84b6-4081-bf26-f2a5dd73937b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i69bbc42f7f2145b3b8aa5df8ee14b12c_D20200221-20200221"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcwOTQ0OQ_f924b7ab-4e79-4fd2-aaa7-52045372db8b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares
      contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2ODk5OA_a0261f4f-634a-473a-b21b-7971ac6ef04a"
      unitRef="shares">203997</hcat:BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2OTAyMQ_900791e0-b350-4eff-8d65-07b45f51829d"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcyNzkzMw_e5dd2f7f-2863-485c-8e24-e68ba3639ea0">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id10adc4ae8854029957496d9f5339693_D20200901-20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2OTAyNw_d703c08d-bd3e-4a4f-aa9e-24adf4c561c7"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie516bf906d7b41ef97a1feed6fd0c5a3_D20200901-20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMzg0ODI5MDcyNzkyMA_85a2b244-4025-42d0-a8d3-43cb1509ffc3">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="icf8b76871176404b8081eb0c5b32f0ba_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfNjA0NzMxMzk2OTAzNg_d1bfeac7-46c5-4e0b-a116-c34df1ced97d"
      unitRef="shares">89250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i63d5a2a619c74cd49c4313f5d1b1c0f3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTAyNjE_ea07c67f-153f-42ee-8d2f-3d2225cddfa0"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0fbb179f359b4f038e44fe90cd706e8a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV83OS9mcmFnOmI4YzZmZmJiYTQ4ODQxMGY4MTAyYzIzNDg2ZmMzMWVkL3RleHRyZWdpb246YjhjNmZmYmJhNDg4NDEwZjgxMDJjMjM0ODZmYzMxZWRfMTA0MTQ_47a2bc1e-b0db-40b7-b545-f32a2c04a146">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfMjczOA_483d3da2-85e5-4e1a-b800-437ea110637c">Income Taxes&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, we update our estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, we make a cumulative adjustment in such period. The quarterly tax provision and the estimate of our annual effective tax rate are subject to variation due to several factors, including variability in our loss before income taxes, the mix of jurisdictions to which such income or loss relates, changes in how we conduct business, and tax law developments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the&#160;three months ended March&#160;31, 2021 and 2020, our estimated effective tax rate was (0.4)% and 6.6%, respectively. The variations between our estimated effective tax rate and the U.S. statutory rate are&#160;primarily due to our full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all available evidence to evaluate the recovery of deferred tax assets, including historical levels of income, legislative developments, and risks associated with estimates of future taxable income. We have provided a full valuation allowance for our net deferred tax assets as of March&#160;31, 2021 and December&#160;31, 2020, due to the uncertainty surrounding the future realization of such assets and the cumulative losses we have generated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As we have a full valuation allowance on net deferred tax assets, our income tax provision for the three months ended March 31, 2021 consists primarily of minimal state and foreign income taxes. The income tax benefit of $1.2 million recorded for the three months ended March 31, 2020, is primarily related to the discrete deferred tax benefit attributable to the release of a portion of the valuation allowance during the quarter. The release of valuation allowance is attributable to the acquisition of Able Health, which resulted in deferred tax liabilities that, upon acquisition, allowed us to recognize certain deferred tax assets of $1.3 million that had previously been offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions when it is more likely than not, based on the technical merits, that the position will be sustained upon examination.  We believe that we have provided adequate reserves for income tax uncertainties in all open tax years.  We do not anticipate material changes in the total amount of our unrecognized tax benefits within 12 months of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted and signed into U.S. law to provide economic relief to individuals and businesses facing economic hardship as a result of the COVID-19 pandemic. On March 11, 2021, the American Rescue Plan Act of 2021 (ARPA) was enacted and signed into U.S. law to provide additional economic stimulus and tax credits. Changes in tax laws or rates are accounted for in the period of enactment. We are continuing to analyze these legislative developments and believe that the income tax provisions of the CARES Act and ARPA do not have a significant impact on our current taxes, deferred taxes, or uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfNzUx_f564cb5a-d799-447c-9c29-7c5b371ea561"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfNzU4_e6adf7c8-337c-40d2-82c6-4a1bec618cd4"
      unitRef="number">0.066</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfMTM1OQ_525fddf0-bee4-4321-afe7-0688641034c0"
      unitRef="usd">-1200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84NS9mcmFnOjc2NzE1NTFiY2JhNzRhNWY4MWM0NWIyODJmMTE2MGM0L3RleHRyZWdpb246NzY3MTU1MWJjYmE3NGE1ZjgxYzQ1YjI4MmYxMTYwYzRfMTczNw_0bc1dd66-10b6-4803-bdd7-b710dde9d0af"
      unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV84OC9mcmFnOjhhYWQyYmI4MDlhNjQyMDQ5NDFjODhhNjcxMmJjMjNkL3RleHRyZWdpb246OGFhZDJiYjgwOWE2NDIwNDk0MWM4OGE2NzEyYmMyM2RfMTkzNw_314b429c-aa30-4224-98cc-ef12a721ad70">Commitments and Contingencies&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal proceedings from time to time that arise in the normal course of business. As of March&#160;31, 2021 and December&#160;31, 2020, there were no significant outstanding claims against us.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMTkw_1f2c5125-95a6-4459-8ed7-c4388a08ff97"
      unitRef="number">0.42</hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage>
    <hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMTk3_dbc4a3e6-1d4c-4ed0-a29b-fac40afdbf8c"
      unitRef="number">0.33</hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage>
    <hcat:DeferredRevenueArrangementForServiceContractTerm
      contextRef="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMzg0ODI5MDY5ODA3OQ_edb39cb8-afc2-44c8-8811-c29acf021f2c">P3Y</hcat:DeferredRevenueArrangementForServiceContractTerm>
    <hcat:DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod
      contextRef="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNTEy_bbb7d39f-02f5-4d51-8040-2410eedb2d5b">P1Y</hcat:DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod>
    <hcat:DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination
      contextRef="i5be0f16605664a7a8f5393f1c4f5ee0f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNTIx_92f14b64-1706-4852-82e1-4034601c61b1">P90D</hcat:DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i7a1863db2fdb471eb95b9d4e35b94e91_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNjM5_7e4010f1-087f-4a2f-b7d7-9147ddc9909b"
      unitRef="usd">79600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i0653e44dccde41d79e0c4dcca4805fd7_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfNzM5_21496521-b95f-44e2-81c0-becbe830112d"
      unitRef="number">0.75</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i0653e44dccde41d79e0c4dcca4805fd7_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85MS9mcmFnOmM3MzAyODY3YjdiZTRiZDVhMzQ4MWNiODBkMWE3ZTNjL3RleHRyZWdpb246YzczMDI4NjdiN2JlNGJkNWEzNDgxY2I4MGQxYTdlM2NfMjc0ODc3OTA3MTEzNw_09365ad4-ec6b-4d24-ba3f-eae75fee52c5">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTA0NQ_b98b306e-fa90-44d0-829b-89cb15f4319b">Related Parties&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into arrangements with a customer, Mass General Brigham (formerly Partners Healthcare), where, at that time, a member of the customer&#x2019;s management was a member of our board of directors. He resigned from his executive position with our customer on March 31, 2021 and remains on staff. He served on our board of directors from January 2018 to May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from this related party of $0.9 million and $0.7 million for the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, we had receivables from this related party of $0.8 million and $0.6 million, respectively, and deferred revenue with this related party of $0.4 million and $0.7 million, respectively. We also had acquisition-related consideration payable to this related party for a prior year asset acquisition, of which the final $1.2 million was paid during the year ended December 31, 2020.  This asset acquisition occurred prior to this entity becoming a related party. There was no acquisition-related consideration payable to this related party as of March&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into revenue arrangements with customers that are also our investors. None of these customers hold a significant amount of ownership in our equity interests.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i3448fe61af4c4aacaf336c73188b521b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMzIy_51f738d9-96af-4638-b70d-44e4d4937812"
      unitRef="usd">900000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i64b094898f5e4db7b34432cbd11ef1b0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMzI5_747f1a12-2365-40b0-a357-cb6844970e03"
      unitRef="usd">700000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i2374c5eff6d04980b4a36a67bb87de2d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNDQ3_257dd4a6-1c54-4cda-995d-19a6639b645f"
      unitRef="usd">800000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i7ad4008f49a049feb88a7b75269882ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNDU0_25354b87-414f-4b34-8016-760a130a5411"
      unitRef="usd">600000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i2374c5eff6d04980b4a36a67bb87de2d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNTIw_4912f4b1-82a2-4351-9730-624047003640"
      unitRef="usd">400000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i7ad4008f49a049feb88a7b75269882ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfNTI3_0c3c10d7-f348-444f-be6e-27e83c0cdbbc"
      unitRef="usd">700000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="ib54854387397459a8c725ddfa3ed8859_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTY0OTI2NzQ0MzAzNg_fef4d6cd-23a7-4f1f-942b-fe4a965986ff"
      unitRef="usd">1200000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i7ad4008f49a049feb88a7b75269882ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTY0OTI2NzQ0MzA0NA_6a9dbf5c-60bc-4d20-acf1-502d49aad4ff"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i2374c5eff6d04980b4a36a67bb87de2d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV85Ny9mcmFnOjY3OWZjOWEyYzY2ZDRkZDBiZDBhMjFiMTNhYTNhZDllL3RleHRyZWdpb246Njc5ZmM5YTJjNjZkNGRkMGJkMGEyMWIxM2FhM2FkOWVfMTY0OTI2NzQ0MzA0NA_7ab0ae4f-7d6a-4df4-9317-653451d946cd"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzEzODY_daf6678b-194b-4970-bc4e-e12111a8df62">Segments&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate our business in two operating segments that also represent our reportable segments. Our business is organized based on our technology offerings and professional services. Accordingly, our segments are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Technology - Our technology segment (Technology) includes our data platform, analytics applications and support services. Technology generates revenues primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Professional Services - Our professional services segment (Professional Services) is generally the combination of data and analytics, domain expertise, outsourcing, and implementation services to deliver expertise to our customers to more fully configure and utilize the benefits of our Technology offerings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and cost of revenues generally are directly attributed to our segments. All segment revenues are from our external customers. Asset and other balance sheet information at the segment level is not reported to our Chief Operating Decision Maker.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenue and Adjusted Gross Profit for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reportable segments Adjusted Gross Profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Adjusted Gross Profit reconciling items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less other reconciling items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss before income taxes &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzQ1_af22bf15-61d2-4e83-9c4e-9459d52dddf6"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzQ1_cc6c8d86-f503-437c-a266-c86ae786b35d"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzEzODc_2a1f251a-8d91-4825-86d8-13ded05aaaf0">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenue and Adjusted Gross Profit for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72c95150cded4d7da0ed5115a50de8ca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzMtMS0xLTEtMA_d9704eba-ade6-4dcc-8563-b3576927f01c"
      unitRef="usd">33839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i375d7f606b334e22897257297115deeb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzMtMy0xLTEtMA_489429df-4fbc-48e6-8a54-759d759e6c0b"
      unitRef="usd">24699000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f46ff336b1840e7b034030cf5eae332_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzQtMS0xLTEtMA_3955890c-4550-4842-a9a6-c6a0d2146ab0"
      unitRef="usd">22007000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e4830aba629412daaa0cc0a46d3c18e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzQtMy0xLTEtMA_11f6a327-1b2c-4e8b-97f7-c9c0a304beb0"
      unitRef="usd">20417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzUtMS0xLTEtMA_446bef58-8575-4caa-9887-c9b88b249552"
      unitRef="usd">55846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTpmYjg5ZGI2YTgzN2I0N2UyYjQxNWViNjVmMzk4MWJmOC90YWJsZXJhbmdlOmZiODlkYjZhODM3YjQ3ZTJiNDE1ZWI2NWYzOTgxYmY4XzUtMy0xLTEtMA_b45ec4a5-e05c-49b9-9f2f-458897816d90"
      unitRef="usd">45116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90ZXh0cmVnaW9uOmE4MmQ5MjUyNTA3NjRkODc4NWRlZDc3OTIxOTMxODFlXzEzODg_c43d6d9d-9f49-439a-a496-0141d7ab4afd">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reportable segments Adjusted Gross Profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Adjusted Gross Profit reconciling items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less other reconciling items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss before income taxes &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:GrossProfit
      contextRef="i285babe5ab964ef29cef5180c50abd82_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzMtMS0xLTEtMA_5e253d42-2625-416c-b622-b812bc989eb9"
      unitRef="usd">23388000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i74c07cafe2db4a11803bb4bf98296039_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzMtMy0xLTEtMA_03c92e7a-d6b3-44b4-87ce-e25de364ed68"
      unitRef="usd">16969000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if49eeee1198d4d19aadbc2d7fd7450bb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzQtMS0xLTEtMA_b3e3d4ed-ca22-44d0-ab84-febc5d07b074"
      unitRef="usd">6929000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4814ebae7b6547faaa86c64eccc633f1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzQtMy0xLTEtMA_a1b2d0ed-3886-459b-9400-67db4f9ad9ef"
      unitRef="usd">5071000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic35f3002cf13457c85971a5a2c22d04e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzUtMS0xLTEtMA_49fedd5a-eba5-4e5b-8031-bc9bb0e49177"
      unitRef="usd">30317000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib160b8d6aaec4f898595c6488b4def77_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzUtMy0xLTEtMA_826acb20-2ed3-4b3c-a3a5-301a1bc05021"
      unitRef="usd">22040000</us-gaap:GrossProfit>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzctMS0xLTEtMA_30f79c38-a7fb-4cd7-a9f2-55f6a67840fe"
      unitRef="usd">1809000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzctMy0xLTEtMA_e762dbbb-69d3-4226-a679-66e0680d376b"
      unitRef="usd">992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEwLTEtMS0xLTA_47a54f2c-a71a-42e7-840a-bae6a8ddecd4"
      unitRef="usd">15651000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEwLTMtMS0xLTA_bbc8d8f5-c418-4853-8a20-2297630f19b4"
      unitRef="usd">13487000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzExLTEtMS0xLTA_3363df49-0ad9-4518-aa59-3758cc576a8d"
      unitRef="usd">14345000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzExLTMtMS0xLTA_9950296f-bdb4-46c1-be56-59f787a5913d"
      unitRef="usd">13088000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEyLTEtMS0xLTA_ae63fe3d-a788-4241-8074-b426b2333d80"
      unitRef="usd">15015000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEyLTMtMS0xLTA_1949898d-8aad-4a5a-a45b-4ec1b09a2526"
      unitRef="usd">9701000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEzLTEtMS0xLTA_83d49ac8-ba2b-4bd3-9a1d-3371d881ee5b"
      unitRef="usd">7814000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzEzLTMtMS0xLTA_c60448fb-a340-4ab7-af70-ccbade565c4a"
      unitRef="usd">2877000</us-gaap:DepreciationAndAmortization>
    <hcat:InterestAndOtherExpenseNet
      contextRef="i4b0909ed29af4c36bbf0a7fe9514e55a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE1LTEtMS0xLTA_df07c757-0f92-4bcf-9b70-9995689b9682"
      unitRef="usd">3952000</hcat:InterestAndOtherExpenseNet>
    <hcat:InterestAndOtherExpenseNet
      contextRef="i3e8376e3cd964a6d8d296de942cde664_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE1LTMtMS0xLTA_fec38111-7527-419b-b756-ffc45f0fa8d8"
      unitRef="usd">621000</hcat:InterestAndOtherExpenseNet>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE2LTEtMS0xLTA_e1f2fd26-c7c7-421a-9b85-4d68ae1eb38b"
      unitRef="usd">-28269000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5ece495212884ea7a688a503a845633c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xMDAvZnJhZzphODJkOTI1MjUwNzY0ZDg3ODVkZWQ3NzkyMTkzMTgxZS90YWJsZTo3NDc4ODU5MjNhYjk0M2M5ODViOTQ0ODA0NjQwMTVhOC90YWJsZXJhbmdlOjc0Nzg4NTkyM2FiOTQzYzk4NWI5NDQ4MDQ2NDAxNWE4XzE2LTMtMS0xLTA_39aa4cf2-f406-4c5b-945a-f37cef4cb431"
      unitRef="usd">-18726000</us-gaap:IncomeLossAttributableToParent>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0xLTEtMS0w_955fb2f4-dfae-45bb-a8cd-b520deef26f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0xLTEtMS0w_955fb2f4-dfae-45bb-a8cd-b520deef26f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0xLTEtMS0w_7250e1a3-5ba0-475a-9ed5-653c3392b0eb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0xLTEtMS0w_7250e1a3-5ba0-475a-9ed5-653c3392b0eb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0xLTEtMS0w_6112616b-0505-4343-83e3-ce6afd1552ae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0xLTEtMS0w_6112616b-0505-4343-83e3-ce6afd1552ae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0zLTEtMS0w_4b09ec26-7fc3-4a32-b1cf-74667c274ce0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0zLTEtMS0w_4b09ec26-7fc3-4a32-b1cf-74667c274ce0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0zLTEtMS0w_00c50cdd-e9cd-4b76-8678-954a4470c020"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0zLTEtMS0w_00c50cdd-e9cd-4b76-8678-954a4470c020"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0zLTEtMS0w_09b64410-8c75-432e-ae83-490ea8a3e660"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0zLTEtMS0w_09b64410-8c75-432e-ae83-490ea8a3e660"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes amounts attributable to related party transactions. See Note 16 for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0xLTEtMS0w_955fb2f4-dfae-45bb-a8cd-b520deef26f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0xLTEtMS0w_7250e1a3-5ba0-475a-9ed5-653c3392b0eb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0xLTEtMS0w_6112616b-0505-4343-83e3-ce6afd1552ae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNS0zLTEtMS0w_4b09ec26-7fc3-4a32-b1cf-74667c274ce0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfMy0zLTEtMS0w_00c50cdd-e9cd-4b76-8678-954a4470c020"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RhYmxlOjg3ZTUzZTgxZDg4ZjQ5OWRiYmMzYTQ5NDYxZWM0YTgzL3RhYmxlcmFuZ2U6ODdlNTNlODFkODhmNDk5ZGJiYzNhNDk0NjFlYzRhODNfNC0zLTEtMS0w_09b64410-8c75-432e-ae83-490ea8a3e660"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8yMi9mcmFnOjI3NGM4MjdlZmI1OTQ0MTE4ZjJhOTAxZjM4MDc1YWFhL3RleHRyZWdpb246Mjc0YzgyN2VmYjU5NDQxMThmMmE5MDFmMzgwNzVhYWFfMzM2_8ac8af0a-b71b-46df-a342-c29127754285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMzc3Ng_183754e7-e126-4bbc-8a62-dd5bcff30a7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMzc3Ng_183754e7-e126-4bbc-8a62-dd5bcff30a7e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMzc3Ng_eda0e928-76c1-4314-a439-b53de6ab4a91"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMzc3Ng_eda0e928-76c1-4314-a439-b53de6ab4a91"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0xLTEtMS0w_192c6583-7c7a-4592-b6e3-8000c933980e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0xLTEtMS0w_192c6583-7c7a-4592-b6e3-8000c933980e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0zLTEtMS0w_1ca04824-0b8b-4f86-8c91-006a1433b454"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0zLTEtMS0w_1ca04824-0b8b-4f86-8c91-006a1433b454"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMA_93c76e98-5e07-47cd-8681-684959c98a3f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMA_93c76e98-5e07-47cd-8681-684959c98a3f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtMA_faba9f23-af9a-40a1-8681-f0f00c33ad42"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtMA_faba9f23-af9a-40a1-8681-f0f00c33ad42"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes amounts attributable to related party transactions. See Note 16 for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMS0xLTEtMzc3Ng_183754e7-e126-4bbc-8a62-dd5bcff30a7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjMtMy0xLTEtMzc3Ng_eda0e928-76c1-4314-a439-b53de6ab4a91"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0xLTEtMS0w_192c6583-7c7a-4592-b6e3-8000c933980e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfNy0zLTEtMS0w_1ca04824-0b8b-4f86-8c91-006a1433b454"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMS0xLTEtMA_93c76e98-5e07-47cd-8681-684959c98a3f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RhYmxlOmYyNDg1NzcxZjc1ZDRhYjA4ZWMyNjQ3NjE0NDA4NzZmL3RhYmxlcmFuZ2U6ZjI0ODU3NzFmNzVkNGFiMDhlYzI2NDc2MTQ0MDg3NmZfMjItMy0xLTEtMA_faba9f23-af9a-40a1-8681-f0f00c33ad42"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV8xOS9mcmFnOmJkMzE4MGI3ZTI0MzQ0Yjc4N2U1NzQ5MjY0ODgxNGFjL3RleHRyZWdpb246YmQzMTgwYjdlMjQzNDRiNzg3ZTU3NDkyNjQ4ODE0YWNfMzI3_393d9928-2159-4652-a7ec-330b220050a3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050313960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HEALTH CATALYST, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3337483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10897 South River Front Parkway #300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Jordan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">708-6800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HCAT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,520,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745128350680">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 132,627<span></span>
</td>
<td class="nump">$ 91,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">133,807<span></span>
</td>
<td class="nump">178,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,905<span></span>
</td>
<td class="nump">48,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,404<span></span>
</td>
<td class="nump">10,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">324,743<span></span>
</td>
<td class="nump">329,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,653<span></span>
</td>
<td class="nump">12,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,840<span></span>
</td>
<td class="nump">98,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,093<span></span>
</td>
<td class="nump">24,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,822<span></span>
</td>
<td class="nump">107,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,068<span></span>
</td>
<td class="nump">3,606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">571,219<span></span>
</td>
<td class="nump">577,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,626<span></span>
</td>
<td class="nump">5,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,946<span></span>
</td>
<td class="nump">16,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51,634<span></span>
</td>
<td class="nump">47,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,454<span></span>
</td>
<td class="nump">2,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,902<span></span>
</td>
<td class="nump">14,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessCombinationConsiderationPayableCurrent', window );">Acquisition-related consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Convertible senior notes, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">171,864<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">259,426<span></span>
</td>
<td class="nump">88,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Convertible senior notes, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">168,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,083<span></span>
</td>
<td class="nump">23,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,509<span></span>
</td>
<td class="nump">16,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,230<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">302,383<span></span>
</td>
<td class="nump">301,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 25,000,000 shares authorized as of March&#160;31, 2021 and December&#160;31, 2020; no shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 500,000,000 shares authorized as of March&#160;31, 2021 and December&#160;31, 2020; 44,340,036 and 43,376,848 shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,022,781<span></span>
</td>
<td class="nump">1,001,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(754,020)<span></span>
</td>
<td class="num">(725,650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">268,836<span></span>
</td>
<td class="nump">276,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 571,219<span></span>
</td>
<td class="nump">$ 577,740<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes amounts attributable to related party transactions. See Note 16 for further details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities And Employee-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessCombinationConsiderationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Payable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessCombinationConsiderationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049607672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,340,036<span></span>
</td>
<td class="nump">43,376,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,340,036<span></span>
</td>
<td class="nump">43,376,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745129115320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 55,846<span></span>
</td>
<td class="nump">$ 45,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue, excluding depreciation and amortization:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Total cost of revenue, excluding depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,338<span></span>
</td>
<td class="nump">24,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,651<span></span>
</td>
<td class="nump">13,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,345<span></span>
</td>
<td class="nump">13,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,015<span></span>
</td>
<td class="nump">9,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,814<span></span>
</td>
<td class="nump">2,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,825<span></span>
</td>
<td class="nump">39,153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,317)<span></span>
</td>
<td class="num">(18,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_InterestAndOtherExpenseNet', window );">Interest and other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,952)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28,269)<span></span>
</td>
<td class="num">(18,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101<span></span>
</td>
<td class="num">(1,236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (28,370)<span></span>
</td>
<td class="num">$ (17,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,870<span></span>
</td>
<td class="nump">37,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,870<span></span>
</td>
<td class="nump">37,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hcat_TechnologyMember', window );">Technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 33,839<span></span>
</td>
<td class="nump">$ 24,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue, excluding depreciation and amortization:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Total cost of revenue, excluding depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,825<span></span>
</td>
<td class="nump">7,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember', window );">Professional services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,007<span></span>
</td>
<td class="nump">20,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue, excluding depreciation and amortization:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Total cost of revenue, excluding depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,513<span></span>
</td>
<td class="nump">$ 16,162<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes amounts attributable to related party transactions. See Note 16 for further details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_InterestAndOtherExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest And Other Expense, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_InterestAndOtherExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hcat_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hcat_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745044355576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (28,370)<span></span>
</td>
<td class="num">$ (17,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in net unrealized gains (losses) on available for sale investments</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustment</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (28,400)<span></span>
</td>
<td class="num">$ (17,523)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049475400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,678,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">200,644<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 811,049<span></span>
</td>
<td class="num">$ (610,514)<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">9,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability', window );">Issuance of common stock for settlement of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for settlement of contingent consideration</a></td>
<td class="nump">3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(17,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,838,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 204,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">832,167<span></span>
</td>
<td class="num">(628,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">43,709,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,376,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 276,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">1,001,645<span></span>
</td>
<td class="num">(725,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">537,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 6,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares', window );">Issuance of common stock for settlement of contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability', window );">Issuance of common stock for settlement of contingent consideration</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for settlement of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(28,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">$ (30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">44,454,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,340,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 268,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 1,022,781<span></span>
</td>
<td class="num">$ (754,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047826568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,370)<span></span>
</td>
<td class="num">$ (17,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,814<span></span>
</td>
<td class="nump">2,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">2,870<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Non-cash operating lease expense</a></td>
<td class="nump">965<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Investment discount and premium amortization</a></td>
<td class="nump">417<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLossesExpensed', window );">Provision for expected credit losses</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">13,510<span></span>
</td>
<td class="nump">8,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision (benefit)</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(1,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liabilities</a></td>
<td class="nump">2,156<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">2,090<span></span>
</td>
<td class="num">(7,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Deferred costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,173)<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities', window );">Accounts payable, accrued liabilities, and other liabilities</a></td>
<td class="num">(5,352)<span></span>
</td>
<td class="num">(4,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,745<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,143)<span></span>
</td>
<td class="num">(16,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,882)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_CapitalizedOfInternalUseSoftware', window );">Capitalization of internal-use software</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(8,621)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from the sale and maturity of short-term investments</a></td>
<td class="nump">53,240<span></span>
</td>
<td class="nump">66,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(480)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,249)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">37,376<span></span>
</td>
<td class="nump">50,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">6,488<span></span>
</td>
<td class="nump">9,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related consideration</a></td>
<td class="num">(1,391)<span></span>
</td>
<td class="num">(748)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,446<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">40,673<span></span>
</td>
<td class="nump">42,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">91,954<span></span>
</td>
<td class="nump">18,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">132,627<span></span>
</td>
<td class="nump">60,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability', window );">Common stock issued for settlement of contingent consideration</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Common stock issued in connection with acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Stock-based compensation capitalized as internal-use software</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities', window );">Deferred offering costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Purchase of intangible assets included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_CapitalizedOfInternalUseSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Of Internal Use Software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_CapitalizedOfInternalUseSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLossesExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of credit loss expense (reversal of expense) for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLossesExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045624424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text">Description of Business and Summary of Significant Accounting Policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of operations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Catalyst, Inc. (Health Catalyst) was incorporated under the laws of Delaware in September 2011. We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Our customers, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts on the condensed consolidated statements of cash flows have been reclassified to conform to the current year presentation. A reclassification was made to separately present the non-cash operating lease expense as a non-cash reconciling adjustment from net loss and the change in the operating lease liabilities due to cash payments as a change in operating assets and liabilities. This net change is not material and does not affect previously reported net cash used in operating activities in the condensed consolidated statements of cash flows. This reclassification had no effect on our other condensed consolidated financial statements for the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim Unaudited Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accompanying interim condensed consolidated balance sheet as of&#160;March&#160;31, 2021, the interim condensed consolidated statements of operations for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020, our interim condensed consolidated statements of stockholders' equity for the&#160;three months ended March&#160;31, 2021 and 2020, and our interim condensed consolidated statements of cash flows for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020&#160;are unaudited. Our condensed consolidated balance sheet as of&#160;December&#160;31, 2020&#160;was derived from audited financial statements, but does not include all disclosures required by GAAP. Our interim unaudited condensed consolidated financial statements have been prepared on a basis consistent with our annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company's financial position, its operations and cash flows for the periods presented. The historical results are not necessarily indicative of future results, and the results of operations for the&#160;three months ended March&#160;31, 2021&#160;are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (the CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as the effect is antidilutive.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We derive our revenues primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, we satisfy the performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue net of any taxes collected from customers and subsequently remitted to governmental authorities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology revenue primarily consists of subscription fees charged to customers for access to use our technology. We provide customers access to our technology through either an all-access or limited-access, modular subscription. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our subscription arrangements are cloud-based and do not provide customers the right to take possession of the technology or contain a significant penalty if the customer were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the customer. Most of our subscription contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#8217; notice.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriptions that allow the customer to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the customer. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have certain perpetual license arrangements. Revenue from these arrangements is recognized at a point in time upon delivery of the software. Technology revenue also includes maintenance and support revenue which generally includes bug fixes, updates, and support services. Revenue related to maintenance and support is recognized over the contract term beginning on the date that the service is made available to the customer.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services revenue primarily includes data and analytics services, domain expertise services, outsourcing services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our customers on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our customer. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the &#8220;right to invoice&#8221; practical expedient. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include customer demographics and the types of users. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we use the residual estimation method due to a limited number of standalone transactions and/or prices that are highly variable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable consideration</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into at-risk and shared savings arrangements with certain customers whereby we receive variable consideration based on the achievement of measurable improvements which may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets resulting from services performed prior to invoicing customers are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of March&#160;31, 2021 and December&#160;31, 2020, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $1.3 million and $1.6 million, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the customer. As of March&#160;31, 2021 and December&#160;31, 2020, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.8 million and $49.0 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize sales commissions and associated fringe costs, such as payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with customers, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the customer contract. As of March&#160;31, 2021 and December&#160;31, 2020, $0.7&#160;million and $0.5 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and were included in prepaid expenses and other assets on the consolidated balance sheets. As of March&#160;31, 2021 and December&#160;31, 2020, the remaining $1.9&#160;million and $1.4 million, respectively, of deferred contract acquisition costs were included in non-current other assets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average customer life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average customer life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs is included within sales and marketing expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. As of March&#160;31, 2021 and December&#160;31, 2020, $0.5&#160;million and $0.5&#160;million, respectively, of deferred fulfillment costs were included in prepaid expenses and other assets on the condensed consolidated balance sheets. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of revenue, excluding depreciation and amortization</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue excludes costs related to depreciation and amortization.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">cash equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term investments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, the establishment of specific reserves for customers in an adverse financial condition, and our expectations of changes in macro-economic conditions, including the current COVID-19 pandemic, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses on Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Write-offs, net of recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset in the asset group. If the carrying amount of the asset group exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets. We did not incur any long-lived impairment charges for the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technologies, customer relationships, customer contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets&#8217; estimated useful lives. The estimated useful life of each asset category is as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, customer relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually or more frequently if indicators of impairment are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present or circumstances suggest that impairment may exist. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value. There was no impairment of goodwill for the three months ended March&#160;31, 2021 and 2020.&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the customer-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for customer relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of assets acquired and liabilities assumed in a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2020, we expensed $0.9 million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our consolidated statements of operations. No such costs were incurred or recorded for the three months ended March&#160;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent consideration liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements. We value the expected contingent consideration and the corresponding liabilities using a probability model such as the Monte Carlo method based on estimates of potential pay-out scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes to the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All advertising costs are expensed as incurred. We recorded advertising costs of&#160;$0.4 million&#160;and&#160;$0.6 million&#160;for the&#160;three months ended March&#160;31, 2021&#160;and&#160;2020, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development costs and internal-use software</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our customers on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. Our standard stock-based awards vest solely on a service-based condition. &#160;For these awards, we recognize stock-based compensation expense on a straight-line basis over the vesting period. Awards that contain both service-based and performance conditions are recognized using the accelerated attribution method once the performance condition is probable of occurring. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because we have NOLs. Significant judgment is required to evaluate uncertain tax positions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of acquisition-related consideration payable and operating lease liabilities approximate fair value based on interest rates available for debt with similar terms at March&#160;31, 2021 and December&#160;31, 2020. Money market funds and short-term investments are measured at fair value on a recurring basis. Our contingent consideration liabilities are measured at fair value on a recurring basis based primarily on significant inputs not observable in the market.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1- Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3- Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease contracts do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We do not have lease agreements that contain non-lease components, which generally would be accounted for separately.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of our international subsidiaries is generally their local currency. We translate these subsidiaries&#8217; financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholders&#8217; equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting pronouncements adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for income taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We adopted ASU 2019-12 as of January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for convertible instruments</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting For Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The new standard also simplifies the diluted net income per share calculation in certain areas and is effective for annual and interim periods beginning after December 15, 2021. We are currently evaluating the impact this standard will have on our consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745133174216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business acquisitions discussed below are included in our results of operations from their respective dates of acquisition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Able Health, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, we acquired Able Health, Inc. (Able Health)</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a leading software-as-a-service provider of quality and regulatory measurement tracking and reporting to healthcare providers and risk-bearing entities, in a transaction accounted for as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business combination</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The acquisition consideration transferred was  $21.5 million and was comprised of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net cash consideration of $15.2 million, Health Catalyst common shares with a fair value of $3.3 million, and contingent consideration based on achievement of Able Health specified incremental customer billings for the year ending December 31, 2020, with an initial fair value of $3.0 million. The acquisition consideration is subject to certain working capital escrow adjustments. The purchase resulted in Health Catalyst acquiring 100% ownership in Able Health.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional 179,392 shares of our common stock subject to restriction agreements, or restricted shares, were issued pursuant to the terms of the acquisition agreement and 60,000 restricted stock units were issued in connection with the acquisition agreement. The value of these restricted shares and restricted stock units is recognized as post-combination stock-based compensation expense over their respective vesting terms. The vesting of the restricted shares was subject to one year of continuous service by the applicable team members and fully vested on the one-year anniversary of the acquisition closing date. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he service-based condition for the restricted stock units issued pursuant to the terms of the acquisition agreement is satisfied over&#160;two years with a 50% cliff vesting period of one year and ratable quarterly vesting thereafter.</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 12 for additional details related to our stock-based compensation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Able Health (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include customer relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of six years, three years, and two years, respectively. The resulting goodwill from the Able Health acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthfinch, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2020, we acquired Healthfinch, Inc. (Healthfinch), which provides a workflow integration engine delivering insights and analytics into electronic medical record (EMR) workflows to automate physicians&#8217; ability to close patient care gaps in real-time, in a transaction accounted for as a business combination.  We believe this acquisition will strengthen our existing population health capabilities. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition consideration transferred was $50.5 million and was comprised of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net cash consideration of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Health Catalyst common shares with a fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$27.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and contingent consideration based on certain earn-out performance targets for Healthfinch during an earn-out period that ends on July&#160;31, 2021, with an initial fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purchase resulted in Health Catalyst acquiring 100% ownership in Healthfinch. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Healthfinch (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contract backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,507&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include customer relationships and contract backlog, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, three years, and two years, respectively. The resulting goodwill from the Healthfinch acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vitalware, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;1, 2020, we acquired Vitalware, LLC (Vitalware)</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a provider of revenue workflow optimization and analytics SaaS technology solutions to healthcare organizations, in a transaction accounted for as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business combination</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Vitalware&#8217;s flagship offering is a chargemaster management solution that delivers results for the complex regulatory and compliance functions needed by healthcare provider systems. Additionally, Vitalware brings to bear newer product suites to help health systems capture lost revenue and to support compliance with expanding pricing transparency regulation. The acquisition consideration transferred was $119.2 million and was comprised of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net cash consideration of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$69.6 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Health Catalyst common shares with a fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$41.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and contingent consideration based on certain earn-out performance targets for Vitalware during an earn-out period that ended on March&#160;31, 2021, with an initial fair value of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purchase resulted in Health Catalyst acquiring 100% ownership in Vitalware.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional 203,997 shares of our common stock subject to a restriction agreement, or restricted shares, were issued pursuant to the terms of the acquisition agreement. The value of these restricted shares is recognized as post-combination stock-based compensation expense on a straight-line basis over the 12-month vesting term. 75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of these restricted shares will vest on a monthly basis over a term of approximately one year with the remaining 25% vesting on the one year anniversary of the acquisition closing date.</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 12 for additional details related to our stock-based compensation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Vitalware (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contract backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets were valued utilizing an income approach, and include customer relationships, contract backlog, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, two years, four years, and for trademarks <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY5N2VjMmRlY2E0MzRiZmJiYTRlZWEyMWE1MWY1ZTExL3NlYzo2OTdlYzJkZWNhNDM0YmZiYmE0ZWVhMjFhNTFmNWUxMV80My9mcmFnOjZjNGQ4NjYxNzJiYzRhNjZhMjFlMTRhNWNlYjQ2M2RmL3RleHRyZWdpb246NmM0ZDg2NjE3MmJjNGE2NmEyMWUxNGE1Y2ViNDYzZGZfMTA5OTUxMTY0MDcyOQ_4220c2f0-de6b-4637-b12c-d886b4eb2b01">two</span> to five years, respectively. The resulting goodwill from the Vitalware acquisition was fully allocated to the technology reporting unit and is deductible for income tax purposes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our unaudited pro forma combined results of operations for the years ended December&#160;31, 2020 and 2019 as if the acquisitions of Able Health, Healthfinch, and Vitalware had taken place on January 1, 2019:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pro forma revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma information is not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2019 or to project potential results as of any future date or for any future periods. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma adjustments are based upon available information and certain assumptions that we believe are reasonable. The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma revenues or net loss, as applicable, are attributable to fair value adjustments to deferred revenues, amortization of acquired intangible assets, acquisition-related income tax considerations, and acquisition transaction costs that had a net impact on the pro forma combined net loss of $9.5 million and $30.8 million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045334056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Health Catalyst&#8217;s revenue disaggregated by type of arrangement (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurring technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time technology (i.e., perpetual license)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, 99.9% and 99.9%, respectively, of revenue was related to contracts with customers located in the United States.</span></div>Deferred Revenue and Performance Obligations<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized.&#160;For the three months ended March&#160;31, 2021 and 2020, 42% and 33%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div>Most of our technology and professional services contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#8217; notice. For arrangements that do not allow the customer to cancel within one year or less, we expect to recognize $79.6 million of revenue on unsatisfied performance obligations as of March&#160;31, 2021. We expect to recognize approximately 75% of the remaining performance obligations over the next 24 months, with the balance recognized thereafter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047050008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in two operating segments that also represent our reporting units. Our reporting units are organized based on our technology and professional services. We have not incurred any goodwill impairment charges.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill by reporting unit is as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,764&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,482)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,631)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of acquired intangible assets was $7.1 million and $2.2 million for the three months ended March&#160;31, 2021, and&#160;2020, respectively. Amortization expense for intangible assets is included in depreciation and amortization in our condensed consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045350344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital lease equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-lived assets are located in the United States. Depreciation expense totaled $0.7 million and $0.7 million for the three months ended March&#160;31, 2021 and 2020, respectively. Depreciation expense includes amortization of assets recorded under a capital lease and the amortization of capitalized internal-use software costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalized $1.0 million and $0.1 million of internal-use software costs for the three months ended March&#160;31, 2021 and 2020, respectively. We incurred $0.3 million and $0.1 million of capitalized internal-use software cost amortization expense for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047545912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text">Short-term Investments<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale. Available-for-sale securities are recorded on our condensed consolidated balance sheets at fair market value and any unrealized gains or losses are reported as part of other comprehensive loss on our condensed consolidated statements of comprehensive loss. We determine realized gains or losses on the sales of investments through the specific identification method and record such gains or losses as part of interest and other expense, net on our condensed consolidated statements of operations. We did not have any material realized gains or losses on investments during the three months ended March&#160;31, 2021 and 2020. We measure the fair value of investments on a recurring basis. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables related to our available-for-sale securities of $0.6 million and $0.5 million as of March&#160;31, 2021 and December&#160;31, 2020 were included within prepaid expenses and other assets on our condensed consolidated balance sheets. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of March&#160;31, 2021:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:24.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,185&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of December&#160;31, 2020:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:24.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis we evaluate unrealized losses on our available-for-sale debt securities and the related accrued interest receivables to determine whether a decline in the fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors. We do not intend to sell investments that are in an unrealized loss position and it is not likely that we will be required to sell any investments before recovery of their amortized cost basis. As of March&#160;31, 2021 and December&#160;31, 2020, there were no material unrealized losses due to credit-related factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045654888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,508&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,444)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1 and Level 2 during the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2021, the estimated fair value of the our convertible senior notes, with aggregate principal totaling&#160;$230.0 million,&#160;was&#160;$391.3 million. We estimate the fair value based on quoted market prices in an inactive market on the last trading day of the reporting period (Level 2). These convertible senior notes are recorded at face value less unamortized debt discount and transaction costs on our consolidated balance sheets. Refer to&#160;Note 9 &#8212;Convertible Senior Notes for further information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 fair value measurements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Healthfinch acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Healthfinch during an earn-out period that ends on July&#160;31, 2021. The Healthfinch contingent consideration will be paid in a combination of cash and shares of our common stock in the same proportion as the initial acquisition consideration. The Vitalware acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Vitalware during an earn-out period that ended on March&#160;31, 2021. The Vitalware contingent consideration is capped at $30.0 million and will be paid in a combination of approximately 50% cash and 50% in shares of our common stock. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value the expected contingent consideration and the corresponding liabilities using the Monte Carlo valuation method based on estimates of potential pay-out scenarios. The resulting contingent consideration liabilities are categorized as Level 3 fair value measurements and are remeasured as of each reporting period. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of the revenue-based earn-out contingent consideration liabilities is approximately $32.5 million based on a point estimate of our internal forecasting of the ultimate earn-outs that will be earned and our common stock price as of March&#160;31, 2021. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs as of March&#160;31, 2021:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation Method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market Price of Revenue Risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Price Volatility</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue-based earn-out liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">million</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Able Health acquisition consideration included an initial estimate for contingent consideration for shares of our common stock if certain incremental billing targets for Able Health were met during an earn-out period that ended on December 31, 2020.  This Able Health earn-out contingent consideration liability was settled during the three months ended March&#160;31, 2021.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,411&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045704984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued liabilities</a></td>
<td class="text">Accrued liabilities<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,946&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045706088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;14, 2020, we issued $230.0&#160;million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025 (the Notes), in a private placement to qualified institutional buyers exempt from registration under the Securities Act (the Note Offering). The net proceeds from the issuance of the Notes were approximately $222.5&#160;million, after deducting the initial purchasers&#8217; discounts and offering expenses payable by us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are governed by an indenture (the Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Indenture does not contain any financial or operating covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the Notes prior to April 20, 2023. On or after April 20, 2023, we may redeem, for cash, all or a portion of the Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes have an initial conversion rate of 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock). Following certain corporate events that occur prior to the maturity date, we will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event. Additionally, upon the occurrence of a corporate event that constitutes a &#8220;fundamental change&#8221; per the Indenture, holders of the Notes may require the Company to repurchase for cash all or a portion of their Notes at a purchase price equal to 100% of the principal amount of the Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes may convert all or any portion of their Notes at any time prior to the close of business on October 14, 2024, in integral multiples of $1,000 principal amount, only under the following circumstances:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During any calendar quarter commencing after the calendar quarter ended on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the five business day period after any five consecutive trading day period (the measurement period) in which the trading price as defined in the Indenture per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we call such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upon the occurrence of specified corporate events described in the Indenture.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing circumstances. Upon conversion, holders will receive cash, shares of our common stock or a combination of cash and shares of common stock, at our election.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For at least twenty trading days during the period of thirty consecutive trading days ended March&#160;31, 2021, the last reported sale price of the Company&#8217;s common stock was equal to or exceeded 130% of the conversion price of the Notes on each applicable trading day. As a result, the Notes are convertible at the option of the holders during the fiscal quarter ending June 30, 2021 and are classified as current liabilities on the condensed consolidated balance sheet as of March&#160;31, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Notes as separate liability and equity components. We determined the carrying amount of the liability component as the present value of its cash flows using a discount rate of approximately 10% based on comparable debt transactions for similar companies. The estimated interest rate was applied to the Notes, which resulted in a fair value of the liability component of $166.7 million upon issuance, calculated as the present value of future contractual payments based on the $230.0 million aggregate principal amount. The excess of the principal amount of the liability component over its carrying amount, or the debt discount, is amortized to interest expense over the term of the Notes using the effective interest method. The $63.3 million difference between the gross proceeds received from issuance of the Notes of $230.0 million and the estimated fair value of the liability component represents the equity component, or the conversion option, of the Notes and was recorded in additional paid-in capital. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated issuance costs related to the issuance of the Notes to the liability and equity components using the same proportions as the initial carrying value of the Notes. Issuance costs attributable to the liability component were $5.5 million and are being amortized to interest expense using the effective interest method over the term of the Notes. Issuance costs attributable to the equity component were $2.1 million and are netted with the equity component of the Notes in stockholders&#8217; equity on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized related to the Notes was as follows (in thousands):</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs and discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying value of the liability component of the Notes was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying value of the equity component of the Notes was as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds allocated to the conversion option (debt discount)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the closing price of our common stock of $46.77 on March&#160;31, 2021, the if-converted value of the Notes was $121.5 million more than their respective principal amount.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Calls</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (Base Capped Calls) with certain option counterparties. In addition, in connection with the initial purchasers&#8217; exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used approximately $21.7 million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. As the Capped Call transactions are considered indexed to our own stock and are considered equity classified, they will be recorded in stockholders&#8217; equity and will not be accounted for as derivatives. The cost incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital on our condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047095208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has the authority, without further action by our stockholders, to issue up to 25,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, and privileges thereof, including voting rights. As of March&#160;31, 2021 and December&#160;31, 2020, no shares of this preferred stock were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had 500,000,000 shares of $0.001 par value common stock authorized, of which 44,454,783 and 43,709,237 shares were legally issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The shares legally issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020 included 114,747 shares and 332,389 shares, respectively, issued pursuant to the Able Health and Vitalware acquisition agreements, which are subject to a restriction agreement and were unvested, and as such, for accounting purposes they were not considered to be outstanding common stock shares.  Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on our common stock through March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049653176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in calculating net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,870,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,108,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, we incurred net losses and, therefore, the effect of our stock options, restricted stock units, performance-based restricted stock units, convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed or shares issued under our employee stock purchase plan were not included in the calculation of diluted net loss per share as the effect would be anti-dilutive. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains share totals with a potentially dilutive impact:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,640,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares related to convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable as acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,889,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,053,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion spread of the Notes will have a potentially dilutive impact when the average market price of our common stock for a given period exceeds the conversion price of $30.60 per share. The shares related to the Notes in the table above are calculated based on the average market price of our common stock for the three months ended March&#160;31, 2021. Capped Calls are excluded from the calculation of diluted earnings per share, as they would be antidilutive.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares issuable as acquisition-related contingent consideration in the table above are calculated based on the earn-out achieved and the estimated amount of shares that would be issuable if the contingent consideration liabilities from the acquisitions of Healthfinch and Vitalware were to be settled as of March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047054152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-Based Compensation <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, our board of directors adopted the Health Catalyst, Inc. 2011 Stock Incentive Plan (2011 Plan), which provided for the direct award, sale of shares, and granting of RSUs and options for our common stock to our directors, team members, or consultants.  In connection with our IPO, our board of directors adopted the 2019 Stock Option and Incentive Plan (2019 Plan). The 2019 Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce, including the grant of incentive and nonstatutory stock options, restricted and unrestricted stock, RSUs, and stock appreciation rights to our directors, team members, or consultants.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initially reserved 2,756,607 shares of our common stock (2,500,000 under the 2019 Plan and 256,607 shares under the 2011 Plan that were available immediately prior to the IPO registration date). The 2019 Plan provides that the number of shares reserved available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. As of January&#160;1, 2021, there were an additional 2,185,461 shares reserved for issuance under the 2019 Plan.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, there were 15,294,920 and 13,109,459 shares authorized for grant, respectively, and 3,086,399 and 2,481,818 shares available for grant, respectively, under the 2019 Plan and 2011 Plan (collectively the Stock Incentive Plan). All options were granted with an exercise price determined by the board of directors that was equal to the estimated fair value of our common stock at the date of grant, based on the information known on the date of grant. Subject to certain exceptions defined in the Stock Incentive Plan related to an employee&#8217;s termination, options generally expire on the tenth anniversary of the applicable grant date.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options, which vest in accordance with service schedules, is estimated on the date of grant using the Black-Scholes option pricing model. The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our consolidated statements of operations (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock options granted during the three months ended March 31, 2021 or 2020. A summary of the share option activity under the 2019 Plan for the three months ended March 31, 2021, is as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Time-Based Option Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,892,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,946,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,047&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,946,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,231,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised was $18.7 million for the three months ended March&#160;31, 2021. The total grant-date fair value of stock options vested during the three months ended March&#160;31, 2021 was $1.8 million. As of March&#160;31, 2021, approximately $6.3 million of unrecognized compensation expense related to our stock options is expected to be recognized over a remaining weighted-average period of 1.4 years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (RSUs)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service-based condition for RSUs is generally satisfied over&#160;four years with a 25% cliff vesting period of one year and ratable quarterly vesting thereafter. The following table sets forth the outstanding RSUs and related activity for the&#160;three months ended March&#160;31, 2021:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had $114.1 million of unrecognized stock-based compensation expense related to outstanding RSUs expected to be recognized over a remaining weighted-average period of 3.2 years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units (PRSUs)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we granted PRSUs to all employees that included both service conditions and performance conditions related to company-wide goals. These PRSUs will vest to the extent the applicable performance conditions are achieved for the year ended December 31, 2021, and if the individual employee continues to provide services to us through the vesting date of March 1, 2022. The number of PRSUs that will ultimately vest from the 2021 PRSU grants can range from 0% to 100% of the original amount granted depending on our performance during 2021 against the pre-established targets. We also granted additional executive PRSUs based on the same performance conditions described above, but with an extended four-year service condition whereby one quarter of such shares will vest on March 1, 2022, and the remainder in quarterly installments thereafter.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding PRSUs, including executive PRSUs, and related activity for the&#160;three months ended March&#160;31, 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.717%"><tr><td style="width:1.0%"/><td style="width:69.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSUs forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had $10.3 million of unrecognized stock-based compensation expense related to outstanding PRSUs expected to be recognized over a remaining weighted-average period of 1.0 year.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO in July 2019, our board of directors adopted the ESPP and a total of 750,000 shares of common stock were initially reserved for issuance under the ESPP. The number of shares of common stock available for issuance under the ESPP will be increased on the first day of each calendar year beginning January 1, 2020 and each year thereafter until the ESPP terminates. The number of shares of common stock reserved and available for issuance under the ESPP shall be cumulatively increased by the least of (i) 750,000 shares, (ii) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of common stock as determined by the ESPP Administrator. As of January&#160;1, 2021, the number of shares of common stock available for issuance under the ESPP increased by 437,092 shares. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP generally provides for six-month offering periods, the exception being the first offering period. The offering periods generally start on the first trading day after June 30 and December 31 of each year. The ESPP permits participants to elect to purchase shares of common stock through fixed percentage contributions from eligible compensation during each offering period, not to exceed 15% of the eligible compensation a participant receives during an offering period or accrue at a rate which exceeds $25,000 of the fair value of the stock (determined on the option grant date(s)) for each calendar year. A participant may purchase the lowest of (a) a number of shares of common stock determined by dividing such participant&#8217;s accumulated payroll deductions on the exercise date by the option price, (b) 2,500 shares; or (c) such other lesser maximum number of shares as shall have been established by the Administrator in advance of the offering period. Amounts deducted and accumulated by the participant will be used to purchase shares of common stock at the end of each offering period. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of the shares will be 85% of the lower of the fair value of common stock on the first trading day of each offering period or on the purchase date, except for the first offering period, for which the purchase price will be 85% of the lower of (i) the IPO price or (ii) the fair value of common stock on the purchase date. Participants may end their participation at any time during an offering period and will be paid their accumulated contributions that have not been used to purchase shares of common stock. Participation ends automatically upon termination of employment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, a total of 72,892 shares were issuable to employees based on ESPP contribution elections and unrecognized ESPP compensation cost was $0.4 million, which is expected to be recognized over the remaining portion of the current offering period during the three months ending June 30, 2021. As of March&#160;31, 2021, 1,245,652 shares are available for future issuance under the ESPP.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Shares</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Able Health acquisition that closed on February 21, 2020, 179,392 shares of our common stock were issued pursuant to the terms of the acquisition agreement and are a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares were subject to one year of continuous service by the applicable team members and vested fully during the three months ended March&#160;31, 2021 on the one-year anniversary of the acquisition closing date.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vitalware acquisition that closed on September 1, 2020, 203,997 shares of our common stock were issued pursuant to the terms of the acquisition agreement and are a stock-based compensation arrangement subject to a restriction agreement. 75% of these restricted shares will vest on a monthly basis over a term of approximately one year with the remaining 25% vesting on the one-year anniversary of the acquisition closing date. As of March&#160;31, 2021, 89,250 of these restricted shares had vested. As of March&#160;31, 2021, we had $2.8 million of unrecognized stock-based compensation expense related to outstanding restricted shares expected to be recognized over a weighted-average period of 0.4 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745046861000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, we update our estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, we make a cumulative adjustment in such period. The quarterly tax provision and the estimate of our annual effective tax rate are subject to variation due to several factors, including variability in our loss before income taxes, the mix of jurisdictions to which such income or loss relates, changes in how we conduct business, and tax law developments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;three months ended March&#160;31, 2021 and 2020, our estimated effective tax rate was (0.4)% and 6.6%, respectively. The variations between our estimated effective tax rate and the U.S. statutory rate are&#160;primarily due to our full valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all available evidence to evaluate the recovery of deferred tax assets, including historical levels of income, legislative developments, and risks associated with estimates of future taxable income. We have provided a full valuation allowance for our net deferred tax assets as of March&#160;31, 2021 and December&#160;31, 2020, due to the uncertainty surrounding the future realization of such assets and the cumulative losses we have generated.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we have a full valuation allowance on net deferred tax assets, our income tax provision for the three months ended March 31, 2021 consists primarily of minimal state and foreign income taxes. The income tax benefit of $1.2 million recorded for the three months ended March 31, 2020, is primarily related to the discrete deferred tax benefit attributable to the release of a portion of the valuation allowance during the quarter. The release of valuation allowance is attributable to the acquisition of Able Health, which resulted in deferred tax liabilities that, upon acquisition, allowed us to recognize certain deferred tax assets of $1.3 million that had previously been offset by a valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions when it is more likely than not, based on the technical merits, that the position will be sustained upon examination.  We believe that we have provided adequate reserves for income tax uncertainties in all open tax years.  We do not anticipate material changes in the total amount of our unrecognized tax benefits within 12 months of the reporting date.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted and signed into U.S. law to provide economic relief to individuals and businesses facing economic hardship as a result of the COVID-19 pandemic. On March 11, 2021, the American Rescue Plan Act of 2021 (ARPA) was enacted and signed into U.S. law to provide additional economic stimulus and tax credits. Changes in tax laws or rates are accounted for in the period of enactment. We are continuing to analyze these legislative developments and believe that the income tax provisions of the CARES Act and ARPA do not have a significant impact on our current taxes, deferred taxes, or uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745046984920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings from time to time that arise in the normal course of business. As of March&#160;31, 2021 and December&#160;31, 2020, there were no significant outstanding claims against us.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745149697528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue and Performance Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Deferred Revenue and Performance Obligations</a></td>
<td class="text">Revenue<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Health Catalyst&#8217;s revenue disaggregated by type of arrangement (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurring technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time technology (i.e., perpetual license)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, 99.9% and 99.9%, respectively, of revenue was related to contracts with customers located in the United States.</span></div>Deferred Revenue and Performance Obligations<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized.&#160;For the three months ended March&#160;31, 2021 and 2020, 42% and 33%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div>Most of our technology and professional services contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#8217; notice. For arrangements that do not allow the customer to cancel within one year or less, we expect to recognize $79.6 million of revenue on unsatisfied performance obligations as of March&#160;31, 2021. We expect to recognize approximately 75% of the remaining performance obligations over the next 24 months, with the balance recognized thereafter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045618536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into arrangements with a customer, Mass General Brigham (formerly Partners Healthcare), where, at that time, a member of the customer&#8217;s management was a member of our board of directors. He resigned from his executive position with our customer on March 31, 2021 and remains on staff. He served on our board of directors from January 2018 to May 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from this related party of $0.9 million and $0.7 million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, we had receivables from this related party of $0.8 million and $0.6 million, respectively, and deferred revenue with this related party of $0.4 million and $0.7 million, respectively. We also had acquisition-related consideration payable to this related party for a prior year asset acquisition, of which the final $1.2 million was paid during the year ended December 31, 2020.  This asset acquisition occurred prior to this entity becoming a related party. There was no acquisition-related consideration payable to this related party as of March&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into revenue arrangements with customers that are also our investors. None of these customers hold a significant amount of ownership in our equity interests.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745149697528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in two operating segments that also represent our reportable segments. Our business is organized based on our technology offerings and professional services. Accordingly, our segments are:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Technology - Our technology segment (Technology) includes our data platform, analytics applications and support services. Technology generates revenues primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Professional Services - Our professional services segment (Professional Services) is generally the combination of data and analytics, domain expertise, outsourcing, and implementation services to deliver expertise to our customers to more fully configure and utilize the benefits of our Technology offerings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and cost of revenues generally are directly attributed to our segments. All segment revenues are from our external customers. Asset and other balance sheet information at the segment level is not reported to our Chief Operating Decision Maker.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and Adjusted Gross Profit for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Gross Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments Adjusted Gross Profit</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Adjusted Gross Profit reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less other reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,269)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,726)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745130731032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts on the condensed consolidated statements of cash flows have been reclassified to conform to the current year presentation. A reclassification was made to separately present the non-cash operating lease expense as a non-cash reconciling adjustment from net loss and the change in the operating lease liabilities due to cash payments as a change in operating assets and liabilities. This net change is not material and does not affect previously reported net cash used in operating activities in the condensed consolidated statements of cash flows. This reclassification had no effect on our other condensed consolidated financial statements for the three months ended March&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (the CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as the effect is antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We derive our revenues primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, we satisfy the performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue net of any taxes collected from customers and subsequently remitted to governmental authorities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology revenue primarily consists of subscription fees charged to customers for access to use our technology. We provide customers access to our technology through either an all-access or limited-access, modular subscription. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our subscription arrangements are cloud-based and do not provide customers the right to take possession of the technology or contain a significant penalty if the customer were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the customer. Most of our subscription contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days&#8217; notice.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriptions that allow the customer to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the customer. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have certain perpetual license arrangements. Revenue from these arrangements is recognized at a point in time upon delivery of the software. Technology revenue also includes maintenance and support revenue which generally includes bug fixes, updates, and support services. Revenue related to maintenance and support is recognized over the contract term beginning on the date that the service is made available to the customer.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services revenue primarily includes data and analytics services, domain expertise services, outsourcing services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our customers on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our customer. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the &#8220;right to invoice&#8221; practical expedient. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include customer demographics and the types of users. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we use the residual estimation method due to a limited number of standalone transactions and/or prices that are highly variable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable consideration</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into at-risk and shared savings arrangements with certain customers whereby we receive variable consideration based on the achievement of measurable improvements which may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets resulting from services performed prior to invoicing customers are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of March&#160;31, 2021 and December&#160;31, 2020, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $1.3 million and $1.6 million, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the customer. As of March&#160;31, 2021 and December&#160;31, 2020, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.8 million and $49.0 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize sales commissions and associated fringe costs, such as payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with customers, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the customer contract. As of March&#160;31, 2021 and December&#160;31, 2020, $0.7&#160;million and $0.5 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and were included in prepaid expenses and other assets on the consolidated balance sheets. As of March&#160;31, 2021 and December&#160;31, 2020, the remaining $1.9&#160;million and $1.4 million, respectively, of deferred contract acquisition costs were included in non-current other assets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average customer life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average customer life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs is included within sales and marketing expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. As of March&#160;31, 2021 and December&#160;31, 2020, $0.5&#160;million and $0.5&#160;million, respectively, of deferred fulfillment costs were included in prepaid expenses and other assets on the condensed consolidated balance sheets. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of revenue, excluding depreciation and amortization</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue excludes costs related to depreciation and amortization.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">cash equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term investments</a></td>
<td class="text">Short-term investmentsOur investments consist of highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, the establishment of specific reserves for customers in an adverse financial condition, and our expectations of changes in macro-economic conditions, including the current COVID-19 pandemic, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr></table></div>When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset in the asset group. If the carrying amount of the asset group exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technologies, customer relationships, customer contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets&#8217; estimated useful lives. The estimated useful life of each asset category is as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, customer relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually or more frequently if indicators of impairment are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present or circumstances suggest that impairment may exist. </span></div>Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business combinations</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the customer-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for customer relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of assets acquired and liabilities assumed in a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2020, we expensed $0.9 million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our consolidated statements of operations. No such costs were incurred or recorded for the three months ended March&#160;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent consideration liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements. We value the expected contingent consideration and the corresponding liabilities using a probability model such as the Monte Carlo method based on estimates of potential pay-out scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.</span></div>The portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes to the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">costs</span>All advertising costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Development cost and internal-use software</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development costs and internal-use software</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our customers on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. Our standard stock-based awards vest solely on a service-based condition. &#160;For these awards, we recognize stock-based compensation expense on a straight-line basis over the vesting period. Awards that contain both service-based and performance conditions are recognized using the accelerated attribution method once the performance condition is probable of occurring. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because we have NOLs. Significant judgment is required to evaluate uncertain tax positions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of acquisition-related consideration payable and operating lease liabilities approximate fair value based on interest rates available for debt with similar terms at March&#160;31, 2021 and December&#160;31, 2020. Money market funds and short-term investments are measured at fair value on a recurring basis. Our contingent consideration liabilities are measured at fair value on a recurring basis based primarily on significant inputs not observable in the market.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1- Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3- Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease contracts do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We do not have lease agreements that contain non-lease components, which generally would be accounted for separately.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of our international subsidiaries is generally their local currency. We translate these subsidiaries&#8217; financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholders&#8217; equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting pronouncements adopted and recent accounting pronouncements not yet adopted</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting pronouncements adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for income taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We adopted ASU 2019-12 as of January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for convertible instruments</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting For Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The new standard also simplifies the diluted net income per share calculation in certain areas and is effective for annual and interim periods beginning after December 15, 2021. We are currently evaluating the impact this standard will have on our consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745130756168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of allowance for accounts receivable</a></td>
<td class="text">We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses on Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Write-offs, net of recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, useful life</a></td>
<td class="text">The estimated useful life of each asset category is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr></table><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital lease equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible asset, useful life</a></td>
<td class="text">The estimated useful life of each asset category is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr></table><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,764&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,482)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,631)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047620280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of recognized identified assets acquired and liabilities assumed</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Able Health (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Healthfinch (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contract backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,507&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Vitalware (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contract backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Summary</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our unaudited pro forma combined results of operations for the years ended December&#160;31, 2020 and 2019 as if the acquisitions of Able Health, Healthfinch, and Vitalware had taken place on January 1, 2019:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pro forma revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745046979704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of revenue disaggregated by type of arrangement</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Health Catalyst&#8217;s revenue disaggregated by type of arrangement (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurring technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time technology (i.e., perpetual license)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047620280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill by reporting unit</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill by reporting unit is as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text">The estimated useful life of each asset category is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr></table><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, intangible assets consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,764&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,482)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,631)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745046870008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text">The estimated useful life of each asset category is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr></table><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital lease equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047103896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of cash equivalents and short-term investments measured at fair value</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of March&#160;31, 2021:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:24.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,185&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis (in thousands) as of December&#160;31, 2020:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:24.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745136669880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair value, assets measured on recurring basis</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,508&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,444)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Fair value, liabilities measured on recurring basis</a></td>
<td class="text">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs as of March&#160;31, 2021:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation Method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market Price of Revenue Risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Price Volatility</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue-based earn-out liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">million</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Able Health acquisition consideration included an initial estimate for contingent consideration for shares of our common stock if certain incremental billing targets for Able Health were met during an earn-out period that ended on December 31, 2020.  This Able Health earn-out contingent consideration liability was settled during the three months ended March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Liabilities measured on recurring basis, unobservable input reconciliation</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,411&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745046932968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,946&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045602760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized related to the Notes was as follows (in thousands):</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs and discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying value of the liability component of the Notes was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying value of the equity component of the Notes was as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds allocated to the conversion option (debt discount)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047162728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the calculation of basic and diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in calculating net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,870,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,108,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of share totals with a potentially dilutive impact</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains share totals with a potentially dilutive impact:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,640,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares related to convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable as acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,889,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,053,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745128528136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our consolidated statements of operations (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of information related to stock options</a></td>
<td class="text">A summary of the share option activity under the 2019 Plan for the three months ended March 31, 2021, is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Time-Based Option Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,892,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,946,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,047&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,946,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,231,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of outstanding RSUs and related activity</a></td>
<td class="text">The following table sets forth the outstanding RSUs and related activity for the&#160;three months ended March&#160;31, 2021:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding PRSUs, including executive PRSUs, and related activity for the&#160;three months ended March&#160;31, 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.717%"><tr><td style="width:1.0%"/><td style="width:69.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSUs forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of the purchase right for the ESPP option assumptions</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045602760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and Adjusted Gross Profit for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of segment adjusted gross profit</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Gross Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments Adjusted Gross Profit</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Adjusted Gross Profit reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less other reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,269)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,726)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745048612200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2019</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_RevenueFromSubscriptionContractTermofContract', window );">Subscription contract, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod', window );">Subscription contracts, terminable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination', window );">Subscription contracts, days notice of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Unbilled accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetCurrent', window );">Capitalized contract cost, net, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized contract cost, amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Capitalized contract cost, net, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_CommissionPaymentEstimatedBenefitPeriod', window );">Estimated period of benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Deferred contract fulfillment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long lived impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_CommissionPaymentEstimatedBenefitPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission Payment, Estimated Benefit Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_CommissionPaymentEstimatedBenefitPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_RevenueFromSubscriptionContractTermofContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Subscription Contract, Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_RevenueFromSubscriptionContractTermofContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Subscription Contract, Allowed Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Subscriptions Contract, Notice Required For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745048536824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Current period provision for expected credit losses</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Less: Write-offs, net of recoveries</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745128384056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Capitalized internal-use software costs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Capitalized internal-use software costs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050074488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_CustomerRelationshipsAndContractsMember', window );">Customer relationships and contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_CustomerRelationshipsAndContractsMember', window );">Customer relationships and contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software licenses | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software licenses | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_CustomerRelationshipsAndContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_CustomerRelationshipsAndContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745040825544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common shares issued in acquisition, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc | Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares', window );">Number of restricted shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc | Restricted Shares Pursuant To Acquisition Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc | Vest in year one | Restricted Shares Pursuant To Acquisition Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember', window );">Healthfinch Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common shares issued in acquisition, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="nump">$ 119,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common shares issued in acquisition, at fair value</a></td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares', window );">Number of restricted shares issued (in shares)</a></td>
<td class="nump">203,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares', window );">Number of restricted shares issued (in shares)</a></td>
<td class="nump">203,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Vest in year one | Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Able Health Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Healthfinch Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Vitalware L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Able Health Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Healthfinch Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Vitalware L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Able Health Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Healthfinch Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Vitalware L L C | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Vitalware L L C | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_ContractBacklogsMember', window );">Contract Backlogs | Vitalware L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Stock-based Compensation Shares Issuable, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hcat_RestrictedSharesPursuantToAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hcat_RestrictedSharesPursuantToAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_ContractBacklogsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_ContractBacklogsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050508904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Less liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 107,822<span></span>
</td>
<td class="nump">$ 107,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Less liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther', window );">Accounts payable and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc | Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember', window );">Healthfinch Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Less liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther', window );">Accounts payable and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember', window );">Healthfinch Inc | Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember', window );">Healthfinch Inc | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember', window );">Healthfinch Inc | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Less liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther', window );">Accounts payable and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_HealthfinchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049866168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Unaudited Pro Forma Financial Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total pro forma revenues</a></td>
<td class="nump">$ 209,409<span></span>
</td>
<td class="nump">$ 173,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Pro forma net loss</a></td>
<td class="num">(124,485)<span></span>
</td>
<td class="num">(90,850)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonrecurringAdjustmentAxis=hcat_AcquisitionRelatedFairValueAdjustmentsMember', window );">Acquisition Related Fair Value Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=hcat_AcquisitionRelatedFairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=hcat_AcquisitionRelatedFairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745130710744">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 55,846<span></span>
</td>
<td class="nump">$ 45,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hcat_RecurringTechnologyMember', window );">Recurring technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,567<span></span>
</td>
<td class="nump">24,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hcat_OneTimeTechnologyMember', window );">One-time technology (i.e., perpetual license)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">272<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember', window );">Professional services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 22,007<span></span>
</td>
<td class="nump">$ 20,417<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes amounts attributable to related party transactions. See Note 16 for further details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hcat_RecurringTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hcat_RecurringTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hcat_OneTimeTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hcat_OneTimeTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050318520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk | Revenue from Contract with Customer Benchmark | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue related to contracts with customers (percentage)</a></td>
<td class="nump">99.90%<span></span>
</td>
<td class="nump">99.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745130702104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets | $</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045358744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 107,822<span></span>
</td>
<td class="nump">$ 107,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=hcat_TechnologyMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">107,040<span></span>
</td>
<td class="nump">107,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=hcat_ProfessionalServicesMember', window );">Professional Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=hcat_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=hcat_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=hcat_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=hcat_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745129123208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">$ 136,552<span></span>
</td>
<td class="nump">$ 136,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(44,712)<span></span>
</td>
<td class="num">(37,631)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">91,840<span></span>
</td>
<td class="nump">98,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">69,729<span></span>
</td>
<td class="nump">69,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(28,676)<span></span>
</td>
<td class="num">(25,293)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">41,053<span></span>
</td>
<td class="nump">44,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_CustomerRelationshipsAndContractsMember', window );">Customer relationships and contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">57,764<span></span>
</td>
<td class="nump">57,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,520)<span></span>
</td>
<td class="num">(7,482)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">47,244<span></span>
</td>
<td class="nump">50,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">7,359<span></span>
</td>
<td class="nump">7,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,123)<span></span>
</td>
<td class="num">(4,615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(393)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_CustomerRelationshipsAndContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_CustomerRelationshipsAndContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745130694168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 29,202<span></span>
</td>
<td class="nump">$ 22,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(10,549)<span></span>
</td>
<td class="num">(10,009)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">18,653<span></span>
</td>
<td class="nump">12,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">9,562<span></span>
</td>
<td class="nump">8,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">10,536<span></span>
</td>
<td class="nump">8,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3,614<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Capitalized internal-use software costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hcat_AssetsHeldUnderFinanceLeasesMember', window );">Capital lease equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hcat_AssetsHeldUnderFinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hcat_AssetsHeldUnderFinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050082456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized computer software, net</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050662168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">259,183<span></span>
</td>
<td class="nump">258,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">259,185<span></span>
</td>
<td class="nump">258,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">125,378<span></span>
</td>
<td class="nump">79,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">125,378<span></span>
</td>
<td class="nump">79,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">49,123<span></span>
</td>
<td class="nump">59,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,130<span></span>
</td>
<td class="nump">59,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">57,067<span></span>
</td>
<td class="nump">68,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">57,067<span></span>
</td>
<td class="nump">68,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">27,615<span></span>
</td>
<td class="nump">48,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,610<span></span>
</td>
<td class="nump">48,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">125,378<span></span>
</td>
<td class="nump">79,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">125,378<span></span>
</td>
<td class="nump">79,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">133,807<span></span>
</td>
<td class="nump">178,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember', window );">Short-term Investments | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember', window );">Short-term Investments | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,130<span></span>
</td>
<td class="nump">59,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember', window );">Short-term Investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">57,067<span></span>
</td>
<td class="nump">68,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember', window );">Short-term Investments | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 27,610<span></span>
</td>
<td class="nump">48,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember', window );">Short-term Investments | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745043950088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 259,185,000<span></span>
</td>
<td class="nump">$ 258,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_FairValueMeasurementAggregateIntrinsicValue', window );">Fair value</a></td>
<td class="nump">32,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member', window );">Senior Notes Due 2025 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="nump">$ 391,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability', window );">Shares issuable, contingent consideration (in shares)</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash', window );">Contingent consideration paid in a combination cash</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares', window );">Contingent consideration paid in a combination shares</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_FairValueMeasurementAggregateIntrinsicValue', window );">Fair value</a></td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,130,000<span></span>
</td>
<td class="nump">59,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">57,067,000<span></span>
</td>
<td class="nump">68,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,610,000<span></span>
</td>
<td class="nump">48,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">125,378,000<span></span>
</td>
<td class="nump">79,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="num">(32,444,000)<span></span>
</td>
<td class="num">(31,264,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">226,741,000<span></span>
</td>
<td class="nump">227,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">125,378,000<span></span>
</td>
<td class="nump">79,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">174,508,000<span></span>
</td>
<td class="nump">138,776,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">84,677,000<span></span>
</td>
<td class="nump">119,528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="num">(32,444,000)<span></span>
</td>
<td class="num">(31,264,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="num">(32,444,000)<span></span>
</td>
<td class="num">(31,264,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,130,000<span></span>
</td>
<td class="nump">59,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | U.S. Treasury notes | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,130,000<span></span>
</td>
<td class="nump">59,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | U.S. Treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | U.S. Treasury notes | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">57,067,000<span></span>
</td>
<td class="nump">68,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">57,067,000<span></span>
</td>
<td class="nump">68,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Commercial paper | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,610,000<span></span>
</td>
<td class="nump">48,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Corporate bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,610,000<span></span>
</td>
<td class="nump">48,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Corporate bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Asset-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Asset-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Contingent Consideration, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_FairValueMeasurementAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_FairValueMeasurementAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049371832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Contingent Consideration Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_FairValueMeasurementAggregateIntrinsicValue', window );">Fair value</a></td>
<td class="nump">$ 32.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_FairValueMeasurementAggregateIntrinsicValue', window );">Fair value</a></td>
<td class="nump">$ 32.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=hcat_MeasurementInputMarketPriceOfRevenueRiskMember', window );">Measurement Input Market Price Of Revenue Risk | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Revenue-based earn-out liabilities</a></td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=hcat_MeasurementInputRevenueVolatilityMember', window );">Measurement Input Revenue Volatility | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Revenue-based earn-out liabilities</a></td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Revenue-based earn-out liabilities</a></td>
<td class="nump">0.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_FairValueMeasurementAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_FairValueMeasurementAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=hcat_MeasurementInputMarketPriceOfRevenueRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=hcat_MeasurementInputMarketPriceOfRevenueRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=hcat_MeasurementInputRevenueVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=hcat_MeasurementInputRevenueVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047149224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details) - Shares issuable as acquisition-related contingent consideration<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of December&#160;31, 2020</a></td>
<td class="nump">$ 31,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Settlement of contingent consideration</a></td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value of contingent consideration liabilities</a></td>
<td class="nump">2,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of March&#160;31, 2021</a></td>
<td class="nump">$ 32,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=hcat_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=hcat_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049954072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefit expenses</a></td>
<td class="nump">$ 7,024<span></span>
</td>
<td class="nump">$ 9,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">5,922<span></span>
</td>
<td class="nump">6,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 12,946<span></span>
</td>
<td class="nump">$ 16,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities And Employee-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050698152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 09, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 08, 2020 </div>
<div>$ / instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 46.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Capped Call | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCostOfHedge', window );">Derivative, cost of hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price (in dollars per share) | $ / instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure', window );">Convertible debt liability component fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member', window );">Senior Notes Due 2025 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross', window );">Proceeds allocated to the conversion option (debt discount)</a></td>
<td class="nump">$ 63,270,000<span></span>
</td>
<td class="nump">$ 230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Basis rate (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued in conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00326797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="nump">$ 391,300,000<span></span>
</td>
<td class="nump">$ 230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure', window );">Convertible debt liability component fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DebtIssuanceCostGrossLiabilityComponent', window );">Debt issuance cost gross liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DebtIssuanceCostGrossEquityComponent', window );">Debt issuance cost gross equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Debt instrument, convertible, if-converted value in excess of principal</a></td>
<td class="nump">$ 121,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member', window );">Senior Notes Due 2025 | Convertible Notes Payable | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member', window );">Senior Notes Due 2025 | Convertible Notes Payable | Debt Instrument Convertible Sale Price Of Stock Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt Liability Component Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Carrying Amount Of Equity Component Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DebtIssuanceCostGrossEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>DebtIssuance Cost Gross Equity Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DebtIssuanceCostGrossEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DebtIssuanceCostGrossLiabilityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Cost Gross Liability Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DebtIssuanceCostGrossLiabilityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCostOfHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The premium (cost) of a hedge, expensed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCostOfHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=hcat_CappedCallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=hcat_CappedCallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DebtInstrumentConvertibleThresholdTypeAxis=hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DebtInstrumentConvertibleThresholdTypeAxis=hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049008424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">$ 2,870<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member', window );">Senior Notes Due 2025 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Contractual interest expense</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">2,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total</a></td>
<td class="nump">$ 4,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745048536824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Net Carrying Value Of the Liability (Details) - Senior Notes Due 2025 - Convertible Notes Payable<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">$ 230,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized debt discount</a></td>
<td class="num">(53,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Less: Unamortized issuance costs</a></td>
<td class="num">(4,559)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 171,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745128296200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Net Carrying Value Of the Equity (Details) - Senior Notes Due 2025 - Convertible Notes Payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross', window );">Proceeds allocated to the conversion option (debt discount)</a></td>
<td class="nump">$ 63,270<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DebtIssuanceCostsGrossEquityComponent', window );">Less: Issuance costs</a></td>
<td class="num">(2,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Net carrying amount</a></td>
<td class="nump">$ 61,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Carrying Amount Of Equity Component Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DebtIssuanceCostsGrossEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs Gross Equity Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DebtIssuanceCostsGrossEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745128181912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">44,454,783<span></span>
</td>
<td class="nump">43,709,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">44,454,783<span></span>
</td>
<td class="nump">43,709,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_StockholdersVote', window );">Stockholders vote | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Able Health Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">114,747<span></span>
</td>
<td class="nump">332,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">114,747<span></span>
</td>
<td class="nump">332,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_StockholdersVote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Vote</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_StockholdersVote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hcat_VitalwareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hcat_VitalwareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047007704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (28,370)<span></span>
</td>
<td class="num">$ (17,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used in calculating net loss per share basic and diluted (in shares)</a></td>
<td class="nump">43,870,288<span></span>
</td>
<td class="nump">37,108,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745049403640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">9,889,785<span></span>
</td>
<td class="nump">9,053,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member', window );">Senior Notes Due 2025 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">3,344,047<span></span>
</td>
<td class="nump">6,640,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">2,937,690<span></span>
</td>
<td class="nump">2,145,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">307,859<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember', window );">Shares related to convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">2,768,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hcat_ContingentConsiderationMember', window );">Shares issuable as acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">344,436<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">72,892<span></span>
</td>
<td class="nump">87,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares with a potentially dilutive impact (in shares)</a></td>
<td class="nump">114,747<span></span>
</td>
<td class="nump">179,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hcat_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hcat_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745040494248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Shares exercised in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant-date fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Nonvested award options, unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested awards, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested awards, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense related to RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Vest in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Performance-based restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Performance-based restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested awards, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense related to RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">72,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares', window );">Percentage increase of the number of common stock shares (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,245,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense related to RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">ESPP share increase in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod', window );">Employee stock purchase plan period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee', window );">Maximum purchase value during offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed', window );">Denominator of lowest purchase of a participant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember', window );">Able Health Inc | Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares', window );">Number of restricted shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares', window );">Number of restricted shares issued (in shares)</a></td>
<td class="nump">203,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested awards, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense related to RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares', window );">Number of restricted shares issued (in shares)</a></td>
<td class="nump">203,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember', window );">Vitalware L L C | Restricted shares | Vest in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Cliff vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hcat_StockIncentivePlanMember', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,294,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,109,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,086,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,481,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hcat_StockIncentivePlan2011Member', window );">2011 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,756,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares', window );">Percentage increase of the number of common stock shares (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hcat_StockIncentivePlan2019Member', window );">2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hcat_VitalwareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hcat_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hcat_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hcat_StockIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hcat_StockIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hcat_StockIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hcat_StockIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745040638504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 13,510<span></span>
</td>
<td class="nump">$ 8,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,818<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,626<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">2,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">5,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,368<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050596792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Time-Based Option Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at January 1, 2021 (in shares) | shares</a></td>
<td class="nump">3,892,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(537,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled/forfeited (in shares) | shares</a></td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at March 31, 2021 (in shares) | shares</a></td>
<td class="nump">3,344,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, outstanding (in shares) | shares</a></td>
<td class="nump">3,344,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based payment award, options, exercisable (in shares) | shares</a></td>
<td class="nump">1,715,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 11.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share) | $ / shares</a></td>
<td class="nump">12.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options cancelled/forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share) | $ / shares</a></td>
<td class="nump">11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 10.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Option shares outstanding, weighted average remaining contractual life in years</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life in years</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable, weighted average remaining contractual life in years</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Option shares outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 117,946,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Option shares vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="nump">117,946,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Option shares vested and exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 62,231,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745052079272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares) | shares</a></td>
<td class="nump">186,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 33.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">1,839,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares) | shares</a></td>
<td class="nump">1,329,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares) | shares</a></td>
<td class="num">(45,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">2,937,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding, beginning balance, grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 34.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in USD per share) | $ / shares</a></td>
<td class="nump">49.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">35.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding, ending balance, grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 41.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares) | shares</a></td>
<td class="nump">313,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares) | shares</a></td>
<td class="num">(5,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">307,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding, beginning balance, grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in USD per share) | $ / shares</a></td>
<td class="nump">49.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">49.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding, ending balance, grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 49.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745047051656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details) - Employee stock purchase plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">40.40%<span></span>
</td>
<td class="nump">54.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in months)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050021880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (101)<span></span>
</td>
<td class="nump">$ 1,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745130683960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue and Performance Obligations - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage', window );">Percentage of revenue recognized was included in deferred revenue (in percentage)</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation amount</a></td>
<td class="nump">$ 79.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hcat_TechnologyAndProfessionalServicesMember', window );">Technology and professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DeferredRevenueArrangementForServiceContractTerm', window );">Service contract term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod', window );">Allowed termination period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination', window );">Notice required for termination</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Revenue Recognized, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Arrangement For Service Contract, Allowed Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Arrangement For Service Contract, Notice Required For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_DeferredRevenueArrangementForServiceContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Arrangement For Service Contract, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_DeferredRevenueArrangementForServiceContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hcat_TechnologyAndProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hcat_TechnologyAndProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745045699112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue and Performance Obligations - Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation (in percentage)</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745050339288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - Board member - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue recognized from related party</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Receivables from related party</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Deferred revenue with related party</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Acquisition-related consideration payable to related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745046844632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745128568408">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segments - Scheduled of Segment Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 55,846<span></span>
</td>
<td class="nump">$ 45,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=hcat_TechnologyMember', window );">Technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,839<span></span>
</td>
<td class="nump">24,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=hcat_ProfessionalServicesMember', window );">Professional Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,007<span></span>
</td>
<td class="nump">$ 20,417<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes amounts attributable to related party transactions. See Note 16 for further details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hcat_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hcat_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hcat_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hcat_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745048529832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Segment Adjusted Gross Profit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract', window );"><strong>Less Adjusted Gross Profit reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="num">$ (13,510)<span></span>
</td>
<td class="num">$ (8,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_LessOtherReconcilingItemsAbstract', window );"><strong>Less other reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="num">(15,651)<span></span>
</td>
<td class="num">(13,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(14,345)<span></span>
</td>
<td class="num">(13,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(15,015)<span></span>
</td>
<td class="num">(9,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(7,814)<span></span>
</td>
<td class="num">(2,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_InterestAndOtherExpenseNet', window );">Interest and other expense, net</a></td>
<td class="num">(3,952)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income taxes</a></td>
<td class="num">(28,269)<span></span>
</td>
<td class="num">(18,726)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Adjusted Gross Profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">30,317<span></span>
</td>
<td class="nump">22,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Adjusted Gross Profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">23,388<span></span>
</td>
<td class="nump">16,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Professional Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Adjusted Gross Profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">6,929<span></span>
</td>
<td class="nump">5,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment reconciling items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract', window );"><strong>Less Adjusted Gross Profit reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="num">(1,809)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_LessOtherReconcilingItemsAbstract', window );"><strong>Less other reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="num">(15,651)<span></span>
</td>
<td class="num">(13,487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(14,345)<span></span>
</td>
<td class="num">(13,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(15,015)<span></span>
</td>
<td class="num">(9,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(7,814)<span></span>
</td>
<td class="num">(2,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hcat_InterestAndOtherExpenseNet', window );">Interest and other expense, net</a></td>
<td class="num">$ (3,952)<span></span>
</td>
<td class="num">$ (621)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_InterestAndOtherExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest And Other Expense, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_InterestAndOtherExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_LessAdjustedGrossProfitreconcilingitemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Less Adjusted Gross Profit reconciling items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_LessAdjustedGrossProfitreconcilingitemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hcat_LessOtherReconcilingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Less Other Reconciling Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hcat_LessOtherReconcilingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hcat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hcat_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hcat_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hcat_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hcat_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139745046834056">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML?UJMSSGU0-7!Z^"MT 0+ZJ$UK;*;G=C&J.A2R]L1OLO:IV[?CYVWNWXO9K
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M#V38.!,Z UD?5$#-'_;F6"M7B*+&:N0,T1W+X* ;UX$:OG!CW^9W-/ (![,
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M*'Z!B(/GMCRM[7N5?57UOUXX9[.O%DAT#XF>".D8&+5-?QR&NX?A#L)8%LE
M6'Z-R@<\Q+'A<8\-B[?'XYV"YQ@,WK$Q\?<8_*?-EH5OA(7Z?A"&GFM'%NR1
M!4^0-(&!1O4O;HNEKJF!$<<I5@8/A1:F$ VZ(DM3),38<35+;RS+^=CQL ;K
M[3&PKDVA@-A#'>Y#'58ZM"?44'N@XQ.P]Q#?:O1<D9F5\/Y\Q[,,0<>TB\KD
MKX%Z-=\O/A\^!=]8&:>P.)1:H59$=;D5AYEH2[RYL=40^3#P>TX$=MIFP'D<
M(BNI.P:,N>/Z6BHU4H>;AK54LAOR>IPYZ&SPH#/5)DY58YL@8!CH]D6DG+'Z
M@@T(8> :0$>DND!;VL+#O'4CQ+8ZYA#UN.XXZN##U00))F56M6+UWX6$PJ!F
M,!0I)&B_3T>S&6[I# _SV2#4*(:#(JJ6IXMN+)^;13L)C1W?[SG<N*4]/,Q[
M3Q59DQ II43/EA&IKD\M=>)A[OP-+K2_<&$_DIZQY!0'[MS1JO*X7!=<RZEX
MF%3K_B[N]'=9'UB3/Z>4:B5_1*@+LR58/,RP_ZX?6F"3:VD0TI $?@^REH]P
M^*,[H\;B884ECHL)UBNQ*4=#/6=#L\)1@OU 3R!3;NJ3$!-C_TQ!.N\)4LN;
M>)@X3VG=>F)F4FA/[I.6/,DP>8ZU;78DQ.3'/B0M\Y%AYCL^O;$5DDES?9 .
MKF;#'#><UW88Y.C(M/Q%3KV/G9HYQ.0JEP;.G.@=\L(J20,_=,,>-UI>(\.\
M]LA4<\U" 4WC7._^+7*N=JZ7Q"0W[#C8/VC;ZDIA$9P&Q/,]C9.N+8)^3VM%
M6K(DWG_?WY.6#LDP'7YD0C45JK^ !)-E&JN'('4+LBU2.=KI$Y/^7(?.@[[
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M@A@#_?M."'7\8&YP>E?FYA]02P,$%     @ #I2F4LPQ8=I!)P  &84  !@
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M\3S"0:C1\\RII"!H<W!!P7L6GI,-@*!:<]+2LU0JZ0.DDH3CGDQ[)5K%H$@
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MJ@YM@Z0.-]BW09M2O@@TFVGK$:LF)C+VP4&9%<&=QT %V17LU 3)$A_TN?O
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M[.S-+R 4#@&#&)X-FG6\'5'N74*PHT8,W# Y>GA!OMRU4"G@2(##'JK2LU?
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MC/AII<2\>2/3WROM='B3:8<\<2H3<RHQ(:T2NDCS"H' '\)4%M7CD*5.F(5
M.=M:YL*:M? KI7E!J;A 1":]XI4=+3WQ?)XK\;V2N5]%XG61]L3?"O&=FML*
MI2R2$*@X$M<J[+-0?GO/:>?1F8B$%#F 1!=+X<S"7\/T<^G.Y;E3]DJG2I36
M7.E,63+G]TKFVF^$+#*8NZQRZ0U4KY5TE57 "2\HE)<D+:PIC?7TR1NQ8I4I
M^::1Z<(J[2[/YTI:6@@9.*YR$?E-DKC"R08]4E,5'J<"$ J)S=MPI-M B1Y'
MJN,ZO 6"9;73@\R%LN2?:XAYE/1[(Q1VGK.6(CR%Q!*680T.7@":4^E6>Y+P
MYE%_U$N:S5'M5_$2.)!OG"<I:RQT*QS; 5?P3HJ%1+BO9%XIEC#H#;8"2#V4
MD-/(G;OZ"/M@#[EBI=55\#A$=$(J*(GT0G/BI2$H,J]A#%&<DZ)BZ=B'2#RQ
M@>/A=<Z ;U6JUG.L&FR3B4TN( RNA*!;ML>-[9]SNW9H._/?D.*4#:FR'OV*
M&P:I3F6IR5#E4JIYF?T&B\EX%^26E4U7.'Y=1Z&N]KT=TI[$]>/X&V&N"^38
M2I>TMN,CE!)<F&5L)73V)[-H,$N:*%&%HF";T'F37G8MQQ)O=9V22ZO8Q<A7
M8]M7L"[(HF(D+'"NPC.<P56R8"GD>J_LFM7Y/<>U8CD=QG$4Q_&.<+:I0DC<
MC@+-/B_J;LNA.RHZN+6-)-8%Y^X>H"[C@YH14*M2LRST1[Q!R93&^?-N)?+J
M\Y"U5$\@$N&%NJ&_H?A*V=OP=P5]#!KDG]K.^E'MK-MV4LEV@F2*.K.Q(913
M92JLJ$%MO@F.*<M<IY(RPRNY!I!1]H=#+ZH\W[#>4'*T'E+/6:HL"AAJ'0'O
M@?BEN7%D+>$X[ ?T-9I;9Q0A^]HR/.KC^V8.E1N<[1@*@I^O#?NDQ:$1:B3-
M]6+1NA>-21M&O-:!G  H,'(2\-]"=>T7#M$*Z2<7>-@3[]6"M!CQH_%*]),
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M0*,\MA2P7<+'_&U>ZBL>S 6/AXPS59[A]%<T#</II2<:I++@D'V'\I) BGW
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MX7 V&3#MOP;ZCE5K]P5NH:Q5I6OF@L,L6H#YI<(%VG3H@.Z3[/F?4$L#!!0
M   (  Z4IE+G>:;]?P(  (D%   9    >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;*5436_;, S]*X310PL8M6,G:1HD 9)VPW88%K3[. P[R#8="Y4E3Y*;
M]M^/DATOP])<=K$DBGQ\I/RXV"O]9"I$"R^UD&895-8V\R@R>84U,]>J04DW
MI=(ULW34N\@T&EGA@VH1)7$\C6K&9;!:>-M6KQ:JM8)+W&HP;5TS_;I!H?;+
M8!0<# ]\5UEGB%:+ANWP$>W79JOI% TH!:]1&JXD:"R7P7HTWXR=OW?XQG%O
MCO;@*LF4>G*'C\4RB!TA%)A;A\!H><8[%,(!$8U?/68PI'2!Q_L#^GM?.]62
M,8-W2GSGA:V6P2R  DO6"ON@]A^PKV?B\'(EC/_"OO--TP#RUEA5]\'$H.:R
M6]E+WX>C@%G\1D#2!R2>=Y?(L[QGEJT66NU!.V]"<QM?JH\F<ERZ1WFTFFXY
MQ=G5.L]UBP4(SC(NN.5H%I$E8'<=Y3W(I@-)W@!)X9.2MC+P3A98_!T?$:&!
M57)@M4G. GYB^AK240A)G(S.X*5#E:G'2]_ V[)7E@DTP&0!OF0F#/Q89\9J
M^B]^GDDQ'E*,?8KQ_S7R+(A3X-PT+,=E0!(SJ)\Q.(4,:P.J!&I37@U]\L7=
M8XYUAOI@C4/Z\?^-SQ7)REBR$HRM$$HE2)]<[N"22[*HUA"<N9KWJ;JO3^-0
MX;*5K"TX(5S!@6"N:IH5AG5R(S(92BRY!7QQ=DI[ 3=AG(QIO0UGZ0P^4VI]
MDN DO$T2F(;3FP2^*,O$2:\+&"7A[7CJ-M-P,HKAU$M&1_*H4>_\$' ]:*7M
ME#)8ASFS[N3UQ[T;4M3Q'9<&!)84&E_?3 +0G?"[@U6-%UNF+$G7;RN:E:B=
M ]V72MG#P248IN_J-U!+ P04    "  .E*92DDK3H#@-  "E)P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6RU6EMSV[@5_BL8U^W8,UQ9%]MRKC-.
MTIU-I[N;V6RZ#YT^0"0D84,26@",HO[Z?N< !$E9DI.T?4E,$3@XU^]<P.=;
M8S^ZM5)>?*[*VKTX6WN_>7IUY?*UJJ0;F8VJ\69I;"4]'NWJRFVLD@5OJLJK
MZ7A\>U5)79^]?,Z_O;,OGYO&E[I6[ZQP355)NWNE2K-]<38Y:W_X1:_6GGZX
M>OE\(U?JO?(?-N\LGJX2E4)7JG;:U,*JY8NS^\G35]>TGA?\0ZNMZ_TM2)*%
M,1_IX6WQXFQ,#*E2Y9XH2/SW2;U694F$P,8?D>99.I(V]O]NJ7_/LD.6A73J
MM2E_TX5?OSB[.Q.%6LJF]+^8[0\JRG-#]')3.OY7;,/:Z?Q,Y(WSIHJ;P4&E
MZ_"__!SUT-MP-SZR81HW3)GO<!!S^49Z^?*Y-5MA:36HT1\L*N\&<[HFH[SW
M%F\U]OF7KTW]25FO%Z42[U6MC14_&:_<\RL/ZK3F*H^47@5*TR.49N)'4_NU
M$W^M"U4,]U^!J\3:M&7MU?0DP1^E'8G9)!/3\71R@MXLB3IC>K,C]-ZHA1=O
MM,M+XQJKQ#_O%\Y;N,6_3A"_3L2OF?CU_T"/WT9)''WQ<RWN-U:78G+-RAIG
M8JN$=JY1A3B?SL:C,5RG+"D*- )AM;)J);T2V%3G>B-+(2O3U%Z8I9B.;L9_
M/GY6T2@ZXD9<^+4*OUUF3)6H?6*JI<P5XM8+;\0?C2SU4H,173NO?4.QB ,7
MS4Y9)]1G56V\6%I3(<17F@S"T=K B:R@,]ZKO+'::QQ^G_ON7/'S<JD@P.IR
M)'[%;S40;&--KE3A D%:25J0=:Y(M,0QU /[RPV6?]:(;%7NH*<I1&_UE FY
M]&  GMP -^I5(%:##S"_:6R^!A18]Y<_W4TG\V>B@%N1!IV0=8&S F<0#^#I
M<.!&[B3I<K$3C0O\!DXD&%D9Z+J&BO!6DHD**(\\E&5]VSY>BH7R6Z6@' ?^
M7))/V8R/_3!Z/Q*O9/U1_"2CFN^=,[GFI[#% E*4VN? -,!I-G,&S3O2.-@Q
MBU*O>&\02^:Y;4@+T(QR/@GE5*5E7</2T".Y@D5Z@'%-\LL;WO]S[LT"2L4C
MK*%DOA8[+,P@UTK7-2D,6[I5K3-+#^^RY%K)/S=80'O[@FQA.D C:ZYW-%.Y
M(;E*Y>!QTI8:N_/@X:K(X'B%@L/B+[BY5:UUBT \Z5\4!J?4QM->+TG0>B>6
MNH9_D5=@,W(E^2\$R6%3O(!#,$WXM<Z#)L$:&0[*HQAQ)%.A/VD<4L"LP<V@
M?ZNBUY([+,!G#>Z9PZ%;]SFFY:X+%W8V6D%\XA5;N5DX76AIL6 D?E-0V(YE
M"DKHQ0C41X>9J$@R!!0Y&Q'<$$V.C^$[QATB&(AE D6#R*5;PX8E*P@H82P'
M>#\>V<3$G=D$3]7A92D=,49;X(Y.E@Q902VT/#=5!5)(DOE' 07 D1 =H%4J
MVCF9P5/B.<'<7$H$$OB1T5 A5@$KQ&G:.!TC4&1!=BSDSHF+[5IAO24)HOU)
MS51/,/CE95.T&-';*'0%K](!7U RY2JM*MB;:[%=:T3!EN0RY -$/@I(.JRB
M/HJ&X83L.!OWCQ\<!^?3IA!PI!!* 142>]G_B[\8H-UST+ B["<'FHP[.QQ*
M.9W/8?%"]>)Q4\*! ^P4+$Q3;Z0N.@CR!NC1> #M0,@>+R3)".2%T_5'$F_9
MD%)<*U'!ID\L] %E+:%@!N0 ^ST?:M%H-AW=SI_,A5L#1MU!OR2H.I]DX_'X
MH/#AJ(N@:+ %K2&-EC%]'CX]!<%>"D.FOQWS@<S/(7:0++\W)4IQ!BD (.%8
M;BQBC$12GQB3_)H",@>2=#! *F)TU7['6N5H9]"%5$!\I_8CC4ER9(FU*2FA
M;]=&<$7.MHX8+#0>@QZ8F;J.)?M6^S40"XK9XW D[HM"AQQ7[H#MFXBJS'."
M3KF_+PA&\<.E"&4_02E\.GY&;B$)D4G5:UFO%+^8/&-]#A)Q%J5Q0^<-P ?S
MV:"(UZ;:4,1"T!Y$MY!X#!%U6VEQ4*5MWQQ2CX702/QP3)C6/"VGD.4$KR0I
MVK6APU"MS:98-(@_RK_]#!_*U6NN'XF?E840%?HIO2E#-!T)'.3!&@[?%8G+
MSJ>US9O*><J.[FFP[NTS\:9#T)RBJY"6:E/K58@/N R_YZS&G.^O4M36$/M_
M:VH%& [5B;C@@H^XB2 =_'5O]^6WY;1OSDHI8[1)@;#J:.9PC^0,YKF?.**K
M',X?#S0'5$/'(8-F)5</G2.?RM'X@ZM$P%RI<ZXU>UP\VS<N.P*)EIRMEQ6#
M94/%]DD]ED.Y\JZ@=H0[MS+A]TORU #5_5P:N$7]42B4@]SK#!'CRY( 69OE
M/:#JA[R(+0[DDI:5^N2N!PB&NI;V\:L\CJQ_",5;4[!W'S3"VR7E@YS @A=U
M,O4KF:]#"GI!<ZBB*<'ZEY4N>[G_&;E;R^.'PWG";50>FM0'F;!0+K=Z<<"F
MPT)XKVNYIG[#HS0^+9J"FHNOEG O"[?)Z*LA^Y"=^_;1T!"IAH,D.A/LJ5;F
M =".@FH[:AU;7"$0_QQVW R<J)8X(^*7!=JJENV0+DE1:5]_3^H>VE$?E3@]
MW$3/7$-9 [PK.L3H -*OM?6[DR )&_THD9+37"I[-,1ZI4"<%KBAR!3'"0\)
M C[3# -T3F-C/UN?!DI42XX+=(?4FO6V48V8]R8]T2="%]:>T-JQZ(.L0YSW
M,R.]Z>?%21@8$'WHQH7@@IPAZF 9+1>Z#&UJ# 8*!1J6%&P 4VKR[D(L9,F-
M;AA12[;^T 3<QJ+"83 =%/.TW*F-9,]NC]PQ:U2GL:TK^"U%.E,I%.2I&,)#
M#6#MCM/HH+#J**7M[3@&@>KH$15\$[IW8 C[[Q+UB1,$ )25VWE1:B2&E?P$
MAJ=9,]<;= A$( /1)( L6SL9IPDDK].5+J4-"VO=-C$H[IA>KUWBT\C?V%%(
M2M/OPD-F"WX2$$^*I01D)'&.B<^EVNWM:)X&C5R2MV.*C/)"WI3,S3%5+1M.
ME31<H:DL!40:DB1ET,Z]D>;Q>6;4 ^+)N2XY'JZ6#TKUB:H7MN# $=(8ANW1
MVC*C0@<+$$S_#JI->H]SP$"0*P>XV3"$@V?0<YA($/JD_14*/1/G4>>WL]$L
M"5]HFC5R(FNG@T1C98USW3@TPF\1YJ*'9Z)DPCW%QEJ@<Z0O<P8 8;!M,/1^
MJ"7M]3"M'?P,.*+SR5G!O;%%=,C4]PEJ8[ZCAE%N-+JV:.R]P\@F8;P5*RCV
MO]*0+=%NAEF>KILP?*@(8UHPTEV$M50CEN4RI!G"'?0=>0BR5JNY<9Z8#MX>
M(^RPSN/+1Z"IYQM.<MUD8E)W:0S<#@E:1QT8*4XVW@XYE-ZCLFE\2!?[G'0:
MY&'Y^4TW'$_8OE Q)DZX_!?X]8FP^"*F']@\<#P=31YP7"M/1N'!PL&M _/H
MF*)C"FR'_7'35^2MB,@/E$.>O:I9=WO^$D?:DBT<NEMT?%R#FL9!''?Y%#2M
M4H-K-W'1U!*=&RA=TB5.0M('1Y^+278]FXO[8+U4;#&D[?DR:2]EK&EV-Q^+
M7PT-2L[%=38;S]/]RV'W.Y(POEC,8;H?B/@NH?FY 'AQ@_5WH/U3\:'N_'(
MT^+B9I;=S.>7!Q;NR7UQG=W</+D4/_5%BVD#^IM/LKO;ZT>$/^UA_XWD$=L[
M!&H[J7U8%1<#!5R"]]M9-IVWJMH+L8MI-KZ9'Y/Z=I)-)S/QJI^0J<'I^N"#
M93V2RS7*@SEM.51!Z^5WZ4;F 'BQHLXG*/8Z%(+55.A]0U_3:U8>%@*O4?&
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M:7.U_]K>:&^7V_\7 !&M-3)(JE;8&@YFDS-;*?@?5;'E^^W+HD(QPE\W2B+
MT@*\7Q5%Y7\0@N8_/+SY+U!+ P04    "  .E*92'O6,$=L&  "J$   &0
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MTK*3?P>&&"#[C?=\,&*!^6^T^PU02P,$%     @ #I2F4EDYW(Z+ P  [@<
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M'BUF$>CPNH2-5:V?Z+FR5#6_K.E!1NT,Z/M.*=MO7(#AB=_\"U!+ P04
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M;"]W;W)K<VAE971S+W-H965T,C0N>&ULG59;;]LV%/XKA%<,-J#&NO@BITF
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M#WXO-ML6'SSYZ>4^W9A;TW[<OV_@KR=^EKS8F<H6=94T9OWCH^NK[U\MG^$
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M1D +@)^1?$H#,C Q7_9X KS>-+P%2]2 'R6^E^:?0'KA<9)U4^^2"C0,()Z
M+T*IP@CZ"Y1%NH*)B++SCO9(2^S3HZ =KASF"./AC$;04DV"] /,$7?A!B$1
MMP !9 > 8S@@KPT_3==K4!L0%G=%W5D "S,)Q&^< K?26<'3L#2J&+SGXJNN
M6G9Y<E7;%.DJ,;RKFFFC1AI[$.T[$FRWC3')CJ4NDR+(S&SKA28! PERBLJ^
M\53VS22)O ^"  _K=SDBX[YZ,I)T#P&',!N6-2RX:-8_F[0$-G@#^E1YM"T!
MHX"?#ML:./Z\/E1XA=W*%GF1-H1<;U&HB(P%+;%$WBZHWJ2533/F#8&235F
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MA&L$7H*!56+. YDP)WEJ,[G8B3-$>8$#OS\(J)BJ]:>KQ5/<;NDBZO#@&_>
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M0J'\AW")_N$45H?2_:OI<OM?ZCI'=\X@,D\.Q792WUN0DN;'1WL1[(_\?"I
MN7&/Q%W*E:R4#+ R[<&(!RL$E>.@(;E&*!-X$%.#7S*J&28'D-2?D,S$JHJ
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M^R%I&3VTTEL?<PJ&CQ9P$S0.;'/8J%>:SSOT"G-O3][-'D[K.XKQHU!WU_N
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M@*DLL0"5E25B4'/#Z,0=Z-B2Y%JCT:_PNN3'@5&Z=,;9XSH'P)T!B8O\_+P
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MU,Z [@NE[)/B O3+?/D'4$L#!!0    (  Z4IE(S:;XKW0,  *()   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;+666X_B-A2 _\I1M \@>2>)DQ!
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MHRQ"],,:+U%<.P%\7REECQ/GX'0M6_T%4$L#!!0    (  Z4IE)"L^1+-P,
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M6+)6V(]J_P[[?,:.+U?"^"?L.]^,(N:ML:KNP32NN>S>[+&OPS/ +#X#2'I
MXG5W@;S*U\RR]5*K/6CG36S.\*EZ-(GCTFW*)ZMIE1/.KC>:]E?;)V"R@#<_
M6]Y0Q2U<W+.M0'.YC"P%<:Y1WA/>=H3)&<(4/BAI*P-O9('%[_B(Q T*DX/"
MV^1%P@],7T,Z"B&)D]$+?.F0<>KYTK]D',)&,$KU]\2_W6R-U716OK\0*AM"
M93Y4]B_%Q4.,4S5]D<==S(5I6(ZK@&Z>0?V P?J^0D!C.9U,+* U6+8"!"\1
M5 G(\@J8,72K<UK?*?T$W- ,E$K0130+N%-UTUK41V&07*7PA$P;>-MJR6VK
MT4LO^:.S#1R6_T.Z")42!?"ZT>H!'=Q-4T3MX@OG ,1>@])G9 X"C"KMGE&L
MY&K<![AC#;=,\/\)PR4Y22:N"'STS96AB$?%IVM-;M0_C M-JBR5K,N?RQU<
M<$DSJC6$,)<+N#'.IWNZL^8>,5RTDK4%)X;+4R5[!?-P/$GH/0O'T\FYRHSB
M<)Q.R">>S<\6-YR,,AB%TS3[Y_RS<!Q/")D1[9_UG&=3_^_9^ETYBD^G[G>O
MW%ISNG[)/*0R0)*$LVGB-WA!G31OZU;X#2V03F3.F6^Q%R[-;'[IC3@FX_2N
MA"#1E6XT"R?CU!E$/TGAU)6+GO6V&O7.=W!#Z;?2=FUNF!T^$C==;SRZ=U\8
MZB0[+@V5H21H?#T=!Z"[KMT-K&I\I]PJ2WW7FQ5]Z% [!UHOE;*'@0LP?#K7
MOP!02P,$%     @ #I2F4F<0Z(S  P  NPD  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&ULU5;;;MM&$/V5 1L4-L"(-]&D7$F +"=I@ 8P(CM]*/JP
M(D?BUB27V5U:4;^^LR1%W2P#?2G0!XD[LS-S9F;/7L8;(9]5AJCA1Y&7:F)E
M6E>WCJ.2# NF!J+"DF960A9,DRC7CJHDLK1Q*G+'=]T;IV"\M*;C1O<@IV-1
MZYR7^"!!U47!Y/8.<[&96)ZU4WSEZTP;A3,=5VR-"]1/U8,DR>FCI+S 4G%1
M@L35Q)IYMW=#8]\8?..X40=C,)4LA7@VPN=T8KDF(<PQT28"H\\+SC'/32!*
MXWL7T^HAC>/A>!?]8U,[U;)D"N<B_YVG.IM8L04IKEB=ZZ]B\RMV]80F7B)R
MU?S#IK6-1A8DM=*BZ)PI@X*7[9?]Z/IPX!"[%QS\SL%O\FZ!FBSOF6;3L10;
MD,::HIE!4VKC3<GQTBS*0DN:Y>2GIXM,2/U>HRS@<_F"2E/#M8*K1[;,45V/
M'4T@QM1)NH!W;4#_0L  OHA29PH^E"FFQ_X.)==GZ.\RO//?#/B%R0$$G@V^
MZWMOQ OZBH,F7G AWD&9-MSC4@,K4_CPO>9Z"PM,:LDU1P5_S)9*2V+-GV^
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MS4%@QVX$_S^NW6."Q9(:V]'-_8_H]BK%HI$=Q-$%AO639U9/"]#'[ J-B7_
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MQ(5AW[BL@.D%^R045YG@DGU1UID*O>\L.WG@<PGV]&+@4"+1#;*&^W7-/3[
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MP,/]'OVSSYURR9G!.R5^\-+6\V 20(D5:X5]4MLON,MGY/ *)8S_PK;S3=,
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MPMOAV&W&X6@0P[$_&!WT1X-Z[:> JT$K;=<JO;4?-(NNO_ZZ=U.**K[FTH#
MBD+CZYM1 +KK_.Y@U<9W6ZXL]:[?UC0L43L'NJ^4LON#(^C';_8'4$L#!!0
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MAKK5_13N-U:U?O*ME,4YZI<U?K@P[0SP_5HAJ=W&'3!\"BW_ E!+ P04
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M=D85K88!-BR,[-S0V$I#(\B)%<U\5%:!SG=2FM/"7C#^BUC_ U!+ P04
M"  .E*92"@7D_SP$  "K#P  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6REE]]OXC@0Q_\5"]W#KK1JXA!H65&DMO1^K.Y.55'O'D[W8)()6$WLK.U
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M43L#NL^5LON-(^C^,Y(_4$L#!!0    (  Z4IE)9Q:Y_. ,  "P.   9
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+U744_;,!#^*U:>-@E([!8*J*U$
M"VA((%54; _3'DQR:2T<.]C."M-^_&RG38H$#MM47JCMW'UW]UWRX1NNI'K0
M2P"#G@HN]"A:&E.>QK%.EU!0?2!+$/9)+E5!C=VJ1:Q+!33S3@6/29(<Q05E
M(AH/_=E,C8>R,IP)F"FDJZ*@ZGD"7*Y&$8XV![=LL33N(!X/2[J .9B[<J;L
M+FY0,E: T$P*I" ?16?X=$)ZSL%;?&6PTEMKY$JYE_+!;:ZR492XC(!#:AP$
MM3\_80J<.R2;Q^,:-&IB.L?M]0;]TA=OB[FG&J:2?V.968ZBXPAED-.*FUNY
M^@+K@@X=7BJY]G_1:FV;1"BMM)'%VMEF4#!1_]*G-1%;#A;G=0>R=B ^[SJ0
MS_*<&CH>*KE"REE;-+?PI7IOFQP3KBMSH^Q39OW,^!QTJECI&9(YFE3:&FB-
MJ,C0O.Z4.Y^SA6 Y2ZDPZ"Q-924,$PLTDYRE##3:1W/[OF05!V<]4_:M4>;9
MHUP\5JRT?33H3D-><73-<D"?SL%0QO7G86QL&2Z9.%VG/*E3)F^DW$,W4IBE
M1A<B@^RE?VS+;S@@&PXF) AX0]4!ZN$]1!*" WB]AM.>Q^N_@3>515D94 B:
MTG^C&R98414!^'X#W_?PO3?@-^SNH1EW_7A)\O=K:XZN#!3Z1R#881/L,%A+
M&ZQL@C5E[:&J;BFW+7VMD6%L@IZ!*AW(\JC)\N@?&*=/'8P/&OC![AD_;H(=
M[Y#Q,':OD_&3)LN3(-)EI00SE0*?7\Z>W#H$C)-6D9+=LXVW!!#OD.\.\&["
M,6D3)>][R;7,S8I:ZM^C*KA5+=S[ -Y;%</]7?(>!N^6%MPJ( [+U*N\=VH+
M;K4+'WT [ZV6X<$N>0^#'W;SWNH@#HO5E);,4,Y^08:8L T0E._;]-H^I%(;
M_;ZOH-4U?++[;I!6[$BRPVYT@'=_!:2521)6LK_H1N>W05K-(^0#NM%*( G?
MW/ZS&V'PP/^">.L"7X!:^#%%(W_/KN_RS6DS"IW5 T!K7L]1]C*[8$(C#KEU
M30X&5MQ4/9K4&R-+/P[<2V.'"[]<VG$.E#.PSW,IS6;C C0#XO@/4$L#!!0
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MFNI&.:$*\J"E2 58\I9LL%ZR1H+??:L<5X5XQ-F5M> L^60A;R2Y$SF0OV[
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M8V*\H.H-#8,?WRPS@,S' =0I<W]H^$ H?[B'&#Z@R<>KI?[0P/T$1ID# %F
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MT_4-]O-%69K[B_HW ON?J9S^#U!+ P04    "  .E*927:FLTLX"  !7!P
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M/D-=3]OBI9)K]TLVM6_@D;341A9U,#(HF*C^Z6NMPTY V#D2$-4!T7Y ZTA
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M)HS&!?!^KC5M)RY!W]:GOP%02P,$%     @ #I2F4OM05I:" @  4 8  !D
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MAC(879@.RBZ_NHD6M8N M= F4-RP-)&/TFXP[S="Z.W$"@Q_(NE?4$L#!!0
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MR;"\Y@7)]9T=%QE6^E3L;5D(@I,Z*&,V<IS SC#-K?6ROG8GUDM>*D9S<B>
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MV'+BO,-7,^);A\KB*V=KO3-&-I4[*7_8R8?%Q/$L(B98:FP("H\'-F-"V$B
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M*6L WY=2FNW$=B=--SK]#U!+ P04    "  .E*9242E(P8H"  "$!@  &0
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M#5CLX37OD?0QBUGKFIIBV)H"LSV<V?,LWV1YJ"199'@!YP%FO6"T[ & >CA
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MY_3Q-]T,2)3M+=(HK_XGCXVL,R&+35ZD<:-L+(C#I/ZKOC<3T5(P[=@5:*-
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M?>Y)R[V 1=)U T'[;P8X,)\?PWRLBL&!^7RDS.? ?/XSF,^[(._X"A/9/?\
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MI^:HR.[3.@!J.0#4+W$7%L(DH%B.](Q2 K/E,6>4TG+R:-]K%DE\KTE@MAS
M[)<X#XMF$J@L1WJ**8'E\IA33+F_DH**[!H%])9#G\A[[JZAYYFR]1C>2,\S
M)2!;'G.>*0>?9UHD\?-,"<B60Y\-03TV*);YP&1_I">=/O#;/^*D\]+O%CN>
M.PT5V34*B.T?5@?I\Q86RGR L#_2:H@/P/:/J8;XW1I'STZS2.([S0=@^X=5
M0_I\AT4R'XCLC[02X@/(_6,J(8VRA^VT;@FDSUNM!ZX/JWV\_/D/'UCLC[3J
M$0"X@R.J'K.@6]) G_\(@,;!886-'G<,"E<!8#<8:7$C $8'1Q0W9L'@RD4
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M?=_%YW0CU9.N 0QY:42K)UYMS.K&]W510\/TI5Q!BR>55 TS&*JEKU<*6.E
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MLPM;1C<W2Q.0JOQPSA794??+PE[&J%V"W5\H.S1MX.:]N]Y'?P%02P,$%
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M/ODP5MTI<&V@UA=,U5@YT?U/U>^._@-02P,$%     @ #I2F4L!&(_GO @
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M94&O(VKG0-_72MG]QAW0OK?3/U!+ P04    "  .E*92!T/K:X,$   W%
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M!1J#* +T]37GZM@I;E ?!D[_ 5!+ P04    "  .E*92=\UQW#0$  "3$
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MA.TZ^&J1@%888;LR=LCPFS*Y0*II+#6-G:;Q$G6I2!W)2]"'33EGQ16&W;9
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M:X)3PO4 ]7[)F'SNZ GJDZ/Q?U!+ P04    "  .E*92KDW7B=X"  #E!P
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M5SO6LJ0:II+_8)DIQMX7CV20TXJ;1[G]!DT]-Y8OE5R[)]G6L4,,3BMM9-F
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MCM8GZ)BUP;W1U':+UWK%A"8<<J0,^I^Q.ZJVL'IBY-JYP%(:]!0W+-#U0=D
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MZ6RF]I8S"2M-S%X(JG\M@*MF'L3!Z6#-=I5U!V$VJ^D.-F"_U2N-5MBA%$R
M-$Q)HJ&<!W?Q=)&Z>!_PG4%C>GOBE&R5>G'&0S$/(D<(..36(5!<7N$>.'=
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M\7S^CDK&592EX6QGLE1W3G %.T-L)R4SO[<@=+^.%M'I8,_KQOD#FJ4MJ^$
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MO(%4BI0A(B=7!DKR_2."W5+_Z'&=M*X3YSHYX[KQT\'!93_P>_BCJY U:.1
MMI7L%\/A)!G-_/TQO4^UDF$8/F@]2F78IC+LC>@+I(607.9W/;R,6F.C_UV2
M<>MZ_,R2+&O@\(BW.)[$TQ-VGVI%R6@Z[69WTD8UZ8WJ6LDM:-O%*<>?7NU9
M"KHGVVEK=_J_B0Z#AYX6/)?J!GG\C48X(\<G7'>I!4DX[B8[M-WVL21ZB#5Z
MQ@]W^1?4E4AYE8$FM)25;=_4&,4VE:$;#L1(',F<&FSE.ZK,'3&*"DW=I-4#
M+#.0S]( "4<$;PYD6RE3@,)QZ5K\H*L&_M&(*4'E;E1KDEKO=5MJI>UUX-(-
MP1/YTEX3.N1OP_!B&7:=(!=XXFSY#Z[K>PFV[)P)33AL,8Q@8 >YJD=]O3%R
MYX;?1AH<I6Y9X/4(E%7 \ZU$(IJ-==!>N!9_ %!+ P04    "  .E*92 ,GH
MY98$  #Y$@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6R]6&MOVS84
M_2N$T0\MT$0B]0X< WEL78&U#>)V^\Q(UY862?1(.DZ'_?B1DB+9,L4T0[8O
MMA[W7IY[1!X=<;YC_%[D !(]5F4MSF>YE)LSQQ%I#A45IVP#M;JS8KRB4IWR
MM2,V'&C6)%6E0UPW="I:U+/%O+EVPQ=SMI5E4<,-1V);591_OX22[<YG>/9T
MX;98YU)?<!;S#5W#$N2WS0U79TY?)2LJJ$7!:L1A=3Z[P&=7)-$)3<1O!>S$
MWC'2K=PQ=J]//F;G,U<C@A)2J4M0]?< 5U"6NI+"\6=7=-:/J1/WCY^J_]PT
MKYJYHP*N6/E[D<G\?!;/4 8KNBWE+=O] EU#@:Z7LE(TOVC7Q;HSE&Z%9%67
MK!!41=W^T\>.B+T$5<><0+H$,D[P)Q*\+L%K&FV1-6U=4TD7<\YVB.MH54T?
M--PTV:J;HM:/<2FYNENH/+E8PEH]%"G0"5JJ*9)M2T!LA;K+Z"+[0V& #'W@
M3 ATP]FJD.CM-4A:E.*=ROJVO$9OW[Q#;U!1HZ\YVPI:9V+N2 5.#^&D'9#+
M%@B9 .*A3ZR6N4 _U1EDA_F.:JKOC#QU=DFL!3]1?HH\_!X1EV #GJL?3W<M
M<+R>:*^IYTW4^Q44?V8Z.:2L3@N5L4:%A$J<6<;S^_'\9CQ_ZL%*EMZ?Z!F>
MH915:MD+JA>.Z<FTE<*FDE[W#XL3[ 58M?VP3Y@A+(Y\W$<=X QZG,'SO#"9
M W\9#V%?/[3S0$L02,U)M6KX/4A5W$1!6R0XH" ( SRBP!3F^7%DYB#J,496
MC+<@@/(T;V!F\*#$=:.7GPEH9$#@>WXP FH*\]PX-@.->Z"Q%>@'J('3LL%)
M,R5'A9"<:B$V08U-G+IX#-40ED3NQ+1*>J2)%>DUJ+=:6M#V7:'A5HS+XJ_)
M-9 <HXAB[(^P&J)('$T\?NP.(NQ:T7ZL)7 0LD':+@9XU$L6WJ,:C/.@JW@
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MN_AX18D=[O#@H&GC>18&_:6*9N.?/=B0X/=WQN#!"3=K^I'D?P!02P,$%
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M0B^C\S&1@U)F!_648?SLV,=$#DJ9'00QNS<=.2CEWM<Y5#%Z,R&ER$$ILX,
MYL?YW)^04N2@]%CU-[KU=,K'A ^4_8XG _HQ;RFI\S&1A5)F"Z%H4O<^)K)0
MRFPA?T>^-^-(D7Q2]B(<V/;NS$,9DD_&7H1#F'[*GB'Y9,SR>;4[WWN[,Z2=
MC/NALWUI_;]*,1FR3O:;GB;PE%@TBXM=NX^)K)-Q6^<MID?IYY<9LD[&;)VO
M.J=W7C0_<J P7M6R:HB7U'@2CMIG;EXPD76RUCK#]F)W?E;(N=*RN*:W<-2>
MBS*_L4'SIWT&*HR3YCFH^;HL+ZGM'_W%B&+_0X?]CS3.?P)02P,$%     @
M#I2F4G-\>"Q1 @  ^RP  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<\W:2VZC0!2%X:U8+""X[JN25IQ13S*-L@'DE!^*;1#02K+[MIR!?5 />A)Q
M1JA 7/X)GQ#P^%(.S;AO3\-NWPV+S^/A-*RJW3AVO^IZ6._*L1GNVJZ<SD<V
M;7]LQO.RW]9=LWYOMJ66Y3+J_G9&]?1X.W/Q^M65_YG8;C;[=?G=KO\<RVG\
MQ^#ZH^W?AUTI8[5X;?IM&5=5_7FX[A[JRR;=G2=7B^>W5=4_OZ6JGCM(($CF
M#U((TOF##()L_B"'()\_*" HY@_*$)3G#[J'H/OY@QX@Z&'^H+1$&9<$21.L
M";1.R'4B\#HAV(E [(1D)P*S$Z*="-1.R'8B<#LAW(E [H1T)P*[$^*="/06
MU%L(]!;46PCTELG#-H'>@GH+@=Z">@N!WH)Z"X'>@GH+@=Z">@N!WH)Z"X'>
M@GH+@=Z*>BN!WHIZ*X'>BGHK@=XZ>5E"H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@
MMZ+>2J"WHMY*H+>AWD:@MZ'>1J"WH=Y&H+>AWD:@MTU>=A/H;:BW$>AMJ+<1
MZ&VHMQ'H;:BW$>AMJ+<1Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMDX^5
M!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>@?J'01Z!^H=!'H'ZAT$>@?J'01Z!^H=
M!'H'ZAT$>L?D9Q,"O0/U#@*] _4. KT#]0X"O3/JG0GTSJAW)M [H]Z90.^,
M>F<"O3/JG0GTSJAW)M [H][Y)_4>QJ]#&:X]WVN\_D]2/9[/+=?+7Y;?.R?W
M^ 7G^K9B>/H+4$L#!!0    (  Z4IE+.%<Q?#P(  .HK   3    6T-O;G1E
M;G1?5'EP97-=+GAM;,W:S6[B,!0%X%=!V5;$^#?3$;"9F6V'15_ 32XE(HDM
MVVWA[<<);:56'305(_5LB,#V/3>^TK=B>7OT%&>'OAOBJMBEY+\S%NL=]3:6
MSM.05[8N]#;EK^&>>5OO[3TQL5@85KLAT9#F::Q1K)<_:6L?NC3[=<@_Q]8-
MJR)0%XO9C]/&,6M56.^[MK8IK[/'H7F7,G].*//):4_<M3Y>Y0T%^S!A7/E[
MP/.YWX\40MO0;&-#NK%]WL4.'8OIV%$LSY?XH$>WW;8U-:Y^Z/.1,OI MHD[
MHM1WY:GHU?GDE&^83I_\XORIS+G O',3G(]Y8H$^'_<RDO'TW.="%%)[_A5?
M$W/IB]^/QFDWU/QC=K[>)Q?VTSPBFQZ7W_';&;_6_V0? J0/"=*' NE#@_1A
M0/JH0/KX!M+'-4@??('2"(JH'(54CF(J1T&5HZC*45CE**YR%%@YBJP"15:!
M(JM D56@R"I09!4HL@H4606*K )%5H$BJT215:+(*E%DE2BR2A19)8JL$D56
MB2*K1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56AR*I09%4HLFH4636*K!I%
M5HTBJT:15:/(JE%DU2BR:A19-8JL!D56@R*K09'5H,AJ4&0U*+(:%%D-BJP&
M15:#(FN%(FN%(FN%(FN%(FN%(FN%(FOUE;+>.;?_S_'3L^QM.[SDL^DOONL_
M4$L! A0#%     @ #I2F4@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  .E*921$!XL^X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  .E*92F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    (  Z4IE): '.=1@4  'H5   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  .E*92X*"Z3%H'  #M'@  &               @(&)#0  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ #I2F4AIL11_; @  OPD  !@
M             ("!&14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    (  Z4IE(<GB=DLP4  (@7   8              " @2H8  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  .E*92 567RN<"  "_
M!P  &               @($3'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ #I2F4B3DW=!'!@  \AX  !@              ("!,"$
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  Z4IE*GJ*7N
M*P@  #<C   8              " @:TG  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    "  .E*92S#%AVD$G   9A0  &
M@($.,   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #I2F
M4M&F+-;O"P  XR<  !@              ("!A5<  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    (  Z4IE*MB9E:? ,  )\'   9
M      " @:IC  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ #I2F4C+]$ !+!   -@H  !D              ("!76<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  .E*92VPR\D84#  "R"
M&0              @('?:P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    (  Z4IE+Z&*BBX 4   <0   9              " @9MO  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ #I2F4GM."N)F
M!P  GA4  !D              ("!LG4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    "  .E*92YWFF_7\"  ")!0  &0
M@(%/?0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  Z4
MIE*22M.@. T  *4G   9              " @06   !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ #I2F4NXYQW8R!   Z@D  !D
M         ("!=(T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    "  .E*92%,UXVQP%   -#0  &0              @('=D0  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  Z4IE(ALF19U \  /PP
M   9              " @3"7  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ #I2F4A[UC!';!@  JA   !D              ("!.Z<
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  .E*92[7(;
MD>T"  "9!@  &0              @(%-K@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    (  Z4IE)9.=R.BP,  .X'   9
M  " @7&Q  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M#I2F4ND[*A3J P  >PD  !D              ("!,[4  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    "  .E*92-GC9YSP%  #*"P  &0
M            @(%4N0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    (  Z4IE+[>SAM*"D  '".   9              " @<>^  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ #I2F4M!A0KE0!0
M,0X  !D              ("!)N@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    "  .E*92RDB_+K<$  !9#@  &0              @(&M
M[0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  Z4IE(8
M'W]8S@(  -@%   9              " @9OR  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ #I2F4C-IOBO= P  H@D  !D
M     ("!H/4  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z4IE(TJ]Q?*@,  #P'   9              "
M@6@) 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ #I2F
M4L*(!_'U P  %@D  !D              ("!R0P! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    "  .E*92O@:Y$A$&  "S$   &0
M        @('U$ $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   (  Z4IE)6=4)OLP,  %$(   9              " @3T7 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ #I2F4@H%Y/\\!   JP\
M !D              ("!)QL! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    "  .E*92+WL!:J("   _!@  &0              @(&:'P$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  Z4IE)9Q:Y_
M. ,  "P.   9              " @7,B 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ #I2F4O/-7I5? P  "P\  !D
M ("!XB4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  .
ME*92KGQ4Y&X'  "D,0  &0              @(%X*0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  Z4IE)]]$RW: 8  +(B   9
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M970T-RYX;6Q02P$"% ,4    "  .E*92CT+G?FT"   )!P  &0
M    @('$0P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M  Z4IE).6?LCV ,  %$0   9              " @6A& 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ #I2F4NG3*\F+ P  F0X  !D
M             ("!=TH! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    "  .E*9242E(P8H"  "$!@  &0              @($Y3@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  Z4IE)#GEBD: 8
M &@H   9              " @?I0 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ #I2F4H[]JC(H"   13L  !D              ("!
MF5<! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  .E*92
MR?C\?_,"  "&"@  &0              @('X7P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    (  Z4IE+BIYE@T@(  ,D&   9
M      " @2)C 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ #I2F4@0.R&95 @  R@4  !D              ("!*V8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  .E*921O^X6]4%  #_&
M&0              @(&W: $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    (  Z4IE(K:/@5RP(  *8'   9              " @<-N 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ #I2F4L%WF_A_
M @  N 4  !D              ("!Q7$! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    "  .E*92>-E,ZY("  #J!0  &0
M@(%[= $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (  Z4
MIE*ZXO)3$0,  /L*   9              " @41W 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ #I2F4L!&(_GO @  >P<  !D
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M=#8V+GAM;%!+ 0(4 Q0    (  Z4IE(7HK$P^P,  $42   9
M  " @5>3 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
M#I2F4JY-UXG> @  Y0<  !D              ("!B9<! 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    "  .E*92,4K7"GH"  !3!@  &0
M            @(&>F@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    (  Z4IE)W)F-.(0,  ,8(   9              " @4^= 0!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ #I2F4@HJ^H\X @
M;04  !D              ("!IZ ! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    "  .E*92>OUD(]L"  !I"   &0              @($6
MHP$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (  Z4IE+'
MGC!K$@(  - $   9              " @2BF 0!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ #I2F4G<8V34A P  ? D  !D
M     ("!<:@! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
M"  .E*92 ,GHY98$  #Y$@  &0              @(')JP$ >&PO=V]R:W-H
M965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (  Z4IE+:7/B]X0$  %0$   9
M              " @9:P 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L!
M A0#%     @ #I2F4JTE03(Y P  ^!,   T              ( !KK(! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  .E*92EXJ[',     3 @  "P
M        @ $2M@$ 7W)E;',O+G)E;'-02P$"% ,4    "  .E*92G<#,,8@%
M   H,@  #P              @ '[M@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ #I2F4G-\>"Q1 @  ^RP  !H              ( !L+P! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #I2F4LX5S%\/ @
MZBL  !,              ( !.;\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     %0 5  #%P  ><$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>279</ContextCount>
  <ElementCount>425</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108102 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/ShorttermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134108 - Disclosure - Accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/Accruedliabilities</Role>
      <ShortName>Accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.healthcatalyst.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143110 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2145111 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2156113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Deferred Revenue and Performance Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations</Role>
      <ShortName>Deferred Revenue and Performance Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2162116 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2164117 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/BusinessCombinations</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/Revenue</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/PropertyandEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/ShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/ShorttermInvestments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2335308 - Disclosure - Accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/AccruedliabilitiesTables</Role>
      <ShortName>Accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/Accruedliabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2338309 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2346310 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/NetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2350311 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2365312 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/Segments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Business Combinations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Business Combinations - Unaudited Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails</Role>
      <ShortName>Business Combinations - Unaudited Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails</Role>
      <ShortName>Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails</Role>
      <ShortName>Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/ShorttermInvestmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Fair Value of Financial Instruments - Contingent Consideration Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Contingent Consideration Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/AccruedliabilitiesDetails</Role>
      <ShortName>Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/AccruedliabilitiesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Convertible Senior Notes - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails</Role>
      <ShortName>Convertible Senior Notes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails</Role>
      <ShortName>Convertible Senior Notes - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Convertible Senior Notes - Net Carrying Value Of the Liability (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails</Role>
      <ShortName>Convertible Senior Notes - Net Carrying Value Of the Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Convertible Senior Notes - Net Carrying Value Of the Equity (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails</Role>
      <ShortName>Convertible Senior Notes - Net Carrying Value Of the Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stockholders??? Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails</Role>
      <ShortName>Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/IncomeTaxes</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2460433 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails</Role>
      <ShortName>Deferred Revenue and Performance Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2461434 - Disclosure - Deferred Revenue and Performance Obligations - Remaining Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails</Role>
      <ShortName>Deferred Revenue and Performance Obligations - Remaining Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2463435 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.healthcatalyst.com/role/RelatedParties</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2466436 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2467437 - Disclosure - Segments - Scheduled of Segment Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails</Role>
      <ShortName>Segments - Scheduled of Segment Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Segments - Schedule of Segment Adjusted Gross Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails</Role>
      <ShortName>Segments - Schedule of Segment Adjusted Gross Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="hcat-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - hcat-20210331.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - hcat-20210331.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="hcat-20210331.htm">hcat-20210331.htm</File>
    <File>exhibit311-q12021xcertific.htm</File>
    <File>exhibit312-q12021xcertific.htm</File>
    <File>exhibit321-q12021xcertific.htm</File>
    <File>hcat-20210331.xsd</File>
    <File>hcat-20210331_cal.xml</File>
    <File>hcat-20210331_def.xml</File>
    <File>hcat-20210331_lab.xml</File>
    <File>hcat-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "hcat-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 279,
   "dts": {
    "calculationLink": {
     "local": [
      "hcat-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hcat-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "hcat-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hcat-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hcat-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "hcat-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 580,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 9
   },
   "keyCustom": 35,
   "keyStandard": 390,
   "memberCustom": 23,
   "memberStandard": 49,
   "nsprefix": "hcat",
   "nsuri": "http://www.healthcatalyst.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.healthcatalyst.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Revenue",
     "role": "http://www.healthcatalyst.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - Property and Equipment",
     "role": "http://www.healthcatalyst.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Short-term Investments",
     "role": "http://www.healthcatalyst.com/role/ShorttermInvestments",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134108 - Disclosure - Accrued liabilities",
     "role": "http://www.healthcatalyst.com/role/Accruedliabilities",
     "shortName": "Accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Convertible Senior Notes",
     "role": "http://www.healthcatalyst.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143110 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://www.healthcatalyst.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145111 - Disclosure - Net Loss Per Share",
     "role": "http://www.healthcatalyst.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.healthcatalyst.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156113 - Disclosure - Income Taxes",
     "role": "http://www.healthcatalyst.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.healthcatalyst.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Deferred Revenue and Performance Obligations",
     "role": "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations",
     "shortName": "Deferred Revenue and Performance Obligations",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162116 - Disclosure - Related Parties",
     "role": "http://www.healthcatalyst.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164117 - Disclosure - Segments",
     "role": "http://www.healthcatalyst.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.healthcatalyst.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Revenue (Tables)",
     "role": "http://www.healthcatalyst.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.healthcatalyst.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Short-term Investments (Tables)",
     "role": "http://www.healthcatalyst.com/role/ShorttermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335308 - Disclosure - Accrued liabilities (Tables)",
     "role": "http://www.healthcatalyst.com/role/AccruedliabilitiesTables",
     "shortName": "Accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338309 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346310 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.healthcatalyst.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350311 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.healthcatalyst.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365312 - Disclosure - Segments (Tables)",
     "role": "http://www.healthcatalyst.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "lang": "en-US",
      "name": "hcat:RevenueFromSubscriptionContractTermofContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)",
     "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i0b1145c0be2f4abd984b071985b91ff7_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)",
     "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i0b1145c0be2f4abd984b071985b91ff7_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i1c6b011b06cd4b56805334a4b840ea06_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)",
     "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i23793db4aa3a4118a87890e37cc5f76a_D20210101-20210331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Business Combinations - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
     "shortName": "Business Combinations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "ibc9f01dcb1f34ba081cdd1f89c30dbe7_D20200221-20200221",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "ie3b7cc7ef9a64f1b8a237c7f744187d7_I20200221",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i563042bec9ce44faad7f33151e649064_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Business Combinations - Unaudited Pro Forma Financial Information (Details)",
     "role": "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails",
     "shortName": "Business Combinations - Unaudited Pro Forma Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i563042bec9ce44faad7f33151e649064_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details)",
     "role": "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails",
     "shortName": "Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i04a82e47b69b4d3eb01ecc169fcbbdff_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i2b5ac1f2270243679239715132a65f39_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Revenue - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i2b5ac1f2270243679239715132a65f39_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details)",
     "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "id3c750b2d03c4e43bd847dd5399458fa_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)",
     "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)",
     "role": "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Components of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Short-term Investments (Details)",
     "role": "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails",
     "shortName": "Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "if709f4c82b2c40929782386201a2329e_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "hcat:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "hcat:FairValueMeasurementAggregateIntrinsicValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Fair Value of Financial Instruments - Contingent Consideration Liabilities (Details)",
     "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
     "shortName": "Fair Value of Financial Instruments - Contingent Consideration Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i86af83c7eb5046eda62a9143eb75002f_I20210331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i530512a1ce4642378115de9c7b137ee4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details)",
     "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails",
     "shortName": "Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i530512a1ce4642378115de9c7b137ee4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Accrued liabilities (Details)",
     "role": "http://www.healthcatalyst.com/role/AccruedliabilitiesDetails",
     "shortName": "Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i0e584e43e4fa4dfe91200285e31ccff9_I20200414",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Convertible Senior Notes - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
     "shortName": "Convertible Senior Notes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "id441c0a6737547208b92c291c8d51e05_D20200409-20200409",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeCostOfHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Convertible Senior Notes - Interest Expense (Details)",
     "role": "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
     "shortName": "Convertible Senior Notes - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "ibaad3de365a845369ab8d51789f54b13_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i59fcfef1efb441dea240055b2986ee9d_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Convertible Senior Notes - Net Carrying Value Of the Liability (Details)",
     "role": "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
     "shortName": "Convertible Senior Notes - Net Carrying Value Of the Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i59fcfef1efb441dea240055b2986ee9d_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i384152dcce9849d1bba93e9d52950c6b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i384152dcce9849d1bba93e9d52950c6b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i59fcfef1efb441dea240055b2986ee9d_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "hcat:DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Convertible Senior Notes - Net Carrying Value Of the Equity (Details)",
     "role": "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
     "shortName": "Convertible Senior Notes - Net Carrying Value Of the Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i59fcfef1efb441dea240055b2986ee9d_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "hcat:DebtIssuanceCostsGrossEquityComponent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stockholders\u2019 Equity - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders\u2019 Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i7a1863db2fdb471eb95b9d4e35b94e91_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails",
     "shortName": "Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details)",
     "role": "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
     "shortName": "Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details)",
     "role": "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
     "shortName": "Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i83724b12cbb24c4a98f79788141daf04_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i5d85d0eb3d6a4f159e0a1cfcee127595_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details)",
     "role": "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i4ad9b09a12ab4c2bb88a6ced24732527_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Income Taxes (Details)",
     "role": "http://www.healthcatalyst.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "hcat:IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460433 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
     "shortName": "Deferred Revenue and Performance Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i0653e44dccde41d79e0c4dcca4805fd7_I20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461434 - Disclosure - Deferred Revenue and Performance Obligations - Remaining Performance Obligation (Details)",
     "role": "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails",
     "shortName": "Deferred Revenue and Performance Obligations - Remaining Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i0653e44dccde41d79e0c4dcca4805fd7_I20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i3448fe61af4c4aacaf336c73188b521b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463435 - Disclosure - Related Parties (Details)",
     "role": "http://www.healthcatalyst.com/role/RelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i3448fe61af4c4aacaf336c73188b521b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466436 - Disclosure - Segments - Narrative (Details)",
     "role": "http://www.healthcatalyst.com/role/SegmentsNarrativeDetails",
     "shortName": "Segments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467437 - Disclosure - Segments - Scheduled of Segment Revenue (Details)",
     "role": "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
     "shortName": "Segments - Scheduled of Segment Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i72c95150cded4d7da0ed5115a50de8ca_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Segments - Schedule of Segment Adjusted Gross Profit (Details)",
     "role": "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails",
     "shortName": "Segments - Schedule of Segment Adjusted Gross Profit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "ic35f3002cf13457c85971a5a2c22d04e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108102 - Disclosure - Business Combinations",
     "role": "http://www.healthcatalyst.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hcat-20210331.htm",
      "contextRef": "i6c905158f36e4672846a0ec33ac1f532_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - hcat-20210331.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - hcat-20210331.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 83,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "hcat_AbleHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Able Health Inc",
        "label": "Able Health Inc [Member]",
        "terseLabel": "Able Health Inc"
       }
      }
     },
     "localname": "AbleHealthIncMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/AccruedliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities And Employee-Related Liabilities, Current",
        "label": "Accrued Liabilities And Employee-Related Liabilities, Current",
        "totalLabel": "Total accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/AccruedliabilitiesDetails",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_AcquisitionRelatedFairValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Related Fair Value Adjustments",
        "label": "Acquisition Related Fair Value Adjustments [Member]",
        "terseLabel": "Acquisition Related Fair Value Adjustments"
       }
      }
     },
     "localname": "AcquisitionRelatedFairValueAdjustmentsMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_AssetsHeldUnderFinanceLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Held Under Finance Leases [Member]",
        "label": "Assets Held Under Finance Leases [Member]",
        "terseLabel": "Capital lease equipment"
       }
      }
     },
     "localname": "AssetsHeldUnderFinanceLeasesMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares",
        "label": "Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares",
        "terseLabel": "Number of restricted shares issued (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Stock-based Compensation Shares Issuable, Vesting Period",
        "label": "Business Acquisition, Stock-based Compensation Shares Issuable, Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "BusinessAcquisitionStockBasedCompensationSharesIssuableVestingPeriod",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_BusinessCombinationConsiderationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Payable, Current",
        "label": "Business Combination, Consideration Payable, Current",
        "terseLabel": "Acquisition-related consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationPayableCurrent",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Contingent Consideration, Liability",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Contingent Consideration, Liability",
        "terseLabel": "Shares issuable, contingent consideration (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationLiability",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Cash",
        "label": "Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Cash",
        "terseLabel": "Contingent consideration paid in a combination cash"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInCash",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hcat_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Shares",
        "label": "Business Combination Consideration Transferred Equity Interests Issued And Issuable Contingent Consideration Percent Paid In Shares",
        "terseLabel": "Contingent consideration paid in a combination shares"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableContingentConsiderationPercentPaidInShares",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Other",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Other",
        "terseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOther",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_CapitalizedOfInternalUseSoftware": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Of Internal Use Software",
        "label": "Capitalized Of Internal Use Software",
        "negatedTerseLabel": "Capitalization of internal-use software"
       }
      }
     },
     "localname": "CapitalizedOfInternalUseSoftware",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_CappedCallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Call",
        "label": "Capped Call [Member]",
        "terseLabel": "Capped Call"
       }
      }
     },
     "localname": "CappedCallMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_CommissionPaymentEstimatedBenefitPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission Payment, Estimated Benefit Period",
        "label": "Commission Payment, Estimated Benefit Period",
        "terseLabel": "Estimated period of benefit"
       }
      }
     },
     "localname": "CommissionPaymentEstimatedBenefitPeriod",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Shares issuable as acquisition-related contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_ContractBacklogsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Backlogs",
        "label": "Contract Backlogs [Member]",
        "terseLabel": "Contract Backlogs"
       }
      }
     },
     "localname": "ContractBacklogsMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Revenue Recognized, Percentage",
        "label": "Contract With Customer, Liability, Revenue Recognized, Percentage",
        "terseLabel": "Percentage of revenue recognized was included in deferred revenue (in percentage)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedPercentage",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hcat_ConvertibleDebtLiabilityComponentFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt Liability Component Fair Value Disclosure",
        "label": "Convertible Debt Liability Component Fair Value Disclosure",
        "terseLabel": "Convertible debt liability component fair value disclosure"
       }
      }
     },
     "localname": "ConvertibleDebtLiabilityComponentFairValueDisclosure",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_CustomerRelationshipsAndContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Relationships And Contracts [Member]",
        "label": "Customer Relationships And Contracts [Member]",
        "terseLabel": "Customer relationships and contracts",
        "verboseLabel": "Customer relationships and contracts"
       }
      }
     },
     "localname": "CustomerRelationshipsAndContractsMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Carrying Amount Of Equity Component Gross",
        "label": "Debt Instrument Convertible Carrying Amount Of Equity Component Gross",
        "terseLabel": "Proceeds allocated to the conversion option (debt discount)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfEquityComponentGross",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Sale Price Of Stock Threshold",
        "label": "Debt Instrument Convertible Sale Price Of Stock Threshold [Member]",
        "terseLabel": "Debt Instrument Convertible Sale Price Of Stock Threshold"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleSalePriceOfStockThresholdMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_DebtInstrumentConvertibleThresholdTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Threshold Type",
        "label": "Debt Instrument Convertible Threshold Type [Axis]",
        "terseLabel": "Debt Instrument Convertible Threshold Type [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTypeAxis",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hcat_DebtInstrumentConvertibleThresholdTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Threshold Type",
        "label": "Debt Instrument Convertible Threshold Type [Domain]",
        "terseLabel": "Debt Instrument Convertible Threshold Type [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTypeDomain",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_DebtIssuanceCostGrossEquityComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DebtIssuance Cost Gross Equity Component",
        "label": "DebtIssuance Cost Gross Equity Component",
        "terseLabel": "Debt issuance cost gross equity component"
       }
      }
     },
     "localname": "DebtIssuanceCostGrossEquityComponent",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_DebtIssuanceCostGrossLiabilityComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Cost Gross Liability Component",
        "label": "Debt Issuance Cost Gross Liability Component",
        "terseLabel": "Debt issuance cost gross liability component"
       }
      }
     },
     "localname": "DebtIssuanceCostGrossLiabilityComponent",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_DebtIssuanceCostsGrossEquityComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs Gross Equity Component",
        "label": "Debt Issuance Costs Gross Equity Component",
        "negatedTerseLabel": "Less: Issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsGrossEquityComponent",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities",
        "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Arrangement For Service Contract, Allowed Termination Period",
        "label": "Deferred Revenue Arrangement For Service Contract, Allowed Termination Period",
        "terseLabel": "Allowed termination period"
       }
      }
     },
     "localname": "DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Arrangement For Service Contract, Notice Required For Termination",
        "label": "Deferred Revenue Arrangement For Service Contract, Notice Required For Termination",
        "terseLabel": "Notice required for termination"
       }
      }
     },
     "localname": "DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_DeferredRevenueArrangementForServiceContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Arrangement For Service Contract, Term",
        "label": "Deferred Revenue Arrangement For Service Contract, Term",
        "terseLabel": "Service contract term"
       }
      }
     },
     "localname": "DeferredRevenueArrangementForServiceContractTerm",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_FairValueMeasurementAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurement Aggregate Intrinsic Value",
        "label": "Fair Value Measurement Aggregate Intrinsic Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "FairValueMeasurementAggregateIntrinsicValue",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_HealthfinchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthfinch Inc",
        "label": "Healthfinch Inc [Member]",
        "terseLabel": "Healthfinch Inc"
       }
      }
     },
     "localname": "HealthfinchIncMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities",
        "label": "Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities, and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets",
        "negatedTerseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_InterestAndOtherExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      },
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest And Other Expense, Net",
        "label": "Interest And Other Expense, Net",
        "negatedTerseLabel": "Interest and other expense, net"
       }
      }
     },
     "localname": "InterestAndOtherExpenseNet",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_LessAdjustedGrossProfitreconcilingitemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less Adjusted Gross Profit reconciling items [Abstract]",
        "label": "Less Adjusted Gross Profit reconciling items [Abstract]",
        "terseLabel": "Less Adjusted Gross Profit reconciling items:"
       }
      }
     },
     "localname": "LessAdjustedGrossProfitreconcilingitemsAbstract",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hcat_LessOtherReconcilingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less Other Reconciling Items [Abstract]",
        "label": "Less Other Reconciling Items [Abstract]",
        "terseLabel": "Less other reconciling items:"
       }
      }
     },
     "localname": "LessOtherReconcilingItemsAbstract",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hcat_MeasurementInputMarketPriceOfRevenueRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input Market Price Of Revenue Risk",
        "label": "Measurement Input Market Price Of Revenue Risk [Member]",
        "terseLabel": "Measurement Input Market Price Of Revenue Risk"
       }
      }
     },
     "localname": "MeasurementInputMarketPriceOfRevenueRiskMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_MeasurementInputRevenueVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input Revenue Volatility",
        "label": "Measurement Input Revenue Volatility [Member]",
        "terseLabel": "Measurement Input Revenue Volatility"
       }
      }
     },
     "localname": "MeasurementInputRevenueVolatilityMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability",
        "label": "Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability",
        "terseLabel": "Common stock issued for settlement of contingent consideration",
        "verboseLabel": "Issuance of common stock for settlement of contingent consideration"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability, Shares",
        "label": "Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability, Shares",
        "terseLabel": "Issuance of common stock for settlement of contingent consideration (in shares)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiabilityShares",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "hcat_OneTimeTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One-Time Technology",
        "label": "One-Time Technology [Member]",
        "terseLabel": "One-time technology (i.e., perpetual license)"
       }
      }
     },
     "localname": "OneTimeTechnologyMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_ProfessionalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services [Member]",
        "label": "Professional Services [Member]",
        "terseLabel": "Professional Services",
        "verboseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalServicesMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails",
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_RecurringTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recurring Technology [Member]",
        "label": "Recurring Technology [Member]",
        "terseLabel": "Recurring technology"
       }
      }
     },
     "localname": "RecurringTechnologyMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_RestrictedSharesPursuantToAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Shares Pursuant To Acquisition Agreement",
        "label": "Restricted Shares Pursuant To Acquisition Agreement [Member]",
        "terseLabel": "Restricted Shares Pursuant To Acquisition Agreement"
       }
      }
     },
     "localname": "RestrictedSharesPursuantToAcquisitionAgreementMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_RevenueFromSubscriptionContractTermofContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Subscription Contract, Term of Contract",
        "label": "Revenue From Subscription Contract, Term of Contract",
        "terseLabel": "Subscription contract, term"
       }
      }
     },
     "localname": "RevenueFromSubscriptionContractTermofContract",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_RevenueFromSubscriptionsContractAllowedTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Subscription Contract, Allowed Termination Period",
        "label": "Revenue From Subscriptions Contract, Allowed Termination Period",
        "terseLabel": "Subscription contracts, terminable period"
       }
      }
     },
     "localname": "RevenueFromSubscriptionsContractAllowedTerminationPeriod",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Subscriptions Contract, Notice Required For Termination",
        "label": "Revenue From Subscriptions Contract, Notice Required For Termination",
        "terseLabel": "Subscription contracts, days notice of termination"
       }
      }
     },
     "localname": "RevenueFromSubscriptionsContractNoticeRequiredForTermination",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]",
        "label": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]",
        "terseLabel": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]"
       }
      }
     },
     "localname": "ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hcat_SeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2025",
        "label": "Senior Notes Due 2025 [Member]",
        "terseLabel": "Senior Notes Due 2025"
       }
      }
     },
     "localname": "SeniorNotesDue2025Member",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period",
        "terseLabel": "Employee stock purchase plan period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee",
        "terseLabel": "Maximum purchase value during offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed",
        "terseLabel": "Denominator of lowest purchase of a participant (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares",
        "terseLabel": "Percentage increase of the number of common stock shares (in percentage)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hcat_ShortTermMarketableSecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term Marketable Security [Member]",
        "label": "Short Term Marketable Security [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermMarketableSecurityMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_StockIncentivePlan2011Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2011 [Member]",
        "label": "Stock Incentive Plan 2011 [Member]",
        "terseLabel": "2011 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2011Member",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_StockIncentivePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2019",
        "label": "Stock Incentive Plan 2019 [Member]",
        "terseLabel": "2019 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2019Member",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan [Member]",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_StockholdersVote": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Vote",
        "label": "Stockholders Vote",
        "terseLabel": "Stockholders vote"
       }
      }
     },
     "localname": "StockholdersVote",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hcat_TechnologyAndProfessionalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology And Professional Services [Member]",
        "label": "Technology And Professional Services [Member]",
        "terseLabel": "Technology and professional services"
       }
      }
     },
     "localname": "TechnologyAndProfessionalServicesMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_TechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology [Member]",
        "label": "Technology [Member]",
        "terseLabel": "Technology",
        "verboseLabel": "Technology"
       }
      }
     },
     "localname": "TechnologyMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hcat_VitalwareLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vitalware L L C",
        "label": "Vitalware L L C [Member]",
        "terseLabel": "Vitalware L L C"
       }
      }
     },
     "localname": "VitalwareLLCMember",
     "nsuri": "http://www.healthcatalyst.com/20210331",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r156",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r182",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r156",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r182",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r48",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r112",
      "r119",
      "r218",
      "r373",
      "r374",
      "r375",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r112",
      "r119",
      "r218",
      "r373",
      "r374",
      "r375",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r112",
      "r119",
      "r218",
      "r373",
      "r374",
      "r375",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board member"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r331",
      "r333",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r582",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r331",
      "r333",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r582",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r188",
      "r309",
      "r312",
      "r525",
      "r581",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r188",
      "r309",
      "r312",
      "r525",
      "r581",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r320",
      "r331",
      "r333",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r582",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r320",
      "r331",
      "r333",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r582",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r309",
      "r313",
      "r584",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r309",
      "r313",
      "r584",
      "r602",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r396",
      "r397",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting standards update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/Accruedliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of allowance for accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r195",
      "r196"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Investment discount and premium amortization"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r261"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r52",
      "r53",
      "r54",
      "r567",
      "r593",
      "r597"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r109",
      "r110",
      "r111",
      "r438",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r376"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r334",
      "r336",
      "r379",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising cost"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AirlineProductsAndServicesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of each product and service or each group of similar products and services of an entity by various financial or nonfinancial attributes.",
        "label": "Products and Services [Table]",
        "terseLabel": "Products and Services [Table]"
       }
      }
     },
     "localname": "AirlineProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r336",
      "r365",
      "r378"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedLabel": "Stock-based compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r201",
      "r221",
      "r223",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Less: Write-offs, net of recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r91",
      "r478"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r91",
      "r247",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Shares with a potentially dilutive impact (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r210",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities",
        "verboseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r164",
      "r177",
      "r184",
      "r214",
      "r433",
      "r439",
      "r466",
      "r542",
      "r565"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r47",
      "r102",
      "r214",
      "r433",
      "r439",
      "r466"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r206",
      "r231"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r205",
      "r207",
      "r231",
      "r548"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r330",
      "r332",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Pro Forma Summary"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Pro forma net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total pro forma revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r424",
      "r425",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Common shares issued in acquisition, at fair value"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r90",
      "r430"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r423",
      "r426",
      "r429"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Contingent consideration liabilities",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r423",
      "r427"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Revenue-based earn-out liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r423",
      "r427"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration liabilities, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Less liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total assets acquired, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration transferred, net of cash acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r99",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r617",
      "r619"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r616"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Capitalized computer software, net"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Capitalized contract cost, amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Deferred contract fulfillment costs"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetCurrent": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.",
        "label": "Capitalized Contract Cost, Net, Current",
        "terseLabel": "Capitalized contract cost, net, current"
       }
      }
     },
     "localname": "CapitalizedContractCostNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Capitalized contract cost, net, noncurrent"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r29",
      "r93"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r94",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r93",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r467"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r272",
      "r552",
      "r571"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 500,000,000 shares authorized as of March\u00a031, 2021 and December\u00a031, 2020; 44,340,036 and 43,376,848 shares issued and outstanding as of March\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r69",
      "r556",
      "r577"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r248",
      "r251",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "verboseLabel": "Computer software licenses"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r192",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r192",
      "r464",
      "r465",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r192",
      "r464",
      "r465",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r146",
      "r147",
      "r192",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Revenue related to contracts with customers (percentage)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r192",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r287",
      "r289",
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Unbilled accounts receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r287",
      "r288",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r287",
      "r288",
      "r310"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r287",
      "r288",
      "r310"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r543",
      "r563",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Total cost of revenue, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Cost of revenue, excluding depreciation and amortization:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r95",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Number of shares issued in conversion (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r543",
      "r544",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r277",
      "r544",
      "r563"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "Debt instrument, convertible, if-converted value in excess of principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r477",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Amount borrowed"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Basis rate (in percentage)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Debt instrument, measurement input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r476",
      "r479"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and short-term investments measured at fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation capitalized as internal-use software"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "negatedTerseLabel": "Less: Unamortized issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r103",
      "r394",
      "r400",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r91",
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r91",
      "r259"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedTerseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCapPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.",
        "label": "Derivative, Cap Price",
        "terseLabel": "Cap price (in dollars per share)"
       }
      }
     },
     "localname": "DerivativeCapPrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeCostOfHedge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The premium (cost) of a hedge, expensed during the period.",
        "label": "Derivative, Cost of Hedge",
        "terseLabel": "Derivative, cost of hedge"
       }
      }
     },
     "localname": "DerivativeCostOfHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r444",
      "r446",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technologies",
        "verboseLabel": "Developed technologies"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails",
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r309",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails",
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of revenue disaggregated by type of arrangement"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r107",
      "r486",
      "r549",
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Receivables from related party"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r107",
      "r486",
      "r550",
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Acquisition-related consideration payable to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r42",
      "r107",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "verboseLabel": "Deferred revenue with related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r125",
      "r128",
      "r131",
      "r132",
      "r133",
      "r137",
      "r138",
      "r557",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "Net loss per share basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r128",
      "r131",
      "r132",
      "r133",
      "r137",
      "r138",
      "r557",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/AccruedliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefit expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/AccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Nonvested awards, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Nonvested award options, unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options",
        "verboseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114",
      "r122",
      "r124",
      "r140",
      "r218",
      "r283",
      "r284",
      "r373",
      "r374",
      "r375",
      "r396",
      "r397",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair value, assets measured on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r457",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r453",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r452",
      "r453",
      "r455",
      "r456",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r321",
      "r322",
      "r327",
      "r329",
      "r453",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r321",
      "r322",
      "r327",
      "r329",
      "r453",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r453",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair value, liabilities measured on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value Measurements Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r457",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Liabilities measured on recurring basis, unobservable input reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value of contingent consideration liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Settlement of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of March\u00a031, 2021",
        "periodStartLabel": "Balance as of December\u00a031, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r99",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r222",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r252",
      "r254",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r252",
      "r527"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r248",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r252",
      "r526"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedTerseLabel": "General and administrative",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r238",
      "r240",
      "r541"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r99",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r91",
      "r239",
      "r241",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r74",
      "r102",
      "r164",
      "r176",
      "r180",
      "r183",
      "r186",
      "r214",
      "r466"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit [Abstract]",
        "terseLabel": "Adjusted Gross Profit"
       }
      }
     },
     "localname": "GrossProfitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r444",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r91",
      "r258",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Long lived impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r389",
      "r390",
      "r393",
      "r398",
      "r403",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r123",
      "r124",
      "r162",
      "r387",
      "r399",
      "r404",
      "r580"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r99",
      "r385",
      "r386",
      "r390",
      "r391",
      "r392",
      "r395",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Deferred costs"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r99",
      "r251",
      "r522",
      "r523",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r246",
      "r250"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r158",
      "r475",
      "r478",
      "r558"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r77",
      "r281"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r99",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Development cost and internal-use software"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r213",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r540",
      "r561",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r102",
      "r178",
      "r214",
      "r434",
      "r439",
      "r440",
      "r466"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r102",
      "r214",
      "r466",
      "r545",
      "r569"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r102",
      "r214",
      "r434",
      "r439",
      "r440",
      "r466"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r36",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r278",
      "r544",
      "r566"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Convertible senior notes, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r41",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheEquityDetails",
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNetCarryingValueOftheLiabilityDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment reconciling items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r89",
      "r92"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r56",
      "r59",
      "r67",
      "r92",
      "r102",
      "r113",
      "r117",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r129",
      "r164",
      "r176",
      "r180",
      "r183",
      "r186",
      "r214",
      "r466",
      "r554",
      "r575"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r125",
      "r126",
      "r130",
      "r133",
      "r164",
      "r176",
      "r180",
      "r183",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting pronouncements adopted and recent accounting pronouncements not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Purchase of intangible assets included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonrecurringAdjustmentAxis": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Axis]",
        "terseLabel": "Nonrecurring Adjustment [Axis]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonrecurringAdjustmentDomain": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Domain]",
        "terseLabel": "Nonrecurring Adjustment [Domain]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "verboseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.healthcatalyst.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.healthcatalyst.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r164",
      "r176",
      "r180",
      "r183",
      "r186"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/AccruedliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/AccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r57",
      "r60",
      "r63",
      "r68",
      "r283",
      "r468",
      "r473",
      "r474",
      "r555",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r50",
      "r52"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in net unrealized gains (losses) on available for sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payments of acquisition-related consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "terseLabel": "Consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of business, net of cash acquired",
        "terseLabel": "Acquisition of business, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PhantomShareUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded as phantom share or unit.",
        "label": "Phantom Share Units (PSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units"
       }
      }
     },
     "localname": "PhantomShareUnitsPSUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 25,000,000 shares authorized as of March\u00a031, 2021 and December\u00a031, 2020; no shares issued and outstanding as of March\u00a031, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r83",
      "r368"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from the sale and maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r83",
      "r368"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r56",
      "r59",
      "r87",
      "r102",
      "r113",
      "r123",
      "r124",
      "r164",
      "r176",
      "r180",
      "r183",
      "r186",
      "r214",
      "r432",
      "r436",
      "r437",
      "r441",
      "r442",
      "r466",
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r266",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r260"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r262",
      "r570"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r99",
      "r262",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment",
        "verboseLabel": "Schedule of property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r72",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Current period provision for expected credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForLoanLossesExpensed": {
     "auth_ref": [
      "r224",
      "r553"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.",
        "label": "Financing Receivable, Credit Loss, Expense (Reversal)",
        "terseLabel": "Provision for expected credit losses"
       }
      }
     },
     "localname": "ProvisionForLoanLossesExpensed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r176",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of segment adjusted gross profit"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r175",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r328",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r328",
      "r485",
      "r488",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r483",
      "r484",
      "r486",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r384",
      "r618"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedTerseLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted shares"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r284",
      "r376",
      "r568",
      "r592",
      "r597"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114",
      "r122",
      "r124",
      "r218",
      "r373",
      "r374",
      "r375",
      "r396",
      "r397",
      "r588",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r155",
      "r156",
      "r175",
      "r181",
      "r182",
      "r188",
      "r189",
      "r192",
      "r308",
      "r309",
      "r525"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r146",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r311",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue",
        "verboseLabel": "Deferred Revenue and Performance Obligations"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations",
      "http://www.healthcatalyst.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r73",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue recognized from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue remaining performance obligation amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Remaining performance obligation (in percentage)"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/AccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of share totals with a potentially dilutive impact"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the calculation of basic and diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r248",
      "r251",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r248",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible asset, useful life",
        "verboseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill by reporting unit"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of recognized identified assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r104",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r164",
      "r167",
      "r179",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenue"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of outstanding RSUs and related activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r344",
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of information related to stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of the purchase right for the ESPP option assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r192",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r164",
      "r168",
      "r180",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "negatedTerseLabel": "Sales and marketing",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r551",
      "r572"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Shares related to convertible senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Cliff vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested and outstanding, ending balance (in shares)",
        "periodStartLabel": "Unvested and outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested and outstanding, ending balance, grant date fair value (in USD per share)",
        "periodStartLabel": "Unvested and outstanding, beginning balance, grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "RSUs vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs vested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based payment award, options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Shares exercised in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled/forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period",
        "terseLabel": "ESPP share increase in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Option shares outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r346",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at March 31, 2021 (in shares)",
        "periodStartLabel": "Outstanding at January 1, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Time-Based Option Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in USD per share)",
        "periodStartLabel": "Outstanding, beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Option shares vested and expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r335",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vest in year one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r99",
      "r337",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share-based payment award, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r360",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in months)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Option shares vested and exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable, weighted average remaining contractual life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Option shares outstanding, weighted average remaining contractual life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total grant-date fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (in percentage)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r546",
      "r547",
      "r564"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software",
        "verboseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Capitalized internal-use software costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r192",
      "r242",
      "r265",
      "r267",
      "r268",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
      "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r45",
      "r109",
      "r110",
      "r111",
      "r114",
      "r122",
      "r124",
      "r140",
      "r218",
      "r283",
      "r284",
      "r373",
      "r374",
      "r375",
      "r396",
      "r397",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.healthcatalyst.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r140",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r18",
      "r19",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock for acquisition consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r283",
      "r284",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r45",
      "r283",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock for settlement of contingent consideration",
        "verboseLabel": "Common stock issued in connection with acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r283",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r102",
      "r203",
      "r214",
      "r466"
     ],
     "calculation": {
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r284",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks",
        "verboseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
      "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r210",
      "r211",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r321",
      "r329",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury notes",
        "verboseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.healthcatalyst.com/role/ShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of shares used in calculating net loss per share basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r125",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131251-203054"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r622": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r623": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r624": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r625": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001636422-21-000046-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001636422-21-000046-xbrl.zip
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MD_HI;/S@:47EKG]JKE1XB'Q>V$V5>WXC57[Z7VRYWXZ=_@U02P,$%     @
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MR7^\I5)\YN_,R+=WCO\%4$L#!!0    (  Z4IE(8)CCC[A,#  0;'@ 1
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MDN=44,J!30E"0K:NT>=7@/S=03"#X_[ C>"O?B]6CH9YHU-26AL@5N0Y-VO
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M^=Q3E9B,H0)[Y1?7ME<9%U8&+S"6YE([(;7T,F=5X!"1!WCN*K#ANP)\O<H
M24I%ZK6-@EL!!@-]SZ)5:-5M$,21*@-D'LL*9KDAV8!!\L6\,P)YF<7>"T%Q
M)L%'FRI RI:>%.5UE4 4ESRB=;72FVB,4"1)R:+T9/%7?ER<I_@7]GD>ORYS
M.6T.X#\GT MG-S+43 M?*3J\./YM9N;VLDD7'__&EW2#T#I[G9,+?*556[WC
MD]&P+$$KLB[%4LNT V)C(,)S[O,A5E9$XX,42.<J!: ?EA:[!^C<,YH7!4 \
MIS(SBB'C+[?XN2 344DZ)S1058'M $MJ@7A% (1P2<P390)U(H&RS ,%2F7
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MQW S/NE]@L&H[3O0Z(]@^,:=Y:3;L\)&?NA-6(P3?4.OW1^4CUP_ >Q#>:^
MF-U^H:2)32(8YAF:#<NL-GFA-5H-QSBS\&&]! 3^4RPZ,OXZ&;9[,!RNA?^<
MM(?M&ZG8W[5'KO/9#>#UZY>SEPWV_V"TCG'Q1#KYWXMZ+JY=]%N\4O2J(*=7
M?D"0^2P4K8RF5.<S)KTAAH(G07K.$O$5R'LV3_G=BVXQ=,\Z.F:33()*XVVR
M-EJAN?3!NRHDL5WXT;L9[IQ4+AD>-'A)A(+H%'.6"@Y>2T)8!9*[7*%%9?]?
MNL=2@VY>'I])\6;0#K"==E!4O1/8:0\_5BD.6!3PA!AL-$QJDY"2,[2^:'F1
M4A$2$4GDD>1BFUG4]B^1/ 'ONW['C=J=^SY<98:H4<%0_,]'(41PRJ,)4DZ*
M:! [DE8@]>37!?6U$J6]N;.D%@J^BP(;R8FDS-$  N7)M:%41K!!>\HU0+5&
MK5ZWG2^1\++CD/M=*CF&<B,,Z[%B_#3$IP[*TY4J$FC'")Y#"HZB]==6&2\A
MGR<I@A:.@ZE07+50PII_H(4=C"0QY;R521AM'=.!4V:HUB1Y4(MOM!=*H/=S
MZ)0)U$?+/3$@O)/(QW047$5-F59QLA:*""H6549/PURE.2:BH&(6H3BZ3*N%
MB)YQD;1V0=F OW%N&-6*E^:X!$3QA(Q%1<8UVW\#&]^R_3>*_CO;?])KCS$4
MW=D%)+IC4CM^=;PPO7?Z^_1[OODK,S>R/%L#1'(B)K 40<<,<@2:SZZW#V>@
MYJ61%K!-J'])"2L4,89*@@26&L\EXP8JH)&E]*]KQ!7U:[8&,&SU._%&\/K5
M&W9=!R:C,;NC?OAX4<&LE/?)<CRHY;B^4,:YR",@Y/-1MUQ9YTV45!N;I,"X
MK4+QP!.,YA=\\&1\L-3:&*.(#JTE1(PF05FI0$T&J1?26/[XB-%Z>QCZ)[W1
M#O;9DRE<2'H=&/,A168BLTBRM6-*:)-\<(1:)LCBP_(^ +$HTA'&,% 4J)=>
M*.\LIT8I+X@N'<YTCA]=SI/O65B]O>E[KCJ4A_$]40@:B%.::RDT(\9;%IBE
M(1,9('+*V(DMIA\6%4;K^-:?W*C]"2[E.7SEVKW7_>'PK[._(1ZV>X<[T"D'
MO8:M]O$-H+EA:[/3_SPI."N 3:I;AV'[L.<N%T!<-GM\ >+:<%+VLOVS0_F7
M?9.GA:\.#KKC8X@O7:?S$%2=V#M3]<NB/QCDGPSC&QA<OO@%@&/[$P+O:OD&
M%ABX4?\"AM/@OSWL"T;U\[W=]6^-"WQQ?_YQ'7K];KMW6[5ES[<O6O:MJJ_5
M\NSZ"WQO9$(!)5))(1/1 M!U&)*"U#8ZHR6]9)C$/"GWDW+_)+TA9@;TQIN@
MB!*@#0?AE; V@4TN2)+W5.D%GD4?#O)$"X8V,#A&RW;6<%WXL25O=P; MQ?9
MK2%;^AM<9]3:ZH6*S/4H$"YIKZ5$6D*BM?B=6)87XL0 :8%W73YB\?_41/N%
MM_Z$C/OV,?E\Y5\/ROO$H\88-4J+42QQ7BG&$Q6*JL 5\Q4:HUO#&F*[<Y(M
M_>4FA8W3T#F)$#<'_>[+?O?X9%3ZH>VTX08]]#=#Y#Z[+43<7V>W5W#=8VUT
MCSO],X!RM'K[>%DG_*,WP(,AA'DCK%:&1#0GZ'&T]#QH,HE[)K @3[!X<%B0
MN\."S P6QEC.##=2"I,/@W0N.)%LI%%+)Q5YLA;78;$#2#C; ?EM"8P]M,+#
MG=V]9;08)/BDHM&@213*$N\]I=I)S@G(9-F3Q5@$:,S%:DB,I0.%8+PT&%PK
M[Z4VVC-IG$>*^F0U;D#C30MY8;];WE'BXLWNWCULMIR_S3 ,HQ:GI(Y1"1DP
MIE$Q*0I(-"3W2C_9C/D#8RX6(UB'(8E)(9^*$ZAU6F)8 @ECW)0P-GFR&->!
M<64R9AGMA+8YEU0PAF,TPDER)EK/A5"0J XV/=F)><%A+M8A)NFM#)YRZ@5A
MVI$\6.$I2PQ]B;9/UN%Q[E*0S-(4(TO"!H%@,"9RX[6(VE(M17PR$W/'Q5SL
M!>6!, 2!XV"%SWO'M 'AE!#.6RK8D[WXQF#6,AJ*?.J.C,%P991(R>>%A%I9
MH15$SU-X,A3S \1<+ 0WCD(>JS)Y*9\/QGF22CRH)!FM4D:8>0Q>+:.-((%J
M,$& #T(P;2QS F0(G%FB980G&S%/2,QG5$)K0 <A@8LD E/.)V01DF,<*I0D
M%4@W]*;C>C=FW$MI;?5"KOP3Y *,T/O-_S^[=1!(WRQU!K1E("PCR/B%1,XO
M9/313M*G+X5$;$4DDA<DY1,Y V@F("7#& \^FD2-]YJ'"GG2.2K+_-U?]-Z
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MPDE 8NJ \RHE?K^+,!_+: 4%83AQWBEF!671.4="($ZHR ,U54I'M*!BG4^
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M04\S/WKL2MU7CSX[[H]9[.0$MD_PU</0)DTAE[<X/^QW3D9?O^6>SD_[MV?
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MI23KG"U,2[+'H[HJO!*/1U;AY:GPF&M@)W$0 @)#530M: A (^6!XU(PR9C
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M=RUBZK\TAG;7([X8'K;"VHY_E4LK)TL_AI=]G3(QJ99"$PFTX 1012R0PFD
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M".2% A?UY!9N^UF]>*&UX136#MO#5@J9B.H3FK8Y>&6]>7Y9"9OHQ^>,K^9
MI8]^H.-@W5O=Z\0I[4](:K<45 :HN0!JJA4/D0Y*IA (2CE ";7 1*$"CBU5
M0BM%4UR38+1>A-_?@*=;%0*S%V(=U?GQW"*K<Q74><PWN#!0:@E!0%*GA%8.
MC!0A%<TS6ECD%511G3&K<U81=7YMSHL)HM$M&O'8;ON\YQN^TV]^\[5F)_[;
M9T?&4Q]E3,BAZ."Q,RF%O4(([[O]_H$?'(8C_2.#TAR@%.\QU8L'N63T2" (
MXH!B[H 1 0*,"&$24Z*"W-@BV7WQ@M5V62<=66V?6&TG6O"88)P*" @C$* <
M,Z"=<2!PRZU4Q+G4I9-726U?0S7+LO]._]Z:EKD=3U4/2";KD+XM9)7A:2YX
MFNK*0R(82<HD@ 'R%'NN4@X# 5H%HR#74K+4(8S+NKPCUK*BC3IR5Y[U("59
MYU>H\V-*8AAG5/%H28A4,D$C ;3 +AV*4B0@I=PGG1>\#M6R.H>OJCG/LY=J
M5M7)RK[58["(!)V!\TS%?_YL D>2'56S)U%\KCM,Q>RO'G Q:*P<<_S7O)1\
MB1/T8O:,U;9MW.ZXO(,LN(/L3;)&@2D*AC @8>H+[0P$,J7K> Z%8$B80,W&
M%A.HCM'".\C2U>B9W5D94#.@KB,)SX"Z;$"=")?&"GO!-#!!2A 9N ,*PP"$
MEEPHAIPR. &JJ MZ^\1Q70'UX299M[LN+5L-Y4P]J+[<\9][&V?=T3UJNG"3
M_'D_*3#14&K%S_H+NCZ]7OFO3T^4W.3RJN5@Z'8'G=1-<QUAI>7__'AQ\MF=
M&TSY<?O#Y?[1Z??C,]?:/_MP>;#[L7EP>1KO$V%C]VN"&'JX^Q8>?SX(^Y=[
MY M1Q"F%)< 1TP'EJ>2-\!80 @W&$#*H"PPO)^AC-TFK,1B<O_GUU^_?OV_^
M,+W69K=W^FO\*/FU%R__>O79C:V]CFT-73(+VQ$>4A/3P:#7-,.R%]F@6RLZ
MTGF7*N4,+FJ#7I1LB3C]S=HG[VMEAU.>MI!:&/:*<WB7(E-:_<T"I*Y^Z_Y&
M<P]W6WOJWG/%'=^D\-RFG4$[CAJ^IFV*--"=BY1SF9XM3ELOOMVI->-83WM%
M.D5OD'(QXWST?=JFHU;W?=$?ML#08DY#LZ,[MED<0L0WBOZ6]\Y2[A<X8[]
M>G^_P#3: C^XB@J$(\G1E*33.:.I]QHCS5!@'J$O&&^\P":#J]2KD8S$G3+Z
M\^WV^Z,_:SO;1]OOCS\=U6M[!SN;%5I9=X]ZYUJ-=R;5^-.U\B:-/SSW/5T
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M8@TP01C C=>01_A5]J']MJH+9;0)WUHO>:D\?JD$C9DS2@('XP*AU%M@/"=
MA!23JD1PSFUL45*7=YQ0+JERVQ(Q>OU"V//.= _@K+*Z4MZ9GA1NQD: %!11
MX3APTB% K>) 28V <<(0PQ#R4JWA0LD[T_*7BH-$:L$Y\$RD5L!( "TE!H%I
M8:QVC"820T0=P=M)4B]G9RKLRE^+;)OXMVM^V_I/_.-JY*-? ,E"?(/D] YP
M-NP/FN%BVG),'UHV_LN?P3].\/_EUG^NQ7'SL=JZ=]KL7,T[PO'^Z_2DOZ!K
M!\7*?WUZHN0F+V<AJD/H=@>=[L"O)1*U_)\?+TX^NW.#*=\_L_#X\O0BCK-]
M?/9W1* //_:/&NW]]ENVO_LNXM+I]X/+?QKQNV'_<A]_D=I*': &1J#(<KD+
M0!.*@<4*82$8Q9*E7:"<H(_=)*W&8'#^YM=?OW__OOG#]%J;W=[IKVGW^+47
M+_]Z]=DB&:@U=*G1<3LBR"#^/9$@5QMT:SW?TG%SJ)WKWN"B-NA%R9:@U-^L
M??*^=I!D@GC:A&IAV"L*K#@_T,U6?[/ L:O?VII'7R:TP_I4=^#I2%]QQS?-
M0?PU.X-V'#5\35O;;<?17!1.H/AL<=IZ\>U.K1G'>IJ:+:7IJG5#+<Y'WZ<=
MWZ6<@,2Q.T7$3S&GH=G1'=N,'X];[L"GKF3]>V=I- I1P$FWWTPR>%-(I_G-
M__:]Z0:-*Z8Z\:W1I,+Q5[2) XC[_;U?N2&.,0YM_<?T?KU?C"N4V8,28M,C
MG/PSC;; #ZZ$MSC2)$T)-<$83;W7&&F&HNF(T!?,-JZ^U.B-]ZM3#TS/ZZ]
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MNJ/<Y37*<1NH=5(#C*T&5!&1VC<(H)AE2E@N#'5+R)I<<0>:&][6Y)7;6'Z
MQ;K?XS6P]:+&<<U.>?-&U6!_24&?_WXSB^7WZ"I.SWF/5]:Q>J>A.Z=)N$5
M[[#3\W%0E][53G6STR^E[?O_KJ5^UM]TLU6X^M)Y5S_N'/%KWWQ_,'UVDWOB
M/G7MO$([IUSMY9[^][7T_NRVTH3^$668-OK#SB=OA[WFH.G[V[UF/U[:C?_L
MG/X5'[[K(BDX#$?Z1^8#<_"!@T\35@^#6+M@+:#"1:N'J%3#7$- D* $.2&@
M5Y$/+%QY[P&L68.XR354\^<B]%GAJZCP8P, *<XHE 2$U+.)<B:!#,P"&Z2"
M4!C!>.I#N7C%E H5]BTIS=KPF=3"( ZG%O6@YSMV%+_3*GI/UK1+QY>)N+RR
MFK_/Y8>=#= 2=KTKY;8S$MO1..IJN^..QC+<OA9AAK/'P-F4UY9@"76@@&/L
M ;40 Q,P!UI)K;BEPBBSL44KTH<E%PU>?^J2-7V5FCXF+D)CZ@(7(/A4)%RA
MJ.0\,*"\4Q'< ^2!1^*R!*]EA5*SJ\U8IKQL"U07GBG78=J!_*+/EI8\.R\'
M[9_E?/V./2"C^6/0_&*"MWF!F+): T5DZG,)'9#>>6"Y0T1 *$6PQ6E[7#1+
MJ]ZYJ":M1PWCC*893:M[CI_1=&EH.N;&"AG+*!(12)$%%&$--#$,((>]95QS
M1EAQJL_P$CQ[SXRF#V>G/C(](&>SY6RV)6:S\:5DL\D7E\U&<C;;*K+9/@VZ
M]FNCVXHHW/]__Q^)D?BM]O9_P^;@H@K/MTA66[WF?UB?-I54]Z(6'UZ_U$2W
MI>OF0SFFU4N&PW(3<K[T_#*QB=#C4NP>OD:$?/%CS3/P<L:*"<EC?>UCI;.-
M==$D4BJKEFDK'IEI6[O.LJW=RB*])Q9=/A"+/D>*\CIDD<XVJW_U?/"]7D%:
M(TU=?29N6<[IUHT6^Y67**F=;KO=[:Q.3+WN]UMQ#2]F,K?C6)/S0[=J?^FF
M WN=VHX^3Q9#GMI%I];:87M85KS:]:%IF_<'Q^4YG7].RZ2:Z>/^TG6?IWE1
MBM&- #"+O^:1V6XOK$[%;)-:UD3-)3X>H_9%0<$9IFYIM.M53G->H95:H2O\
MZ%H'!OZT&&PAH=]U2W>LK^GB+&+76Y\J5E\9S7"1?,O%RDVL,%QCMIF:L^BX
MD\Q!;XCCF@;$E(<:V6"]1U@PQ;[LI>E%>#I,8^_@W71XQJ7O=9WN-VY&9ASY
M]GFWIWL7)?.XO[#X<S>B.MRY*N?;:.Q?-AJ'1WOD^.R_7P]V/WX].3J)G]^F
M)V?;/^+[=!_ODV.\#\>%Q3^PX[.O</_L;Q8_AT[.XG?:\?[X[^_'E[^?'9]9
M>GQYT-[?_>?L9GC&P6ZK>7CTX>+@Z.M%O-X^^.-C^_CS6W)R]/O9_A\'S8/+
MQMD^/OY^\/D@[$\&NTD,&;&, AU,BM$@$&@-!1#&6&FY"4'0C:V"^.'?EEM&
M_/D+S"PGJ*WR!69F4_C'1JU5M[[,@D!W1U3:HU#N9D>%&4%N1_=Z*8*F)!7;
M$U6TC[I_1?SK#"H3E+8FJ#<.2J-*6H41 E0)"JB& 6@#'8#>,J28ULR2UXIZ
M\]QC0?,ILZJ'696FWF'D(%>>4DBAE,1IAD3<LQ55VL_(JAX,>LU<:D%4P=>H
M HU4T&D-$$4,4.8ID,(H( B5 G)DB-)%\S B>%U2^<J )=.I3*>6 &^W2_=,
MNJA+[I29T7P81L=)Z](2'30'TA,+J.$!*$09@)PA@QV"%,.$81F[,G:]9NP*
MB%"$/%0,$LH]DMI9S93Q0A/-_8RFX,/,+,/:HFZN_9WK_GE"8\]\",!CZ:/)
MYR P@1L 4ZH#L5X%AC>V4!U"5.>497S+^/;B\&V>#$R'B>*2VL"QIM X&<F:
M\<@CA56 AMP/</,G7F:D6QSIFM=(AR'Q$$L"4M%D0*W5J9\L!H1#Y /F@<MH
MA@K,ZIPM+X$]0URE5/VU0MP\WGQ,.:.8"1H<A9IKZWVD<LXYI@*',)N?*T.O
M@S%/"Q@*CA0"VC,**%4*2&TM"%@;J:'R09J-+;ZLJJ\9O3)Z5>>Y5WX6F6G9
M$P/;F)9QKABWP@/MA !44 6,5"2=/AHB-28415J&!:]#=;N#>T71;9E5<!&_
MN[+_5!=S=5XIA?W']P>IRD4WU'KQ9:]I4U!Z/RE.H;R/J^!?P?J8LTW'Z,1\
MSL6:JYAF*2TDI1GN\821"FN[#N8+1I">6DZ4H=%@HEP$R23T3&!F"(9&B9\4
M.)PS*B$AZ%Z_/_1NLL9^&:SP\1IIBX]M?]>]LOK^NVXO^.9@6 P^1S',S%2B
M^36.8K"*4RP#!%PB"2BW'LA ,,!&VN L\H[BC2T*25V)A:VP"H/*BU3Y%P?]
M64I92EE*64I92EE*%2B*_^P="F>;[K<_?,\V^S[Y+4IG1?<\T;<7TW#P*5?=
M Y)_[I#]+*5UD%(E$BO6;QVLJ[NBN'A8XNL5\+KLGYC'/_%IPC^AL+<&$05P
M4!K0*#=@@M/ 24H$Y\H*9S:V&!%U*9=UCE)%%'E=.G[[ '1!!;\GCN.V$O^C
M6T/_L [GT]"9='B<90"=%\A  B"6#E"G*=!$6H")-E!X3HR'&UNYL^_+U5[(
MA8>>*P@)I%H0213EB&LDB3,0AQFT=]'=.2OVLA1[,LX>2^1DT!! R@B@#$*@
M#%9 4*B8@!)Y&3:V>)U*D=5[O=3[Q1EB64I92M7?*I?063!OE979*B<B ITG
MQG"'@=;& &HB"U8:8T"5DL@&*05%Y5:YK%(!50OYJ[ZGO%CTP.BR.57[W'?Z
M1?OD'->7#]&RE')<7UX'65NSE%ZNE"KJTMIVJ<E:T53OJ#MNWY"Z-^QU1KT;
MBM.G@KGL3!"7C_Y_PV:_.?"??.];T_J2X'_TMGO:*>Y2</U,Z^>A]<TI#QA"
MW*26Q<!0SB.9YP0HKBB(2P$;I9&AT&YL(5+G]';Z=8:#2L-!!NTLI2RE%^T"
MRUMKQ;;6"8\9X\8I[PPPEN+D,5,@_A\!%1#QDB"!#:K@UKK,X-)US))-#N6B
M[4(W)"=::MQ61IU&I:SU_6#0*OI#EY<[*:$V_2OU@F]&X_[Q_K:U/1W(9SA9
M2CDP=5W6004#4QM6#]X<=#M6]QN'O;]T;S#ZQ[8M.4H<9]E"<^+$[UVW]^D:
MC _#SC44[TPB\?NF-LW6=1>6',@Z#YV9+!?.&//:>@V\9@C0H!F02'#@/)<<
M!FN4@QM;&-4)KM+Y7]X:7N/6\"*E5#'G[BI .UN?\\'UI&-74X6,1PHH&'RT
M/@D%&A,)B&!!2QP(U:0L(9SS#M8,"3)>9REE*;U(OV[>52NXJT[X=*7$UA%F
M@$')ITLX!\9J#+ P@0@9L)6L>KOJZXJ"//"#6JO;S]4,\S%BEE*.>LSK(&MK
MEE*64I;2VK3SL=&N(O$_@2--(:)*."2Y<DHACXG@,UA:\_?UB;1QKV.[;?\^
M<L=L(\UA(QWN3+7TD4P()0T$B @%*%<,2&4M(#**%*%H-'FYL85EG8A%.OID
M!<XPFZ6T",PNP:&587:U,#OIBJ+<".@=((H;0!5R0',4 &%&.ZV8(<94"V9?
M5]G*PT'#]XHTW)YO^$Z_^<T_WBVUMO[U? J2I92# _,ZR-J:I92EE*64I92E
M],16K1'$<0,ME(8B'J(IY& (.CBJN3)^'JMVVG0M&/W.)*$?6[)%2Z<C_2-;
MM/-8M)^FNNE*$8QPS@-$!0540@$D102(X#1A2CEMX<8664(;\*RX553<);JC
MLN(^O>).U(83QB C-4 X:$"95T Z9D"@AGK#/'0(54=QEQ0-]3/?TZ![_CPZ
M][MN%?FKNI]R5/=USS9J!-5K26D6B8D:&<SE9+XA<?9==VA:_MIF7JRM=^6P
M:[Y,.:&1Y,09')RA GFCF%&.>A+_HEZAHL7USQ/D+GVOZW2_<1/"CGS[O-O3
MO8NRMW69SG8X'/0'NI/F-6>VS=/L^F@[9;5=P9<5@G"5B(8U'%#,%%#$QU?4
M:1EE2(.@UY;"DC+UEZ=,SWR<]LRH436O_[^>;R',L0"JA*:WB>#CH/1F?/V,
M2+JC>[V+.(7;[2B<P?9@T&N:X4!'"1QU_XH@VQED9C@OM%Y<0RNW06,/ ^!(
MDPBMR@,) P?<!\:-9!0:GJ%U+8)L,_U[B/Y9CX6)2QO%94VML$IX&O] U 2H
M"90STK^'ZYUGTK<@,DU69\+,4"U2I4/H +68 "4M!H1 RZ&D-D"UL45IG5!8
MAX1G<,J\+_.^)^5]C\/0>WJC-;JM.'W]DN1E"C<G4!Y.>.4UT0ZBB(S"!$"Y
M44!&V0#%:41-2I"$, %E!L@,D!D@G[:+I/"$<X0)891*;K71QC%)D%<4,N1G
M,XQ_WE,G8^="YN^U=W'["Q1!"*<1H%%6R?[EP"#K@$*,4>Z$B'\5^>(8UX5<
MN(=DQM",H:\10^<Y9D8R4DD6@1-23(U&A@NJ/!126F\%A_>#Z/S)#AE-EX"F
M>]=H2K1T&'D/HEU  57. BF]!I9%AHHA5%3AC2W!:,33)>0\9!C-,/JJ8'0>
M6]UA)[#RDFA!'6::4^\I(O'&T@:KLZV^0H3\<(V01F%5G%T[BD0TU@4!!G,/
M4C*8P81BF(ZR22::&2$S0J[#*7:FET\-GL?7X.D@XHX: 3RS%M 0(%!>"\"<
M# @%RP5B&UN8R[I\0>=!13CDKT7$0_S;-;]M_2?^<37PMNZ=-CL3XQOIW=9_
M3._7K>NG??AKO/A:\1/7$U(^5IR,EC[O^S=7+WYSS?YY2U^\:78*[2N^=$=H
MY6_?FV[02%JY"4O-'$5TCNX_NKQ97+HAC/(:EIN0\WLOPTUT[[6';BLV$1*/
MNNO#UXB0+WZL>09>SE@Q(7FLKWVL=+:Q_B0B_Z?12U3>^NP=)-OZR,YZ*PC3
M%S>HI+B32AXU>M[7]N/G&OW:VX[S;CI6'TY1B=$478WQZDZRW%D?-VUJ;"_-
M03)^/J5/0]!GF]6_>C[X7B].9D&.[\UW(/,]^RRA>0]&X"WV*R]14F49Z]6)
MJ=?]?BO6\<5,YKCU8RWU?@1[G=JH^V.>VD6GUMIA>]C2@X@INSXT;7.0YW2)
M<UK629K*SJR5Z9EYFA>E&-T( +5)+U$1:2]^JY7>HED8!EZ$8<PIJ.J3MC($
M>_6L8MWGK<RNF6'>ED:X7M\<Y[59G;6YPH\NJ:KBFJ2S[WKKVR82AM)*1FJ1
M<HJO.F.)2(H8=M9Z):ERR!BMB%>.8<6@Y2:=3R&%<$Y8?^BDZNW%\>7!V<F1
M:^]__F_SY.C#CY/VWS1^[^S@TJ+]W4;K\//>CSB6]LV3JOVC_Y[MXX/6 3[^
M<=S^;^M@]UW[Y*C1.FCODX/+O[\?_O$W.SY[%Y_[)%QG5*96K-XQPC2W0##&
M )7" (V4!-QZC26WHCBF6E).Y;R:\LS5=)Y6X]?WF'[NQU]/H+M]"O\XE,NY
MY!5!O<MKU*.:,Q)8"O9T*5\3<: 9#D $2AQQ*C"WO"(=:X9Z\]SCZ<O>OFI6
MQ4,PF,=-V1L2EZS53DG&'*>I/E;<KV=D5:\R#WQEJ#+1UMY1)UQ$%:151!7O
M$5#08P EATQQ"+4-&UN$U[F0=<D63G)<,V#)="K3J27 VRL*^UX9AM%K#(.4
M6JDH!<H0&3&,&B"A"$ )B[&P$E,?[4$B,G9E['K-V"4#A=PC[30RU(B@D<,>
M>H.0$<8A/ILI^#H#LE?GYMH?5YY0 CFH P0\;C" :@6!]LP!%E>G5-H'Q?7&
MED2H#NFRVFUG=,OH5IWGGB>OF6"C#2?48PNIU5)#([' QJ9L!H3P_?"6\YJ?
M ^?&I<BB[8DQ%!@$)W3$.>F!XE8!@K1@%DJL.=_8X@C6&;IM@<Y=0SM#7(:X
MZCSW' AG K(P.&*9,:DFLX(><:0L@00QQ&DV/E>&7A-=.TC<760T- $**I5X
MC51-8LD!I%#0@(/5.K(T@3-!R^CUFM%K.2>1F98],;!-5(@U @8C*' <*D"-
MU< 800#GAAB"J!,4;VQA".M\\>J'JT*W%34_N?[1B9S@T2U&1X]LHH%OL^-\
M9_ &J.OTXE6K\>1OQGM8T/P!&DT7A_4FJ\P#*A-YP/?Q81JB&CD4=<51"JCP
M#&A(%%#&!8VU$M;3C:V]]GE4D13+IUWW?!!71&W0\#4[[*4 B9K_<>YMR@NP
M/>^:@Z)E<JTXZ-0]=ZU.DVGG<YU1KVUC]\<U*EQB]^XE55K)4EHK*56B]4!>
M!\^^#K*4LI2RE+*4EM/IDSCMH>)08T0%M-H%9@DC$E$%G80S'%5DPW>Y+'[R
M/,(1%%1(?CRF(: !8J"]10!")PQC" MI-[80NGWF.G>)U:R>&42SE!X%HH*8
M8#FW\4]"M9<:!DV0M1PC0:*F9A!=/8A.> ^]$L'20(!7U@.*#0;&$06P<EA#
M&S<Z2"L$HDO*(BU^6TRX]JIY7/'VA^_99M\G+U0_+?M:\D1U._=G3[_([NR/
MVQ0>D/QSY[]D*:V#E"J1I;1^ZV"^1"3HE3(<*8KB-F0A-"%.A7.84N*M#_C+
M;JHQ!Q%$H'BQ6&?*A*%[_?[0N]UA+T[K7_$)NZY,5"HN'I;X>@6\+J<LS4,M
M/DVD+'F('78D "MT )1A!E1D?,"G4%D#J4;$%RV%J*P+?KL-QLO!D=>EY;<M
M@ 55_)[ J-MJ_(]N#?W#6IP-A)FT>)RT8[U!R7@#3"4?"X_ZK"4748NCF)@A
M 5H4M3AK[XO57F61L $C8PFB7DIM- _"2&HH8E"P&;1WT?TY*_:R%'LR;06S
MB,N,>H QY8#2*$#I&0<!&:,\\T:%L+&EX@;-LGJOEWJ_.%,L2RE+J?I;)8MT
MEBH6A2HE]5IH'K=+!HF6E'%";-XJUVFKG'"2&V:0(<9% LPDH$$I("7' %,?
MHM"-0\R56^7"_7:6J-Y+BJ%=$U]YL>B!T?T4D]EMG_M.7R<!/,I5OK8G<_G\
M-$LIAU_F=9"U-4OI=4FIHBZM;7<V[ _:OC/H'W7'[4]2]Y.]SJCW27'^5#"7
MG0GB\M'_;]CL-P?^D^]]:UI?$OR/WG9/.\5="JZ?:?T\M+XYY0'S3G@KI #<
MI&P@#C60F%J 4FB2(2A J3:V9%W0934BSFB0,3M+*4MIK:1440]8WEDKMK-.
MYJ1[[07S#FA$-* PE0HB 0'KA:<6LOA7!7?6%;4H6;.D\^1D+CJ;=$-RK*5F
MB&4L:M34FK:E*B5<B$C0;T8;?]KM-G_N\]H>%>0#G2RE'*>Z+NM@7>-4M\>0
MV\_AJ?-PE,F*^HHHKQ@U("A& !58 &UM )!*;9A4&K,4V(9@G?-EU02K(GB\
M2-5^<1#_(J5448_M0Y$5=V)OM@]GPMY)SRLU"BN. A!(6T IP\!8)H%CWF,%
ME2>(;&R1.B$9>]=,JS/V9BEE*;UHSVO>(9]HAYSPH :%O1+: (*,!U12"HRW
M"E"(@M-4,^I#]7;(UQ5R>.#+NH\YQ# ?VF4IY1##O ZRMF8I92EE*:U+<3(N
MO*#$26*XIR1P#877VF/GL$'1>)K!:IJ_*U6DC7L=VVW[]Y$[9AMI#AOI<+H
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M5DL>ZXQ* O:O(#2"Y68<FQ4'4F@OB:(,^Q2/+XNYXLJY+SJLIN%\5M$>5JA
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MY0(3C?+#,,/J&\N'1N&TGI5O-NPP0@16DWN*@X&A@:J"B?+UQP80=7/ )PU
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M_?)V.W%(1'7GLFLV*M+'O$..-(Q^5BG)45O/:#"JDP^(',K+#S]BB].6$?O
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M2@B'21"<<6RDU; RA*"1*N^#=@]QA6_!4/=K#'6W8FBU#KX6TISC5,?[S6C
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MM)=D94VHIV+:/;CR[)BVW([E1M9&Z)[G3$WTAV=9Q:$3'P=D#_4SEQK(:*"
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M[[3].=_[X4E[8_VR^"ZZ^W-K ZZQ\<<DMR<\_W>V3["#>,E[Y#W$2AP'AXR
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M=/0N&,$04R8@;K5$QAN*\@D/8U[R0.(B@L][: R97W/JN^B?=\$3*K&-4D3
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M%V6O[/J$PG<]9'<.63L.YEHC1L2[+A)[#PG"C?A//.F>YW[T8>U6Y^8)8%U
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M/27,"\:X$-)&DU+TR8/!H).^9;) [<Q_+G1JOIMRYF=%0W*%44C&(FY9J#*
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MU!L5,+%:XTB<,&K!6UAK/EX,'T^\^8XIJ2E5* A,0"JGA$ST#&GNHG'*2;S
M]N\U(R\O(_-DK#&,4NTM)\8ZGB@G0=EDG#-,U5)Y:;EYVILON5 @EQ/2-H"6
M+14!6YI14+J)C=8PG<(RRN4WEH#_KML[[O; UBQ<=T[%N#K&.-XBZ8)U0L6
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M:1HB@M5UEEKBB!<KZT344%I#:0VEC[0CY[FQM([E/0!+)[$\26C$6"101E5
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MQCZWM@C(6B]1" Q8V5DP!WW-R&^ D0GS.O @%26*.QQMTL)@EV,_4CF\"*=
MS<V/P\U3S;*$TB00@Q+.59P,L:!H.X:XMT9(ZY/ ? G5ZS>6B%0WR+XM*"F-
M&2<&D$<ISC'3$0P%L/>MQ-JKP&OM8NGP:+9!MH!%8E@C&Y3)>Q4ILBZ;"<13
MBQW&:O&!F26*O=2,/"X7)C7U2@@1O> A=W,PU#G";;"4"UL[[Y:7FZ<:9&/0
M!%VT2(KLLO/<(V.Y1%XZKQC8"CJEE76I5S%Y<.VPFIF7EYEIXHGS&"G5D4?
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M,"L.1;!G(]CJQ>-N+Z<4%,> F]U0_#(4B+^N%2!&^_%*4"ML+U_NLYH2"CN
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MT'F+8PN60T8'.#[.),H X&W_H&3&_@$P<U: AAQX!,HOK&#7_\C799SH@S0
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M67'2O[JX\8O2-';&?)0+F'[O E)T@,'A%<MB['EX8"94G+HU^O/7PL7!:8S
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M[V:ZL$F2YYUO@U;[!C;(G7'#G;GA0I;!*-A^YQC?/.B=YN46+'->WU))'3?
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MH' .+LG<L12=*P]7)S69NX ;\.7H97/9[_Z%NM\;_8LX,3N 8;^_?BL,GQ]
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M$:(319 5AB+I.?&$LV!2F:5AVNSAX4F37+F3SFYEPI/%1"?CJ:8\),LRSU+
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M=:@1BOC<\6<99U': !8'"VEU(#8QUN"BY39(LXW:5# I$A/(,9(0Q\0@DZA
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M(=#MA7;G/Y%5[GZZ@-X<,=0$RE$$8<U%UPZ9H!VBPE%K2 !I82MKHLWEY3'
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M.&$C.-W<VJ<[DKAD+!5(61MR.W) SB6/&-->@3 $+]W*FN"KE^E:_O$P?_Y
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M\3_&L8>8(<^W*P\#5RI ])?UCW^N_WKG9\M$3%DO<M9T<L<Y<#KN'X^GF4:
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MMN,^0#.IC+,>2_)3&AA*D@\KR8V-X7FN ?LV'?BA[PR<46 .?.Z.!JXW'4_
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M\)92KDJY'EZY'J#=D%*N1U>NC0EM>XPYP=0:3!UC-' "%X&X7#:8VN. 3YW
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M]POX%9HB993/4/?HJ-K!2-(*]DVP(DJ(]MP'=3*-BA?ZW==B.M!P?2HLZ+@
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MR%MH"NON2'5L8TR@'I:12[ DL*HO%VA![63*#BI.>PMERFDK0U/>0*RD+;<
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M9"9BZTLX;5H<@=K+[DHLZYN8W'=VM!7D1F(=7TO>/S6E*@^E*O\F8F9",81
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MF72$(<VN62*C(#EB6#32@= +"<\D0!]5YX.2R(NL# I"])' B_A6ON"!A*]
MM$T$F&@P:B4Z7*.>P%%@P/'YK(4 7+T)RYNR  ,>%#T2JTQA?_WV_N:TO^UP
M-.%O$/Y$2[ 0]X,AKB+^-H[FI!8J1% %3/?P>RKWI.ZIGD13>KW6E*\1QB!
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M84EQN]L,MS93./-E+3"YP4[?":$B2C_<0_DX-NP+5XCT)8/$K5J< CZM322
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M]O):$]D8^@(,)CPF! CKMJ8N-#:_$-7;X9)+QSS31**"%7ZO-_%//GLK0),
M)G(-IB!E.*-3*JR*\)P=>F.WO8E(P=\PJ/A"HRP*YK*+T^=;, 5NQB$<O0R>
MHU(]"%_:EBI,XZJ::M$8]F+%X!_GFRFR'1 P/*TDZK.:A\.+*;(=B?B[=ZFM
M7-F%+I<+148M%D@E"\8'*V1\1,6GTT*3/*%1$ RV&^SH893+CE"W/6^;\/_3
M'A *E*'\A#B*VKQJY<%P"7#U1&T7.G* DYA#5BR@4Z?]=BBK>M9N$8^J5_D9
MDXBBS97/EBNI>&,,AY-0-GGB$X55XP;7JBJN?%LYU8^>Z!>C/"M'7;9#I!XG
M1@50U %$.X^E#'X:+2G.AK$,K3;MQ SYE9$,>4RL_=E76XD9#2B9A,W]9',2
M(N[Q(%!2Z302_LE#OW[+-0@#,0%KSM_SE+DJ9-WO=D2JA"^:)B$F.\$</A+C
M<WHF$3(W;VN6%+%Y.CDS<&&,AB&?(\E!-T!,+DX7CJ.!%2]YPNP4/#4CN0R&
MGVW9? PZXT+WK*--MJWWUQP6/!R34*6@Q@ #H[HC=E<?SH--VYFLU<87I;VH
MRMWZ2I+= ,OSOU.PL P;U7]*I?JI!/T1PEIMD.WE=$V#',;,,96!0+K&>7_(
M4R[PXR;DT^8(#WXL@C]! L!*1L*."W>!2ZP=T7()FZ]K0$"[P=,<?^ Y1B>P
M;P#J5'$I94V1.:U.] &90&WO$7[QND_S^A&,+I-6YQ&Q0E8SK0P15=!>SLW4
M;D((R41GDB_(LU-/D_H1)G77_.+IF6)S#I/_+*O2,+LIA.9!Q6HA6Y)^?)K/
MCS"?2ZJKED=F#.F2G,S37'V\PFC,B$/EP 2&PGPQ%]F^)TZ/)SC7QYPD5ZR.
M''; 9YFNX1-"Z]T16G]X0FC]?K976J"V G.F:!>B0$IO=]HFKE"%)VOX,1#E
MS.F:"@A%7BE-WY[D3X@\9D_3]W"GC_NBN$@PY[9[FKD//7,F,))HDJ@: A6T
M-6W=+\CA+'._/,WBQTU_0A>62Q HJB](Q#Y-T<?S]S-LD8=%.B[YB&E]FJL/
M/%=N<M +U43^[*>Y^ BN!?L3Q8JN52C[5;T=1!E)F.,2C41)0I7K_YT:CG"?
MT-\??.ZFJ'A&BDBML0-[YBIB5-]&SI2Q/APXV2\;[@G>_>$G[F*"\K *!2VB
M]>48X_-J!)26NWPY[!YSTHE' J5)\=<*!E$V 4)P&L1(=,=TK/HU9\D%\\*X
M,J!7^7([$53P:)(3"!*(Z5XW54W2?"]& )B!#4U8W 5-<G;HSQ18PK659G3P
MF-LA*PD:IB12>&)@Q6:]!/Y%_DC,3F$M +!'ZL\$O*J<5.4<B/-(UL2+FTA$
MHIJB6#\0I4J"E@#3S2^L/2'BQ2H[?0DBIWK8\0I2 6*FH&L. %33LF/LDZ,8
M33!041DL0R]*(6#3:$MQ6$CK=8_/$C)OZO@ZCNX=C[0IVS;8;X NSPAV?3;[
MG!+%HYJG/"(XGA?>@=^.>@%FU]/\79<^J"8/M@2]N<,=%,J)9U(F%1!]RR7R
MD7!J'+P7_>PZ/_[T%CV!ZX*D4HH"EEF1#[3'&[9@A(TIQ!+$4J?PDK=A\8#/
M!=LJ#-,]L7FT#%*H9+&J&PA/C5,5-B03O &53JB9QX2)I;&!UEZI7*;Q/0V5
MX,)Q(YF%YE:3X:09_WX;C'[INC<1R3T.P_K*"YEJWU!9T5/6E:CD*6S FP'C
ML<WA7YFJ6N=XH+DC&%N4>8"(B<\V<;CHEU\\^Y,<LMNRF\/,=%G,.J/")Q,5
M R$:FL*T*S_7)NK"2:^$*:D#G?HO-O%B+:21ZV=P]A+'7,T='HS*'96B-\)B
MN=.'KCQPIQ#J]$)FR-;*ZS[0,B.%IW&F.&?JDXDPPH4TF^@(R,:W']U@I#T+
M7J#%X\5YBFV"L=F8*CSA1Q1YEM,3S+L3X]U9ZTPM;$_4/*6:OZ"E:N1XT%O*
MY6>#AQ,:;4%TI)C\CS!)97U>UQ&@)DLVZ0/$:]$5P^KZNM!A=<^IXP(&W*'>
MH!]A/BZK-]3#IH>39&N3SV@7 _6.W=4TG1 +OZ^(A9%ASKF[E#!Z&:C]?DZ-
M6PK43Q7TNU;0O_Y4*N@/V(%XE7*710I<[8E,3*P CIW6K[*F:XBIW/44E<+]
MJB5[DI&D4=01C'J_;A"PH]5P4X9-?#365W*2N>=.*!-8/;:(AI[[=F]355R;
MLBT>-LHKLNE_?SIWGY0O\SH[J0J=OB(]L[0M9>1&VT5^W]F,G>W*MV3I+XZZ
MC@:3"6!-\T0ONKSHIX.IFZMF-*EC] .Z\YUT<(MYU,_$?N:8V!">X<C<()^6
M_L]7<PIB]^Y1B)S#V5^[1G'$)X(-J;CG;9S0KITG*HQZO3@6BT079K'$S1M%
M/%GF@,>' TC'-I-[AMKD](@6N=6$3ZWI-)<8!:M/+>O"&T=A1;AA\8(9?!S#
M+P"!I#4BV4Q\(UO;P7?Z>[";8 PHR+)&?I]1UN2>DM@=4A*=*(3"*,^]3UYV
M1]%68"*]0^V4+J""M@N/%OYKQ<!UN8?G@_ \K*>87Q0U>&'SI1[3X#-#4<.G
MT*OP0I<%1AFQ/$9@2_2V0S.*+@=:(:+MCCMZ5[8BBUK[/R/>Q($RWRL7"3V#
M-_<+4KIH .^#)]#I\4$)?DV/<N3,0XZ#;QWN?:1FJJAGO:7/<'VT)/X05E"E
M$>3H4!PP$<'C#D'HT8JR=YAFI&R%AL0;PN#5]S3+0DN ZCBT(2&U&T\Z4]5.
M)<"OB2B?DJ&FR X1C:YJ!?_BB(EL,XAT;(>N[ODS/2)+8/MY.U&NFF*'L+#:
M+6G67^YDIYHVO5J)JZ:^IC[BT5%6N''T?0-"F4"7Y_[S3G2EG 3BFH6"D-F,
M'E0T G:@Q(9U=S:9;'NX^ 5R+-)6WPP5GWBUG&;H! RWX%6L(L$^_$O^:NW3
M+*<,M2-M<X$$D>.9L =:DDB/6VY_>1QU(Y*IF&*R(3H%TL6Z>'G;LYB*<4)H
MWFRB26.1SCS; OH4_V[8\NNR@_+-.")ET4]N?YHZ1(3O%:M@C\B"F^0 ]ILR
MY:NYP'!52.MJW.WTV*&<A/NIONF@@L!.UL;$YU=0BSQZS\6YU,F3DHMM"_>1
M;%'2@V-_2,H5F$@U]^B.'*>T1%M(0:'5)4O.^G0@0:WB5N])G:>*3.7!;5(A
MY1LIHTG+OY==YE,+BRH;A8! );>_(-">!D%8F'23'0NK(66#XZP76I24LX5L
M/-\8/M]5G9=!1]IDI@?EOF6FS[FH55-NNQ[E;SU\>RC&ARF1-^E'/L_%)"D[
M.N?);/_<Y0',85?]=DA0A3=X2WO9V>!%(VV_-.LL#Q@.:I*0'_<-2Z<@V5@'
M+U>F"4C0MNW7L1"1/1S*/33N\1-QP$?6)F2%O#EYCV0AZPXB3D0%4J#]OV%R
M>U0>YR[(=8.G[ \UE,EX;2U.<I9?Y(ZUUGT6NX(-"6R4LR3"[K,"$X]Z'S<Z
M6?&C^FX^!WIA'-LM"U3QJC;Z$VX5B9E9^RQVGIE$AN5*AI5\+5]X#A9O6\\=
MO*Q.Q5$-F=5!2M3!J<*7W,LR8R;IJ$C[%_W]?/7ZU-W86 B7!/QH]P+Y6#X2
M@QMYGWCG4+WT(/6W@D]9U4IF'8_V!-/2+4(>_>/.I'@FN6#>AF.^8I#S7MAY
MLO2:+NX*4>E1W 2,9=3JHX^V6/'B-H5XZJT<4U79F5Q7G \GR*Y/X/:[7_K+
MYZ0<<R7)ILKC.;X5V$U#;BSLDU6Z<Y,>VP4J,O(F37%>\D7ZIV#6=\VT8\.K
M)?V4OT=]6-[RA?.C:+F.4LW2RJ73%O7R(F45CC<:ZUL?=M':6:G#'-Q!J+*2
MAR.B*&=!.9G#_%%AFSV6C='9&MN!FBM+;RE*B073L6@X(>-7DA3T:(1:T0?8
MD)2=7*RXT\)U=^8@'!X?G -S\69R]5;CCI/);F!$T<#'\&GDWUCX*-U.I1_?
M6TPS&V%U5)]DW-^]^O3-@ZP^/<Q2TQ=?J0SE/56N$/^0GS8F@E 4*K8];2#E
MDHR.AE(7RB6Q232<XDVJ^HGMT5>!9<>=WAIW-[1W7\(/S&+_P%GK-0.HHH07
M@)2@'%)]JFZBZAHD=%*>X)NF]M"'M9) _L(9R)X/R80U5W08,B<D4P3/IGY5
M37"GOOSBRR^ 'J6,<K7Z^OR;?RM6?\#_TV6_.O_SOV7K":OCV1_.G_V;GL3E
M=DO9@\-=[_CLS^Z.?*^OW!V_6;[CL_,_+=V15C CT["0=:7*%>9/P9G\Y>5]
MXDLN6+UWC5-A1YRF1./)-'!=+1Y>Y$]U6SIFR85E"4<*Q28)0OD<<P^\2"G+
M/;1[P1T!:ZI23%YQ5*M[D4O:726,;)B\'<?9L1 !%$==LX)<<E?57="7J4?)
M"U11SWI5';NPR=:YOB257\:(%2US07O45)0K81U/X%@JG+\R\AQ^=#G\VH=!
MC^#8[5!RN, >!W\"/FZS!TGB=4IMN\Z(AQ.A]4(RQP02)&:;AE)F8UV_94;4
MJ-##=<LXP*HE>6J-X#'BM-?S6<NO-5L/:^H)7 L:$6K$()CE6@7QX8V:JN'
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MUE.1[9V+;'_Z=(ML#\99D/0:5% HSF$^+]3XQ6DP'.8LI2OIF+1%=YZ2\?W
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M_M<JLR17X34$O[VL+*E#C[A%GJ1:)9J$SO4I1VZ=9ZD_Z IO&@)<\]FJB %
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M+K.DH8^:7H&::G>.VZZUF&TA-D%[?S]758R/&B'<QBO>NVT?UVVCLOT/W[W
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MZC88)[ D.TXW@PQ..)V2,QJ;:NXPV])6%G>3A9>$:H#B^Z.618%J!%))I0A
M\0/D95:<U%AGXGGPJ?1,%1)$5<*8>XX6,2/RE":^$U] 4YO,!&1/$WN2!$WX
M>K#!QA=.["RTXIL=13_<1G.1C7DNMI%;9#=@MWBA[Z8/W>XT"Q"#0"P4E1V@
MFZGMTM'YX]>KU].I/:>,ZM^$;+^[Q %3!FSMK'F H=7K!,\$2U,,6VJ97-5M
MC-+KC7*]Q%=0PBD<5&I]"05T!D%>W; _N.]0C3$FW'!K%GO=G.ST>1 3G-4D
M$[O"ZGHHYOK%N)$YTRZW(8\TT@TT3\/9HT]-5NK[MXP=5O7VH^<GCUF@T'[R
M2'BX!,"$> 'FFNC'\W:1__//?SAZ>OAM<*(-GLD8F*:O"J5.\=BGZ%0X%UV5
MQ&,3?B#U^[%0;A2,@EJ#W *T\8%(;>A9>1X/*?G!AK<@;F9:0-!L4P+(]P=F
M:'4_P(FT\A>EWVL.SQU# X.CNT.B286K. N]:9T=;'WC(&\<EI0FT5]W>/ $
M1+,E0T0_<R;H3 :^.V<WR'-P<-L;R3AFM#\:9]B$5$:9GS0WE2)NC-KTDXYJ
M)*[CXU*<>&]I"]MB+/Z\H27DF3_24QK#X:(UCX,S]NH3]D0:_]CT^/@/(^1?
MR4V>BU')2^1\FDJ(-,/R[2U50O;EJ?>U=,\//]_RU+TY+9Q;!C=7R[%YY89J
ML9F<@^/+^%$A0]:!OKP$OC&]7]O8-(^X'.CB0I_AKQJ'#F33UF=(EO<=\8!9
MMUZWXH!:).K+#=08$0X'EE'AM9FU)IK,TT.+=QR##$*2A^F;F+B=S#?;'$J3
M5$*[WQ2<KP0H?QW26TO?]6A-E"'_8':GZTX=+OP@*94\>^(#1RE,KGW;@7=P
MZ;QQX?6U &6PQ:V$GMG=<=$K[,#YQ>XD ]V?YH>0NG77S[C)1&D]^,LF]XE*
M&SEO5(H +QB.@I@JAM#29\2L"<*B5HO\$&>PHEWNI8(2U*Q>E)Z[E^UV"$3%
M%1A.$_=ZLZR:'_L5'1G2A2'4*TQNPWKF)<,4*)6\/JO9GQ)"4WC[9G7XY\-U
M];4?#('+KS;=*GP^%BT5\%'8560WV&AX:LK12HT7:B:A%N1 ?1J09>QU9M4B
M>-IRCAL6;D.4",K+RR*H<^,S=@&4ESSA,_ ZI*]ZYP'.@G<3#")(7XW73MB@
M'E>DA$*#,=!F@9T;E7Q+TFQ4[AFS_WGD1WN"],(&6T(W;KZ:E6Y7L=<=*74,
MMBC3+O)BS28)E3R5F/&-B&S-K&9) ,7[:ID?/7'$/DBN\A[M!:25;-"R)2J6
M]$'+])$[XA?.&W5#ZBDZ6QB:*#ET38GQ2%,T0O2!'FWGYH'51R)>JH&>+%7/
M+CIA^U^8ZG4CS' 1 BRVB^%)]&=Z$JF@C,'V12\5.$3#2R6"^Q##2_3NTV\(
MZ8E1.60% [\I4VE1G:W0""OO%X!Y4I-45Q02H:UH:'/)I,M'V2![$!(,,L(/
M*H400C5S?@%7"1BGGMQ+(#&-S"1EWT;YAU&0F"I9E.+"T-$YJP* (3+NN;7O
M0<_)]N HUMP">7V+P4PI2[GS+N0BW)GB%H[7PW@IY.F06%+_2'E/$R^4!H<.
MJC"!WER1G')YJ2*%US0@9WHC:%^T/D)F#.QES>RIK5Y&#\<B'%?AP&57A;*L
MJ(3A8D)6), 13L )V$E^-:Z-)5'*'R[Z_:PVRFLPM+FG+Q=NQ3$^:5U?38RF
M*O.J@FW>#&)7Y"N.MY29V:2?\3U[3E2; X+G%(OHP$C\,I$Y"0&&D/56Q5ON
M+;Q@GU<%$P>A"1>%MSQYQ&*H3,!U$Q$2"W<6J(P)<U#ZJL_P],/)&,M7QQ7@
MX,K 2:/2<4#A >\>*'$?2D[]5U]:#@XUU7.PV H2=:T3$FH(M[Q26:=*;49
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MW>9"NHAU\S<1D'F0YJ<'ZQ5I+1O8?;3/H'[J<YPP,@6IH .3*ZYX-'>^="[
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MO.UND[B]1<;R-ESS]Y1C[%YE3)YLSYA\-:L7&_<_Y]VJ^K?_ U!+ P04
M"  /E*92XCP[Z203  #MV@  $0   &AC870M,C R,3 S,S$N>'-D[3UI;^,X
MLM_G5W#]@#V ==NRY"3.F_0BG73O!DAW@B3=L]\&M$39W)8H+R4E\?OUCX<N
M6Q)UV(ZR*P.#Z5AB':PJ%JO($OGKWUY=!SPCZF./7 RT#^,!0,3T+$P6%X/O
M3U^&9X._??SEEU__,!S^\]/#+;CVS-!%) !7%,$ 6> %!TOPFX7\G\"FG@M^
M\^A/_ R'PX\"Z,I;K2E>+ ,P&4^T[;?T')J&K<_/YL-3;0*'A@Y/AC/[3!O.
M9Z8]/3N;P9/3V5\7Y_,38VKHYG1HSME+8W(V&<ZFVGAHZ98]U\;F%*$S@?35
M/_?-)7(A8!TC_OFK?S%8!L'J?#1Z>7GY\*)_\.AB-!F/M=$_O]X^BJ:#J*V#
MR<^-UJ]SZL3M]1%_/8<^BILO31AL-%\BZ 3\*736?O#!]-P1[_18U[48AF/$
M"AJ8^ $D9D*#>(2$;C& %=!1L%ZA$6LT9*T0Q68"5PVT"< ;6&EWLEQ-1_+E
M , @H'@>!NB+1]UK9,/082 A^7<('6QC9#'C<1 WCXT&F=<!I L4?(,N\E?0
M1+7%]_$7 +ANL;OR: !(#H$-_;E@V*<!!QL/Q]J0RUU:PZW'\ H3SW8P!S1"
M3N#S7\,4Q8=7WQJ,ZC,0^L,%A*OF3&0!)2/1D^;,9$Q=F\UFHU=NNZ5LY,U0
MM!_R/X?:I!G9,GNN3YO]&L9P^^ A';?->(CA=N2A>)C6824+^4T"<EYFG!?M
M9#=>VO'1EHEB=U)3'3$ )SMM0M!'YH>%]SPRO9 $=%TY(GT58/RC^6#<0&DA
MW)R/&(C_44H?$N(% @M_$CU;K3"Q/?F />(F?1[;]0.R8^>?F_D*G(?XYQQ2
MDWI.A:<9K:BW0C3 R,_.F@+!DB*;0;/^#F/O_KL#YQ\8)W&3'('-P<E?CQ@(
M<F[3GL2PW$XO!CY3AH.D;-YSQTWH-.TX S%#1^CY/[[[%K*;=I^!8(+_*WJ_
MHJAI[QF(SZ*K-MKG\$_L/<#6Q>#*8R'_/5PP_OCS[P\W59&8()^"Q;AC[*E:
M/HY9;,W^ \,T5Q@" 0DXZ*^C;8 M5*&/K#OR4?R]W=\(.&JB -P:);7A-LVK
M$"QZ&,M3*65B(<* V1^^YV"+)TR?H,,#F\<E0H'?5/R5^!1ZT81>)DP9CTR@
M*%%,A!-DD8((*Y!HCSK+R/@>4M:])0HP8WC?"MQ$KM8F=PMMM G^O$'E+WW7
M;B) W[/OF ,7/.YC:)8@5FM5'X^->EI-T0//!BF!HSY3L5]Y+NOADK7!S^C6
M\_>MUCQ^M78-EL*TT>X&'< )';6<:N$Q\,R?2\^Q$/4__SO$P7K/:BX@H-;S
M=#P^::/G+*$_ 4GJJ.G,>(/^\HOCO>Q]'"=XU7H]&8]/6XU?AA\( CW2YC7R
M38I7')MG?PI]3)#O0V(]AJX+Z9H-*[P@V&9!" DN3;&^@LGBGHG09#E4,PWO
M2$NA=9:M:9K,9[!O.IX?4L1_I 2Y@F.2@-$$$5$QH%.R(*4+8L)':ZBIH2ZL
MHI9UL'1^<BCK8)%Z]%>?@O3=E/8$Y\[;FDE$464D^EC7#V<DDH&CB=15V#4*
M(';>U$9BDBHC,<:&<3@CB3@X6DE=E5TZ+%SCRR9?/'I%D84#GG9U8CU5K*BM
M:FJ(5;]#6-40)*P!QAN0S ')W='F&BN:UZ-8H8,\^U[N):P9*,\"5SR3^.XC
M.W1NL8TZL,&FK*EM\L00:Y>'L<F85=XZ9E9@2=@%DE_ &3Z:Z0ZV<,,D0!:8
MQ1^7;,@'_CLQT6JVU.9Y:HA%V,.;9\HHD)SVWC)CN5YY[AR3-FOQA1C4"?Z9
MEI\B$P5G\?1<$6V2*P4>=<HTTVLJI8\94)%4OT'*MX">V_G>6AB5;E,;&V)W
MHX;&AB!!??1RD5#2Z>L!F1Z;1?X/67)2N#19X,)":S;5W&(XQP[F12;L7>@B
M:V_*WI&^VC0T0VR(U#*-[ 29LA)/D#$S8N+-L ,B?H[V%$GR.X$AR\:0Q6)@
M7H\-O[ WQ,30N2$V_\U;[<UZ&E%3VPH/P.K:2D*61_I $ 8)99 AW4NS>$#/
MB(0-J[QB(&7(I.E:/H.+(/LGX#9QT2:H,A32#+U4V'T,?J*N9R<L\8#)!RX6
M%"WX#NQ\S=M[]B6+,\A";,6V<G:[$E/[NJDQ/BO3[/9,*)]NT 7S-1!B80TR
MM/OL[':+@LN0J+5X8HQGY5KL=ZC[=\^S7K#CL'!M>UFFF6I4B-1SU:F67\Z)
ML8DP,K<,<]0/ET*;::T:G7JJ.].;ZJJ/,Z!"RKOYOR:(U3YQ9FCCAHH\NLI2
MX:?A1]QHOGY _(LS3!;?&0?[UG9M@DHKF(Q9ZM_8"K)A3]*813H)?< 9.)I(
MF<:VWQS.-LHHJ8U"8SG^3D91, ?TT!:*-F*;Z;@0@S*6FDRT_!IO\29KSS71
M)GA2X%%&31-=KZN5/D9+16+E7U1X1%9_%[UOY3-W(:1VF8:AY5: 2A0\!"E)
M10G$T6-*0>P6+]?"J%;MU-!R&4^I:OL=(#\N6?P7(.K>D&?D!^+SBF;Z*L2@
MGO%.M/S6E4 SY'A !E'/-=%FQE/@4<]XIWI=K?1QQBL2:RO_ID*D=FMGAI8+
M2<H4U$-7]@5B^@,Z(4NB,CNE?D##%EZM"IG:P<VT_'XKQP@$2AY"9'=4$ZQ'
M9<62:./XZJ%4^D!]K+=27!\=8H6X6_G&FCB5;E+7#"TWC]72X=%G;@O\RA.U
MMB+G(CZVH@,1,C5"AU!S?:IJ0Y@86JO!++Y CC@ &RQL5$<=[26GN709LT2'
MAS"7VD35UJ(;6JYNH)ZU9-=12RVGC]9R:9HT1):3#IIFBB^ 5\9=3(7YVH\(
M"<A@Z;4*VH16I5C4T=14KZ6./D9/>8FV<HWE:-3.[L30<N4UA9KIH==B?ON9
M'SK(3/(1$>S1;U[0=,"4X%![KU,M7_.4000D)B!0]5X?;=R8$I/:E9WI]773
M1W]6+-K==@)JXE1[NIDQR17-E"JN[[L!Q1*_(0%BW0H^OZ[XL4Q[U&4)9J5&
MC;$QR17 *#0:TP 1D:-BTZ&$@BMF[VN6L(@DY\X.EBA.<=?['+.U"*G5KAF3
M7(F+:B CEH%%-*,4[LX&C&R2PZ^/EJ!6D#PL[]!FL$E%;0,38Y+;LV]E Y)H
M+PU@UZ,=FYW<.-$,7<N7K6:1_/%_SB;:Z?_V[VS&O"1WBY=JX%,/+S[ ZFNJ
M]]$2<R_\7)Y[1!^7D#;\)G ;6#V&IEJ^Z)=[-XX",!Q (.FO[-MD@\4HE&F@
M<:+G?5E>#WU, +>DF2[*L^GV*F70LS]!GY_E8EUC)PR0M05W&5V(Q>47>%>>
MZWHDZX):.<8WYDWM9$^-2:Z*H\"$-K<5>,R2X50<E\-Y%=5L$;=%6+(L@\ #
MDND-IWYTW5F+D*[ 8Q;D\WOXX#T+)4F H>.LA9C97'?CKJ#9KIIU?V35-G9F
M3');X)4V)I]))N0EA!!D^  Q(T!RTDN[$0.'C3Q^[K7+EQ,$/RW"M#P.=0 P
MT_(?> A$0X$)9%'U7A^MRB95F)1!P72LYX.S,MWT,30H%NT><IUJG$HW.=6,
M2:Y I%1Q?<]VBB7^V;:1&43W.<QS;^62*P^3HK/[L_>V[%'Q^V!#;2N\_K:!
MK4B&D@LHAO-\HW@]6L1C\>T'&_?.'.TLD99X>B?.BKPTV1ALNS#9&+O:*G1C
MDML65%B%> 4D(1!3.FHY$=$#\EF^8HJK1-A[_DWR ;1=@XI:ZX:A%Z]H%FL]
MI1<9@/C6^JC^_##,)N;W(367_#9&?M>Y[5&^5?!X?Q^-4GXRW6K?L\A.]-4F
M,S7T^C%B/O>/F0&"&\#8D=L8C*'$G:0L]=*D;@C3+GJ"KTTC_RR@,@F;GFCY
M3T8E-!#@_91VJP%8 *\>0*>&GDN L[+OI<WSY3PL/_F"Q$IJCYM?ZZ-"I!X3
M9UK^6]L,-K% N8&O1^JY1C:B%%G1P65,%/>(BO,SB8GNY@Y>R#B_Z9'N-;&J
M%3?3\E\3QJB3H]:X]C+800;]48\YB>^VI-&:BM)QGHP-O>!BB/IZ[OW"1UN]
M_*Z]C?X9G:,%O L+>$ N9%3)HO#U09U"/=)J.]$,O>".CD9VDK!1TN9H/KOJ
M\%!>I2[QHPEU84(/R.&'$]]#VOPKNBU8951X,M'R'T]'"$"$H;=B;WG\<1$*
M]2C2#3T7FF\IH9>CX!$MVAQ0%$.I+=_0\E^+QZ ]E'&K/?1-6.6N^<E4+ZAH
MB!#T<I<\ZON.^^)E6-0>Y\30\V<_Q<KH>_@?"R)>E+<\.WH47URPBZ8JL:HU
M=VKHI6XKLY%@B:UH^3R]Z.*H3)1(_=+Z5^BS&?;OE%?H4<]N>0)T&P)J%9\9
M>K[T(*_BK(9C6D 0 Y+:?[N^?QV]^N=PM<+$]O@3^9L03_(N'K$GR)&E%MP:
MN/Y^?T+FDGB.MUA_1>X<T0& <S^@T PN!@'EE_T0Z**+0;X=X:<YLXDJ;O<Z
MIPX^7R&*/8OS=3&P0AJ5"/HA0XJ#D/]B6@E7%P/9' ?('8! -"<>(:%[;GD\
M![IA+SB6P:B4]8)[H]+[O6XL7KMI8Y@<)AW?]'59=.W85<BR-!)D7\C;-OU[
MN!8XB'47+#?E8T/'3P34$3?56L#$#R _REF^FD.')Y47 U/<KEQ3-_*)ZQ$V
MB.BZAG+XM@>7TF\X6%ZQX>BYB"8?'T8^.)4/RW9-/LP6J%2^[1'NWU"9E:XD
M@79FNG$Z3J322.=-[$N)YKT:1J2J+]1S'QF!^!+<6+U/B+KR,"/^JU0:#;'L
MW03DDQBH1K>OT3Q(3T[*?+?YM&13#/\<@2.X%KZOS <WP]&Y?[XAS)(@_[)=
M_GM#MKV8/'0EZ^8BOW:;/36IQ 3VA;Z)G+9&BH7FAQLH^?Y%Q9%D<<M_MY.1
M L=[%43)6/?CX7WI.-X+LOB8CQSCO>"YJ?.H@;![/U(U#3Q12'RYYBR_5(V/
M@/!O6&PAX@W^AY@JBD^,BZ;.>XBM&W(%_67K*>D@O#28UPXPF=\1](1=5#=J
M+FW>N7..=2?B4%\D'"5U@?S+*#_6T[>0\W\GO]DJ]SM[PGZ@X>9+HM5"$GSD
M>,[<C/AI+9J( G<VZXA,]P52ZRM\Q6[HQI6+XOB%ZY R"[^SV8"0.TVL$^S_
MG]V5XZU1>>#[MDSL, D<-FZ\9>8D)F\>Y!.3S5IDP<'\RTAL96.P!N"A["R@
M$:W.G7J2*77HS#,\=#VP123-N66&>^6Q/HBE(MFOY+J34E'5A&Z?@1TTG/K&
M!@&;2>\HWTV+?F3\=.;3;JG8+QY]1$$@T=R5G3.;*+=B9G@CZET;6%6(^<T+
ML(D>D%P$8IW,!)NMXU8UTM[%KC5CE#?FIMOX]0JN5BR0@(ZC#ESS[3J/6,5M
M']RBOT+Z$XE3'1Z1R>*9H"((KP'8>>?J+>U<OF)_M\4AB6$/W;6"<XME-LS:
MY=!O&?G$8RI>F8F^"_V&RF=?%<A[7<+8CAAV"C?V'6T<-FY/<Y.2]&5>+WVQ
MI .-UF;4V=(!R.W;;;<)6(M&]R-TT#UET_Z=_/X[&>UJG]@>7^>N,G.FXG6(
M)N/)M,+]E[;OO"MQ=6B<CXMDXH:83F@A*[^>3:S\DK;":^P!]W^4/TV2@)8N
MM0C^O7K5K<KFC'\3"1-]QB;:*=?8'X'N\X[D#I6O"/(2$N'S%PN*%C! +)Q@
MP\/'IFA1*H]&.-YIYI\N0[/ASLMB6/;#"$ GTJ=?MP2D KQSOQK7!XBZ89XA
M+_&*;_[%!EO1T=K@G7>4KVT6E%;1=*43UUTB;82FZP73 Z\B=;5Z]8Z7WR\9
M4_\057\LAE /G\*FG0\5J17"UTGP,[IG0IN,-:TB=%3"=-XE64GV#^18WPFS
M)7E%%Q(;^Q4>K@YDY]W+9"4\7LN'9\F<G%:'JLK'6B![K^&?.&1 S+Y1"ON9
M$7'Y-S*?$$',=5=40-2&[SYXR\1;-V05Q@7B/SP^-SN5BW^UP3LW][K[O)^V
M5RZ$E^+.:7-;=^<-Y?J$NK>2TO6,^ J$2Y>GNW?VUKJ9B';4:6)[K._5>S3)
M[1H75^T'>?<655@]&-=)1!\D9EY6E>^V1?=>;2A[BO8/+U"4K^0:'F8I%9,
M+1 ]Y(IT6E0>UU7>V4_+I&HI$_U7;#V^(0<=%[]?P14.H,-+\N]LL7-#H//=
M1X^>';Q 5;Q6"?AN4Z4?G''.X^WME3HX*6K9>1RR'3')7=-H3R#^T +[/YO%
M7558.N]V/M=KFAN^FZYDSO@47N ^I'RI.WCR,FL5EPN*!)RZF^UP=2Z"JL)W
M<93DG<T<BDR%6U?0YQ&]6[\41UV?H/G3\195BZ EK3M7[0.OW>#91]TB; 5
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MY!S>3:;%/3W)G_SW072">L,SL=RCO2,X"I2Q3)QFUFJMA)!-3,!'TMFG0_5
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MS#X0;R(EUCO/G<T^TRI5_1I@.]D]:Q5.-%VKCM1-A7B>_:/'!ZS.^9M K!D
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ML;/@6H?M ONDVB$Z.T&[P%3*XZ8<"+#L2X5Y15P$15*$<J*LO7-5,I,??;O
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MC,\FLYMU+:$6I8J XU6XY\EHB#-1$EX:_1EALH8JQ\2-$5XN:[I5SC:+9*L
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M(KU)Q)K B 03LDS:&*C34'0OI.^;71VIJE)0_*V%_<Q/IU]1,D^N)M?C^2!
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M6K_[^-.Q<D[%HR"MS[C^>TMQ)V ^$!LL@N:.F@ R<UGW&JAO_CR4"'4.]#E
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MBF536M*E*AT53L26A_KJG(0LA^B@0Y(L,C/^.9S[T9]^"J]>/5M?Q,4L0E1
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MAIY@B5=F*M/ >-"RD<&$#[W#!?QIDP??O/5[M8..%WV'!7MN0*Q3Y1O .,"
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M[NOI -I#8JA!RZDCTI:$0(<_1H[6$U5HYN1-C^# [,RM=UZ&D5!3T!UFJ!P
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M]8+:)$0A#=>9-I1(6TL,!;Q+=*(I<DMT$5K')@W5]I,U_IY^) 8V]_,!I=[
M]]M&74VF$64))=/<.\B9V]HZ@BA#.LZTY(XL'<5UFZC.;I(N$@L'2+N!M;>-
ML@\WR\42K]/T^O-$$SR%5<2FB0Z4E@*(8 _.H'*,"6_X:)O# [HN$A&'RKU!
M7.#[V=>OL^OM.Y?V 2-G&LC25: 2KQ6.9)1:Y#+H'*-B3?:'/32]>#@,)>\&
M]T<?D/81YQ_F*\[3JLSL8YZOJ)U$VL6XDPI8R>3W%$9HI0,,3$#O;>3)V393
M,I^G[9*@,8C\GT)$'0N11P>:Y84,&)X@6A9 6:_ Y7K-G6ETA=OH<Y.>3!=E
M,!PLT:?:/7H"]]/#B5QC A:=1B9D.IR*"."3X" D$22$L/9)P=J *KXD,^ X
MV3Y5]L&C3F\350_<[-]GRSSQBC,5C0&#3()RUI"[DNLX1C28"D/OGHU#;'WR
MBU7<\7)ZJK2#!]+=$A._Y'1SE6>KFN]2<EPN5I]_JR&6^0?ZSOQ3_N-F'K_@
M(G^<3V/^4 .-],N+Y?1K/4Q^PNE\=:"L_N[!@?,IITQ"2[?)+XZ.N<@,2-(O
M$$S)5>$5GSKZJ 1+_LDTCQUH&(ODL8K+!@776>KSU.5IB_F2+*&;.MCB#YS7
M^-_7=0*F!@B=M: =UMD6G,[%Y"-D.C.38 Y-I]YG]/P'YQ#]:_,,VD7 V#GJ
M<\;(;$!=#1CKJ/1\D\:[S_.<;RMZ'Y-XEX?M0&2/W'<G8'6F;MP4^#"*G(VE
MA9-!QNOL4W(<8@Z:B-4:T%@-]:)?LB&ZG+NXOR\!*CMRY"=$2A_A#UT7]_MT
MB5?_)A/^YY^_7R=J?2*/6Z$#+2TQK#R=^[8DD#EBD=8EES9;4V\WDIX^>SRC
MN:$&9L.)KT%:Y+N;!5EPB\6[^#\WT\7T?D9MO8EI:B:_9%][/62"L7,)%+*<
MBU'DG3<I@=]!SYO1L;.,8@@--@BH;R.K?J25=3?0HP.!+6ONGJ7P-.5W@^BS
M T:.5T:#[-SSA/I8K*]S?5A4CI:*MH"%MF*T@A=IT"FS&:%YR6AYID3O-&#I
MHX.A+9!WM%_^QZHJY_UUO&LEI272GDEGJ* ORM)Y'*)A8"R/ :-%EKJ-0=KR
M\/$#=P/+?S:@\,8LM/LE+W^>+1;W::T#*L(V'S%8^==>VC8'=T<=)2_U#K93
M649?LBHQAE("DTK+R1XJ!Y#;RL XJ)YN^X-:R7 ;G1N2E))<JI*L(^-;Z8C>
M>L:*CLZ8:(1AFY)\2O$ \GQD%'Z/5_'F:C6!>%:^P\4T8AT\?'5#IM_&W[U;
M+N?3<+.L-"UG#RS!=5C]B,+'D2ELA8!1);L!+5>49$$K%H*E3R5D*6H;RZ1M
M43:K36B-*.-!,7N[+F;T^XM_3Y=?\..,Q+"<XM75WRN"IW_F]U__P+AL <?>
M+V^/M./DL5E)'2P96>2MQ2!4#!Z3=#KY+)RB4YD]V>F/(.,X*_L=/3NMG_MK
MCC=S$FQ>_/A7O+HA;GXBBZ0V=B"4WHY6_Q'GU]/KS_=T?\OY\*13=+( =T&
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M[M.T1\5FJ'DP[30(T*QI67NF78AI&;=[1,UI0G8#:FL3!T>+NKG^;5$LZ5)
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M8E6"U[D@I>#@]ZR\ W_CHO@-R'Q]#_ZVSG_+'@F$_U'=]'K]\)1GMW<E"+S
MW_]M_F?"D PIIC#Q P)12&*82NQ#FC(989R2.$FO;O],8Q2AD$604?5+%.
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M<2N'8SG_F)9A5FX- 5"ORFS"7@.';18A,5O=?XQPV< 1F2Y!]H3\B\)LA=)
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MC@XIJYPT;QP/SE&I[W*MIN7*T5 \(-?QGOPR1UO??A<YRXI=%O#"BU":Q"B
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M2O-U40CU?_Z5?%]P''$OY@1&G#*=1Q-"-3$A7?Z:QTG*HB@*%X\BIVO3Z6F
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MLD$'K\PG'3T7Z_UI#'B1*,*D8W,J-C&M$@/70+H%U'TE826JLW&+&$=Z2T7
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M"C3*CD>;9J",27YG)$Y*86;6[Q.1X5U#&F:3AP=%;V2Y;,[O!CQ,6!HR*/R
MJO6ZU.SA2>@''DK\2.I"5^:-L/>>/C>RJ/4#6D&;?LC[F/6SP<5(./[X.R ,
M.1]^@(9-U^<+4)FJF[/!*V+9E_F$T?W]EO=OFK"/\@E]G_='/G71,!?GHRA?
MD^+N4[Y^S+C@KYZ^%3H+\^9!Y&J\5[?7K,P>*PY<A$GB"RXP%%&J5LD)11 +
M'T&$4!@S'@0^]Q;ENB1+,W?'7+05FVT5</>JZDZ$3*D.-GIMI%:ZZU9GY0^U
M2MNY01;C8.82N4'7,4-J8+76H%5;KT-_^E:C_$>P51Y<GX?9VE^R1VQ,W\E"
M^J1^E#TJ^S[5@"<,[6/X6NCB1,OW*RZ^_S_B:2%2+&D4>= G2/?E0 )22I6/
M)4,J:.+CB!OMB9R4,#<_JU82-%J"2DV@]+1M9[@/9#_GC */8VJQ1F9 5\,3
MUE_<UW#_N1-W-CQAUF%OPU,7#G--/HLE*76X)R_;:MQ<^"3$/(4R$CY$$9<P
MY2&!$1,$^30*D\ J"^90Q-P^Z$9#4*DX\&39$2#-?(C+X''\05LB8^T.G#9^
MS&G_B)1)I_?35NY/XSU77ICA\.JID]_]+A=_WX@5>[K^GA4+&2!?!"B!GF ,
M(B()Q%BF,(V1SZ*8B"@*!R4UG)8Y-P;H'K[8*@I^U:H.[7S0 [@9,8P,HV.F
M&(3@\+2#\Y@XR33H$?LRR07G<3B93V!PZY 0[*X1D6[TLCT6HO><UBLMJ96_
M.[^_2%"0Q %+8<AUF5$>A9"2((2![L2"L$A\L],9@S68&Q]UVSEQW;1HN3W7
MQ5HS@-PF7P&^M<0FUCEDJ$RBPXX'P'4$N8-]U3!J=Z9N:P'H-'5Y,QGV-K%H
MQV,P5;QZ_+&P#&]?@&-_"'S(@R<,DU]@]_-0^B4/&AAN;_(5/HL'73I[=?MM
ME97%(F813JCR<(-$A]99I-:U"8V5KYOXC,D0!=*J^-9Q,7.;27991'FK)]AH
M12U#Y\<Q-0R37XR4ZY#X%J2MBN!;+TCV@>]>#$8-<A^7-&U N]?:@^!U_]4#
MVW4H@MFH+^S+6I:_DUSL53UIMG<37PH>2@8I3Y$B!1WL(C*!(?%I0B6B-$T6
MW>[VY_M(F,BU>?>[TEW.M+7:H&CT5BXGTX7U+(G"#'8SWA@=2N>>8X-AJ_#5
M04VE\SD)]LTX;% :M1&'D>!IFW#88''0@,/JYLOC[5]SLBKT7O9Z]2%;B?>Z
M._(B)+'//1' - XE5#X)AS0*E;\B0I]P+Q:(6P7CS@F<F[_R/.+<T1C\JG4&
ME=(7Q.:/@FX?J;\4RDGC]M8H7A3'[X/&553_J,P7B_'W(= 7\>^];VB;]#Q[
M5(OT1\5F19E7:W;=(***0W.2H%@Q"HPP%A"E40J)ERJ@24B93&*?<:O<ZCYA
M<^.9G:Y@I^R@B'\OQ&;,,A9PCEEE$&8#VJ>?!V/<'NH]\B9NI'[>\L-NZ@;W
M#...BHZD^A:O5_R+R!\SII9F-_)=MB(KEND4A%9@\55)*([_JMD,#X/()S$C
M4#>H4/_""%(O$3!(:"*3E. HLNJ).*9R<^.FK::=SZP8F)<PZB":L=E+#8UC
M]ALX*M;\YP*^,?ER5/TFY5<7R.[SL1,9 _9A7VT*Y4(6A5K44B5 ^Y2OUZLB
MXU5"Z'K5ZID+_O;OFZQ\4JM=H3Z7LGA?%)NJ^(;^@S[HI[M1*B.47L^>\$FH
M#VM5?B(9?[_2R:>+*,24>(SIU$\.$4Y2B".)(<>)0*GP$\D2XVW<%S!@;O/
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M9(W)/D/9/^"2)%']H.NRS#.Z*:LCM.M/:D&]*A=)@(7/D(0<Q1%$DON0TE#
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MZ Y*UXZ?T(FG6O6FV/VN/KZ.#]<&@*X%5Z"R8427;QAXHWIZEBI,Z^ -P^?
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M1.!H'\CT/L><J<'!]W;7^>-Z*YK??GU<5EWCIUJ)_J(52!:IXAD80^4B49(
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ML]AH8>1.4=L_UKKVX/N5^E85G=6[X ])>,ZII*"D!*OEHT@!2;$ F$HF\DQ
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M/OH"RV+9[P>TB5;ZKN#9+>XO0S*ZGA^Y?;HE_&4;GJW:#2YW6ZA_K\4GV;L
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M@;]Q:V2LIN=1ZZ^8IT\_=[()>]2LX<P]?J%;,.!+>TCMB]#44*WNU+/E>O-
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MKD;2X:"J(3I^SZA>$CKQ\51##(Y/IIK>&#!VK'[)]#&1.[%@@I0P$0*H_S$
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ML]9>4X7GV?.F*\-SRHQG=7A.7N V_?\FB$XJUU_R^]7C4^-[-+%RQ&5<2$E
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MEXH@("E# (D<RY@02+E56S #F7-CO?VI^\?=J?M=FXF;Z*E1/%HJS3U5,!C
M;T9DGD$-S%^C50QNHE;GZ,,8GO[J&!PC-$DE@X'8>=0R.,;!N)K!B5L=^N7V
MS:2[-+Y!GH2FOK9#8M^>]W:Y7/_1=)IYZ*I9M25Y%YPQ1G!"0"PP!Q!G!"!&
M(6"Z^2OFA4RD48:>-XWFQF6=GM%VKZ@N<: TM6B#ZF6HQIGM108@^+JM:Y?>
M)Q /#(J417U[U5U3<+6RZX9K8%97VGOJX;+H;SOUL$W4"7>:X;-KG.L3ZM$6
MNUX$3=>,UR<NS]KV>GVP>W+ZMR['=1'S#!*6%R#AN>[X4)8 8XE D>,R9ZD0
M1<(6V_66+,V6Y\.'6\U=.Q'A/D!]U)R1S>:GSG8B#[HUGWWZ^0XYLY6U*QZ!
MIY+GJ>9^<\L/S?6=4;Y[_N1YY(>6G<H>/[KFNO*G'W8U^D4I"IBD">!<9X(H
M]QG@+"E 5I9E0:G(6&EU>.1(PMR6FKM2F^XM$HY1-/MJK\(F\*=K!XMS@=$C
MTT/4$/WP,L7_S]IXKA+H\85N7_7[%=L(4HLWHOWO^U4_U_^SVMZ_?JJWZP>Q
MV1<49X5D.$$*0IRHV9G39O>6@"++<\RH$(A:U<>PE#\W1MBMH+LR&79D8 N^
M&54$A#0PD?2:1[_TNO^JMU![]:,_E/Y1;T"00NZ.V/ED(EL5)N4I1WP.6<SU
M,6X<UR:^:.:L;U>\<VG>_MF5='HC'C>"58TWHWY>BN;<_HK?/NA23_]NHP-<
MTDQ( H&4N@$L(1@05*0@4;X*YQD726RU97J]2G-CPF_:7=HEP&WZTIBBMRGB
M Z.: #D96&/'FQX&U(Q*IQVFP.S:9]XUYC0CT!FD^TCUHS2TZ2;:6=7VR+XU
M&3%KSO4'LD\:]J#5I,SL#\5#LO;X9#?^?D>J39,WLZ]U7^_.NL2,8I;'!"2"
M,@ EBP&F(@6D(%F.=;? PBKG>$S8W#A7Z]IEF@VT=:X_/XJS&6'Z0B\P%;H#
M9\UN)HCXY*U1>9,RDHGEAUQC=(\;B]PRM=9LR&G 3)^D%J3CKIK;/F_$0_7T
M4+_?)WHM<E1(I,/1RO,5 (I$ "RR'.1%FI:*7YCR@?OV9M_,:<9-&Z-/Z'F;
MLV\3\-!>0UTFLC&@62\\MA9<L=)S'#0SL@HX!M/0V,Z Z)>A";_J5=[.BF8D
M>CMT*=N=)?Y([CHD?=*?HR:3$N-U:!U2YI5/<W6I5[K>?=M@[4M5_^O5SU=B
MQ>X?R.9?S4E&6I1E#B$'><ES "DJ 2H9!A0B*#&.62*L.C=?$CBWI=DS?2.M
M<+33U^G,Z$7$33U:?S@&]U?=(71P0LUP\>MB7I YL0-IAL"Q>VAXGR/3=,'
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M7@/=)'%#7\"9^;G7P!&8%/>J!4@Q/F>W3_?Q2,:DGN Y"P^=NK/7N;'?04V
M_IQO4U)@4#K@%:DKII.3J^63NGJ!<RQYBC.0%"4'D%*B'#F!0)PG)1:E))@9
M90M?I\;<R*"W I"NGLAJ=XJ]UI;4T9.N35*M(D:6K.G]M;K3:4#1LJF)K"YM
MKHNHMK,]_]!:&OVB;FJ?\:L=T3@.L!D=A1^VP*1U5 %F7W?@:SMBSPK&O-J-
M2V>*/X:[#DJ?/.BHR:1L>1U:AYQZY=-<(F/WZ\U65S+[33&YZ HJ-)&YG]UZ
M0"VC$I%R-4!8+Y\*7NB"!5@M145&)49E@2U"99?$S8U)&X6!+K\9O5_]$&T7
M1,,EEB' )A$UG["%#K%I79M"B=%>VWX+X>?E)9G3.VH1B?,)Y52AN2LAM0S8
MF2(T'L&[^)0)0WJF%CV/\1G?Y<2[9M6TZ&$UK=_(G]7#T\-G]6[=JW_[ARY\
M\D8IM;K[)*70_VV[MZH_WSX\+M<_A5A(E!(N,P%R5"!%X30%&!+U1\KS).,4
M\M@HCCBYYG.;#3H3HL?.AJ[N#&^L4&NUU@R]?E9V6#'<A&^#T7PSSS$./G7I
MNHVOQNL[OAJM[]B_(3T"40-!U&(0]2!T3;.;YME1#\1<WQ>KR76>[\UD\_0L
MWQ_;Z7_Z,;RPDIA0H2D7)=/C?+"^>0$%KBB031U4[75L2HOJPDD/#_JL\9K]
M2RG']&DUQEA"<);H/M52;[+D #/! 6)EF>$LAZ7,K0MA!U%U;HNA'44]-C6*
MF^)[6N>HUDHW@<+'5G-R)RR#A0$'W"R@.(]AG&2]<U4]Z]U+\+E_"5J+VVZZ
MS03%O)Z$##\PWLM3A]%V^C+405$_66XZK$371,+W*_V8ZH?039;2.,%=%$JD
M/"NH+ "2HE1NMDR <KPA*!#*BR)+9$J->G)>E#2WF4!KUG[PT4[CIJF8;7;=
M.61-7%9/>(6FW!,H10U^+H'1,<QLLQ,]8#=EIN(I#'UF+%Z XW+VXKD'3)S)
M>,&.XZS&2S=<5Y!GD1(I9%H2(+($ H@(4B19"" 2(B"E-$>E42SR\,%SX\1>
M+[=*.Y:U=69$<!?M=BZ>$V)]MGOVBQ3(.;?V.?IW1Z^YZW[]21X>P-@?OOA0
MK4135G3!DX0B$:= PIP"F,D<D!S1AMZ4D7E:8*NNM%;2Y_;U&AQ[BG[7VK>E
M;PTG;;>!,7180\$=F"^\(6WO2;H@YM4YM%)@6G_/!9LC%\[I(?8G*-YTR\YO
MRC>L*[WV;+N#+!C-J*1JF1$+A@"460DH0D2Y9I G@J B*XUB>V-"9L=<G9[1
M7M&N<XWYP8FS@(Y3D2^80C../4)6YR4N07#%:8FSCY[LK,0EXX8G)2Y>ZQ*
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M#'4AMX( A D&0C,'S7F1)%;$,7CVW(BB4RWZ72MG>;YJ")D9 3@"$?B#-\3
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M=1@)GK:,APT61S4^K&YV(Z2W_^=)MRJC^MELN^ P2TB!4H"@/@Z/DUC]E)6
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M08ET^1,.TD1D!8QS(I!102M3@7/CJ;W.4:OT3>?8-#M;G>)62?/&T(_S4PA
M0Z^??&!IS$NV (T0DGK4@(S4WPZ)R%C6) QD:WE//=;W7=%<V,5M_-363-5'
M"@2_77&=NL74C]_6^E>?GK;-2D(QYL>G)@TQ*2CFE.6 EOH< $$E0#P7@,)8
MLCPN8R2L#EY/I?C<.+#5N]FW$9WFT78=Z2#]3;3>:]^T(*XU K5+^^$I7@G#
MM(P9#O3\8[V=\3?1X'UY.WA?_M&\+P,0;J(6!L_-BB<<..^MBZ?0??I&QA..
MR,FVQE/*]U%^<'!JHOVQ5JHT_963A2 QC!E7:W$&,P#S- <HH1QD&2\P24O*
MTBOJ$8Y(GMNLM-<O>FQZH>O9AZ^72[*I]=9A.Q-93D3FXV VDP1!-_!4<%3:
M<*!V_Y<&]D;S4,4.#; *5_UP3/@+ED,TP&2\/J+) UP);%/]:/R&/M8Z/)!;
M"$9TL40A. :P9"6@:2I 3+E:HA<<B<)J(3XF;&XTM=<UVNT?V)T#-8+8E([\
M !><@1PP<^";RV#XI9@1>1.SRF7+CXG$X!XW[OBGT/V:U"I+$1*Y$^V"ZI-\
MHY-Y!6^69_5@P;6@F1!Q!@7 % L L7+I,4]3( @NLP0E)4566RB6\N?&,+WZ
M$6GUCU:- 3JHUCKC0Q_])N*M6>[.NNUPF5%3P$$(S%8[_#O5.Z]VU\&J?N[S
M=A;YXS%'Y'Q2FZT*D[*=(SZ'!.CZ&,>CI ?'$Y1_6K$%RC%#RO$#21X7 ,*B
M!$2D$O D+H0H(2_SQ.I$Z2DI<^.WW5&@G5-W$U&MJ!>/[S309IQU-7R!F>GX
M$-5-U.CH\33J& 1>#Z6>%#3MV=0Q6X^.J(Y>?,7.";T<S**'P:Q=!>Q!Z[E=
M0$ML'I(%+'FNUE YR""5 &:H!!@S!CB*29E!+#-<+!3ST;75;DD096V^L*'*
M 3^T79A;Z=?0TH-:)-\[;8.$&5^+C8\7'[/Y;W4,F@8-#+[9;W=HFSUO:P0=
M%N\;&6&TG7[K(BCJ)S<KPDITFWCZQ>ZGQZ:*[^KNJ[C3PNL%CJDD)4J 1%D*
M8$$I(!)B-8VP#$*>(Y'F=O/&65GSH_V]H[?NE8WJ3EL[YC\/,)6TX!1SH/[0
MQ0P1 B0KA0(XC7/E"Z@)VNI(L!=XIUCV3P&NV:SH!;+ D]H>K9V6T==+:%E/
M1!>1\#F/G!<VZ31PT>9#%K]\@WVSF;>K;;7]^:Y:=G&'10$11CH(P$I.U7J=
M08 X)"")"4,EH8H5C/(R3SU\;DS0ZA=I!2]EC%P&;OR3OQ:.T Z].1)6+63.
MF7Q%[YBC1T[6-.:<,<-N,6>OF3BEL2UDM=^@K3]M[\7FVSU9=?DG[]8;*2JU
MC'N_Z@ZOPIQD!,894!^^\M1Q)@"!' %<DD)F6<9$F2]638=,;N&I3Z.]T;>$
MVV]I:$.X3^K+U^]U)'L]7R"%T>$5L'#F9S2L?QGOOBO>-P @:A"(MO?Z@'/O
M[.]0B-0[X^NT\PL.WBR2&1W4_VOD,[J/B[>4QBM4<,]J/%$."9<H)WF2@UCR
M&$"J.R3&RJ5-I4Q0CA L<JN*S*?%S&T5VZ35V94XL@'5;$ZX'JK ].V DE.B
MX33EG<Y(FCR%T+P4TX6KO751_"+8^FY5_5MQ#5=45,E*U]^[K6NQK6^9(JI-
MDW7]8=\!L EMJE^VE_2O?2YR+F,D0:;6C?I\8@YHPB20!61I!GF99%;-F,.I
M.C<^:K6+2&?!WZ[NL.AK2,V8;!X#%9@-3_=CW-L9#0V-NA'M36T.X R,C3IK
M;_H+0W!K^&$)W,+1E[8OW=G1,^H&#1]]2W0,Q8CELBT=^!O9_$OH^&M7XG]1
MQA#R)$N!*$JJUIUE K L,X!%AC*6, RYU5QQ7M3<N/XK6:KO7_/!0Z^I973C
M/*H*.<@1R@ 24A](TAM4:8$ )A 5G+*,R:2/1WV;#-SG,:1O?W&,#0,^7M['
MT/&95LD&J)V:?0,5C_&3BUAX#7><ES9M=.*BU4?!A,MW.-9#>M#]9?_=5=O>
ME7%]O:X5U:^X]C%T?9-ZD90)XGD)@6 \!U DBI 1(FI!ST2>\H0FLK JB&0H
M>&X</=1;[^-R[0GS3MOF<ZG4=*F,$1'3ME@613(=#C.J"0%R8.(YQ+<]YMA#
MVFC>H+S3W6-I)$NTO-9&,I4];7$D2T2.JB/9WN]0&?J6L<V3>+9>7?&^8/$7
ML6PVI_;_V)<^3%$12Z)8+,<E 3 M&2""QD"M.;,,9B3.,#?+B+I"B_GE2G5V
M1,N]KA8E@!W'@J4H9JB940A6<TO. ,T3"%((,YSG$C.9+[;K+5G.8B3VFH0;
MAV]:1D1>8C3&IY:), X]RW3 /HN[Z$(HG0V@,V)XP>6RH=Z&P*+R=?BAF*B^
M=9@AL:M??1V8HU6J'1\]72WJZVQ_5G'ZRD<Y)C^+K6Y0\7FS_E%QP5_]_%[K
M'=(3G2D6!<]C5"8QR&"BS^>A'* TIJ!(*&(QQ$6!H<E\8R]Z;M.,TCQJ^KX\
M=KKKG(M]+QZR4]PRE==\+,P<F3 (!YYD-+A-BYW/ W!_T9I'U>K7D\UU/.8
M6R/F-2G87/JT6<+6J!RE#=L_P8W/OK15W[\(7;JA+;[?-,92=GZBR^JN71M
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M?*AZ0T=L#; _[BSP]Z]&?R8\=E\G-M)C;=*^B5-_HS;H6-X)9FF,;[S%NC?
M]E'9(?#V7C?;L';'W/31GY0>^[X3>V+&WAZ>SI/3;RMYQ.%SVG$>0Y_Q-Z9'
M1/GH_O68\GLX2/=*/"Z6\^7#JQ'X?;741F5S;S9O&\VWK>'-FHRDN8"2*FE6
M;41#KI(,J@SA.(HH25/F[-PX"IV:8[)3N^*.YX[BH&PT]YA=7*%W\"$& '3@
M^;^#I5$9='4&K=)]&M"[@NHQW0X [DA391B0_68W3[3.SDRN]QIO5O&T[LV,
MX'MM#S;?+T?S0[VHQ>:PEI+ -"%"IS 2FD D<P49SW*8")ZJA(M(X<29S1V%
M3HW-#RHO@49Q[SI67M [L/D @ [,YBY8]F%S5U ]V'P <$=B\ZL>6#\2]P3I
M+(F[WFL\$O>T[@V)^UX;O.27+7(0TSA!(B60IL(XXR@2D$1)"K,TBO,(42*8
M5W#^>7%3(^X+Y;V\2U!< -OUX"04A(.?F)RMX!6TT(,;*".5ZQJ]#(.;]1ZE
MN:XODO!UN7BX5ZLG6U&UTP.;<,HB\S^8"1N_(86 3' %J4PDPLCXA+E7Z,9Q
M,9/CD>7B1:W652_&4BV*Y0HLEFL;B& H!"PU:/0&565PWUJ!)Z!V8Y/K 1R8
M1:R"T S2$[ JVF8?8KZ1]JBU+63_=[;>K,Y']WGSR7E80O+("4FC\L=Y:_=Y
MX\*W>^86J@?KZ6R+XV\#*C72/%99"CGB"40T,8PAJ8912J(\BPDEN5]ZX E!
M4^.,1L].FX:^C;Y/0NO&$"$ &Y@C>F'EGRUW 8B@"6^G9(V;LW;!XH.TLTO?
M[UF CY5%>:>_FT>F7?O>+N3/XF%1Z$*PQ?I6B.6F.KFH*O^9F6!7FI+$.!8T
M5C"*J"U5+"4D-+%)8PF*>"0))MB'/ZY19FH<\U&58E74S=6,%[(][[1G#C\W
M3T]L]6H_[Q@'=M:!UCS/,GS7#*8;8XTU1$,'+E@S+/Y=0^JQ.3\@X/=!BI.&
M@#5HY;QK]!FW3%X Y YJXH6X9Z@">(VL\H<2JGBQ)\FS)%4DIR@V*SV.(4J$
M@EQ3 8F,E:0RTU&"@E2^.Y3M] Z/7_*N512LMIKVV$-R M^-)X-A^:[E[K:P
M[I0>LLC=:8B&K6YW1.X[E[4[C<3E>G9GKNW'2??JR3B=QF%IFO4T8;VW3U;,
M[7J]*OAF;>7<+[^S:G\D93$GC*8P35)F""HV"TLN8Y@DBC*=:XE3/JLSZ7^N
MV6KMQD_>>OB\8/O:#.A[J(=B86MJ \[FMAN2'TGYCP9-A4YCD4%*L("(I6:Z
MH'D&M4(Z3[#QXJ5H1N/30DYF+%I=AAL)(V'$87";. 8%=N!99*M[$ZUYL\O=
MJ/6_ 5T+P'H):AO"32J]X0LYP_@K,>ITTQNC_;FG_XUZ;F0:7[PZM+W39MI;
M/BF;=;)\>EZI1[4HBQ?5?-INPN4\YBJ1$L:,$XB(CB"3/(,Q588*8Y[%PJ\K
MO)_\J6U);-6W"]\W>H-:\?[;H)X#X[@[.AS<0V^:AD#:?Q.U'UY!]U8]51AW
MR[4?/@<[L3UOTY?SEN*?C\NYN:)IECF3(M61BC14*$HARF(-:28)U"2B).+F
MKR3S:7)R*,*+N4;K4U)V]/P?_YTD,?[?5;ZM;Z?*(Y#&*F>Y(!(:1SF&**5F
MILAR!#DB/,^XX@G-_!<LUP'[EUF1',$SCP33*<M@CF-LEAPD@E0SV\10Y3J-
M5*+3S'?)$0+-::\IC@#I.E-> \W@D^%.N?_9YG$-O0XXC4C8Z>Y RL@SVBDK
M#R>MD]\<("'[.WNM4IZ:<!E.C -NWGM(I& 0Q9)!GN@$2J1B&>.,$<J#Y52_
ME3TU'[Q3" VNU-SNC^^E0S_7^@=,<-T;C?.4,C#&0Y_K.:25-LK?M$%.PR$=
M,!NX/^(32NAU1CYL*NYQ[*[*IMV[Y7028H_;ZI73>N(6?>N,+6R)X_K./XKR
MG_?F/A^73ZQ8S+AQ$3FF"=2:1Q!%.H,LYQ1&D3#N(<:YHGX!\*=E36T:>*,J
ML+H"JRSXO5;7<_OE',AN#F0@Z 9F]]ZH]2@Z=A&/L(7'3HL;N?C81;L/"Y!=
MOB18<]A3R??Q+).)PB1&D%)J?$P<YY#G<09IDB9))C@Q*WFO6#0/X1-DEYVB
M5W=R/8VY&[<,A>0$7,F.ZH,V5KV(U\!=4T_+?^^6J!>1<>AW>OD>/?-T.@U2
M%_+81JZ6F$N:0JPIABBG$E*AC!<4Y1@)S31#R&<C]Y+ :6[KSCNMBFT$9JAM
MWHOPN]%72% 'IJRO>TA^.H^:?^:.(Q1!<W@NR1PWF\<1@8.\'M?K^C'-K3!K
M_$VUFU2U,3MR'/5U69;?U/I.W[,_9YEF7!"60I&+#*(DB0WG(&X68A%7F.H$
M(:?*$3WE3\U?ZJ@/EE5O1?'FS+:H+/!C']\A<2.C 8$>F)NZ&-?]*X^>B_]B
MU?];E<%LS\Z-#>'HJR=X(=G,5X51R:TG/OM<U_<VO0/FS0W-?3X6I9@O;5F'
M3H(2X1H)J6&>X1BB6%#(\MC^HQ1'6@KS5Q^>.R=L:J36O%!&6=\THK.0NO%4
M** &)J4=1F"GZ$ I/BZ0! YS/RUO[/#VBY8?"6N_?(T?8TA5S#XMUL;;NI5R
M99> YL>[U?WRC\5,$\PS)@5$469/*#,%211E$&<B,?A2H3.GK>@S,J;&#[6:
MH-'S!EA-#8[ ZNK&%^< /4\3@6 :F!UZ(>3,"PX8[.B@;/F@5.)?'I8O_\M<
M75.!^6&? <[=>907W\&T]GUW^6H_Q^#3T_-\^:K4C_J4O;,":X]GL<A9DI(4
M9AI%$.DDAPSG&E*6D8CJ7&!%?;R#BQ*G1@'&4UMMFOI+VTY\=N. JX72Q1JH
M/^WGOO[#9>3=G(B@> [-%8VNVZ".CK8!S[N]H0GI45P6.JI;X8S!OF_A?F$_
MYMGVA/_U=?OCOQ=J96[T^/I5O1A4_BS*F8Q8S#3)81ZEAGZPX2!&HAQB0N*8
M2LD, ?G0CYO8J7&05;7N[ *VRE8<].WV'^!WJ['G8;@C^FX4%![3@7GH&CB]
M6<@/G9!4Y"AY5#[R0V.?E#RO[L=,33OR\GY9Q2&NU)?%VCP]MGC:;5FJ=3G3
M6#":2 P5Y@JB-$\@42F&A&JL8IUE>1;W*"UP4;#3*S1^78'OYD:/-B]^J4&Q
M51FP2F<_7KJ,O1LEA8%R'#9J=;41WHVV8*<NN#T/HS<?.4,3DHHN"QV5A9PQ
MV"<@]PO[<<\/5:Y7A3 O;G7\]=NB6)<_?O[6U'Y.&&9Y;+R?!#,!$4<$<EO7
MQ'!/3+!&2J#<QQDZ*VUJ/M!.V?KP&VRLNG[T<AY>-VH)!MK M-+!JU(45)J"
M7XRNY=\"MD+PPB4DIYP7."J?.-F^SR5N%_5,B+2MX@[ZQ]^N5N8)J=(R?WW=
M?:4AM=L_V$K^G?U9/&V>VM7?SPW?5FC[8?R)62)BHG!D?!TB$$3$1N,PPT,4
M$YGF>4RY3+VRQ0=2=&KLU:@+5*,O*#L*@Y71V#,+;J@!=B/!*0S;P/Q9Z0^Y
M-0!TC00=*VWC^>[W&DM!9>H-: >]M19TS04_S@VZ?R[?P",2-"-P*%W'S2L<
M&/&#[,2AY04+0/^AQ/)A8>NZ?Y%&B4(7;.L@-WZS_+?E4OY1S.>WB^[>HOG.
MYDE)VXQ XCS-24ZAQ$38S@\<4I%@F&(D22Z3)$LCG[C/@?3TFFA&"Q=]FRVY
M[O:(;"N^5^VD&R.O#G\/,N)N4\\$QG'@F>=X4/W.2-"ULMD?:'<.S "WEMY4
M6YK=<-?&VL"M+P8>D(&C]H.H^MX!_B'Q=L@%""INU%GGJ#:=3V:"T4RGB88X
M2FV[N(A EI <:J)9&D4)Y@R/,.M<TG.:L\Z;)(5:YU%FEHNC.NC,$G*LICRS
MG)Y..A^^^[3B.AH3F%8NJOI7F%9<\0XTK3B+ZS>M?%2KXL4H8V.PR_6JJ@E1
M_ALK%C88^]?7?U?RH5@\5#$11N'RL7BNHQ04B@4C!/+,UE 4,H<D,ZN6%/%,
MY5%":1K[[(KU4V-J>UZ-FJ"K9Z]HA9ZCXL;ZPV,],*GW@=F;C:]#*239]M1D
M5"Z]#JU]JKSR;OV8\-_40JV8==]OY5.Q*,JJ>,&+^E1'.\ZT4BA3+(.(XQRB
MB O(S&<P03CC>:2ISKS.(B_(FQJW->I6/A%[H[ ?M5V".<>:Y@F24!*10*02
M!@G.$,0)R32+=<32/J$F(= >/]!D+-#=)HZ 3^S ,T07M[>Z@D;9<!.%(RHA
M9X1+(D>E?D?[]SG>];*>P;;&PUZ(@LUW$TCE(;&,)I+)%'(><4/B*H54H@P2
MEF<JHGG*A?2*KCTN9VKDO543[/3L%T9[ E<W @F UL#$T0<H_P#9\S $C8@]
M(6K<$-CS]A[$O%[X>C]&^+9<K)3MG&I;$<C_W)3K'2E@'J5Q1&"&XA0BE A(
MXIQ#F4L6)]S6*?4BA=.BIL8+74W!3M5>U' &8#=V" /;P 31$S%OCK@,1DB:
M."-M5*:X;/4^63A<T;-XRF)=R&*^L3[)3RNAVFVK>V$K^=FH7K=PKY:@=_H3
M6]E2Z>5WM:IB$NIN)S.A)(ZY633B'!.(4A9!)@2&.8LS$65"I5GD55(EA%93
M8Z%*M1+\4:P? 0//R[7="V7S^2MH307%D[EV#7XI%J"LOOTWS[HK04;3C<=&
M'Z.!*:]K#]@9!%J+@'V/0<<F&VW16@6,677$V$W3[2E@Y9:00 >MYQ)$L7&K
MO(3$\J#V2]";]TQR6BV%4K*TTGZRN?H[6UL]7JLV+?.Y$M56HFW>\J+J2:2<
M16FBN%D6PISKQ+!WDD"J<@VS6*G(IHD+[G7*T4.'J7%U:T+]TJ\?%2B937U:
M2/#46&-?__)QN5I#H] 3*';&>*9&]1@Q-X8>>!P&YN.W0V#UMX&W#?9V('8V
MV*'XXH"_?TY5?P2#9EGU4&/<O*O^.!UD8EUQJ[Z52A?J3G]8*5FL/S-A#YQ?
M[6=?UNJIG&F2IQ&.8YA(Q""22$.:<@R-4YMCQK26Q*N-WEEI4Z-!JUC5Q:U2
M%[3Z@M^K/U0J>RZ?SX/MQFO!(!R8P:Y"KT=]4@=4PA8G/2=PY,JD#K8?EB5U
MN2A,@Z#>(3!-48[N'YH.UTVG"G-556APEFH58Y1A2!*;O"YC ;E,I%F#8ZEC
MQ'+AEL'U?B9,C?VV#>";KD25U]&42*UMZD9&7M=)9X0'Y#RY_C6&?6#&OBZ.
M\O94'&4#Q=NR2-NGJX&CNKP"9/)/TG6MG:;U1+UKAZC)/%E7]YP:;U!]6U>-
MH-F[=L :#_E+C;1&U*2'5U8EXW^IVO44+^J[>3N3*(Z;$A&*D(R*6$(4Q=K\
MDU+((I["A&'-B6),1<S9>3HG:6H^CM6LJ2.QU1A8E3TFH;/(.G@=H? :V#DX
MAA*H\+M8=,,3,X_Y-11V(TV#5V#H-T6YX')V)CE[@_$(W\6.-[SL=$'O:+-B
MK;Z:V\J]\DB_E4IOYE\+K6:Y3+.<I +J2!LFE91!PDD.$5%IGA#.HXC.7M2*
M+SV"SRZ*]7G4N\*'>](_E>OBJ2J&NJFT-$M%[1G.ZH2WVY99: P'IMI:75CI
M>U S[0;4.H.OYQ#M$Z[F#%'@V+7+<L<.9'-&XDA4F_NU/6M;5TV#[%'J<F%8
MKFGU:=A;V8;:D%#KP;'(\ Y3$HJ()2B5N1+(:Y_^J)2I>6]-/_FMECU;J!Y'
MU(U9KL9I8"KQA\B_'O4Y"(+6H#XJ:-RZT^=L/:@U??;+/=9P]TH\+I;SY<-K
M6SDQB3(4\1ABB;AYZW,&:8S-^R^8I!'7VI8M<_(VCMY_>F[%3D./Q<8!;)%.
M#"_F.4RIH4A$!88\1@1*E<HH(3+.E!-97@W:&"09!C*'=>PU0 S,@CO5^BQ6
M#\#P6*!> \I(BU(?</Q6H:>,/[OR/+AHO-7F*7W?K#!/?JEG0NIJ69;?5TM=
MK&=81I1J6_Z62041QL(X<91#G!K"2KC4/'':ACMR[ZFQ4J4:>*YT\\QR[ #F
MYJ/UA&%@3JH1^'X> ?\\Q4-;@^8D=FX_;O[AH5T'N89'OM([BO19K=:O=OMH
M?;N0UI%[MDQLR[E%,HDI)PK:<GT02>MS18F&'*64"2VX(D[MPER$3>VM;76M
M0@%4JVA5?,\[ZO,TPHQPS;B6D"#.; X^A3S"$:1<QRA'F=0B\2E6%0SA$2I.
MC8.P&V^&PFU@(FW5O*FVT]?;[M<-<D&+ KI $CCT];2\L6-<+UI^))CU\C5]
M&SG>LS_;<U91><C?-DTW 8I2''&H4VX[NXG<+.Z8AI)K$9$811GG?NT<3TB:
M&CG7RE8-3=^J"VI]?1L[G@+X/'D$A6WHS;&^B/5H]'@!C:O;/9ZZ_\A-'R^8
M>=CZ\=(%?1N.O*C%1M5)1XOUBHGU?Q3KQP^;<KU\4JOORWDA7G>-C1/-",6&
M*7224H@H32#)I(!Q%J<\T2G#?N7__<1/C4@:[<&J#FBQ@^+;C\0+?3=O9#A,
M!V:9%LXF@;)6O<Z#;94'O]?J@T&Z3_=#+FQ/$R\-1FYRT@>=PZXGO>[2LYSC
MMB_VG>X6S6^:6GY8ENORH&9^N7OA<LZR",<:9KFMCX.UW?^.J/&8""9Y0B.5
M>NTS7:G/U/BOBB$YTB+#L[KCE8/DQHHC0C\P31YM.-+I2?+[(-P8"+^@E2"O
M5&G<DI!A\#NH#1GHMCVK"*GUEX4PO&TK4<Y42EE,N(38CA?"BD&64@D)%H0+
MHAEEU&<[ZLW=I[;_9)0#!GC/).X]P'@D2!*E,$9$042,(TUSBF&L8J9R(K!9
MBOO%P/6&;)Q3:0O:UVM!RUD>4:9@A#6"")DE"$^XF9B31"F=((*QT[;%]4_9
M&!6I CQE;O-C;Q@&GNTL K5BX!>KVM_ [7J]*OAF7:6LK)=F#@S;-OXH$D'+
M2[T1,&Y%J6.V'121.OJE?C.$N=%*F:GGHZK_^V5Q]URU)5H\?&#/A>'I6UY6
MJX"9Y#+*I1*0D\R\V$DJC;.=YI!GF:0DEU&2>947<1<]M;?^PZ-UYD"Q ,M6
MXZ:;<K5GWTDF_5<_8O 8#3?6& ;C@2FE51K\TJK]-XOU5G/0J Y^;Y4/Z$?[
M(Q:2>CRDC\I+_JCLDU:/._1M$<'7NU*<'Y8+XSJM;?3R![9:O=JZ>U5]ICM]
M_ZCV AMG5"LJ8IS!K-H^)9Q!DE(!(\FHDH8 !4(^'O(5NDS1GQ:-UH"=+XT6
M?%P<MQ#&07M@]K-6=,KYWH".(>:7=@AJ6ZK:=7N1T2&;2EP-:-C.$OW5&;F]
MQ-6X'?:8N/Z6/0*U3XJU)9V^KPJA[G2URWAO!KI\7,YE&YELUGQ4Y!G$MAN"
M[3D!6<H83%&*2!XG&+F56[I*BZGYC7NO=O?-K@JC@<H6<*>;3-ZM.1XQOKU'
M[#S'CC8.X[*K^Q#TB;?N/18><=ECC,E(\=OA7P^_*.]KH3P;#=[[YN-%C5]K
M_YOH\JMOUCOB]:4HS6/Z>;GZNF15"R9;N[7JTB%G.,]B'>4,JH@2B+1Q\"G/
M(IC(C&H2L8ASKP+7Y\5-;?[9:@OT<@64T5+8Q&91U[6;5[I[!V>>@]O-;P\'
MXL"31]/JH>KE)E3QPFJ7O(;/:GW3]NL!O]AS]%7)YJ<K?_>)V73 *7#4YCF)
M8\=M.EA_)'+3Y:I^9%/5LK%^]DH]FOM5#>#:?5FS7C;../MS)I".I$04<F6<
M8)2@"!*%&,QYI*7$@B&%?2C'1>C4B.>N+K;75;K'L8D3W&Z4$QK$@8FGQN^-
MOF\/7:KH<+L98/0.1S@^*(6D'2>YHY*/#Q+[%.1U;8\U>EV8Z]_57/ZV,)?4
MDY3Z:C=9RW8USB+*<21@G H,49102+0A(H$C&L4T3G/I=";K*&]J]-.>%\RK
M4X5M,HK'2LX!8X?U<UCD!N:<IG:AU194ZH)&7U KW&=![ "CQ](W+)PC+7*O
MA]5O4>L.TMGEJ\-MQENHNMOT9DGJ<5D/&FXC9+M]?LNJVGT=1=L^X"E"!"<D
MACR-JXZQ.:2IXC#+*<YCD0O-D4>I"T>QTXLUVH:,K[J:5P?HHM7=@UI<X<\2
M%HL(QQ"G5?<\02&-= ZUH#D77.-(NF],#P#^*//A^T#O,$,. .C T^06RS<J
M5Z5ZMTKWF2I=0?68+P< =Z1),PS(?A.G)UIG9T_7>XTWA7I:]V8>];VV9SN7
MY>+!=F2R&\GWYA95:TXJN!19)J'69@9%F$C(9!;!6/ HX3A/DH1Z=7$Y(F1J
M;&UUK'M362UO@-6S5\O3HXBZ[9=<B]/ )-P'(O_&+&<P"-J/Y9B<<=NPG+'T
MH/O*N>_V[&5:^>E-,?%9G O,4JQAHA,)49)KR',60VI<M3AG.<H1\8G)>G/W
MJ459W5L9VZXD=4RI9^O0-^"YO=V](1EE"V+;'2%@*\YC!@=MJ?E&P+BM,8_9
M=M#B\NB7_"M8-'?X7)2"S?^O8JM/"_F1K=5,:RHB%DNH"#9O+3)+74(P@1GF
M*=4,H2C+78M7G!(RM8FZ;>)1*PJLIL"H"JRN[C4K3D)Z_ET.!=3@RZ4>&'E5
MJ;@$PA4%*D[>>K3:%)>,ZY:EN/C=/LTWQ*.2F[E:ZO6C^J2U,MY^]?.]LEMJ
M=^83LRQX-D_+(RN;, \;^&&^W-91_\R*U3_8?%/?X\/RZ6FYJ )!?BBIU).2
M]_98?9;% BF:(YBH2$-$&(9$40DYCJ0069YBZGYD,9K:4Z.DUG![-&B[WS:V
MM[_6YH/*?K #H VT,A#45VUKX%L40 5#>XL:B28BJ\4"_%ZAX=5(8[0GRV$;
M:I+/R\#,_/\>E<-'Q:>!RQ0?F;&ZP4STT?%L-3/V")[O6S.:-B,VP1D;X;<=
M=4:7WC?AHBPW]F32%H>H:L'NIT,E+$HE9P)JQ#*SN+*]K#FF4 LF2<8T3J+,
M+[GB@L2IN355I'C1* V$T1H\5%6(59T+)2[F0O5$WL%W"(WGP--^5UU@]05U
M/6?GK+*>2/JF. 1$=,1TAJN0[9&]X(C2Y4R%2S<:.2O!T:[## 37"WL& +<I
MS$U <;E-S\=$QZE9P4*4,O./B@0D,HYM>XZ,I0G+:>Y5+.&DI*E1\RY+7S6:
M>M9 .(VIVV9V$*0&)MT=2*V2@]0RN A%T*#=D\+&C=2]9/-!>.[%"WJV-V.K
MA;EK^5VMJ@)?NSHJE$1IDFF8I(F B.,8,ITD,"."DR@W!"&=O+=+@J;&#*V>
MP"@**DU='GH_;-TH(@1B S-$/[#\6YY=0")HU[-3LL9M?';!XH/>9Y>^W_.,
M>[$N9#'?V.:N/Y78K*IR09_^%/.--.O,JOKJT_.F]E'O]+X67XN%^K)63^4,
MISI+69Q!:N-@*F^#9%D,\TQDF"+.:.R57A1*L:FQ3]<NL#,,M):U58VWME6E
M-8Z\A=9"4)GH25K!AMSQ4/\=!G+H>( QQ] _J" PX$'C$4+I-FXH0V!$#Z(@
M0M^_WUSP4SW8[8@?ZGFYLHYH4X+[A[(P%>;"!RNE0_E"42Z2#&)A*1^SR)"_
ME#!C$B6:9$)D7A4V/>5/C=D;]<%6_QO05JKOF%"][E>PM^\@N9'T@- /?5P8
M&G5OONV)74A:]55A5/;LB<\^2?:]38_#CS,U JLLK1_%P^/Z3O]6UIW(RUF>
M1"3F*H$TDS&T[<$-$V(!$RUSF_!*B,2SA7JP9S?WCN<AODHXO9.T?B</5!GN
M_?RV7$#!RL=.B=(F_;7>YO#8S_<>%H=3DD%0?K_RI%^ZY4DK PP=6A/@G8;&
M"'#K$<K;#W2/ Y4AP1_I<&6(0? [;^D+XMFS%^^;CG<.T]?>-V<RO6_2T[.V
M9_.VMI0AW/KD9[M3R B)B>(9)$(HB+1*S4]9#+'&:2*$P''D%*!\6=3D_.6.
MIO_COY,DQO^[.3?W/*DY@ZZC]QL$LZ$=W8Z2_[,]O#U>XWZ0+=K+( 7U:$]+
M&]=YO6CU@9]Z^8J^!:5?U-QX47+7,+VBJ6U&>:YTHE,%*;$9Y81QXXX20R>Y
M%(RD2'&NO9I0G9<W-3K9J@O6K;Z%;QFY2Q KI%.,4P:I,MX]8D1!+@F!><9Q
M3@3)L/'SO1JQ! 1YG'()8\#LQMH!H1N8NG>8[52M/<*0V>*>N(2MB'U>Y,A5
MKYWL/ZQL[7993P]PVUNKVWVKTX[MU]>#]ENW?["5O'NN4MOO-NMRS1;2;GPL
MY_//RY7]XTPG%-EBH5#KS'B/.$_MQD,*,Q$3B7"F:22]O,=!U)S:5'%?/"E8
MF0!JO>OS&$\6&VA('5W6=Q^HH=W=3O?"KHEO6ACR5W"TRZ&UY:89V]+\L#,6
M_&[-!8V](=WC00<DJ&L]C*;CNN6#HGW@T@\KS3_=^6.SN57G5'Y7JV(I/YO/
MRAFC7"@11S!.-8:(*PHYT0)&2<90A&B<Q\(UW_FDE*GQ>:MHF\U;JPHJ7=T3
MGD^#>IZ2@T$UM!?:!R6OE.>+*%R1\WSZWJ,E/5\TKYOU?/G+/1W)I5X;]E"-
MNVI%M!6XN$QB:5;]4N;<K/^3&'**;'BG$E',DIQ)KR;4)R5-[?5ORJH6_V5<
M@&)A)"[8'&Y*!<K&@BHSQ]>[.XFSHX,6 KVA?:P6GXZ2 RQ(+T(1U+LY*6Q<
M!^62S0<^QL4+^O%%YYC\85%4?LM"?E1:K59*-G_<;I>C-)8J8@)F)*$0,:TA
M1W$*!<YX3G66$Y7X4(B/\*FQ2C>*I%&^JDS9JK\-,^D;/.XU,FZD,Q3> _-0
M2*B]V:D/9B$)RTO^J!S6!YE]6NMUCWY,UY9]_(]B_=B6AOS:M,!]_69,;FJ1
MH2A5.,41E#26$*640)(H 6D61Q@)&6GNM6?F*'=J_+9]N5;U*-R 1=VZH:WZ
M5L59+1=^I.8Z"&Y\-@"T U-9JS'XPZ@,6IUOP%;K&[#3.QR)>0(5DK]<18]*
M79YX[+.6[^7O="9@&WJTD2QE&\I2?EG4J\T9091G*#4<%R'CS=$40YIR!K'0
M$<.1RF*WTE4CZ3LU@OST\_MW4%:)&D4;Y54LP'.];?*+^;'Z8WFZL]:[C/I(
MYP?AQO*O=)!0]3_:FKT+^BNKSO"U[1,Z4W ;I$D=+EQ0^:]URN"&?_#C!D>Q
M/2+C&X_=IB3]W/!2K(I*9#M?WJO5TU*WO\UBIJG&5$$41Y&=@ 1D2G 8$Q$S
M26A,E%-$DK_HJ<TE78VWO2UN@"U8[1&+[8?^^8E@6$Q'VC"PBH,WV'[88FN5
MM\N9]I/!</8(>!\,[Y&BW8/B[A?FW@NZLS'N?G<<+\"]EZ5OHMO[W:''=/#K
MIBP6JBS-/,6+!6N$E(6L8NF7BWLS997U-D,="OO%'L^H<EW:@DA*WBYD51F)
MSY55IS#S6]6C>7<',V4)\]EW5L@OBSI*9T9EG&8I2<V8\MQ,*RR&A&0*DAA%
M:<P5%JG30=?[F3"UZ6FGN9V<=JJ#9Z.T]6R9+677XM.L>SP(]7V>$X<)</*C
M/_!$VMH/.@" -_J##@1MUL$6!%"C4#5 :G$ G8?I[9T:*(#%PB9)^03=O>-C
MY#&_3_YQ&LE/F/)CY>=VO.N(GG5?WD>S\=R@=T7^C3OUOIKTVUMN=;X51J.R
M/GBS/ZZ4^KA\8L5BEF*<I0DVJ_&,2XA$%$/.601U$BO"DSS-$Z_=X8L2I^;T
M;$FJH_$-:'4&O]=:>Q[J7\;=;7\V*)IC.1$]@?3>%W4&)^3.YF6AH^Y-.F.P
MO[OH?F'?-$6^_K(HUZM-7:Y#JJ=J]5D5,F^(CCVH68XPQMPLX+@@&40LQI#'
MB>VCR#(:97$FXL@O7=%)[M18:*<H>+::WM@#ID97WZPZ-^#="&@ . >FH:H8
M^T[E&]"!]GL-[??+T/9(M_,"*FS:G9OHD=/OO/ X3,/SNSS<(4;9[HA]6ZZ-
MK!^J(D7Y>;FR&V:-XS>+!$=1)AA,D3W82%,"28H9I(3I+*>,:X:N/=-PTF1J
M1';TB*.\ 9*]EF!1&5)U4=E9</V.O-N0]3\("3X0[W4N4G8VZ&M;0&N,S84#
M]^./RO7')L%'Y[U/44*,4I!3%2]D^QRRN EX]S,7+QQ<CF#\;NB?&/AIL2[6
MKY^+N5I]8&OUL%R]SFB:RCR3"F:1TF:A;WXB+&=08:*1%HA1MU[E)^X_M7FH
M5A%4.H)62?<LP&,(GI]  N R\+3@!XE7RM\9PZ](]CMVU]'2_,Z8U$WP._>U
MO@'LVSY>3:I93&*:YQB9=Q6E$.G4+(^5BFQ>GV0I,TMHY/3JGI0PM9>WVU_/
M-_!\'SRW=>Y5D S\WK[I-A@^+^^DZ6'#P_>%C!P(?L+&PY#O4U_L]S)_7]F"
MI^O7[V9$U[>+ZF2@RNK[NBW-G"8I)I3G,(NY74KF$G*A%4R3+-=Q*B5AQ.?M
MOBQR:J][J_$-J'2NDKZV6E]1)-L!?#=V" OIP'01 $UO#G$'*"2I.$@=E67<
M4=BG'8\K_7BH7*WMS>5&K$MSWY]J]6(6'&5S"!4AFQRB&<PQM@6K60I)I,R:
M0&8YX3SB-'/*@3LK98)L8Q6MWHM&4\]3OO.@GJ>48% -SR+^*#GSAA,*9ZC"
M7-^A"?/;/D6<%S **SC9V!*!VY<#^R#WYGY;)N"*Z32"2.(<HEADD$5$0(3C
M+"81P0D/XX3L9$Z0%T[/FS? *MXS&L!E *YT1/K!.C"'?%TN'N#7XL56O#2?
M%S9^JRJD/4 P@ <RH[@@';'3\$$.<7!V0HY<VH^)JIZW1HPNUMN2%K8Q;9PD
M%,K4.")(1@RR1'*8Z01E,4HCB;R*C1R1,36FN97_N2G7YJVH.S#7ROI1RC$D
MW2CD2GP&IHPN(H/4^3AC?DA>."9F5!XX8^?^>W_NJ[UK<-@#^CJJ\4=1_O-7
MM1"/3VSUSV:V8TF2H0QS6W)#0222'-*<8BB5%GFB4,*H5]/92P*GQ@!O] 56
M8;#5N*>3<1%SUXW0<$@.OB]Z#8A]BFLX(1.XJL9YF6.7TW!"X$@=#;?K>D3Q
M?%5EG>F\UP%LUZ<=B4A*GA##,$D&D9)F:9/@#%(M>$89-PL?ITT.-W%38QJK
M,%A6!0M6G49XA=79L<&*(\[G^24\>D,O7BQP=:6'_0Z"I7>Q-T<(/8)A@D(Y
M4L3+M9#Z!;4X(W0V<N7R7<8+3W&VZ$T,BOM5/9V]7=W5-JSEP[)<?U/K#TV5
M+ZXB%F-B5G<9BVP]2059F@NH,A%KAA0S2T O;^^2Q*F1<+<T;1L3656CK:JM
MW8!+A<!ZXN[H\85$<VB7KP/DML;:APK(;Q;(#\$KJKF"$]3KNRAT7+?/%8,#
MO\_YPIXY)AMUO_RAYK:)Z7>VLMVRFQO?+F2GRF D;#E\A:#0V*PV22HAQSF#
M,LER1",=8>&5X^8H=VHLU$GU@:M:^X,\_]>VA5S[A6=CGV/<G.^PN-'3 & /
M3%)&8XM@HS-HE Z8:N*'2-!4$T?1XZ::^.%QD&KB>7G/K6^U?%BQY\="'*R&
MFT UKA.**35N49X95TGEMDXC09 G'*4T4S36RFLC_)+$J?'33F%PN+7CN3U^
M$6W'S?*0& Z]=7X.O@'B!IVQ";JO?E'HN+OLKA@<[+D[7QCZS%_]N?[5F/#/
M62)HQ&P:@.3&-4(HS2%A3$$MHD0JF6N.E5\7R\M"?5Z7<1I9_A2/2F[F55+:
M<Z-_=?2O=D?_FU+IS1S,"^V9B^LP"EDL,AVS&&HN#>LGF$+"20252AB54<YR
M'(<)O.@S!F/&7;Q%/3C0;H0?%KZ!&?]"I.=]Y<M;Q4&E^2C1%OLPC1-LL94Z
MD5B+?13<0RT.K@Q1?N'OBI6;554T]LOB>6-6Q"D7A D,,56)81W$(=$D@5F6
M1ISGB4JH5Y.H\^*FQCA5B8"B4R+@::>P^=QH?$W)A0.P'=>YP2 <>GF[7V"A
MHROX<A:]*ZLJG )EN&(*!Q+?L8;"*>O/ETXX>54_7OGMY_VJNN/K3V46QH5=
M+3<K*JTX)C%',,HB>\Y:U711J4UKX223"4]TYN=/GA8V/3_RMW_Y^2^@5=<6
M.O#M(WP&617A1&F90Q'9"%T69Y G",%$)"EF'*>*.A70#HOK&$P])*INM!P&
MJX$I^;>?.Y!V:@ZPYK^,1D@N/B-M5!Z^;/4^!SM<T2/6Y439P)9_1:PB%"F8
MH9A A+6 #,6Y 96R7#!!4N%>#_FLJ*FQ1%TJ$11MC5!6 G;\K.-H>6./$([S
M(W">4<+B.O1!ZZDRJQ<YQ1<TCYB78."-%.]R"L1  2Y.<)P-;CE_A_$"6YPL
M>1/4XG9%/Q_W,RM6_V#SC:IR5<K&@Y9WBQ^6RU=&[*^L+,K?%DM>JM6+I9S*
MM=[&U]3E8.WG,R&1+;RB(9.(V2Z#*62:FIF.XA21E"FJO YU NHV-1:WIH'*
MMILZ2ZAL5Y82V%.,UD!067@#NC;6ZT[PULIF!\PSCCKDZ+NYF.\TI@//(.,/
MI[<W.P#P(=W?D.J-ZB\/@.N^@SV$B'ZSQ5?;5>MQ.9=?GIY7RY=JIZ5=8G(A
MI< 1ASK),N.2RQAREL>0X-0LZ7.18>T5>'1&UM38?*LJ*#JZ^E'Q.6C=J#40
M8 -3Y0ZKKIH#+-\=X A)8.?$C4I(#G;O$XS+)7V6\+N0R#M=-0A8L/EOI?JY
MU.L_S"IV)A V/(', IXP!1%B$M+$_(JE2F),\A0).ENH![NBO7==S%\0ZO0J
MT/I5.! ]X/*I5;N>_I<:%(WN<%,J4#;:^ZQ$+Z'OLH(/ >;XT=)W&K3* J,M
M^#D >CY+^8 HCK6:OP9-SY6](SKG%_>7;C+B^M[1GK=+?->+>J[RBT6Q5E5U
M"G/SICQ%[4U6"=&SB$<D9\HV15$8&B*FQF_C'$J"<VYG/,S]ENX7!$[-@ZN4
M\EP[7\+4<4$<$*FA5[F5JDV1DYVRS8KW!IP'T7_%ZHA,T&7H)9GCKBT=$3A8
M,+I>UX]-?JI%L5Q]LP>4LSCF!$D=P33+<H@BD4(NLQ3&-"4\4\+X4DX)QT?N
M/36.^+!<O*C5NGKDRTK-^I"VRFOSXXXN@FXTT1.7@1FAU@I\.WM6[=\#_M#6
MH/W:.[<?M[?ZH5T'?="/?"5$4%S;GNV'6<_\7%?9'[ON.#(52:*QAIPC\PY+
M:M[AC%&H<,8D2J@BRNL==A<]M5>\VD<#*Z,D^*58=-H2_>V:(+FSX+N]_L-
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M]=8F@1=KDV?8R+L]1(Y!*G^%1V/HD!AK(.360M!% 71@ /P5=+_70 $J+&Y
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M>^<;4@XPB#J53.<1A5P09E?_ G*9I##-DXQRH7".=#.(GQ:.U#_R$+9ZO=,
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MA^ 0[;I=57B7OMV>^)QJX.U[FWY4MU<K\: _QBR/T@1AAJ!F]FPMCS/#;9&
M681Y*F*92ZS\#T@OB9WF&>BOVV-.SN956D_O5CP7<:<\9BK#$61)*B#BL8*$
MQC'4.F:(:2(EEKYGFN%1'_[8\E.EV0B NTTC(2$<>-[8KV_;IH!T&QN%FQU<
M@0DY'5R4.2K_NR*P3_C.U_DQ?+E:SSYLGC:VJ/>+^J2U$NOOU4M[IV]EW:.V
M*1854X;B-&=0*=LQ$IDE*(LXA5&&<A9)'$=N,8GN(J?FLNZT!K7:-Z!6O&J
MV*CN69G+8P#.<\\PL [,/H$0=>8A?Y#.,)&Y68>%S&_[#.0A;10.\K>^9:$>
M5UZWJ/ZP?.+%@M4I99U$L:H#05UAHB;"MME-6:>;W2YDE4UMCY12H6*9V-8
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M>^I][P[*5_/3__EO[2?F'WL$]7_^V_\/4$L#!!0    (  ^4IE*H[/?JEK$
M *EA"  5    :&-A="TR,#(Q,#,S,5]P<F4N>&ULY+U9<UM)DB;ZWK\B;\WK
M]<K8E[;N'E,J,ZME5Y722,JJF7F!Q>(AH8L$- "HE.K77P^ .T$2RPF>H,:J
MD@L(X?CR182[AR__]M^_GI[\\ 47R^E\]N]_XG]F?_H!9VF>I[./__ZGWS_\
M"NY/__T__N5?_NW_ ?B?/[U[_<//\W1VBK/5#R\7&%:8?_ACNOKTP]\S+O_Q
M0UG,3W_X^WSQC^F7 / ?ZW_T<O[YVV+Z\=/J!\$$O_W7Q;^&I(J,+H+E(H"2
MP8 OCD/TJ6CG?##6_[\?_S4:I95,&E*D/RKA!'C-&6292^0L:42W_M"3Z>P?
M_UJ_Q+#$'XBYV7+]Z[__Z=-J]?E??_SQCS_^^//7N#CY\WSQ\4?!F/SQXMU_
M.G_[USOO_T.NW\V]]S^N_WKYUN5TVQOI8_F/__.OK]^G3W@:8#I;KL(LU0<L
MI_^Z7+_X>I[":BWS1^GZX=YWU-_@XFU07P(N0/(_?UWF/_W'O_SPPT8<B_D)
MOL/R0_W^^[M7-Q[Y"</)ZA/1$DZ^+5=_3O/3'^O;?GPY)U"\#1\KT>L/67W[
MC/_^I^7T]//)Y6N?%ECHT^A?0]4NDYM'_[>K?_SC%16?%[@DX*RY?DTOG']&
M?=HQ%.'7%<XR;OB]>-;)/-UXTTF5]GQQ\2]/0L23]:N3C-/)^I-?Q.5J$=)J
MPGFQ3A .H]8.E'8!@G,&F%;6!Q^M$.F6 (CX)5&_5LX2TY\_SK_\2!],2A*L
M_E"EPX#Q<]7\MSL/W<CI,.HO5N0'>N\$2W'9%@X\" DJFDCKI! F4N&H$'-6
M80#BKS_S)NW7M?QBD7Z8+S(N:&.Y>&A8I#L:OPGJ\W?\^#DLZ(,@?9J>Y(M_
M77>8(?2VF@\@OXURB-P__4!<%UPL,+_>Z.9>YM:<K6B[Q?4[A]#[_S@+"_K$
MDV_O\/-\L9J$8FT* @&E1E!6./#,.MH9M*!?K"W%#PB!6X_?"0VB?S0<(]5.
M@/$6%]-Y_F66?Z:#>J(X8=<9.C)3(($@6F(@>(BHC/$J98+]@+"X\?"=0"'[
M!\7A$NT$$A\68;:<5L&?PSJF+*25'JS09'X)YB%8B1"X<8Z94J*^?=H?=5[<
M>OY.P%#] ^,HN8Z,C5]FJ^GJVZ_3$_SM[#3B8J*2<1Q9!AVB)US[",Y&"S$A
MIAB"USX.@(G;S]T)"[I?+!PEQRXP\ X_3JL09JO?PBE.M/2L\)#!%J% &5T%
MP14$Q5QB%KG)0YP8VYZ]$Q9,[U@X0IY=X.'5+,T7M)VM!?^>Y(\OYV>SU>+;
MRWG&2<S1%(^EVD$)5"+%^LP=&"VX+2E)4_)@\'B0E)W08GM'RW#2[@(\'\+7
M5YG$-RW33:3C?%?D+(J"L4 PQ="NR )$;Q$BDPJ+S<8)/AAL[B%B)\"XW@$S
MA(2[@,J+G$D%R_-OKZ<SY),BD_/621 NT&:IM(0HR/T*4>2(G%F;U6 PV4+
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M8>"=*R!2M,IE&34;'AO7"-@-'1V'1X<1[<CX>$$<Y#47)^'C1& .1B8.JN:
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M-W9L:V ,/1SE&D1''1AF-[G:3*1Z<;;Z-%],_XEYHFBG#D4RH$7NSKM09HQ
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M#K.[FJ4'/CVL#M7',YSV=RG<Y;R<U[/07P>+PM[S\:TCL+MP-5#T=7.[>/G
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M)2/6\U3(A&V3YK"-FDZ <[RV;]];'RWZ#O!SK6GJ>7^AXIQ(-A0P*F50B6S
M4)T@GH/V!CE7MG6+[3%;>PVHW?O[TQX@Z@ZP<L_4V7-F,DM6225 R$!+R<@,
M/A@+SHOBK:$=.3=ILO(@5>-&(X;'T' JZ !/MX?-GG/A2L3DZX6W*W2V<UE#
M,1Q!!*2]F4<ZVIM8/]O)&3<Z,#R"!A!Z!]#985+L.6/<Z2@UG>O.!$LGO!/@
M"D8ZX55.Z'U.KDG :6<*QRU[:K!%-5'-R,UO7VY8JI7'I6!:;6+(;\J+//^\
M5E4U)JTWI3H?H'6=L\**!^>2ABA-%LPPS'&76KJ=^N#N0E G-[>'>VQ-)-\Y
MDLY78+"9,5;S#9DPQ!$&\)(90&]HV<B:!K;+(3@(EL9NL#P\!/; UP'ZZ!QA
M5Q=,%_NP+%'3(0]:Q4!G/Z^S,7(&-%9R,B(-+[L<D</L6[>(ZQ=UAP!CGWWM
M&"UU8*%M2YU-);LZ1R$%$4$5ZX@#SJ%Z)II)+SG:%J;8@5U_VU_Y#1C+/$S*
M'>"$S,7YV:Q6RK^O:<]AD9>_?ZZ76;_4^ZGEE"3T>KI<300KD=4$_*)5 27(
M6/1&,?#:^D)<25V:E/?M2%\G0<X#87#7A!]<)QU [7;*QZO9!R2_9Q$6WS9N
MT+OYR<FO\\4?Q/ DFN"\10?&9T';K:ZM]TL!'XT0RKC@9)-PUCY$=F+@#P.Z
M9MKI 'FW.+E;Z6&4UMZQ""R(6GF=7>T &B!%X65&YD.;?,G'"!M]-%,C2,P;
MZN=@O'U>FX"TK!:K%JA[&1:+;[7KXVG=W+?VCG"V]K@*F=:O(ADRFR!Z*R$Q
M9FK=;@IMJL+VIG3<G6\L7 ZLP5Z!>G?Y67+@=>T('U'7_LRAD(F<"B1A6";;
M0SC;Q',89'MLYD?TLSWNHY\C4??++(^T.<IHHE')@_.1)!@(,4XR$JAUR?E<
MAVDW&0799G-L=J/0\>:XCP8[@>E=:=[-I[LNT.1YC#$C8/"Y=K)7U5!1$"6J
M*+3.W#7I5+$GG9T$8%IY+L/IJ(OZQ[L;?BH>E4H"'/=(GG\A<0F-M56XR]ES
M:6,3F'7OH RH^=NAOJ.4T(VM=U= $ZYR<2(PD@HG/F*=S:U-ID.@&(]!Z=!F
MS[HO0;\?MZ(AFHY30U]P>K5<GF&^7F*X62SO<$E60%H71M#;7E2IK0M>2((%
MIZLS>L]$"[(!-%FL-B8#RGH.+DMR[8/612O!=KNU/PQ]QU#>F_/1&*Q/IN0.
MXH4/,KS^XYOU)>'REZ^X2--E[985M&-6U;:?EM&76K:H0R;4>1-YB;KPVUUY
MV\-X*ZF]N2<CX?9X-?8+U+^%DS/<SB CBT76ZTU:?N2#D?C .7+[6*VK-8QE
M%1I51^U)Z;@]J#N Z4!*[ "E5[D4RP_S>U*HUXLRAG5!Y6GMBKM6]3LD22^G
M*SR?Z[:1S#M,\X^S]:>LA33)S KE"X,2+<E#1D^6.'T14?"PSN/73;J[M&9L
MW+[93[D&NH+(B$MFW;3^M_DLA>6G-XNW9*:?__(B;=@DAJX5LFQV#5+ >URM
M3LXK/NNT5]I%Z.=:FSS-ZTD(M<HYQ.G)9?QX$A5YJ('1 1=5K7Z)ZVG7 A)/
MSEF=;)&W^UYLGR/P).2.VP#\*99"IZK_SA?#1'I14@D>+%.2SE(Z5;V0"5R0
MZ&*0FM^IU1QE&8S;VOQ[60![J;N/X.]#3LPUR="JYJ:(I#-9A::FPM)A1QPY
MT%XK6METP/$FE:,[4SANP_4.3/HCE=:!*?^0KW*#+R\+\YXC!+V>KH/T4S"^
MSOPR*0<KC'O*L-X= D?NX=X!&(_360=8O-G55"B7?'$>#+-$LJ7=W=5DL>*=
MX%B+V4236XP#6LI^%_=AATN_BV-UETYU$Z5D2ID%0(PU;*TL1.8M)(^^V,*D
M;Q-7V(6XD5NS/R74!M=5!YO7W>MDE:UBN7:V+U*!*H9^LMP"<\(8%2R9 FUN
M$ Z[T_\^;K:.TD(G.4K;[I(STSERL2EG4MQS"(8)L$C"8)99Z1KU>SOH2I]_
M/]=-A^MA4#2--$6"G/5?3^9_-)H><?GI3SHU8CM/P[=OO'S05:_1@,Z'V@G4
MUYKJ0.:53RZ!%3D9LK:4,XT2<^XG:@"CO7[FV\7\RY3$]].WWTGVKV:7\WI?
MI-7TRZ9S]848LF7D'!.EM!!I$8F0P64O((H8A1,,2YO>_?N3VDD5XK%8VF+J
MM]19!];836>&>>TXG?>09"0;(.<(,?H +/J$$96WK$E'\(ZFD[16^8/.Y#[R
M[P \-^XNZ\7C+$U/\ 9+'^;[2E-:9K1U"D*L<Z[(A0'/:GYT9#I))$.TS:3,
M%LR,F];YQ% >'0T=K(B?D9Z<IN&\N_Z+T_EB-?WG^M<):NF%<P0\D34HYY"8
M<@6L1!*K+!C;C'YZ@*9QM]KQ 3-OH[TNXGS7J7]3?IW. HEW]O'E?+E:$G,_
M3Y?K7@O+25:"<RXX("O$F74:0O*QMGOANA!_$9O<GNU*X+B;:'<@;:+7L7,=
M[D8K+L7WNO[^KLZO?%-(LB^62R3FN,#$([%DU]V/LO)D*:&'0N)#)DLN>/N6
M;7ORPKY/'C?YO1LTMM?:_I#T&TC.\&,-97P8LE/0 M<:OK'T+E<:K;JW"SR=
MGITN7\V^X+E^)KXFV!''0!8]&?.Z7B_RG,&+8'6(B@7;IB_Q0>2.FQS?#:Z?
M4.?] 'PMU"4Q^.M\\7H>UJ/4</G+U\_K^. $4=D4DR+3IW!0/!;PMF1 E";:
M1"NW39G<PV2-FR;?'6 'U&$'?M3Z>NJGVQG/$R&<CI%+0@HGDP:YH?,C23"<
M(:TMC4*WJ>'82LZX2>K=(7  G76 O)_/'[N1XH?P]7P)_80S+-/5)(0L9%$)
MK*I-RSD3$# F<")[9SU+$9NT WR$KG&SQ+O#XI!:[ "4/YTMIS-<+FEA17+X
M-OG 6_-]7RP6@5Y=J^+EI_KCJ]FF,<GC*<)\XF3-6#)DD%M3UZJO:U5R8-)H
M9C&A\$VZP3T1?^-FDG>W2'I$50>+;9UTM47F%U>+E[>-$RUKB(7,^[+>1921
M$+P-P&,R67I5)#9)7-J9PG'SSKL#?!O-=@#9!P(QYR6$5]?AJ=0 ( /%7*;%
M: RX) VPX(C?5(2633"[.XDC)ZAWA]I&RNT2MN<-H)<D=YQ^67<ICX)C#C*"
M4*6V^*OMYW.,P+U#EXN30C6YGMB%N-Z:0 T#C$?Q=Z26^@E\W66M6C-58G^?
MKCZ]I'V 5OQB';R>.(/<<RR@M,::UIC!*8=@!%?%J9P">R(<WDMC;UVDG@B.
MP^BL9U2^7>#G,,T77NVY,_MBMAET=7ZYDGR(U6H!&ZP$E9*'*$*"))Q(LM3^
M&$_4@7$7<GMK(O5$6!U<D^/#]IZKP(M#XFWX5D^(>J%R1J2=NX75.#IG^MI+
MD\!2M%DR$";5W/'$('*I@">2=2B&%W';.MWU6O<0>GKK&#4H2,?26Y>&Y[8S
MY*IVOA@E2)X"I GD#F)M>$D<@2@ZNR**L;I)7&Q/.GOK'#7B^7^8[GI/@[F^
MY+36(I"U#:'.3%6!SH=@G07M,'F564*Q6Q>;/1[:6UNFI]@/A]% !YO>[NG
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M+S@[PUKXNZU)_VWN,,I$#&@0(M(NS3T#AT5!XDC'N4LDNR:]J_8C<^11NVV
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MR!MW6QH,,SMT#3Y6-WTG=6V3Y-J2&&Q3.O^TQEO3-IJ?8H,2B?FBJN7M?1W
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M7*OC8%UNQ\0!@NT %>\_D:Q^"DO,M7 =9\N-^&E[S!\6@8Y*?#.[*%4R/.C
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M(++T)9;$/7(5FF1>->%FM]L-]FRPWH_J.\#_3@,BT-+!4HVL4%>RDMZ 2RA
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MN))E(*DUG:[VI-SV<6/T?\M:' QWW]GBO/+UEA-7. K!;9V@YLE(89+L$ZM
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M]>3$!%8XD.)P)5BV/C8"W@ZJQIVDT!$ AY)<%T!<=C+]$-*_\/EAM!:I#HL
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M++D+Y&Y&%=OTY1Q*:,?&[! <;35F+>3509#[<+[WDQ GUZO\_4N'-,@*BI"
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M-9CTCV9B3Y[H0(TGW$LCN>7@+/?D\D<!T=D(5F6E/$.=?9-'?V-,$^C\T=6
MV8 1P#%V"OZ01BBE94ZQ%OOC,N90%KQ,"LA@8)UBG S?+PT_>,-:WP@]$AG'
M]JL=(J8.3/,13W'7T\M7*BB=G2!OUJ@"*@8%G@)5,+98U()%3$U&G@] ^VM(
MR)X&\+& <-&]FK^G3YAOK^E/M_"H7:OFWE]]OD[-X[AQCD;-@(3(J@:.DTNB
M9%;DDI"'P@5Y)$$$0;_]9V[4+(F9Q+@ 1)WJ._8,T=31-L&RD"B*C+SM4OE7
MW:AY"/I:-FH>(N4.7)(G=9^'J^;M=5@LEJDSE80O@DL(9CGL,7.(148(F(1"
M[D,L3:9A[J2J$Q">&RO;Z[HG"JXG%#YY<' D9]?9<;]"4SN!IB XB;EV^]3\
M3?2 PA:#PG,MVM;@6IVL$VTX'87;\-T%),;.76SQ]5892N&9I("#06*"PN#B
M$7SB#E@Q42MKI-3[-:#N_)I.D-8''F9-A-.3*1XH3':!871TQW&FZGMQE8!\
M,0Y<UARF3%[H)GWW8Z2/.\]=#.ATC ".GG3C=!OT-ERGV^OEC[_-KJ]_GLW_
M$^;YJF05,44$&>JV(B-B+5992,$B4XXK&]LZW*U.ULGE,09NVSDV X"H)ZUZ
MDN+\/Y.;3\\.O_C^](OO>?5PI]^5!J3,S-M M[DV'!2KUVY].2\R9RQY78QK
M^VQXR--THCU](':/MM+SPN=H'?J"\\DL_WX3YC>C:M(63OQZ.T^?P@(75S+X
M9)4-@,E:4+XN)DK% \O>)W*:'9HFSTI:':@3;^Y5Z=.@(+K@:VD;'Y:Z_FZ:
MYO1Q^"/>_>]5'0V> FK@I110$DE2F2>P+@F+M9LC^TO0K(VGZZ1O^$^A9J?#
MZX)U;O==CL)YG4NBNUQZ4 49T*]KN9Y,C\G$"M9DV<)XKF#[/K97I5/#P>=$
M5_"G:6[=;/$FI?DMYNM'^1W3-['A4P9L@7B)QH&Z&59+PQ9OIGGYC>'ZL9SL
M$TN898'(0FWZ-0&B#0J"CTSHG+5Z-F1X$)NQ@Z:3E].D5.=*W^]*N_\& NB3
M*5\/E?4_B,D_T#__UY6-.3I;YU![YR@48AXB9PE,,E[F(H0V32+I(^D=-U8>
M"E//UM"<07A]=XD]-PK+?/9 YFOU64V-V"9ZSV#*G+61>8V S#-0EFL(69(/
M*)23FFF31!/];6C*[IO@/I3G6K#D\J,"Y,RTSG6<D2R&/.# P 6KB-ZD,0CF
M.&]R^OU)[-=@'8*<=8/52$279J-.Z$W=_F%-K53+_M%=8", U'D"$83AA (1
M>%U5;B&*F&S&$IEN\LZHH9GZB<0\^X8$H^OEIJM')K^E<(/$=I5#8J%NOF4J
MYSI>$B$:S<'HX$+.#EV;>M^+E/5KE [!R;I1&E8@'21,/MQ\POES WM_FAC0
M8-81;!*!3A,=\4HA<&(8Y\4:T6;:YFZRQLV^M\+6@*(8N]OL^2F(62_K3J3X
M15D=0-1V)X5:0I 5'\P(F5E]J;7^VGAS&]IQWS]NMGEH6)U+$(/MSFOB4#W9
M\_X[3B>S^7+;^S'>U)9/&M"5VH?6@?RHNC/L,=I_P%G247O/%!1OZY0YH<%K
M\JN+9R%Y@R&G)B[49G*&V&6W*:51'-/<L Q:9@N*QPP^8 $F N-%H+6^2<EL
M"SWC>DH#(&'30KI3^=YWF+994X]/)^W\O.86IF%::0NZI!:I.)6!V=K7KY0!
MYU6"B-Y2Q)Y4HY[>-G;F"5?K%ZPE)U"8Z-!G$%*1WY:BAN@%!Q93%KH(D;')
MPY&=5'5I<PY!Q;K-&4X&EVAY?@GS^F3@*YZ0+=KSDYM;H]UG:6N71"@4OSL!
M5M;:L:B#*;5&R#II$8TPTC0IVK6Q2R03_%#>$GXG=2WLLB*]F@!CA)(Z!-#(
M'=W$6=+M+A"8R74X54C"-&EHV$I1E_;H$#2LVZ-A>-]!@NC[[<++5WD^UDUB
M28'+&"DZI&C4U_Y69FS=B<I+SF?81C[^2]Z!9+QSG?/!#.\.,K^$S_=CTK/7
MV@7K@:NZ':Z$ M&P6%<CI>P"9]J=88?X(T'C6YU3!+T3-T=R?>S$X1,_X,?;
M.CU?W\^_MT8%*R64+!)IE)!$OQ:0HA-"&L%MVN^%ZK9OZ D+QPIO-C0G.S F
M[V?3C_1IGY=>_?V*(2%%R,YXJ"/#Z69F%@*K\XML,ES'*&UIDJ?:1,RXQ8@V
M=]#)3.\0."N%8I8SB\)"8:*.%- :G*1X4$G4FD=7L$V*<S,Y(SLP)XOY!=P<
MP?,.D/,D+EW:SU5E9F4_H\T%!9V#131UCZZMFU@8"#0I8K'>Y28ET9U4]86C
M8\2^/9]SH@S&=FF^O]J?G.L/0L?BT^PZ/Z@>FH"9D_2=8!Z4DZ1ZGGZ9!+D!
M3--]7=;]X\U.SO[?.6[-<]C;JR6[+P-%*\63A47F.(.<1$U<* X1F8 <DQ?1
MVAC9B^G @[]U'!/45.:'X^H( 72+K-_#-:Y6)_Y^,TO_>CCHR@@K'H4U$<&F
MPD$9E^F0-@ WW$23Y8;"QH$H>X&"[A%W#!KVPMR0HNG X=JZ2I87PXMP"HS
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MC;-E7T4IF&X6RY__J/R<?Z#?F?^&7V[GZ5-8W"W1^%!O;_K+BYO)Y^KN/:R
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M\^M61W#H)44:#(*L]C$H23]%#D5+IC/S,CZ;/#B\7WT AIH]NCR?1WT$YSL
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M=U&031>:..K(F6"6+O_@R1]H\J!XJ .,/):PGPMV%$1<OB;<K4^](J:CR,P
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M(W -']Y4%D5Y'UT"JR01KS$#\JR!LZA3(O;RV&06PZML3G 0$G8V)SA$+"/
M5),[GSPIFZ3.%')A'3=M!3F-K@9?)21O?;%ZF#,^9]Z<X"!LO41S@D,$/0*P
M_T[.[?Q7SIV'N+I'S H*Q!# *U5HYY--0FTM9-026?0\MFE)L(66D=>GFP-D
MWJ^T1@"X'@[L\)Q9DJ[>-)8)5/ .,)4$G#:]Y#Y++..ZV?/AM=WZ/L4W>&$
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M^)A?3A-VLYEO5XU>R]IQ"DSA'E0A=Q*]8U 2.L695RHURJ3V0?[ &?X6\!U
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M,7AC97)T:69I8RYH=&U02P$"% ,4    "  .E*926P54.(X%   8)   '@
M            @ '%$   97AH:6)I=#,R,2UQ,3(P,C%X8V5R=&EF:6,N:'1M
M4$L! A0#%     @ #I2F4A@F../N$P, !!L> !$              ( !CQ8
M &AC870M,C R,3 S,S$N:'1M4$L! A0#%     @ #Y2F4N(\.^DD$P  [=H
M !$              ( !K"H# &AC870M,C R,3 S,S$N>'-D4$L! A0#%
M  @ #Y2F4G6%BFA )   _(D! !4              ( !_ST# &AC870M,C R
M,3 S,S%?8V%L+GAM;%!+ 0(4 Q0    (  ^4IE(UAO^4KGX  ,K(!0 5
M          "  7)B P!H8V%T+3(P,C$P,S,Q7V1E9BYX;6Q02P$"% ,4
M"  /E*92-J$GW*@2 0"QH@L %0              @ %3X0, :&-A="TR,#(Q
M,#,S,5]L86(N>&UL4$L! A0#%     @ #Y2F4JCL]^J6L0  J6$( !4
M         ( !+O0$ &AC870M,C R,3 S,S%?<')E+GAM;%!+!08     "0 )
+ &X"  #WI04    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
